,drug_name,pubmed_id,title,authors,mesh_terms,paper_url
0,ALFENTANIL,28688027,Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.,"['Ziesenitz VC', 'Vaughns JD', 'Koch G', 'Mikus G', 'van den Anker JN']","['Adolescent', 'Alfentanil/administration & dosage/pharmacokinetics', 'Analgesics, Opioid/administration & dosage/*pharmacokinetics', 'Body Weight', 'Child', 'Child, Preschool', 'Fentanyl/administration & dosage/*pharmacokinetics', 'Humans', 'Infant', 'Infant, Newborn', 'Linear Models', 'Models, Biological', 'Remifentanil/administration & dosage/pharmacokinetics', 'Sufentanil/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28688027/
1,ALFENTANIL,8896944,"Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.","['Scholz J', 'Steinfath M', 'Schulz M']","['Aging/metabolism', 'Alfentanil/*administration & dosage/*pharmacokinetics', 'Analgesics, Opioid/*administration & dosage/*pharmacokinetics', 'Fentanyl/*administration & dosage/*pharmacokinetics', 'Half-Life', 'Humans', 'Obesity/metabolism', 'Sufentanil/*administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8896944/
2,ALFENTANIL,16119498,Phentermine and anaesthesia.,"['Stephens LC', 'Katz SG']","['Alfentanil/administration & dosage', 'Androstanols/administration & dosage', '*Anesthesia', 'Anesthetics, Intravenous/administration & dosage', 'Appetite Depressants/*adverse effects', 'Blood Pressure/drug effects', 'Diagnosis, Differential', 'Drug Interactions/physiology', 'Female', 'Fentanyl/administration & dosage', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*chemically induced', 'Hysterectomy/methods', 'Intraoperative Complications/chemically induced', 'Leiomyoma/surgery', 'Midazolam/administration & dosage', 'Middle Aged', 'Neuromuscular Nondepolarizing Agents/administration & dosage', 'Phentermine/*adverse effects', 'Propofol/administration & dosage', 'Reoperation/methods', 'Rocuronium']",https://pubmed.ncbi.nlm.nih.gov/16119498/
3,ALFENTANIL,8875131,Remifentanil.,"['Patel SS', 'Spencer CM']","['Alfentanil/therapeutic use', 'Analgesics, Opioid/adverse effects/pharmacokinetics/*therapeutic use', 'Anesthetics, Intravenous/*therapeutic use', 'Clinical Trials as Topic', 'Guidelines as Topic', 'Humans', 'Intraoperative Care', 'Piperidines/adverse effects/pharmacokinetics/*therapeutic use', 'Receptors, Opioid, mu/agonists', 'Remifentanil']",https://pubmed.ncbi.nlm.nih.gov/8875131/
4,ALFENTANIL,24676025,Methadone and oedema in the palliative care setting: a case report and review of the literature.,"['Dawson C', 'Paterson F', 'McFatter F', 'Buchanan D']","['Adult', 'Alfentanil/*therapeutic use', 'Analgesics, Opioid/*administration & dosage/adverse effects', 'Back Pain/*drug therapy', 'Drug Administration Schedule', 'Drug-Related Side Effects and Adverse Reactions', 'Edema/*chemically induced', 'Ependymoma/complications/*drug therapy', 'Humans', 'Infusions, Spinal', 'Male', 'Methadone/*administration & dosage/adverse effects', 'Palliative Care', 'Scrotum', 'Spinal Neoplasms/complications/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24676025/
5,ALFENTANIL,39443850,Comparison of the anesthetic effects of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery.,"['Zhang H', 'Fu M', 'Yue F', 'Wei Y', 'Shi X', 'Yu S', 'Ji F']","['Humans', 'Female', '*Hysteroscopy/methods', 'Adult', 'Middle Aged', 'Young Adult', '*Benzodiazepines/administration & dosage', 'Anesthesia Recovery Period', 'Adolescent', 'Aged', 'Hypnotics and Sedatives/administration & dosage', 'Anesthesia, Intravenous/methods', 'Alfentanil/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39443850/
6,ALFENTANIL,26847795,Alfentanil anesthetic augmentation lengthens seizure duration in electroconvulsive therapy with older people.,"[""D'Cunha C"", 'Plakiotis C', ""O'Connor DW""]","['Aged', 'Aged, 80 and over', 'Alfentanil/*administration & dosage', 'Anesthesia Recovery Period', 'Anesthetics/*administration & dosage', 'Anesthetics, Intravenous/*administration & dosage', 'Dose-Response Relationship, Drug', 'Electroconvulsive Therapy/adverse effects/*methods', 'Female', 'Humans', 'Male', 'Propofol/therapeutic use', 'Seizures/diagnosis/drug therapy/etiology/*physiopathology/*therapy', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26847795/
7,ALFENTANIL,21132842,"Determination of fentanyl, metabolite and analogs in urine by GC/MS.","['Strano-Rossi S', 'Alvarez I', 'Tabernero MJ', 'Cabarcos P', 'Fernandez P', 'Bermejo AM']","['Alfentanil/*analogs & derivatives/chemistry/toxicity/*urine', 'Calibration', 'Fentanyl/*analogs & derivatives/chemistry/toxicity/urine', 'Fluorocarbons/metabolism', 'Gas Chromatography-Mass Spectrometry/*methods', 'Humans', 'Limit of Detection', 'Linear Models', 'Liquid-Liquid Extraction', 'Reproducibility of Results', 'Sufentanil/*analogs & derivatives/chemistry/toxicity/*urine']",https://pubmed.ncbi.nlm.nih.gov/21132842/
8,ALFENTANIL,39161682,"Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.","['Weng M', 'Wang D', 'Zhong J', 'Qian M', 'Zhang K', 'Jin Y']","['Adolescent', 'Adult', 'Aged', 'Female', 'Humans', 'Middle Aged', 'Young Adult', '*Alfentanil/administration & dosage', 'Anesthetics, Intravenous/administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', '*Hysteroscopy', '*Ketamine/administration & dosage/adverse effects', '*Propofol/administration & dosage/adverse effects/pharmacology', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/39161682/
9,ALFENTANIL,8280538,Awareness during total i.v. anaesthesia.,"['Sandin R', 'Norstrom O']","['Adult', 'Alfentanil/administration & dosage', 'Anesthesia, General/methods/*psychology', 'Anesthesia, Intravenous/methods/*psychology', '*Awareness', 'Drug Administration Schedule', 'Female', 'Humans', 'Middle Aged', 'Propofol/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/8280538/
10,ALFENTANIL,2611070,Modification by fentanyl and alfentanil of the intraocular pressure response to suxamethonium and tracheal intubation.,"['Sweeney J', 'Underhill S', 'Dowd T', 'Mostafa SM']","['Aged', 'Alfentanil/*therapeutic use', 'Anesthesia, General', 'Double-Blind Method', 'Female', 'Fentanyl/*therapeutic use', 'Hemodynamics/drug effects', 'Humans', 'Intraocular Pressure/*drug effects', '*Intubation, Intratracheal', 'Male', 'Ophthalmologic Surgical Procedures', 'Premedication', 'Random Allocation', 'Succinylcholine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2611070/
11,ALFENTANIL,33422129,Oxycodone versus other opioid analgesics after laparoscopic surgery: a meta-analysis.,"['Li Y', 'Dou Z', 'Yang L', 'Wang Q', 'Ni J', 'Ma J']","['Alfentanil/adverse effects/therapeutic use', 'Analgesics, Opioid/adverse effects/therapeutic use', 'Fentanyl/adverse effects/therapeutic use', 'Humans', 'Laparoscopy/*methods', 'Morphine/adverse effects/therapeutic use', 'Oxycodone/*adverse effects/therapeutic use', 'Pain/*drug therapy/pathology', '*Pain Management', 'Sufentanil/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33422129/
12,ALFENTANIL,2605072,Effects of incremental doses of alfentanil and propofol on the breathing of anaesthetized patients.,"['Goodman NW', 'Vanner RG', 'Wade JA']","['Adult', 'Alfentanil/*pharmacology', '*Anesthesia, General', 'Humans', 'Middle Aged', 'Propofol/*pharmacology', 'Respiration/*drug effects', 'Tidal Volume/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2605072/
13,ALFENTANIL,28504483,Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies.,"['Gufford BT', 'Ainslie GR', 'White JR Jr', 'Layton ME', 'Padowski JM', 'Pollack GM', 'Paine MF']","['Administration, Intranasal', 'Administration, Intravenous', 'Adult', 'Alfentanil/administration & dosage/pharmacology', 'Analgesics, Opioid/pharmacology', 'Area Under Curve', 'Chemistry, Pharmaceutical', 'Female', 'Healthy Volunteers', 'Humans', 'Injections, Intramuscular', 'Male', 'Miosis/drug therapy', 'Naloxone/*administration & dosage/pharmacokinetics/therapeutic use', 'Time Factors', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28504483/
14,ALFENTANIL,8307657,A rule-based postoperative pain controller: simulation results.,"['Carollo A', 'Tobar A', 'Hernandez C']","['Alfentanil/*administration & dosage/blood/pharmacokinetics', 'Analgesia, Patient-Controlled/*methods/statistics & numerical data', 'Blood-Brain Barrier', '*Computer Simulation', 'Drug Therapy, Computer-Assisted', 'Expert Systems', 'Fuzzy Logic', 'Humans', 'Infusion Pumps', 'Infusions, Intravenous', '*Models, Biological', 'Pain Measurement', 'Pain, Postoperative/*prevention & control', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8307657/
15,ALFENTANIL,23386287,Pairwise comparisons with ordered categorical data.,"['Lin Y', 'Cheung SH', 'Poon WY', 'Lu TY']","['Alfentanil/pharmacology', 'Child', 'Child, Preschool', 'Clinical Trials as Topic/*methods', 'Computer Simulation', 'Humans', '*Logistic Models', 'Pain/drug therapy', 'Piperidines/pharmacology', 'Propofol/adverse effects', 'Remifentanil']",https://pubmed.ncbi.nlm.nih.gov/23386287/
16,ALFENTANIL,21291302,A new technique of alfentanil-induced conscious sedation for oculoplastic surgery.,"['Ghosh YK', 'Beamer J', 'Ahluwalia HS']","['Alfentanil/*administration & dosage', 'Anesthetics, Intravenous/*administration & dosage', 'Anesthetics, Local/administration & dosage', 'Conscious Sedation/*methods', 'Humans', '*Ophthalmologic Surgical Procedures', '*Surgery, Plastic']",https://pubmed.ncbi.nlm.nih.gov/21291302/
17,ALFENTANIL,3086065,Alfentanil in anesthesia and analgesia.,['Reitz JA'],"['Alfentanil', '*Analgesia', '*Anesthesia', 'Blood Proteins/metabolism', 'Drug Compounding', 'Drug Interactions', 'Fentanyl/administration & dosage/adverse effects/*analogs & derivatives/blood/metabolism/pharmacology/therapeutic use', 'Formularies as Topic', 'Humans', 'Pain/drug therapy', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/3086065/
18,ALFENTANIL,12151928,Memory function during propofol and alfentanil anesthesia: predictive value of individual differences.,"['Kerssens C', 'Lubke GH', 'Klein J', 'van der Woerd A', 'Bonke B']","['Adult', 'Alfentanil/*pharmacology', '*Anesthesia, Intravenous', 'Anesthetics, Intravenous/*pharmacology', 'Female', 'Humans', 'Male', 'Memory/*drug effects', 'Middle Aged', 'Postoperative Period', 'Propofol/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12151928/
19,ALFENTANIL,1588504,Measuring the predictive performance of computer-controlled infusion pumps.,"['Varvel JR', 'Donoho DL', 'Shafer SL']","['Adult', 'Aged', 'Alfentanil/administration & dosage/blood', '*Computers', 'Evaluation Studies as Topic', 'Female', 'Humans', 'Infusion Pumps/*standards', 'Male', 'Medication Errors', 'Middle Aged', 'Predictive Value of Tests']",https://pubmed.ncbi.nlm.nih.gov/1588504/
20,ATOVAQUONE,36116841,Human Babesiosis.,"['Waked R', 'Krause PJ']","['Atovaquone/therapeutic use', 'Azithromycin/therapeutic use', '*Babesiosis/diagnosis/drug therapy/epidemiology', 'Clindamycin/therapeutic use', 'Humans', 'Quinine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36116841/
21,ATOVAQUONE,31027664,Recognition and Management of Malaria.,['Gerstenlauer C'],"['Antimalarials/*therapeutic use', 'Atovaquone/*therapeutic use', 'Drug Combinations', 'Ghana', 'Humans', 'Malaria/*diagnosis/*drug therapy/*prevention & control', 'Male', 'Middle Aged', '*Practice Guidelines as Topic', 'Proguanil/*therapeutic use', 'Risk Factors', 'Severity of Illness Index', '*Travel-Related Illness', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/31027664/
22,ATOVAQUONE,24399475,[Malaria].,['Burchard GD'],"['Antimalarials/*therapeutic use', 'Artemisinins/*administration & dosage', 'Artesunate', 'Atovaquone/*administration & dosage', 'Drug Therapy, Combination/methods', 'Humans', 'Malaria/*diagnosis/*drug therapy/epidemiology', 'Prevalence', 'Proguanil/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/24399475/
23,ATOVAQUONE,27789127,Is the Mitochondrion a Good Malaria Drug Target?,"['Goodman CD', 'Buchanan HD', 'McFadden GI']","['Antimalarials/pharmacology', 'Atovaquone/pharmacology', '*Drug Delivery Systems', '*Drug Resistance', 'Humans', 'Malaria/drug therapy/*prevention & control', 'Mitochondria/drug effects/*metabolism', 'Plasmodium falciparum/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27789127/
24,ATOVAQUONE,34960706,Atovaquone and Berberine Chloride Reduce SARS-CoV-2 Replication In Vitro.,"['Rodriguez-Rodriguez BA', 'Noval MG', 'Kaczmarek ME', 'Jang KK', 'Thannickal SA', 'Cifuentes Kottkamp A', 'Brown RS', 'Kielian M', 'Cadwell K', 'Stapleford KA']","['Alveolar Epithelial Cells', 'Animals', 'Antiviral Agents/*pharmacology', 'Atovaquone/*pharmacology', 'Berberine/chemistry/*pharmacology', 'Cell Proliferation/drug effects', 'Chlorides/chemistry/pharmacology', 'Chlorocebus aethiops', 'Drug Synergism', 'Humans', 'Proguanil/pharmacology', 'SARS-CoV-2/*drug effects', 'Vero Cells', 'Virion/drug effects', 'Virus Replication/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34960706/
25,ATOVAQUONE,39109671,"Babesiosis in immunosuppressed hosts: pathogenesis, diagnosis and management.",['Heller HM'],"['Humans', '*Babesiosis/diagnosis/drug therapy', '*Immunocompromised Host', 'Antiprotozoal Agents/therapeutic use', 'Atovaquone/therapeutic use', 'Drug Resistance', 'Babesia/pathogenicity']",https://pubmed.ncbi.nlm.nih.gov/39109671/
26,ATOVAQUONE,38859743,"Late Parasitological Failure and Subsequent Isolated Gametocytemia of Uncomplicated Plasmodium falciparum Malaria in a Returned Traveler From Ghana, 2023.","['Bae J', 'Kim JH', 'Kim S', 'Huh J', 'Choi HJ']","['Humans', '*Malaria, Falciparum/drug therapy/diagnosis', 'Ghana', '*Antimalarials/therapeutic use', 'Middle Aged', 'Male', '*Plasmodium falciparum/isolation & purification', '*Proguanil/therapeutic use', '*Atovaquone/therapeutic use', 'Travel', 'Artemisinins/therapeutic use', 'Artesunate/therapeutic use', 'Parasitemia/drug therapy/diagnosis', 'Doxycycline/therapeutic use', 'Drug Combinations', 'Treatment Failure', 'Artemether, Lumefantrine Drug Combination/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38859743/
27,ATOVAQUONE,34782311,A typical babesiosis in an immunocompetent patient.,"['Voisin O', 'Monpierre L', ""Le Lorc'h E"", 'Pilmis B', 'Le Monnier A', 'Mourad JJ', 'Senghor Y', 'Mizrahi A']","['Atovaquone/therapeutic use', 'Azithromycin/therapeutic use', '*Babesia', '*Babesiosis/complications/diagnosis/drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/34782311/
28,ATOVAQUONE,29358624,Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.,"['Bakshi RP', 'Tatham LM', 'Savage AC', 'Tripathi AK', 'Mlambo G', 'Ippolito MM', 'Nenortas E', 'Rannard SP', 'Owen A', 'Shapiro TA']","['Animals', 'Anopheles/parasitology', 'Antimalarials/*therapeutic use', 'Atovaquone/*blood/*therapeutic use', 'Chemoprevention/methods', 'Disease Models, Animal', 'Drug Carriers/*therapeutic use', 'Drug Resistance/genetics', 'Female', 'Humans', 'Malaria/*drug therapy/*prevention & control', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Nanoparticles/therapeutic use', 'Plasmodium berghei/*drug effects', 'Theranostic Nanomedicine']",https://pubmed.ncbi.nlm.nih.gov/29358624/
29,ATOVAQUONE,38583518,Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.,"['Prosty C', 'Katergi K', 'Sorin M', 'Rjeily MB', 'Butler-Laporte G', 'McDonald EG', 'Lee TC']","['Humans', '*Pneumonia, Pneumocystis/prevention & control', '*Randomized Controlled Trials as Topic', '*Network Meta-Analysis', '*Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use/administration & dosage/adverse effects', '*Pneumocystis carinii/drug effects', '*HIV Infections/complications', 'AIDS-Related Opportunistic Infections/prevention & control/drug therapy', 'Dapsone/therapeutic use/adverse effects/administration & dosage', 'Pentamidine/therapeutic use/administration & dosage/adverse effects', 'Atovaquone/therapeutic use/adverse effects', 'Antifungal Agents/therapeutic use/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38583518/
30,ATOVAQUONE,14719625,"Military aviators, special operations forces, and causal malaria prophylaxis.",['Chambers JA'],"['Aminoquinolines/therapeutic use', 'Antimalarials/*therapeutic use', 'Atovaquone', 'Aviation', 'Chloroquine/therapeutic use', 'Doxycycline/therapeutic use', 'Drug Combinations', 'Humans', 'Malaria/*prevention & control', 'Mefloquine/therapeutic use', '*Military Personnel', 'Naphthoquinones/therapeutic use', 'Primaquine/therapeutic use', 'Proguanil/therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/14719625/
31,ATOVAQUONE,38154441,Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer.,"['Zhou TJ', 'Zhang MM', 'Liu DM', 'Huang LL', 'Yu HQ', 'Wang Y', 'Xing L', 'Jiang HL']","['Humans', 'Dihydroorotate Dehydrogenase', '*Triple Negative Breast Neoplasms/drug therapy', '*Ferroptosis', 'Lipid Peroxides', 'Serum Albumin, Bovine', 'Atovaquone', 'Glutathione', 'Cell Line, Tumor', 'Tumor Microenvironment']",https://pubmed.ncbi.nlm.nih.gov/38154441/
32,ATOVAQUONE,11316521,Mode of action and mechanisms of resistance for antimalarial drugs.,['Olliaro P'],"['Animals', 'Antimalarials/*pharmacology/therapeutic use', '*Artemisinins', 'Atovaquone', 'Drug Resistance', 'Drug Therapy, Combination', 'Folic Acid Antagonists/pharmacology/therapeutic use', 'Humans', 'Lactones/pharmacology/therapeutic use', 'Mutation', 'Naphthoquinones/pharmacology/therapeutic use', 'Nucleic Acids/antagonists & inhibitors', 'Plasmodium/drug effects', 'Proguanil/pharmacology/therapeutic use', 'Quinolines/pharmacology/therapeutic use', 'Sesquiterpenes/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11316521/
33,ATOVAQUONE,31964796,Lead Optimization of Dehydroemetine for Repositioned Use in Malaria.,"['Panwar P', 'Burusco KK', 'Abubaker M', 'Matthews H', 'Gutnov A', 'Fernandez-Alvaro E', 'Bryce RA', 'Wilkinson J', 'Nirmalan N']","['Antimalarials/adverse effects/*pharmacology', 'Atovaquone/pharmacology', 'Cell Line, Tumor', '*Drug Repositioning', 'Drug Resistance, Multiple/genetics', 'Drug Synergism', 'Emetine/adverse effects/*analogs & derivatives/chemistry/pharmacology', 'Female', 'Hep G2 Cells', 'Humans', 'Malaria, Falciparum/*drug therapy', 'Male', 'Membrane Potential, Mitochondrial/drug effects', 'Plasmodium falciparum/*drug effects/genetics', 'Proguanil/pharmacology', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/31964796/
34,ATOVAQUONE,27001821,Advanced Molecular Detection of Malarone Resistance.,"['Talundzic E', 'Plucinski MM', 'Biliya S', 'Silva-Flannery LM', 'Arguin PM', 'Halsey ES', 'Barnwell JW', 'Vannberg F', 'Udhayakumar V']","['Adult', 'Antimalarials/therapeutic use', 'Atovaquone/therapeutic use', 'Cytochromes b/*genetics', 'Drug Combinations', 'Drug Resistance/*genetics', 'Gene Expression', 'High-Throughput Nucleotide Sequencing', 'Humans', 'Malaria, Falciparum/drug therapy/parasitology', 'Male', '*Mutation', 'Nigeria', 'Plasmodium falciparum/drug effects/*genetics/isolation & purification', 'Proguanil/therapeutic use', 'Protozoan Proteins/*genetics', 'Travel', 'Treatment Failure', 'United States']",https://pubmed.ncbi.nlm.nih.gov/27001821/
35,ATOVAQUONE,17824955,Drug-resistant malaria - an insight.,['Hyde JE'],"['Animals', 'Antimalarials/*pharmacology', 'Artemisinins/pharmacology', 'Atovaquone/pharmacology', 'Chloroquine/pharmacology', '*Drug Resistance', 'Folic Acid Antagonists/pharmacology', 'Humans', 'Malaria/*drug therapy/*parasitology']",https://pubmed.ncbi.nlm.nih.gov/17824955/
36,ATOVAQUONE,12737754,Atovaquone/proguanil: the need for family protection.,['Kain KC'],"['Adult', 'Africa South of the Sahara', 'Aged', 'Antimalarials/administration & dosage/adverse effects/*therapeutic use', 'Atovaquone', 'Child', 'Drug Combinations', 'Drug Resistance', 'Family', 'Humans', 'Malaria/mortality/*prevention & control', 'Naphthoquinones/administration & dosage/adverse effects/*therapeutic use', 'New Guinea', 'Proguanil/administration & dosage/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Travel', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/12737754/
37,ATOVAQUONE,28833985,Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.,"['McLaughlin MM', 'Galal A', 'Richardson CL', 'Sutton SH', 'Barr VO', 'Patel N', 'Mitchell P', 'Stosor V']","['Adult', 'Anti-Infective Agents/*therapeutic use', 'Antibiotic Prophylaxis/*methods', 'Atovaquone/therapeutic use', '*Drug Substitution', 'Humans', 'Kidney Transplantation/*adverse effects', 'Pneumocystis carinii/drug effects', 'Pneumonia, Pneumocystis/microbiology/*prevention & control', 'Postoperative Complications/microbiology/*prevention & control', 'Retrospective Studies', 'Treatment Outcome', 'Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28833985/
38,ATOVAQUONE,23037693,[Mitochondria as targets of chemotherapy].,['Minagawa N'],"['Alkenes/*pharmacology/therapeutic use', 'Animals', 'Anti-Infective Agents/*pharmacology/therapeutic use', 'Antimalarials/*pharmacology', 'Atovaquone/*pharmacology', 'Humans', 'Mitochondria/*drug effects', 'Phenols/*pharmacology/therapeutic use', 'Sesquiterpenes/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/23037693/
39,ATOVAQUONE,30234826,Variable clinical presentations of babesiosis.,"['Paparone P', 'Paparone PW']","['Animals', 'Anti-Infective Agents/*therapeutic use', 'Atovaquone/therapeutic use', 'Azithromycin/therapeutic use', 'Babesiosis/*diagnosis/*drug therapy/epidemiology', 'Clindamycin/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Quinine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30234826/
40,AURANOFIN,32732975,Auranofin mitigates systemic iron overload and induces ferroptosis via distinct mechanisms.,"['Yang L', 'Wang H', 'Yang X', 'Wu Q', 'An P', 'Jin X', 'Liu W', 'Huang X', 'Li Y', 'Yan S', 'Shen S', 'Liang T', 'Min J', 'Wang F']","['Animals', 'Auranofin/*pharmacology', 'Cell Line, Tumor', 'Female', 'Ferroptosis/*drug effects/genetics', 'HEK293 Cells', '*Hemochromatosis/drug therapy/genetics/metabolism/pathology', 'Humans', '*Iron Overload/drug therapy/genetics/metabolism/pathology', 'Male', 'Mice', 'Mice, Knockout', 'Signal Transduction/*drug effects/genetics']",https://pubmed.ncbi.nlm.nih.gov/32732975/
41,AURANOFIN,39059206,TrxR1 is involved in the activation of Caspase-11 by regulating the oxidative-reductive status of Trx-1.,"['Bai D', 'Zhou C', 'Du J', 'Zhao J', 'Gu C', 'Wang Y', 'Zhang L', 'Lu N', 'Zhao Y']","['*Thioredoxins/metabolism/genetics', 'Animals', 'Mice', '*Oxidation-Reduction/drug effects', '*Pyroptosis/drug effects', '*Auranofin/pharmacology', '*Sepsis/metabolism', 'Humans', 'Caspases, Initiator/metabolism', 'Thioredoxin Reductase 1/metabolism/genetics', 'Disease Models, Animal', 'Male', 'Macrophages/metabolism/drug effects']",https://pubmed.ncbi.nlm.nih.gov/39059206/
42,AURANOFIN,35730208,Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- kappaB signaling pathways.,"['Lee SM', 'Koh DH', 'Jun DW', 'Roh YJ', 'Kang HT', 'Oh JH', 'Kim HS']","['Mice', 'Humans', 'Animals', '*Non-alcoholic Fatty Liver Disease/complications/drug therapy/metabolism', 'NF-kappa B/metabolism/pharmacology', 'NF-E2-Related Factor 2/genetics/metabolism/pharmacology', 'Transforming Growth Factor beta1/genetics/metabolism/pharmacology', 'Auranofin/pharmacology/therapeutic use/metabolism', 'NF-KappaB Inhibitor alpha/metabolism', 'Thrombospondin 1/metabolism/pharmacology', 'Fibronectins/metabolism/pharmacology', 'Palmitic Acid/toxicity/metabolism', 'Reactive Oxygen Species/metabolism', 'Endothelin-1/metabolism/pharmacology', 'Antioxidants/pharmacology/therapeutic use/metabolism', 'Mice, Inbred C57BL', 'Signal Transduction', 'Liver Cirrhosis/pathology', 'Transforming Growth Factors/metabolism/pharmacology', 'Collagen/metabolism/pharmacology', 'Liver/pathology']",https://pubmed.ncbi.nlm.nih.gov/35730208/
43,AURANOFIN,24350852,Metal-N-heterocyclic carbene complexes as anti-tumor agents.,"['Hu C', 'Li X', 'Wang W', 'Zhang R', 'Deng L']","['Antineoplastic Agents/*chemical synthesis/pharmacology', 'Auranofin/chemistry/pharmacology', 'Cell Line, Tumor', 'Cisplatin/chemistry/pharmacology', 'Coordination Complexes/*chemical synthesis/pharmacology', 'Copper/chemistry', 'Gold/chemistry', 'Heterocyclic Compounds/*chemical synthesis/pharmacology', 'Humans', 'Methane/*analogs & derivatives/chemistry', 'Neoplasms/drug therapy', 'Palladium/chemistry', 'Platinum/chemistry', 'Silver/chemistry', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/24350852/
44,AURANOFIN,6785437,Other penicillamine-like drugs.,['Huskisson EC'],"['*Anti-Inflammatory Agents/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Auranofin', 'Aurothioglucose/administration & dosage/analogs & derivatives/therapeutic use', 'Dapsone/therapeutic use', 'Humans', 'Levamisole/administration & dosage/therapeutic use', 'Penicillamine/*pharmacology', 'Phosphines/administration & dosage/therapeutic use', 'Sulfhydryl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6785437/
45,AURANOFIN,35358852,Redox proteome analysis of auranofin exposed ovarian cancer cells (A2780).,"['Chiappetta G', 'Gamberi T', 'Faienza F', 'Limaj X', 'Rizza S', 'Messori L', 'Filomeni G', 'Modesti A', 'Vinh J']","['*Auranofin/pharmacology', 'Cell Line, Tumor', 'Female', 'Humans', '*Ovarian Neoplasms/drug therapy/genetics', 'Oxidation-Reduction', 'Proteome/metabolism', 'Thioredoxin-Disulfide Reductase/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35358852/
46,AURANOFIN,39218122,On the binding of auranofin to Prdx6 and its potential role in cancer cell sensitivity to treatment.,"['Inague A', 'Nakahata DH', 'Viviani LG', 'Alegria TGP', 'Lima RS', 'Iijima TS', 'Netto LES', 'Angeli JPF', 'Miyamoto S', 'de Paiva REF']","['*Auranofin/pharmacology', 'Humans', '*Peroxiredoxin VI/metabolism/genetics', 'Cell Line, Tumor', 'Ferroptosis/drug effects', 'Protein Binding', 'Antineoplastic Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/39218122/
47,AURANOFIN,39284817,Adaptation mechanisms of Clostridioides difficile to auranofin and its impact on human gut microbiota.,"['Anjou C', 'Royer M', 'Bertrand E', 'Bredon M', 'Le Bris J', 'Salgueiro IA', 'Caulat LC', 'Dupuy B', 'Barbut F', 'Morvan C', 'Rolhion N', 'Martin-Verstraete I']","['Humans', '*Auranofin/pharmacology', '*Clostridioides difficile/drug effects/genetics', '*Gastrointestinal Microbiome/drug effects', '*Anti-Bacterial Agents/pharmacology', '*Microbial Sensitivity Tests', 'Thioredoxin-Disulfide Reductase/metabolism/genetics', 'Mutation', 'Drug Resistance, Bacterial', 'Adaptation, Physiological', 'Sigma Factor/genetics/metabolism', 'Bacterial Proteins/genetics/metabolism', 'Vancomycin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/39284817/
48,AURANOFIN,35053228,Breast Cancer Treatment: The Case of Gold(I)-Based Compounds as a Promising Class of Bioactive Molecules.,"['Galassi R', 'Luciani L', 'Wang J', 'Vincenzetti S', 'Cui L', 'Amici A', 'Pucciarelli S', 'Marchini C']","['*Antineoplastic Agents/chemistry/therapeutic use', '*Auranofin/chemistry/therapeutic use', '*Breast Neoplasms/drug therapy/metabolism', 'Female', '*Gold/chemistry/therapeutic use', 'Humans', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/35053228/
49,AURANOFIN,28358030,Allosteric cross-talk in chromatin can mediate drug-drug synergy.,"['Adhireksan Z', 'Palermo G', 'Riedel T', 'Ma Z', 'Muhammad R', 'Rothlisberger U', 'Dyson PJ', 'Davey CA']","['Allosteric Regulation/drug effects', 'Auranofin/chemistry/pharmacology', 'Cell Death/drug effects', 'Cell Line, Tumor', 'Chromatin/*metabolism', 'Crystallography, X-Ray', '*Drug Synergism', 'Histones/chemistry/metabolism', 'Humans', 'Models, Molecular', 'Nucleic Acid Conformation', 'Nucleosomes/metabolism', 'Organometallic Compounds/chemistry/pharmacology', 'Protein Structure, Secondary']",https://pubmed.ncbi.nlm.nih.gov/28358030/
50,AURANOFIN,39087522,Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C.,"['Hei Z', 'Yang S', 'Ouyang G', 'Hanna J', 'Lepoivre M', 'Huynh T', 'Aguinaga L', 'Cassinat B', 'Maslah N', 'Bourge M', 'Golinelli-Cohen MP', 'Guittet O', 'Vallieres C', 'Vernis L', 'Fenaux P', 'Huang ME']","['*Auranofin/pharmacology', 'Humans', '*Leukemia, Myeloid, Acute/drug therapy/pathology/metabolism', '*Ascorbic Acid/pharmacology', '*Oxidation-Reduction/drug effects', '*Drug Synergism', 'Reactive Oxygen Species/metabolism', 'Female', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use', 'Cell Line, Tumor', 'Male', 'Middle Aged', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/39087522/
51,AURANOFIN,1472122,Auranofin-induced vasomotor reaction.,"['Proudman SM', 'Cleland LG']","['Administration, Oral', 'Adult', 'Arthritis, Rheumatoid/drug therapy/physiopathology', 'Auranofin/adverse effects/*pharmacology/therapeutic use', 'Female', 'Gold Sodium Thiomalate/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Vasomotor System/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/1472122/
52,AURANOFIN,26184149,Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents.,"['Gandin V', 'Fernandes AP']","['Animals', 'Antineoplastic Agents/chemical synthesis/*pharmacology', 'Auranofin/chemical synthesis/pharmacology', 'Aurothioglucose/chemical synthesis/pharmacology', 'Enzyme Inhibitors/chemical synthesis/*pharmacology', 'Humans', 'Isoenzymes/antagonists & inhibitors/chemistry', 'Models, Molecular', 'Neoplasm Proteins/*antagonists & inhibitors/chemistry', 'Neoplasms/drug therapy/enzymology/pathology', 'Organoplatinum Compounds/chemical synthesis/pharmacology', 'Oxidative Stress', 'Phosphines/chemical synthesis/pharmacology', 'Ruthenium Compounds/chemical synthesis/pharmacology', 'Thioredoxin-Disulfide Reductase/*antagonists & inhibitors/chemistry']",https://pubmed.ncbi.nlm.nih.gov/26184149/
53,AURANOFIN,1351972,Anti-inflammatory drugs in the treatment of allergic disease.,['Szefler SJ'],"['Adrenergic beta-Agonists/therapeutic use', '*Anti-Inflammatory Agents/administration & dosage/classification/therapeutic use', 'Asthma/classification/*drug therapy/psychology', 'Auranofin/administration & dosage/therapeutic use', 'Bronchodilator Agents/administration & dosage/therapeutic use', 'Cromolyn Sodium/therapeutic use', 'Drug Therapy, Combination', 'Glucocorticoids/administration & dosage/chemistry/therapeutic use', 'Humans', 'Hydroxychloroquine/pharmacology/therapeutic use', 'Immunoglobulins, Intravenous/therapeutic use', 'Methotrexate/administration & dosage/adverse effects/therapeutic use', 'Quality of Life', 'Severity of Illness Index', 'Steroids', 'Theophylline/therapeutic use', 'Troleandomycin/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1351972/
54,AURANOFIN,30520183,Antiparasitic Activity of Auranofin against Pathogenic Naegleria fowleri.,"['Peroutka-Bigus N', 'Bellaire BH']","['Amebiasis/drug therapy/parasitology', 'Amebicides/*pharmacology', 'Auranofin/*pharmacology', 'Central Nervous System Protozoal Infections/drug therapy/parasitology', 'Naegleria fowleri/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30520183/
55,AURANOFIN,34731781,"Auranofin: Past to Present, and repurposing.",['Yamashita M'],"['Animals', 'Antirheumatic Agents/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Auranofin/*therapeutic use', 'Communicable Diseases/drug therapy', 'Drug Repositioning', 'Humans', 'Neoplasms/drug therapy', 'SARS-CoV-2', 'Tuberculosis/drug therapy', 'COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/34731781/
56,AURANOFIN,34381018,Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation.,"['Meier S', 'Cantilena S', 'Niklison Chirou MV', 'Anderson J', 'Hargrave D', 'Salomoni P', 'de Boer J', 'Michod D']","['Alcoholism/*drug therapy', 'Auranofin/pharmacology/therapeutic use', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Child', 'Disulfiram/pharmacology/*therapeutic use', 'Down-Regulation/drug effects/genetics', 'Drug Repositioning', 'Drug Synergism', 'Gene Expression Regulation, Neoplastic/drug effects', 'Glioma/*drug therapy/genetics/*metabolism/pathology', 'Histone-Lysine N-Methyltransferase/*metabolism', 'Histones/metabolism', 'Humans', 'Lysine/metabolism', 'Methylation/drug effects', 'Myeloid-Lymphoid Leukemia Protein/*metabolism', 'Neoplasm Grading', 'Protein Processing, Post-Translational/drug effects', '*Proteolysis/drug effects', 'Transcription, Genetic/drug effects']",https://pubmed.ncbi.nlm.nih.gov/34381018/
57,AURANOFIN,37931662,Discovery of novel organoarsenicals as robust thioredoxin reductase inhibitors for oxidative stress mediated cancer therapy.,"['She W', 'Shi X', 'Liu T', 'Liu Y', 'Liu Y']","['Humans', '*Thioredoxin-Disulfide Reductase', 'Oxidative Stress', 'Reactive Oxygen Species', 'Antioxidants/pharmacology', 'Auranofin/pharmacology', '*Neoplasms/drug therapy', 'Enzyme Inhibitors/pharmacology', 'Apoptosis']",https://pubmed.ncbi.nlm.nih.gov/37931662/
58,AURANOFIN,18521545,Anti-cancer potential of gold complexes.,['Tiekink ER'],"['Animals', 'Antineoplastic Agents/*pharmacology', 'Auranofin/analogs & derivatives', 'Humans', 'Organogold Compounds/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18521545/
59,AURANOFIN,26431378,Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer.,"['Zou P', 'Chen M', 'Ji J', 'Chen W', 'Chen X', 'Ying S', 'Zhang J', 'Zhang Z', 'Liu Z', 'Yang S', 'Liang G']","['Animals', 'Antineoplastic Combined Chemotherapy Protocols/*pharmacology', 'Antirheumatic Agents/pharmacology', 'Apoptosis/*drug effects', 'Auranofin/administration & dosage/*pharmacology', 'Dioxolanes/administration & dosage/*pharmacology', 'Drug Synergism', 'Endoplasmic Reticulum Stress/*drug effects/physiology', 'Female', 'Humans', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Mitochondria/drug effects/metabolism', 'Reactive Oxygen Species/*metabolism', 'Stomach Neoplasms/*drug therapy/metabolism/pathology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/26431378/
60,Acamprosate,37934220,Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.,"['McPheeters M', ""O'Connor EA"", 'Riley S', 'Kennedy SM', 'Voisin C', 'Kuznacic K', 'Coffey CP', 'Edlund MD', 'Bobashev G', 'Jonas DE']","['Humans', '*Acamprosate/adverse effects/therapeutic use', 'Alcohol Drinking', '*Alcoholism/drug therapy/epidemiology/psychology/therapy', 'Drug-Related Side Effects and Adverse Reactions/epidemiology/etiology', '*Naltrexone/adverse effects/therapeutic use', 'Prospective Studies', 'Quality of Life', 'United States/epidemiology', '*Alcohol Deterrents/adverse effects/therapeutic use', 'Psychosocial Intervention']",https://pubmed.ncbi.nlm.nih.gov/37934220/
61,Acamprosate,30167705,Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.,"['Kranzler HR', 'Soyka M']","['Acamprosate', 'Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*diagnosis/*drug therapy', 'Counseling', 'Disulfiram/therapeutic use', 'Humans', 'Naltrexone/therapeutic use', 'Taurine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30167705/
62,Acamprosate,37525595,Overview of Alcohol Use Disorder.,['Kranzler HR'],"['Humans', 'United States/epidemiology', 'Child', '*Alcoholism/drug therapy', '*Alcohol Deterrents/therapeutic use', 'Acamprosate/therapeutic use', 'Disulfiram/therapeutic use', 'Naltrexone/therapeutic use', 'Ethanol']",https://pubmed.ncbi.nlm.nih.gov/37525595/
63,Acamprosate,35133639,Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.,"['Burnette EM', 'Nieto SJ', 'Grodin EN', 'Meredith LR', 'Hurley B', 'Miotto K', 'Gillis AJ', 'Ray LA']","['Acamprosate', '*Alcohol Deterrents/pharmacology/therapeutic use', '*Alcoholism/drug therapy', 'Baclofen/therapeutic use', 'Disulfiram/pharmacology/therapeutic use', 'Humans', 'Naltrexone/therapeutic use', 'Topiramate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35133639/
64,Acamprosate,16670409,Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.,"['Anton RF', ""O'Malley SS"", 'Ciraulo DA', 'Cisler RA', 'Couper D', 'Donovan DM', 'Gastfriend DR', 'Hosking JD', 'Johnson BA', 'LoCastro JS', 'Longabaugh R', 'Mason BJ', 'Mattson ME', 'Miller WR', 'Pettinati HM', 'Randall CL', 'Swift R', 'Weiss RD', 'Williams LD', 'Zweben A']","['Acamprosate', 'Adult', 'Alcohol Deterrents/*therapeutic use', 'Alcoholism/*therapy', '*Behavior Therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Naltrexone/*therapeutic use', 'Narcotic Antagonists/*therapeutic use', 'Placebo Effect', 'Taurine/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16670409/
65,Acamprosate,38357896,Pharmacological management of gambling disorder: an update of the literature.,"['Mestre-Bach G', 'Potenza MN']","['Humans', '*Gambling/drug therapy', 'Naltrexone/therapeutic use', '*Behavior, Addictive/drug therapy/psychology', 'Narcotic Antagonists/therapeutic use', 'Selective Serotonin Reuptake Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/38357896/
66,Acamprosate,36637087,Baclofen for alcohol use disorder.,"['Agabio R', 'Saulle R', 'Rosner S', 'Minozzi S']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', 'Acamprosate/adverse effects/therapeutic use', 'Alcohol Drinking/drug therapy', '*Alcoholism/drug therapy', '*Baclofen/adverse effects/therapeutic use', 'Chronic Disease', 'Naltrexone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36637087/
67,Acamprosate,32446635,Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls.,"['Fairbanks J', 'Umbreit A', 'Kolla BP', 'Karpyak VM', 'Schneekloth TD', 'Loukianova LL', 'Sinha S']","['Acamprosate/administration & dosage/adverse effects', 'Alcohol Deterrents/administration & dosage/adverse effects', 'Alcoholism/*drug therapy/psychology', 'Anticonvulsants/administration & dosage/adverse effects', 'Disulfiram/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Humans', 'Mass Screening/methods', 'Naltrexone/administration & dosage/adverse effects', 'Off-Label Use', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/32446635/
68,Acamprosate,37194540,[Pharmacological Treatment for Alcohol Dependence].,['Matsushita S'],"['Humans', '*Alcoholism/complications/drug therapy', 'Narcotic Antagonists/therapeutic use', '*Substance Withdrawal Syndrome/drug therapy', 'Acamprosate/therapeutic use', 'Ethanol/therapeutic use', 'Alcohol Drinking']",https://pubmed.ncbi.nlm.nih.gov/37194540/
69,Acamprosate,39362720,Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies.,"['Tareen K', 'Clifton EG', 'Perumalswami P', 'Mellinger JL', 'Winder GS']","['Humans', '*Alcohol Deterrents/therapeutic use', '*Alcoholism/therapy/complications', 'Liver Diseases, Alcoholic/therapy', 'Behavior Therapy', 'Psychotherapy/methods', 'Disulfiram/therapeutic use', 'Acamprosate/therapeutic use', 'Naltrexone/therapeutic use', 'Cognitive Behavioral Therapy', 'Alcohol-Related Disorders/therapy']",https://pubmed.ncbi.nlm.nih.gov/39362720/
70,Acamprosate,25747924,Alcohol use disorders in pregnancy.,"['DeVido J', 'Bogunovic O', 'Weiss RD']","['Acamprosate', 'Alcohol Drinking', 'Alcoholism/*epidemiology/*therapy', 'Cognitive Behavioral Therapy', 'Disulfiram/therapeutic use', 'Female', 'Humans', 'Naltrexone/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*epidemiology', 'Substance Withdrawal Syndrome/therapy', 'Taurine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25747924/
71,Acamprosate,32696076,[Pharmacotherapy of alcohol withdrawal: update and new developments].,"['Soyka M', 'Rosner S']","['Acamprosate/therapeutic use', '*Alcohol Deterrents/therapeutic use', '*Alcoholism/diagnosis/drug therapy', 'Germany', 'Humans', 'Naltrexone/therapeutic use', 'Narcotic Antagonists', 'Taurine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32696076/
72,Acamprosate,39523052,Introduction: Approved treatments for alcohol use disorder by regulatory agencies.,"['Camarini R', 'Cruz FC']","['Humans', '*Alcoholism/drug therapy', '*Alcohol Deterrents/therapeutic use', 'Disulfiram/therapeutic use', 'Drug Approval', 'Naltrexone/therapeutic use/analogs & derivatives', 'Acamprosate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39523052/
73,Acamprosate,28064151,"Supervised Disulfiram's Superior Effectiveness in Alcoholism Treatment: Ethical, Methodological, and Psychological Aspects.","['Brewer C', 'Streel E', 'Skinner M']","['Acamprosate', 'Alcohol Deterrents/therapeutic use', 'Alcoholism/*drug therapy/*psychology', '*Bioethical Issues', 'Disulfiram/*therapeutic use', 'Humans', 'Naltrexone/therapeutic use', 'Taurine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28064151/
74,Acamprosate,24825644,Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.,"['Jonas DE', 'Amick HR', 'Feltner C', 'Bobashev G', 'Thomas K', 'Wines R', 'Kim MM', 'Shanahan E', 'Gass CE', 'Rowe CJ', 'Garbutt JC']","['Acamprosate', 'Alcohol-Related Disorders/*drug therapy', 'Fructose/adverse effects/analogs & derivatives/therapeutic use', 'Harm Reduction', 'Humans', 'Naltrexone/adverse effects/analogs & derivatives/therapeutic use', 'Outpatients', 'Randomized Controlled Trials as Topic', 'Taurine/adverse effects/analogs & derivatives/therapeutic use', 'Topiramate']",https://pubmed.ncbi.nlm.nih.gov/24825644/
75,Acamprosate,35653782,Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.,"['Bahji A', 'Bach P', 'Danilewitz M', 'Crockford D', 'Devoe DJ', 'El-Guebaly N', 'Saitz R']","['Adult', 'Humans', 'Acamprosate/adverse effects', '*Alcoholism/drug therapy', 'Baclofen/adverse effects', 'Disulfiram/adverse effects', 'Naltrexone/adverse effects', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35653782/
76,Acamprosate,31628604,Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies.,"['Leggio L', 'Falk DE', 'Ryan ML', 'Fertig J', 'Litten RZ']","['Acamprosate', 'Alcohol Deterrents/*therapeutic use', 'Alcoholism/*drug therapy', 'Disulfiram', 'Drug Development', 'Humans', 'Naltrexone']",https://pubmed.ncbi.nlm.nih.gov/31628604/
77,Acamprosate,23889161,Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.,"['Litten RZ', 'Falk D', 'Ryan M', 'Fertig J']","['Acamprosate', 'Alcohol Deterrents/therapeutic use', 'Alcoholism/diagnosis/*drug therapy', 'Biomedical Research/*trends', 'Drug Industry/*trends', 'Health Services Needs and Demand/*trends', 'Humans', 'Insurance, Health, Reimbursement/*trends', 'Naltrexone/therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Taurine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23889161/
78,Acamprosate,35597734,Perspectives on the pharmacological management of alcohol use disorder: Are the approved medications effective?,"['Antonelli M', 'Sestito L', 'Tarli C', 'Addolorato G']","['Acamprosate', '*Alcohol Deterrents', 'Alcohol Drinking', '*Alcoholism', 'Disulfiram', 'Humans', 'Naltrexone']",https://pubmed.ncbi.nlm.nih.gov/35597734/
79,Acamprosate,7580816,Acamprosate in alcohol dependence: how does it work?,['Littleton J'],"['Acamprosate', 'Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/psychology/*rehabilitation', 'Behavior Therapy', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Humans', '*Motivation', 'Recurrence', 'Taurine/adverse effects/*analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/7580816/
80,Amethopterin,30243154,Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review.,"['Wang W', 'Zhou H', 'Liu L']","['Animals', 'Antirheumatic Agents/*adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Methotrexate/*adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/30243154/
81,Amethopterin,39433528,Methotrexate-Induced Epidermal Necrosis.,"['Loesch AJ', 'Jin A', 'Huang S', 'Motaparthi K', 'Lee JB', 'Hsu S']","['Humans', '*Methotrexate/adverse effects/therapeutic use/administration & dosage', 'Female', 'Aged', '*Necrosis/chemically induced', '*Psoriasis/drug therapy/chemically induced/pathology', 'Dermatologic Agents/adverse effects/therapeutic use', 'Epidermis/pathology', 'Drug Eruptions/etiology/pathology/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/39433528/
82,Amethopterin,7011005,Intrathecal methotrexate-induced neurotoxicities.,"['Nelson RW', 'Frank JT']","['Humans', 'Injections', 'Injections, Spinal', 'Lumbosacral Region', 'Methotrexate/administration & dosage/*adverse effects/cerebrospinal fluid', 'Nervous System Diseases/*chemically induced/prevention & control', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/7011005/
83,Amethopterin,29975207,Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review.,"['Liu L', 'Liu S', 'Wang C', 'Guan W', 'Zhang Y', 'Hu W', 'Zhang L', 'He Y', 'Lu J', 'Li T', 'Liu X', 'Xuan Y', 'Wang P']","['Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Folic Acid/*therapeutic use', 'Humans', 'Leucovorin/*therapeutic use', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29975207/
84,Amethopterin,32066146,Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.,"['Solomon DH', 'Glynn RJ', 'Karlson EW', 'Lu F', 'Corrigan C', 'Colls J', 'Xu C', 'MacFadyen J', 'Barbhaiya M', 'Berliner N', 'Dellaripa PF', 'Everett BM', 'Pradhan AD', 'Hammond SP', 'Murray M', 'Rao DA', 'Ritter SY', 'Rutherford A', 'Sparks JA', 'Stratton J', 'Suh DH', 'Tedeschi SK', 'Vanni KMM', 'Paynter NP', 'Ridker PM']","['Aged', 'Antirheumatic Agents/*administration & dosage/*adverse effects', 'Cardiovascular Diseases/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Methotrexate/*administration & dosage/*adverse effects', 'Middle Aged', 'Placebos', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32066146/
85,Amethopterin,3913771,Drug interactions with methotrexate.,"['Evans WE', 'Christensen ML']","['Absorption', 'Anti-Bacterial Agents/pharmacology', 'Arthritis, Rheumatoid/drug therapy', 'Aspirin/pharmacology', 'Biological Transport/drug effects', 'Cell Membrane/metabolism', 'Cisplatin/pharmacology', 'Dose-Response Relationship, Drug', '*Drug Interactions', 'Folic Acid/pharmacology', 'Humans', 'Kidney Tubules/drug effects/metabolism', 'Methotrexate/administration & dosage/adverse effects/*metabolism/therapeutic use', 'Probenecid/pharmacology', 'Protein Binding/drug effects', 'Salicylates/pharmacology', 'Serum Albumin/metabolism', 'Sulfamethoxazole/pharmacology', 'Sulfonamides/pharmacology', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/3913771/
86,Amethopterin,27993660,Much more than you expected: The non-DHFR-mediated effects of methotrexate.,"['Sramek M', 'Neradil J', 'Veselska R']","['Animals', 'Folic Acid/*metabolism', 'Folic Acid Antagonists/pharmacology/therapeutic use', 'Humans', 'Methotrexate/*pharmacology/*therapeutic use', 'Signal Transduction/*drug effects', 'Tetrahydrofolate Dehydrogenase/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/27993660/
87,Amethopterin,39392455,Methotrexate polyglutamates.,"['Yang Z', 'Mo J', 'Li W', 'Zhao Z', 'Mei S']","['*Methotrexate/analogs & derivatives/adverse effects/administration & dosage/pharmacology/pharmacokinetics', 'Humans', '*Polyglutamic Acid/analogs & derivatives/pharmacology', 'Animals', 'Antirheumatic Agents/adverse effects/administration & dosage/pharmacology/pharmacokinetics', 'Precision Medicine']",https://pubmed.ncbi.nlm.nih.gov/39392455/
88,Amethopterin,31276602,Optimising low-dose methotrexate for rheumatoid arthritis-A review.,"['Lucas CJ', 'Dimmitt SB', 'Martin JH']","['Administration, Oral', 'Antirheumatic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Arthritis, Rheumatoid/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Methotrexate/*administration & dosage/adverse effects/pharmacokinetics', 'Polyglutamic Acid/metabolism', ""Practice Patterns, Physicians'""]",https://pubmed.ncbi.nlm.nih.gov/31276602/
89,Amethopterin,1918470,The pharmacology of methotrexate.,['Olsen EA'],"['Bone Marrow/drug effects', 'Central Nervous System/drug effects', 'Digestive System/drug effects', 'Drug Therapy, Combination', 'Humans', 'Kidney/drug effects', 'Leucovorin/administration & dosage/metabolism/pharmacology', 'Lung/drug effects', 'Methotrexate/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Skin/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1918470/
90,Amethopterin,21044430,Methotrexate bioavailability.,"['van Roon EN', 'van de Laar MA']","['Antirheumatic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Biological Availability', 'Drug Administration Routes', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Drug Interactions', 'Humans', 'Intestinal Absorption', 'Methotrexate/administration & dosage/adverse effects/analogs & derivatives/*pharmacokinetics', 'Polyglutamic Acid/analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21044430/
91,Amethopterin,26349496,Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate.,"['Flores SE', 'Rial-Hermida MI', 'Ramirez JC', 'Pazos A', 'Concheiro A', 'Alvarez-Lorenzo C', 'Peralta RD']","['Animals', 'Antimetabolites, Antineoplastic/*administration & dosage/chemistry/pharmacology/therapeutic use', 'Chemistry, Pharmaceutical/methods', 'Colon/drug effects/pathology', 'Colorectal Neoplasms/*drug therapy/pathology', 'Drug Delivery Systems/methods', 'Emulsions/adverse effects/*chemistry', 'Humans', 'Methotrexate/*administration & dosage/chemistry/pharmacology/therapeutic use', 'Oils, Volatile/adverse effects/*chemistry', 'Pharmaceutical Vehicles/adverse effects/*chemistry', 'Surface-Active Agents/adverse effects/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/26349496/
92,Amethopterin,9544409,Methotrexate therapy.,['Schep GN'],"['Antimetabolites, Antineoplastic/*therapeutic use', 'Antirheumatic Agents/*therapeutic use', 'Dermatologic Agents/*therapeutic use', 'Folic Acid Antagonists/*therapeutic use', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9544409/
93,Amethopterin,39356310,"A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment.","['Bielack SS', 'Soussain C', 'Fox CP', 'Houillier C', 'Murciano T', 'Osborne W', 'Zinzani PL', 'Rizzari C', 'Schwartz S']","['Humans', '*Methotrexate/therapeutic use/administration & dosage/adverse effects', '*gamma-Glutamyl Hydrolase/therapeutic use', '*Leucovorin/administration & dosage/therapeutic use', 'Antimetabolites, Antineoplastic/adverse effects/therapeutic use/administration & dosage', 'Consensus', 'Europe', 'Neoplasms/drug therapy', 'Recombinant Proteins/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39356310/
94,Amethopterin,25340735,Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.,"['Lima A', 'Sousa H', 'Monteiro J', 'Azevedo R', 'Medeiros R', 'Seabra V']","['ATP-Binding Cassette Transporters/*genetics', 'Dose-Response Relationship, Drug', 'Drug-Related Side Effects and Adverse Reactions/genetics', 'Humans', 'Membrane Transport Proteins/*genetics', 'Methotrexate/*administration & dosage/adverse effects/pharmacokinetics', '*Pharmacogenetics', 'Polymorphism, Single Nucleotide']",https://pubmed.ncbi.nlm.nih.gov/25340735/
95,Amethopterin,2679014,Methotrexate in the treatment of rheumatoid arthritis.,"['Korn S', 'Dehoratius RJ']","['Arthritis, Rheumatoid/*drug therapy', 'Humans', 'Methotrexate/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2679014/
96,Amethopterin,39791321,Low-dose methotrexate in Rheumatology: A reinvented drug.,"['Gupta K', 'Ravindran V']","['*Methotrexate/adverse effects/administration & dosage/therapeutic use', 'Humans', '*Antirheumatic Agents/adverse effects/administration & dosage/therapeutic use', 'Rheumatic Diseases/drug therapy', 'Skin Neoplasms/drug therapy', 'Dose-Response Relationship, Drug']",https://pubmed.ncbi.nlm.nih.gov/39791321/
97,Amethopterin,12222556,Methotrexate-induced toxic leukoencephalopathy.,"['Gowan GM', 'Herrington JD', 'Simonetta AB']","['Aged', 'Antimetabolites, Antineoplastic/administration & dosage/*adverse effects/therapeutic use', 'Dementia, Vascular/*chemically induced', 'Fatal Outcome', 'Female', 'Humans', 'Injections, Intraventricular', 'Leukemia, Lymphocytic, Chronic, B-Cell/complications/drug therapy/radiotherapy', 'Magnetic Resonance Imaging', 'Methotrexate/administration & dosage/*adverse effects/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/12222556/
98,Amethopterin,9608316,Disease-modifying antirheumatic drugs.,"['Li E', 'Brooks P', 'Conaghan PG']","['Antimalarials/adverse effects/therapeutic use', 'Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Liver/drug effects', 'Lung/drug effects', 'Methotrexate/adverse effects/therapeutic use', 'Organogold Compounds', 'Penicillamine/adverse effects/therapeutic use', 'Sulfasalazine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9608316/
99,Amethopterin,17377896,Medical therapy for ectopic pregnancy.,['Lipscomb GH'],"['Abortifacient Agents, Nonsteroidal/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use', 'Pregnancy', 'Pregnancy, Ectopic/*drug therapy/surgery']",https://pubmed.ncbi.nlm.nih.gov/17377896/
100,Aripiprazole,36867173,Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.,"['Lenze EJ', 'Mulsant BH', 'Roose SP', 'Lavretsky H', 'Reynolds CF 3rd', 'Blumberger DM', 'Brown PJ', 'Cristancho P', 'Flint AJ', 'Gebara MA', 'Gettinger TR', 'Lenard E', 'Miller JP', 'Nicol GE', 'Oughli HA', 'Pham VT', 'Rollman BL', 'Yang L', 'Karp JF']","['Aged', 'Humans', '*Antidepressive Agents/adverse effects/therapeutic use', '*Aripiprazole/adverse effects/therapeutic use', '*Bupropion/adverse effects/therapeutic use', 'Depression', 'Drug Therapy, Combination', '*Nortriptyline/adverse effects/therapeutic use', '*Treatment Switching', '*Lithium Compounds/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36867173/
101,Aripiprazole,38226593,Cannabinoid treatment for the symptoms of autism spectrum disorder.,"['Aran A', 'Cayam Rand D']","['Child', 'Humans', 'Aripiprazole/adverse effects', '*Autism Spectrum Disorder/drug therapy', 'Cannabidiol/therapeutic use', '*Cannabinoids/therapeutic use', 'Irritable Mood', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/38226593/
102,Aripiprazole,33064050,A safety evaluation of aripiprazole in the treatment of schizophrenia.,"['Preda A', 'Shapiro BB']","['Adult', 'Antipsychotic Agents/*administration & dosage/adverse effects/pharmacology', 'Aripiprazole/*administration & dosage/pharmacology', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Humans', 'Medication Adherence', 'Prolactin/blood', 'Schizophrenia/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/33064050/
103,Aripiprazole,37566261,Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.,"['Valdivieso-Jimenez G', 'Pino-Zavaleta DA', 'Campos-Rodriguez SK', 'Ortiz-Saavedra B', 'Fernandez MF', 'Benites-Zapata VA']","['Adult', 'Female', 'Humans', 'Male', 'Aripiprazole/adverse effects', '*Borderline Personality Disorder/drug therapy', '*Antipsychotic Agents/adverse effects', 'Olanzapine/therapeutic use', 'Anxiety Disorders']",https://pubmed.ncbi.nlm.nih.gov/37566261/
104,Aripiprazole,35904579,Cannabidiol for the treatment of autism spectrum disorder: hope or hype?,"['Pedrazzi JFC', 'Ferreira FR', 'Silva-Amaral D', 'Lima DA', 'Hallak JEC', 'Zuardi AW', 'Del-Bel EA', 'Guimaraes FS', 'Costa KCM', 'Campos AC', 'Crippa ACS', 'Crippa JAS']","['Aripiprazole/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Autism Spectrum Disorder/drug therapy', '*Cannabidiol/pharmacology/therapeutic use', 'Child, Preschool', 'Endocannabinoids', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/35904579/
105,Aripiprazole,26589880,Aripiprazole.,['Prommer E'],"['Alzheimer Disease/drug therapy', 'Antipsychotic Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Aripiprazole/pharmacokinetics/pharmacology/*therapeutic use', 'Delirium/*drug therapy', 'Humans', 'Psychotic Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26589880/
106,Aripiprazole,29788886,Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.,"['Pakri Mohamed RM', 'Kumar J', 'Ahmad SU', 'Mohamed IN']","['Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*drug therapy', 'Animals', 'Aripiprazole/adverse effects/therapeutic use', 'Baclofen/adverse effects/therapeutic use', 'Cyclopentanes/adverse effects/therapeutic use', 'Gabapentin/adverse effects/therapeutic use', 'Humans', 'Naltrexone/adverse effects/analogs & derivatives/therapeutic use', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29788886/
107,Aripiprazole,38465894,Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review.,"['Belge JB', 'Sabbe BGCC']","['Humans', '*Bipolar Disorder/drug therapy', '*Antipsychotic Agents/administration & dosage/therapeutic use', '*Delayed-Action Preparations', '*Medication Adherence', '*Injections', 'Randomized Controlled Trials as Topic', 'Hospitalization', 'Adult', 'Aripiprazole/therapeutic use/administration & dosage', 'Risperidone/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38465894/
108,Aripiprazole,32930009,Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale.,"['Azorin JM', 'Simon N']","['Antipsychotic Agents/*administration & dosage/adverse effects', 'Aripiprazole/administration & dosage', 'Clozapine/administration & dosage', 'Drug Therapy, Combination', 'Humans', 'Models, Theoretical', 'Polypharmacy', 'Practice Guidelines as Topic', 'Randomized Controlled Trials as Topic', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32930009/
109,Aripiprazole,28806160,Delirium in hospitalized patients: Risks and benefits of antipsychotics.,"['Thom RP', 'Mock CK', 'Teslyar P']","['Antipsychotic Agents/adverse effects/*therapeutic use', 'Aripiprazole/adverse effects/therapeutic use', 'Benzodiazepines/adverse effects/therapeutic use', 'Delirium/*drug therapy', 'Haloperidol/adverse effects/therapeutic use', 'Hospitalization', 'Humans', 'Olanzapine', 'Quetiapine Fumarate/adverse effects/therapeutic use', 'Risperidone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28806160/
110,Aripiprazole,39079887,"Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis.","['Lu W', 'Liu F', 'Zhang Y', 'He X', 'Hu Y', 'Xu H', 'Yang X', 'Li J', 'Kuang W']","['Humans', '*Antipsychotic Agents/therapeutic use/adverse effects', '*Dementia/drug therapy', '*Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Olanzapine/therapeutic use/adverse effects', 'Aripiprazole/therapeutic use/adverse effects', 'Behavioral Symptoms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39079887/
111,Aripiprazole,35777418,"Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.","['Lopez-Morinigo JD', 'Leucht S', 'Arango C']","['Adolescent', '*Antipsychotic Agents/therapeutic use', 'Aripiprazole/therapeutic use', 'Benzodiazepines/therapeutic use', '*Clozapine/therapeutic use', 'Haloperidol/therapeutic use', 'Humans', 'Lurasidone Hydrochloride/therapeutic use', 'Molindone/therapeutic use', 'Olanzapine', 'Paliperidone Palmitate/therapeutic use', 'Quality of Life', 'Quetiapine Fumarate/therapeutic use', 'Risperidone/adverse effects', '*Schizophrenia/drug therapy', 'Systematic Reviews as Topic']",https://pubmed.ncbi.nlm.nih.gov/35777418/
112,Aripiprazole,31063671,Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.,"['DeVane CL', 'Charles JM', 'Abramson RK', 'Williams JE', 'Carpenter LA', 'Raven S', 'Gwynette F', 'Stuck CA', 'Geesey ME', 'Bradley C', 'Donovan JL', 'Hall AG', 'Sherk ST', 'Powers NR', 'Spratt E', 'Kinsman A', 'Kruesi MJ', 'Bragg JE Jr']","['Adolescent', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Aripiprazole/adverse effects/*therapeutic use', 'Autism Spectrum Disorder/*drug therapy', 'Child', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Risperidone/adverse effects/*therapeutic use', 'Treatment Outcome', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31063671/
113,Aripiprazole,36825499,"Aripiprazole, brexpiprazole, and cariprazine can affect milk supply: Advice to breastfeeding mothers.","['Naughton S', ""O'Hara K"", 'Nelson J', 'Keightley P']","['Animals', 'Female', 'Humans', 'Aripiprazole/adverse effects', '*Milk', '*Breast Feeding', 'Mothers', 'Dopamine Agonists/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36825499/
114,Aripiprazole,29498507,Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents.,"['Mogwitz S', 'Buse J', 'Wolff N', 'Roessner V']","['Animals', 'Antipsychotic Agents/*therapeutic use', 'Aripiprazole/*therapeutic use', 'Dopamine Agents/*therapeutic use', 'Dopamine Antagonists/*therapeutic use', 'Humans', 'Tics/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29498507/
115,Aripiprazole,29341822,Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults.,"['Aggarwal A', 'Schrimpf L', 'Lauriello J']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/*pharmacology', 'Aripiprazole/administration & dosage/adverse effects/*pharmacology', 'Bipolar Disorder/*drug therapy', 'Delayed-Action Preparations', 'Humans', 'Injections']",https://pubmed.ncbi.nlm.nih.gov/29341822/
116,Aripiprazole,30785608,Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.,"['Tiihonen J', 'Taipale H', 'Mehtala J', 'Vattulainen P', 'Correll CU', 'Tanskanen A']","['Adult', 'Antipsychotic Agents/*administration & dosage/therapeutic use', 'Aripiprazole/administration & dosage/therapeutic use', 'Clozapine/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Patient Readmission/*statistics & numerical data', 'Polypharmacy', 'Schizophrenia/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30785608/
117,Aripiprazole,37949235,"Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.","['Terao I', 'Tsuge T', 'Endo K', 'Kodama W']","['Adult', 'Humans', '*Ketamine/adverse effects', 'Aripiprazole/adverse effects', 'Antidepressive Agents/adverse effects', 'Lithium/therapeutic use', 'Network Meta-Analysis', '*Depressive Disorder/drug therapy', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Depression/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37949235/
118,Aripiprazole,33954421,Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.,"['Rusgis MM', 'Alabbasi AY', 'Nelson LA']","['*Antipsychotic Agents/adverse effects', 'Aripiprazole/adverse effects', 'Humans', '*Hyperprolactinemia/chemically induced/diagnosis/drug therapy', '*Mental Disorders/drug therapy', 'Prolactin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33954421/
119,Aripiprazole,37350486,Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.,"['Wang D', 'Schneider-Thoma J', 'Siafis S', 'Burschinski A', 'Dong S', 'Wu H', 'Zhu Y', 'Davis JM', 'Priller J', 'Leucht S']","['Humans', '*Antipsychotic Agents/adverse effects', 'Paliperidone Palmitate/adverse effects', 'Aripiprazole/adverse effects', 'Olanzapine/therapeutic use', 'Risperidone/adverse effects', 'Delayed-Action Preparations/therapeutic use', '*Schizophrenia/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37350486/
120,Colesevelam,21342078,Statin-induced myopathy: a review and update.,"['Abd TT', 'Jacobson TA']","['Animals', 'Drug Interactions', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology/therapeutic use', 'Muscles/drug effects', 'Muscular Diseases/*chemically induced', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/21342078/
121,Colesevelam,29671894,Select medications that unexpectedly lower HbA1c levels.,"['Tillman F', 'Kim J']","['Blood Glucose/drug effects', 'Bromocriptine/therapeutic use', 'Colesevelam Hydrochloride/therapeutic use', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Glycated Hemoglobin/*metabolism', 'Humans', 'Hypoglycemic Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29671894/
122,Colesevelam,28153426,Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review.,"['Skelin M', 'Lucijanic T', 'Amidzic Klaric D', 'Resic A', 'Bakula M', 'Liberati-Cizmek AM', 'Gharib H', 'Rahelic D']","['Gastrointestinal Diseases/*physiopathology', 'Humans', '*Intestinal Absorption', 'Proton Pump Inhibitors/pharmacology', 'Thyrotropin/blood', 'Thyroxine/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28153426/
123,Colesevelam,32400758,Colesevelam in the management of type 2 diabetes.,"['Kalra S', 'Priya G', 'Aggarwal S']","['Anticholesteremic Agents/pharmacology', 'Colesevelam Hydrochloride/*pharmacology', '*Diabetes Mellitus, Type 2/drug therapy/metabolism', 'Dyslipidemias/*drug therapy/metabolism', 'Humans', 'Pharmacovigilance']",https://pubmed.ncbi.nlm.nih.gov/32400758/
124,Colesevelam,24410472,Advances in understanding of bile acid diarrhea.,['Camilleri M'],"['Antidiarrheals/therapeutic use', 'Bile Acids and Salts/*metabolism', 'Diarrhea/drug therapy/*metabolism/*physiopathology', 'Fibroblast Growth Factors/metabolism', 'Humans', 'Ileum/metabolism', 'Receptors, Cytoplasmic and Nuclear/agonists']",https://pubmed.ncbi.nlm.nih.gov/24410472/
125,Colesevelam,23317402,Colesevelam: a new and improved bile acid sequestrant?,"['Tziomalos K', 'Karagiannis A', 'Mikhailidis DP', 'Athyros VG']","['Allylamine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Anticholesteremic Agents/*therapeutic use', 'Bile Acids and Salts/*metabolism', 'C-Reactive Protein/analysis', 'Cholesterol, LDL/blood', 'Clinical Trials as Topic', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Glycated Hemoglobin/analysis', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage', 'Hypercholesterolemia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23317402/
126,Colesevelam,21739227,Use and indications of cholestyramine and bile acid sequestrants.,"['Scaldaferri F', 'Pizzoferrato M', 'Ponziani FR', 'Gasbarrini G', 'Gasbarrini A']","['Anticholesteremic Agents/*therapeutic use', 'Bile/metabolism', 'Cholestasis/complications/*drug therapy', 'Cholestyramine Resin/*therapeutic use', 'Humans', 'Hypercholesterolemia/complications/drug therapy', 'Sequestering Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21739227/
127,Colesevelam,27578074,Itch Management: Treatments under Development.,"['Pereira MP', 'Stander S']","['Acrylamides/therapeutic use', 'Analgesics, Opioid/*therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Antipruritics/*therapeutic use', 'Carrier Proteins/antagonists & inhibitors', 'Cholestasis/complications', 'Colesevelam Hydrochloride', 'Humans', 'Lymphoma, T-Cell, Cutaneous/complications/drug therapy', 'Membrane Glycoproteins/antagonists & inhibitors', 'Nerve Growth Factor/antagonists & inhibitors', 'Neurokinin-1 Receptor Antagonists/*therapeutic use', 'Prurigo/complications/drug therapy', 'Pruritus/*drug therapy/etiology', 'Pyridines/therapeutic use', 'Receptors, Interleukin/antagonists & inhibitors', 'Receptors, Opioid, kappa/agonists', 'Sequestering Agents/*therapeutic use', 'TRPV Cation Channels/antagonists & inhibitors', 'Uremia/complications']",https://pubmed.ncbi.nlm.nih.gov/27578074/
128,Colesevelam,14728043,Colesevelam.,"['Melian EB', 'Plosker GL']","['Allylamine/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Colesevelam Hydrochloride', 'Drug Therapy, Combination', 'Humans', 'Hypercholesterolemia/*drug therapy', 'Hypolipidemic Agents/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14728043/
129,Colesevelam,16568248,Lipid-lowering drugs.,['Pahan K'],"['Alzheimer Disease/drug therapy', '*Clofibric Acid/therapeutic use', 'Diabetes Mellitus/drug therapy', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hyperlipidemias/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', 'Lipids/biosynthesis', 'Neoplasms/drug therapy', 'Osteoporosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16568248/
130,Colesevelam,25041567,Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.,"['Bronden A', 'Hansen M', 'Sonne DP', 'Rohde U', 'Vilsboll T', 'Knop FK']","['Allylamine/*analogs & derivatives/pharmacokinetics/pharmacology', 'Anticholesteremic Agents/pharmacokinetics/pharmacology', 'Cholesterol, LDL/blood/drug effects', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/blood/*drug therapy', 'Glycated Hemoglobin/*drug effects/metabolism', 'Humans', 'Hypercholesterolemia/blood/*drug therapy', 'Hypoglycemic Agents/pharmacokinetics/*pharmacology', 'Polyamines/pharmacokinetics/*pharmacology', 'Sevelamer', 'Treatment Outcome', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/25041567/
131,Colesevelam,25640999,Risk identification and possible countermeasures for muscle adverse effects during statin therapy.,"['Magni P', 'Macchi C', 'Morlotti B', 'Sirtori CR', 'Ruscica M']","['Age Factors', 'Aged', 'Aged, 80 and over', 'Anticholesteremic Agents/*therapeutic use', 'Colesevelam Hydrochloride/therapeutic use', 'Creatine Kinase/blood', 'Drug Interactions', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/epidemiology', 'Ezetimibe/therapeutic use', 'Fatty Acids, Monounsaturated/adverse effects', 'Female', 'Fluvastatin', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects', 'Indoles/adverse effects', 'Male', 'Muscular Diseases/chemically induced/metabolism', 'Myalgia/blood/*chemically induced', 'Rhabdomyolysis/blood/*chemically induced', 'Risk Assessment', 'Risk Factors', 'Rosuvastatin Calcium/adverse effects', 'Sex Factors', 'Vitamin D Deficiency/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/25640999/
132,Colesevelam,12040732,Colesevelam hydrochloride.,['Steinmetz KL'],"['*Allylamine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Cholestyramine Resin/therapeutic use', 'Colesevelam Hydrochloride', 'Colestipol/therapeutic use', 'Drug Administration Schedule', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Hypercholesterolemia/*drug therapy', '*Hypolipidemic Agents/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12040732/
133,Colesevelam,11383377,New therapies on the horizon.,['Brown WV'],"['Allylamine/analogs & derivatives/metabolism/therapeutic use', 'Anticholesteremic Agents/metabolism/*therapeutic use', 'Bile Acids and Salts/metabolism', 'Biological Transport', 'Cholesterol/metabolism', 'Cholestyramine Resin/metabolism/therapeutic use', 'Colesevelam Hydrochloride', 'Esterification', 'Fluorobenzenes/metabolism/therapeutic use', 'Humans', 'Intestinal Absorption', 'Lipoproteins, LDL/*blood', '*Pyrimidines', 'Rosuvastatin Calcium', '*Sulfonamides', 'United States']",https://pubmed.ncbi.nlm.nih.gov/11383377/
134,Colesevelam,30336707,Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes.,"['Nerild HH', 'Christensen MB', 'Knop FK', 'Bronden A']","['Animals', 'Anticholesteremic Agents/administration & dosage/adverse effects/pharmacology', 'Blood Glucose/*drug effects', 'Clinical Trials, Phase III as Topic', 'Colesevelam Hydrochloride/*administration & dosage/adverse effects/pharmacology', 'Diabetes Mellitus, Type 2/*drug therapy/physiopathology', 'Drug Therapy, Combination', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology', 'Patient Selection']",https://pubmed.ncbi.nlm.nih.gov/30336707/
135,Colesevelam,19682080,Combined therapy in the treatment of dyslipidemia.,['Reiner Z'],"['Animals', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/physiopathology', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Hypolipidemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Practice Guidelines as Topic', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/19682080/
136,Colesevelam,20819059,Combination of fenofibrate with non-statin drug regimens.,"['Agouridis AP', 'Filippatos TD', 'Derdemezis CS', 'Mikhailidis DP', 'Elisaf MS']","['Animals', 'Drug Therapy, Combination', 'Fenofibrate/administration & dosage/*pharmacology/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use', 'Hyperlipidemias/*drug therapy/physiopathology', 'Hypolipidemic Agents/administration & dosage/*pharmacology/therapeutic use', 'Lipid Metabolism/drug effects', 'Metabolic Syndrome/drug therapy/etiology/physiopathology', 'Obesity/complications']",https://pubmed.ncbi.nlm.nih.gov/20819059/
137,Colesevelam,22142158,Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?,"['Handelsman Y', 'Fonseca V', 'Rosenstock J']","['Animals', 'Anticholesteremic Agents/administration & dosage', 'Cardiovascular Diseases/blood/drug therapy', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Clinical Trials as Topic/methods', 'Diabetes Mellitus, Type 2/*blood/*drug therapy', 'Drug Therapy, Combination', '*Goals', 'Humans', 'Hypolipidemic Agents/administration & dosage', 'Lipid Metabolism/*drug effects/physiology', 'Lipoproteins, LDL/blood', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22142158/
138,Colesevelam,33471721,Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.,"['Handelsman Y', 'Jellinger PS', 'Guerin CK', 'Bloomgarden ZT', 'Brinton EA', 'Budoff MJ', 'Davidson MH', 'Einhorn D', 'Fazio S', 'Fonseca VA', 'Garber AJ', 'Grunberger G', 'Krauss RM', 'Mechanick JI', 'Rosenblit PD', 'Smith DA', 'Wyne KL']","['Algorithms', '*Anticholesteremic Agents', '*Cardiovascular Diseases/epidemiology/prevention & control', 'Consensus', '*Dyslipidemias/drug therapy/epidemiology', 'Endocrinologists', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Risk Factors', 'United States']",https://pubmed.ncbi.nlm.nih.gov/33471721/
139,Colesevelam,20415686,Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.,"['Fonseca VA', 'Handelsman Y', 'Staels B']","['Adult', 'Allylamine/administration & dosage/*analogs & derivatives/pharmacology', 'Anticholesteremic Agents/*administration & dosage/pharmacology', 'Blood Glucose/*drug effects/metabolism', 'Cardiovascular Diseases/*prevention & control', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Diabetic Angiopathies/*prevention & control', 'Female', 'Glycated Hemoglobin/drug effects/metabolism', 'Humans', 'Lipids/*blood', 'Male']",https://pubmed.ncbi.nlm.nih.gov/20415686/
140,DESFLURANE,36036420,The science behind banning desflurane: A narrative review.,"['Hendrickx JFA', 'Nielsen OJ', 'De Hert S', 'De Wolf AM']","['*Anesthesia', '*Anesthesiology', '*Anesthetics, Inhalation/adverse effects', 'Desflurane', 'Humans', '*Isoflurane']",https://pubmed.ncbi.nlm.nih.gov/36036420/
141,DESFLURANE,12751547,Halogenated inhalational anaesthetics.,"['Reichle FM', 'Conzen PF']","['Anesthetics, Inhalation/*adverse effects', 'Animals', 'Desflurane', 'Enflurane/adverse effects', 'Ethers/adverse effects', 'Halothane/adverse effects', 'Humans', 'Hydrocarbons, Fluorinated/adverse effects', 'Isoflurane/adverse effects/*analogs & derivatives', 'Kidney/drug effects', 'Liver/drug effects', 'Methyl Ethers/adverse effects', 'Organ Specificity', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/12751547/
142,DESFLURANE,19271031,Inhaled anesthesia and cognitive performance.,"['Mandal PK', 'Schifilliti D', 'Mafrica F', 'Fodale V']","['Age Factors', 'Aged', 'Anesthetics, Inhalation/administration & dosage/*adverse effects', 'Cognition Disorders/epidemiology/*etiology', 'Desflurane', 'Humans', 'Isoflurane/administration & dosage/adverse effects/analogs & derivatives', 'Methyl Ethers/administration & dosage/adverse effects', 'Nitrous Oxide/administration & dosage/adverse effects', 'Postoperative Complications/epidemiology/*etiology', 'Risk Factors', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/19271031/
143,DESFLURANE,29161390,Thiopental to desflurane - an anaesthetic journey. Where are we going next?,['Sneyd JR'],"['Anesthesiology/*methods', '*Anesthetics, Inhalation', '*Anesthetics, Intravenous', '*Desflurane', 'Humans', 'Hypnotics and Sedatives', '*Thiopental']",https://pubmed.ncbi.nlm.nih.gov/29161390/
144,DESFLURANE,28438069,Emerging graft protective strategies in clinical liver transplantation.,"['Nickkholgh A', 'Maluf D']","['Anesthetics, Inhalation/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Desflurane', 'Graft Rejection/*prevention & control', '*Graft Survival/drug effects', 'Humans', '*Ischemic Preconditioning', 'Isoflurane/analogs & derivatives/therapeutic use', 'Liver Transplantation/adverse effects/*methods', 'Methyl Ethers/therapeutic use', 'Methylprednisolone/therapeutic use', 'Organ Preservation/*methods', 'Reperfusion Injury/*prevention & control', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/28438069/
145,DESFLURANE,31613372,[Climate footprint of halogenated inhalation anesthetics].,"['Linden-Sonderso A', 'Nielsen N', 'Bentzer P']","['*Anesthetics, Inhalation/analysis/chemistry', 'Anesthetics, Intravenous/analysis/chemistry', '*Carbon Footprint', 'Desflurane/analysis/chemistry', 'Global Warming', 'Humans', 'Isoflurane/analysis/chemistry', 'Nitrous Oxide/analysis/chemistry', 'Propofol/administration & dosage/analysis/chemistry', 'Sevoflurane/analysis/chemistry', 'Sweden']",https://pubmed.ncbi.nlm.nih.gov/31613372/
146,DESFLURANE,38195081,Effect of Volatile Anesthesia Versus Intravenous Anesthesia on Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy: A Randomized Clinical Trial.,"['Zhang YT', 'Chen Y', 'Shang KX', 'Yu H', 'Li XF', 'Yu H']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Anesthesia, Inhalation/adverse effects', 'Anesthesia, Intravenous/adverse effects', '*Anesthetics, Inhalation/adverse effects/administration & dosage', '*Anesthetics, Intravenous/administration & dosage/adverse effects', '*Desflurane/administration & dosage', 'Esophageal Neoplasms/surgery', '*Esophagectomy/adverse effects', '*Lung Diseases/etiology', 'Minimally Invasive Surgical Procedures/adverse effects/methods', '*Postoperative Complications/prevention & control/etiology/epidemiology', '*Propofol/administration & dosage/adverse effects', '*Sevoflurane/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38195081/
147,DESFLURANE,39439451,Effect of Remimazolam on the Incidence of Intraoperative Hypothermia Compared with Inhalation Anesthetics in Patients Undergoing Endoscopic Nasal Surgery: A Prospective Randomized Controlled Trial.,"['Cho SA', 'Lee SJ', 'Kwon W', 'Jung JY', 'You HJ', 'Yoon SE', 'Sung TY']","['Humans', 'Female', 'Male', 'Middle Aged', '*Hypothermia/prevention & control/epidemiology/etiology', 'Prospective Studies', '*Endoscopy/adverse effects/methods', 'Adult', '*Anesthetics, Inhalation/adverse effects/administration & dosage', 'Incidence', '*Nasal Surgical Procedures/adverse effects/methods', '*Benzodiazepines/adverse effects/administration & dosage', 'Aged', 'Intraoperative Complications/epidemiology/prevention & control/etiology', 'Anesthesia, General/adverse effects/methods', 'Remifentanil/administration & dosage/adverse effects', 'Desflurane/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39439451/
148,DESFLURANE,21212710,A randomized comparison of target-controlled infusion of remifentanil and propofol with desflurane and fentanyl for laryngeal surgery.,"['Wang Y', 'Yan M', 'He JG', 'Zhu YM', 'Hu XS', 'Li X', 'Wu WD']","['Adult', 'Aged', 'Anesthesia Recovery Period', 'Anesthesia, General/methods', 'Anesthetics, Intravenous/*administration & dosage', 'Consciousness', 'Desflurane', 'Female', 'Fentanyl/*administration & dosage', 'Hemodynamics/drug effects', 'Humans', 'Isoflurane/administration & dosage/*analogs & derivatives', '*Laryngoscopy', 'Male', 'Piperidines/*administration & dosage', 'Propofol/*administration & dosage', 'Remifentanil', 'Vocal Cords/surgery']",https://pubmed.ncbi.nlm.nih.gov/21212710/
149,DESFLURANE,34030807,Inhaled anesthesia in neurosurgery: Still a role?,"['Badenes R', 'Nato CG', 'Pena JD', 'Bilotta F']","['*Anesthesia Recovery Period', 'Anesthesia, General/adverse effects/*methods', 'Anesthesia, Inhalation/adverse effects/*methods', 'Brain/drug effects/physiology', 'Desflurane/administration & dosage', 'Hemodynamics/drug effects/physiology', 'Humans', 'Neurosurgical Procedures/*methods']",https://pubmed.ncbi.nlm.nih.gov/34030807/
150,DESFLURANE,22735251,Postoperative global amnesia reversed with flumazenil.,"['Rinehart JB', 'Baker B', 'Raphael D']","['Amnesia/*drug therapy/*etiology', 'Analgesics/administration & dosage', 'Anesthesia, General/*adverse effects', 'Cholangiopancreatography, Endoscopic Retrograde', 'Desflurane', 'Diabetes Mellitus, Type 2', 'Fentanyl/administration & dosage', 'Flumazenil/*therapeutic use', 'GABA Modulators/*therapeutic use', 'Humans', 'Hydromorphone/administration & dosage', 'Isoflurane/administration & dosage/analogs & derivatives', 'Male', 'Midazolam/administration & dosage', 'Middle Aged', 'Pancreatitis/surgery', 'Postoperative Complications/*drug therapy', 'Propofol/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/22735251/
151,DESFLURANE,37405905,Myocardial Protection by Desflurane: From Basic Mechanisms to Clinical Applications.,"['Qin H', 'Zhou J']","['Humans', 'Desflurane/adverse effects', '*Isoflurane/adverse effects', '*Anesthetics, Inhalation/adverse effects', 'Reactive Oxygen Species/metabolism', 'Quality of Life', 'Reproducibility of Results', '*Coronary Disease']",https://pubmed.ncbi.nlm.nih.gov/37405905/
152,DESFLURANE,16013685,Pharmacology of modern volatile anaesthetics.,"['Preckel B', 'Bolten J']","['Anesthetics, Inhalation/adverse effects/pharmacokinetics/*pharmacology', 'Desflurane', 'Female', 'Humans', 'Isoflurane/adverse effects/analogs & derivatives/pharmacokinetics/pharmacology', 'Methyl Ethers/adverse effects/pharmacokinetics/pharmacology', 'Pregnancy', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/16013685/
153,DESFLURANE,9849279,The uptake of sevoflurane during anaesthesia.,"['Vagts DA', 'Lockwood GG']","['Adult', 'Anesthesia, Closed-Circuit', 'Anesthetics, Inhalation/administration & dosage/*pharmacokinetics', 'Decision Making, Computer-Assisted', 'Desflurane', 'Drug Delivery Systems', 'Humans', 'Isoflurane/analogs & derivatives/pharmacokinetics', 'Methyl Ethers/administration & dosage/*pharmacokinetics', 'Middle Aged', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/9849279/
154,DESFLURANE,7879584,The Tec 6 vaporizer: why desflurane needs to be heated.,['Miller D'],"['Anesthetics, Inhalation/*administration & dosage', 'Desflurane', 'Equipment Design', '*Hot Temperature', 'Humans', 'Isoflurane/administration & dosage/*analogs & derivatives', '*Nebulizers and Vaporizers', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/7879584/
155,DESFLURANE,20709457,Volatile anesthetics might be more beneficial than propofol for postoperative liver function in cirrhotic patients receiving hepatectomy.,"['Tao KM', 'Yang LQ', 'Liu YT', 'Tao Y', 'Song JC', 'Wu FX', 'Yu WF']","['Anesthetics, Inhalation/*pharmacology/therapeutic use', 'Desflurane', 'Heme Oxygenase (Decyclizing)/metabolism', 'Hepatectomy/*adverse effects', 'Humans', 'Hypoxia-Inducible Factor 1/metabolism', 'Isoflurane/analogs & derivatives/pharmacology/therapeutic use', 'Liver/*drug effects/metabolism', 'Liver Cirrhosis/*surgery', 'Methyl Ethers/pharmacology/therapeutic use', 'Nitric Oxide Synthase Type II/metabolism', 'Propofol', 'Reperfusion Injury/etiology/*prevention & control', 'Sevoflurane', 'Volatilization']",https://pubmed.ncbi.nlm.nih.gov/20709457/
156,DESFLURANE,38358111,Acute Intraoperative Tympanic Membrane Rupture in Patient Anesthetized With Desflurane Without Nitrous Oxide: A Case Report.,"['Cincotta DJ', 'Brandenburg JB']","['Humans', 'Anesthesia, Inhalation/methods', '*Anesthetics, Inhalation/adverse effects', '*Desflurane/adverse effects', 'Isoflurane/adverse effects', 'Nitrous Oxide', '*Tympanic Membrane Perforation']",https://pubmed.ncbi.nlm.nih.gov/38358111/
157,DESFLURANE,26444149,A comparison of single dose dexmedetomidine with propofol for the prevention of emergence delirium after desflurane anaesthesia in children.,"['Makkar JK', 'Bhatia N', 'Bala I', 'Dwivedi D', 'Singh PM']","['Anesthetics, Inhalation/*adverse effects', 'Child', 'Child, Preschool', 'Delirium/*prevention & control', 'Desflurane', 'Dexmedetomidine/*therapeutic use', 'Female', 'Humans', 'Isoflurane/adverse effects/*analogs & derivatives', 'Male', 'Propofol/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26444149/
158,DESFLURANE,1524236,Cardiovascular and respiratory actions of desflurane: is desflurane different from isoflurane?,"['Warltier DC', 'Pagel PS']","['*Anesthesia, Inhalation', 'Anesthetics/*pharmacology', 'Animals', 'Desflurane', 'Hemodynamics/*drug effects/physiology', 'Humans', 'Isoflurane/*analogs & derivatives/*pharmacology', 'Respiration/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/1524236/
159,DESFLURANE,12461828,Desflurane: a reappraisal.,"['Umbrain V', 'Shi L', 'Camu F']","['Anesthesia, Closed-Circuit/adverse effects', 'Anesthetics, Inhalation/*adverse effects/chemistry', 'Animals', 'Carbon Monoxide/chemistry', 'Carbon Monoxide Poisoning/etiology', 'Coronary Disease/physiopathology', 'Desflurane', 'Humans', 'Isoflurane/*adverse effects/*analogs & derivatives/chemistry', 'Malignant Hyperthermia/etiology', 'Respiratory System/drug effects', 'Sympathetic Nervous System/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/12461828/
160,Darunavir,17987220,Darunavir.,"['El-Atrouni WI', 'Temesgen Z']","['Clinical Trials as Topic', 'Darunavir', 'Drug Interactions', 'Drug Resistance, Viral', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Sulfonamides/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17987220/
161,Darunavir,15600245,TMC-114 (Tibotec).,['Shurtleff AC'],"['Anti-HIV Agents/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Darunavir', 'Humans', 'Patents as Topic', 'Randomized Controlled Trials as Topic', 'Structure-Activity Relationship', 'Sulfonamides/adverse effects/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15600245/
162,Darunavir,32479865,Lack of antiviral activity of darunavir against SARS-CoV-2.,"['De Meyer S', 'Bojkova D', 'Cinatl J', 'Van Damme E', 'Buyck C', 'Van Loock M', 'Woodfall B', 'Ciesek S']","['Antiviral Agents/therapeutic use', 'Betacoronavirus/*drug effects', 'COVID-19', 'Cell Line', 'Cell Survival/drug effects', '*Coronavirus Infections/drug therapy', 'Darunavir/*therapeutic use', 'Humans', '*Pandemics', '*Pneumonia, Viral/drug therapy', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/32479865/
163,Darunavir,37449366,Drug-induced liver injury secondary to increased levonorgestrel exposure in a patient taking ritonavir.,"['Oddie PD', 'Heskin J', 'Leung S', 'Naous N', 'Garvey L', 'Cohen CE']","['Female', 'Humans', 'Adult', 'Ritonavir/adverse effects', '*Anti-HIV Agents/adverse effects', 'Levonorgestrel/adverse effects', 'Tenofovir/adverse effects', 'Darunavir/adverse effects', '*HIV Infections/drug therapy', '*Chemical and Drug Induced Liver Injury/diagnosis/etiology/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37449366/
164,Darunavir,32028327,Aging does not impact drug--drug interaction magnitudes with antiretrovirals.,"['Stader F', 'Decosterd L', 'Stoeckle M', 'Cavassini M', 'Battegay M', 'Saldanha SA', 'Marzolini C', 'Courlet P']","['Aged', 'Aged, 80 and over', '*Aging', 'Amlodipine/adverse effects/therapeutic use', 'Anti-Retroviral Agents/therapeutic use', '*Antiretroviral Therapy, Highly Active', 'Atorvastatin/adverse effects/therapeutic use', 'Cardiovascular Agents/adverse effects/*therapeutic use', 'Cardiovascular Diseases/*drug therapy/epidemiology', 'Darunavir/adverse effects/therapeutic use', '*Drug Interactions', 'Female', 'HIV Infections/*drug therapy/epidemiology', 'Heterocyclic Compounds, 3-Ring/adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Oxazines/adverse effects/therapeutic use', 'Piperazines/adverse effects/therapeutic use', 'Pyridones/adverse effects/therapeutic use', 'Rosuvastatin Calcium/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32028327/
165,Darunavir,36738797,"Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2' amide-derivatives: Synthesis, biological evaluation and structural studies.","['Ghosh AK', 'Shahabi D', 'Kipfmiller M', 'Ghosh AK', 'Johnson M', 'Wang YF', 'Agniswamy J', 'Amano M', 'Weber IT', 'Mitsuya H']","['Darunavir/pharmacology', '*HIV-1', '*HIV Protease Inhibitors', 'Amides/pharmacology', 'HIV Protease/metabolism', 'Chloroacetates/pharmacology', 'Crystallography, X-Ray', 'Drug Design', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/36738797/
166,Darunavir,33461696,Darunavir: A comprehensive profile.,"['Darwish IA', 'Al-Majed AA', 'Alsaif NA', 'Bakheit AH', 'Herqash RN', 'Alzaid A']","['*Darunavir/pharmacology/therapeutic use', 'Drug Resistance, Viral', 'Female', '*HIV Infections/drug therapy', '*HIV Protease Inhibitors/pharmacology/therapeutic use', '*HIV-1/drug effects', 'Humans', 'Pregnancy', 'United States']",https://pubmed.ncbi.nlm.nih.gov/33461696/
167,Darunavir,28686287,Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.,"['Daskapan A', 'Dijkema D', 'de Weerd DA', 'Bierman WFW', 'Kosterink JGW', 'van der Werf TS', 'Alffenaar JC', 'Stienstra Y']","['Adult', 'Aged', 'Cross-Sectional Studies', 'Darunavir/blood/*pharmacology', 'Diet Surveys/statistics & numerical data', 'Drug Therapy, Combination/methods', '*Feeding Behavior', 'Female', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/blood/*pharmacokinetics', 'Humans', 'Male', 'Middle Aged', 'Outpatients/*statistics & numerical data', 'Patient Education as Topic', 'Ritonavir/pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28686287/
168,Darunavir,37409412,Two-Drug Regimen Containing Darunavir: Metabolic Evaluation of an Old Dual Therapy.,"['Farinacci D', 'Iannone V', ""D'Angelillo A"", 'Borghetti A', 'Passerotto RA', 'Lamanna F', 'Di Giambenedetto S']","['Humans', 'Darunavir', '*HIV Infections/drug therapy', '*Anti-HIV Agents/adverse effects', 'Cobicistat/therapeutic use', 'Ritonavir/therapeutic use/adverse effects', 'Drug Therapy, Combination', 'Viral Load', '*Dyslipidemias/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37409412/
169,Darunavir,29232276,Contemporary protease inhibitors and cardiovascular risk.,"['Lundgren J', 'Mocroft A', 'Ryom L']","['Antiretroviral Therapy, Highly Active/*adverse effects/methods', 'Atazanavir Sulfate/adverse effects/therapeutic use', 'Cardiovascular Diseases/*chemically induced/*epidemiology', 'Darunavir/adverse effects/therapeutic use', 'HIV Infections/*complications/*drug therapy', 'HIV Protease Inhibitors/*adverse effects/*therapeutic use', 'Humans', 'Risk Assessment', 'Ritonavir/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29232276/
170,Darunavir,38721980,Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study.,"['Nyein PP', 'Petoumenos K', 'Borok M', 'Eriobu N', 'Kumarasamy N', 'Avihingsanon A', 'Azwa I', 'Dao S', 'Cisse M', 'Dharan NJ', 'Hanson J', 'Matthews GV']","['Humans', '*HIV Infections/drug therapy', '*Blood Pressure/drug effects', 'Male', 'Female', '*Ritonavir/therapeutic use', '*Pyridones', 'Middle Aged', 'Adult', '*Oxazines/therapeutic use', 'Piperazines', 'Heterocyclic Compounds, 3-Ring/therapeutic use/adverse effects', 'Anti-HIV Agents/therapeutic use/administration & dosage', 'Darunavir/therapeutic use/administration & dosage', 'Anti-Retroviral Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38721980/
171,Darunavir,28595364,Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?,"['Metsu D', 'Toutain PL', 'Chatelut E', 'Delobel P', 'Gandia P']","['Atazanavir Sulfate/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Blood Proteins/chemistry/metabolism', 'Darunavir/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'HIV Infections/*drug therapy/metabolism', 'HIV Protease Inhibitors/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Hepatocytes/drug effects/metabolism', 'Humans', 'Pregnancy', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/28595364/
172,Darunavir,27551725,Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study).,"['Gianotti N', 'Galli L', 'Maserati R', 'Sighinolfi L', 'Ripamonti D', 'Palvarini L', 'Lo Caputo S', 'Foca E', 'Celesia BM', 'Baldelli F', 'Sterrantino G', 'Lazzarin A']","['Adult', 'Anti-HIV Agents/therapeutic use', 'Antiretroviral Therapy, Highly Active', 'Darunavir/administration & dosage/*therapeutic use', 'Female', 'HIV Infections/*drug therapy', 'Humans', 'Lopinavir/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Ritonavir/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27551725/
173,Darunavir,32418190,Early experience with remdesivir in SARS-CoV-2 pneumonia.,"['Durante-Mangoni E', 'Andini R', 'Bertolino L', 'Mele F', 'Florio LL', 'Murino P', 'Corcione A', 'Zampino R']","['Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & derivatives', 'Alanine/administration & dosage/adverse effects/*analogs & derivatives', 'Antiviral Agents/*administration & dosage/adverse effects', 'Betacoronavirus/*drug effects/immunology', 'COVID-19', 'Chemical and Drug Induced Liver Injury/diagnosis/etiology/physiopathology/virology', 'Convalescence', 'Coronavirus Infections/*drug therapy/virology', 'Critical Illness', 'Darunavir/administration & dosage/adverse effects', 'Drug Administration Schedule', 'Drug Combinations', 'Fatal Outcome', 'Humans', 'Hydroxychloroquine/administration & dosage/adverse effects', 'Lopinavir/administration & dosage/adverse effects', 'Multiple Organ Failure/chemically induced/diagnosis/physiopathology/virology', 'Pandemics', 'Pneumonia, Viral/*drug therapy/virology', 'RNA, Viral/*blood', 'Ritonavir/administration & dosage/adverse effects', 'SARS-CoV-2', 'Torsades de Pointes/chemically induced/diagnosis/physiopathology/virology']",https://pubmed.ncbi.nlm.nih.gov/32418190/
174,Darunavir,29430854,Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.,"['Gutierrez-Valencia A', 'Trujillo-Rodriguez M', 'Fernandez-Magdaleno T', 'Espinosa N', 'Viciana P', 'Lopez-Cortes LF']","['Adult', 'Anti-HIV Agents/*therapeutic use', 'Cobicistat/*administration & dosage', 'Darunavir/administration & dosage/pharmacokinetics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'HIV Infections/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Prospective Studies', 'Reverse Transcriptase Inhibitors/therapeutic use', 'Ritonavir/*therapeutic use', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/29430854/
175,Darunavir,32926254,"Synthesis of 3,3'-methylenebis(4-hydroxyquinolin-2(1H)-ones) of prospective anti-COVID-19 drugs.","['Aly AA', 'Hassan AA', 'Mohamed AH', 'Osman EM', 'Brase S', 'Nieger M', 'Ibrahim MAA', 'Mostafa SM']","['Antiviral Agents/*chemical synthesis/pharmacology', 'Coronavirus 3C Proteases/antagonists & inhibitors', 'Darunavir/pharmacology', 'Humans', 'Hydrogen Bonding', 'Molecular Docking Simulation/methods', 'Molecular Dynamics Simulation', 'Protease Inhibitors/*chemical synthesis/pharmacology', 'Quinolones/*chemical synthesis/pharmacology', 'SARS-CoV-2/*drug effects/metabolism', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32926254/
176,Darunavir,30722751,A case of late presentation of darunavir-related cholestatic hepatitis.,"['Yancheva N', 'Tzonev R']","['Adult', 'Antiretroviral Therapy, Highly Active', 'Antiviral Agents/*therapeutic use', 'Cholestasis, Intrahepatic/*chemically induced/diagnosis/therapy', 'Darunavir/administration & dosage/*adverse effects', 'HIV Infections/*complications/*drug therapy/virology', 'HIV Protease Inhibitors/administration & dosage/*adverse effects', 'Homosexuality, Male', 'Humans', 'Male', 'Raltegravir Potassium/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/30722751/
177,Darunavir,33171603,Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance.,"['Liu Z', 'Tran TT', 'Pham L', 'Hu L', 'Bentz K', 'Savin DA', 'Fanucci GE']","['Amino Acid Substitution', 'Darunavir/*pharmacology', '*Drug Resistance, Multiple, Viral', 'Genetic Variation', 'HIV/*drug effects/genetics', 'HIV Protease/*chemistry/genetics', 'HIV Protease Inhibitors/*pharmacology', 'Mutation', 'Protein Conformation']",https://pubmed.ncbi.nlm.nih.gov/33171603/
178,Darunavir,29913082,Darunavir for the treatment of HIV infection.,"['Spagnuolo V', 'Castagna A', 'Lazzarin A']","['Adenine/analogs & derivatives/therapeutic use', 'Clinical Trials as Topic', 'Cobicistat/therapeutic use', 'Darunavir/chemistry/pharmacokinetics/*therapeutic use', 'Drug Therapy, Combination', 'Emtricitabine/therapeutic use', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/chemistry/pharmacokinetics/*therapeutic use', 'Half-Life', 'Humans', 'Tenofovir/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29913082/
179,Deprenyl,34957948,"Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.","['Tan YY', 'Jenner P', 'Chen SD']","['Dopamine Agents/therapeutic use', 'Humans', 'Monoamine Oxidase/therapeutic use', 'Monoamine Oxidase Inhibitors/pharmacology/therapeutic use', '*Parkinson Disease/drug therapy', 'Selegiline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34957948/
180,Deprenyl,1801544,Selegiline hydrochloride and cognition.,['Lees AJ'],"['Aged', 'Alzheimer Disease/*drug therapy/psychology', 'Attention/drug effects', 'Dementia/*drug therapy/psychology', 'Depressive Disorder/drug therapy/psychology', 'Humans', 'Mental Recall/drug effects', 'Middle Aged', 'Neurologic Examination/drug effects', '*Neuropsychological Tests', 'Parkinson Disease/*drug therapy/psychology', 'Reaction Time/drug effects', 'Selegiline/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1801544/
181,Deprenyl,1801538,"Monoamine oxidase, dopamine and Parkinson's disease.",['Oreland L'],"['Animals', 'Brain/drug effects/*physiopathology', 'Dopamine/*physiology', 'Humans', 'Isoenzymes/physiology', 'Monoamine Oxidase/*physiology', 'Neurologic Examination/drug effects', 'Parkinson Disease/drug therapy/*physiopathology', 'Selegiline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1801538/
182,Deprenyl,8858190,Controversies in the treatment of Parkinson's disease.,"['Hely MA', 'Morris JG']","['Antiparkinson Agents/adverse effects/*therapeutic use', 'Dopamine Agonists/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Humans', 'Levodopa/adverse effects/therapeutic use', 'Neurologic Examination/drug effects', 'Parkinson Disease/*drug therapy/mortality', 'Randomized Controlled Trials as Topic', 'Selegiline/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8858190/
183,Deprenyl,21147941,"MAO inhibitors: risks, benefits, and lore.","['Wimbiscus M', 'Kostenko O', 'Malone D']","['Administration, Cutaneous', 'Antidepressive Agents/*adverse effects/therapeutic use', 'Blood Pressure/*drug effects', 'Cheese', 'Depressive Disorder, Major/drug therapy', 'Feeding Behavior', 'Food-Drug Interactions', 'Humans', 'Hypertension/*chemically induced/prevention & control', 'Monoamine Oxidase Inhibitors/*adverse effects/therapeutic use', 'Myocardium', 'Risk Factors', 'Selegiline/adverse effects/pharmacokinetics/*therapeutic use', 'Tyramine']",https://pubmed.ncbi.nlm.nih.gov/21147941/
184,Deprenyl,10093587,Monoamine oxidase and catechol-O-methyltransferase inhibitors.,"['Siderowf A', 'Kurlan R']","['Benzophenones/pharmacology/therapeutic use', '*Catechol O-Methyltransferase Inhibitors', 'Catechols/pharmacology/therapeutic use', 'Dopamine/metabolism', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Humans', 'Monoamine Oxidase Inhibitors/*therapeutic use', 'Nitriles', 'Nitrophenols', 'Parkinson Disease/*drug therapy', 'Randomized Controlled Trials as Topic', 'Selegiline/pharmacology/therapeutic use', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/10093587/
185,Deprenyl,15822104,Other pharmacological treatments for motor complications and dyskinesias.,['Waters C'],"['Amantadine/pharmacology/therapeutic use', 'Antiparkinson Agents/*adverse effects/therapeutic use', 'Catechol O-Methyltransferase Inhibitors', 'Dopamine Agonists/*therapeutic use', 'Dyskinesia, Drug-Induced/*drug therapy/*etiology', 'Gait/drug effects', 'Humans', 'Levodopa/*adverse effects/therapeutic use', 'Monoamine Oxidase/metabolism', 'Monoamine Oxidase Inhibitors/pharmacology/*therapeutic use', 'Parkinson Disease/drug therapy', 'Periodicity', '*Purinergic P1 Receptor Antagonists', 'Purines/pharmacology/therapeutic use', 'Selegiline/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15822104/
186,Deprenyl,29569037,Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.,"['Riederer P', 'Muller T']","['Humans', 'Indans/pharmacology/*therapeutic use', 'Monoamine Oxidase Inhibitors/pharmacology/*therapeutic use', 'Neurons/*drug effects', 'Parkinson Disease/*drug therapy', 'Selegiline/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29569037/
187,Deprenyl,26760951,Automated radiosynthesis of [(11)C]L-deprenyl-D2 and [(11)C]D-deprenyl using a commercial platform.,"['Buccino P', 'Kreimerman I', 'Zirbesegger K', 'Porcal W', 'Savio E', 'Engler H']","['*Carbon Radioisotopes/chemistry', 'Humans', 'Isotope Labeling/instrumentation/methods', 'Monoamine Oxidase Inhibitors/chemical synthesis/chemistry', 'Positron-Emission Tomography', 'Radiopharmaceuticals/*chemical synthesis/chemistry', 'Selegiline/*chemical synthesis/chemistry']",https://pubmed.ncbi.nlm.nih.gov/26760951/
188,Deprenyl,21272511,Pharmacotherapy for late-life depression.,['Alexopoulos GS'],"['Administration, Cutaneous', 'Adult', 'Age Factors', 'Aged', 'Antidepressive Agents/*therapeutic use', 'Combined Modality Therapy', 'Depressive Disorder, Major/*drug therapy/therapy', 'Humans', 'Monoamine Oxidase Inhibitors/administration & dosage/therapeutic use', 'Placebo Effect', 'Practice Guidelines as Topic/standards', 'Psychotherapy/methods', 'Selegiline/administration & dosage/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21272511/
189,Deprenyl,1510374,Neuroprotective clinical strategies for Parkinson's disease.,['Shoulson I'],"['Drug Therapy, Combination', 'Humans', 'Iron/metabolism', 'Oxidation-Reduction', 'Parkinson Disease/*drug therapy/metabolism', 'Selegiline/therapeutic use', 'Vitamin E/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1510374/
190,Deprenyl,21971003,The pharmacology of selegiline.,['Magyar K'],"['Animals', 'Humans', 'Monoamine Oxidase/metabolism', 'Monoamine Oxidase Inhibitors/chemistry/pharmacology', 'Neuroprotective Agents/chemistry/*pharmacology', 'Parkinson Disease/drug therapy/metabolism', 'Selegiline/chemistry/*pharmacology', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/21971003/
191,Deprenyl,9429838,Drug interactions of clinical significance with selective serotonin reuptake inhibitors.,['Mitchell PB'],"['Antidepressive Agents, Tricyclic/pharmacokinetics', 'Benzamides/pharmacology', '*Cytochrome P-450 Enzyme Inhibitors', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lithium/pharmacology', 'Liver/*drug effects/enzymology', 'Moclobemide', 'Monoamine Oxidase Inhibitors/*pharmacokinetics', 'Selegiline/pharmacokinetics', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/pharmacokinetics/*pharmacology', 'Sumatriptan/pharmacokinetics', 'Tryptophan/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9429838/
192,Deprenyl,370348,Experiences with L-deprenyl in Parkinsonism.,"['Csanda E', 'Antal J', 'Antony M', 'Csanaky A']","['Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Levodopa/therapeutic use', 'Male', 'Movement Disorders/drug therapy', 'Parkinson Disease/*drug therapy', 'Phenethylamines/*therapeutic use', 'Selegiline/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/370348/
193,Deprenyl,6430257,l-Deprenyl in atypical depressives.,"['Quitkin FM', 'Liebowitz MR', 'Stewart JW', 'McGrath PJ', 'Harrison W', 'Rabkin JG', 'Markowitz J', 'Davies SO']","['Adult', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Dextroamphetamine/pharmacology', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Emotions/drug effects', 'Female', 'Humans', 'Male', 'Phenelzine/therapeutic use', 'Phenethylamines/*therapeutic use', 'Placebos', 'Psychiatric Status Rating Scales', 'Selegiline/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6430257/
194,Deprenyl,3114597,The current status of monoamine oxidase and its inhibitors.,"['Jarrott B', 'Vajda FJ']","['Allylamine/analogs & derivatives/pharmacology/therapeutic use', 'Benzamides/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Moclobemide', 'Monoamine Oxidase/classification/*metabolism', 'Monoamine Oxidase Inhibitors/pharmacology/*therapeutic use', 'Oxazoles/pharmacology/therapeutic use', '*Oxazolidinones', 'Selegiline/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3114597/
195,Deprenyl,15261846,Pitfalls of animal model systems in ageing research.,"['Flurkey K', 'Currer JM']","['*Aging', 'Animals', 'Biomarkers', 'Dehydroepiandrosterone/administration & dosage', 'Humans', '*Models, Animal', '*Research', 'Resveratrol', 'Selegiline/administration & dosage', 'Stilbenes/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/15261846/
196,Deprenyl,17163807,Seligiline transdermal system in depression.,['Goodnick PJ'],"['Administration, Cutaneous', 'Depressive Disorder/*drug therapy/epidemiology/psychology', 'Drug Delivery Systems/*methods', 'Humans', 'Psychiatric Status Rating Scales', 'Selegiline/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/17163807/
197,Deprenyl,16274338,Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.,"['Henchcliffe C', 'Schumacher HC', 'Burgut FT']","['Antiparkinson Agents/chemistry/metabolism/*therapeutic use', 'Brain/drug effects/metabolism', 'Clinical Trials as Topic', 'Diet Therapy/methods', 'Dopamine Agents/therapeutic use', 'Drug Evaluation', 'Drug Interactions', 'Expert Testimony', 'Humans', 'Indans/*therapeutic use', 'Levodopa/therapeutic use', 'Monoamine Oxidase Inhibitors/chemistry/metabolism/*therapeutic use', 'Parkinson Disease/*drug therapy', 'Selegiline/chemistry/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16274338/
198,Deprenyl,9749588,Neuroprotection for Parkinson's disease.,['Koller WC'],"['Antiparkinson Agents/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Dopamine Agents/*adverse effects', 'Humans', 'Levodopa/*adverse effects', 'Neuroprotective Agents/*therapeutic use', 'Parkinson Disease/*drug therapy', 'Selegiline/therapeutic use', 'Vitamin E/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9749588/
199,Docetaxol,33186519,Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.,"['Guccini I', 'Revandkar A', ""D'Ambrosio M"", 'Colucci M', 'Pasquini E', 'Mosole S', 'Troiani M', 'Brina D', 'Sheibani-Tezerji R', 'Elia AR', 'Rinaldi A', 'Pernigoni N', 'Ruschoff JH', 'Dettwiler S', 'De Marzo AM', 'Antonarakis ES', 'Borrelli C', 'Moor AE', 'Garcia-Escudero R', 'Alajati A', 'Attanasio G', 'Losa M', 'Moch H', 'Wild P', 'Egger G', 'Alimonti A']","['Animals', 'Cellular Senescence/drug effects', 'Docetaxel/*administration & dosage/pharmacology', '*Gene Deletion', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Male', 'Matrix Metalloproteinases/metabolism', 'Mice', 'Neoplasm Metastasis', 'Neoplasm Transplantation', 'PC-3 Cells', 'PTEN Phosphohydrolase/*genetics', 'Prostatic Neoplasms/drug therapy/genetics/metabolism/*pathology', 'Tissue Inhibitor of Metalloproteinase-1/*genetics']",https://pubmed.ncbi.nlm.nih.gov/33186519/
200,Docetaxol,29384722,Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.,"['Kyriakopoulos CE', 'Chen YH', 'Carducci MA', 'Liu G', 'Jarrard DF', 'Hahn NM', 'Shevrin DH', 'Dreicer R', 'Hussain M', 'Eisenberger M', 'Kohli M', 'Plimack ER', 'Vogelzang NJ', 'Picus J', 'Cooney MM', 'Garcia JA', 'DiPaola RS', 'Sweeney CJ']","['Androgen Antagonists/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Docetaxel/*administration & dosage/adverse effects', 'Humans', 'Male', 'Neoplasm Metastasis', 'Neoplasms, Hormone-Dependent/*drug therapy/mortality/pathology', 'Prostatic Neoplasms/*drug therapy/mortality/pathology', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29384722/
201,Docetaxol,38722620,Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.,"['Hussain M', 'Fizazi K', 'Shore ND', 'Heidegger I', 'Smith MR', 'Tombal B', 'Saad F']","['Humans', 'Male', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Androgen Antagonists/therapeutic use', '*Prostatic Neoplasms/drug therapy/pathology/mortality', 'Treatment Outcome', 'Neoplasm Metastasis', 'Androgen Receptor Antagonists/therapeutic use', 'Docetaxel/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38722620/
202,Docetaxol,30509740,"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","['Cohen EEW', 'Soulieres D', 'Le Tourneau C', 'Dinis J', 'Licitra L', 'Ahn MJ', 'Soria A', 'Machiels JP', 'Mach N', 'Mehra R', 'Burtness B', 'Zhang P', 'Cheng J', 'Swaby RF', 'Harrington KJ']","['Aged', 'Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', 'Cetuximab/administration & dosage/adverse effects/therapeutic use', 'Disease Progression', 'Docetaxel/administration & dosage/adverse effects', 'Drug Administration Schedule', 'Female', 'Head and Neck Neoplasms/*drug therapy/pathology', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Methotrexate/administration & dosage/adverse effects', 'Middle Aged', 'Neoplasm Recurrence, Local/*drug therapy', 'Squamous Cell Carcinoma of Head and Neck/*drug therapy/pathology/secondary']",https://pubmed.ncbi.nlm.nih.gov/30509740/
203,Docetaxol,36184068,"Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.","['Zhou C', 'Huang D', 'Fan Y', 'Yu X', 'Liu Y', 'Shu Y', 'Ma Z', 'Wang Z', 'Cheng Y', 'Wang J', 'Hu S', 'Liu Z', 'Poddubskaya E', 'Disel U', 'Akopov A', 'Dvorkin M', 'Zheng W', 'Ma Y', 'Wang Y', 'Li S', 'Yu C', 'Rivalland G']","['Humans', 'Docetaxel/pharmacology/therapeutic use', 'B7-H1 Antigen/metabolism', '*Lung Neoplasms/pathology', '*Antineoplastic Agents/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/pathology', 'Biomarkers']",https://pubmed.ncbi.nlm.nih.gov/36184068/
204,Docetaxol,38767468,Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy.,"['Ye SJ', 'Huang RD', 'Fei X', 'Tao ZL', 'Liu WH', 'Ma Q']","['Humans', 'Male', '*Androgen Antagonists/therapeutic use', '*Prostatic Neoplasms/drug therapy/pathology', '*Docetaxel/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', 'Quality of Life', 'Antineoplastic Agents, Hormonal/therapeutic use/administration & dosage', 'Neoplasm Metastasis']",https://pubmed.ncbi.nlm.nih.gov/38767468/
205,Docetaxol,31345386,Induction chemotherapy in head and neck cancers: Results and controversies.,"['Gau M', 'Karabajakian A', 'Reverdy T', 'Neidhardt EM', 'Fayette J']","['Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Cetuximab/administration & dosage/adverse effects', 'Chemoradiotherapy/adverse effects/*methods', 'Cisplatin/administration & dosage/adverse effects', 'Docetaxel/administration & dosage/adverse effects', 'Fluorouracil/administration & dosage/adverse effects', 'Head and Neck Neoplasms/pathology/*therapy', 'Humans', 'Induction Chemotherapy/adverse effects/*methods', 'Laryngectomy/adverse effects', 'Larynx/drug effects/pathology/radiation effects/surgery', 'Neoplasm Staging', 'Organ Sparing Treatments/adverse effects/*methods', 'Progression-Free Survival', 'Randomized Controlled Trials as Topic', 'Squamous Cell Carcinoma of Head and Neck/pathology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/31345386/
206,Docetaxol,38729054,Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.,"['Rescigno P', 'Porta N', 'Finneran L', 'Riisnaes R', 'Figueiredo I', 'Carreira S', 'Flohr P', 'Miranda S', 'Bertan C', 'Ferreira A', 'Crespo M', 'Rodrigues DN', 'Gurel B', 'Nobes J', 'Crabb S', 'Malik Z', 'Ralph C', 'McGovern U', 'Hoskin P', 'Jones RJ', 'Birtle A', 'Gale J', 'Sankey P', 'Jain S', 'McLaren D', 'Chadwick E', 'Espinasse A', 'Hall E', 'de Bono J']","['Humans', 'Male', '*Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', '*Phenylthiohydantoin/administration & dosage/therapeutic use/adverse effects', '*Benzamides', '*Docetaxel/administration & dosage/therapeutic use', 'Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Middle Aged', '*Nitriles', 'Double-Blind Method', '*Pyrimidines/therapeutic use/administration & dosage/adverse effects', 'Androstenes/therapeutic use/administration & dosage', 'Aged, 80 and over', 'Pyrroles']",https://pubmed.ncbi.nlm.nih.gov/38729054/
207,Docetaxol,32749138,Current Development of Oral Taxane Formulations: A Review.,"['Chowdhury N', 'Singh M']","['Administration, Oral', 'Animals', 'Antineoplastic Agents/administration & dosage/chemistry/pharmacokinetics', 'Antineoplastic Agents, Phytogenic/administration & dosage/chemistry/pharmacokinetics', 'Clinical Trials as Topic', 'Docetaxel/*administration & dosage/chemistry/pharmacokinetics', 'Drug Carriers/administration & dosage/chemistry', 'Drug Compounding', 'Drug Delivery Systems', 'Humans', 'Lipids/administration & dosage/chemistry', 'Micelles', 'Nanoparticles/administration & dosage/chemistry', 'Paclitaxel/*administration & dosage/chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/32749138/
208,Docetaxol,31977388,Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.,"['Kinsey EN', 'Zhang T', 'Armstrong AJ']","['Androgen Antagonists/administration & dosage/adverse effects/economics', 'Androstenes/administration & dosage/adverse effects/economics', 'Antineoplastic Agents, Hormonal/*administration & dosage/adverse effects/economics', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/economics', 'Benzamides', 'Chemoradiotherapy/economics/*methods/trends', 'Disease-Free Survival', 'Docetaxel/administration & dosage/adverse effects/economics', 'Drug Administration Schedule', 'Drug Costs', 'Humans', 'Male', 'Medical Oncology/economics/*methods/trends', 'Nitriles', 'Phenylthiohydantoin/administration & dosage/adverse effects/analogs & derivatives/economics', 'Prostatic Neoplasms/mortality/pathology/*therapy', 'Randomized Controlled Trials as Topic', 'Thiohydantoins/administration & dosage/adverse effects/economics', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/31977388/
209,Docetaxol,39223303,Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.,"['Wang T', 'Wang X', 'Ding G', 'Liu H', 'Ma X', 'Ma J', 'Cui Y', 'Wu J']","['Humans', 'Male', '*Androgen Antagonists/administration & dosage/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects', 'Benzamides', 'Docetaxel/administration & dosage/therapeutic use', 'Neoplasm Metastasis', 'Network Meta-Analysis', 'Nitriles/therapeutic use/administration & dosage', 'Phenylthiohydantoin/therapeutic use/administration & dosage/adverse effects', 'Progression-Free Survival', '*Prostatic Neoplasms, Castration-Resistant/drug therapy/mortality/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39223303/
210,Docetaxol,32701855,The evolving options in metastatic castration-sensitive prostate cancer.,['Hamilou Z'],"['Androgen Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Androstenes/therapeutic use', 'Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Benzamides/therapeutic use', 'Docetaxel/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Male', 'Neoplasm Metastasis', 'Nitriles/therapeutic use', 'Phenylthiohydantoin/therapeutic use', 'Prostatic Neoplasms/*drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32701855/
211,Docetaxol,30015691,Treatment of hormone-naive metastatic prostate cancer.,"['Hamilou Z', 'Saad F', 'Fizazi K']","['Androgen Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Androstenes/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials, Phase III as Topic', 'Docetaxel/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Male', 'Neoplasm Metastasis', 'Prospective Studies', 'Prostatic Neoplasms/*drug therapy/mortality/pathology', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/30015691/
212,Docetaxol,29722038,Long-term abiraterone withdrawal syndrome.,"['Marin S', 'Querol R', 'Campins L', 'Miarons M', 'Font A', 'Lianes P']","['Abiraterone Acetate/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use', 'Docetaxel/administration & dosage/adverse effects', 'Humans', 'Male', 'Prednisone/administration & dosage/adverse effects', 'Prostate-Specific Antigen/metabolism', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/metabolism', 'Substance Withdrawal Syndrome/*etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29722038/
213,Docetaxol,39250535,"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.","['Ahn MJ', 'Tanaka K', 'Paz-Ares L', 'Cornelissen R', 'Girard N', 'Pons-Tostivint E', 'Vicente Baz D', 'Sugawara S', 'Cobo M', 'Perol M', 'Mascaux C', 'Poddubskaya E', 'Kitazono S', 'Hayashi H', 'Hong MH', 'Felip E', 'Hall R', 'Juan-Vidal O', 'Brungs D', 'Lu S', 'Garassino M', 'Chargualaf M', 'Zhang Y', 'Howarth P', 'Uema D', 'Lisberg A', 'Sands J']","['Humans', '*Docetaxel/therapeutic use/administration & dosage/adverse effects', '*Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/mortality', '*Lung Neoplasms/drug therapy/pathology/mortality', 'Male', 'Middle Aged', 'Female', 'Aged', 'Adult', 'Aged, 80 and over', 'Progression-Free Survival', 'Immunoconjugates/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39250535/
214,Docetaxol,30382284,Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.,"['Mikula-Pietrasik J', 'Witucka A', 'Pakula M', 'Uruski P', 'Begier-Krasinska B', 'Niklas A', 'Tykarski A', 'Ksiazek K']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Cell Physiological Phenomena/*drug effects/genetics/physiology', 'Cisplatin/administration & dosage/adverse effects', 'Docetaxel/administration & dosage/adverse effects', 'Female', 'Humans', 'Models, Biological', 'Ovarian Neoplasms/*drug therapy/genetics/metabolism', 'Paclitaxel/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30382284/
215,Docetaxol,38629735,Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.,"['Hsu TI', 'Chen YP', 'Zhang RL', 'Chen ZA', 'Wu CH', 'Chang WC', 'Mou CY', 'Chan HW', 'Wu SH']","['*Temozolomide/chemistry/pharmacology/therapeutic use/pharmacokinetics', '*Glioblastoma/drug therapy/pathology/metabolism', '*Docetaxel/chemistry/pharmacology/pharmacokinetics/therapeutic use', '*Silicon Dioxide/chemistry', '*Blood-Brain Barrier/drug effects/metabolism', 'Animals', '*Nanoparticles/chemistry', 'Humans', 'Mice', '*Drug Resistance, Neoplasm/drug effects', 'Brain Neoplasms/drug therapy/pathology/metabolism', 'Cell Line, Tumor', 'Porosity', 'Drug Carriers/chemistry', 'Mice, Nude', 'Antineoplastic Agents/chemistry/pharmacology', 'Apoptosis/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38629735/
216,Docetaxol,38565395,All-stage targeted red blood cell membrane-coated docetaxel nanocrystals for glioma treatment.,"['Ding Y', 'Xu Q', 'Chai Z', 'Wu S', 'Xu W', 'Wang J', 'Zhou J', 'Luo Z', 'Liu Y', 'Xie C', 'Lu L', 'Lu W']","['*Docetaxel/administration & dosage/pharmacokinetics/chemistry', '*Glioma/drug therapy', 'Animals', '*Nanoparticles/chemistry', '*Antineoplastic Agents/administration & dosage/pharmacokinetics/chemistry/therapeutic use', '*Erythrocyte Membrane/drug effects/chemistry', 'Cell Line, Tumor', '*Brain Neoplasms/drug therapy', 'Male', 'Drug Delivery Systems', 'Avidin/administration & dosage/chemistry', 'Humans', 'Biotin/chemistry/administration & dosage', 'Rats, Sprague-Dawley', 'Blood-Brain Barrier/metabolism', 'Mice, Inbred BALB C', 'Mice, Nude']",https://pubmed.ncbi.nlm.nih.gov/38565395/
217,Docetaxol,34969724,Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.,"['Quesada S', 'Samalin E', 'Thezenas S', 'Khellaf L', 'Mourregot A', 'Portales F', 'Mazard T', 'Ychou M', 'Adenis A']","['Adenocarcinoma/blood/*drug therapy/pathology', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'CA-19-9 Antigen/blood', 'Carcinoembryonic Antigen/blood', 'Disease-Free Survival', 'Docetaxel/administration & dosage/adverse effects', 'Esophagogastric Junction/drug effects/pathology', 'Female', 'Fluorouracil/administration & dosage/adverse effects', 'Humans', 'Leucovorin/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Neoadjuvant Therapy', 'Organoplatinum Compounds/administration & dosage/adverse effects', 'Oxaliplatin/administration & dosage/adverse effects', 'Perioperative Period', 'Proportional Hazards Models', 'Stomach Neoplasms/blood/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/34969724/
218,Docetaxol,38552197,CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.,"['Neal J', 'Pavlakis N', 'Kim SW', 'Goto Y', 'Lim SM', 'Mountzios G', 'Fountzilas E', 'Mochalova A', 'Christoph DC', 'Bearz A', 'Quantin X', 'Palmero R', 'Antic V', 'Chun E', 'Edubilli TR', 'Lin YC', 'Huseni M', 'Ballinger M', 'Graupner V', 'Curran D', 'Vervaet P', 'Newsom-Davis T']","['Humans', '*Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/mortality', '*Docetaxel/therapeutic use/administration & dosage/adverse effects', '*Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration & dosage', '*Lung Neoplasms/drug therapy/pathology/mortality', '*Pyridines/therapeutic use/administration & dosage/adverse effects', 'Male', 'Female', '*Anilides/therapeutic use/administration & dosage/adverse effects', 'Middle Aged', 'Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Immune Checkpoint Inhibitors/therapeutic use/adverse effects', 'Adult', 'Aged, 80 and over', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38552197/
219,Etiracetam,30036676,Levetiracetam.,"['Howard P', 'Remi J', 'Remi C', 'Charlesworth S', 'Whalley H', 'Bhatia R', 'Hitchens M', 'Mihalyo M', 'Wilcock A']","['Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Hospice Care', 'Humans', 'Levetiracetam/adverse effects/pharmacology/*therapeutic use', 'Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/30036676/
220,Etiracetam,35838207,Management of epilepsy in brain tumor patients.,"['van der Meer PB', 'Taphoorn MJB', 'Koekkoek JAF']","['Anticonvulsants/adverse effects/therapeutic use', 'Benzodiazepines/therapeutic use', '*Brain Neoplasms/complications/drug therapy', '*Epilepsy/drug therapy/etiology/prevention & control', 'Humans', 'Isocitrate Dehydrogenase', 'Lacosamide/therapeutic use', 'Levetiracetam/therapeutic use', 'Seizures/chemically induced/etiology', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35838207/
221,Etiracetam,31774955,Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.,"['Kapur J', 'Elm J', 'Chamberlain JM', 'Barsan W', 'Cloyd J', 'Lowenstein D', 'Shinnar S', 'Conwit R', 'Meinzer C', 'Cock H', 'Fountain N', 'Connor JT', 'Silbergleit R']","['Adolescent', 'Adult', 'Anticonvulsants/adverse effects/*therapeutic use', 'Benzodiazepines/therapeutic use', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Drug Resistance', 'Female', 'Humans', 'Hypotension/chemically induced', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Levetiracetam/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Phenytoin/adverse effects/*analogs & derivatives/therapeutic use', 'Status Epilepticus/*drug therapy', 'Valproic Acid/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31774955/
222,Etiracetam,31917143,Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.,"['Romoli M', 'Perucca E', 'Sen A']","['Anticonvulsants/*adverse effects', 'Diagnostic Tests, Routine', 'Dietary Supplements', 'Drug Therapy, Combination', 'Epilepsy/drug therapy/psychology', 'Humans', 'Levetiracetam/*adverse effects', 'Mental Disorders/*chemically induced/*drug therapy/psychology', 'Prospective Studies', 'Pyridoxine/*administration & dosage', 'Quality of Life/psychology', 'Retrospective Studies', 'Vitamin B Complex/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31917143/
223,Etiracetam,33573557,"Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.","['Kaplan YC', 'Demir O']","['Anticonvulsants/adverse effects', 'Breast Feeding', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lamotrigine/adverse effects', 'Levetiracetam/adverse effects', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', '*Pregnancy Complications/drug therapy', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33573557/
224,Etiracetam,31033711,Brivaracetam for epilepsy.,"['Hellerslia V', 'Asistido JM', 'Iyamu A']","['Anticonvulsants/*therapeutic use', 'Drug Costs', 'Epilepsy/*drug therapy', 'Humans', 'Insurance Coverage/economics', 'Levetiracetam/administration & dosage/adverse effects/economics/therapeutic use', 'Practice Guidelines as Topic', 'Pyrrolidinones/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31033711/
225,Etiracetam,32385134,Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.,"['Sharpe C', 'Reiner GE', 'Davis SL', 'Nespeca M', 'Gold JJ', 'Rasmussen M', 'Kuperman R', 'Harbert MJ', 'Michelson D', 'Joe P', 'Wang S', 'Rismanchi N', 'Le NM', 'Mower A', 'Kim J', 'Battin MR', 'Lane B', 'Honold J', 'Knodel E', 'Arnell K', 'Bridge R', 'Lee L', 'Ernstrom K', 'Raman R', 'Haas RH']","['Anticonvulsants/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Epilepsy, Benign Neonatal/diagnosis/*drug therapy/*physiopathology', 'Female', 'Humans', 'Infant, Newborn', 'Levetiracetam/*therapeutic use', 'Male', 'Phenobarbital/*therapeutic use', 'Seizures/diagnosis/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/32385134/
226,Etiracetam,35523739,Individualizing doses of antiepileptic drugs.,"['Liparoti G', 'Burchiani B', 'Mencaroni E', 'Tripodi D', 'Di Cara G', 'Verrotti A']","['*Anticonvulsants/adverse effects', '*Carbamazepine/therapeutic use', 'Humans', 'Lamotrigine', 'Levetiracetam', 'Topiramate']",https://pubmed.ncbi.nlm.nih.gov/35523739/
227,Etiracetam,32859841,Levetiracetam-Induced Hepatic Dysfunction.,"['Gayatri P', 'Selvam MM', 'Sreeharsha SV']","['*Anticonvulsants/adverse effects', 'Humans', 'Levetiracetam/adverse effects', '*Piracetam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32859841/
228,Etiracetam,35976303,"Status epilepticus: review on diagnosis, monitoring and treatment.","['Pinto LF', 'Oliveira JPS', 'Midon AM']","['Anticonvulsants/therapeutic use', 'Benzodiazepines/therapeutic use', 'Humans', 'Levetiracetam/therapeutic use', 'Seizures/complications', '*Status Epilepticus/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35976303/
229,Etiracetam,29208197,[Treatment of rolandic epilepsy].,"['Miranda MJ', 'Ahmad BB']","['Anticonvulsants/*therapeutic use', 'Child', 'Cognition Disorders/etiology', 'Electroencephalography', 'Epilepsy, Rolandic/complications/diagnosis/*drug therapy', 'Humans', 'Levetiracetam/therapeutic use', 'Thiazines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29208197/
230,Etiracetam,36842341,Epilepsy and brain tumors: Two sides of the same coin.,"['Aronica E', 'Ciusani E', 'Coppola A', 'Costa C', 'Russo E', 'Salmaggi A', 'Perversi F', 'Maschio M']","['Humans', 'Anticonvulsants/therapeutic use', '*Epilepsy/complications', 'Levetiracetam/therapeutic use', 'Valproic Acid/therapeutic use', '*Brain Neoplasms/complications']",https://pubmed.ncbi.nlm.nih.gov/36842341/
231,Etiracetam,34286461,Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis.,"['Fang T', 'Valdes E', 'Frontera JA']","['Adolescent', '*Anticonvulsants/therapeutic use', 'Child', 'Humans', 'Levetiracetam/therapeutic use', 'Prospective Studies', 'Retrospective Studies', '*Seizures/drug therapy/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/34286461/
232,Etiracetam,34164804,Rapid administration of undiluted intravenous levetiracetam.,"['Haller JT', 'Bonnin S', 'Radosevich J']","['Adult', 'Anticonvulsants/adverse effects', '*Drug-Related Side Effects and Adverse Reactions', '*Epilepsy/drug therapy', 'Humans', 'Levetiracetam/therapeutic use', '*Piracetam/adverse effects', 'Seizures/drug therapy', '*Status Epilepticus/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34164804/
233,Etiracetam,36209676,Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses.,"['Jain P', 'Aneja S', 'Cunningham J', 'Arya R', 'Sharma S']","['Adult', 'Child', 'Humans', 'Anticonvulsants/therapeutic use', '*Benzodiazepines/pharmacology', 'Levetiracetam/therapeutic use', 'Network Meta-Analysis', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Seizures/drug therapy', '*Status Epilepticus/drug therapy', 'Valproic Acid/therapeutic use', '*Drug Resistance', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36209676/
234,Etiracetam,33839453,"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.","['Steinhoff BJ', 'Klein P', 'Klitgaard H', 'Laloyaux C', 'Moseley BD', 'Ricchetti-Masterson K', 'Rosenow F', 'Sirven JI', 'Smith B', 'Stern JM', 'Toledo M', 'Zipfel PA', 'Villanueva V']","['*Anticonvulsants/adverse effects', 'Humans', 'Levetiracetam/therapeutic use', 'Nitriles', 'Observational Studies as Topic', 'Pyridones', '*Pyrrolidinones', 'Retrospective Studies', 'Topiramate/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33839453/
235,Etiracetam,32203691,"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.","['Chamberlain JM', 'Kapur J', 'Shinnar S', 'Elm J', 'Holsti M', 'Babcock L', 'Rogers A', 'Barsan W', 'Cloyd J', 'Lowenstein D', 'Bleck TP', 'Conwit R', 'Meinzer C', 'Cock H', 'Fountain NB', 'Underwood E', 'Connor JT', 'Silbergleit R']","['Adolescent', 'Adult', 'Age Distribution', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Anticonvulsants/*administration & dosage/adverse effects', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Infant', 'Levetiracetam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Phenytoin/administration & dosage/adverse effects/*analogs & derivatives', 'Status Epilepticus/*drug therapy', 'Valproic Acid/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32203691/
236,Etiracetam,11449876,Levetiracetam.,"['Nash EM', 'Sangha KS']","['*Anticonvulsants/adverse effects/pharmacokinetics/therapeutic use', 'Area Under Curve', 'Biological Availability', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Interactions', 'Epilepsy/*drug therapy', 'Half-Life', 'Humans', 'Intestinal Absorption', 'Levetiracetam', '*Piracetam/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/11449876/
237,Etiracetam,37378757,Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.,"['Chu H', 'Zhang X', 'Shi J', 'Zhou Z', 'Yang X']","['Humans', 'Child', '*Valproic Acid/adverse effects', 'Topiramate/therapeutic use', 'Network Meta-Analysis', 'Levetiracetam/therapeutic use', 'Ethosuximide/adverse effects', 'Anticonvulsants/adverse effects', '*Epilepsy, Generalized/drug therapy', 'Seizures/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37378757/
238,Etiracetam,34570177,Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.,"['Vossel K', 'Ranasinghe KG', 'Beagle AJ', 'La A', 'Ah Pook K', 'Castro M', 'Mizuiri D', 'Honma SM', 'Venkateswaran N', 'Koestler M', 'Zhang W', 'Mucke L', 'Howell MJ', 'Possin KL', 'Kramer JH', 'Boxer AL', 'Miller BL', 'Nagarajan SS', 'Kirsch HE']","['Aged', 'Aged, 80 and over', 'Alzheimer Disease/complications/*drug therapy', 'Anticonvulsants/*therapeutic use', 'Cognition/*drug effects', 'Cross-Over Studies', 'Double-Blind Method', 'Executive Function/drug effects', 'Female', 'Humans', 'Levetiracetam/*therapeutic use', 'Male', 'Middle Aged', '*Seizures/etiology']",https://pubmed.ncbi.nlm.nih.gov/34570177/
239,Gemifloxacin,24211230,Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.,"['Grossman RF', 'Hsueh PR', 'Gillespie SH', 'Blasi F']","['Anti-Bacterial Agents/therapeutic use', 'Community-Acquired Infections/*diagnosis/drug therapy', 'Diagnosis, Differential', 'Dose-Response Relationship, Drug', 'Fluoroquinolones/therapeutic use', 'Humans', 'Mycobacterium tuberculosis/drug effects', 'Pneumonia/*diagnosis/drug therapy', 'Prevalence', 'Tuberculosis/*diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24211230/
240,Gemifloxacin,16572887,Cutaneous adverse events and gemifloxacin: observations from the clinical trial program.,"['Iannini P', 'Mandell L', 'Patou G', 'Shear N']","['Clinical Trials as Topic', 'Exanthema/*chemically induced', 'Fluoroquinolones/*adverse effects', 'Gemifloxacin', 'Humans', 'Naphthyridines/*adverse effects', 'Respiratory Tract Infections/*drug therapy', 'Risk Factors', 'Skin/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/16572887/
241,Gemifloxacin,17699224,Urinary tract infections in patients with chronic renal insufficiency.,['Gilbert DN'],"['Animals', 'Humans', 'Renal Insufficiency, Chronic/*complications', 'Urinary Tract Infections/*drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/17699224/
242,Gemifloxacin,33038911,"1,8-Naphthyridine Derivatives: A Privileged Scaffold for Versatile Biological Activities.","['Ojha M', 'Yadav D', 'Kumar A', 'Dasgupta S', 'Yadav R']","['Animals', 'Anti-Infective Agents/pharmacology', 'Anti-Inflammatory Agents/chemistry', 'Anticonvulsants/pharmacology', 'Antidepressive Agents/pharmacology', 'Antipsychotic Agents/pharmacology', 'Enoxacin/pharmacology', 'Fluoroquinolones/pharmacology', 'Gemifloxacin/pharmacology', 'Humans', 'Nalidixic Acid/pharmacology', 'Naphthyridines/chemical synthesis/*pharmacology', 'Nitrogen/*chemistry', 'Polypharmacy', 'Thiazoles/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33038911/
243,Gemifloxacin,17095177,13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.,"['Roig J', 'Casal J', 'Gispert P', 'Gea E']","['Anti-Bacterial Agents/*therapeutic use', 'Community-Acquired Infections/*drug therapy', 'Doxycycline/therapeutic use', 'Fluoroquinolones/therapeutic use', 'Humans', 'Ketolides/therapeutic use', 'Macrolides/therapeutic use', 'Pneumonia, Bacterial/*drug therapy', 'Q Fever/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17095177/
244,Gemifloxacin,15102588,New therapies for pneumococcal meningitis.,"['Cottagnoud PH', 'Tauber MG']","['Animals', 'Anti-Bacterial Agents/*therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Humans', 'Meningitis, Pneumococcal/*drug therapy', 'Technology, Pharmaceutical/methods/*trends']",https://pubmed.ncbi.nlm.nih.gov/15102588/
245,Gemifloxacin,14729748,Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae.,"['Morrissey I', 'Tillotson G']","['Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Drug Resistance, Multiple', 'Fluoroquinolones/*pharmacology/therapeutic use', 'Gemifloxacin', 'Haemophilus Infections/drug therapy/microbiology', 'Haemophilus influenzae/*drug effects', 'Humans', 'Naphthyridines/*pharmacology/therapeutic use', 'Pneumococcal Infections/drug therapy/microbiology', 'Streptococcus pneumoniae/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/14729748/
246,Gemifloxacin,12032897,Resistance among Streptococcus pneumoniae: Implications for drug selection.,['Appelbaum PC'],"['4-Quinolones', 'Anti-Bacterial Agents/*pharmacology', 'Anti-Infective Agents/pharmacology', 'Drug Resistance/genetics', 'Drug Resistance, Multiple/*genetics', 'Gene Frequency', 'Humans', 'Macrolides', 'Microbial Sensitivity Tests', 'Pneumococcal Vaccines/therapeutic use', 'Pneumonia, Pneumococcal/prevention & control', 'Streptococcus pneumoniae/*drug effects/genetics', 'Tetracycline/pharmacology', 'Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12032897/
247,Gemifloxacin,10959772,New approaches in the treatment of bacterial infections.,"['Bush K', 'Macielag M']","['Anti-Infective Agents/therapeutic use', 'Bacterial Infections/*drug therapy', 'Humans', 'Molecular Structure']",https://pubmed.ncbi.nlm.nih.gov/10959772/
248,Gemifloxacin,15940410,New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.,['Ferrara AM'],"['Anti-Bacterial Agents/pharmacokinetics/*pharmacology', '*Drug Resistance, Bacterial', 'Fluoroquinolones/pharmacokinetics/*pharmacology', 'Humans', 'Pneumococcal Infections/drug therapy', 'Respiratory Tract Infections/*drug therapy', 'Streptococcus pneumoniae/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/15940410/
249,Gemifloxacin,22156660,QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.,"['Briasoulis A', 'Agarwal V', 'Pierce WJ']","['Action Potentials/drug effects', 'Electrocardiography/drug effects', 'Fluoroquinolones/*adverse effects/pharmacokinetics', 'Humans', 'Long QT Syndrome/*chemically induced', 'Potassium Channels, Voltage-Gated/antagonists & inhibitors', 'Prospective Studies', 'Randomized Controlled Trials as Topic', 'Torsades de Pointes/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/22156660/
250,Gemifloxacin,17267335,Geminofloxacin for the management of community-acquired respiratory tract infections.,"['Blondeau JM', 'Tillotson G', 'Deangelis J']","['Anti-Bacterial Agents/therapeutic use', 'Community-Acquired Infections/drug therapy/economics/microbiology', 'Cost-Benefit Analysis', 'Drug Resistance, Bacterial', 'Fluoroquinolones/*therapeutic use', 'Gemifloxacin', 'Humans', 'Naphthyridines/*therapeutic use', 'Respiratory Tract Infections/*drug therapy/economics/microbiology', 'Streptococcus pneumoniae/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17267335/
251,Gemifloxacin,10824030,Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.,['Hammerschlag MR'],"['Adult', 'Anti-Infective Agents/*pharmacology', 'Chlamydia Infections/drug therapy', 'Chlamydophila pneumoniae/*drug effects', '*Fluoroquinolones', 'Gemifloxacin', 'Humans', 'Microbial Sensitivity Tests', 'Naphthyridines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10824030/
252,Gemifloxacin,20563449,Rhinoscleroma causing severe bilateral nasal obstruction.,"['Moraes MA', 'Magalhaes AV', 'Marinho LC', 'Azevedo AE', 'Carneiro FP', 'Raymundo IT']","['Adult', 'Anti-Bacterial Agents/therapeutic use', 'Female', 'Fluoroquinolones/therapeutic use', 'Gemifloxacin', 'Humans', 'Naphthyridines/therapeutic use', 'Nasal Obstruction/drug therapy/*etiology', 'Rhinoscleroma/*complications/drug therapy', 'Tetracycline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20563449/
253,Gemifloxacin,12454169,"Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan.","['Yu WL', 'Jones RN', 'Hollis RJ', 'Messer SA', 'Biedenbach DJ', 'Deshpande LM', 'Pfaller MA']","['Anti-Infective Agents/*pharmacology', 'Ciprofloxacin/*pharmacology', 'Drug Resistance, Multiple, Bacterial', 'Electrophoresis, Gel, Pulsed-Field', 'Humans', 'Klebsiella Infections/*epidemiology/microbiology', 'Klebsiella pneumoniae/classification/enzymology/*genetics', 'Microbial Sensitivity Tests', '*Molecular Epidemiology', 'Ribotyping', 'Taiwan/epidemiology', 'beta-Lactam Resistance', 'beta-Lactamases/*biosynthesis']",https://pubmed.ncbi.nlm.nih.gov/12454169/
254,Gemifloxacin,12821462,Effect of calcium carbonate on bioavailability of orally administered gemifloxacin.,"['Pletz MW', 'Petzold P', 'Allen A', 'Burkhardt O', 'Lode H']","['Administration, Oral', 'Adult', 'Antacids/*administration & dosage', 'Anti-Infective Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Calcium Carbonate/*administration & dosage', 'Cross-Over Studies', 'Drug Interactions', 'Female', '*Fluoroquinolones', 'Gemifloxacin', 'Humans', 'Male', 'Naphthyridines/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/12821462/
255,Gemifloxacin,12173118,"Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.",['Goldstein EJ'],"['Abdominal Abscess/*drug therapy/microbiology', 'Anti-Bacterial Agents/*therapeutic use', '*Aza Compounds', 'Bacteremia/etiology', 'Bacteria, Anaerobic', 'Bacteroides Infections/*drug therapy/microbiology', 'Bacteroides fragilis/*isolation & purification', 'Carbapenems/therapeutic use', 'Clinical Trials as Topic', 'Ertapenem', 'Fluoroquinolones/therapeutic use', 'Gemifloxacin', 'Humans', '*Indoles', '*Lactams', 'Moxifloxacin', 'Naphthyridines/therapeutic use', '*Quinolines', '*Quinolones', 'beta-Lactams']",https://pubmed.ncbi.nlm.nih.gov/12173118/
256,Gemifloxacin,18727805,"Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis.","['Bebear CM', 'de Barbeyrac B', 'Pereyre S', 'Renaudin H', 'Clerc M', 'Bebear C']","['Anti-Infective Agents/*pharmacology', 'Aza Compounds/*pharmacology', 'Chlamydia Infections/microbiology', 'Chlamydia trachomatis/*drug effects/isolation & purification', 'Female', 'Female Urogenital Diseases/microbiology', 'Fluoroquinolones', 'Humans', 'Male', 'Male Urogenital Diseases/microbiology', 'Microbial Sensitivity Tests', 'Moxifloxacin', 'Mycoplasma Infections/microbiology', 'Mycoplasma genitalium/*drug effects/isolation & purification', 'Mycoplasma hominis/*drug effects/isolation & purification', 'Quinolines/*pharmacology', 'Ureaplasma/*classification/*drug effects/isolation & purification', 'Ureaplasma Infections/microbiology']",https://pubmed.ncbi.nlm.nih.gov/18727805/
257,Glycopyrronium,34342835,Budesonide/Glycopyrronium/Formoterol: A Review in COPD.,['Heo YA'],"['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/*therapeutic use', 'Bronchodilator Agents/therapeutic use', 'Budesonide/*therapeutic use', 'Drug Combinations', 'Formoterol Fumarate/*therapeutic use', 'Glucocorticoids/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Metered Dose Inhalers', 'Muscarinic Antagonists/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/34342835/
258,Glycopyrronium,29079130,Indacaterol/glycopyrronium: a dual bronchodilator for COPD.,"['Banerji D', 'Fogel R', 'Patalano F']","['Adrenergic beta-2 Receptor Agonists/adverse effects/*therapeutic use', 'Bronchodilator Agents/adverse effects/*therapeutic use', 'Drug Approval', 'Drug Combinations', 'Glycopyrrolate/adverse effects/*therapeutic use', 'Humans', 'Indans/adverse effects/*therapeutic use', 'Muscarinic Antagonists/adverse effects/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Quinolones/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29079130/
259,Glycopyrronium,27181606,Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.,"['Wedzicha JA', 'Banerji D', 'Chapman KR', 'Vestbo J', 'Roche N', 'Ayers RT', 'Thach C', 'Fogel R', 'Patalano F', 'Vogelmeier CF']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/*therapeutic use', 'Aged', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Fluticasone-Salmeterol Drug Combination/adverse effects/*therapeutic use', 'Glucocorticoids/*therapeutic use', 'Glycopyrrolate/adverse effects/*therapeutic use', 'Humans', 'Indans/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Muscarinic Antagonists/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/mortality', 'Quinolones/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27181606/
260,Glycopyrronium,32772582,Glycopyrrolate and formoterol fumarate for the treatment of COPD.,"['Grillet PE', 'Le Souder C', 'Rohou J', 'Cazorla O', 'Charriot J', 'Bourdin A']","['Administration, Inhalation', 'Bronchodilator Agents/therapeutic use', '*Formoterol Fumarate/therapeutic use', '*Glycopyrrolate/therapeutic use', 'Humans', '*Pulmonary Disease, Chronic Obstructive/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32772582/
261,Glycopyrronium,25638324,Systemic treatment of hyperhidrosis.,['del Boz J'],"['Antihypertensive Agents/therapeutic use', 'Cholinergic Antagonists/therapeutic use', 'Clinical Trials as Topic', 'Disease Management', 'Evidence-Based Medicine', 'Glycopyrrolate/therapeutic use', 'Humans', 'Hyperhidrosis/*drug therapy', 'Meta-Analysis as Topic', 'Off-Label Use', 'Psychotropic Drugs/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25638324/
262,Glycopyrronium,33929661,Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.,"['Bourdin A', 'Molinari N', 'Ferguson GT', 'Singh B', 'Siddiqui MK', 'Holmgren U', 'Ouwens M', 'Jenkins M', 'De Nigris E']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/therapeutic use', 'Bayes Theorem', 'Bronchodilator Agents/adverse effects', 'Budesonide/adverse effects', 'Drug Combinations', 'Formoterol Fumarate/therapeutic use', 'Fumarates/therapeutic use', '*Glycopyrrolate/adverse effects', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Network Meta-Analysis', '*Pulmonary Disease, Chronic Obstructive/drug therapy', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/33929661/
263,Glycopyrronium,30502972,Pharmacological treatment of COPD - New evidence.,"['Pires N', 'Pinto P', 'Marcal N', 'Ferreira AJ', 'Rodrigues C', 'Barbara C']","['Administration, Inhalation', 'Algorithms', 'Bronchodilator Agents/therapeutic use', 'Disease Progression', 'Drug Combinations', 'Fluticasone-Salmeterol Drug Combination/administration & dosage/therapeutic use', 'Forced Expiratory Volume/*drug effects', 'Glycopyrrolate/administration & dosage/therapeutic use', 'Humans', 'Indans/administration & dosage/therapeutic use', 'Portugal/epidemiology', 'Prevalence', 'Prognosis', 'Pulmonary Disease, Chronic Obstructive/classification/*drug therapy/*mortality/physiopathology', 'Quinolones/administration & dosage/therapeutic use', 'Risk Factors', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/30502972/
264,Glycopyrronium,38008396,Can single-inhaler Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium therapy postpone or save biologics for severe asthma?,"['Dragonieri S', 'Quaranta VN', 'Portacci A', 'Carpagnano GE']","['Humans', 'Formoterol Fumarate/therapeutic use', 'Beclomethasone/therapeutic use', 'Glycopyrrolate/therapeutic use', '*Anti-Asthmatic Agents/therapeutic use', 'Administration, Inhalation', 'Drug Combinations', '*Asthma/drug therapy', 'Nebulizers and Vaporizers', 'Antibodies, Monoclonal/therapeutic use', '*Biological Products/therapeutic use', 'Bronchodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38008396/
265,Glycopyrronium,26455059,Use of Systemic Therapies to Manage Focal Hyperhidrosis.,"['Glaser DA', 'Glaser K']","['Adrenergic beta-Antagonists/therapeutic use', 'Benzodiazepines/therapeutic use', 'Cholinergic Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Disease Management', 'Drug Therapy, Combination', 'Glycopyrrolate/therapeutic use', 'Humans', 'Hyperhidrosis/*drug therapy', 'Mandelic Acids/therapeutic use', 'Patient Selection']",https://pubmed.ncbi.nlm.nih.gov/26455059/
266,Glycopyrronium,28814858,"Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.","['Dhungana S', 'Criner GJ']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Disease Progression', 'Drug Combinations', 'Forced Expiratory Volume', 'Formoterol Fumarate/*administration & dosage/adverse effects', 'Glycopyrrolate/*administration & dosage/adverse effects', 'Humans', 'Lung/*drug effects/physiopathology', 'Metered Dose Inhalers', 'Muscarinic Antagonists/*administration & dosage/adverse effects', 'Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28814858/
267,Glycopyrronium,7317246,Glycopyrrolate in children.,"['Warran P', 'Radford P', 'Manford ML']","['Administration, Oral', 'Atropine/administration & dosage/pharmacology', 'Body Temperature/drug effects', 'Child', 'Child, Preschool', 'Depression, Chemical', 'Glycopyrrolate/*pharmacology', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', '*Preanesthetic Medication', 'Pyrrolidines/*pharmacology', 'Salivation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/7317246/
268,Glycopyrronium,22956075,[Recommendations for death rattle].,"['Pastrana T', 'Reineke-Bracke H', 'Elsner F']","['Airway Resistance/drug effects/physiology', 'Atropine/adverse effects/*therapeutic use', 'Butylscopolammonium Bromide/adverse effects/*therapeutic use', 'Combined Modality Therapy', 'Glycopyrrolate/adverse effects/*therapeutic use', 'Humans', 'Mucus/physiology', 'Octreotide/adverse effects/*therapeutic use', 'Patient Positioning', 'Respiratory Sounds/*drug effects/physiology', 'Saliva/physiology', 'Scopolamine/adverse effects/*therapeutic use', 'Suction', 'Terminal Care/*methods/psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22956075/
269,Glycopyrronium,37213116,Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.,"['Feldman WB', 'Avorn J', 'Kesselheim AS', 'Gagne JJ']","['Humans', 'Female', 'Aged', 'Male', 'Glycopyrrolate/therapeutic use', 'Cohort Studies', 'Adrenergic beta-2 Receptor Agonists/therapeutic use', 'Administration, Inhalation', 'Fluticasone/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Nebulizers and Vaporizers', 'Muscarinic Antagonists/therapeutic use', 'Formoterol Fumarate/therapeutic use', '*Pulmonary Disease, Chronic Obstructive/drug therapy', '*Pneumonia/drug therapy', 'Bronchodilator Agents/adverse effects', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/37213116/
270,Glycopyrronium,39213002,"Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).","['Singh D', 'Martinez FJ', 'Hurst JR', 'Han MK', 'Gale CP', 'Fredriksson M', 'Kisielewicz D', 'Mushunje A', 'Movitz C', 'Ojili N', 'Parikh H', 'Arya N', 'Bowen K', 'Patel M']","['Humans', '*Pulmonary Disease, Chronic Obstructive/drug therapy/complications/physiopathology', 'Male', 'Female', 'Double-Blind Method', 'Aged', 'Middle Aged', '*Glycopyrrolate/therapeutic use', '*Cardiovascular Diseases/prevention & control', '*Formoterol Fumarate/therapeutic use/administration & dosage', 'Drug Therapy, Combination', 'Budesonide/therapeutic use/administration & dosage/adverse effects', 'Bronchodilator Agents/therapeutic use/administration & dosage', 'Administration, Inhalation', 'Treatment Outcome', 'Severity of Illness Index', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/39213002/
271,Glycopyrronium,10783431,Antisecretory agents in gastrointestinal obstruction.,"['Muir JC', 'von Gunten CF']","['Abdominal Pain/etiology', 'Gastric Juice/drug effects', 'Gastrointestinal Agents/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Intestinal Obstruction/*drug therapy/etiology/physiopathology', 'Intubation, Gastrointestinal/adverse effects', 'Muscarinic Antagonists/*therapeutic use', 'Octreotide/*therapeutic use', 'Palliative Care/*methods', 'Scopolamine/*therapeutic use', 'Terminal Care/*methods']",https://pubmed.ncbi.nlm.nih.gov/10783431/
272,Glycopyrronium,26211748,[Are there cardiovascular adverse effects of inhaled anticholinergics?].,['Nagy LB'],"['Administration, Inhalation', 'Bronchodilator Agents/*administration & dosage/*adverse effects', 'Cardiovascular Diseases/*chemically induced/epidemiology', 'Cardiovascular System/*drug effects/physiopathology', 'Cholinergic Antagonists/*administration & dosage/*adverse effects', 'Clinical Trials as Topic', 'Glycopyrrolate/administration & dosage/adverse effects', 'Humans', 'Incidence', 'Ipratropium/adverse effects', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Quinuclidines/administration & dosage/adverse effects', 'Risk Factors', 'Scopolamine Derivatives/administration & dosage/adverse effects', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/26211748/
273,Glycopyrronium,31468315,Glycopyrronium/Formoterol: A Review in COPD.,"['Al-Salama ZT', 'Frampton JE']","['Adjuvants, Anesthesia/*therapeutic use', 'Animals', 'Bronchodilator Agents/*therapeutic use', 'Clinical Trials as Topic', 'Formoterol Fumarate/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Pulmonary Disease, Chronic Obstructive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31468315/
274,Glycopyrronium,12398577,Sialorrhea - therapeutic drug options.,['Tscheng DZ'],"['Adolescent', 'Adult', 'Benztropine/adverse effects/*therapeutic use', 'Botulinum Toxins, Type A/adverse effects/*therapeutic use', 'Cerebral Palsy/complications', 'Child', 'Child, Preschool', 'Glycopyrrolate/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Scopolamine/adverse effects/*therapeutic use', 'Sialorrhea/*drug therapy/etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/12398577/
275,ILOPROST,15165299,Aerosolized prostacyclins.,['Siobal M'],"['Administration, Inhalation', 'Aerosols', 'Alprostadil/administration & dosage', 'Dose-Response Relationship, Drug', 'Epoprostenol/administration & dosage', 'Equipment Design', 'Humans', 'Hypertension, Pulmonary/drug therapy', 'Iloprost/administration & dosage', 'Nebulizers and Vaporizers', 'Nitric Oxide/administration & dosage', 'Prostaglandins I/*administration & dosage/adverse effects', 'Respiratory Distress Syndrome/drug therapy', 'Respiratory Therapy/instrumentation/*methods', 'Treatment Outcome', 'Vasodilator Agents/*administration & dosage/adverse effects', 'Ventricular Dysfunction, Right/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15165299/
276,ILOPROST,7518238,Thromboangiitis obliterans.,['Olin JW'],"['Amputation, Surgical', 'Arteriosclerosis/diagnosis', 'Diagnosis, Differential', 'Embolism/diagnosis', 'Female', 'Humans', 'Iloprost/therapeutic use', 'Male', 'Smoking/adverse effects', 'Thromboangiitis Obliterans/diagnosis/*etiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/7518238/
277,ILOPROST,21083647,Iloprost in dermatology.,"['Wohlrab J', 'Schanz S', 'Ulrich J']","['Dermatology/*trends', 'Humans', 'Iloprost/*adverse effects/*therapeutic use', 'Platelet Aggregation Inhibitors/adverse effects/therapeutic use', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21083647/
278,ILOPROST,28963381,BET 2: Treatment of frostbite with iloprost.,['Kaller M'],"['Frostbite/*drug therapy', 'Humans', 'Iloprost/*pharmacology/therapeutic use', 'Vasodilator Agents/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28963381/
279,ILOPROST,20216163,Prostacyclin in the intensive care setting.,['Ivy DD'],"['Administration, Inhalation', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Child', '*Critical Care', 'Epoprostenol/administration & dosage/analogs & derivatives/therapeutic use', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Iloprost/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20216163/
280,ILOPROST,21510725,Inhaled iloprost for therapy in pulmonary arterial hypertension.,"['Ewert R', 'Glaser S', 'Bollmann T', 'Schaper C']","['Administration, Inhalation', 'Animals', 'Antihypertensive Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Blood Pressure/drug effects', 'Drug Therapy, Combination', 'Evidence-Based Medicine', 'Familial Primary Pulmonary Hypertension', 'Humans', 'Hypertension, Pulmonary/drug therapy/physiopathology', 'Iloprost/*administration & dosage/adverse effects/pharmacokinetics', 'Nebulizers and Vaporizers', 'Risk Assessment', 'Treatment Outcome', 'Vasodilation/drug effects', 'Vasodilator Agents/*administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21510725/
281,ILOPROST,11590846,Medical therapy of pulmonary hypertension. The prostacyclins.,"['Galie N', 'Manes A', 'Branzi A']","['Epoprostenol/administration & dosage/*analogs & derivatives/pharmacology/*therapeutic use', 'Humans', 'Hypertension, Pulmonary/*drug therapy/physiopathology', 'Iloprost/therapeutic use', 'Vasodilation/drug effects', 'Vasodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11590846/
282,ILOPROST,25001057,[Clinical utility of inhaled iloprost in pulmonary arterial hypertension].,"['Santos-Martinez LE', 'Moreno-Ruiz LA', 'Jimenez-Santos M', 'Olmos-Temois SG', 'Bojorquez-Guerrero LA', 'Baranda-Tovar FM']","['Administration, Inhalation', 'Drug Therapy, Combination', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Iloprost/*administration & dosage', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25001057/
283,ILOPROST,17159719,[Pulmonary arterial hypertension and systemic sclerosis].,"['Launay D', 'Humbert M', 'Hachulla E']","['Algorithms', 'Antihypertensive Agents/administration & dosage/therapeutic use', 'Bosentan', 'Cardiac Catheterization', 'Cohort Studies', 'Echocardiography, Doppler', 'Epoprostenol/administration & dosage/analogs & derivatives/therapeutic use', 'European Union', 'Humans', 'Hypertension, Pulmonary/diagnosis/diagnostic imaging/drug therapy/epidemiology/*etiology/mortality', 'Iloprost/administration & dosage/therapeutic use', 'Infusions, Intravenous', 'Middle Aged', 'Phosphodiesterase Inhibitors/administration & dosage/therapeutic use', 'Piperazines/administration & dosage/therapeutic use', 'Prevalence', 'Prognosis', 'Purines', 'Randomized Controlled Trials as Topic', 'Scleroderma, Systemic/*complications', 'Sildenafil Citrate', 'Sulfonamides/administration & dosage/therapeutic use', 'Sulfones', 'Time Factors', 'Vasodilator Agents/administration & dosage/therapeutic use', 'World Health Organization']",https://pubmed.ncbi.nlm.nih.gov/17159719/
284,ILOPROST,24267307,Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.,"['McLaughlin VV', 'Palevsky HI']","['Administration, Inhalation', 'Antihypertensive Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Epoprostenol/*administration & dosage/adverse effects/analogs & derivatives/pharmacokinetics', 'Familial Primary Pulmonary Hypertension', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Iloprost/*administration & dosage/adverse effects', 'Infusions, Intravenous']",https://pubmed.ncbi.nlm.nih.gov/24267307/
285,ILOPROST,25336296,[Digital ulcers in systemic scleroderma].,"['Belz D', 'Hunzelmann N', 'Moinzadeh P']","['Bosentan', 'Fingers/pathology', 'Hand Dermatoses/diagnosis/etiology/therapy', 'Humans', 'Iloprost/*therapeutic use', 'Phosphodiesterase 5 Inhibitors/*therapeutic use', 'Scleroderma, Systemic/*complications/diagnosis/*therapy', 'Skin Ulcer/diagnosis/*etiology/*therapy', 'Sulfonamides/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25336296/
286,ILOPROST,23169366,Cholesterol atheroembolism and combined treatment with steroids and iloprost.,"['Sevillano-Prieto AM', 'Hernandez-Martinez E', 'Caro-Espada J', 'Molina-Gomez M', 'Gutierrez-Martinez E', 'Morales-Ruiz E', 'Gonzalez-Monte E', 'Praga-Terente M']","['Aged', 'Drug Therapy, Combination', 'Embolism, Cholesterol/*drug therapy', 'Female', 'Humans', 'Iloprost/*therapeutic use', 'Steroids/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23169366/
287,ILOPROST,32589047,Decrease of peripheral resistance after intraoperative administration of iloprost in patients with and without type 2 diabetes mellitus and with peripheral arterial occlusive disease.,"['Hirsch K', 'Saemann M', 'Walter C', 'Taher F', 'Edda S', 'Mlekusch I', 'Jager H', 'Assadian A', 'Falkensammer J']","['Adult', 'Aged', 'Aged, 80 and over', 'Case-Control Studies', 'Diabetes Mellitus, Type 2/diagnosis/*physiopathology', 'Female', 'Humans', 'Iloprost/*administration & dosage/adverse effects', 'Infusions, Intra-Arterial', 'Intraoperative Care', 'Male', 'Middle Aged', 'Peripheral Arterial Disease/diagnosis/*drug therapy/physiopathology/*surgery', 'Prospective Studies', 'Treatment Outcome', 'Vascular Resistance/*drug effects', '*Vascular Surgical Procedures/adverse effects', 'Vasodilation/*drug effects', 'Vasodilator Agents/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32589047/
288,ILOPROST,11100895,The management of idiopathic thrombotic microangiopathy. Changing trends.,"['Sagripanti A', 'Sarteschi LM', 'Carpi A']","['Adult', 'Hemolytic-Uremic Syndrome/complications/diagnosis/*therapy', 'Humans', 'Iloprost/pharmacology/therapeutic use', 'Multiple Organ Failure/etiology/*therapy', '*Plasma Exchange', 'Platelet Aggregation/drug effects/physiology', 'Platelet Aggregation Inhibitors/pharmacology/*therapeutic use', 'Purpura, Thrombotic Thrombocytopenic/complications/diagnosis/*therapy', 'Thrombosis/complications/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/11100895/
289,ILOPROST,15316646,[Iloprost and selective pulmonary vasodilation. Clinical results of intraoperative and postoperative inhalation of iloprost].,"['Langer F', 'Wilhelm W', 'Lausberg H', 'Schafers HJ']","['Administration, Inhalation', '*Cardiac Surgical Procedures', 'Endarterectomy', 'Heart Transplantation/physiology', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Iloprost/administration & dosage/adverse effects/*therapeutic use', 'Intraoperative Complications/*drug therapy', 'Mitral Valve/surgery', 'Postoperative Complications/*drug therapy', 'Vasodilator Agents/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15316646/
290,ILOPROST,1281939,Paracetamol toxicity and its prevention by cytoprotection with iloprost.,"['Davies DS', 'Fawthrop DJ', 'Nasseri-Sina P', 'Wilson JW', 'Hardwick SJ', 'Boobis AR']","['Acetaminophen/*toxicity', 'Animals', 'Calcium/metabolism', 'Cell Line', 'Cell Survival/*drug effects', 'Humans', 'Iloprost/*pharmacology', 'Liver/cytology/*drug effects', 'Protein Biosynthesis']",https://pubmed.ncbi.nlm.nih.gov/1281939/
291,ILOPROST,29886070,Inhalation of repurposed drugs to treat pulmonary hypertension.,['Gessler T'],"['Administration, Inhalation', 'Antihypertensive Agents/*administration & dosage/*therapeutic use', '*Drug Repositioning', 'Epoprostenol/administration & dosage/*analogs & derivatives/therapeutic use', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Iloprost/*administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29886070/
292,ILOPROST,39231563,Management of iatrogenic acute limb ischaemia in the neonate.,"['Shaniv D', 'Simpson-Lavy Y', 'Hershkovich Shporen C']","['Humans', 'Infant, Newborn', 'Acute Disease', 'Brachial Artery/diagnostic imaging', 'Catheterization, Peripheral/adverse effects', 'Heparin/administration & dosage/therapeutic use', '*Iatrogenic Disease', 'Iloprost/administration & dosage/therapeutic use', '*Ischemia/etiology/therapy', 'Nerve Block/methods', 'Nitroglycerin/administration & dosage/therapeutic use', 'Vasodilator Agents/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39231563/
293,ILOPROST,18690874,Current pharmacological treatment of pulmonary arterial hypertension.,"['Steiropoulos P', 'Trakada G', 'Bouros D']","['Bosentan', 'Diuretics/therapeutic use', 'Epoprostenol/therapeutic use', 'Humans', 'Hypertension, Pulmonary/*drug therapy/etiology', 'Iloprost/therapeutic use', 'Nitric Oxide/administration & dosage', 'Piperazines/therapeutic use', 'Purines/therapeutic use', 'Sildenafil Citrate', 'Sulfonamides/therapeutic use', 'Sulfones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18690874/
294,ILOPROST,1722990,Treatment of systemic sclerosis.,['Steen V'],"['Calcitonin/therapeutic use', 'Humans', 'Iloprost/therapeutic use', 'Scleroderma, Systemic/*drug therapy', 'Thyroxine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1722990/
295,Lenalidomide,38084760,"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","['Sonneveld P', 'Dimopoulos MA', 'Boccadoro M', 'Quach H', 'Ho PJ', 'Beksac M', 'Hulin C', 'Antonioli E', 'Leleu X', 'Mangiacavalli S', 'Perrot A', 'Cavo M', 'Belotti A', 'Broijl A', 'Gay F', 'Mina R', 'Nijhof IS', 'van de Donk NWCJ', 'Katodritou E', 'Schjesvold F', 'Sureda Balari A', 'Rosinol L', 'Delforge M', 'Roeloffzen W', 'Silzle T', 'Vangsted A', 'Einsele H', 'Spencer A', 'Hajek R', 'Jurczyszyn A', 'Lonergan S', 'Ahmadi T', 'Liu Y', 'Wang J', 'Vieyra D', 'van Brummelen EMJ', 'Vanquickelberghe V', 'Sitthi-Amorn A', 'de Boer CJ', 'Carson R', 'Rodriguez-Otero P', 'Blade J', 'Moreau P']","['Humans', 'Antibodies, Monoclonal/administration & dosage/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bortezomib/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease Progression', 'Lenalidomide/administration & dosage/adverse effects', '*Multiple Myeloma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38084760/
296,Lenalidomide,32325490,"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.","['Voorhees PM', 'Kaufman JL', 'Laubach J', 'Sborov DW', 'Reeves B', 'Rodriguez C', 'Chari A', 'Silbermann R', 'Costa LJ', 'Anderson LD Jr', 'Nathwani N', 'Shah N', 'Efebera YA', 'Holstein SA', 'Costello C', 'Jakubowiak A', 'Wildes TM', 'Orlowski RZ', 'Shain KH', 'Cowan AJ', 'Murphy S', 'Lutska Y', 'Pei H', 'Ukropec J', 'Vermeulen J', 'de Boer C', 'Hoehn D', 'Lin TS', 'Richardson PG']","['Adult', 'Aged', 'Antibodies, Monoclonal/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bortezomib/*administration & dosage/adverse effects', 'Combined Modality Therapy', 'Dexamethasone/*administration & dosage', 'Female', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Lenalidomide/*administration & dosage/adverse effects', 'Maintenance Chemotherapy/methods', 'Male', 'Middle Aged', 'Multiple Myeloma/drug therapy/mortality/pathology/*therapy', 'Patient Selection', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/32325490/
297,Lenalidomide,37738563,Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.,"['Qualls DA', 'Lambert N', 'Caimi PF', 'Merrill M', 'Pullarkat P', 'Godby RC', 'Bond DA', 'Wehmeyer GT', 'Romancik J', 'Amoozgar B', 'Leslie L', 'Nastoupil LJ', 'Crombie JL', 'Abramson JS', 'Khurana A', 'Nowakowski GS', 'Maddocks K', 'Rutherford SC', 'Kahl B', 'Okwali M', 'Buege MJ', 'Seshan V', 'Batlevi CL', 'Salles G']","['Humans', 'Lenalidomide/therapeutic use', 'Treatment Outcome', 'Retrospective Studies', '*Lymphoma, Large B-Cell, Diffuse/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37738563/
298,Lenalidomide,38832972,"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","['Facon T', 'Dimopoulos MA', 'Leleu XP', 'Beksac M', 'Pour L', 'Hajek R', 'Liu Z', 'Minarik J', 'Moreau P', 'Romejko-Jarosinska J', 'Spicka I', 'Vorobyev VI', 'Besemer B', 'Ishida T', 'Janowski W', 'Kalayoglu-Besisik S', 'Parmar G', 'Robak P', 'Zamagni E', 'Goldschmidt H', 'Martin TG', 'Manier S', 'Mohty M', 'Oprea C', 'Bregeault MF', 'Mace S', 'Berthou C', 'Bregman D', 'Klippel Z', 'Orlowski RZ']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Bortezomib/administration & dosage/adverse effects/therapeutic use', '*Dexamethasone/administration & dosage/adverse effects/therapeutic use', 'Kaplan-Meier Estimate', '*Lenalidomide/administration & dosage/adverse effects/therapeutic use', '*Multiple Myeloma/drug therapy/mortality', 'Neoplasm, Residual', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38832972/
299,Lenalidomide,31141632,Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.,"['Facon T', 'Kumar S', 'Plesner T', 'Orlowski RZ', 'Moreau P', 'Bahlis N', 'Basu S', 'Nahi H', 'Hulin C', 'Quach H', 'Goldschmidt H', ""O'Dwyer M"", 'Perrot A', 'Venner CP', 'Weisel K', 'Mace JR', 'Raje N', 'Attal M', 'Tiab M', 'Macro M', 'Frenzel L', 'Leleu X', 'Ahmadi T', 'Chiu C', 'Wang J', 'Van Rampelbergh R', 'Uhlar CM', 'Kobos R', 'Qi M', 'Usmani SZ']","['Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Dexamethasone/*administration & dosage/adverse effects', 'Female', 'Humans', 'Lenalidomide/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Multiple Myeloma/*drug therapy', 'Neutropenia/chemically induced', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/31141632/
300,Lenalidomide,26927826,[Lenalidomide nephrotoxicity].,"['Kheder El-Fekih R', 'Izzedine H']","['Graft vs Host Disease/chemically induced/immunology', 'Humans', 'Immunologic Factors/administration & dosage/*adverse effects/pharmacokinetics', 'Kidney/*drug effects/pathology', 'Kidney Tubules/drug effects/pathology', 'Lenalidomide', 'Necrosis/chemically induced', 'Nephritis, Interstitial/chemically induced', 'Prevalence', '*Renal Insufficiency/epidemiology/metabolism', 'Thalidomide/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26927826/
301,Lenalidomide,30897038,AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.,"['Leonard JP', 'Trneny M', 'Izutsu K', 'Fowler NH', 'Hong X', 'Zhu J', 'Zhang H', 'Offner F', 'Scheliga A', 'Nowakowski GS', 'Pinto A', 'Re F', 'Fogliatto LM', 'Scheinberg P', 'Flinn IW', 'Moreira C', 'Cabecadas J', 'Liu D', 'Kalambakas S', 'Fustier P', 'Wu C', 'Gribben JG']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Female', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', 'Lymphoma, B-Cell, Marginal Zone/*drug therapy', 'Lymphoma, Follicular/*drug therapy', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/drug therapy', 'Placebos', 'Rituximab/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30897038/
302,Lenalidomide,32511983,"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.","['Salles G', 'Duell J', 'Gonzalez Barca E', 'Tournilhac O', 'Jurczak W', 'Liberati AM', 'Nagy Z', 'Obr A', 'Gaidano G', 'Andre M', 'Kalakonda N', 'Dreyling M', 'Weirather J', 'Dirnberger-Hertweck M', 'Ambarkhane S', 'Fingerle-Rowson G', 'Maddocks K']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal, Humanized/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Drug Resistance, Neoplasm/*drug effects', 'Female', 'Follow-Up Studies', 'Humans', 'Lenalidomide/administration & dosage', 'Lymphoma, Large B-Cell, Diffuse/*drug therapy/pathology', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/*drug therapy/pathology', 'Prospective Studies', '*Salvage Therapy', 'Survival Rate', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32511983/
303,Lenalidomide,35660812,"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.","['Richardson PG', 'Jacobus SJ', 'Weller EA', 'Hassoun H', 'Lonial S', 'Raje NS', 'Medvedova E', 'McCarthy PL', 'Libby EN', 'Voorhees PM', 'Orlowski RZ', 'Anderson LD Jr', 'Zonder JA', 'Milner CP', 'Gasparetto C', 'Agha ME', 'Khan AM', 'Hurd DD', 'Gowin K', 'Kamble RT', 'Jagannath S', 'Nathwani N', 'Alsina M', 'Cornell RF', 'Hashmi H', 'Campagnaro EL', 'Andreescu AC', 'Gentile T', 'Liedtke M', 'Godby KN', 'Cohen AD', 'Openshaw TH', 'Pasquini MC', 'Giralt SA', 'Kaufman JL', 'Yee AJ', 'Scott E', 'Torka P', 'Foley A', 'Fulciniti M', 'Hebert K', 'Samur MK', 'Masone K', 'Maglio ME', 'Zeytoonjian AA', 'Nadeem O', 'Schlossman RL', 'Laubach JP', 'Paba-Prada C', 'Ghobrial IM', 'Perrot A', 'Moreau P', 'Avet-Loiseau H', 'Attal M', 'Anderson KC', 'Munshi NC']","['Adult', 'Antineoplastic Agents/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bortezomib/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease Progression', 'Disease-Free Survival', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', '*Maintenance Chemotherapy/methods', 'Melphalan/administration & dosage', '*Multiple Myeloma/diagnosis/drug therapy/surgery', '*Stem Cell Transplantation', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/35660812/
304,Lenalidomide,32586576,Immunomodulatory Agents in Follicular Lymphoma.,"['Ysebaert L', 'Morschhauser F']","['Antineoplastic Agents/pharmacology/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Biomarkers, Tumor', 'Humans', 'Immune Checkpoint Inhibitors/pharmacology/therapeutic use', 'Immunologic Factors/pharmacology/*therapeutic use', 'Immunological Synapses/drug effects', 'Immunomodulation/*drug effects', 'Lenalidomide/pharmacology/therapeutic use', 'Lymphoma, Follicular/diagnosis/*drug therapy/etiology/mortality', 'Molecular Targeted Therapy', 'Treatment Outcome', 'Tumor Microenvironment/drug effects/immunology']",https://pubmed.ncbi.nlm.nih.gov/32586576/
305,Lenalidomide,38820500,Randomized study of induction with bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide for MCL.,"['Smith MR', 'Jegede OA', 'Martin P', 'Till BG', 'Parekh SS', 'Yang DT', 'Hsi ED', 'Witzig T', 'Dave S', 'Scott D', 'Hanson C', 'Kostakoglu Shields L', 'Abdel-Samad N', 'Casulo C', 'Bartlett NL', 'Caimi PF', 'Al Baghdadi T', 'Blum KA', 'Romer MD', 'Inwards DJ', 'Lerner RE', 'Wagner LI', 'Little RF', 'Friedberg JW', 'Leonard JP', 'Kahl BS']","['Humans', '*Rituximab/administration & dosage/therapeutic use', '*Bendamustine Hydrochloride/administration & dosage/therapeutic use', '*Bortezomib/administration & dosage/therapeutic use', '*Lenalidomide/administration & dosage/therapeutic use', 'Female', 'Male', 'Middle Aged', 'Aged', '*Lymphoma, Mantle-Cell/drug therapy/mortality/pathology', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Maintenance Chemotherapy', 'Aged, 80 and over', 'Adult', 'Induction Chemotherapy', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38820500/
306,Lenalidomide,38899693,Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.,"['Melani C', 'Lakhotia R', 'Pittaluga S', 'Phelan JD', 'Huang DW', 'Wright G', 'Simard J', 'Muppidi J', 'Thomas CJ', 'Ceribelli M', 'Tosto FA', 'Yang Y', 'Xu W', 'Davies-Hill T', 'Pack SD', 'Peer CJ', 'Arisa O', 'Mena E', 'Lindenberg L', 'Bergvall E', 'Portell CA', 'Farah RJ', 'Lee ST', 'Pradhan A', 'Morrison C', 'Tadese A', 'Juanitez AM', 'Lu C', 'Jacob A', 'Simmons H', 'Figg WD', 'Steinberg SM', 'Jaffe ES', 'Roschewski M', 'Staudt LM', 'Wilson WH']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Adenine/analogs & derivatives/adverse effects/therapeutic use/administration & dosage', '*Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Bridged Bicyclo Compounds, Heterocyclic/adverse effects/therapeutic use/administration & dosage', '*Lenalidomide/adverse effects/administration & dosage/therapeutic use', '*Lymphoma, Large B-Cell, Diffuse/drug therapy/mortality', 'Molecular Targeted Therapy', '*Piperidines/adverse effects/therapeutic use/administration & dosage', 'Prednisone/adverse effects/administration & dosage/therapeutic use', 'Progression-Free Survival', 'Pyrazoles/adverse effects/therapeutic use/administration & dosage', 'Pyrimidines/adverse effects/therapeutic use/administration & dosage', 'Recurrence', 'Sulfonamides/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38899693/
307,Lenalidomide,32976949,Mechanisms of lenalidomide sensitivity and resistance.,"['Martinez-Hoyer S', 'Karsan A']","['Adaptor Proteins, Signal Transducing/antagonists & inhibitors', 'Anemia, Macrocytic/drug therapy/physiopathology', 'Angiogenesis Inhibitors/pharmacology/therapeutic use', 'Antineoplastic Agents/*pharmacology/therapeutic use', 'Autophagy/drug effects', 'Cell Differentiation/drug effects', 'Chromosome Deletion', 'Chromosomes, Human, Pair 5', 'Cytokines/metabolism', 'Disease Progression', 'Drug Resistance, Neoplasm/physiology', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Ikaros Transcription Factor/antagonists & inhibitors', 'Immunologic Factors/*pharmacology/therapeutic use', 'Lenalidomide/*pharmacology/therapeutic use', 'Megakaryocytes/drug effects', 'Multiple Myeloma/drug therapy/physiopathology', 'Neoplasm Proteins/antagonists & inhibitors', 'Neovascularization, Pathologic/drug therapy/physiopathology', 'Phosphoprotein Phosphatases/antagonists & inhibitors', 'Ubiquitin-Protein Ligases/antagonists & inhibitors/physiology']",https://pubmed.ncbi.nlm.nih.gov/32976949/
308,Lenalidomide,32430504,Genetics of progression from MDS to secondary leukemia.,"['Menssen AJ', 'Walter MJ']","['Cell Count', 'Clonal Evolution', 'DNA Methylation/drug effects', 'DNA Mutational Analysis', 'Disease Progression', 'Epigenesis, Genetic', 'Hematopoietic Stem Cells/pathology', 'Humans', 'Lenalidomide/pharmacology/therapeutic use', 'Leukemia, Myeloid, Acute/etiology/*genetics/prevention & control', 'Mutation', 'Myelodysplastic Syndromes/drug therapy/*genetics/pathology', 'Myelopoiesis', 'Neoplastic Stem Cells/pathology', 'Prognosis', 'Tumor Burden', 'Exome Sequencing', 'Whole Genome Sequencing']",https://pubmed.ncbi.nlm.nih.gov/32430504/
309,Lenalidomide,37506339,"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.","['Rosinol L', 'Oriol A', 'Rios R', 'Blanchard MJ', 'Jarque I', 'Bargay J', 'Hernandez MT', 'Cabanas V', 'Carrillo-Cruz E', 'Sureda A', 'Martinez-Lopez J', 'Krsnik I', 'Gonzalez ME', 'Casado LF', 'Marti JM', 'Encinas C', 'de Arriba F', 'Palomera L', 'Sampol A', 'Gonzalez-Montes Y', 'Cabezudo E', 'Paiva B', 'Puig N', 'Cedena MT', 'de la Cruz J', 'Mateos MV', 'San Miguel J', 'Lahuerta JJ', 'Blade J']","['Humans', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Dexamethasone/therapeutic use', 'Lenalidomide/therapeutic use', '*Multiple Myeloma/therapy']",https://pubmed.ncbi.nlm.nih.gov/37506339/
310,Lenalidomide,37500385,[Treatment of lower risk myelodysplastic syndromes].,['Park S'],"['Humans', '*Myelodysplastic Syndromes/complications/drug therapy', 'Lenalidomide/therapeutic use', '*Anemia/drug therapy/complications', '*Hematinics/therapeutic use', 'Risk', '*Thrombocytopenia/complications']",https://pubmed.ncbi.nlm.nih.gov/37500385/
311,Lenalidomide,38977707,Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.,"['Chari A', 'Kaufman JL', 'Laubach J', 'Sborov DW', 'Reeves B', 'Rodriguez C', 'Silbermann R', 'Costa LJ', 'Anderson LD Jr', 'Nathwani N', 'Shah N', 'Bumma N', 'Holstein SA', 'Costello C', 'Jakubowiak A', 'Wildes TM', 'Orlowski RZ', 'Shain KH', 'Cowan AJ', 'Pei H', 'Cortoos A', 'Patel S', 'Lin TS', 'Voorhees PM', 'Usmani SZ', 'Richardson PG']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Antibodies, Monoclonal/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Bortezomib/therapeutic use/administration & dosage', 'Dexamethasone/administration & dosage/therapeutic use', 'Lenalidomide/therapeutic use/administration & dosage', '*Multiple Myeloma/drug therapy/mortality/therapy/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/38977707/
312,Lenalidomide,31652094,Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.,"['Lonial S', 'Jacobus S', 'Fonseca R', 'Weiss M', 'Kumar S', 'Orlowski RZ', 'Kaufman JL', 'Yacoub AM', 'Buadi FK', ""O'Brien T"", 'Matous JV', 'Anderson DM', 'Emmons RV', 'Mahindra A', 'Wagner LI', 'Dhodapkar MV', 'Rajkumar SV']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Lenalidomide/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Quality of Life', 'Smoldering Multiple Myeloma/*drug therapy/mortality']",https://pubmed.ncbi.nlm.nih.gov/31652094/
313,Lenalidomide,35717005,Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.,"['Rafae A', 'Ehsan H', 'Wahab A', 'Khan SI', 'Khan I', 'Ashraf S', 'Ali S', 'Khalid F', 'Neupane K', 'Valent J', 'Khouri J', 'Samaras C', 'Mazzoni S', 'Anwer F']","['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Bortezomib', 'Dexamethasone', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Humans', 'Lenalidomide/therapeutic use', '*Multiple Myeloma/diagnosis/drug therapy', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/35717005/
314,Lenalidomide,33763699,"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.","['Facon T', 'Venner CP', 'Bahlis NJ', 'Offner F', 'White DJ', 'Karlin L', 'Benboubker L', 'Rigaudeau S', 'Rodon P', 'Voog E', 'Yoon SS', 'Suzuki K', 'Shibayama H', 'Zhang X', 'Twumasi-Ankrah P', 'Yung G', 'Rifkin RM', 'Moreau P', 'Lonial S', 'Kumar SK', 'Richardson PG', 'Rajkumar SV']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Boron Compounds/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease-Free Survival', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Glycine/administration & dosage/adverse effects/analogs & derivatives', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', 'Male', 'Middle Aged', '*Multiple Myeloma/diagnosis/drug therapy/mortality', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/33763699/
315,MOEXIPRIL,17583172,Moexipril and left ventricular hypertrophy.,"['Chrysant GS', 'Nguyen PK']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Blood Pressure/drug effects/physiology', 'Delayed-Action Preparations', 'Humans', 'Hypertrophy, Left Ventricular/*drug therapy/physiopathology', 'Tetrahydroisoquinolines/*therapeutic use', 'Treatment Outcome', 'Ventricular Remodeling/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/17583172/
316,MOEXIPRIL,37417783,"Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis.","['Hu Y', 'Liang L', 'Liu S', 'Kung JY', 'Banh HL']","['Humans', '*Antihypertensive Agents/adverse effects', 'Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Angiotensin Receptor Antagonists/therapeutic use', 'Network Meta-Analysis', 'Cough/chemically induced/epidemiology/drug therapy', '*Hypertension/drug therapy/epidemiology', 'Calcium Channel Blockers/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37417783/
317,MOEXIPRIL,17159885,[Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women].,"['Ostroumova OD', 'Paukov SV', 'Frolova LI']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Blood Pressure/drug effects', 'Delayed-Action Preparations', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', '*Postmenopause', 'Tetrahydroisoquinolines/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17159885/
318,MOEXIPRIL,19255851,Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.,"['Charatcharoenwitthaya P', 'Talwalkar JA', 'Angulo P', 'Gossard AA', 'Keach JC', 'Petz JL', 'Jorgensen RA', 'Lindor KD']","['Administration, Oral', 'Adult', 'Aged', 'Alkaline Phosphatase/blood', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Aspartate Aminotransferases/blood', 'Bilirubin/blood', 'Cholagogues and Choleretics/therapeutic use', 'Delayed-Action Preparations', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Liver Cirrhosis, Biliary/blood/*drug therapy', 'Male', 'Middle Aged', 'Quality of Life', 'Tetrahydroisoquinolines/administration & dosage/*therapeutic use', 'Treatment Outcome', 'Ursodeoxycholic Acid/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19255851/
319,MOEXIPRIL,15286086,Pharmacological and clinical profile of moexipril: a concise review.,"['Chrysant SG', 'Chrysant GS']","['Angiotensin-Converting Enzyme Inhibitors/*pharmacology/*therapeutic use', 'Animals', 'Antihypertensive Agents/*pharmacology/*therapeutic use', 'Bone and Bones/drug effects', 'Diuretics', 'Drug Combinations', 'Heart/drug effects', 'Humans', 'Hydrochlorothiazide/therapeutic use', 'Hypertension/*drug therapy', 'Kidney/drug effects', 'Liver/metabolism', 'Multicenter Studies as Topic', 'Prodrugs/*pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Sodium Chloride Symporter Inhibitors/therapeutic use', 'Tetrahydroisoquinolines/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15286086/
320,MOEXIPRIL,9617599,Moexipril. A review of its use in the management of essential hypertension.,"['Brogden RN', 'Wiseman LR']","['Age Factors', 'Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics/*therapeutic use', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Isoquinolines/pharmacokinetics/*therapeutic use', 'Male', 'Prodrugs/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/9617599/
321,MOEXIPRIL,12182524,Using ACE inhibitors appropriately.,['Bicket DP'],"['Angiotensin-Converting Enzyme Inhibitors/administration & dosage/economics/*therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Benzazepines/therapeutic use', 'Captopril/therapeutic use', 'Cardiovascular Diseases/*drug therapy/mortality/physiopathology/prevention & control', 'Clinical Trials as Topic', 'Contraindications', 'Diabetic Nephropathies/prevention & control', 'Drug Costs', 'Enalapril/therapeutic use', 'Fosinopril/therapeutic use', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/drug therapy', 'Indoles/therapeutic use', 'Isoquinolines/therapeutic use', 'Lisinopril/therapeutic use', 'Meta-Analysis as Topic', 'Myocardial Infarction/drug therapy', 'Perindopril/therapeutic use', 'Quinapril', 'Ramipril/therapeutic use', 'Renin-Angiotensin System/*drug effects', 'Risk', '*Tetrahydroisoquinolines', 'United States']",https://pubmed.ncbi.nlm.nih.gov/12182524/
322,MOEXIPRIL,14728069,ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.,"['Pines A', 'Fisman EZ']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Humans', 'Hypertension/*drug therapy', 'Randomized Controlled Trials as Topic', 'Renal Insufficiency/drug therapy', 'Tetrahydroisoquinolines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14728069/
323,MOEXIPRIL,15030263,Pharmacological profile and clinical use of moexipril.,"['Chrysant SG', 'Chrysant GS']","['Angiotensin-Converting Enzyme Inhibitors/*pharmacokinetics/therapeutic use', 'Delayed-Action Preparations', 'Humans', 'Hypertension/*drug therapy', 'Tetrahydroisoquinolines/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15030263/
324,MOEXIPRIL,8276058,Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.,"['Van Hecken A', 'Verbesselt R', 'Depre M', 'Tjandramaga TB', 'Angehrn J', 'Cawello W', 'De Schepper PJ']","['Adult', 'Angiotensin-Converting Enzyme Inhibitors/*pharmacology', 'Drug Interactions', 'Humans', 'Isoquinolines/*pharmacology', 'Male', 'Partial Thromboplastin Time', 'Prodrugs/*pharmacology', 'Prothrombin Time', '*Tetrahydroisoquinolines', 'Warfarin/administration & dosage/*pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8276058/
325,MOEXIPRIL,11929321,Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.,"['Song JC', 'White CM']","['Age Factors', 'Angiotensin-Converting Enzyme Inhibitors/*pharmacokinetics/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Kidney Diseases/metabolism', 'Liver Diseases/metabolism', 'Renin-Angiotensin System/drug effects/physiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11929321/
326,MOEXIPRIL,26076923,CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.,"['Wang X', 'Wang G', 'Shi J', 'Aa J', 'Comas R', 'Liang Y', 'Zhu HJ']","['Activation, Metabolic/genetics', 'Adult', 'Aged', 'Aged, 80 and over', 'Angiotensin-Converting Enzyme Inhibitors/*metabolism', 'Carboxylic Ester Hydrolases/*genetics/metabolism', 'Cell Line', 'Female', 'Genotype', 'Humans', 'Hydrolysis', 'Intestines/enzymology', 'Kidney/enzymology', 'Kinetics', 'Liver/*enzymology', 'Male', 'Middle Aged', 'Pharmacogenomic Variants/*genetics', 'Phenotype', '*Polymorphism, Single Nucleotide', 'Prodrugs/*metabolism', 'Transfection', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26076923/
327,MOEXIPRIL,37149094,In silico and in vitro screening for carcinogenic potential of angiotensin-converting enzyme inhibitors and their degradation impurities.,"['Regulska K', 'Matera-Witkiewicz A', 'Mikolajczyk A', 'Stanisz BJ']","['Humans', '*Angiotensin-Converting Enzyme Inhibitors/toxicity', 'Carcinogens/toxicity', 'Reproducibility of Results', 'Ramipril/toxicity', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/37149094/
328,MOEXIPRIL,10376852,Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women.,"['Koch B', 'Oparil S', 'Stimpel M']","['Angiotensin-Converting Enzyme Inhibitors/*therapeutic use', 'Blood Pressure/physiology', 'Double-Blind Method', 'Drug Combinations', 'Female', '*Hormone Replacement Therapy', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Isoquinolines/*therapeutic use', 'Middle Aged', '*Postmenopause', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/10376852/
329,MOEXIPRIL,18729835,[Clinico-economical efficacy of angiotensin converting enzyme inhibitors in patients with arterial hypertension and ischemic heart disease].,"['Korennova OIu', 'Petrenko AV', 'Petrenko MA', 'Kurt-Kovalenko EV', 'Turusheva EA', 'Alekseeva SV', 'Mashinskaia LG', 'Shupina MI', 'Osipova EA']","['Angiotensin-Converting Enzyme Inhibitors/*economics/*therapeutic use', 'Cost-Benefit Analysis', '*Drug Costs', 'Female', 'Follow-Up Studies', 'Humans', 'Hypertension/complications/*drug therapy/economics', 'Male', 'Middle Aged', 'Myocardial Ischemia/complications/*drug therapy/economics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18729835/
330,MOEXIPRIL,12419176,Systemic hypertension in postmenopausal women: a clinical approach.,"['Fisman EZ', 'Tenenbaum A', 'Pines A']","['Adult', 'Aged', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Coronary Artery Disease/epidemiology/metabolism/physiopathology', 'Female', 'Gonadal Steroid Hormones/metabolism/pharmacology', 'Humans', 'Hypertension/epidemiology/metabolism/*physiopathology', 'Incidence', 'Middle Aged', 'Postmenopause/*physiology', 'Risk Factors', ""Women's Health""]",https://pubmed.ncbi.nlm.nih.gov/12419176/
331,MOEXIPRIL,9620109,"Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.",['White CM'],"['*Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics/pharmacology/therapeutic use', 'Cardiovascular Diseases/drug therapy/prevention & control', 'Endothelium, Vascular/drug effects/physiopathology', 'Humans', 'Hypertension/drug therapy', 'Kidney Failure, Chronic/drug therapy/prevention & control', 'Randomized Controlled Trials as Topic', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/9620109/
332,MOEXIPRIL,8793166,Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension.,"['Stimpel M', 'Koch B', 'Dickstein K']","['Administration, Oral', 'Adult', 'Aged', 'Analysis of Variance', 'Angiotensin-Converting Enzyme Inhibitors/*administration & dosage/adverse effects', 'Blood Pressure/drug effects', 'Diuretics', 'Double-Blind Method', 'Drug Therapy, Combination', 'Drug Tolerance', 'Female', 'Follow-Up Studies', 'Humans', 'Hydrochlorothiazide/*administration & dosage/adverse effects', 'Hypertension/*drug therapy/physiopathology', 'Isoquinolines/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Posture', 'Sodium Chloride Symporter Inhibitors/*administration & dosage/adverse effects', '*Tetrahydroisoquinolines', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8793166/
333,MOEXIPRIL,10379633,Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause.,"['Agabiti-Rosei E', 'Ambrosioni E', 'Pirelli A', 'Stimpel M', 'Zanchetti A']","['Aged', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Blood Pressure', 'Calcium Channel Blockers/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Isoquinolines/adverse effects/*therapeutic use', 'Middle Aged', 'Nitrendipine/adverse effects/*therapeutic use', '*Postmenopause/physiology', 'Prodrugs/*therapeutic use', '*Tetrahydroisoquinolines']",https://pubmed.ncbi.nlm.nih.gov/10379633/
334,OXANDROLONE,37403125,Personalized nutrition therapy in critical care: 10 expert recommendations.,"['Wischmeyer PE', 'Bear DE', 'Berger MM', 'De Waele E', 'Gunst J', 'McClave SA', 'Prado CM', 'Puthucheary Z', 'Ridley EJ', 'Van den Berghe G', 'van Zanten ARH']","['Humans', '*Intensive Care Units', '*Nutritional Support', 'Critical Care/methods', 'Nutritional Status', 'Enteral Nutrition/methods', 'Critical Illness/therapy']",https://pubmed.ncbi.nlm.nih.gov/37403125/
335,OXANDROLONE,23582468,ESPEN endorsed recommendations: nutritional therapy in major burns.,"['Rousseau AF', 'Losser MR', 'Ichai C', 'Berger MM']","['Adult', 'Amino Acids/administration & dosage', 'Blood Glucose/analysis', 'Burns/*diet therapy', 'Calorimetry, Indirect', 'Child', 'Critical Care/standards', 'Dietary Carbohydrates/administration & dosage', 'Dietary Fats/administration & dosage', 'Dietary Proteins/administration & dosage', 'Energy Intake', 'Enteral Nutrition/*methods', 'Evidence-Based Medicine', 'Guidelines as Topic', 'Humans', 'Intensive Care Units', 'Micronutrients/administration & dosage', 'Nutritional Requirements', 'Practice Guidelines as Topic', 'Resuscitation/methods']",https://pubmed.ncbi.nlm.nih.gov/23582468/
336,OXANDROLONE,33909503,Burn-induced hypermetabolism and skeletal muscle dysfunction.,"['Knuth CM', 'Auger C', 'Jeschke MG']","['Burns/genetics/metabolism/pathology/rehabilitation', 'Cachexia/*drug therapy/genetics/metabolism/pathology', 'Epigenesis, Genetic', 'Exercise', 'Human Growth Hormone/therapeutic use', 'Humans', 'Insulin/therapeutic use', 'Metformin/therapeutic use', 'Muscle Proteins/biosynthesis/*genetics', 'Muscle, Skeletal/drug effects/injuries/*metabolism/physiopathology', 'Muscular Atrophy/genetics/metabolism/pathology/*prevention & control', 'Oxandrolone/therapeutic use', 'Propranolol/therapeutic use', '*Protein Biosynthesis', 'Proteolysis', 'Sepsis/*metabolism/microbiology/pathology/rehabilitation', 'Signal Transduction', 'Wound Healing/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/33909503/
337,OXANDROLONE,30784604,Hormone Therapy in Trauma Patients.,"['Asehnoune K', ""Vourc'h M"", 'Roquilly A']","['Erythropoietin/*therapeutic use', 'Female', 'Hormones/*therapeutic use', 'Humans', 'Hydrocortisone/*therapeutic use', 'Length of Stay/*statistics & numerical data', 'Male', 'Oxandrolone/*therapeutic use', 'Progesterone/*therapeutic use', 'Wounds and Injuries/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30784604/
338,OXANDROLONE,15879740,Altering metabolism.,"['Pereira CT', 'Murphy KD', 'Herndon DN']","['Adrenergic beta-Antagonists/therapeutic use', 'Anabolic Agents/therapeutic use', 'Body Temperature Regulation', 'Burns/*metabolism/*therapy', 'Catecholamines/antagonists & inhibitors', 'Exercise', 'Human Growth Hormone/therapeutic use', 'Humans', 'Hypoglycemic Agents/therapeutic use', 'Insulin/therapeutic use', 'Insulin-Like Growth Factor I/therapeutic use', 'Nutritional Support', 'Oxandrolone/therapeutic use', 'Sepsis/prevention & control', 'Temperature', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/15879740/
339,OXANDROLONE,27535042,Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health.,"['Wu C', 'Kovac JR']","['Anabolic Agents/pharmacology/*therapeutic use', 'Androgen Antagonists/pharmacology/therapeutic use', 'Humans', 'Male', ""Men's Health"", 'Nandrolone/pharmacology/*therapeutic use', 'Oxandrolone/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27535042/
340,OXANDROLONE,11529402,Turner's syndrome.,"['Guarneri MP', 'Abusrewil SA', 'Bernasconi S', 'Bona G', 'Cavallo L', 'Cicognani A', 'Di Battista E', 'Salvatoni A']","['Adolescent', 'Child', 'Female', 'Gonadal Steroid Hormones/administration & dosage/therapeutic use', 'Growth Disorders/etiology/*therapy', 'Growth Hormone/administration & dosage/therapeutic use', 'Humans', 'Male', 'Puberty/drug effects/*physiology', 'Turner Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11529402/
341,OXANDROLONE,38177003,"Persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a review of definitions, potential therapies, and research priorities.","['Chadda KR', 'Puthucheary Z']","['Animals', 'Humans', '*Critical Illness', 'Syndrome', '*Immunosuppression Therapy/adverse effects', 'Inflammation/therapy/etiology', 'Chronic Disease', 'Research']",https://pubmed.ncbi.nlm.nih.gov/38177003/
342,OXANDROLONE,35943186,Experimental studies on androgen administration in animal models: current and future perspectives.,"['Sessa F', 'Esposito M', 'Salerno M']","['Animals', 'Humans', '*Androgens/adverse effects', 'Nandrolone Decanoate', 'Stanozolol', '*Methandrostenolone', 'Trenbolone Acetate', 'Oxandrolone', 'Testosterone', 'Inflammation Mediators']",https://pubmed.ncbi.nlm.nih.gov/35943186/
343,OXANDROLONE,28941540,Adjunctive Steroid Therapy for Treatment of Pediatric Septic Shock.,['Zimmerman JJ'],"['Anti-Inflammatory Agents/*therapeutic use', 'Biomarkers/metabolism', 'Child', 'Combined Modality Therapy', 'Critical Care/*methods', 'Humans', 'Pediatrics', 'Shock, Septic/*drug therapy/metabolism', 'Steroids/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28941540/
344,OXANDROLONE,10959218,Testosterone and muscle protein metabolism.,"['Wolfe R', 'Ferrando A', 'Sheffield-Moore M', 'Urban R']","['Aged', 'Aging/drug effects/physiology', 'Amino Acids/drug effects/physiology', 'Anabolic Agents/metabolism/therapeutic use', 'Androstenedione/metabolism/therapeutic use', 'Growth Hormone/physiology', 'Humans', 'Male', 'Middle Aged', 'Models, Biological', 'Muscle Proteins/drug effects/*metabolism', 'Muscular Atrophy/drug therapy/etiology', 'Oxandrolone/metabolism/therapeutic use', 'Testosterone/*physiology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/10959218/
345,OXANDROLONE,25468473,Effects of pharmacological interventions on muscle protein synthesis and breakdown in recovery from burns.,"['Diaz EC', 'Herndon DN', 'Porter C', 'Sidossis LS', 'Suman OE', 'Borsheim E']","['Adrenergic beta-Antagonists/*therapeutic use', 'Anabolic Agents/*therapeutic use', 'Androgens/*therapeutic use', 'Body Surface Area', 'Burns/*drug therapy/metabolism', 'Human Growth Hormone/therapeutic use', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Insulin/therapeutic use', 'Metformin/therapeutic use', 'Muscle Proteins/*biosynthesis/metabolism', 'Muscle, Skeletal/*metabolism', 'Oxandrolone/therapeutic use', 'Propranolol/therapeutic use', 'Recombinant Proteins', 'Testosterone/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25468473/
346,OXANDROLONE,16432142,The current status of treatment for inclusion-body myositis.,['Griggs RC'],"['Anti-Inflammatory Agents/therapeutic use', 'Disease Progression', 'Forecasting', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Immunotherapy', 'Myositis, Inclusion Body/drug therapy/rehabilitation/*therapy', 'Oxandrolone/therapeutic use', 'Prospective Studies', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Whole-Body Irradiation']",https://pubmed.ncbi.nlm.nih.gov/16432142/
347,OXANDROLONE,20197667,Hormones and genes of importance in bone physiology and their influence on bone mineralization and growth in Turner syndrome.,"['Andrade AC', 'Baron J', 'Manolagas SC', 'Shaw NJ', 'Rappold GA', 'Donaldson MD', 'Gault EJ', 'Savendahl L']","['Adolescent', 'Body Height/drug effects', 'Bone Density', '*Bone Development/drug effects', 'Bone Diseases, Metabolic/etiology', '*Calcification, Physiologic/drug effects', 'Cartilage/drug effects/growth & development', 'Child', 'Female', 'Homeodomain Proteins/genetics/physiology', 'Humans', 'Oxandrolone/therapeutic use', 'Oxidative Stress/physiology', 'Short Stature Homeobox Protein', 'Turner Syndrome/drug therapy/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/20197667/
348,OXANDROLONE,10592451,Treatment of late puberty.,['Brook CG'],"['Adolescent', 'Anabolic Agents/therapeutic use', 'Child', 'Estradiol/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Oxandrolone/therapeutic use', 'Puberty, Delayed/*drug therapy', 'Testosterone/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10592451/
349,OXANDROLONE,3302896,Treatment of short stature and delayed adolescence.,"['Wilson DM', 'Rosenfeld RG']","['Adolescent', '*Body Height', 'Child', 'Female', 'Growth Disorders/*drug therapy/etiology', 'Growth Hormone/deficiency/*therapeutic use', 'Humans', 'Male', 'Oxandrolone/therapeutic use', 'Puberty, Delayed/*drug therapy', 'Testosterone/therapeutic use', 'Turner Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3302896/
350,OXANDROLONE,22541704,Alcoholic hepatitis: a clinician's guide.,"['Choi G', 'Runyon BA']","['Adrenal Cortex Hormones/therapeutic use', 'Anabolic Agents/therapeutic use', 'Baclofen/therapeutic use', 'Dietary Supplements', 'GABA-B Receptor Agonists/therapeutic use', 'Hepatitis, Alcoholic/complications/*diagnosis/*therapy', 'Hepatorenal Syndrome/complications/diagnosis/drug therapy', 'Humans', 'Liver Transplantation', 'Oxandrolone/therapeutic use', 'Pentoxifylline/therapeutic use', 'Phosphodiesterase Inhibitors/therapeutic use', 'Risk Factors', 'Tumor Necrosis Factor-alpha/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/22541704/
351,OXANDROLONE,22946284,Growth hormone therapy in Turner syndrome.,['Davenport ML'],"['Anabolic Agents/therapeutic use', 'Body Height/*drug effects', 'Child', 'Drug Therapy, Combination', 'Estrogens/*therapeutic use', 'Female', 'Growth Hormone/*therapeutic use', 'Hormones/therapeutic use', 'Humans', 'Oxandrolone/*therapeutic use', 'Turner Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22946284/
352,OXANDROLONE,1818011,Treatment of delayed puberty and hypogonadism in girls.,"['Heinrichs C', 'Bourguignon JP']","['Adolescent', 'Anabolic Agents/therapeutic use', 'Body Height', 'Estrogens/therapeutic use', 'Female', 'Growth Hormone/therapeutic use', 'Humans', 'Hypogonadism/*drug therapy', 'Menarche', 'Puberty, Delayed/*drug therapy/etiology', 'Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/1818011/
353,Paliperidone,35486616,Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.,"['Lian L', 'Kim DD', 'Procyshyn RM', 'Cazares D', 'Honer WG', 'Barr AM']","['*Antipsychotic Agents/adverse effects', 'Cohort Studies', 'Delayed-Action Preparations', 'Humans', 'Paliperidone Palmitate', '*Psychotic Disorders/drug therapy', 'Risperidone']",https://pubmed.ncbi.nlm.nih.gov/35486616/
354,Paliperidone,24556260,Paliperidone-associated motor tics.,"['Hsieh MH', 'Chiu NY']","['Antipsychotic Agents/administration & dosage/*adverse effects', 'Blinking/*drug effects', 'Humans', 'Isoxazoles/administration & dosage/*adverse effects', 'Male', 'Paliperidone Palmitate', 'Pyrimidines/administration & dosage/*adverse effects', 'Schizophrenia/*drug therapy', 'Tics/*chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24556260/
355,Paliperidone,38301289,A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.,"['Kishi T', 'Citrome L', 'Sakuma K', 'Iwata N']","['Humans', '*Antipsychotic Agents/administration & dosage/therapeutic use', 'Aripiprazole/administration & dosage/therapeutic use', '*Bipolar Disorder/drug therapy/chemically induced', 'Delayed-Action Preparations/administration & dosage/therapeutic use', 'Paliperidone Palmitate/administration & dosage/therapeutic use', '*Schizophrenia/drug therapy', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/38301289/
356,Paliperidone,35777418,"Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.","['Lopez-Morinigo JD', 'Leucht S', 'Arango C']","['Adolescent', '*Antipsychotic Agents/therapeutic use', 'Aripiprazole/therapeutic use', 'Benzodiazepines/therapeutic use', '*Clozapine/therapeutic use', 'Haloperidol/therapeutic use', 'Humans', 'Lurasidone Hydrochloride/therapeutic use', 'Molindone/therapeutic use', 'Olanzapine', 'Paliperidone Palmitate/therapeutic use', 'Quality of Life', 'Quetiapine Fumarate/therapeutic use', 'Risperidone/adverse effects', '*Schizophrenia/drug therapy', 'Systematic Reviews as Topic']",https://pubmed.ncbi.nlm.nih.gov/35777418/
357,Paliperidone,29389211,Hypersexuality associated with paliperidone.,"['Caykoylu A', 'Karslioglu EH', 'Ozer I', 'Koksal AG']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/pharmacokinetics', 'Delayed-Action Preparations', 'Diagnostic and Statistical Manual of Mental Disorders', 'Female', 'Humans', 'Male', '*Paliperidone Palmitate/administration & dosage/adverse effects/pharmacokinetics', 'Peripheral Nervous System Agents', 'Schizophrenia/diagnosis/*drug therapy', 'Sexual Behavior/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/29389211/
358,Paliperidone,36165513,Aripiprazole: examining the clinical implications of D2 affinity.,"['Anam A', 'Lynch S', 'Mosharraf N', 'Soukas C', 'Gekhman D']","['Humans', 'Aripiprazole/therapeutic use', '*Antipsychotic Agents/therapeutic use', 'Paliperidone Palmitate/therapeutic use', 'Risperidone/therapeutic use', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36165513/
359,Paliperidone,30244607,The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia.,"['Bioque M', 'Bernardo M']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Cost-Benefit Analysis', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Half-Life', 'Humans', 'Paliperidone Palmitate/adverse effects/pharmacokinetics/*therapeutic use', 'Schizophrenia/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/30244607/
360,Paliperidone,37350486,Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.,"['Wang D', 'Schneider-Thoma J', 'Siafis S', 'Burschinski A', 'Dong S', 'Wu H', 'Zhu Y', 'Davis JM', 'Priller J', 'Leucht S']","['Humans', '*Antipsychotic Agents/adverse effects', 'Paliperidone Palmitate/adverse effects', 'Aripiprazole/adverse effects', 'Olanzapine/therapeutic use', 'Risperidone/adverse effects', 'Delayed-Action Preparations/therapeutic use', '*Schizophrenia/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37350486/
361,Paliperidone,35307578,Eosinophilic Pleural Effusion Induced by Paliperidone Palmitate: Case Report and Literature Review.,"['de Ghellinck L', 'Frusch N', 'Duysinx B']","['*Eosinophilia/chemically induced/complications', 'Exudates and Transudates', 'Humans', 'Leukocyte Count', 'Paliperidone Palmitate/adverse effects', '*Pleural Effusion/chemically induced/complications/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/35307578/
362,Paliperidone,33242202,[Rhabdomyolysis induced by paliperidone palmitate].,"['Klein B', 'Silberbauer C']","['*Antipsychotic Agents/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Paliperidone Palmitate/adverse effects', '*Rhabdomyolysis/chemically induced/diagnosis/drug therapy', 'Risperidone/adverse effects', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33242202/
363,Paliperidone,28699847,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone.,"['Schoretsanitis G', 'Spina E', 'Hiemke C', 'de Leon J']","['Administration, Oral', 'Animals', 'Antipsychotic Agents/*administration & dosage/pharmacokinetics', 'Delayed-Action Preparations', 'Drug Monitoring/*methods', 'Humans', 'Injections', 'Microspheres', 'Paliperidone Palmitate/pharmacokinetics', 'Risperidone/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28699847/
364,Paliperidone,20406162,Paliperidone use in the elderly.,"['Madhusoodanan S', 'Zaveri D']","['Age Factors', 'Aged', 'Clinical Trials as Topic/methods', 'Dyskinesia, Drug-Induced/diagnosis/metabolism', 'Humans', 'Isoxazoles/adverse effects/pharmacokinetics/*therapeutic use', 'Nervous System Diseases/chemically induced/diagnosis/metabolism', 'Paliperidone Palmitate', 'Pyrimidines/adverse effects/pharmacokinetics/*therapeutic use', 'Schizophrenia/*drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/20406162/
365,Paliperidone,34791283,"A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.","['Najarian D', 'Sanga P', 'Wang S', 'Lim P', 'Singh A', 'Robertson MJ', 'Cohen K', 'Schotte A', 'Milz R', 'Venkatasubramanian R', ""T'Jollyn H"", 'Walling DP', 'Galderisi S', 'Gopal S']","['Adult', '*Antipsychotic Agents/adverse effects', 'Double-Blind Method', 'Humans', 'Paliperidone Palmitate/adverse effects', 'Recurrence', '*Schizophrenia/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34791283/
366,Paliperidone,27590078,Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report.,"['Tsou CC', 'Huang SY']","['Adult', 'Antipsychotic Agents/*adverse effects', 'Benzodiazepines/*administration & dosage', 'Dyskinesia, Drug-Induced/etiology', 'Dystonia/chemically induced', 'Humans', 'Male', 'Olanzapine', 'Paliperidone Palmitate/*adverse effects', 'Psychiatric Status Rating Scales', 'Schizophrenia, Paranoid/*drug therapy', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/27590078/
367,Paliperidone,36834095,Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis-A Retrospective Mirror-Image Study.,"['Chan CT', 'Verma S', 'Subramaniam M', 'Abdin E', 'Tay J']","['Humans', 'Paliperidone Palmitate/therapeutic use', 'Retrospective Studies', '*Antipsychotic Agents/therapeutic use', '*Psychotic Disorders/drug therapy', 'Hospitalization', '*Mental Health Services']",https://pubmed.ncbi.nlm.nih.gov/36834095/
368,Paliperidone,29968279,Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia.,"['Bell Lynum KS', 'Turkoz I', 'Kim E']","['Adolescent', 'Adult', 'Antipsychotic Agents/therapeutic use', 'Double-Blind Method', 'Drug Administration Schedule', 'Early Medical Intervention', 'Female', 'Humans', 'Male', 'Middle Aged', 'Paliperidone Palmitate/*administration & dosage/adverse effects', 'Psychiatric Status Rating Scales', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/29968279/
369,Paliperidone,34212530,Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review.,"['Kishi T', 'Sakuma K', 'Okuya M', 'Hatano M', 'Iwata N']","['*Antipsychotic Agents/adverse effects', 'Aripiprazole/adverse effects', 'Delayed-Action Preparations/therapeutic use', 'Humans', 'Paliperidone Palmitate/adverse effects', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34212530/
370,Paliperidone,18281731,Paliperidone for schizophrenia.,"['Dolder C', 'Nelson M', 'Deyo Z']","['Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Controlled Clinical Trials as Topic', 'Delayed-Action Preparations', 'Drug Interactions', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects/pharmacokinetics', 'Paliperidone Palmitate', 'Pyrimidines/*administration & dosage/adverse effects/pharmacokinetics', 'Risperidone/metabolism/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18281731/
371,Paliperidone,35093701,Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study.,"['Bartoli F', 'Cavaleri D', 'Callovini T', 'Riboldi I', 'Crocamo C', ""D'Agostino A"", 'Martinotti G', 'Bertolini F', 'Ostuzzi G', 'Barbui C', 'Carra G']","['*Antipsychotic Agents/pharmacology/therapeutic use', 'Aripiprazole/pharmacology/therapeutic use', 'Humans', 'Paliperidone Palmitate/therapeutic use', 'Prospective Studies', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35093701/
372,Paliperidone,26230268,Effectiveness of long-acting paliperidone palmitate in borderline personality disorder.,"['Palomares N', 'Montes A', 'Diaz-Marsa M', 'Carrasco JL']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Borderline Personality Disorder/*drug therapy', 'Delayed-Action Preparations', 'Female', 'Humans', 'Injections, Intramuscular', 'Interpersonal Relations', 'Male', 'Middle Aged', 'Paliperidone Palmitate/administration & dosage/adverse effects/*therapeutic use', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26230268/
373,RACEMETHORPHAN,36301443,Dextromethorphan/Bupropion: First Approval.,['Keam SJ'],"['Adult', 'Humans', 'Antidepressive Agents/therapeutic use', '*Bupropion/pharmacology/therapeutic use', '*Depressive Disorder, Major/drug therapy', 'Dextromethorphan/pharmacology/therapeutic use', 'Receptors, N-Methyl-D-Aspartate', 'Drug Approval']",https://pubmed.ncbi.nlm.nih.gov/36301443/
374,RACEMETHORPHAN,37493197,ALSUntangled #71: Nuedexta.,"['Sun Y', 'Benatar M', 'Mascias Cadavid J', 'Ennist D', 'Wicks P', 'Staats K', 'Beauchamp M', 'Jhooty S', 'Pattee G', 'Brown A', 'Bertorini T', 'Barkhaus P', 'Bromberg M', 'Carter G', 'Bedlack R', 'Li X']","['Humans', '*Amyotrophic Lateral Sclerosis/drug therapy', '*Dextromethorphan/therapeutic use', 'Drug Combinations', '*Quinidine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37493197/
375,RACEMETHORPHAN,26325169,Deuterated Drugs.,['Howland RH'],"['Deuterium/*chemistry/*pharmacokinetics', 'Dextromethorphan/*chemistry/pharmacokinetics', 'Humans', 'Paroxetine/*chemistry/pharmacokinetics', 'Prescription Drugs/*chemistry/*pharmacokinetics', 'Tetrabenazine/*chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26325169/
376,RACEMETHORPHAN,35649167,Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI).,"['Iosifescu DV', 'Jones A', ""O'Gorman C"", 'Streicher C', 'Feliz S', 'Fava M', 'Tabuteau H']","['Bupropion/therapeutic use', '*Depressive Disorder, Major/diagnosis/drug therapy', 'Dextromethorphan/adverse effects', 'Double-Blind Method', 'Humans', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/35649167/
377,RACEMETHORPHAN,15572980,Dextromethorphan abuse.,['Boyer EW'],"['Adolescent', 'Child', 'Dextromethorphan/pharmacology/*poisoning', 'Female', 'Humans', 'Substance-Related Disorders/*diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/15572980/
378,RACEMETHORPHAN,36951340,New Combination Drug for Depression.,['Aschenbrenner DS'],"['Humans', 'Male', 'Female', 'Child', 'Young Adult', '*Depressive Disorder, Major/drug therapy', '*Dextromethorphan/adverse effects/therapeutic use', '*Bupropion/adverse effects/therapeutic use', '*Antidepressive Agents/adverse effects/therapeutic use', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/36951340/
379,RACEMETHORPHAN,37290117,Classics in Chemical Neuroscience: Dextromethorphan (DXM).,"['McClure EW', 'Daniels RN']","['Humans', '*Antitussive Agents/pharmacology/therapeutic use', 'Dextromethorphan/pharmacology/therapeutic use', '*Hallucinogens/pharmacology/therapeutic use', 'Phencyclidine', '*Ketamine/pharmacology/therapeutic use', 'Receptors, N-Methyl-D-Aspartate']",https://pubmed.ncbi.nlm.nih.gov/37290117/
380,RACEMETHORPHAN,29633783,Honey for acute cough in children.,"['Oduwole O', 'Udoh EE', 'Oyo-Ita A', 'Meremikwu MM']","['Adolescent', 'Albuterol/therapeutic use', 'Antitussive Agents/adverse effects/*therapeutic use', 'Apitherapy/adverse effects/*methods', 'Bromelains/therapeutic use', 'Bronchodilator Agents/therapeutic use', 'Child', 'Child, Preschool', 'Cough/*therapy', 'Dextromethorphan/adverse effects/*therapeutic use', 'Diphenhydramine/adverse effects/*therapeutic use', 'Honey/adverse effects', 'Humans', 'Infant', 'Placebos/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29633783/
381,RACEMETHORPHAN,39039791,Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder.,"['Blanco J', 'Quimbaya P', 'Mena M', 'Dodd S', 'Bustos RH']","['Humans', '*Bupropion/therapeutic use/pharmacology', '*Dextromethorphan/therapeutic use/pharmacology', '*Depressive Disorder, Major/drug therapy', 'Drug Therapy, Combination', 'Antidepressive Agents, Second-Generation/therapeutic use', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/39039791/
382,RACEMETHORPHAN,33682569,Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials.,"['Majeed A', 'Xiong J', 'Teopiz KM', 'Ng J', 'Ho R', 'Rosenblat JD', 'Phan L', 'Cao B', 'McIntyre RS']","['Adult', 'Animals', 'Antidepressive Agents/*administration & dosage/adverse effects/pharmacology', 'Bipolar Disorder/drug therapy/physiopathology', 'Bupropion/administration & dosage', 'Depressive Disorder, Major/*drug therapy/physiopathology', 'Dextromethorphan/*administration & dosage/adverse effects/pharmacology', 'Drug Therapy, Combination', 'Excitatory Amino Acid Antagonists/administration & dosage/adverse effects/pharmacology', 'Humans', 'Molecular Targeted Therapy']",https://pubmed.ncbi.nlm.nih.gov/33682569/
383,RACEMETHORPHAN,36317836,Dextromethorphan: From Cough Suppressant to Antidepressant.,['Kverno K'],"['Humans', '*Antitussive Agents/pharmacology/therapeutic use', 'Dextromethorphan/pharmacology/therapeutic use', '*Depressive Disorder, Major/drug therapy', 'Quinidine/therapeutic use', 'Antidepressive Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36317836/
384,RACEMETHORPHAN,35582785,Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.,"['Tabuteau H', 'Jones A', 'Anderson A', 'Jacobson M', 'Iosifescu DV']","['Adolescent', 'Adult', 'Aged', '*Bupropion/adverse effects', '*Depressive Disorder, Major/drug therapy', '*Dextromethorphan/adverse effects', 'Double-Blind Method', 'Humans', 'Middle Aged', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/35582785/
385,RACEMETHORPHAN,12078863,Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.,"['Drachtman RA', 'Cole PD', 'Golden CB', 'James SJ', 'Melnyk S', 'Aisner J', 'Kamen BA']","['Adolescent', 'Adult', 'Dextromethorphan/*therapeutic use', 'Homocystine/cerebrospinal fluid', 'Humans', 'Male', 'Methotrexate/*adverse effects', 'Neurotoxicity Syndromes/*drug therapy', 'Receptors, N-Methyl-D-Aspartate/drug effects']",https://pubmed.ncbi.nlm.nih.gov/12078863/
386,RACEMETHORPHAN,37792265,Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.,"['Akbar D', 'Rhee TG', 'Ceban F', 'Ho R', 'Teopiz KM', 'Cao B', 'Subramaniapillai M', 'Kwan ATH', 'Rosenblat JD', 'McIntyre RS']","['Adult', 'Humans', 'Antidepressive Agents/adverse effects', '*Bupropion/adverse effects', 'Depression/drug therapy', '*Depressive Disorder, Major/drug therapy', 'Dextromethorphan/adverse effects', 'Clinical Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37792265/
387,RACEMETHORPHAN,21324299,Cough syrup psychosis.,"['Amaladoss A', ""O'Brien S""]","['Antitussive Agents/*adverse effects', 'Dextromethorphan/*adverse effects', 'Female', 'Humans', 'Psychoses, Substance-Induced/*etiology/therapy', '*Substance-Related Disorders', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21324299/
388,RACEMETHORPHAN,21606622,Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs.,"['Shin EJ', 'Bach JH', 'Lee SY', 'Kim JM', 'Lee J', 'Hong JS', 'Nabeshima T', 'Kim HC']","['Animals', 'Central Nervous System/*drug effects', 'Dextromethorphan/analogs & derivatives/*pharmacology/toxicity', 'Humans', 'Neuroprotective Agents/*pharmacology/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/21606622/
389,RACEMETHORPHAN,38839290,An Autopsy Case of Dextromethorphan Poisoning.,"['Tanaka T', 'Sato H', 'Kimura S', 'Kasai K', 'Umehara T']","['Humans', '*Dextromethorphan/poisoning', 'Female', '*Autopsy', 'Adult', 'Fatal Outcome']",https://pubmed.ncbi.nlm.nih.gov/38839290/
390,RACEMETHORPHAN,23563875,Pharmacology and pharmacogenomics of neurological medications used in pregnancy.,"['Campbell SC', 'Spigarelli MG']","['Anticonvulsants/*pharmacology/therapeutic use', 'Codeine/*pharmacology/therapeutic use', 'Dextromethorphan/pharmacology', 'Female', 'Humans', 'Nervous System Diseases/*drug therapy', '*Pharmacogenetics', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Teratogens/pharmacology', 'Tetrabenazine/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/23563875/
391,RACEMETHORPHAN,23414979,"""How high do they look?"": identification and treatment of common ingestions in adolescents.","['Woo TM', 'Hanley JR']","['Adolescent', '*Adolescent Behavior/psychology', 'Benzodioxoles/adverse effects/*toxicity', 'Cannabinoid Receptor Agonists/adverse effects/*toxicity', 'Cannabinoids/adverse effects/*toxicity', 'Charcoal/therapeutic use', 'Dextromethorphan/adverse effects/*toxicity', 'Drug Overdose', 'Emergency Medicine/methods', 'Female', 'Humans', 'Illicit Drugs', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine/adverse effects/*toxicity', 'Naloxone/therapeutic use', 'North Carolina/epidemiology', 'Ondansetron/therapeutic use', 'Prevalence', 'Pyrrolidines/adverse effects/*toxicity', 'Substance-Related Disorders/epidemiology/*prevention & control', 'Synthetic Cathinone']",https://pubmed.ncbi.nlm.nih.gov/23414979/
392,RACEMETHORPHAN,21052935,Neuropsychopharmacological understanding for therapeutic application of morphinans.,"['Shin EJ', 'Hong JS', 'Kim HC']","['Animals', 'Astrocytes/drug effects/metabolism', 'Dextromethorphan/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Humans', 'Morphinans/adverse effects/pharmacology/*therapeutic use', 'Naloxone/adverse effects/pharmacology/therapeutic use', 'Neurodegenerative Diseases/*drug therapy', 'Neuroglia/drug effects/metabolism', 'Neurons/drug effects/metabolism', 'Neuroprotective Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21052935/
393,SUFENTANIL,28688027,Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.,"['Ziesenitz VC', 'Vaughns JD', 'Koch G', 'Mikus G', 'van den Anker JN']","['Adolescent', 'Alfentanil/administration & dosage/pharmacokinetics', 'Analgesics, Opioid/administration & dosage/*pharmacokinetics', 'Body Weight', 'Child', 'Child, Preschool', 'Fentanyl/administration & dosage/*pharmacokinetics', 'Humans', 'Infant', 'Infant, Newborn', 'Linear Models', 'Models, Biological', 'Remifentanil/administration & dosage/pharmacokinetics', 'Sufentanil/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28688027/
394,SUFENTANIL,8896944,"Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.","['Scholz J', 'Steinfath M', 'Schulz M']","['Aging/metabolism', 'Alfentanil/*administration & dosage/*pharmacokinetics', 'Analgesics, Opioid/*administration & dosage/*pharmacokinetics', 'Fentanyl/*administration & dosage/*pharmacokinetics', 'Half-Life', 'Humans', 'Obesity/metabolism', 'Sufentanil/*administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8896944/
395,SUFENTANIL,36799783,Preventing postoperative cognitive dysfunction using anesthetic drugs in elderly patients undergoing noncardiac surgery: a systematic review and meta-analysis.,"['Zeng K', 'Long J', 'Li Y', 'Hu J']","['Humans', 'Aged', 'Sevoflurane', '*Anesthetics, Inhalation/therapeutic use', '*Dexmedetomidine/therapeutic use', '*Postoperative Cognitive Complications/drug therapy', 'Sufentanil/adverse effects', 'Postoperative Complications/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/36799783/
396,SUFENTANIL,25388859,The role of sublingual sufentanil nanotabs for pain relief.,"['Minkowitz HS', 'Candiotti K']","['Administration, Sublingual', 'Analgesia, Patient-Controlled/methods', 'Analgesics, Opioid/*administration & dosage/therapeutic use', 'Animals', 'Humans', 'Pain, Postoperative/*drug therapy', 'Sufentanil/*administration & dosage/therapeutic use', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/25388859/
397,SUFENTANIL,26799508,Pharmacokinetic and pharmacodynamic evaluation of sublingual sufentanil in the treatment of post-operative pain.,"['Babazade R', 'Turan A']","['Administration, Sublingual', 'Analgesia, Patient-Controlled/methods', 'Analgesics, Opioid/*administration & dosage/adverse effects/pharmacokinetics', 'Animals', 'Drug Design', 'Humans', 'Pain, Postoperative/*drug therapy', 'Sufentanil/*administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26799508/
398,SUFENTANIL,11574125,Effect of epidural analgesia on the fetal heart rate.,['Capogna G'],"['Analgesics, Opioid/administration & dosage/therapeutic use', 'Anesthesia, Epidural/*adverse effects', 'Clinical Trials as Topic', 'Female', 'Heart Rate, Fetal/*drug effects', 'Humans', 'Hypotension/physiopathology', 'Meperidine/administration & dosage/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/physiopathology', 'Sufentanil/administration & dosage/therapeutic use', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11574125/
399,SUFENTANIL,37673104,Continuous Analgesia with Intercostal Catheterization after Thoracoscopy.,"['Wang Y', 'Sun Q', 'Huang Y', 'Yang Q', 'Chen R', 'Zhang X', 'Zhao X', 'Wang M']","['Humans', '*Pain, Postoperative/etiology/prevention & control/diagnosis', 'Female', 'Male', '*Nerve Block/adverse effects', 'Middle Aged', '*Intercostal Nerves', 'Treatment Outcome', '*Pain Measurement', 'Time Factors', '*Sufentanil/administration & dosage/adverse effects', 'Adult', 'Aged', 'Analgesics, Opioid/administration & dosage', 'Thoracoscopy/adverse effects', 'Thoracic Surgery, Video-Assisted/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37673104/
400,SUFENTANIL,19652596,New and emerging analgesics and analgesic technologies for acute pain management.,"['Heitz JW', 'Witkowski TA', 'Viscusi ER']","['*Analgesia, Patient-Controlled/instrumentation/methods/trends', 'Analgesics/*administration & dosage', 'Catheters, Indwelling/adverse effects', 'Delayed-Action Preparations', 'Drug Delivery Systems', 'Equipment Design', 'Fentanyl/administration & dosage', 'Humans', 'Injections, Intra-Articular', 'Injections, Intraventricular', 'Iontophoresis/methods', 'Morphine/*administration & dosage', 'Sufentanil/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/19652596/
401,SUFENTANIL,33275260,Sufentanil Sublingual Tablet System: from rationale of use to clinical practice.,"['Vergari A', 'Cortegiani A', 'Rispoli M', 'Coluzzi F', 'Deni F', 'Leykin Y', 'Luca Lorini F', 'Martorano PP', 'Paolicchi A', 'Polati E', 'Scardino M', 'Corcione A', 'Giarratano A', 'Rossi M']","['Acute Pain/drug therapy', 'Administration, Sublingual', 'Analgesia, Patient-Controlled/*instrumentation', 'Analgesics, Opioid/administration & dosage/*therapeutic use', 'Humans', 'Pain Management/*instrumentation', 'Pain, Postoperative/*drug therapy', '*Practice Guidelines as Topic', 'Sufentanil/administration & dosage/*therapeutic use', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/33275260/
402,SUFENTANIL,15504182,Low-dose bupivacaine with sufentanil prevents hypotension after spinal anesthesia for hip repair in elderly patients.,"['Olofsson C', 'Nygards EB', 'Bjersten AB', 'Hessling A']","['Aged', '*Anesthesia, Spinal/adverse effects', 'Anesthetics, Intravenous/administration & dosage/adverse effects/*therapeutic use', 'Anesthetics, Local/administration & dosage/adverse effects/*therapeutic use', 'Bupivacaine/administration & dosage/adverse effects/*therapeutic use', 'Double-Blind Method', 'Ephedrine/administration & dosage/therapeutic use', 'Female', 'Hemodynamics/drug effects', 'Hip/*surgery', 'Hip Fractures/surgery', 'Humans', 'Hypotension/physiopathology/*prevention & control', 'Male', 'Nerve Block', '*Orthopedic Procedures', 'Postoperative Complications/physiopathology/*prevention & control', 'Sufentanil/administration & dosage/adverse effects/*therapeutic use', 'Vasoconstrictor Agents/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15504182/
403,SUFENTANIL,30614379,Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain.,"['Miner JR', 'Melson TI', 'Leiman D', 'Minkowitz HS', 'Chiang YK', 'DiDonato KP', 'Palmer PP']","['Acute Pain/*drug therapy', 'Administration, Sublingual', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Analgesics, Opioid/*administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Sufentanil/*administration & dosage/*adverse effects/therapeutic use', 'Tablets', 'Time', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30614379/
404,SUFENTANIL,35060534,Hydromorphone vs sufentanil in patient-controlled analgesia for postoperative pain management: A meta-analysis.,"['Nie ZB', 'Li ZH', 'Lu B', 'Guo YY', 'Zhang R']","['*Analgesia, Patient-Controlled', 'Analgesics, Opioid', 'Anesthetics, Intravenous/*administration & dosage/adverse effects', 'Humans', 'Hydromorphone/*administration & dosage/adverse effects', 'Narcotics', 'Pain, Postoperative/*drug therapy', 'Sufentanil/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35060534/
405,SUFENTANIL,12001185,Funipuncture for fetocide in late termination of pregnancy.,"['Senat MV', 'Fischer C', 'Ville Y']","['Abnormalities, Multiple', 'Abortion, Eugenic/*methods', 'Adult', 'Analgesics, Opioid/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Electrocardiography', 'Female', 'Fetal Death/*chemically induced', 'Fetus/*abnormalities', 'Gestational Age', 'Humans', 'Injections, Intravenous', 'Maternal-Fetal Exchange', 'Potassium Chloride/administration & dosage/pharmacokinetics/*poisoning', 'Pregnancy', 'Sufentanil/administration & dosage/therapeutic use', 'Umbilical Veins']",https://pubmed.ncbi.nlm.nih.gov/12001185/
406,SUFENTANIL,34077940,Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates.,"['Pokorna P', 'Sima M', 'Koch B', 'Tibboel D', 'Slanar O']","['Analgesics, Opioid/administration & dosage/*pharmacokinetics', 'Body Weight', 'Dose-Response Relationship, Drug', 'Drug Monitoring/methods', 'Female', 'Gestational Age', 'Humans', 'Infant, Newborn', 'Male', '*Models, Biological', '*Respiration, Artificial', 'Retrospective Studies', 'Sufentanil/administration & dosage/*pharmacokinetics', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/34077940/
407,SUFENTANIL,24673599,Priapism following continuous thoracic epidural anaesthesia: emergency or a benign condition?,"['Fransen van de Putte EE', 'Ananias HJ', 'Gi NP', 'de Boer HD']","['Anesthesia, Epidural/*adverse effects', 'Anesthetics, Local/administration & dosage/*adverse effects', 'Bupivacaine/administration & dosage/adverse effects/*analogs & derivatives', '*Emergencies', 'Humans', 'Levobupivacaine', 'Male', 'Middle Aged', 'Morphine/therapeutic use', 'Narcotics/therapeutic use', 'Nephrectomy', 'Pain, Postoperative/drug therapy/therapy', 'Parasympathetic Nervous System/physiopathology', 'Penis/blood supply/innervation', 'Postoperative Complications/*etiology', 'Priapism/*etiology/physiopathology', 'Sufentanil/administration & dosage/*adverse effects', 'Sympathetic Nervous System/drug effects/physiopathology', 'Thoracic Vertebrae']",https://pubmed.ncbi.nlm.nih.gov/24673599/
408,SUFENTANIL,31286476,Spinal and epidural sufentanil and fentanyl in early labour.,"['Vaananen A', 'Kuukasjarvi M', 'Tekay A', 'Ahonen J']","['Analgesia, Epidural/*methods', 'Analgesia, Obstetrical/*methods', 'Female', 'Fentanyl/*administration & dosage', 'Heart Rate, Fetal', 'Humans', 'Pregnancy', 'Sufentanil/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31286476/
409,SUFENTANIL,33273644,Pupillometry pain index decreases intraoperative sufentanyl administration in cardiac surgery: a prospective randomized study.,"['Berthoud V', 'Nguyen M', 'Appriou A', 'Ellouze O', 'Radhouani M', 'Constandache T', 'Grosjean S', 'Durand B', 'Gounot I', 'Bahr PA', 'Martin A', 'Nowobilski N', 'Bouhemad B', 'Guinot PG']","['Aged', '*Cardiac Surgical Procedures', 'Female', 'Humans', 'Male', '*Monitoring, Intraoperative', 'Pain, Postoperative/*pathology', 'Prospective Studies', 'Pupil/*drug effects', 'Sufentanil/*administration & dosage/*pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33273644/
410,SUFENTANIL,1469163,Reversal of neurological deficit with naloxone: an additional report.,"['Hans P', 'Brichant JF', 'Longerstay E', 'Damas F', 'Remacle JM']","['Arachnoid Cysts/*surgery', 'Female', 'Hemiplegia/diagnostic imaging/*drug therapy/etiology', 'Humans', 'Middle Aged', 'Naloxone/administration & dosage/pharmacology/*therapeutic use', 'Postoperative Complications/diagnostic imaging/*drug therapy/etiology', 'Sufentanil/adverse effects', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/1469163/
411,SUFENTANIL,24782286,Efficacy and Safety of Sufentanil and Pethidine in Spinal Anesthesia for Painless Labor.,"['Salarian S', 'Fathi M', 'Farzanegan B', 'Bagheri B']","['Adult', 'Analgesics, Opioid/adverse effects/therapeutic use', '*Anesthesia, Spinal', 'Female', 'Humans', 'Labor Pain/*drug therapy', 'Meperidine/*adverse effects/*therapeutic use', 'Pregnancy', 'Sufentanil/*adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24782286/
412,SUFENTANIL,31280585,Sufentanil Sublingual Tablet: A New Option for Acute Pain Management.,"['Reardon CE', 'Kane-Gill SL', 'Smithburger PL', 'Dasta JF']","['Acute Pain/*drug therapy', 'Administration, Intravenous', 'Administration, Sublingual', 'Analgesia/methods', 'Analgesics, Opioid/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Emergency Service, Hospital', 'Humans', 'Pain Management/*methods', 'Pain, Postoperative/*drug therapy', 'Sufentanil/administration & dosage/adverse effects/*therapeutic use', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/31280585/
413,Salbutamol,36430683,Salbutamol in the Management of Asthma: A Review.,"['Marques L', 'Vale N']","['Humans', 'Albuterol/therapeutic use', '*Asthma/drug therapy', 'Bronchi', '*Drug-Related Side Effects and Adverse Reactions', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/36430683/
414,Salbutamol,11253864,Single-isomer beta-agonists.,['Handley DA'],"['Administration, Inhalation', 'Adrenergic beta-Agonists/chemistry/*pharmacology', 'Albuterol/adverse effects/chemistry/pharmacology', 'Asthma/*drug therapy', 'Bronchi/drug effects', 'Bronchodilator Agents/chemistry/*pharmacology', 'Ethanolamines/adverse effects/chemistry/pharmacology', 'Formoterol Fumarate', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/11253864/
415,Salbutamol,11802253,Levalbuterol hydrochloride.,"['Slattery D', 'Wong SW', 'Colin AA']","['Adrenergic beta-Agonists/adverse effects/chemistry/pharmacology/*therapeutic use', 'Albuterol/adverse effects/chemistry/pharmacology/*therapeutic use', 'Asthma/*drug therapy', 'Bronchial Provocation Tests', 'Bronchodilator Agents/adverse effects/chemistry/pharmacology/*therapeutic use', 'Eosinophils/drug effects', 'Humans', 'Mucociliary Clearance/drug effects', 'Receptors, Adrenergic, beta-2/*metabolism', 'Research', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/11802253/
416,Salbutamol,7875287,Salmeterol-induced vertigo.,"['Lopez-Guillen A', 'Marques L', 'Lopez-Llorente MT', 'Pastor E', 'Figueras A']","['Administration, Inhalation', 'Aged', 'Albuterol/adverse effects/*analogs & derivatives/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Salmeterol Xinafoate', 'Vertigo/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7875287/
417,Salbutamol,9877002,Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy.,"['Buchwald A', 'Hochhaus G']","['Adrenergic beta-Agonists/*pharmacokinetics/*pharmacology/therapeutic use', 'Albuterol/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Asthma/drug therapy', 'Bronchodilator Agents/*pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/9877002/
418,Salbutamol,17547854,Levalbuterol for asthma: a better treatment?,['Kelly HW'],"['Albuterol/adverse effects/*therapeutic use', 'Animals', 'Asthma/*drug therapy', 'Bronchial Hyperreactivity/chemically induced', 'Bronchodilator Agents/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Disease Models, Animal', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/17547854/
419,Salbutamol,12562558,Single-isomer levalbuterol: a review of the acute data.,['Nowak R'],"['Acute Disease', 'Albuterol/economics/pharmacokinetics/*pharmacology', 'Asthma/*drug therapy', 'Bronchodilator Agents/economics/pharmacokinetics/*pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/12562558/
420,Salbutamol,26742192,Usefulness Of Glucocorticoids In The Management Of Foreign Body Aspiration.,"['Pagan Rivera BL', 'Anselmi FJ', 'Torres Mdel M', 'Segarra A', 'Rivera JR']","['Acetaminophen/administration & dosage/therapeutic use', 'Analgesics/therapeutic use', 'Anti-Bacterial Agents/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Azithromycin/administration & dosage/therapeutic use', 'Bronchodilator Agents/administration & dosage/therapeutic use', 'Ceftriaxone/administration & dosage/therapeutic use', 'Cough/etiology', 'Drug Therapy, Combination', 'Dyspnea/etiology', 'Fluoroquinolones/administration & dosage/therapeutic use', 'Foreign Bodies/diagnostic imaging/*drug therapy', 'Humans', 'Levalbuterol/administration & dosage/therapeutic use', 'Male', 'Methylprednisolone/administration & dosage/*therapeutic use', 'Moxifloxacin', 'Play and Playthings', 'Pneumonia, Aspiration/*drug therapy/etiology', 'Ranitidine/administration & dosage/therapeutic use', 'Tomography, X-Ray Computed', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26742192/
421,Salbutamol,36865421,Loeffler's Syndrome and Multifocal Cutaneous Larva Migrans: Case report of an uncommon occurrence and review of the literature.,"['Sil A', 'Bhanja DB', 'Chandra A', 'Biswas SK']","['Male', 'Humans', 'Adult', '*Larva Migrans/diagnosis/drug therapy', 'Skin', 'Albendazole/therapeutic use', 'India', 'Levalbuterol']",https://pubmed.ncbi.nlm.nih.gov/36865421/
422,Salbutamol,10452792,Clinical experience with levalbuterol.,['Nelson HS'],"['Adrenergic beta-Agonists/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Adult', 'Albuterol/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Child', 'Clinical Trials as Topic', 'Female', 'Humans', 'Male', 'Respiratory Hypersensitivity/drug therapy', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10452792/
423,Salbutamol,1897692,Cyclosporin for steroid-dependent asthma.,"['Szczeklik A', 'Nizankowska E', 'Dworski R', 'Domagala B', 'Pinis G']","['Adult', 'Albuterol/administration & dosage/therapeutic use', 'Aminophylline/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/therapeutic use', 'Cyclosporins/administration & dosage/blood/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Peak Expiratory Flow Rate/drug effects', 'Prednisone/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1897692/
424,Salbutamol,39213627,beta-Adrenergic Agonist-Induced Lactic Acidosis: A Case Report.,['Blush RR 3rd'],"['Humans', '*Acidosis, Lactic/chemically induced', '*Adrenergic beta-Agonists/adverse effects', '*Albuterol/adverse effects/therapeutic use/administration & dosage', 'Asthma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39213627/
425,Salbutamol,12493336,The long and short of beta2-agonists.,['Lotvall J'],"['Administration, Inhalation', '*Adrenergic beta-2 Receptor Agonists', 'Adrenergic beta-Agonists/*administration & dosage/therapeutic use', 'Albuterol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Animals', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/therapeutic use', 'Budesonide/adverse effects/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Ethanolamines/adverse effects/pharmacology/therapeutic use', 'Formoterol Fumarate', 'Humans', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/12493336/
426,Salbutamol,12810191,Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?,"['Tennant RC', 'Erin EM', 'Barnes PJ', 'Hansel TT']","['*Adrenergic beta-2 Receptor Agonists', 'Adrenergic beta-Agonists/administration & dosage/therapeutic use', 'Albuterol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/pharmacology/therapeutic use', 'Bronchodilator Agents/administration & dosage/pharmacology/*therapeutic use', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Ethanolamines/administration & dosage/pharmacology/therapeutic use', 'Exercise Tolerance/drug effects', 'Formoterol Fumarate', 'Humans', 'Mucus/metabolism', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Quality of Life', 'Randomized Controlled Trials as Topic', 'Salmeterol Xinafoate', 'Scopolamine Derivatives/administration & dosage/pharmacology/*therapeutic use', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/12810191/
427,Salbutamol,19671384,Levalbuterol versus albuterol.,"['Ameredes BT', 'Calhoun WJ']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/chemistry/*therapeutic use', 'Albuterol/administration & dosage/chemistry/*therapeutic use', 'Animals', 'Asthma/*drug therapy/immunology', 'Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/19671384/
428,Salbutamol,8322251,Prolonged hypoxaemia after nebulised salbutamol.,"['Connett G', 'Lenney W']","['Acute Disease', 'Albuterol/administration & dosage/*adverse effects', 'Asthma/drug therapy', 'Child', 'Child, Preschool', 'Humans', 'Hypoxia/*chemically induced', 'Infant', 'Nebulizers and Vaporizers']",https://pubmed.ncbi.nlm.nih.gov/8322251/
429,Salbutamol,889727,The effect of intravenous and oral salbutamol on fetus and mother in premature labour.,"['Dawson AM', 'Davies HJ']","['Administration, Oral', 'Adolescent', 'Adult', 'Albuterol/administration & dosage/*therapeutic use', 'Blood Pressure/drug effects', 'Depression, Chemical', 'Female', 'Fetal Heart/drug effects', 'Fetus/drug effects', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Obstetric Labor, Premature/*drug therapy', 'Pregnancy', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/889727/
430,Salbutamol,7780253,"Acute asthma, salbutamol and hyperglycaemia.","['Dawson KP', 'Penna AC', 'Manglick P']","['Acute Disease', 'Age Factors', 'Albuterol/administration & dosage/*adverse effects/blood', 'Asthma/*drug therapy', 'Blood Glucose/analysis', 'Child', 'Child, Preschool', 'Chromatography, High Pressure Liquid', 'Fluorometry', 'Humans', 'Hyperglycemia/*chemically induced', 'Nebulizers and Vaporizers', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7780253/
431,Salbutamol,32051218,Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.,"['Knopfel N', 'Oesch V', 'Theiler M', 'Szello P', 'Weibel L']","['Adrenergic beta-2 Receptor Agonists/administration & dosage/*adverse effects', 'Albuterol/administration & dosage/*adverse effects', 'Bronchitis/drug therapy', 'Child, Preschool', 'Female', 'Hemangioma/drug therapy/*pathology', 'Humans', 'Infusions, Intravenous', 'Neoplasm Recurrence, Local/*chemically induced', 'Propranolol/therapeutic use', 'Skin Neoplasms/drug therapy/*pathology', 'Vasodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32051218/
432,Salbutamol,10678290,Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?,"['Asmus MJ', 'Hendeles L']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/*economics/*therapeutic use', 'Albuterol/administration & dosage/*economics/*therapeutic use', 'Anti-Asthmatic Agents/administration & dosage/*economics/*therapeutic use', 'Asthma/*drug therapy/*economics', 'Humans', 'Nebulizers and Vaporizers', 'Pharmaceutical Solutions', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10678290/
433,Solifenacin,29043374,[Overactive bladder-which treatment when?].,['Pannek J'],"['Behavior Therapy', 'Botulinum Toxins, Type A/therapeutic use', 'Diagnosis, Differential', 'Electric Stimulation Therapy', 'Female', 'Gabapentin/therapeutic use', 'Humans', 'Injections, Intramuscular', 'Lumbosacral Plexus/drug effects', 'Male', 'Muscarinic Antagonists/therapeutic use', 'Patient Preference', 'Physical Therapy Modalities', 'Solifenacin Succinate/therapeutic use', 'Tadalafil/therapeutic use', 'Urinary Bladder/drug effects', 'Urinary Bladder, Overactive/diagnosis/etiology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/29043374/
434,Solifenacin,28394529,[Comprehensive pharmacologic management of overactive bladder].,"['Krivoborodov GG', 'Tur EI']","['Acetanilides/therapeutic use', 'Adrenergic beta-3 Receptor Agonists/therapeutic use', 'Drug Combinations', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Randomized Controlled Trials as Topic', 'Solifenacin Succinate/therapeutic use', 'Sulfonamides/therapeutic use', 'Tamsulosin', 'Thiazoles/therapeutic use', 'Urinary Bladder, Neurogenic/drug therapy/etiology', 'Urinary Bladder, Overactive/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/28394529/
435,Solifenacin,37506033,Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.,"['He W', 'Huang G', 'Cui W', 'Tian Y', 'Sun Q', 'Zhao X', 'Zhao Y', 'Li D', 'Liu X']","['Humans', '*Urinary Bladder, Overactive/drug therapy', 'Solifenacin Succinate/adverse effects', 'Tolterodine Tartrate/therapeutic use', 'Network Meta-Analysis', 'Double-Blind Method', 'Constipation/drug therapy', '*Xerostomia/drug therapy', 'Treatment Outcome', 'Muscarinic Antagonists/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37506033/
436,Solifenacin,32432436,Conservative management of urinary incontinence following robot-assisted radical prostatectomy.,"['Marchioni M', 'Primiceri G', 'Castellan P', 'Schips L', 'Mantica G', 'Chapple C', 'Papalia R', 'Porpiglia F', 'Scarpa RM', 'Esperto F']","['*Conservative Treatment', 'Humans', 'Male', 'Postoperative Complications/*therapy', 'Prostatectomy/*adverse effects', 'Prostatic Neoplasms/complications/surgery', 'Robotic Surgical Procedures/*adverse effects', 'Urinary Incontinence/*etiology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/32432436/
437,Solifenacin,31066800,Overactive bladder - pharmacological treatment.,"['Sacomani CAR', 'Almeida FG', 'Silvinato A', 'Bernardo WM']","['Acetanilides/*administration & dosage', 'Adrenergic beta-3 Receptor Agonists/*administration & dosage', 'Antidepressive Agents/administration & dosage', 'Benzilates/administration & dosage', 'Benzofurans/administration & dosage', 'Brazil', 'Clinical Decision-Making', 'Drug Therapy, Combination', 'Humans', 'Mandelic Acids/administration & dosage', 'Muscarinic Antagonists/*administration & dosage', 'Nortropanes/administration & dosage', 'Pyrrolidines/administration & dosage', 'Solifenacin Succinate/administration & dosage', 'Thiazoles/*administration & dosage', 'Tolterodine Tartrate/administration & dosage', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31066800/
438,Solifenacin,25741549,[Current pharmacotherapy of overactive bladder in neurological patients].,"['Shvarts PG', 'Vinarov AZ', 'Kadykov AS', 'Borodulina IV', 'Popov SV', 'Kravchenko MA']","['Humans', 'Muscarinic Antagonists/*therapeutic use', 'Quinuclidines/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/therapeutic use', 'Urinary Bladder, Overactive/*drug therapy/etiology/physiopathology', 'Urination', 'Urological Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25741549/
439,Solifenacin,21607875,Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients.,"['Pagoria D', ""O'Connor RC"", 'Guralnick ML']","['Aged', 'Cognition Disorders/*chemically induced', 'Humans', 'Muscarinic Antagonists/*adverse effects/therapeutic use', 'Receptors, Muscarinic/drug effects', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21607875/
440,Solifenacin,16908335,Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.,"['Brubaker L', 'Chapple C', 'Coyne KS', 'Kopp Z']","['Benzhydryl Compounds/therapeutic use', 'Clinical Trials as Topic', 'Cresols/therapeutic use', 'Health Status', 'Humans', 'Mandelic Acids/therapeutic use', 'Muscarinic Antagonists/therapeutic use', 'Patient Compliance', 'Patient Satisfaction', 'Phenylpropanolamine/therapeutic use', '*Quality of Life', 'Quinuclidines/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/therapeutic use', 'Tolterodine Tartrate', 'Treatment Outcome', 'Urinary Bladder, Neurogenic/drug therapy/physiopathology/psychology/*therapy', 'Urinary Incontinence, Stress/therapy']",https://pubmed.ncbi.nlm.nih.gov/16908335/
441,Solifenacin,36336627,Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review.,"['Raman G', 'Tunnicliffe D', 'Lai E', 'Bennett T', 'Caldwell P']","['Child', 'Adolescent', 'Humans', 'Solifenacin Succinate/adverse effects', '*Urinary Bladder, Overactive/drug therapy', 'Treatment Outcome', 'Cholinergic Antagonists/adverse effects', '*Xerostomia/chemically induced/drug therapy', 'Constipation', 'Muscarinic Antagonists/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36336627/
442,Solifenacin,15461562,The emerging role of solifenacin in the treatment of overactive bladder.,"['Robinson D', 'Cardozo L']","['Clinical Trials as Topic', 'Humans', 'Muscarinic Antagonists/adverse effects/pharmacology/therapeutic use', 'Quinuclidines/adverse effects/pharmacology/*therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome', 'Urinary Incontinence/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15461562/
443,Solifenacin,20157218,Solifenacin pharmacology.,"['Morales-Olivas FJ', 'Estan L']","['Animals', 'Humans', 'Muscarinic Antagonists/pharmacokinetics/*pharmacology/therapeutic use', 'Quinuclidines/pharmacokinetics/*pharmacology/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/pharmacokinetics/*pharmacology/therapeutic use', 'Urinary Bladder, Overactive/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20157218/
444,Solifenacin,19388996,Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome.,"['Chapple CR', 'Rosenberg MT', 'Brenes FJ']","['Benzofurans/administration & dosage', 'Drug Administration Schedule', 'Humans', 'Mandelic Acids/administration & dosage', 'Multicenter Studies as Topic', 'Muscarinic Antagonists/*administration & dosage', '*Patient Satisfaction', 'Pyrrolidines/administration & dosage', 'Quinuclidines/administration & dosage', 'Randomized Controlled Trials as Topic', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/administration & dosage', 'Urinary Bladder, Overactive/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/19388996/
445,Solifenacin,15963212,Darifenacin in the treatment of overactive bladder.,"['Parsons M', 'Robinson D', 'Cardozo L']","['Absorption', 'Benzofurans/adverse effects/metabolism/*therapeutic use', 'Central Nervous System Diseases/chemically induced', 'Drug Interactions', 'Drug Tolerance', 'Heart Rate/drug effects', 'Humans', 'Muscarinic Antagonists/adverse effects/metabolism/*therapeutic use', 'Pyrrolidines/adverse effects/metabolism/*therapeutic use', 'Receptors, Muscarinic/metabolism', 'Treatment Outcome', 'Urinary Bladder Diseases/*drug therapy', 'Urination Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15963212/
446,Solifenacin,30306278,Management of Overactive Bladder Symptoms After Radical Prostatectomy.,"['Peyronnet B', 'Brucker BM']","['Botulinum Toxins, Type A/therapeutic use', 'Humans', 'Male', 'Muscarinic Antagonists/*therapeutic use', 'Neuromuscular Agents/*therapeutic use', 'Postoperative Complications/physiopathology/*therapy', 'Prostate', '*Prostatectomy', 'Solifenacin Succinate/therapeutic use', 'Tolterodine Tartrate/therapeutic use', 'Urethral Stricture/surgery', 'Urinary Bladder Neck Obstruction/physiopathology/surgery', 'Urinary Bladder, Overactive/physiopathology/*therapy', 'Urinary Incontinence, Stress/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/30306278/
447,Solifenacin,16503831,The emergence of new drugs for overactive bladder.,"['McCrery RJ', 'Smith PP', 'Appell RA']","['Acetylcholine/metabolism', 'Amines/pharmacology/therapeutic use', 'Animals', 'Anticonvulsants/pharmacology/*therapeutic use', 'Benzhydryl Compounds/pharmacology/therapeutic use', 'Cresols/pharmacology/therapeutic use', 'Cyclohexanecarboxylic Acids/pharmacology/therapeutic use', 'Drug Evaluation, Preclinical', 'Gabapentin', 'Humans', 'Mandelic Acids/pharmacology/therapeutic use', 'Muscarinic Antagonists/pharmacology/*therapeutic use', 'Muscle, Smooth/*drug effects/innervation/metabolism', 'Phenylpropanolamine/pharmacology/therapeutic use', 'Product Surveillance, Postmarketing', 'Quinuclidines/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Receptor, Muscarinic M3/antagonists & inhibitors/metabolism', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/pharmacology/therapeutic use', 'Tolterodine Tartrate', 'Urinary Bladder/drug effects/innervation/metabolism', 'Urinary Incontinence/*drug therapy', 'gamma-Aminobutyric Acid/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16503831/
448,Solifenacin,30350884,Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.,"['Wang J', 'Zhou Z', 'Cui Y', 'Li Y', 'Yuan H', 'Gao Z', 'Zhu Z', 'Wu J']","['Acetanilides/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Solifenacin Succinate/adverse effects/*therapeutic use', 'Thiazoles/adverse effects/*therapeutic use', 'Urinary Bladder, Overactive/*drug therapy', 'Urological Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30350884/
449,Solifenacin,16483863,Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.,"['Staskin DR', 'MacDiarmid SA']","['Benzhydryl Compounds/therapeutic use', 'Benzilates', 'Benzofurans/therapeutic use', 'Cholinergic Antagonists/*therapeutic use', 'Cresols/therapeutic use', 'Humans', 'Mandelic Acids/therapeutic use', 'Nortropanes/therapeutic use', 'Phenylpropanolamine/therapeutic use', 'Pyrrolidines/therapeutic use', 'Quinuclidines/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/therapeutic use', 'Tolterodine Tartrate', 'Urinary Incontinence/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16483863/
450,Solifenacin,21069103,Gateways to clinical trials.,"['Tomillero A', 'Moral MA']","['*Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/21069103/
451,Solifenacin,34493055,History and current trends in the treatment of idiopathic overactive bladder.,"['Habes Dominik', 'Lesko Daniel', 'Stepan Martin', 'Spacek Jiri', 'Kestranek Jan']","['Benzhydryl Compounds', 'Humans', 'Muscarinic Antagonists/therapeutic use', 'Quality of Life', 'Solifenacin Succinate', 'Treatment Outcome', '*Urinary Bladder, Overactive/therapy']",https://pubmed.ncbi.nlm.nih.gov/34493055/
452,Solifenacin,39353751,Toxic Epidermal Necrolysis Observed in a Patient With the HLA-B*1502 Treated With Levofloxacin.,"['Wang X', 'Cheng G', 'Liang X', 'Yang J', 'Deng A', 'Chen D', 'Liu C', 'Gao Y', 'Li J']","['Humans', '*Stevens-Johnson Syndrome/genetics/etiology/drug therapy', 'Female', '*Levofloxacin/adverse effects', 'Aged', 'Anti-Bacterial Agents/adverse effects/administration & dosage', 'HLA-B15 Antigen/genetics', 'Cystitis/genetics/chemically induced/drug therapy', 'Mutation', 'Alleles']",https://pubmed.ncbi.nlm.nih.gov/39353751/
453,Sorafenib,38382875,Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.,"['Sangro B', 'Chan SL', 'Kelley RK', 'Lau G', 'Kudo M', 'Sukeepaisarnjaroen W', 'Yarchoan M', 'De Toni EN', 'Furuse J', 'Kang YK', 'Galle PR', 'Rimassa L', 'Heurgue A', 'Tam VC', 'Van Dao T', 'Thungappa SC', 'Breder V', 'Ostapenko Y', 'Reig M', 'Makowsky M', 'Paskow MJ', 'Gupta C', 'Kurland JF', 'Negro A', 'Abou-Alfa GK']","['Humans', '*Carcinoma, Hepatocellular/drug therapy/mortality/pathology', '*Liver Neoplasms/drug therapy/mortality/pathology', 'Male', 'Female', '*Antibodies, Monoclonal/administration & dosage/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects/administration & dosage', '*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', 'Aged', 'Sorafenib/administration & dosage/therapeutic use/adverse effects', 'Survival Rate', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38382875/
454,Sorafenib,38319892,Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.,"['Abou-Alfa GK', 'Lau G', 'Kudo M', 'Chan SL', 'Kelley RK', 'Furuse J', 'Sukeepaisarnjaroen W', 'Kang YK', 'Van Dao T', 'De Toni EN', 'Rimassa L', 'Breder V', 'Vasilyev A', 'Heurgue A', 'Tam VC', 'Mody K', 'Thungappa SC', 'Ostapenko Y', 'Yau T', 'Azevedo S', 'Varela M', 'Cheng AL', 'Qin S', 'Galle PR', 'Ali S', 'Marcovitz M', 'Makowsky M', 'He P', 'Kurland JF', 'Negro A', 'Sangro B']","['Humans', '*Carcinoma, Hepatocellular/drug therapy/mortality/pathology', '*Liver Neoplasms/drug therapy/mortality/pathology', 'Male', '*Antibodies, Monoclonal/therapeutic use/administration & dosage/adverse effects', 'Female', 'Middle Aged', '*Antibodies, Monoclonal, Humanized/therapeutic use/administration & dosage/adverse effects', 'Aged', '*Sorafenib/therapeutic use/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Adult', 'Antineoplastic Agents, Immunological/therapeutic use/adverse effects/administration & dosage', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38319892/
455,Sorafenib,32532960,The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.,"['Tang W', 'Chen Z', 'Zhang W', 'Cheng Y', 'Zhang B', 'Wu F', 'Wang Q', 'Wang S', 'Rong D', 'Reiter FP', 'De Toni EN', 'Wang X']","['Apoptosis/drug effects', 'Carcinoma, Hepatocellular/*drug therapy/genetics/pathology', 'Cell Proliferation/drug effects', 'Drug Resistance, Neoplasm/drug effects/*genetics', 'Humans', 'Liver Neoplasms/*drug therapy/genetics/pathology', 'Sorafenib/adverse effects/*therapeutic use', 'Tumor Microenvironment/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32532960/
456,Sorafenib,30993651,Lenvatinib: A Review in Hepatocellular Carcinoma.,"['Al-Salama ZT', 'Syed YY', 'Scott LJ']","['Antineoplastic Agents/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Liver Neoplasms/*drug therapy', 'Phenylurea Compounds/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Protein Kinase Inhibitors/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Quinolines/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Sorafenib/pharmacology/therapeutic use', 'Treatment Outcome', 'Tyrosine/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/30993651/
457,Sorafenib,31918403,The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.,"['Xia S', 'Pan Y', 'Liang Y', 'Xu J', 'Cai X']","['Carcinoma, Hepatocellular/*drug therapy/*metabolism/pathology', '*Drug Resistance, Neoplasm/drug effects', 'Epigenesis, Genetic/drug effects', 'Humans', 'Liver Neoplasms/*drug therapy/*metabolism/pathology', 'Sorafenib/pharmacology/*therapeutic use', '*Tumor Microenvironment/drug effects/genetics']",https://pubmed.ncbi.nlm.nih.gov/31918403/
458,Sorafenib,29915898,Regorafenib: A Review in Hepatocellular Carcinoma.,"['Heo YA', 'Syed YY']","['Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Disease Progression', 'Disease-Free Survival', 'Drug Approval', 'Humans', 'Liver Neoplasms/*drug therapy', 'Phenylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Protein Kinase Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Sorafenib/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29915898/
459,Sorafenib,32699265,Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.,"['Li ZJ', 'Dai HQ', 'Huang XW', 'Feng J', 'Deng JH', 'Wang ZX', 'Yang XM', 'Liu YJ', 'Wu Y', 'Chen PH', 'Shi H', 'Wang JG', 'Zhou J', 'Lu GD']","['Animals', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/pharmacology', 'Artesunate/administration & dosage/*pharmacology', 'Carcinoma, Hepatocellular/*drug therapy/pathology', 'Cell Line, Tumor', 'Drug Synergism', 'Ferroptosis/drug effects', 'Humans', 'Lipid Peroxidation/drug effects', 'Liver Neoplasms/*drug therapy/pathology', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Oxidative Stress/drug effects', 'Sorafenib/administration & dosage/*pharmacology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/32699265/
460,Sorafenib,33859758,Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.,"['Kong FH', 'Ye QF', 'Miao XY', 'Liu X', 'Huang SQ', 'Xiong L', 'Wen Y', 'Zhang ZJ']","['Animals', 'Antineoplastic Agents/*pharmacology/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Drug Delivery Systems/methods', 'Humans', 'Liver Neoplasms/*drug therapy', 'Nanoparticles/*chemistry', 'Sorafenib/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33859758/
461,Sorafenib,30575484,Sorafenib for Advanced and Refractory Desmoid Tumors.,"['Gounder MM', 'Mahoney MR', 'Van Tine BA', 'Ravi V', 'Attia S', 'Deshpande HA', 'Gupta AA', 'Milhem MM', 'Conry RM', 'Movva S', 'Pishvaian MJ', 'Riedel RF', 'Sabagh T', 'Tap WD', 'Horvat N', 'Basch E', 'Schwartz LH', 'Maki RG', 'Agaram NP', 'Lefkowitz RA', 'Mazaheri Y', 'Yamashita R', 'Wright JJ', 'Dueck AC', 'Schwartz GK']","['Adolescent', 'Adult', 'Aged', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Desmoid Tumors/*drug therapy/mortality', 'Follow-Up Studies', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Sorafenib/adverse effects/*therapeutic use', 'Survival Rate', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30575484/
462,Sorafenib,32375062,Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.,"['Jian C', 'Fu J', 'Cheng X', 'Shen LJ', 'Ji YX', 'Wang X', 'Pan S', 'Tian H', 'Tian S', 'Liao R', 'Song K', 'Wang HP', 'Zhang X', 'Wang Y', 'Huang Z', 'She ZG', 'Zhang XJ', 'Zhu L', 'Li H']","['Animals', 'Antineoplastic Agents/*pharmacology', 'Carcinoma, Hepatocellular/*drug therapy/metabolism', 'Cell Line', 'Dose-Response Relationship, Drug', 'Humans', 'Liver Neoplasms/*drug therapy/metabolism', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Mitochondria/*drug effects/metabolism', 'Non-alcoholic Fatty Liver Disease/*drug therapy/metabolism', 'Sorafenib/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32375062/
463,Sorafenib,38458013,Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.,"['Dong R', 'Wang T', 'Dong W', 'Zhu H', 'Liu Q', 'Liang H', 'Chen X', 'Zhang B', 'Zhang X']","['Humans', 'Sorafenib/pharmacology/therapeutic use', '*Carcinoma, Hepatocellular/pathology', '*Antineoplastic Agents/pharmacology/therapeutic use', '*Liver Neoplasms/pathology', 'Cell Line, Tumor', 'Cell Proliferation', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/38458013/
464,Sorafenib,34185551,"Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.","['Qin S', 'Bi F', 'Gu S', 'Bai Y', 'Chen Z', 'Wang Z', 'Ying J', 'Lu Y', 'Meng Z', 'Pan H', 'Yang P', 'Zhang H', 'Chen X', 'Xu A', 'Cui C', 'Zhu B', 'Wu J', 'Xin X', 'Wang J', 'Shan J', 'Chen J', 'Zheng Z', 'Xu L', 'Wen X', 'You Z', 'Ren Z', 'Liu X', 'Qiu M', 'Wu L', 'Chen F']","['Antineoplastic Combined Chemotherapy Protocols/pharmacology/*therapeutic use', 'Carcinoma, Hepatocellular/*drug therapy', 'Female', 'Humans', 'Liver Neoplasms/*drug therapy', 'Male', 'Middle Aged', 'Neoplasm Metastasis', 'Pyridines/pharmacology/*therapeutic use', 'Sorafenib/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34185551/
465,Sorafenib,36202608,Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.,['Baste Rotllan N'],"['*Carcinoma', 'Humans', 'Immunocompromised Host', 'Sorafenib/adverse effects', '*Thyroid Neoplasms/drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/36202608/
466,Sorafenib,38151184,Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.,"['El-Khoueiry AB', 'Trojan J', 'Meyer T', 'Yau T', 'Melero I', 'Kudo M', 'Hsu C', 'Kim TY', 'Choo SP', 'Kang YK', 'Yeo W', 'Chopra A', 'Soleymani S', 'Yao J', 'Neely J', 'Tschaika M', 'Welling TH', 'Sangro B']","['Humans', 'Nivolumab/adverse effects', '*Carcinoma, Hepatocellular/drug therapy', 'Sorafenib/therapeutic use', 'B7-H1 Antigen/metabolism', 'Follow-Up Studies', '*Liver Neoplasms/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Ipilimumab/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38151184/
467,Sorafenib,36202606,Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.,['Herranz UA'],"['*Adenocarcinoma/drug therapy', '*Antineoplastic Agents/adverse effects', 'Humans', 'Iodine Radioisotopes/therapeutic use', 'Phenylurea Compounds/adverse effects', 'Protein Kinase Inhibitors/adverse effects', 'Quinolines', 'Sorafenib/therapeutic use', '*Thyroid Neoplasms/drug therapy/pathology/radiotherapy']",https://pubmed.ncbi.nlm.nih.gov/36202606/
468,Sorafenib,39002440,Research progress of sorafenib drug delivery system in the treatment of hepatocellular carcinoma: An update.,"['Fan QQ', 'Tian H', 'Cheng JX', 'Zou JB', 'Luan F', 'Qiao JX', 'Zhang D', 'Tian Y', 'Zhai BT', 'Guo DY']","['Humans', '*Carcinoma, Hepatocellular/drug therapy/pathology', '*Sorafenib/administration & dosage/therapeutic use', '*Liver Neoplasms/drug therapy/pathology', '*Antineoplastic Agents/administration & dosage/therapeutic use', '*Drug Delivery Systems/methods', 'Animals', 'Nanoparticles', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/39002440/
469,Sorafenib,30220234,Lenvatinib as a therapy for unresectable hepatocellular carcinoma.,"['Spallanzani A', 'Orsi G', 'Andrikou K', 'Gelsomino F', 'Rimini M', 'Riggi L', 'Cascinu S']","['Antineoplastic Agents/administration & dosage/adverse effects/pharmacology', 'Carcinoma, Hepatocellular/*drug therapy/pathology', 'Humans', 'Liver Neoplasms/*drug therapy/pathology', 'Phenylurea Compounds/*administration & dosage/adverse effects/pharmacology', 'Protein Kinase Inhibitors/administration & dosage/adverse effects/pharmacology', 'Quinolines/*administration & dosage/adverse effects/pharmacology', 'Sorafenib/administration & dosage', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/30220234/
470,Sorafenib,31801872,"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.","['Kudo M', 'Ueshima K', 'Ikeda M', 'Torimura T', 'Tanabe N', 'Aikata H', 'Izumi N', 'Yamasaki T', 'Nojiri S', 'Hino K', 'Tsumura H', 'Kuzuya T', 'Isoda N', 'Yasui K', 'Aino H', 'Ido A', 'Kawabe N', 'Nakao K', 'Wada Y', 'Yokosuka O', 'Yoshimura K', 'Okusaka T', 'Furuse J', 'Kokudo N', 'Okita K', 'Johnson PJ', 'Arai Y']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Carcinoma, Hepatocellular/*therapy', '*Chemoembolization, Therapeutic/adverse effects', 'Combined Modality Therapy', 'Disease Progression', 'Female', 'Humans', 'Liver Neoplasms/*therapy', 'Male', 'Middle Aged', 'Progression-Free Survival', 'Prospective Studies', 'Sorafenib/adverse effects/*therapeutic use', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/31801872/
471,Sorafenib,35395582,"Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.","['Brown ZJ', 'Gregory S', 'Hewitt DB', 'Iacono S', 'Choe J', 'Labiner HE', 'Pawlik TM']","['Antibodies, Monoclonal', '*Carcinoma, Hepatocellular/pathology', 'Humans', 'Immune Checkpoint Inhibitors/adverse effects', '*Liver Neoplasms/pathology', 'Sorafenib/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35395582/
472,Sorafenib,35349331,Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.,"['Pollard JA', 'Alonzo TA', 'Gerbing R', 'Brown P', 'Fox E', 'Choi J', 'Fisher B', 'Hirsch B', 'Kahwash S', 'Getz K', 'Levine J', 'Brodersen LE', 'Loken MR', 'Raimondi S', 'Tarlock K', 'Wood A', 'Sung L', 'Kolb EA', 'Gamis A', 'Meshinchi S', 'Aplenc R']","['Child', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Humans', '*Leukemia, Myeloid, Acute/drug therapy/genetics', 'Mutation', 'Phenylurea Compounds/adverse effects', 'Protein Kinase Inhibitors/adverse effects', 'Remission Induction', 'Sorafenib/therapeutic use', 'fms-Like Tyrosine Kinase 3/genetics']",https://pubmed.ncbi.nlm.nih.gov/35349331/
473,Tolcapone,33983835,Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.,"['Griffin JM', 'Rosenblum H', 'Maurer MS']","['Aging', 'Alkylating Agents/therapeutic use', 'Amyloid/chemistry/metabolism', 'Amyloid Neuropathies, Familial/diagnosis', 'Amyloidosis/diagnosis/*etiology/physiopathology/*therapy', 'Antibodies, Monoclonal/therapeutic use', 'Benzoates/therapeutic use', 'Benzoxazoles/therapeutic use', 'Bridged Bicyclo Compounds, Heterocyclic/therapeutic use', 'Cardiomyopathies/diagnosis/*etiology/physiopathology/*therapy', 'Catechol O-Methyltransferase Inhibitors/therapeutic use', 'Heart Transplantation', 'Humans', 'Immunomodulating Agents/therapeutic use', 'Oligonucleotides/therapeutic use', 'Proteasome Inhibitors/therapeutic use', 'Protein Folding', 'Pyrazoles/therapeutic use', 'RNA, Small Interfering/therapeutic use', 'Stem Cell Transplantation', 'Sulfonamides/therapeutic use', 'Tolcapone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33983835/
474,Tolcapone,28273839,Parkinson's Disease: From Pathogenesis to Pharmacogenomics.,['Cacabelos R'],"['Adult', 'Aged', 'Aged, 80 and over', 'Animals', 'Antiparkinson Agents/*pharmacology/*therapeutic use', 'Disease Susceptibility', 'Dopaminergic Neurons/drug effects/metabolism/pathology', 'Humans', 'Middle Aged', 'Oxidative Stress', 'Parkinson Disease/*drug therapy/*etiology/metabolism', '*Pharmacogenetics', '*Pharmacogenomic Variants', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/28273839/
475,Tolcapone,36964457,Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.,"['Regensburger M', 'Ip CW', 'Kohl Z', 'Schrader C', 'Urban PP', 'Kassubek J', 'Jost WH']","['Humans', '*Parkinson Disease/drug therapy', 'Antiparkinson Agents/pharmacology/therapeutic use', 'Monoamine Oxidase/metabolism', 'Catechol O-Methyltransferase/metabolism', 'Levodopa/therapeutic use', 'Catechol O-Methyltransferase Inhibitors/pharmacology/therapeutic use', 'Monoamine Oxidase Inhibitors/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36964457/
476,Tolcapone,38357896,Pharmacological management of gambling disorder: an update of the literature.,"['Mestre-Bach G', 'Potenza MN']","['Humans', '*Gambling/drug therapy', 'Naltrexone/therapeutic use', '*Behavior, Addictive/drug therapy/psychology', 'Narcotic Antagonists/therapeutic use', 'Selective Serotonin Reuptake Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/38357896/
477,Tolcapone,38710208,Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments.,"['Komatsu Y', 'Takehara M', 'Hart X', 'Takahashi Y', 'Hori S', 'Ueno F', 'Uchida H']","['Humans', '*Schizophrenia/drug therapy', '*Antipsychotic Agents/therapeutic use', 'Clinical Trials, Phase II as Topic']",https://pubmed.ncbi.nlm.nih.gov/38710208/
478,Tolcapone,35044481,[Relevance of COMT inhibitors in the treatment of motor fluctuations].,"['Jost WH', 'Buhmann C', 'Classen J', 'Eggert K', 'Kohl Z', 'Outeiro T', 'Tonges L', 'Woitalla D', 'Reichmann H']","['Antiparkinson Agents/adverse effects', 'Catechol O-Methyltransferase/therapeutic use', '*Catechol O-Methyltransferase Inhibitors/therapeutic use', 'Humans', 'Levodopa/adverse effects', '*Parkinson Disease/diagnosis/drug therapy', 'Tolcapone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35044481/
479,Tolcapone,27599671,Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.,"['Fabbri M', 'Rosa MM', 'Ferreira JJ']","['Antiparkinson Agents/*therapeutic use', 'Catechol O-Methyltransferase Inhibitors/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Levodopa/therapeutic use', 'Oxadiazoles/*therapeutic use', 'Parkinson Disease/*drug therapy', 'Pharmacology, Clinical']",https://pubmed.ncbi.nlm.nih.gov/27599671/
480,Tolcapone,37549460,Drug repurposing of dopaminergic drugs to inhibit ataxin-3 aggregation.,"['Figueiredo F', 'Sarkany Z', 'Silva A', 'Vilasboas-Campos D', 'Maciel P', 'Teixeira-Castro A', 'Martins PM', 'Macedo-Ribeiro S']","['Animals', 'Humans', 'Ataxin-3/genetics', '*Nuclear Proteins/metabolism', 'Repressor Proteins/metabolism', 'Dopamine', 'Drug Repositioning', 'Caenorhabditis elegans/metabolism', '*Machado-Joseph Disease/drug therapy/metabolism/pathology', 'Dopamine Agents']",https://pubmed.ncbi.nlm.nih.gov/37549460/
481,Tolcapone,10093587,Monoamine oxidase and catechol-O-methyltransferase inhibitors.,"['Siderowf A', 'Kurlan R']","['Benzophenones/pharmacology/therapeutic use', '*Catechol O-Methyltransferase Inhibitors', 'Catechols/pharmacology/therapeutic use', 'Dopamine/metabolism', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Humans', 'Monoamine Oxidase Inhibitors/*therapeutic use', 'Nitriles', 'Nitrophenols', 'Parkinson Disease/*drug therapy', 'Randomized Controlled Trials as Topic', 'Selegiline/pharmacology/therapeutic use', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/10093587/
482,Tolcapone,9591516,COMT inhibition: a new treatment strategy for Parkinson's disease.,"['Kurth MC', 'Adler CH']","['Antiparkinson Agents/pharmacokinetics/*pharmacology', 'Benzophenones/*pharmacology', '*Catechol O-Methyltransferase Inhibitors', 'Catechols/*pharmacology', 'Drug Therapy, Combination', 'Enzyme Inhibitors/*pharmacology', 'Half-Life', 'Humans', 'Levodopa/blood/*pharmacokinetics', 'Nitriles', 'Nitrophenols', 'Parkinson Disease/*drug therapy', 'Psychomotor Performance/drug effects', 'Randomized Controlled Trials as Topic', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/9591516/
483,Tolcapone,34784871,How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.,"['Agnieszka W', 'Pawel P', 'Malgorzata K']","['Antiparkinson Agents/therapeutic use', 'Dietary Supplements', 'Humans', '*Levodopa/therapeutic use', 'Monoamine Oxidase', 'Monoamine Oxidase Inhibitors/therapeutic use', '*Parkinson Disease/drug therapy', 'Selegiline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34784871/
484,Tolcapone,12083995,Entacapone in the management of Parkinson's disease.,"['Henchcliffe C', 'Waters C']","['Antiparkinson Agents/adverse effects/pharmacology/*therapeutic use', '*Catechol O-Methyltransferase Inhibitors', 'Catecholamines/blood', 'Catechols/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Drug Therapy, Combination', 'Enzyme Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Levodopa/pharmacokinetics/therapeutic use', 'Nitriles', 'Parkinson Disease/*drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12083995/
485,Tolcapone,9633684,Extending levodopa action: COMT inhibition.,"['Martinez-Martin P', ""O'Brien CF""]","['Antiparkinson Agents/*administration & dosage/adverse effects', 'Benzophenones/administration & dosage/adverse effects', 'Catechol O-Methyltransferase/physiology', '*Catechol O-Methyltransferase Inhibitors', 'Catechols/administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Drug Therapy, Combination', 'Enzyme Inhibitors/*administration & dosage/adverse effects', 'Humans', 'Levodopa/*administration & dosage/adverse effects/pharmacokinetics', 'Nitriles', 'Nitrophenols', 'Parkinson Disease/diagnosis/*drug therapy/enzymology', 'Pentanones/administration & dosage/adverse effects', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/9633684/
486,Tolcapone,38606899,Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder.,"['Kohne S', 'Hillemacher T', 'Glahn A', 'Bach P']","['Humans', '*Alcohol Deterrents/therapeutic use/pharmacology/administration & dosage', '*Drug Development', '*Alcoholism/drug therapy', '*Clinical Trials, Phase II as Topic', 'Animals', 'Clinical Trials, Phase III as Topic']",https://pubmed.ncbi.nlm.nih.gov/38606899/
487,Tolcapone,37902578,Dopamine Modulates Effective Connectivity in Frontal Cortex.,"['Vogelsang DA', 'Furman DJ', 'Nee DE', 'Pappas I', 'White RL 3rd', 'Kayser AS', ""D'Esposito M""]","['Humans', '*Dopamine', '*Catechol O-Methyltransferase', 'Frontal Lobe/physiology', 'Prefrontal Cortex/physiology', 'Dopamine Agonists/pharmacology', 'Magnetic Resonance Imaging']",https://pubmed.ncbi.nlm.nih.gov/37902578/
488,Tolcapone,36306808,"Development of a Highly Potent Transthyretin Amyloidogenesis Inhibitor: Design, Synthesis, and Evaluation.","['Pinheiro F', 'Pallares I', 'Peccati F', 'Sanchez-Morales A', 'Varejao N', 'Bezerra F', 'Ortega-Alarcon D', 'Gonzalez D', 'Osorio M', 'Navarro S', 'Velazquez-Campoy A', 'Almeida MR', 'Reverter D', 'Busque F', 'Alibes R', 'Sodupe M', 'Ventura S']","['Humans', '*Prealbumin/chemistry', 'Amyloid/metabolism', '*Amyloid Neuropathies, Familial/drug therapy/metabolism', 'Tolcapone/therapeutic use', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/36306808/
489,Tolcapone,17059382,Tolcapone in the management of Parkinson's disease.,"['Leegwater-Kim J', 'Waters C']","['Animals', 'Benzophenones/adverse effects/pharmacokinetics/*therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'Humans', 'Levodopa/therapeutic use', 'Nitrophenols/adverse effects/pharmacokinetics/*therapeutic use', 'Parkinson Disease/*drug therapy/*metabolism', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/17059382/
490,Tolcapone,33415500,Safety and efficacy of tolcapone in Parkinson's disease: systematic review.,"['Artusi CA', 'Sarro L', 'Imbalzano G', 'Fabbri M', 'Lopiano L']","['Antiparkinson Agents/adverse effects/*therapeutic use', 'Catechol O-Methyltransferase Inhibitors/adverse effects/*therapeutic use', 'Chemical and Drug Induced Liver Injury/epidemiology', 'Humans', 'Levodopa/administration & dosage', 'Liver Function Tests', 'Parkinson Disease/*drug therapy', 'Quality of Life', 'Randomized Controlled Trials as Topic', 'Severity of Illness Index', 'Tolcapone/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33415500/
491,Tolcapone,10855610,Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.,['Waters C'],"['Antiparkinson Agents/administration & dosage/*pharmacology', 'Benzophenones/administration & dosage/*pharmacology', '*Catechol O-Methyltransferase Inhibitors', 'Catechols/administration & dosage/*pharmacology', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Humans', 'Levodopa/administration & dosage/*pharmacology', 'Male', 'Middle Aged', 'Nitriles', 'Nitrophenols', 'Parkinson Disease/*enzymology', 'Patient Selection', 'Tolcapone']",https://pubmed.ncbi.nlm.nih.gov/10855610/
492,Tolcapone,32998442,Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.,"['Cotrina EY', 'Oliveira A', 'Leite JP', 'Llop J', 'Gales L', 'Quintana J', 'Cardoso I', 'Arsequell G']","['Amyloid/antagonists & inhibitors', 'Benzbromarone/*chemistry/metabolism', 'Benzoxazoles/chemistry/metabolism', 'Binding Sites', 'Binding, Competitive', 'Crystallography, X-Ray', 'Diflunisal/analogs & derivatives/chemistry/metabolism', '*Drug Repositioning', 'Gene Expression', 'Humans', 'Hydrogen Bonding', 'Kinetics', 'Molecular Docking Simulation', 'Neuroprotective Agents/*chemistry/metabolism', 'Prealbumin/agonists/*chemistry/genetics/metabolism', 'Protein Binding', 'Protein Conformation, alpha-Helical', 'Protein Conformation, beta-Strand', 'Protein Interaction Domains and Motifs', 'Protein Multimerization', 'Protein Stability', 'Recombinant Proteins/chemistry/genetics/metabolism', 'Thermodynamics', 'Thyroxine/*chemistry/metabolism', 'Tolcapone/chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/32998442/
493,Valdecoxib,15270001,[Etoricoxib (Arcoxia)].,"['Leclercq P', 'Malaise MG']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Gouty/*drug therapy', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2', 'Etoricoxib', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Osteoarthritis/*drug therapy', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Sulfones/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15270001/
494,Valdecoxib,18182814,Etoricoxib-induced erythema-multiforme-like eruption.,"['Thirion L', 'Nikkels AF', 'Pierard GE']","['Aged', 'Arthritis/drug therapy', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Erythema Multiforme/*chemically induced/pathology', 'Etoricoxib', 'Humans', 'Male', 'Pyridines/*adverse effects', 'Skin/pathology', 'Sulfones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18182814/
495,Valdecoxib,27697053,Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents.,"['Abdellatif KR', 'Abdelall EK', 'Bakr RB']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/chemistry/*therapeutic use', 'Humans', 'Inflammation/*drug therapy', 'Molecular Structure', 'Nitric Oxide/chemistry/*therapeutic use', 'Prodrugs/chemistry/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27697053/
496,Valdecoxib,27150366,Medicinal Chemistry Perspective of Fused Isoxazole Derivatives.,"['Barmade MA', 'Murumkar PR', 'Sharma MK', 'Yadav MR']","['Antineoplastic Agents/chemistry/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Central Nervous System Diseases/drug therapy', '*Chemistry, Pharmaceutical', 'Humans', 'Hypoglycemic Agents/chemistry/therapeutic use', 'Isoxazoles/*chemistry/pharmacology/therapeutic use', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/27150366/
497,Valdecoxib,12269850,Valdecoxib.,"['Ormrod D', 'Wellington K', 'Wagstaff AJ']","['Arthritis/drug therapy/metabolism', 'Clinical Trials as Topic/statistics & numerical data', 'Dysmenorrhea/drug therapy/metabolism', 'Female', 'Humans', 'Isoxazoles/chemistry/pharmacokinetics/*therapeutic use', 'Pain/*drug therapy/metabolism', 'Sulfonamides/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12269850/
498,Valdecoxib,19667717,COX-2 selective inhibitors and heart health.,"['Simon LS', 'White WB']","['Adult', 'Cardiovascular Diseases/*chemically induced', 'Celecoxib', 'Child', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Humans', 'Hypertension/chemically induced', 'Isoxazoles/adverse effects', 'Lactones/*adverse effects', 'Meta-Analysis as Topic', 'Prospective Studies', 'Pyrazoles/adverse effects', 'Randomized Controlled Trials as Topic', 'Sulfonamides/adverse effects', 'Sulfones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19667717/
499,Valdecoxib,12852704,Valdecoxib: a review.,"['Chavez ML', 'DeKorte CJ']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Clinical Trials as Topic', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Female', 'Humans', 'Isoxazoles/*pharmacology/*therapeutic use', 'Male', 'Osteoarthritis/drug therapy', 'Pain, Postoperative/drug therapy', 'Sulfonamides/*pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12852704/
500,Valdecoxib,12466002,Etoricoxib.,"['Cochrane DJ', 'Jarvis B', 'Keating GM']","['Administration, Oral', 'Arthritis/drug therapy', 'Back Pain/drug therapy', 'Clinical Trials as Topic', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Etoricoxib', 'Gout/drug therapy', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Oral Surgical Procedures/adverse effects', 'Pain, Postoperative/drug therapy/etiology', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/adverse effects/pharmacology/*therapeutic use', 'Sulfones/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12466002/
501,Valdecoxib,15182039,[Valdecoxib (Bextra)].,"['Scheen AJ', 'Malaise M']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Isoxazoles/administration & dosage/*therapeutic use', 'Osteoarthritis/drug therapy', 'Pain, Postoperative/drug therapy', 'Prodrugs', 'Sulfonamides/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15182039/
502,Valdecoxib,27710942,Crystal structure of rofecoxib bound to human cyclooxygenase-2.,"['Orlando BJ', 'Malkowski MG']","['Amino Acid Motifs', 'Binding Sites', 'Celecoxib/*chemistry', 'Crystallography, X-Ray', 'Cyclooxygenase 2/*chemistry/genetics/metabolism', 'Cyclooxygenase 2 Inhibitors/*chemistry', 'Gene Expression', 'Humans', 'Kinetics', 'Lactones/*chemistry', 'Models, Molecular', 'Protein Binding', 'Protein Conformation, alpha-Helical', 'Protein Conformation, beta-Strand', 'Protein Interaction Domains and Motifs', 'Recombinant Proteins/chemistry/genetics/metabolism', 'Safety-Based Drug Withdrawals', 'Substrate Specificity', 'Sulfones/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/27710942/
503,Valdecoxib,12198983,Selecting new drugs for pain control: evidence-based decisions or clinical impressions?,['Jeske AH'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use', 'Chronic Disease', 'Clinical Trials as Topic/standards', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use', 'Evidence-Based Medicine', 'Facial Pain/*drug therapy', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Lactones/administration & dosage/*therapeutic use', 'Membrane Proteins', 'Oral Surgical Procedures/adverse effects', 'Pain, Postoperative/*drug therapy/etiology', 'Prostaglandin-Endoperoxide Synthases', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/12198983/
504,Valdecoxib,23517091,Valdecoxib : the rise and fall of a COX-2 inhibitor.,"['Atukorala I', 'Hunter DJ']","['Animals', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2 Inhibitors/*administration & dosage/adverse effects', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects', 'Osteoarthritis/*drug therapy', 'Sulfonamides/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23517091/
505,Valdecoxib,15335413,Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.,"['Lazzaroni M', 'Bianchi Porro G']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/15335413/
506,Valdecoxib,12911075,Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.,"['Smith HS', 'Baird W']","['Analgesics, Non-Narcotic/pharmacology/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Cyclooxygenase Inhibitors/pharmacology/*therapeutic use', 'Diclofenac/analogs & derivatives', 'Dose-Response Relationship, Drug', 'Etoricoxib', 'Humans', 'Isoxazoles/therapeutic use', 'Meloxicam', 'Organic Chemicals/therapeutic use', 'Pain/*drug therapy/physiopathology', 'Palliative Care/*methods', 'Pyridines/therapeutic use', 'Sulfonamides/therapeutic use', 'Sulfones/therapeutic use', 'Thiazines/pharmacology/*therapeutic use', 'Thiazoles/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12911075/
507,Valdecoxib,16082427,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['*Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/16082427/
508,Valdecoxib,16202197,"Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.","['Klasser GD', 'Epstein J']","['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Celecoxib', 'Chronic Disease', 'Clinical Trials as Topic', 'Cyclooxygenase 2 Inhibitors/adverse effects', 'Humans', 'Isoxazoles/adverse effects', 'Lactones/adverse effects', 'Myocardial Infarction/*chemically induced', 'Peptic Ulcer/chemically induced', 'Pyrazoles/adverse effects', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects', 'Toothache/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16202197/
509,Valdecoxib,15279595,The second generation of COX-2 inhibitors: clinical pharmacological point of view.,['Stichtenoth DO'],"['Arthritis/chemically induced', 'Cardiovascular Diseases/chemically induced', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacokinetics/*pharmacology', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Isoenzymes/*antagonists & inhibitors/chemistry', 'Membrane Proteins', 'Prostaglandin-Endoperoxide Synthases/chemistry']",https://pubmed.ncbi.nlm.nih.gov/15279595/
510,Valdecoxib,20524091,Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?,['Elliott WJ'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology/therapeutic use', 'Blood Pressure/*drug effects', 'Celecoxib', 'Cyclooxygenase 2 Inhibitors/*adverse effects/pharmacology/therapeutic use', 'Diclofenac/adverse effects/analogs & derivatives', 'Etoricoxib', 'Humans', 'Hypertension/*chemically induced', 'Isoxazoles/adverse effects', 'Lactones/adverse effects', 'Pyrazoles/adverse effects', 'Pyridines/adverse effects/pharmacology/therapeutic use', 'Risk', 'Risk Factors', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20524091/
511,Valdecoxib,37254803,Pharmacological inhibition of TRPV2 attenuates phagocytosis and lipopolysaccharide-induced migration of primary macrophages.,"['Raudszus R', 'Paulig A', 'Urban N', 'Deckers A', 'Grassle S', 'Vanderheiden S', 'Jung N', 'Brase S', 'Schaefer M', 'Hill K']","['Humans', 'Rats', 'Animals', '*Lipopolysaccharides/pharmacology', 'HEK293 Cells', '*Macrophages', 'Phagocytosis', 'Gene Expression', 'TRPV Cation Channels/genetics']",https://pubmed.ncbi.nlm.nih.gov/37254803/
512,Visudyne,10755329,Verteporfin.,"['Scott LJ', 'Goa KL']","['Animals', 'Antineoplastic Agents/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', '*Photochemotherapy', 'Photosensitizing Agents/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Porphyrins/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Verteporfin']",https://pubmed.ncbi.nlm.nih.gov/10755329/
513,Visudyne,30444459,Photodynamic therapy of cancer with liposomal photosensitizers.,"['Duzgunes N', 'Piskorz J', 'Skupin-Mrugalska P', 'Goslinski T', 'Mielcarek J', 'Konopka K']","['Animals', 'Disease Models, Animal', 'Humans', 'Liposomes', 'Neoplasms/*drug therapy', 'Photochemotherapy/*methods/trends', 'Photosensitizing Agents/*administration & dosage', 'Treatment Outcome', 'Verteporfin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30444459/
514,Visudyne,32803351,Intractable Ocular Diseases and Treatment Progress.,"['Zhang X', 'Li S', 'Tang Y', 'Guo Y', 'Gao S']","['Adrenergic beta-Antagonists/administration & dosage/metabolism', 'Antihypertensive Agents/administration & dosage/metabolism', 'Cataract/diagnosis/drug therapy/metabolism', 'Diabetic Retinopathy/diagnosis/drug therapy/metabolism', 'Drug Delivery Systems/*methods', 'Dry Eye Syndromes/diagnosis/drug therapy/metabolism', 'Eye Diseases/diagnosis/*drug therapy/*metabolism', 'Glaucoma/diagnosis/drug therapy/metabolism', 'Humans', 'Latanoprost/administration & dosage/metabolism', 'Macular Degeneration/drug therapy/epidemiology/physiopathology', 'Photosensitizing Agents/administration & dosage/metabolism', 'Timolol/administration & dosage/metabolism', 'Treatment Outcome', 'Verteporfin/administration & dosage/metabolism']",https://pubmed.ncbi.nlm.nih.gov/32803351/
515,Visudyne,39970235,Inhibiting mechanotransduction prevents scarring and yields regeneration in a large animal model.,"['Mascharak S', 'Griffin M', 'Talbott HE', 'Guo JL', 'Parker J', 'Morgan AG', 'Valencia C', 'Kuhnert MM', 'Li DJ', 'Liang NE', 'Kratofil RM', 'Daccache JA', 'Sidhu I', 'Davitt MF', 'Guardino N', 'Lu JM', 'Abbas DB', 'Deleon NMD', 'Lavin CV', 'Adem S', 'Khan A', 'Chen K', 'Henn D', 'Spielman A', 'Cotterell A', 'Akras D', 'Downer M Jr', 'Tevlin R', 'Lorenz HP', 'Gurtner GC', 'Januszyk M', 'Naik S', 'Wan DC', 'Longaker MT']","['Animals', '*Mechanotransduction, Cellular/drug effects', '*Cicatrix/pathology/prevention & control/metabolism', 'Humans', '*Wound Healing/drug effects', '*Regeneration/drug effects', '*Fibroblasts/metabolism', '*Disease Models, Animal', 'Verteporfin/pharmacology', 'YAP-Signaling Proteins/metabolism', 'Interleukin-33/metabolism', 'Mice', 'Swine', 'Mice, Nude', 'Male']",https://pubmed.ncbi.nlm.nih.gov/39970235/
516,Visudyne,26980565,Non-Photoinduced Biological Properties of Verteporfin.,"['Gibault F', 'Corvaisier M', 'Bailly F', 'Huet G', 'Melnyk P', 'Cotelle P']","['Animals', 'Humans', 'Macular Degeneration/*drug therapy', 'Photosensitizing Agents/*therapeutic use', 'Porphyrins/*therapeutic use', 'Verteporfin']",https://pubmed.ncbi.nlm.nih.gov/26980565/
517,Visudyne,34657158,Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models.,"['Barrette AM', 'Ronk H', 'Joshi T', 'Mussa Z', 'Mehrotra M', 'Bouras A', 'Nudelman G', 'Jesu Raj JG', 'Bozec D', 'Lam W', 'Houldsworth J', 'Yong R', 'Zaslavsky E', 'Hadjipanayis CG', 'Birtwistle MR', 'Tsankova NM']","['Cell Line, Tumor', 'Cell Proliferation', '*Glioblastoma/drug therapy', '*Glioma', 'Humans', 'Transcription Factors/genetics', 'Verteporfin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34657158/
518,Visudyne,36736143,Deciphering the role of Hippo pathway in lung cancer.,"['Ghafouri-Fard S', 'Poornajaf Y', 'Hussen BM', 'Tavakkoli Avval S', 'Taheri M', 'Mokhtari M']","['Humans', 'Hippo Signaling Pathway', 'Signal Transduction', 'Protein Serine-Threonine Kinases/genetics', 'Verteporfin/pharmacology', '*Drosophila Proteins/genetics/metabolism/pharmacology', '*Lung Neoplasms/pathology']",https://pubmed.ncbi.nlm.nih.gov/36736143/
519,Visudyne,35793781,Photodynamic therapy in the treatment of circumscribed choroidal hemangioma: Current perspectives.,"['Kumar A', 'Shankar S', 'Singh A', 'Mishra S', 'Kumar P', 'Arora A']","['*Central Serous Chorioretinopathy/drug therapy', '*Choroid Neoplasms/drug therapy', 'Fluorescein Angiography', '*Hemangioma/drug therapy', 'Humans', '*Photochemotherapy/methods', 'Photosensitizing Agents/therapeutic use', '*Porphyrins/therapeutic use', 'Verteporfin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35793781/
520,Visudyne,37705491,Red Light-Triggered Anti-Angiogenic and Photodynamic Combination Therapy of Age-Related Macular Degeneration.,"['Xu S', 'Cui K', 'Long K', 'Li J', 'Fan N', 'Lam WC', 'Liang X', 'Wang W']","['Humans', 'Reactive Oxygen Species/therapeutic use', '*Porphyrins', '*Photochemotherapy', 'Verteporfin/therapeutic use', '*Macular Degeneration/drug therapy/pathology', '*Choroidal Neovascularization/drug therapy/metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/37705491/
521,Visudyne,30950971,PHOTODYNAMIC THERAPY FOR EXTRAFOVEOLAR CHOROIDAL OSTEOMA.,"['Mazloumi M', 'Dalvin LA', 'Ancona-Lezama D', 'Mashayekhi A', 'Shields CL']","['Adolescent', 'Adult', 'Choroid/*pathology', 'Choroid Neoplasms/diagnosis/*drug therapy', 'Female', 'Humans', 'Male', 'Osteoma/diagnosis/*drug therapy', 'Photochemotherapy/*methods', 'Photosensitizing Agents/therapeutic use', 'Retrospective Studies', 'Tomography, Optical Coherence/methods', 'Verteporfin/*therapeutic use', '*Visual Acuity', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30950971/
522,Visudyne,32112410,Paraptosis and Photodynamic Therapy: A Progress Report.,['Kessel D'],"['Apoptosis/*drug effects', 'Cell Line, Tumor', 'Dose-Response Relationship, Drug', 'Endoplasmic Reticulum/metabolism', 'Endoplasmic Reticulum Stress/drug effects', 'Humans', 'Mitogen-Activated Protein Kinases/metabolism', '*Photochemotherapy', 'Photosensitizing Agents/pharmacology', 'Verteporfin/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32112410/
523,Visudyne,25843911,Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives.,"['Kawczyk-Krupka A', 'Bugaj AM', 'Potempa M', 'Wasilewska K', 'Latos W', 'Sieron A']","['Adrenal Cortex Hormones/therapeutic use', 'Angiogenesis Inhibitors/therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Choroidal Neovascularization/*drug therapy', 'Clinical Trials as Topic', 'Drug Therapy, Combination', 'Humans', 'Macular Degeneration/*drug therapy', 'Photochemotherapy/*methods', 'Photosensitizing Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Porphyrins/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Vascular Endothelial Growth Factor A/antagonists & inhibitors', 'Verteporfin']",https://pubmed.ncbi.nlm.nih.gov/25843911/
524,Visudyne,14680447,Verteporfin ocular photodynamic therapy.,"['Bakri SJ', 'Kaiser PK']","['Choroidal Neovascularization/etiology/metabolism/*therapy', 'Humans', '*Photochemotherapy', 'Photosensitizing Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Porphyrins/adverse effects/pharmacokinetics/*therapeutic use', 'Product Surveillance, Postmarketing', 'Randomized Controlled Trials as Topic', 'Verteporfin']",https://pubmed.ncbi.nlm.nih.gov/14680447/
525,Visudyne,7992105,Photosensitizers in photodynamic therapy.,['Levy JG'],"['Antiviral Agents/therapeutic use', 'Arteriosclerosis/drug therapy', 'Autoimmune Diseases/drug therapy', 'Bone Marrow Purging', 'Hematoporphyrin Derivative/administration & dosage/therapeutic use', 'Humans', 'Macular Degeneration/drug therapy', 'Neoplasms/*drug therapy', '*Photochemotherapy', 'Photosensitizing Agents/administration & dosage/*therapeutic use', 'Porphyrins/administration & dosage/therapeutic use', 'Psoriasis/drug therapy', 'Radiation-Sensitizing Agents/administration & dosage/therapeutic use', 'Skin/drug effects/radiation effects', 'Time Factors', 'Verteporfin']",https://pubmed.ncbi.nlm.nih.gov/7992105/
526,Visudyne,38696259,Verteporfin inhibits TGF-beta signaling by disrupting the Smad2/3-Smad4 interaction.,"['Nong J', 'Shen S', 'Hong F', 'Xiao F', 'Meng L', 'Li P', 'Lei X', 'Chen YG']","['Humans', '*Cell Movement/drug effects', '*Epithelial-Mesenchymal Transition/drug effects', '*Signal Transduction/drug effects', '*Smad2 Protein/metabolism', '*Smad3 Protein/drug effects/metabolism', '*Smad4 Protein/drug effects/metabolism', '*Transforming Growth Factor beta/drug effects/metabolism', '*Verteporfin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38696259/
527,Visudyne,37828756,Verteporfin Suppresses YAP-Induced Glycolysis in Breast Cancer Cells.,"['Chen H', 'Zhang LF', 'Miao Y', 'Xi Y', 'Li X', 'Liu MF', 'Zhang M', 'Li B']","['Female', 'Humans', '*Breast Neoplasms/drug therapy/genetics', 'Fluorodeoxyglucose F18', 'Glycolysis/genetics', 'In Situ Hybridization, Fluorescence', '*Positron Emission Tomography Computed Tomography', '*Verteporfin/pharmacology/therapeutic use', 'YAP-Signaling Proteins/drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37828756/
528,Visudyne,34623712,Targeted inhibition of YAP/TAZ alters the biological behaviours of keloid fibroblasts.,"['Gao N', 'Lu L', 'Ma X', 'Liu Z', 'Yang S', 'Han G']","['Fibroblasts/metabolism', 'Humans', '*Keloid/metabolism', 'Transcription Factors/genetics', 'Transcriptional Coactivator with PDZ-Binding Motif Proteins', 'Verteporfin/metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34623712/
529,Visudyne,35932958,In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma.,"['Jeising S', 'Geerling G', 'Guthoff R', 'Hanggi D', 'Sabel M', 'Rapp M', 'Nickel AC']","['Humans', '*Photochemotherapy/methods', 'Verteporfin/pharmacology/therapeutic use', 'Protoporphyrins/metabolism', 'Aminolevulinic Acid/therapeutic use', '*Glioblastoma/drug therapy/metabolism', 'Photosensitizing Agents/pharmacology/therapeutic use', '*Glioma/drug therapy', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/35932958/
530,Visudyne,11672876,Photosensitizer delivery for photodynamic therapy of choroidal neovascularization.,"['Renno RZ', 'Miller JW']","['Choroidal Neovascularization/*drug therapy', 'Clinical Trials as Topic', 'Humans', 'Liposomes', 'Metalloporphyrins/administration & dosage', '*Photochemotherapy', 'Photolysis', 'Photosensitizing Agents/*administration & dosage/classification/pharmacokinetics', 'Porphyrins/administration & dosage', 'Verteporfin']",https://pubmed.ncbi.nlm.nih.gov/11672876/
531,Visudyne,16823995,Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.,"['Fenton C', 'Perry CM']","['Aging', 'Choroidal Neovascularization/*drug therapy', 'Clinical Trials as Topic', 'Databases, Bibliographic', 'Drug Utilization', 'Eye/drug effects', 'Fovea Centralis/pathology', 'Humans', 'Macular Degeneration/drug therapy', 'Myopia, Degenerative/drug therapy', 'Porphyrins/*therapeutic use', 'Treatment Outcome', 'Verteporfin']",https://pubmed.ncbi.nlm.nih.gov/16823995/
532,Voriconazole,26684607,"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.","['Maertens JA', 'Raad II', 'Marr KA', 'Patterson TF', 'Kontoyiannis DP', 'Cornely OA', 'Bow EJ', 'Rahav G', 'Neofytos D', 'Aoun M', 'Baddley JW', 'Giladi M', 'Heinz WJ', 'Herbrecht R', 'Hope W', 'Karthaus M', 'Lee DG', 'Lortholary O', 'Morrison VA', 'Oren I', 'Selleslag D', 'Shoham S', 'Thompson GR 3rd', 'Lee M', 'Maher RM', 'Schmitt-Hoffmann AH', 'Zeiher B', 'Ullmann AJ']","['Administration, Oral', 'Adult', 'Aged', 'Antifungal Agents/administration & dosage/adverse effects/*therapeutic use', 'Aspergillosis/drug therapy/mortality', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Injections, Intravenous', 'Male', 'Middle Aged', 'Mycoses/*drug therapy/mortality', 'Nitriles/administration & dosage/adverse effects/*therapeutic use', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects/*therapeutic use', 'Voriconazole/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26684607/
533,Voriconazole,35969068,New Perspectives on Antimicrobial Agents: Isavuconazole.,"['Lewis JS 2nd', 'Wiederhold NP', 'Hakki M', 'Thompson GR 3rd']","['Antifungal Agents/pharmacokinetics/therapeutic use', '*Candidiasis, Invasive/drug therapy', 'Caspofungin/therapeutic use', 'Fungi', 'Humans', '*Invasive Fungal Infections/drug therapy', 'Nitriles/pharmacokinetics/therapeutic use', 'Pyridines', 'Triazoles/pharmacokinetics/therapeutic use', 'Voriconazole/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35969068/
534,Voriconazole,16802848,Pharmacokinetic/pharmacodynamic profile of voriconazole.,"['Theuretzbacher U', 'Ihle F', 'Derendorf H']","['Animals', 'Antifungal Agents/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic use', 'Biotransformation', 'Drug Interactions', 'Fungi/drug effects', 'Half-Life', 'Humans', 'Mycoses/*drug therapy/microbiology', 'Protein Binding', 'Pyrimidines/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic use', 'Tissue Distribution', 'Triazoles/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/16802848/
535,Voriconazole,25599346,Combination antifungal therapy for invasive aspergillosis: a randomized trial.,"['Marr KA', 'Schlamm HT', 'Herbrecht R', 'Rottinghaus ST', 'Bow EJ', 'Cornely OA', 'Heinz WJ', 'Jagannatha S', 'Koh LP', 'Kontoyiannis DP', 'Lee DG', 'Nucci M', 'Pappas PG', 'Slavin MA', 'Queiroz-Telles F', 'Selleslag D', 'Walsh TJ', 'Wingard JR', 'Maertens JA']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anidulafungin', 'Antifungal Agents/adverse effects/*therapeutic use', 'Aspergillosis/complications/diagnosis/*drug therapy/mortality', 'Double-Blind Method', 'Drug Therapy, Combination', 'Echinocandins/adverse effects/*therapeutic use', 'Female', 'Galactose/analogs & derivatives', 'Hematologic Neoplasms/*complications/therapy', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Karnofsky Performance Status', 'Male', 'Mannans/blood', 'Middle Aged', 'Platelet Count', 'Treatment Outcome', 'Voriconazole/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25599346/
536,Voriconazole,33549194,"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.","['Maertens JA', 'Rahav G', 'Lee DG', 'Ponce-de-Leon A', 'Ramirez Sanchez IC', 'Klimko N', 'Sonet A', 'Haider S', 'Diego Velez J', 'Raad I', 'Koh LP', 'Karthaus M', 'Zhou J', 'Ben-Ami R', 'Motyl MR', 'Han S', 'Grandhi A', 'Waskin H']","['Administration, Intravenous', 'Administration, Oral', 'Adolescent', 'Adult', 'Antifungal Agents/*administration & dosage/adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Invasive Pulmonary Aspergillosis/*drug therapy/mortality', 'Male', 'Middle Aged', 'Prospective Studies', 'Triazoles/*administration & dosage/adverse effects', 'Voriconazole/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33549194/
537,Voriconazole,36622029,Optimization of Antimicrobial Stewardship Programs Using Therapeutic Drug Monitoring and Pharmacokinetics-Pharmacodynamics Protocols: A Cost-Benefit Review.,"['Telles JP', 'Morales R Jr', 'Yamada CH', 'Marins TA', ""D'Amaro Juodinis V"", 'Sztajnbok J', 'Silva M Jr', 'Bassetti BR', 'Albiero J', 'Tuon FF']","['Humans', 'Aminoglycosides', 'Anti-Bacterial Agents/therapeutic use', '*Antimicrobial Stewardship', 'Ceftazidime', 'Cost-Benefit Analysis', 'Drug Monitoring', '*Vancomycin/therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/36622029/
538,Voriconazole,33084474,Dementia-Like Symptoms Associated With Posaconazole.,"['Corallo CE', 'Ivulich SP', 'Kotecha DS', 'Morrissey O']","['*Antifungal Agents/adverse effects', '*Dementia/drug therapy', 'Humans', 'Triazoles/adverse effects', 'Voriconazole/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33084474/
539,Voriconazole,37300337,A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.,"['Kato H', 'Hagihara M', 'Asai N', 'Umemura T', 'Hirai J', 'Mori N', 'Yamagishi Y', 'Iwamoto T', 'Mikamo H']","['Humans', '*Antifungal Agents/adverse effects', '*Invasive Fungal Infections/drug therapy/prevention & control', 'Voriconazole/therapeutic use', 'Triazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37300337/
540,Voriconazole,21668526,Anidulafungin: when and how? The clinician's view.,"['George J', 'Reboli AC']","['Anidulafungin', 'Antifungal Agents/therapeutic use', 'Aspergillosis/drug therapy/microbiology', 'Aspergillus/drug effects/pathogenicity', 'Candida/*drug effects/pathogenicity', 'Candidiasis/*drug therapy/microbiology', 'Drug Resistance, Fungal', 'Drug Synergism', 'Drug-Related Side Effects and Adverse Reactions', 'Echinocandins/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Itraconazole/administration & dosage/pharmacology', 'Microbial Sensitivity Tests', 'Pyrimidines/administration & dosage/pharmacology', 'Triazoles/administration & dosage/pharmacology', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/21668526/
541,Voriconazole,36424314,Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.,"['Takesue Y', 'Hanai Y', 'Oda K', 'Hamada Y', 'Ueda T', 'Mayumi T', 'Matsumoto K', 'Fujii S', 'Takahashi Y', 'Miyazaki Y', 'Kimura T']","['Humans', 'Adult', 'Voriconazole/adverse effects', 'Drug Monitoring', 'Consensus', 'East Asian People', 'Antifungal Agents/therapeutic use', '*Drug-Related Side Effects and Adverse Reactions', '*Chemical and Drug Induced Liver Injury/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36424314/
542,Voriconazole,34494173,Broad-spectrum azoles and flucloxacillin: a dangerous match.,"['Vangheluwe T', 'Van Hoecke F', 'Dumoulin A', 'Vogelaers D']","['Aged', 'Anti-Bacterial Agents/*therapeutic use', 'Antifungal Agents/*therapeutic use', 'Aspergillosis/*drug therapy/microbiology', 'Aspergillus fumigatus/drug effects', 'Azoles', '*Drug Interactions', 'Drug Therapy, Combination/adverse effects', 'Female', 'Floxacillin/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Nitriles/*therapeutic use', 'Pyridines/*therapeutic use', 'Staphylococcal Infections/*drug therapy/microbiology', 'Staphylococcus aureus/drug effects', 'Triazoles/*therapeutic use', 'Voriconazole/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34494173/
543,Voriconazole,33030550,Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.,"['Wang J', 'Zhou M', 'Xu JY', 'Zhou RF', 'Chen B', 'Wan Y']","['Adult', 'Aged', 'Aged, 80 and over', 'Antifungal Agents/*administration & dosage', 'Female', 'Hematologic Diseases/*drug therapy', 'Hematopoietic Stem Cell Transplantation/*methods', 'Humans', 'Male', 'Middle Aged', 'Mycoses/*prevention & control', 'Pre-Exposure Prophylaxis/*methods', 'Triazoles/*administration & dosage', 'Voriconazole/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/33030550/
544,Voriconazole,38752732,Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.,"['Boutin CA', 'Durocher F', 'Beauchemin S', 'Ziegler D', 'Abou Chakra CN', 'Dufresne SF']","['Humans', '*Antifungal Agents/therapeutic use', '*Invasive Fungal Infections/prevention & control/drug therapy', '*Voriconazole/therapeutic use', '*Hematologic Diseases/complications', '*Triazoles/therapeutic use', 'Drug Resistance, Fungal', 'Aspergillus/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38752732/
545,Voriconazole,38161768,Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients.,"['Silva JT', 'Husain S', 'Aguado JM']","['Humans', 'Antifungal Agents/therapeutic use/pharmacology', '*Aspergillosis/drug therapy/chemically induced', 'Nitriles/therapeutic use/pharmacology', '*Organ Transplantation/adverse effects', 'Transplant Recipients', 'Voriconazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38161768/
546,Voriconazole,34637660,Fusarium Causing Recalcitrant Post-operative endophthalmitis-Report of a Case with Review of Literature.,"['Agarwal M', 'Shah S', 'Garg A', 'Gandhi A', 'Kumar B']","['Adult', 'Antifungal Agents/therapeutic use', '*Endophthalmitis/diagnosis/drug therapy', '*Eye Infections, Fungal/diagnosis/drug therapy', '*Fusarium', 'Humans', 'Male', 'Postoperative Complications/drug therapy', 'Vitrectomy/adverse effects', 'Voriconazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34637660/
547,Voriconazole,28835093,Voriconazole-refractory invasive aspergillosis.,"['Park SY', 'Yoon JA', 'Kim SH']","['Antifungal Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Aspergillus/*drug effects/pathogenicity', 'Biopsy', 'Coinfection', 'Cytochrome P-450 CYP2C19/genetics/metabolism', 'Diagnosis, Differential', 'Diagnostic Errors', 'Drug Monitoring', '*Drug Resistance, Fungal', 'Female', 'Humans', 'Immunocompromised Host', 'Invasive Pulmonary Aspergillosis/diagnosis/*drug therapy/immunology/microbiology', 'Male', 'Middle Aged', 'Pharmacogenetics', 'Pharmacogenomic Variants', 'Predictive Value of Tests', 'Tomography, X-Ray Computed', 'Voriconazole/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28835093/
548,Voriconazole,36642232,"Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.","['Veringa A', 'Bruggemann RJ', 'Span LFR', 'Biemond BJ', 'de Boer MGJ', 'van den Heuvel ER', 'Klein SK', 'Kraemer D', 'Minnema MC', 'Prakken NHJ', 'Rijnders BJA', 'Swen JJ', 'Verweij PE', 'Wondergem MJ', 'Ypma PF', 'Blijlevens N', 'Kosterink JGW', 'van der Werf TS', 'Alffenaar JC']","['Humans', 'Adolescent', 'Adult', 'Voriconazole/adverse effects', 'Prospective Studies', 'Antifungal Agents/adverse effects', 'Drug Monitoring', 'Retrospective Studies', '*Aspergillosis/drug therapy', '*Invasive Fungal Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36642232/
549,Voriconazole,29477782,[Not Available].,"['Simon L', 'Gastaud L', 'Martiano D', 'Bailleux C', 'Hasseine L', 'Gari-Toussaint M']","['Aged', 'Amphotericin B/therapeutic use', 'Anti-Bacterial Agents/administration & dosage', 'Antifungal Agents/therapeutic use', 'Endophthalmitis/diagnosis/*drug therapy/*microbiology', 'Eye/microbiology/pathology', 'Female', 'Fusarium/*isolation & purification', 'Humans', 'Hyphae/drug effects/isolation & purification', 'Immunocompromised Host', 'Leukemia, Myeloid, Acute/complications/*drug therapy/microbiology', 'Treatment Outcome', 'Triazoles/administration & dosage', 'Vitrectomy', 'Voriconazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29477782/
550,Voriconazole,36929539,Invasive aspergillosis in liver transplant recipients.,"['Melenotte C', 'Aimanianda V', 'Slavin M', 'Aguado JM', 'Armstrong-James D', 'Chen YC', 'Husain S', 'Van Delden C', 'Saliba F', 'Lefort A', 'Botterel F', 'Lortholary O']","['Humans', 'Antifungal Agents/therapeutic use', '*Liver Transplantation/adverse effects', '*Aspergillosis/drug therapy/epidemiology/diagnosis', 'Voriconazole/therapeutic use', 'Aspergillus', '*Invasive Fungal Infections/drug therapy/epidemiology/complications', 'Transplant Recipients']",https://pubmed.ncbi.nlm.nih.gov/36929539/
551,Voriconazole,27147607,Adrenal Insufficiency With Voriconazole and Inhaled/Intranasal Corticosteroids: Case Report and Systematic Review.,"['Duman AK', 'Fulco PP']","['Administration, Inhalation', 'Adrenal Cortex Hormones/administration & dosage/*adverse effects/blood', 'Adrenal Insufficiency/blood/*chemically induced/*diagnosis', 'Antifungal Agents/administration & dosage/*adverse effects/blood', 'Cushing Syndrome/blood/chemically induced/diagnosis', 'Cytochrome P-450 CYP3A Inhibitors/administration & dosage/adverse effects/blood', 'Drug Interactions/physiology', 'Female', 'Humans', 'Middle Aged', 'Voriconazole/administration & dosage/*adverse effects/blood']",https://pubmed.ncbi.nlm.nih.gov/27147607/
552,Ziprasidone,12973403,Antipsychotic medication and seizures: a review.,"['Hedges D', 'Jeppson K', 'Whitehead P']","['Antipsychotic Agents/*adverse effects/therapeutic use', 'Aripiprazole', 'Benzodiazepines', 'Clinical Trials as Topic', 'Clozapine/pharmacology/therapeutic use', 'Dibenzothiazepines/pharmacology/therapeutic use', 'Humans', 'Imidazoles/pharmacology/therapeutic use', 'Indoles/pharmacology/therapeutic use', 'Olanzapine', 'Piperazines/pharmacology/therapeutic use', 'Pirenzepine/*analogs & derivatives/pharmacology/therapeutic use', 'Quetiapine Fumarate', 'Quinolones/pharmacology/therapeutic use', 'Risperidone/pharmacology/therapeutic use', 'Seizures/*chemically induced', 'Thiazoles/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12973403/
553,Ziprasidone,16172203,Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.,"['Lieberman JA', 'Stroup TS', 'McEvoy JP', 'Swartz MS', 'Rosenheck RA', 'Perkins DO', 'Keefe RS', 'Davis SM', 'Davis CE', 'Lebowitz BD', 'Severe J', 'Hsiao JK']","['Adult', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Benzodiazepines/adverse effects/therapeutic use', 'Chronic Disease', 'Dibenzothiazepines/adverse effects/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Lipids/blood', 'Male', 'Olanzapine', 'Patient Compliance', 'Perphenazine/adverse effects/therapeutic use', 'Piperazines/adverse effects/therapeutic use', 'Proportional Hazards Models', 'Quetiapine Fumarate', 'Risperidone/adverse effects/therapeutic use', 'Schizophrenia/blood/*drug therapy', 'Thiazoles/adverse effects/therapeutic use', 'Treatment Outcome', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/16172203/
554,Ziprasidone,30346242,Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.,"['Girard TD', 'Exline MC', 'Carson SS', 'Hough CL', 'Rock P', 'Gong MN', 'Douglas IS', 'Malhotra A', 'Owens RL', 'Feinstein DJ', 'Khan B', 'Pisani MA', 'Hyzy RC', 'Schmidt GA', 'Schweickert WD', 'Hite RD', 'Bowton DL', 'Masica AL', 'Thompson JL', 'Chandrasekhar R', 'Pun BT', 'Strength C', 'Boehm LM', 'Jackson JC', 'Pandharipande PP', 'Brummel NE', 'Hughes CG', 'Patel MB', 'Stollings JL', 'Bernard GR', 'Dittus RS', 'Ely EW']","['Aged', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Critical Illness/mortality/*psychology/therapy', 'Delirium/*drug therapy', 'Dopamine Antagonists/*therapeutic use', 'Double-Blind Method', 'Female', 'Haloperidol/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Piperazines/administration & dosage/adverse effects/*therapeutic use', 'Respiratory Insufficiency/psychology', 'Shock/psychology', 'Thiazoles/administration & dosage/adverse effects/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/30346242/
555,Ziprasidone,33341539,Antipsychotics and hemodialysis: A systematic review.,"['Sutar R', 'Atlani MK', 'Chaudhary P']","['*Antipsychotic Agents/adverse effects', 'Benzodiazepines', 'Humans', 'Olanzapine', 'Renal Dialysis', 'Risperidone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33341539/
556,Ziprasidone,29915922,Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.,"['Mauri MC', 'Paletta S', 'Di Pace C', 'Reggiori A', 'Cirnigliaro G', 'Valli I', 'Altamura AC']","['Animals', 'Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Monitoring/*methods', 'Humans', 'Medication Adherence']",https://pubmed.ncbi.nlm.nih.gov/29915922/
557,Ziprasidone,27919473,Kounis syndrome and ziprasidone.,"['Hamera L', 'Khishfe BF']","['Acute Coronary Syndrome/*chemically induced/*immunology', 'Adult', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Bipolar Disorder/*drug therapy', 'Drug Hypersensitivity/*complications', 'Emergency Service, Hospital', 'Humans', 'Male', 'Piperazines/*adverse effects/therapeutic use', '*Suicidal Ideation', 'Syndrome', 'Thiazoles/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27919473/
558,Ziprasidone,29885904,"Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.","['Klein LR', 'Driver BE', 'Miner JR', 'Martel ML', 'Hessel M', 'Collins JD', 'Horton GB', 'Fagerstrom E', 'Satpathy R', 'Cole JB']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antipsychotic Agents/administration & dosage/*therapeutic use', 'Cohort Studies', 'Emergency Medical Services', 'Female', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Injections, Intramuscular', 'Male', 'Mental Status and Dementia Tests', 'Midazolam/administration & dosage/therapeutic use', 'Middle Aged', 'Olanzapine/administration & dosage/therapeutic use', 'Piperazines/administration & dosage/therapeutic use', 'Prospective Studies', 'Psychomotor Agitation/*drug therapy', 'Thiazoles/administration & dosage/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29885904/
559,Ziprasidone,31974576,"Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.","['Gomez-Revuelta M', 'Pelayo-Teran JM', 'Juncal-Ruiz M', 'Vazquez-Bourgon J', 'Suarez-Pinilla P', 'Romero-Jimenez R', 'Setien Suero E', 'Ayesa-Arriola R', 'Crespo-Facorro B']","['Adolescent', 'Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/*pharmacology', 'Aripiprazole/administration & dosage/adverse effects/*pharmacology', 'Female', 'Follow-Up Studies', 'Haloperidol/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Olanzapine/administration & dosage/adverse effects/*pharmacology', '*Outcome Assessment, Health Care', 'Piperazines/administration & dosage/adverse effects/*pharmacology', 'Psychotic Disorders/*drug therapy', 'Quetiapine Fumarate/administration & dosage/adverse effects/*pharmacology', 'Risperidone/administration & dosage/adverse effects/*pharmacology', 'Schizophrenia/*drug therapy', 'Thiazoles/administration & dosage/adverse effects/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31974576/
560,Ziprasidone,23859663,Atypical antipsychotics in the treatment of delirium.,"['Wang HR', 'Woo YS', 'Bahk WM']","['Amisulpride', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Benzodiazepines/therapeutic use', 'Delirium/*drug therapy', 'Dibenzothiazepines/therapeutic use', 'Humans', 'Olanzapine', 'Piperazines/therapeutic use', 'Quetiapine Fumarate', 'Randomized Controlled Trials as Topic', 'Risperidone/therapeutic use', 'Sulpiride/analogs & derivatives/therapeutic use', 'Thiazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23859663/
561,Ziprasidone,38701817,"Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial.","['Mart MF', 'Boehm LM', 'Kiehl AL', 'Gong MN', 'Malhotra A', 'Owens RL', 'Khan BA', 'Pisani MA', 'Schmidt GA', 'Hite RD', 'Exline MC', 'Carson SS', 'Hough CL', 'Rock P', 'Douglas IS', 'Feinstein DJ', 'Hyzy RC', 'Schweickert WD', 'Bowton DL', 'Masica A', 'Orun OM', 'Raman R', 'Pun BT', 'Strength C', 'Rolfsen ML', 'Pandharipande PP', 'Brummel NE', 'Hughes CG', 'Patel MB', 'Stollings JL', 'Ely EW', 'Jackson JC', 'Girard TD']","['Humans', '*Antipsychotic Agents/therapeutic use/adverse effects', '*Delirium/drug therapy', 'Male', '*Critical Illness/psychology/therapy', 'Female', 'Middle Aged', 'Double-Blind Method', 'Aged', '*Quality of Life', 'Haloperidol/therapeutic use', 'Treatment Outcome', 'Piperazines/therapeutic use/adverse effects', 'Adult', 'Thiazoles/therapeutic use/adverse effects/administration & dosage', 'Follow-Up Studies', 'Intensive Care Units']",https://pubmed.ncbi.nlm.nih.gov/38701817/
562,Ziprasidone,26033792,Rational Use of Second-Generation Antipsychotics for the Treatment of ICU Delirium.,"['Mo Y', 'Yam FK']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Cytochrome P-450 Enzyme System/genetics', 'Delirium/diagnosis/*drug therapy', 'Humans', '*Intensive Care Units', 'Synaptic Transmission/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26033792/
563,Ziprasidone,15468580,[Psychotropics and weight gain].,"['Sahli Ch', 'Bryois Ch']","['Adolescent', 'Adult', 'Amisulpride', 'Antidepressive Agents/administration & dosage/adverse effects', 'Antimanic Agents/administration & dosage/adverse effects', 'Antipsychotic Agents/administration & dosage/adverse effects', 'Aripiprazole', 'Benzodiazepines/administration & dosage/adverse effects', 'Body Mass Index', 'Child', 'Clozapine/administration & dosage/adverse effects', 'Dibenzothiazepines/administration & dosage/adverse effects', 'Double-Blind Method', 'Female', 'Fructose/administration & dosage/adverse effects/*analogs & derivatives', 'Haloperidol/administration & dosage/adverse effects', 'Humans', 'Imidazoles/administration & dosage/adverse effects', 'Indoles/administration & dosage/adverse effects', 'Male', 'Obesity/*chemically induced', 'Olanzapine', 'Piperazines/administration & dosage/adverse effects', 'Placebos', 'Psychotropic Drugs/administration & dosage/*adverse effects', 'Quetiapine Fumarate', 'Quinolones/administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic', 'Risperidone/administration & dosage/adverse effects', 'Socioeconomic Factors', 'Sulpiride/administration & dosage/adverse effects/*analogs & derivatives', 'Thiazoles/administration & dosage/adverse effects', 'Time Factors', 'Topiramate', 'Valproic Acid/administration & dosage/adverse effects', '*Weight Gain']",https://pubmed.ncbi.nlm.nih.gov/15468580/
564,Ziprasidone,10340682,Receptor pharmacology of neuroleptics: relation to clinical effects.,['Richelson E'],"['Adrenergic alpha-Antagonists/pharmacology', 'Animals', 'Antipsychotic Agents/*pharmacology/therapeutic use', 'Dopamine Antagonists/pharmacology', 'Drug Interactions', 'Humans', 'Muscarinic Antagonists/pharmacology', 'Receptors, Dopamine/drug effects', 'Receptors, Muscarinic/drug effects', 'Receptors, Neurotransmitter/*drug effects', 'Receptors, Serotonin/drug effects', 'Serotonin Antagonists/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10340682/
565,Ziprasidone,33763203,Case Report: Ziprasidone induced neuroleptic malignant syndrome.,"['Sedhai YR', 'Atreya A', 'Phuyal P', 'Basnyat S', 'Pokhrel S']","['*Antipsychotic Agents/adverse effects', 'Humans', '*Neuroleptic Malignant Syndrome/etiology', 'Piperazines/adverse effects', 'Thiazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33763203/
566,Ziprasidone,16487905,A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania.,"['Jones RM', 'Thompson C', 'Bitter I']","['Antipsychotic Agents/*adverse effects/therapeutic use', 'Benzodiazepines/adverse effects', 'Bipolar Disorder/*drug therapy', 'Clozapine/adverse effects', 'Dibenzothiazepines/adverse effects', 'Humans', 'Olanzapine', 'Piperazines/adverse effects', 'Quetiapine Fumarate', 'Risperidone/adverse effects', 'Thiazoles/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16487905/
567,Ziprasidone,15517848,Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders.,"['Gupta S', 'Masand P']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Aripiprazole', 'Basal Ganglia Diseases/chemically induced', 'Bipolar Disorder/*drug therapy', 'Body Weight/drug effects', 'Cognition/drug effects', 'Dyskinesia, Drug-Induced/etiology', 'Electrocardiography/drug effects', 'Humans', 'Lipoproteins/drug effects', 'Piperazines/adverse effects/pharmacokinetics/*therapeutic use', 'Quinolones/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15517848/
568,Ziprasidone,19164500,Ziprasidone-induced spontaneous orgasm.,"['Boora K', 'Chiappone K', 'Dubovsky S', 'Xu J']","['Antipsychotic Agents/adverse effects/therapeutic use', 'Bipolar Disorder/*drug therapy', 'Female', 'Humans', 'Middle Aged', '*Orgasm', 'Piperazines/*adverse effects/therapeutic use', 'Sexual Dysfunctions, Psychological/*chemically induced', 'Thiazoles/*adverse effects/therapeutic use', 'Torticollis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19164500/
569,Ziprasidone,15222776,Dose response and atypical antipsychotics in schizophrenia.,"['Kinon BJ', 'Ahl J', 'Stauffer VL', 'Hill AL', 'Buckley PF']","['Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Humans', 'Schizophrenia/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15222776/
570,Ziprasidone,25351397,[Sparse evidence of antipsychotic drugs for the treatment of delirium].,"['Andersen CU', 'Hoimark L', 'Dabrowski K', 'Hansen KB', 'Saedder E']","['Amisulpride', 'Antipsychotic Agents/*therapeutic use', 'Benzodiazepines/therapeutic use', 'Delirium/*drug therapy', 'Evidence-Based Medicine', 'Humans', 'Olanzapine', 'Piperazines/therapeutic use', 'Quetiapine Fumarate/therapeutic use', 'Risperidone/therapeutic use', 'Sulpiride/analogs & derivatives/therapeutic use', 'Thiazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25351397/
571,Ziprasidone,21448108,Antipsychotic treatment--side-effect and/or metabolic syndrome.,"['Dadic-Hero E', 'Ruzic K', 'Grahovac T', 'Palijan TZ', 'Petranovic D', 'Sepic-Grahovac D']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Benzodiazepines/*adverse effects/*therapeutic use', 'Combined Modality Therapy', 'Drug Substitution/psychology', 'Female', 'Humans', 'Metabolic Syndrome/*chemically induced/*diagnosis/psychology', 'Olanzapine', 'Piperazines/adverse effects/therapeutic use', 'Psychotherapy', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Social Adjustment', 'Thiazoles/adverse effects/therapeutic use', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21448108/
572,acarbose,32457534,International consensus on the diagnosis and management of dumping syndrome.,"['Scarpellini E', 'Arts J', 'Karamanolis G', 'Laurenius A', 'Siquini W', 'Suzuki H', 'Ukleja A', 'Van Beek A', 'Vanuytsel T', 'Bor S', 'Ceppa E', 'Di Lorenzo C', 'Emous M', 'Hammer H', 'Hellstrom P', 'Laville M', 'Lundell L', 'Masclee A', 'Ritz P', 'Tack J']","['Acarbose/therapeutic use', 'Bariatric Surgery/adverse effects', 'Blood Glucose/analysis', '*Consensus', 'Diet Therapy', 'Dumping Syndrome/*diagnosis/physiopathology/*therapy', 'Esophagus/surgery', 'Evidence-Based Medicine', 'Gastrectomy/adverse effects', 'Gastric Emptying', 'Gastrointestinal Hormones/metabolism', 'Humans', 'Meals', 'Postoperative Complications', 'Practice Guidelines as Topic', 'Quality of Life', 'Stomach/pathology/surgery', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/32457534/
573,acarbose,30469486,Calorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism.,"['Shintani H', 'Shintani T', 'Ashida H', 'Sato M']","['Acarbose/*pharmacology', 'Aging/*drug effects', 'Animals', 'Blood Glucose/*metabolism', 'Caloric Restriction', 'Chitosan/*pharmacology', 'Deoxyglucose/pharmacology', 'Glucosamine/pharmacology', 'Glycolysis/*drug effects', 'Hexoses/*pharmacology', 'Humans', 'Longevity/*drug effects', 'Sodium-Glucose Transporter 2 Inhibitors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30469486/
574,acarbose,37818579,An Updated Overview of Synthetic alpha-glucosidase Inhibitors: Chemistry and Bioactivities.,"['Cai YS', 'Xie HX', 'Zhang JH', 'Li Y', 'Zhang J', 'Wang KM', 'Jiang CS']","['Humans', 'Glycoside Hydrolase Inhibitors/pharmacology', '*Diabetes Mellitus, Type 2/drug therapy', 'Hypoglycemic Agents/pharmacology/therapeutic use', 'Acarbose', '*Hyperglycemia/drug therapy', 'alpha-Glucosidases']",https://pubmed.ncbi.nlm.nih.gov/37818579/
575,acarbose,36748934,Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder.,"['Carpentieri GB', 'Goncalves SEAB', 'Mourad WM', 'Pinto LGC', 'Zanella MT']","['Humans', '*Gastric Bypass/adverse effects', '*Hypoglycemia/drug therapy/etiology/diagnosis', '*Bariatric Surgery/adverse effects', 'Glucagon', 'Acarbose/therapeutic use', '*Obesity, Morbid/surgery', 'Blood Glucose']",https://pubmed.ncbi.nlm.nih.gov/36748934/
576,acarbose,31456442,Clinical and genetic predictors of diabetes drug's response.,"['Fodor A', 'Cozma A', 'Suharoschi R', 'Sitar-Taut A', 'Roman G']","['Acarbose/pharmacokinetics/therapeutic use', 'Diabetes Mellitus, Type 2/*drug therapy/*genetics/metabolism', 'Humans', 'Hypoglycemic Agents/pharmacokinetics/*therapeutic use', 'Metformin/pharmacokinetics/therapeutic use', 'Precision Medicine', 'Predictive Value of Tests', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/31456442/
577,acarbose,24320031,Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome.,"['Gouni-Berthold I', 'Berthold HK']","['Acarbose/therapeutic use', 'Cardiovascular Diseases/complications/*drug therapy', 'Drug Combinations', 'Dyslipidemias/complications/*drug therapy', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypoglycemic Agents/*therapeutic use', 'Hypolipidemic Agents/*therapeutic use', 'Incretins/therapeutic use', 'Insulin/therapeutic use', 'Metabolic Syndrome/complications/*drug therapy', 'Metformin/therapeutic use', '*Risk Reduction Behavior', 'Thiazolidinediones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24320031/
578,acarbose,19275550,"Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.","['Yamagishi S', 'Matsui T', 'Ueda S', 'Fukami K', 'Okuda S']","['Acarbose/pharmacology/*therapeutic use', 'Animals', 'Cardiovascular Diseases/etiology/*prevention & control', 'Diabetes Complications/prevention & control', 'Enzyme Inhibitors/pharmacology/*therapeutic use', 'Glycoside Hydrolase Inhibitors', 'Humans', 'Hyperglycemia/drug therapy', 'Insulin Resistance', 'Metabolic Syndrome/drug therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/19275550/
579,acarbose,24864650,Alpha glucosidase inhibitors.,['Kalra S'],"['Acarbose/administration & dosage', 'Diabetes Mellitus/drug therapy', 'Drug Therapy, Combination', '*Glycoside Hydrolase Inhibitors', 'Humans', 'Hyperglycemia/prevention & control', 'Hypoglycemic Agents/administration & dosage/*therapeutic use', 'Metformin/administration & dosage', 'Prediabetic State/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24864650/
580,acarbose,22321466,Management of overt hepatic encephalopathy.,"['Khungar V', 'Poordad F']","['Acarbose/therapeutic use', 'Ammonia/metabolism', 'Disease Management', 'Gastrointestinal Agents/therapeutic use', 'Hepatic Encephalopathy/*diagnosis/metabolism/*therapy', 'Humans', 'Lactulose/therapeutic use', 'Randomized Controlled Trials as Topic', 'Rifamycins/therapeutic use', 'Rifaximin']",https://pubmed.ncbi.nlm.nih.gov/22321466/
581,acarbose,20621253,Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.,"['Saha SA', 'Tuttle KR']","['Acarbose/therapeutic use', 'Biguanides/therapeutic use', 'Cardiovascular Diseases/complications/etiology/*prevention & control', 'Combined Modality Therapy', 'Contraindications', 'Diabetes Mellitus/*drug therapy', 'Diabetic Nephropathies/complications/*prevention & control', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin/therapeutic use', 'Sulfonylurea Compounds/adverse effects/therapeutic use', 'Thiazolidinediones/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20621253/
582,acarbose,11743518,Acarbose treatment of postprandial hypoglycemia in children after Nissen fundoplication.,"['Ng DD', 'Ferry RJ Jr', 'Kelly A', 'Weinzimer SA', 'Stanley CA', 'Katz LE']","['Acarbose/*therapeutic use', 'Child, Preschool', 'Female', 'Fundoplication/*adverse effects', 'Gastroesophageal Reflux/*surgery', 'Humans', 'Hypoglycemia/*drug therapy/*etiology', 'Hypoglycemic Agents/*therapeutic use', 'Infant', 'Male', 'Postprandial Period/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/11743518/
583,acarbose,28978421,Dietary Carbohydrates Impair Healthspan and Promote Mortality.,"['Ravichandran M', 'Grandl G', 'Ristow M']","['Acarbose/metabolism', 'Animals', 'Diet, Carbohydrate Loading/*adverse effects', 'Diet, Ketogenic', 'Dietary Carbohydrates/*adverse effects/metabolism', 'Dietary Fats/metabolism', 'Energy Intake', 'Glucose/metabolism', 'Glycolysis', 'Humans', '*Longevity', 'Prospective Studies', 'Sodium-Glucose Transporter 2/metabolism']",https://pubmed.ncbi.nlm.nih.gov/28978421/
584,acarbose,11469270,"Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.",['Marcus AO'],"['Acarbose/therapeutic use', 'Cardiovascular Diseases/epidemiology/mortality/prevention & control', 'Chromans/therapeutic use', 'Diabetes Mellitus, Type 2/*drug therapy', 'Diabetic Angiopathies/epidemiology/mortality/prevention & control', 'Humans', 'Hyperlipidemias/*drug therapy', 'Hypertension/*drug therapy', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin/therapeutic use', 'Metformin/therapeutic use', 'Safety', 'Sulfonylurea Compounds/therapeutic use', 'Syndrome', 'Thiazoles/therapeutic use', '*Thiazolidinediones', 'Troglitazone']",https://pubmed.ncbi.nlm.nih.gov/11469270/
585,acarbose,25620403,Using oral agents to manage gestational diabetes: what have we learned?,"['Buschur E', 'Brown F', 'Wyckoff J']","['Acarbose/administration & dosage', 'Administration, Oral', 'Birth Weight', 'Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/*administration & dosage', 'Humans', 'Hypoglycemic Agents/*administration & dosage', 'Infant, Newborn', 'Metformin/*administration & dosage', 'Practice Guidelines as Topic', 'Pregnancy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25620403/
586,acarbose,33754231,Development of anti-acanthamoebic approaches.,"['Mungroo MR', 'Tong T', 'Khan NA', 'Anuar TS', 'Maciver SK', 'Siddiqui R']","['Acanthamoeba Keratitis/*drug therapy/*parasitology', 'Acanthamoeba castellanii/*drug effects', 'Acarbose/pharmacology', 'Antiprotozoal Agents/*pharmacology', 'Carbamates/pharmacology', 'Cell Line', 'Contact Lens Solutions/pharmacology', 'Contact Lenses/adverse effects/*parasitology', 'HaCaT Cells', 'Humans', 'Indenes/pharmacology', 'Inositol/pharmacology', 'Nanoparticles', 'Piperidines/pharmacology', 'Sulfonylurea Compounds/pharmacology', 'Triazines/pharmacology', 'Vildagliptin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33754231/
587,acarbose,21251886,Oral hypoglycaemic agents during pregnancy: The evidence for effectiveness and safety.,"['Nicholson W', 'Baptiste-Roberts K']","['Acarbose/administration & dosage/*therapeutic use', 'Administration, Oral', 'Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/administration & dosage/*therapeutic use', 'Humans', 'Hypoglycemic Agents/administration & dosage/*therapeutic use', 'Infant, Newborn', 'Insulin/administration & dosage/therapeutic use', 'Metformin/administration & dosage/*therapeutic use', 'Pregnancy', 'Pregnancy Outcome', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21251886/
588,acarbose,14530603,Acarbose and idiopathic reactive hypoglycemia.,['Peter S'],"['Acarbose/*therapeutic use', 'Adult', 'Female', 'Glucose Tolerance Test', 'Humans', 'Hypoglycemia/diagnosis/*drug therapy', 'Hypoglycemic Agents/*therapeutic use', 'Male', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/14530603/
589,acarbose,10523467,The use of insulin secretagogues in the treatment of type 2 diabetes.,"['Luna B', 'Hughes AT', 'Feinglos MN']","['Acarbose/therapeutic use', 'Carbamates/therapeutic use', 'Chromans/therapeutic use', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Therapy, Combination', 'Glucagon/therapeutic use', 'Glucagon-Like Peptide 1', 'Humans', 'Hypoglycemic Agents/adverse effects/pharmacology/*therapeutic use', 'Metformin/therapeutic use', 'Peptide Fragments/therapeutic use', 'Piperidines/therapeutic use', 'Protein Precursors/therapeutic use', 'Risk Factors', 'Sulfonylurea Compounds/adverse effects/pharmacology/*therapeutic use', 'Thiazoles/therapeutic use', '*Thiazolidinediones', 'Troglitazone']",https://pubmed.ncbi.nlm.nih.gov/10523467/
590,acarbose,27194587,An in vivo invertebrate evaluation system for identifying substances that suppress sucrose-induced postprandial hyperglycemia.,"['Matsumoto Y', 'Ishii M', 'Sekimizu K']","['Acarbose/administration & dosage/pharmacology', 'Animals', 'Bombyx/*metabolism/microbiology', 'Dietary Sucrose/*adverse effects', 'Disease Models, Animal', 'Glucose/metabolism', 'Glycoside Hydrolase Inhibitors/*administration & dosage/pharmacology', 'Hemolymph/metabolism/microbiology', 'Humans', 'Hyperglycemia/*chemically induced/*drug therapy', 'Inositol/administration & dosage/analogs & derivatives/pharmacology', 'Lactobacillales/classification/drug effects/isolation & purification', 'Phylogeny', 'Postprandial Period']",https://pubmed.ncbi.nlm.nih.gov/27194587/
591,acarbose,11072952,Acarbose and lymphocytic colitis.,"['Piche T', 'Raimondi V', 'Schneider S', 'Hebuterne X', 'Rampal P']","['Acarbose/*adverse effects', 'Colitis/*chemically induced/pathology', 'Colon/chemistry/pathology', 'HLA-DR Antigens/analysis', 'Humans', 'Hypoglycemic Agents/*adverse effects', 'Immunohistochemistry', 'Lymphocytes/*drug effects/pathology', 'Male', 'Middle Aged', 'Receptors, Interleukin-2/analysis']",https://pubmed.ncbi.nlm.nih.gov/11072952/
592,amantadine,34678171,Amantadine in the treatment of Parkinson's disease and other movement disorders.,"['Rascol O', 'Fabbri M', 'Poewe W']","['Amantadine/pharmacology/therapeutic use', 'Antiparkinson Agents/adverse effects', '*Dyskinesia, Drug-Induced/drug therapy', 'Humans', 'Levodopa/adverse effects', '*Parkinson Disease/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34678171/
593,amantadine,37419676,Amantadine toxicity causing visual hallucinations.,"['Barbara JM', 'Pace A']","['Female', 'Humans', '*Antiparkinson Agents/adverse effects', 'Levodopa/therapeutic use', 'Amantadine/adverse effects', 'Hallucinations/chemically induced/drug therapy', '*Multiple Sclerosis/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37419676/
594,amantadine,33242419,"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.","['Nourbakhsh B', 'Revirajan N', 'Morris B', 'Cordano C', 'Creasman J', 'Manguinao M', 'Krysko K', 'Rutatangwa A', 'Auvray C', 'Aljarallah S', 'Jin C', 'Mowry E', 'McCulloch C', 'Waubant E']","['Adult', 'Amantadine/administration & dosage/adverse effects/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', '*Drug-Related Side Effects and Adverse Reactions', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Modafinil/administration & dosage/adverse effects/*pharmacology', 'Multiple Sclerosis/*complications', '*Outcome Assessment, Health Care', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33242419/
595,amantadine,4568331,Augmenting the action of levodopa.,"['Rao SK', 'Vakil SD', 'Calne DB', 'Hilson A']","['Amantadine/therapeutic use', 'Antacids/therapeutic use', 'Apomorphine/adverse effects', 'Carboxy-Lyases/antagonists & inhibitors', 'Catechol O-Methyltransferase Inhibitors', 'Dihydroxyphenylalanine/administration & dosage/adverse effects/*therapeutic use', 'Dopamine beta-Hydroxylase/antagonists & inhibitors', 'Drug Synergism', 'Humans', 'Methyldopa/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Parasympatholytics/therapeutic use', 'Parkinson Disease/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/4568331/
596,amantadine,770132,Treatment of parkinsonism.,['Selby G'],"['Amantadine/adverse effects/therapeutic use', 'Aromatic Amino Acid Decarboxylase Inhibitors', 'Drug Therapy, Combination', 'Humans', 'Levodopa/therapeutic use', 'Parasympatholytics/therapeutic use', 'Parkinson Disease/diagnosis/*drug therapy/etiology/metabolism/pathology/surgery']",https://pubmed.ncbi.nlm.nih.gov/770132/
597,amantadine,36100228,Pharmacologic Therapies to Promote Recovery of Consciousness.,"['Barra ME', 'Edlow BL', 'Brophy GM']","['Adult', 'Amantadine/therapeutic use', '*Consciousness', '*Consciousness Disorders/drug therapy', 'Humans', 'Recovery of Function']",https://pubmed.ncbi.nlm.nih.gov/36100228/
598,amantadine,22375973,Placebo-controlled trial of amantadine for severe traumatic brain injury.,"['Giacino JT', 'Whyte J', 'Bagiella E', 'Kalmar K', 'Childs N', 'Khademi A', 'Eifert B', 'Long D', 'Katz DI', 'Cho S', 'Yablon SA', 'Luther M', 'Hammond FM', 'Nordenbo A', 'Novak P', 'Mercer W', 'Maurer-Karattup P', 'Sherer M']","['Adult', 'Amantadine/adverse effects/*therapeutic use', 'Brain Injuries/complications/*drug therapy', 'Coma, Post-Head Injury/*drug therapy', 'Disability Evaluation', 'Dopamine Agents/adverse effects/*therapeutic use', 'Female', 'Glasgow Coma Scale', 'Humans', 'Male', 'Persistent Vegetative State/drug therapy/etiology', 'Recovery of Function']",https://pubmed.ncbi.nlm.nih.gov/22375973/
599,amantadine,10412704,['Fatigue' in multiple sclerosis].,"['Zimmermann C', 'Hohlfeld R']","['Amantadine/therapeutic use', 'Aminopyridines/therapeutic use', 'Disease Progression', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Multiple Sclerosis/*complications/drug therapy', 'Pemoline/adverse effects/therapeutic use', 'Potassium Channel Blockers', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/10412704/
600,amantadine,12768511,[Memantine].,['Molinuevo JL'],"['Aged', 'Alzheimer Disease/*drug therapy', 'Antiparkinson Agents/*therapeutic use', 'Brain/*drug effects', 'Glutamic Acid/metabolism', 'Humans', 'Memantine/adverse effects/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12768511/
601,amantadine,10680275,Antiviral agents for treating influenza.,"['Long JK', 'Mossad SB', 'Goldman MP']","['Acetamides/therapeutic use', 'Amantadine/therapeutic use', 'Antiviral Agents/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Guanidines', 'Humans', 'Influenza A virus/isolation & purification', 'Influenza B virus/isolation & purification', 'Influenza Vaccines/therapeutic use', 'Influenza, Human/*drug therapy/prevention & control/virology', 'Oseltamivir', 'Pyrans', 'Rimantadine/therapeutic use', 'Sialic Acids/therapeutic use', 'Zanamivir']",https://pubmed.ncbi.nlm.nih.gov/10680275/
602,amantadine,926844,Antiviral agents.,['Hermans PE'],"['Amantadine/pharmacology/therapeutic use', 'Antiviral Agents/*pharmacology', 'Humans', 'Idoxuridine/therapeutic use', 'Influenza, Human/drug therapy', 'Methisazone/pharmacology', 'Ribavirin/pharmacology', 'Vidarabine/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/926844/
603,amantadine,16905701,"Treating viral hepatitis C: efficacy, side effects, and complications.","['Manns MP', 'Wedemeyer H', 'Cornberg M']","['Amantadine/therapeutic use', 'Antiviral Agents/adverse effects/*therapeutic use', 'Hepatitis C, Chronic/*drug therapy', 'Humans', 'Interferon-alpha/adverse effects/therapeutic use', 'Ribavirin/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16905701/
604,amantadine,23229767,Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.,"['Lyseng-Williamson KA', 'McKeage K']","['Alzheimer Disease/*drug therapy', 'Cost-Benefit Analysis', 'Drug Administration Schedule', 'European Union', 'Humans', 'Memantine/*administration & dosage/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23229767/
605,amantadine,6435991,Anti-parkinsonian drugs today.,['Quinn NP'],"['Amantadine/adverse effects/therapeutic use', 'Amphetamines/therapeutic use', 'Antiparkinson Agents/*therapeutic use', 'Brain Chemistry', 'Catechol O-Methyltransferase Inhibitors', 'Dopamine beta-Hydroxylase/antagonists & inhibitors', 'Droxidopa/therapeutic use', 'Humans', 'Kinetics', 'Levodopa/adverse effects/therapeutic use', 'Mental Disorders/etiology', 'Parasympatholytics/adverse effects/therapeutic use', 'Parkinson Disease/complications/metabolism', 'Selegiline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6435991/
606,amantadine,16133722,The spectrum of differential diagnosis in neurological patients with livedo reticularis and livedo racemosa. A literature review.,"['Kraemer M', 'Linden D', 'Berlit P']","['Adolescent', 'Adult', 'Amantadine/adverse effects/therapeutic use', 'Autoantibodies/analysis', 'Cerebrovascular Disorders/diagnosis/pathology', 'Diagnosis, Differential', 'Female', 'Humans', 'Male', 'Middle Aged', 'Migraine Disorders/complications', 'Nervous System Diseases/*diagnosis/drug therapy/*etiology/pathology', 'Phospholipids/immunology', 'Prognosis', '*Review Literature as Topic', 'Skin Diseases, Vascular/*diagnosis/pathology', 'Syndrome', 'Vascular Diseases/complications/etiology']",https://pubmed.ncbi.nlm.nih.gov/16133722/
607,amantadine,2873715,The neuroleptic malignant syndrome: agent and host interaction.,"['Shalev A', 'Munitz H']","['Adolescent', 'Adult', 'Aftercare', 'Aged', 'Akathisia, Drug-Induced', 'Amantadine/therapeutic use', 'Antiparkinson Agents/therapeutic use', 'Antipsychotic Agents/administration & dosage/*adverse effects', 'Benzodiazepines/therapeutic use', 'Bromocriptine/therapeutic use', 'Carbidopa/therapeutic use', 'Child', 'Child, Preschool', 'Dantrolene/therapeutic use', 'Dose-Response Relationship, Drug', 'Electroconvulsive Therapy', 'Female', 'Haloperidol/adverse effects', 'Humans', 'Leukocytosis/chemically induced', 'Male', 'Middle Aged', 'Neuroleptic Malignant Syndrome/drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/2873715/
608,amantadine,14521495,Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?,['Doggrell S'],"['Alzheimer Disease/*drug therapy/metabolism', 'Clinical Trials as Topic', 'Humans', 'Memantine/administration & dosage/adverse effects/*therapeutic use', 'Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/14521495/
609,amantadine,33604795,Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.,"['Cortes-Borra A', 'Aranda-Abreu GE']","['Amantadine/*therapeutic use', 'Antiviral Agents/*therapeutic use', 'Humans', 'SARS-CoV-2/*drug effects', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33604795/
610,amantadine,9565792,[Amantadine-induced livedo reticularis].,"['Loffler H', 'Habermann B', 'Effendy I']","['Adult', 'Amantadine/*adverse effects/therapeutic use', 'Drug Eruptions/*diagnosis', 'Female', 'Humans', 'Lymphedema/chemically induced/diagnosis', 'Parkinson Disease/*drug therapy', 'Skin Diseases, Vascular/*chemically induced/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/9565792/
611,amantadine,24343538,[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].,"['Pagonabarraga J', 'Kulisevsky J']","['Amantadine/administration & dosage/adverse effects/therapeutic use', 'Antiparkinson Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Cardiovascular Diseases/chemically induced', 'Catechol O-Methyltransferase', 'Catechol O-Methyltransferase Inhibitors', 'Clinical Trials as Topic', 'Dopamine Agonists/administration & dosage/adverse effects/classification/*therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Enzyme Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Food-Drug Interactions', 'Humans', 'Indans/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Indoles/therapeutic use', 'Levodopa/administration & dosage/therapeutic use', 'Mental Disorders/chemically induced/prevention & control', 'Monoamine Oxidase Inhibitors/administration & dosage/pharmacology/therapeutic use', 'Multicenter Studies as Topic', 'Parkinson Disease/*drug therapy', 'Serotonin Syndrome/etiology/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24343538/
612,amifostine,24130023,Radioprotectors - the evergreen topic.,"['Kuntic VS', 'Stankovic MB', 'Vujic ZB', 'Brboric JS', 'Uskokovic-Markovic SM']","['Amifostine/chemistry/therapeutic use', 'Antioxidants/chemistry/therapeutic use', 'Biological Products/chemistry/therapeutic use', 'Humans', 'Plants/chemistry/metabolism', 'Polyphenols/chemistry/therapeutic use', 'Radiation Injuries/*prevention & control', 'Radiation-Protective Agents/*chemistry/therapeutic use', 'Sulfhydryl Compounds/chemistry/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24130023/
613,amifostine,16015537,Treatment-related esophagitis.,['Werner-Wasik M'],"['Amifostine/therapeutic use', 'Antineoplastic Agents/adverse effects', 'Dose Fractionation, Radiation', 'Esophagitis/*etiology/*prevention & control', 'Humans', 'Lung Neoplasms/drug therapy/*radiotherapy', 'Radiation Injuries/*prevention & control', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16015537/
614,amifostine,32443117,Prevention of Platinum-Induced Hearing Loss in Children with Cancer.,['Navarro-Ruiz NE'],"['Amifostine/standards/therapeutic use', 'Humans', 'Neoplasms/*drug therapy/nursing', 'Ototoxicity/drug therapy/nursing/*prevention & control', 'Platinum/*adverse effects/pharmacology/therapeutic use', 'Practice Guidelines as Topic', 'Thiosulfates/standards/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32443117/
615,amifostine,30914026,Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.,"['Rohilla S', 'Dureja H', 'Chawla V']","['Amifostine/*therapeutic use', 'Antineoplastic Agents/*adverse effects', '*Cytoprotection', 'Drug-Related Side Effects and Adverse Reactions/etiology/*prevention & control', 'Humans', 'Neoplasms/*drug therapy/pathology', 'Protective Agents/*therapeutic use', 'Radiation-Protective Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30914026/
616,amifostine,16586122,Amifostine in the management of radiation-induced and chemo-induced mucositis.,"['Bensadoun RJ', 'Schubert MM', 'Lalla RV', 'Keefe D']","['Amifostine/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Combined Modality Therapy', 'Esophagitis/drug therapy/etiology', 'Evidence-Based Medicine', 'Gastrointestinal Diseases/*drug therapy/etiology', 'Head and Neck Neoplasms/therapy', 'Hematologic Neoplasms/therapy', 'Humans', 'Lung Neoplasms/therapy', 'Mucositis/*drug therapy/etiology', 'Neoplasms/complications/*therapy', 'Pelvic Neoplasms/therapy', 'Practice Guidelines as Topic', 'Proctitis/drug therapy/etiology', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/adverse effects', 'Research Design', 'Stomatitis/*drug therapy/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16586122/
617,amifostine,12868117,Cisplatin nephrotoxicity affects magnesium and calcium metabolism.,['Goren MP'],"['Adult', 'Amifostine/therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Calcium/*metabolism', 'Child', 'Cisplatin/*adverse effects', 'Clinical Trials as Topic', 'Humans', 'Kidney/*drug effects/metabolism', 'Kidney Diseases/*chemically induced/metabolism', 'Magnesium/*metabolism', 'Magnesium Deficiency', 'Oxidative Stress', 'Radiation-Protective Agents/therapeutic use', 'Water-Electrolyte Imbalance']",https://pubmed.ncbi.nlm.nih.gov/12868117/
618,amifostine,12621500,Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment.,"['Filicko J', 'Lazarus HM', 'Flomenberg N']","['Amifostine/therapeutic use', 'Humans', 'Interleukin-11/therapeutic use', 'Mucous Membrane/*pathology', 'Stem Cell Transplantation/*adverse effects', 'Transforming Growth Factor beta/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12621500/
619,amifostine,18328585,Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.,"['Valeyrie-Allanore L', 'Poulalhon N', 'Fagot JP', 'Sekula P', 'Davidovici B', 'Sidoroff A', 'Mockenhaupt M']","['Adult', 'Adverse Drug Reaction Reporting Systems', 'Aged', 'Amifostine/*adverse effects', 'Europe', 'Female', 'Head and Neck Neoplasms/*radiotherapy', 'Humans', 'Male', 'Middle Aged', 'Prospective Studies', 'Radiation-Protective Agents/*adverse effects', 'Stevens-Johnson Syndrome/*chemically induced/*etiology']",https://pubmed.ncbi.nlm.nih.gov/18328585/
620,amifostine,31526195,The efficacy and safety of amifostine for the acute radiation syndrome.,"['Singh VK', 'Seed TM']","['Acute Radiation Syndrome/*drug therapy', 'Amifostine/*administration & dosage/adverse effects', 'Animals', 'Drug Approval', 'Drug Design', 'Humans', 'Radiation-Protective Agents/*administration & dosage/adverse effects', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/31526195/
621,amifostine,16015536,Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.,['Gopal R'],"['Amifostine/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/*radiotherapy', 'Clinical Trials as Topic', 'Combined Modality Therapy/adverse effects', 'Esophagitis/etiology/prevention & control', 'Humans', 'Lung/drug effects/radiation effects', 'Lung Neoplasms/*drug therapy/*radiotherapy', 'Radiation Pneumonitis/*prevention & control', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16015536/
622,amifostine,17578604,"[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].","['Kowalski T', 'Maier C', 'Reinacher-Schick A', 'Schlegel U']","['Adrenergic Uptake Inhibitors/therapeutic use', 'Amifostine/therapeutic use', 'Animals', 'Antineoplastic Agents/administration & dosage/*adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use', 'Calcium Carbonate/therapeutic use', 'Calcium Gluconate/therapeutic use', 'Colorectal Neoplasms/*drug therapy', 'Cyclohexanols/therapeutic use', 'Humans', 'Hyperalgesia/*chemically induced/drug therapy/physiopathology', 'Magnesium Chloride/therapeutic use', 'Nerve Fibers/drug effects/physiology', 'Neurotoxicity Syndromes/drug therapy/*physiopathology', 'Organoplatinum Compounds/administration & dosage/*adverse effects', 'Oxaliplatin', 'Paresthesia/*chemically induced/drug therapy/physiopathology', 'Peripheral Nerves/drug effects/physiopathology', 'Rats', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sodium Channels/drug effects/physiology', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/17578604/
623,amifostine,18537748,Prevention and treatment of regimen-related mucosal toxicity.,['Bowen JM'],"['Amifostine/therapeutic use', 'Animals', 'Antineoplastic Agents/*adverse effects', 'Apoptosis/drug effects', 'Cell Proliferation/drug effects', 'Cytoprotection', 'Humans', 'Immunologic Factors/therapeutic use', 'Mucositis/*chemically induced/*drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/18537748/
624,amifostine,37747899,Advances of Amifostine in Radiation Protection: Administration and Delivery.,"['Ji L', 'Cui P', 'Zhou S', 'Qiu L', 'Huang H', 'Wang C', 'Wang J']","['Humans', '*Amifostine/pharmacology/therapeutic use', '*Radiation Protection', '*Radiation-Protective Agents/pharmacology', 'Administration, Intravenous', 'Adjuvants, Immunologic', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/37747899/
625,amifostine,25774860,Mucositis: pathobiology and management.,"['Villa A', 'Sonis ST']","['Amifostine/therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Drug-Related Side Effects and Adverse Reactions', 'Fibroblast Growth Factor 7/therapeutic use', 'Humans', 'Neoplasms/complications/*drug therapy/*radiotherapy', 'Post-Exposure Prophylaxis', 'Quality of Life', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/*adverse effects', 'Risk Factors', 'Stomatitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25774860/
626,amifostine,8976823,"Amifostine (Ethyol): dosing, administration and patient management guidelines.",['Bukowski RM'],"['Amifostine/*administration & dosage/adverse effects', 'Antineoplastic Agents/*adverse effects/antagonists & inhibitors', 'Drug Administration Schedule', 'Humans', 'Hypotension/chemically induced/therapy']",https://pubmed.ncbi.nlm.nih.gov/8976823/
627,amifostine,15726526,Randomized trials of amifostine and radiotherapy: effect on survival?,"['Bourhis J', 'Thephamongkhol K', 'Pignon JP']","['Amifostine/*therapeutic use', 'Combined Modality Therapy', 'Cytoprotection', '*Databases as Topic', 'Humans', 'Meta-Analysis as Topic', 'Neoplasms/*therapy', 'Radiation-Protective Agents/*therapeutic use', '*Randomized Controlled Trials as Topic', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/15726526/
628,amifostine,18794784,Amifostine protection against mitomycin-induced chromosomal breakage in fanconi anaemia lymphocytes.,"['Camelo RM', 'Kehdy FS', 'Salas CE', 'Lopes MT']","['Adolescent', 'Adult', 'Amifostine/*pharmacology', 'Blood Cells', 'Case-Control Studies', 'Child', 'Chromosome Breakage/*drug effects', 'Fanconi Anemia/*drug therapy/genetics', 'Female', 'Humans', 'Lymphocytes/*drug effects', 'Male', 'Micronuclei, Chromosome-Defective/drug effects', 'Mitomycin/*adverse effects', 'Reactive Oxygen Species/metabolism']",https://pubmed.ncbi.nlm.nih.gov/18794784/
629,amifostine,29776830,Pharmacological modulation of radiation-induced oral mucosal complications.,"['Bockel S', 'Vallard A', 'Levy A', 'Francois S', 'Bourdis M', 'Le Gallic C', 'Riccobono D', 'Annede P', 'Drouet M', 'Tao Y', 'Blanchard P', 'Deutsch E', 'Magne N', 'Chargari C']","['Amifostine/therapeutic use', 'Analgesics/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Benzydamine/therapeutic use', 'Dietary Supplements', 'Fibroblast Growth Factor 7/therapeutic use', 'Glutamine/therapeutic use', 'Humans', 'Low-Level Light Therapy', 'Mouthwashes', 'Mucositis/*etiology/*therapy', 'Oral Hygiene', 'Radiation-Protective Agents/therapeutic use', 'Radiotherapy/*adverse effects', 'Risk Factors', 'Zinc/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29776830/
630,amifostine,10882182,"Supportive care in hematologic malignancies: hematopoietic growth factors, infections, transfusion therapy.","['Fetscher S', 'Mertelsmann R']","['Adult', 'Amifostine/pharmacology/therapeutic use', 'Amphotericin B/administration & dosage/therapeutic use', 'Animals', 'Antifungal Agents/administration & dosage/therapeutic use', 'Aspergillosis/prevention & control', 'Blood Transfusion/statistics & numerical data', 'Bone Marrow/drug effects/pathology', 'Clinical Trials, Phase I as Topic', 'Hematologic Neoplasms/complications/*therapy', 'Hematopoietic Cell Growth Factors/pharmacology/therapeutic use', 'Hematopoietic Stem Cells/drug effects', 'Humans', 'Infection Control', 'Neutropenia/etiology/therapy', 'Patient Care', 'Practice Guidelines as Topic', 'Radiation-Protective Agents/pharmacology/therapeutic use', 'Societies, Medical', 'Transfusion Reaction']",https://pubmed.ncbi.nlm.nih.gov/10882182/
631,amifostine,6090369,Toxicity of WR-2721 administered in single and multiple doses.,"['Kligerman MM', 'Glover DJ', 'Turrisi AT', 'Norfleet AL', 'Yuhas JM', 'Coia LR', 'Simone C', 'Glick JH', 'Goodman RL']","['Amifostine/administration & dosage/*toxicity', 'Drug Administration Schedule', 'Drug Evaluation', 'Humans', 'Organothiophosphorus Compounds/*toxicity', 'Radiation-Protective Agents/administration & dosage/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/6090369/
632,aztreonam,37846568,Treatment approaches for severe Stenotrophomonas maltophilia infections.,"['Mojica MF', 'Bonomo RA', 'van Duin D']","['Humans', '*Stenotrophomonas maltophilia', 'Combined Modality Therapy', 'Aztreonam', 'Microbial Sensitivity Tests', 'Minocycline']",https://pubmed.ncbi.nlm.nih.gov/37846568/
633,aztreonam,37754204,Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.,"['Holland TL', 'Cosgrove SE', 'Doernberg SB', 'Jenkins TC', 'Turner NA', 'Boucher HW', 'Pavlov O', 'Titov I', 'Kosulnykov S', 'Atanasov B', 'Poromanski I', 'Makhviladze M', 'Anderzhanova A', 'Stryjewski ME', 'Assadi Gehr M', 'Engelhardt M', 'Hamed K', 'Ionescu D', 'Jones M', 'Saulay M', 'Smart J', 'Seifert H', 'Fowler VG Jr']","['Adult', 'Humans', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', '*Bacteremia/drug therapy/microbiology', 'Cephalosporins/administration & dosage/adverse effects/therapeutic use', '*Daptomycin/administration & dosage/adverse effects/therapeutic use', 'Methicillin-Resistant Staphylococcus aureus', '*Staphylococcal Infections/drug therapy/microbiology', '*Staphylococcus aureus', 'Treatment Outcome', 'Double-Blind Method', 'Administration, Intravenous', 'Aztreonam/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37754204/
634,aztreonam,20431562,Inhaled aztreonam.,"[""O'Sullivan BP"", 'Yasothan U', 'Kirkpatrick P']","['Administration, Inhalation', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Aztreonam/administration & dosage/adverse effects/*therapeutic use', 'Cystic Fibrosis/*complications/microbiology', 'Drug Discovery', 'Humans', 'Lysine/chemistry', 'Pseudomonas Infections/complications/*drug therapy/microbiology', 'Pseudomonas aeruginosa/isolation & purification', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20431562/
635,aztreonam,37823536,Management strategies for severe Pseudomonas aeruginosa infections.,"['Do Rego H', 'Timsit JF']","['Humans', '*Pseudomonas Infections/drug therapy', 'Anti-Bacterial Agents/therapeutic use', 'Aztreonam/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37823536/
636,aztreonam,33998665,Antibiotic regimens for late-onset neonatal sepsis.,"['Korang SK', 'Safi S', 'Nava C', 'Greisen G', 'Gupta M', 'Lausten-Thomsen U', 'Jakobsen JC']","['Amikacin/adverse effects/therapeutic use', 'Ampicillin/adverse effects/therapeutic use', 'Anti-Bacterial Agents/adverse effects/*therapeutic use', 'Aztreonam/adverse effects/therapeutic use', 'Bias', 'Cefazolin/adverse effects/therapeutic use', 'Clavulanic Acid/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Floxacillin/adverse effects/therapeutic use', 'Gentamicins/adverse effects/therapeutic use', 'Humans', 'Infant, Newborn', 'Neonatal Sepsis/*drug therapy', 'Randomized Controlled Trials as Topic', 'Ticarcillin/adverse effects/therapeutic use', 'Vancomycin/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33998665/
637,aztreonam,8442309,Aztreonam.,['Cunha BA'],"['*Aztreonam/adverse effects/pharmacokinetics/therapeutic use', 'Gram-Negative Aerobic Bacteria/*drug effects', 'Gram-Negative Bacterial Infections/*drug therapy', 'Humans', 'Urinary Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8442309/
638,aztreonam,39389071,"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.","['Carmeli Y', 'Cisneros JM', 'Paul M', 'Daikos GL', 'Wang M', 'Torre-Cisneros J', 'Singer G', 'Titov I', 'Gumenchuk I', 'Zhao Y', 'Jimenez-Rodriguez RM', 'Liang L', 'Chen G', 'Pyptiuk O', 'Aksoy F', 'Rogers H', 'Wible M', 'Arhin FF', 'Luckey A', 'Leaney JL', 'Pypstra R', 'Chow JW']","['Humans', 'Male', 'Female', '*Aztreonam/therapeutic use/administration & dosage', '*Meropenem/therapeutic use', 'Middle Aged', '*Anti-Bacterial Agents/therapeutic use/adverse effects', 'Aged', '*Gram-Negative Bacterial Infections/drug therapy/mortality', '*Intraabdominal Infections/drug therapy/microbiology', 'Prospective Studies', '*Azabicyclo Compounds/therapeutic use/adverse effects', 'Adult', 'Gram-Negative Bacteria/drug effects', 'Pneumonia, Ventilator-Associated/drug therapy/microbiology', 'Drug Combinations', 'Treatment Outcome', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/39389071/
639,aztreonam,38258529,Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-beta-lactamase production: a systematic review and meta-analysis.,"['Gupta N', 'Boodman C', 'Prayag P', 'Manesh A', 'Kumar TP']","['Humans', '*Anti-Bacterial Agents/pharmacology/administration & dosage', '*Azabicyclo Compounds/pharmacology/administration & dosage', '*Aztreonam/pharmacology/administration & dosage', 'Bacteremia/drug therapy/microbiology/mortality', 'beta-Lactamases/metabolism', '*Carbapenem-Resistant Enterobacteriaceae/drug effects/isolation & purification', '*Ceftazidime/pharmacology/administration & dosage', 'Drug Combinations', 'Drug Therapy, Combination', '*Enterobacteriaceae Infections/drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/38258529/
640,aztreonam,15123864,Aztreonam.,"['Kapoor S', 'Gathwala G']","['Anti-Bacterial Agents/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Aztreonam/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Child', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/15123864/
641,aztreonam,31828337,Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.,"['Cornely OA', 'Cisneros JM', 'Torre-Cisneros J', 'Rodriguez-Hernandez MJ', 'Tallon-Aguilar L', 'Calbo E', 'Horcajada JP', 'Queckenberg C', 'Zettelmeyer U', 'Arenz D', 'Rosso-Fernandez CM', 'Jimenez-Jorge S', 'Turner G', 'Raber S', ""O'Brien S"", 'Luckey A']","['Adult', 'Anti-Bacterial Agents/adverse effects', 'Azabicyclo Compounds/adverse effects', '*Aztreonam/adverse effects', 'Ceftazidime', 'Drug Combinations', 'Humans', '*Intraabdominal Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31828337/
642,aztreonam,38277033,Evaluation of the MTS aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-beta-lactamase-producing Enterobacterales.,"['Emilie CM', 'Alice CM', 'Marine G', 'Farfour E', 'Pourbaix A', 'Dortet L', 'Lucie L', 'Marc V']","['Humans', '*Aztreonam/pharmacology', '*Anti-Bacterial Agents/pharmacology/therapeutic use', 'Ceftazidime/therapeutic use', 'beta-Lactamases', 'Drug Combinations', 'Microbial Sensitivity Tests', '*Azabicyclo Compounds']",https://pubmed.ncbi.nlm.nih.gov/38277033/
643,aztreonam,38289725,Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-beta-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.,"['Senchyna F', 'Murugesan K', 'Rotunno W', 'Nadimpalli SS', 'Deresinski S', 'Banaei N']","['Humans', '*Azabicyclo Compounds/therapeutic use/administration & dosage', '*beta-Lactamases/genetics/metabolism', '*Aztreonam/therapeutic use/administration & dosage/pharmacology', '*Drug Combinations', '*Ceftazidime/therapeutic use/administration & dosage', '*Anti-Bacterial Agents/therapeutic use/administration & dosage', '*Escherichia coli/drug effects/genetics/enzymology/isolation & purification', '*Escherichia coli Infections/drug therapy/microbiology', 'Fatal Outcome', '*Cefiderocol', '*Bacteremia/drug therapy/microbiology', '*Cephalosporins/therapeutic use/administration & dosage', '*Treatment Failure', 'Microbial Sensitivity Tests', 'Male', 'Drug Resistance, Multiple, Bacterial']",https://pubmed.ncbi.nlm.nih.gov/38289725/
644,aztreonam,2230052,Aztreonam.,"['Tunkel AR', 'Scheld WM']","['*Aztreonam/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Bacterial Infections/*drug therapy', 'Gram-Negative Bacteria/drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2230052/
645,aztreonam,37982631,"In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates.","['Li D', 'Yu H', 'Huang X', 'Long S', 'Zhang J']","['Humans', 'Aztreonam/pharmacology/therapeutic use', 'Klebsiella pneumoniae', 'Bacterial Proteins', 'beta-Lactamases', 'Anti-Bacterial Agents/pharmacology/therapeutic use', '*Carbapenem-Resistant Enterobacteriaceae', 'Imipenem/pharmacology/therapeutic use', 'Carbapenems/pharmacology/therapeutic use', '*Klebsiella Infections/drug therapy/microbiology', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/37982631/
646,aztreonam,7791420,Aztreonam.,"['Johnson DH', 'Cunha BA']","['Aztreonam/pharmacokinetics/*therapeutic use', 'Gram-Negative Bacterial Infections/*drug therapy', 'Humans', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/7791420/
647,aztreonam,34397982,Evaluation of Antibiotic Allergies in Surgical Patients.,"['Larry RC', 'Bertram CM']","['Aminoglycosides/administration & dosage/adverse effects', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Aztreonam/administration & dosage/adverse effects', 'Cefazolin/administration & dosage/adverse effects', 'Clindamycin/administration & dosage/adverse effects', 'Drug Hypersensitivity/diagnosis/immunology', 'Humans', 'Hypersensitivity/*diagnosis', 'Retrospective Studies', 'Vancomycin/administration & dosage/adverse effects', 'beta-Lactams/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34397982/
648,aztreonam,20836577,Aztreonam lysine for inhalation solution: in cystic fibrosis.,['Plosker GL'],"['Administration, Inhalation', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Aztreonam/administration & dosage/adverse effects/*therapeutic use', 'Cystic Fibrosis/*drug therapy/microbiology', 'Humans', 'Lysine/administration & dosage/adverse effects/*therapeutic use', 'Pharmaceutical Solutions', 'Pseudomonas Infections/drug therapy/microbiology', 'Pseudomonas aeruginosa/drug effects']",https://pubmed.ncbi.nlm.nih.gov/20836577/
649,aztreonam,1436929,Aztreonam.,['Clark P'],"['*Aztreonam/adverse effects/chemistry/therapeutic use', 'Bacterial Infections/*drug therapy', 'Costs and Cost Analysis', 'Female', 'Genital Diseases, Female/*drug therapy/microbiology', 'Humans', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy', 'Urinary Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1436929/
650,aztreonam,22029514,Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.,['Assael BM'],"['Administration, Inhalation', 'Adolescent', 'Adult', 'Aerosols', 'Anti-Bacterial Agents/*pharmacokinetics/therapeutic use', 'Aztreonam/*pharmacokinetics/therapeutic use', 'Bacterial Load', 'Child', 'Chronic Disease', 'Cystic Fibrosis/complications/*physiopathology', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Humans', 'Lung/*drug effects/microbiology/physiopathology', 'Nebulizers and Vaporizers', 'Pseudomonas Infections/complications/*drug therapy/microbiology/physiopathology', 'Pseudomonas aeruginosa/*drug effects/physiology', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22029514/
651,aztreonam,1902290,The use of aztreonam in pediatric patients: a review.,"['Bosso JA', 'Black PG']","['Adult', 'Aztreonam/administration & dosage/pharmacokinetics/*therapeutic use', 'Bacterial Infections/*drug therapy', '*Gram-Negative Aerobic Bacteria', 'Humans', 'Infant, Newborn', 'Meningitis/drug therapy', 'Pseudomonas aeruginosa', 'Respiratory Tract Infections/drug therapy', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1902290/
652,betaxolol,2569884,Betaxolol.,['Goldberg I'],"['Adrenergic beta-Antagonists/pharmacology', 'Betaxolol', 'Glaucoma/*drug therapy', 'Humans', 'Intraocular Pressure/drug effects', 'Propanolamines/*pharmacology', 'Time Factors', 'Timolol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2569884/
653,betaxolol,34182907,A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic beta-blockers with Clinically Relevant Drugs-An Overview.,"['Maideen NMP', 'Rajkapoor B', 'Muthusamy S', 'Ramanathan S', 'Thangadurai SA', 'Sughir AA']","['Adrenergic beta-Antagonists/*pharmacokinetics', '*Drug Interactions', 'Humans', 'Medication Therapy Management', 'Pharmaceutical Preparations/classification/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34182907/
654,betaxolol,26526633,Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.,"['Li T', 'Lindsley K', 'Rouse B', 'Hong H', 'Shi Q', 'Friedman DS', 'Wormald R', 'Dickersin K']","['Antihypertensive Agents/*therapeutic use', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/*drug effects', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26526633/
655,betaxolol,10571351,Early Manifest Glaucoma Trial: design and baseline data.,"['Leske MC', 'Heijl A', 'Hyman L', 'Bengtsson B']","['Adrenergic beta-Antagonists/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Betaxolol/*therapeutic use', 'Disease Progression', 'Female', 'Glaucoma, Open-Angle/physiopathology/*therapy', 'Humans', 'Intraocular Pressure/*drug effects', 'Male', 'Middle Aged', '*Research Design', 'Tonometry, Ocular', '*Trabeculectomy', 'Vision Disorders/physiopathology', 'Visual Acuity', 'Visual Field Tests', 'Visual Fields']",https://pubmed.ncbi.nlm.nih.gov/10571351/
656,betaxolol,11153162,Beta blockers and lactation: an update.,"['Shannon ME', 'Malecha SE', 'Cha AJ']","['Adrenergic beta-Antagonists/*adverse effects/*pharmacokinetics', 'Adult', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Infant', 'Milk, Human/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/11153162/
657,betaxolol,6426371,Treatment of glaucoma.,"['Remis LL', 'Epstein DL']","['Betaxolol', 'Epinephrine/therapeutic use', 'Glaucoma/diagnosis/*drug therapy/surgery', 'Glaucoma, Open-Angle/diagnosis/*drug therapy/surgery', 'Humans', 'Hydroxydopamines/therapeutic use', 'Laser Therapy', 'Levobunolol/therapeutic use', 'Oxidopamine', 'Pilocarpine/therapeutic use', 'Propanolamines/therapeutic use', 'Timolol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6426371/
658,betaxolol,19425476,[Neuroprotection in glaucoma].,"['Kuprjanowicz L', 'Karczewicz D']","['Betaxolol/therapeutic use', 'Brimonidine Tartrate', 'Disease Progression', 'Glaucoma/*drug therapy/epidemiology/etiology', 'Guanidines/therapeutic use', 'Humans', 'Memantine/therapeutic use', 'Neuroprotective Agents/*therapeutic use', 'Quinoxalines/therapeutic use', 'Sulfonamides/therapeutic use', 'Thiophenes/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19425476/
659,betaxolol,33461701,Betaxolol: A comprehensive profile.,"['Al-Wadei MJ', 'Bakheit AH', 'Abdel-Aziz AA', 'Wani TA']","['*Adrenergic beta-Antagonists/pharmacology', '*Betaxolol/pharmacology', 'Blood Pressure/drug effects', 'Eye Diseases/*drug therapy', 'Heart/drug effects', 'Humans', 'Intraocular Pressure/drug effects', 'Kidney/drug effects', 'Renin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/33461701/
660,betaxolol,12365904,Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.,"['Heijl A', 'Leske MC', 'Bengtsson B', 'Hyman L', 'Bengtsson B', 'Hussein M']","['Adrenergic beta-Antagonists/therapeutic use', 'Aged', 'Aged, 80 and over', 'Betaxolol/therapeutic use', 'Disease Progression', 'Female', 'Glaucoma, Open-Angle/*physiopathology/*therapy', 'Humans', '*Intraocular Pressure/drug effects', 'Laser Therapy', 'Male', 'Middle Aged', 'Single-Blind Method', 'Trabeculectomy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12365904/
661,betaxolol,11753897,Contact dermatitis to topical drugs for glaucoma.,['Holdiness MR'],"['Dermatitis, Allergic Contact/*etiology', 'Epinephrine/adverse effects/*analogs & derivatives', 'Glaucoma/*drug therapy', 'Humans', 'Ophthalmic Solutions/*adverse effects', 'Pilocarpine/adverse effects', 'Sulfonamides/adverse effects', 'Thiophenes/adverse effects', 'Timolol/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11753897/
662,betaxolol,24666291,Congenital hypothyroidism in Rieger Syndrome.,"['Ornek N', 'Ogurel R', 'Ornek K']","['Adrenergic beta-1 Receptor Antagonists/therapeutic use', 'Anterior Eye Segment/*abnormalities', 'Betaxolol/therapeutic use', 'Child', 'Congenital Hypothyroidism/*complications/diagnosis', 'Eye Abnormalities/*complications/diagnosis', 'Eye Diseases, Hereditary', 'Gonioscopy', 'Humans', 'Intraocular Pressure/drug effects', 'Male', 'Tomography, Optical Coherence', 'Visual Acuity']",https://pubmed.ncbi.nlm.nih.gov/24666291/
663,betaxolol,6367723,Betaxolol and timolol. A comparison of efficacy and side effects.,"['Berry DP Jr', 'Van Buskirk EM', 'Shields MB']","['Aged', 'Betaxolol', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Glaucoma, Open-Angle/*drug therapy', 'Humans', 'Intraocular Pressure/*drug effects', 'Male', 'Middle Aged', 'Ophthalmic Solutions', 'Propanolamines/adverse effects/*therapeutic use', 'Prospective Studies', 'Pulse/drug effects', 'Timolol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6367723/
664,betaxolol,2545641,Effects of betaxolol/timolol on epinephrine stimulated cyclic-AMP levels in human trabecular meshwork cells.,"['Polansky J', 'Friedman Z', 'Fauss D', 'Kurtz R', 'Alvarado J']","['Betaxolol', 'Cells, Cultured', 'Cyclic AMP/*biosynthesis', 'Epinephrine/*pharmacology', 'Humans', 'Propanolamines/*pharmacology', 'Time Factors', 'Timolol/*pharmacology', 'Trabecular Meshwork/cytology/*drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2545641/
665,betaxolol,32332749,Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles.,"['Peladeau C', 'Adam N', 'Bronicki LM', 'Coriati A', 'Thabet M', 'Al-Rewashdy H', 'Vanstone J', 'Mears A', 'Renaud JM', 'Holcik M', 'Jasmin BJ']","[""5' Untranslated Regions/genetics"", 'Animals', 'Betaxolol/pharmacology/therapeutic use', 'Cell Line', 'Disease Models, Animal', 'Drug Evaluation, Preclinical', 'Drug Repositioning', 'Humans', 'Internal Ribosome Entry Sites/genetics', 'Mice', 'Mice, Inbred mdx', 'Mice, Knockout', 'Muscular Dystrophy, Duchenne/*drug therapy/genetics', 'Myoblasts', 'Peptide Elongation Factor 1/*antagonists & inhibitors/genetics/metabolism', 'Pravastatin/pharmacology/therapeutic use', 'Protein Biosynthesis/*drug effects/genetics', 'Up-Regulation/drug effects', 'Utrophin/*genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/32332749/
666,betaxolol,39490635,beta-Blockers and Asthma: Surprising findings from the FAERS database.,"['Cazzola M', 'Ora J', 'Calzetta L', 'Rogliani P', 'Matera MG']","['*Asthma/drug therapy/epidemiology', 'Humans', '*Adrenergic beta-Antagonists/adverse effects/therapeutic use', 'United States/epidemiology', 'Adverse Drug Reaction Reporting Systems/statistics & numerical data', 'United States Food and Drug Administration', 'Male', 'Female', 'Databases, Factual']",https://pubmed.ncbi.nlm.nih.gov/39490635/
667,betaxolol,23208385,Evaluation of skin permeation of beta-blockers for topical drug delivery.,"['Chantasart D', 'Hao J', 'Li SK']","['Administration, Topical', 'Adrenergic beta-Antagonists/chemistry/*pharmacokinetics', 'Adult', 'Atenolol/chemistry/*pharmacokinetics', 'Betaxolol/chemistry/*pharmacokinetics', 'Epidermis/metabolism', 'Humans', 'Middle Aged', 'Propranolol/chemistry/*pharmacokinetics', 'Skin/*metabolism', 'Skin Absorption', 'Timolol/chemistry/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23208385/
668,betaxolol,35404141,Effects of Topical Antiglaucomatous Medications on Conjunctival Thickness: A Prospective Anterior Segment Optical Coherence Tomography Study.,"['Kutluturk G', 'Altan C', 'Yasar T']","['Antihypertensive Agents/pharmacology/therapeutic use', 'Conjunctiva', '*Glaucoma, Open-Angle/diagnosis/drug therapy', 'Humans', 'Latanoprost/therapeutic use', 'Prospective Studies', '*Tomography, Optical Coherence/methods']",https://pubmed.ncbi.nlm.nih.gov/35404141/
669,betaxolol,11971492,Spirometry for patients prescribed topical beta-blockers.,"['Snape JP', 'Waldock A']","['Administration, Topical', 'Adrenergic beta-Antagonists/administration & dosage/*adverse effects', 'Age Factors', 'Aged', 'Betaxolol/administration & dosage/adverse effects', 'Brimonidine Tartrate', 'Drug Monitoring', 'Forced Expiratory Volume/drug effects', 'Glaucoma, Open-Angle/*drug therapy', 'Humans', 'Latanoprost', 'Lung Diseases/*chemically induced/*diagnosis', 'Prospective Studies', 'Prostaglandins F, Synthetic/administration & dosage/adverse effects', 'Quinoxalines/administration & dosage/adverse effects', 'Spirometry/methods/*nursing', 'Timolol/administration & dosage/adverse effects', 'Vital Capacity/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11971492/
670,betaxolol,33636071,[Type IV hypersensitivity to timolol].,"['Espinola S', 'Mora D']","['Adrenergic beta-Antagonists/adverse effects', 'Adult', '*Carteolol', '*Glaucoma, Open-Angle/drug therapy', 'Humans', '*Hypersensitivity, Delayed', 'Male', 'Timolol/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33636071/
671,betaxolol,15036567,Effectiveness of levobetaxolol and timolol at blunting retinal ischaemia is related to their calcium and sodium blocking activities: relevance to glaucoma.,"['Osborne NN', 'Wood JP', 'Chidlow G', 'Casson R', 'DeSantis L', 'Schmidt KG']","['Animals', 'Betaxolol/pharmacology/*therapeutic use', 'Calcium/antagonists & inhibitors/metabolism', 'Glaucoma/drug therapy/metabolism', 'Humans', 'Ischemia/*drug therapy/metabolism', 'Retina/*drug effects/metabolism', 'Sodium/antagonists & inhibitors/metabolism', 'Sodium-Calcium Exchanger/*antagonists & inhibitors/metabolism', 'Timolol/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15036567/
672,bicalutamide,19359544,Development of a second-generation antiandrogen for treatment of advanced prostate cancer.,"['Tran C', 'Ouk S', 'Clegg NJ', 'Chen Y', 'Watson PA', 'Arora V', 'Wongvipat J', 'Smith-Jones PM', 'Yoo D', 'Kwon A', 'Wasielewska T', 'Welsbie D', 'Chen CD', 'Higano CS', 'Beer TM', 'Hung DT', 'Scher HI', 'Jung ME', 'Sawyers CL']","['Androgen Antagonists/metabolism/pharmacokinetics/pharmacology/*therapeutic use', 'Anilides/metabolism/pharmacology', 'Animals', 'Antineoplastic Agents/metabolism/pharmacokinetics/pharmacology/*therapeutic use', 'Benzamides', 'Biological Availability', 'Cell Line, Tumor', 'Cell Nucleus/metabolism', 'Cell Proliferation/drug effects', 'DNA/metabolism', 'Drug Screening Assays, Antitumor', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Male', 'Mice', 'Nitriles/metabolism/pharmacology', 'Phenylthiohydantoin/*analogs & derivatives/metabolism/pharmacokinetics/pharmacology/therapeutic use', 'Prostatic Neoplasms/*drug therapy/pathology', 'Receptors, Androgen/chemistry/genetics/metabolism', 'Tosyl Compounds/metabolism/pharmacology', 'Transcription, Genetic/drug effects', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/19359544/
673,bicalutamide,35032336,Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know.,"['Carvalho RM', 'Santos LDN', 'Ramos PM', 'Machado CJ', 'Acioly P', 'Frattini SC', 'Barcaui CB', 'Donda ALV', 'Melo DF']","['Female', 'Humans', '*Quality of Life', '*Dermatologists', 'Alopecia/therapy', 'Minoxidil']",https://pubmed.ncbi.nlm.nih.gov/35032336/
674,bicalutamide,38377363,Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy.,"['Muniz M', 'Childs DS', 'Orme JJ', 'Johnson GB', 'Sartor O']","['Male', 'Humans', 'Aged', '*Gynecomastia/chemically induced/diagnostic imaging', 'Androgen Antagonists/adverse effects', 'Androgens', 'Positron Emission Tomography Computed Tomography', '*Prostatic Neoplasms/complications/drug therapy', '*Anilides', '*Nitriles', '*Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/38377363/
675,bicalutamide,22266222,ARN-509: a novel antiandrogen for prostate cancer treatment.,"['Clegg NJ', 'Wongvipat J', 'Joseph JD', 'Tran C', 'Ouk S', 'Dilhas A', 'Chen Y', 'Grillot K', 'Bischoff ED', 'Cai L', 'Aparicio A', 'Dorow S', 'Arora V', 'Shao G', 'Qian J', 'Zhao H', 'Yang G', 'Cao C', 'Sensintaffar J', 'Wasielewska T', 'Herbert MR', 'Bonnefous C', 'Darimont B', 'Scher HI', 'Smith-Jones P', 'Klang M', 'Smith ND', 'De Stanchina E', 'Wu N', 'Ouerfelli O', 'Rix PJ', 'Heyman RA', 'Jung ME', 'Sawyers CL', 'Hager JH']","['Androgen Antagonists/pharmacokinetics/*therapeutic use', 'Anilides/pharmacokinetics/therapeutic use', 'Animals', 'Antineoplastic Agents, Hormonal/blood/pharmacokinetics/*therapeutic use', 'Benzamides', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Male', 'Mice', 'Nitriles/pharmacokinetics/therapeutic use', 'Phenylthiohydantoin/analogs & derivatives/blood/pharmacokinetics/therapeutic use', 'Prostatic Neoplasms/*drug therapy', 'Rats', 'Receptors, Androgen/drug effects', 'Thiohydantoins/blood/chemical synthesis/pharmacokinetics/*therapeutic use', 'Tosyl Compounds/pharmacokinetics/therapeutic use', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/22266222/
676,bicalutamide,16631454,Combined androgen blockade: an update.,['Klotz L'],"['Androgen Antagonists/*therapeutic use', 'Anilides/therapeutic use', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Drug Therapy, Combination', 'Humans', 'Male', 'Nitriles', '*Orchiectomy', 'Prostatic Neoplasms/*therapy', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/16631454/
677,bicalutamide,28146658,Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.,"['Shipley WU', 'Seiferheld W', 'Lukka HR', 'Major PP', 'Heney NM', 'Grignon DJ', 'Sartor O', 'Patel MP', 'Bahary JP', 'Zietman AL', 'Pisansky TM', 'Zeitzer KL', 'Lawton CA', 'Feng FY', 'Lovett RD', 'Balogh AG', 'Souhami L', 'Rosenthal SA', 'Kerlin KJ', 'Dignam JJ', 'Pugh SL', 'Sandler HM']","['Aged', 'Aged, 80 and over', 'Androgen Antagonists/adverse effects/*therapeutic use', 'Anilides/adverse effects/*therapeutic use', 'Combined Modality Therapy', 'Double-Blind Method', 'Follow-Up Studies', 'Gynecomastia/chemically induced', 'Humans', 'Incidence', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Neoplasm Metastasis', 'Neoplasm Recurrence, Local/*drug therapy/mortality/*radiotherapy', 'Neoplasm Staging', 'Nitriles/adverse effects/*therapeutic use', 'Prostatectomy', 'Prostatic Neoplasms/*drug therapy/mortality/*radiotherapy/surgery', 'Radiotherapy/adverse effects', 'Survival Rate', 'Tosyl Compounds/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28146658/
678,bicalutamide,36075260,"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.","['Gu W', 'Han W', 'Luo H', 'Zhou F', 'He D', 'Ma L', 'Guo H', 'Liang C', 'Chong T', 'Jiang J', 'Chen Z', 'Wang Y', 'Zou Q', 'Tian Y', 'Xiao J', 'Huang J', 'Zhu S', 'Dong Q', 'Zhang X', 'Li H', 'Yang X', 'Chen C', 'Li J', 'Jin C', 'Zhang X', 'Ye D']","['*Androgen Antagonists/adverse effects', 'Androgens', 'Anilides', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Disease-Free Survival', 'Humans', 'Male', 'Nitriles', '*Prostatic Neoplasms/drug therapy/pathology', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/36075260/
679,bicalutamide,9144890,The antiandrogen withdrawal syndrome.,"['Wirth MP', 'Froschermaier SE']","['Androgen Antagonists/administration & dosage/*adverse effects/therapeutic use', 'Humans', 'Male', 'Mutation', 'Neoplasms, Hormone-Dependent/drug therapy/genetics/immunology', 'Prognosis', 'Prostate-Specific Antigen/blood', 'Prostatic Neoplasms/*drug therapy/genetics/immunology', 'Receptors, Androgen/drug effects/genetics', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/9144890/
680,bicalutamide,39690158,"Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study.","['Wang H', 'Jiang S', 'Luo H', 'Zhou F', 'He D', 'Ma L', 'Guo H', 'Liang C', 'Chong T', 'Jiang J', 'Chen Z', 'Wang Y', 'Zou Q', 'Tian Y', 'Xiao J', 'Huang J', 'Chen J', 'Dong Q', 'Zhang X', 'Li H', 'Yang X', 'Lian J', 'Wang W', 'Ye D']","['Humans', 'Male', '*Nitriles/therapeutic use', '*Anilides/administration & dosage/therapeutic use', '*Tosyl Compounds/therapeutic use/administration & dosage', 'Aged', '*Patient Reported Outcome Measures', '*Prostatic Neoplasms/drug therapy/pathology', '*Androgen Antagonists/therapeutic use/administration & dosage', 'Middle Aged', 'Neoplasm Metastasis', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39690158/
681,bicalutamide,33926033,Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.,"['Kim GY', 'Song CW', 'Yang YS', 'Lee NR', 'Yoo HS', 'Son SH', 'Lee SJ', 'Park JS', 'Lee JK', 'Inn KS', 'Kim NJ']","['Androgen Antagonists/chemical synthesis/*chemistry/pharmacology', 'Anilides/*chemistry/pharmacology', 'Binding Sites', 'Cell Line', 'Chemistry Techniques, Synthetic', 'Humans', 'Models, Biological', 'Models, Molecular', 'Molecular Conformation', 'Molecular Structure', 'Nitriles/*chemistry/pharmacology', 'Protein Binding', 'Proteolysis/drug effects', 'Receptors, Androgen/*chemistry/metabolism', 'Structure-Activity Relationship', 'Thalidomide/*chemistry/pharmacology', 'Tosyl Compounds/*chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33926033/
682,bicalutamide,14748655,Bicalutamide (Casodex) in the treatment of prostate cancer.,['Fradet Y'],"['Androgen Antagonists/pharmacokinetics/*therapeutic use', 'Anilides/pharmacokinetics/*therapeutic use', 'Animals', 'Clinical Trials as Topic', 'Humans', 'Male', 'Neoplasm Staging', 'Nitriles', 'Prostatic Neoplasms/*drug therapy/metabolism', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/14748655/
683,bicalutamide,28433972,Paraneoplastic jaundice and prostate cancer.,"['Vieira AC', 'Alvarenga MJ', 'Santos JC', 'Silva AM']","['Aged', 'Anilides/*administration & dosage/therapeutic use', 'Humans', 'Jaundice/*etiology', 'Male', 'Neoplasm Metastasis', 'Nitriles/*administration & dosage/therapeutic use', 'Paraneoplastic Syndromes/*diagnosis/drug therapy', 'Prostatic Neoplasms/*diagnosis/drug therapy', 'Tosyl Compounds/*administration & dosage/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28433972/
684,bicalutamide,34089393,Peripheral androgen blockade in men with castrate-sensitive biochemical recurrent prostate cancer.,"['Reyes DK', 'Pienta KJ']","['Aged', 'Androgen Antagonists/*administration & dosage', 'Androgens/metabolism', 'Anilides/administration & dosage', 'Antineoplastic Agents, Hormonal/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage', 'Finasteride/administration & dosage', 'Humans', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/diagnosis/*drug therapy/*metabolism', 'Nitriles/administration & dosage', 'Prostatic Neoplasms, Castration-Resistant/diagnosis/*drug therapy/*metabolism', 'Tosyl Compounds/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/34089393/
685,bicalutamide,29211833,A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.,"['Fushimi C', 'Tada Y', 'Takahashi H', 'Nagao T', 'Ojiri H', 'Masubuchi T', 'Matsuki T', 'Miura K', 'Kawakita D', 'Hirai H', 'Hoshino E', 'Kamata S', 'Saotome T']","['Aged', 'Aged, 80 and over', 'Androgen Antagonists/administration & dosage/*therapeutic use', 'Anilides/administration & dosage/therapeutic use', 'Disease-Free Survival', 'Female', 'Humans', 'Leuprolide/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', '*Neoplasm Metastasis', 'Nitriles/administration & dosage/therapeutic use', 'Prospective Studies', 'Receptors, Androgen/*metabolism', 'Salivary Gland Neoplasms/*drug therapy/metabolism/pathology', 'Tosyl Compounds/administration & dosage/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29211833/
686,bicalutamide,16927907,Hot flashes.,['Engstrom C'],"['Adenocarcinoma/diagnosis/*drug therapy', 'Aged', 'Androgen Antagonists/*adverse effects', 'Anilides/*adverse effects', 'Antineoplastic Agents/*adverse effects', 'Arrhythmias, Cardiac/chemically induced', 'Evidence-Based Medicine', 'Hot Flashes/*chemically induced/prevention & control', 'Humans', 'Male', 'Nitriles', 'Nursing Assessment', 'Patient Care Planning', 'Prostatic Neoplasms/diagnosis/*drug therapy', 'Sweating/drug effects', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/16927907/
687,bicalutamide,9074908,Casodex (bicalutamide): overview of a new antiandrogen developed for the treatment of prostate cancer.,"['Blackledge GR', 'Cockshott ID', 'Furr BJ']","['Androgen Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Anilides/adverse effects/pharmacokinetics/*therapeutic use', 'Antineoplastic Agents, Hormonal/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Nitriles', 'Prostatic Neoplasms/*drug therapy', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/9074908/
688,bicalutamide,11048610,Bicalutamide treatment for locally advanced prostate cancer.,['Anderson J'],"['Androgen Antagonists/*therapeutic use', 'Anilides/*therapeutic use', 'Antineoplastic Agents, Hormonal/*therapeutic use', 'Bone Density/drug effects', 'Humans', 'Male', 'Nitriles', 'Prostatic Neoplasms/*drug therapy', 'Quality of Life', 'Tosyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/11048610/
689,bicalutamide,23225433,Effects of bicalutamide and 4OH-tamoxifen on androgen-regulated gene expression in the LNCaP cell line.,"['Mangerini R', 'Argellati F', 'Pfeffer U', 'Boccardo F']","['Androgens/*physiology', 'Anilides/administration & dosage/*pharmacology', 'Antineoplastic Combined Chemotherapy Protocols/*pharmacology', 'Cell Growth Processes/drug effects/genetics', 'Cell Line, Tumor', 'Gene Expression Regulation, Neoplastic/*drug effects', 'Humans', 'Kallikreins/biosynthesis', 'Male', 'Neoplasms, Hormone-Dependent/drug therapy/genetics', 'Nitriles/administration & dosage/*pharmacology', 'Prostate-Specific Antigen/biosynthesis', 'Prostatic Neoplasms/*drug therapy/*genetics', 'Tamoxifen/administration & dosage/*analogs & derivatives/pharmacology', 'Tosyl Compounds/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/23225433/
690,bicalutamide,29339807,"Overexpression of alpha (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.","['Hoti N', 'Yang S', 'Hu Y', 'Shah P', 'Haffner MC', 'Zhang H']","['Androgens/genetics/*metabolism', 'Anilides/administration & dosage', 'Animals', 'Cell Line, Tumor', 'Cell Movement/genetics', 'Fucose/metabolism', 'Fucosyltransferases/*genetics', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Male', 'Mice', 'Nitriles/administration & dosage', 'Prostatic Neoplasms, Castration-Resistant/*drug therapy/*genetics/metabolism/pathology', 'Tosyl Compounds/administration & dosage', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/29339807/
691,bicalutamide,15685254,Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.,"['Saltzstein D', 'Sieber P', 'Morris T', 'Gallo J']","['Aged', 'Aged, 80 and over', 'Anastrozole', 'Anilides/*adverse effects/*therapeutic use', 'Antineoplastic Agents/*adverse effects/*therapeutic use', 'Antineoplastic Agents, Hormonal/*adverse effects/*therapeutic use', 'Breast Diseases/*chemically induced/*prevention & control', 'Double-Blind Method', 'Gynecomastia/*chemically induced/*prevention & control', 'Humans', 'Male', 'Middle Aged', 'Nitriles/*adverse effects/*therapeutic use', 'Pain/chemically induced/prevention & control', 'Placebos', 'Prostatic Neoplasms/*drug therapy/pathology/surgery', 'Tamoxifen/pharmacology/*therapeutic use', 'Testosterone/blood', 'Tosyl Compounds', 'Treatment Outcome', 'Triazoles/*adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15685254/
692,bumetanide,35524444,Clarifications regarding bumetanide for neonatal seizures.,['Staley KJ'],"['Bumetanide/therapeutic use', '*Epilepsy', 'Humans', 'Infant, Newborn', '*Infant, Newborn, Diseases', 'Seizures/drug therapy', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Solute Carrier Family 12, Member 2']",https://pubmed.ncbi.nlm.nih.gov/35524444/
693,bumetanide,32094236,BRASH syndrome.,"['Srivastava S', 'Kemnic T', 'Hildebrandt KR']","['Antihypertensive Agents/adverse effects', '*Atrioventricular Block', '*Bradycardia', 'Bumetanide/adverse effects', 'Carvedilol/adverse effects', 'Female', 'Humans', '*Hyperkalemia', 'Metolazone/adverse effects', 'Middle Aged', '*Renal Insufficiency', '*Shock', 'Syndrome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32094236/
694,bumetanide,8233492,Ototoxicity of loop diuretics.,['Rybak LP'],"['Animals', 'Bumetanide/adverse effects', 'Cochlea/*drug effects', 'Diuretics/*adverse effects', 'Ethacrynic Acid/adverse effects', 'Furosemide/adverse effects', 'Hearing Disorders/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/8233492/
695,bumetanide,22293138,Aquaporins in drug discovery and pharmacotherapy.,"['Huber VJ', 'Tsujita M', 'Nakada T']","['Acetazolamide/pharmacology', 'Animals', 'Aquaporins/antagonists & inhibitors/chemistry/*metabolism', 'Biological Transport/drug effects', 'Brain Edema/*drug therapy/metabolism/pathology', 'Bumetanide/pharmacology', 'Drug Discovery', 'Humans', 'Molecular Targeted Therapy', 'Neoplasms/*drug therapy/metabolism/pathology', 'Niacinamide/analogs & derivatives/pharmacology', 'Thiadiazoles/pharmacology', 'Water/*metabolism', 'Water-Electrolyte Balance/drug effects', 'Water-Electrolyte Imbalance/*drug therapy/metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/22293138/
696,bumetanide,35524446,Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel.,"['Kaila K', 'Loscher W']","['Bumetanide/therapeutic use', '*Epilepsy/drug therapy', 'Humans', 'Infant, Newborn', '*Infant, Newborn, Diseases/drug therapy', 'Seizures/drug therapy', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Solute Carrier Family 12, Member 2']",https://pubmed.ncbi.nlm.nih.gov/35524446/
697,bumetanide,3511654,Disposition and response to bumetanide and furosemide.,['Brater DC'],"['Adult', 'Aged', 'Biological Availability', '*Bumetanide/metabolism/pharmacology', '*Diuretics/metabolism/pharmacology', '*Furosemide/metabolism/pharmacology', 'Heart Failure/metabolism', 'Humans', 'Kidney Diseases/metabolism', 'Kidney Transplantation', 'Kinetics', 'Liver Cirrhosis/metabolism', 'Middle Aged', 'Nephrotic Syndrome/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3511654/
698,bumetanide,37021422,"Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder.","['Shaker E', 'El Agami O', 'Salamah A']","['Child', 'Humans', 'Bumetanide/therapeutic use', 'Diuretics/therapeutic use', '*Autism Spectrum Disorder/drug therapy', '*Autistic Disorder', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37021422/
699,bumetanide,3511657,Diuretic therapeutics in the pediatric patient.,"['Witte MK', 'Stork JE', 'Blumer JL']","['Acid-Base Equilibrium', 'Bumetanide/metabolism/therapeutic use', 'Calcium/urine', 'Child', 'Child, Preschool', 'Chlorides/metabolism', 'Diuretics/adverse effects/metabolism/pharmacology/*therapeutic use', 'Ethacrynic Acid/metabolism/therapeutic use', 'Furosemide/metabolism/therapeutic use', 'Glomerular Filtration Rate', 'Glomerulonephritis/drug therapy', 'Humans', 'Hydrocephalus/drug therapy', 'Infant', 'Infant, Newborn', 'Infant, Premature', 'Kidney/blood supply/drug effects/embryology/physiology', 'Kinetics', 'Metabolic Clearance Rate', 'Nephrotic Syndrome/drug therapy', 'Prostaglandins/biosynthesis', 'Pulmonary Edema/drug therapy', 'Regional Blood Flow', 'Water-Electrolyte Balance']",https://pubmed.ncbi.nlm.nih.gov/3511657/
700,bumetanide,22536874,Unexpected extra-renal effects of loop diuretics in the preterm neonate.,"['Cotton R', 'Suarez S', 'Reese J']","['Biomarkers/metabolism', 'Bronchopulmonary Dysplasia/drug therapy', 'Bumetanide/*pharmacology/therapeutic use', 'Central Nervous System/drug effects/metabolism', 'Diuretics/*pharmacology/therapeutic use', 'Ductus Arteriosus/drug effects', 'Furosemide/*pharmacology/therapeutic use', 'Gastrointestinal Tract/drug effects', 'Humans', 'Hyaline Membrane Disease/drug therapy', 'Infant, Newborn', '*Infant, Premature', '*Intensive Care, Neonatal', 'Lung/drug effects', 'Muscle, Smooth, Vascular/drug effects', 'gamma-Aminobutyric Acid/metabolism']",https://pubmed.ncbi.nlm.nih.gov/22536874/
701,bumetanide,29483603,"Bumetanide for autism: more eye contact, less amygdala activation.","['Hadjikhani N', 'Asberg Johnels J', 'Lassalle A', 'Zurcher NR', 'Hippolyte L', 'Gillberg C', 'Lemonnier E', 'Ben-Ari Y']","['Adolescent', 'Adult', 'Amygdala/diagnostic imaging/*drug effects/*physiology', 'Autistic Disorder/diagnostic imaging/*physiopathology', 'Bumetanide/*pharmacology/therapeutic use', 'Double-Blind Method', 'Emotions/drug effects/physiology', 'Female', 'Fixation, Ocular/drug effects/physiology', 'Humans', 'Magnetic Resonance Spectroscopy', 'Male', 'Pilot Projects', 'Sodium Potassium Chloride Symporter Inhibitors/pharmacology/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29483603/
702,bumetanide,15162897,Food: an unrecognized source of loop diuretic resistance.,"['Bard RL', 'Bleske BE', 'Nicklas JM']","['Administration, Oral', 'Area Under Curve', '*Bumetanide/metabolism/pharmacokinetics/pharmacology', 'Clinical Trials as Topic', 'Diuresis/*drug effects', '*Diuretics/metabolism/pharmacokinetics/pharmacology', '*Food', '*Furosemide/metabolism/pharmacokinetics/pharmacology', 'Humans', 'Intestinal Absorption', 'Sulfonamides/metabolism/pharmacokinetics/pharmacology', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/15162897/
703,bumetanide,36562420,A new role for an old drug: acetazolamide in decompensated heart failure.,['Doggrell SA'],"['Humans', '*Acetazolamide/therapeutic use', 'Bumetanide', 'Diuretics/therapeutic use', 'Quality of Life', 'Treatment Outcome', '*Heart Failure/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36562420/
704,bumetanide,34883135,CNS pharmacology of NKCC1 inhibitors.,"['Loscher W', 'Kaila K']","['Animals', 'Bumetanide/*pharmacokinetics', 'Central Nervous System/*drug effects', 'Humans', 'Sodium Potassium Chloride Symporter Inhibitors/*pharmacokinetics', 'Solute Carrier Family 12, Member 2/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34883135/
705,bumetanide,33385505,Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?,"['Lemonnier E', 'Rabiei H', 'Makowski D', 'Hadjikhani N', 'Ben-Ari Y']","['*Autism Spectrum Disorder/drug therapy', '*Autistic Disorder', 'Bumetanide/pharmacology', 'Child', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/33385505/
706,bumetanide,34860628,Long-term bumetanide administration altered behavioral pattern in mosaic Down's Syndrome: A case report.,"['Gharaylou Z', 'Shafaghi L', 'Pestehei SK', 'Hadjighassem M']","['Humans', '*Down Syndrome/complications', 'Bumetanide/pharmacology', 'Trisomy', 'Mosaicism']",https://pubmed.ncbi.nlm.nih.gov/34860628/
707,bumetanide,35292925,A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.,"['Georgoula C', 'Ferrin M', 'Pietraszczyk-Kedziora B', 'Hervas A', 'Marret S', 'Oliveira G', 'Rosier A', 'Crutel V', 'Besse E', 'Severo CA', 'Ravel D', 'Fuentes J']","['Humans', 'Child', 'Male', 'Adolescent', 'Female', '*Autism Spectrum Disorder/drug therapy', 'Bumetanide/adverse effects', '*Autistic Disorder/diagnosis', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35292925/
708,bumetanide,3330836,Loop diuretics.,"['Greger R', 'Wangemann P']","['Animals', 'Bumetanide/pharmacology', 'Diuresis/drug effects', '*Diuretics/pharmacology', 'Dose-Response Relationship, Drug', 'Furosemide/pharmacology', 'Humans', 'Kidney/*physiology', 'Sodium Chloride/metabolism', 'Structure-Activity Relationship', 'Sulfonamides/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3330836/
709,bumetanide,6872415,Bumetanide and furosemide.,"['Brater DC', 'Chennavasin P', 'Day B', 'Burdette A', 'Anderson S']","['Administration, Oral', 'Biological Availability', 'Bumetanide/administration & dosage/*urine', 'Diuretics/*urine', 'Dose-Response Relationship, Drug', 'Furosemide/administration & dosage/*urine', 'Humans', 'Injections, Intravenous', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6872415/
710,bumetanide,9158273,Frusemide-induced bullous pemphigoid.,"['Panayiotou BN', 'Prasad MV', 'Zaman MN']","['Aged', 'Bumetanide/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Female', 'Furosemide/*adverse effects', 'Humans', 'Male', 'Pemphigoid, Bullous/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9158273/
711,bumetanide,35657748,Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine.,"['Catry E', 'Colsoul ML', 'Closset M', 'Hubert J', 'Soumoy L', 'Bihin B', 'Thiry E', 'Jamart J', 'Hecq JD', 'Galanti L']","['*Bumetanide', 'Chromatography, High Pressure Liquid', 'Drug Stability', 'Drug Storage', 'Humans', 'Pharmaceutical Preparations', '*Polypropylenes/chemistry', 'Scopolamine', 'Syringes']",https://pubmed.ncbi.nlm.nih.gov/35657748/
712,busulfan,27481448,Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.,"['Palmer J', 'McCune JS', 'Perales MA', 'Marks D', 'Bubalo J', 'Mohty M', 'Wingard JR', 'Paci A', 'Hassan M', 'Bredeson C', 'Pidala J', 'Shah N', 'Shaughnessy P', 'Majhail N', 'Schriber J', 'Savani BN', 'Carpenter PA']","['Busulfan/*administration & dosage', 'Hematopoietic Stem Cell Transplantation/methods', 'Humans', 'Myeloablative Agonists/therapeutic use', 'Precision Medicine/*methods', 'Transplantation Conditioning/*methods']",https://pubmed.ncbi.nlm.nih.gov/27481448/
713,busulfan,27746112,"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.","['Bartelink IH', 'Lalmohamed A', 'van Reij EM', 'Dvorak CC', 'Savic RM', 'Zwaveling J', 'Bredius RG', 'Egberts AC', 'Bierings M', 'Kletzel M', 'Shaw PJ', 'Nath CE', 'Hempel G', 'Ansari M', 'Krajinovic M', 'Theoret Y', 'Duval M', 'Keizer RJ', 'Bittencourt H', 'Hassan M', 'Gungor T', 'Wynn RF', 'Veys P', 'Cuvelier GD', 'Marktel S', 'Chiesa R', 'Cowan MJ', 'Slatter MA', 'Stricherz MK', 'Jennissen C', 'Long-Boyle JR', 'Boelens JJ']","['Adolescent', 'Adult', '*Area Under Curve', 'Busulfan/*administration & dosage/*pharmacokinetics/therapeutic use/toxicity', 'Child', 'Child, Preschool', 'Cohort Studies', 'Disease-Free Survival', '*Dose-Response Relationship, Drug', 'Female', 'Graft Rejection/epidemiology', 'Graft Survival/drug effects', 'Graft vs Host Disease/epidemiology', 'Hematopoietic Stem Cell Transplantation/*adverse effects/*mortality', 'Humans', 'Infant', 'Male', 'Recurrence', 'Retrospective Studies', 'Transplantation Conditioning/adverse effects/*methods', 'Transplantation, Homologous/*adverse effects/*mortality', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27746112/
714,busulfan,20836619,High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.,"['Glowka FK', 'Romanski M', 'Wachowiak J']","['Antineoplastic Agents, Alkylating/administration & dosage/adverse effects/chemistry/pharmacokinetics', 'Busulfan/administration & dosage/adverse effects/*analogs & derivatives/chemistry/pharmacokinetics', 'Clinical Trials as Topic', 'Drug Interactions', 'Drug Therapy, Combination', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Myeloablative Agonists/*administration & dosage/adverse effects/chemistry/pharmacokinetics', '*Transplantation Conditioning']",https://pubmed.ncbi.nlm.nih.gov/20836619/
715,busulfan,6576177,Busulfan-induced hemorrhagic cystitis.,"['Pode D', 'Perlberg S', 'Steiner D']","['Adult', 'Busulfan/administration & dosage/*adverse effects', 'Cystitis/*chemically induced', 'Female', 'Hemorrhage/*chemically induced', 'Humans', 'Leukemia, Myeloid/drug therapy', 'Time Factors', 'Urinary Bladder Diseases/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/6576177/
716,busulfan,18978748,Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.,"['Glowka FK', 'Karazniewicz-Lada M', 'Grund G', 'Wrobel T', 'Wachowiak J']","['Adolescent', 'Antineoplastic Agents, Alkylating/*pharmacokinetics', 'Busulfan/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Female', 'Half-Life', 'Hematologic Neoplasms/*therapy', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Injections, Intravenous', 'Male', 'Transplantation Conditioning/*methods', 'Transplantation, Homologous']",https://pubmed.ncbi.nlm.nih.gov/18978748/
717,busulfan,1403036,High-dose busulfan in patients with myeloma.,"['Mansi J', 'da Costa F', 'Viner C', 'Judson I', 'Gore M', 'Cunningham D']","['Adult', 'Bone Marrow Transplantation', 'Busulfan/administration & dosage/adverse effects/*therapeutic use', 'Combined Modality Therapy', 'Creatinine/blood', 'Female', 'Hematologic Diseases/chemically induced', 'Humans', 'Male', 'Melphalan/therapeutic use', 'Middle Aged', 'Multiple Myeloma/blood/*drug therapy/surgery', 'Pilot Projects', 'Remission Induction', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/1403036/
718,busulfan,8599861,Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.,"['Bhagwatwar HP', 'Phadungpojna S', 'Chow DS', 'Andersson BS']","['Acetamides', 'Animals', 'Antineoplastic Agents, Alkylating/administration & dosage/*chemistry/pharmacokinetics/pharmacology', 'Busulfan/administration & dosage/*chemistry/pharmacokinetics/pharmacology', 'Cell Survival/drug effects', 'Chemistry, Pharmaceutical', 'Drug Stability', 'HL-60 Cells', 'Hemolysis', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Male', 'Osmolar Concentration', 'Polyethylene Glycols', 'Rats', 'Solubility', 'Solvents', 'Water']",https://pubmed.ncbi.nlm.nih.gov/8599861/
719,busulfan,36039450,Treosulfan-based Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Adults With Primary Immunodeficiency: A Case Series.,"['Dalla Via V', 'Stelmes A', 'Recher M', 'Arranto C', 'Junker T', 'Matteazzi F', 'Heim D', 'Passweg JR', 'Medinger M', 'van den Berg J']","['Adult', '*Busulfan/analogs & derivatives/therapeutic use', 'Female', 'Graft vs Host Disease/etiology/prevention & control', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Humans', 'Male', 'Middle Aged', '*Primary Immunodeficiency Diseases/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/36039450/
720,busulfan,33128207,Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.,"['Lawson R', 'Staatz CE', 'Fraser CJ', 'Hennig S']","['Administration, Intravenous', 'Body Weight', '*Busulfan/pharmacokinetics/pharmacology', 'Child', 'Genotype', '*Hematopoietic Stem Cell Transplantation', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/33128207/
721,busulfan,26292764,Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.,"['Lombardi LR', 'Kanakry CG', 'Zahurak M', 'Durakovic N', 'Bolanos-Meade J', 'Kasamon YL', 'Gladstone DE', 'Matsui W', 'Borrello I', 'Huff CA', 'Swinnen LJ', 'Brodsky RA', 'Ambinder RF', 'Fuchs EJ', 'Rosner GL', 'Jones RJ', 'Luznik L']","['Adult', 'Aged', 'Busulfan/*administration & dosage/adverse effects/pharmacokinetics', 'Cyclophosphamide/*administration & dosage/adverse effects/pharmacokinetics', '*Drug Monitoring', 'Female', 'Graft vs Host Disease/etiology', 'Hematologic Neoplasms/diagnosis/mortality/therapy', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Retrospective Studies', '*Transplantation Conditioning', 'Transplantation, Homologous', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26292764/
722,busulfan,22732703,"Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.","['Kebriaei P', 'Madden T', 'Wang X', 'Thall PF', 'Ledesma C', 'de Lima M', 'Shpall EJ', 'Hosing C', 'Qazilbash M', 'Popat U', 'Alousi A', 'Nieto Y', 'Champlin RE', 'Jones RB', 'Andersson BS']","['Adult', 'Age Factors', 'Antineoplastic Agents, Alkylating/administration & dosage/adverse effects/*therapeutic use', 'Busulfan/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination/adverse effects', 'Female', 'Follow-Up Studies', 'Graft vs Host Disease/epidemiology/etiology/prevention & control', 'Hematopoietic Stem Cell Transplantation/*adverse effects', 'Humans', 'Incidence', 'Infusions, Intravenous', 'Male', 'Melphalan/adverse effects/*therapeutic use', 'Middle Aged', 'Myeloablative Agonists/administration & dosage/adverse effects/*therapeutic use', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/prevention & control/*therapy', 'Secondary Prevention', 'Survival Analysis', 'Texas', '*Transplantation Conditioning/adverse effects', 'Transplantation, Homologous', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22732703/
723,busulfan,9720736,Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.,"['Schuler US', 'Ehrsam M', 'Schneider A', 'Schmidt H', 'Deeg J', 'Ehninger G']","['Administration, Oral', 'Adult', 'Animals', 'Biological Availability', 'Busulfan/*administration & dosage/adverse effects/*pharmacokinetics', 'Dimethyl Sulfoxide', 'Dogs', '*Hematopoietic Stem Cell Transplantation', 'Hepatic Veno-Occlusive Disease/chemically induced', 'Humans', 'Immunosuppressive Agents/*administration & dosage/adverse effects/*pharmacokinetics', 'Injections, Intravenous', 'Leukemia/therapy', 'Middle Aged', 'Multiple Myeloma/therapy', 'Solutions', 'Transplantation Conditioning/*methods']",https://pubmed.ncbi.nlm.nih.gov/9720736/
724,busulfan,12665836,The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.,"['Nilsson C', 'Aschan J', 'Hentschke P', 'Ringden O', 'Ljungman P', 'Hassan M']","['Adolescent', 'Adult', 'Busulfan/adverse effects/*pharmacokinetics', 'Drug Interactions', 'Female', 'Graft vs Host Disease/prevention & control', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Immunosuppressive Agents/adverse effects/*pharmacokinetics', 'Liver/drug effects/physiology', 'Male', 'Metronidazole/*therapeutic use', 'Middle Aged', 'Radiation-Sensitizing Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12665836/
725,busulfan,30626239,Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?,"['Jain T', 'Kunze KL', 'Khetarpal BK', 'McCallen MR', 'Betcher JA', 'Ofori HT', 'Khera N', 'Slack JL', 'Leis JF', 'Sproat LZ', 'Noel P', 'Palmer J']","['Adult', 'Aged', 'Busulfan/*administration & dosage/*pharmacokinetics', 'Drug Monitoring', 'Female', 'Graft Survival', 'Graft vs Host Disease/diagnosis/etiology/prevention & control', '*Hematopoietic Stem Cell Transplantation/adverse effects/methods', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Myeloablative Agonists/*administration & dosage/*pharmacokinetics', 'Prognosis', 'Recurrence', '*Transplantation Conditioning/adverse effects/methods', 'Transplantation, Homologous', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30626239/
726,busulfan,10673681,Busulfan clearance in renal failure and hemodialysis.,"['Ullery LL', 'Gibbs JP', 'Ames GW', 'Senecal FM', 'Slattery JT']","['Administration, Oral', 'Biological Availability', 'Blood Transfusion, Autologous', 'Busulfan/administration & dosage/*pharmacokinetics/therapeutic use', 'Hematopoietic Stem Cell Transplantation', 'Humans', 'Kidney Failure, Chronic/complications/*metabolism/physiopathology/therapy', 'Lymphoma, Non-Hodgkin/complications/*metabolism/therapy', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', '*Renal Dialysis', 'Time Factors', '*Transplantation Conditioning/methods']",https://pubmed.ncbi.nlm.nih.gov/10673681/
727,busulfan,36939456,Individualizing busulfan dose in specific populations and evaluating the risk of pharmacokinetic drug-drug interactions.,"['Combarel D', 'Tran J', 'Delahousse J', 'Vassal G', 'Paci A']","['Child', 'Humans', '*Busulfan/pharmacokinetics', '*Hematopoietic Stem Cell Transplantation/methods', 'Drug Interactions', 'Drug Monitoring/methods', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/36939456/
728,busulfan,2653511,Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation.,['Santos GW'],"['Bone Marrow/pathology', '*Bone Marrow Transplantation', 'Busulfan/adverse effects/*therapeutic use', 'Cyclophosphamide/adverse effects/*therapeutic use', 'Evaluation Studies as Topic', 'Humans', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery', 'Leukemia, Myeloid, Acute/*surgery', 'Neoplastic Stem Cells/drug effects', '*Preoperative Care', 'Transplantation, Autologous', 'Transplantation, Homologous']",https://pubmed.ncbi.nlm.nih.gov/2653511/
729,busulfan,589308,Acute leukaemia after busulphan.,"['Stott H', 'Fox W', 'Girling DJ', 'Stephens RJ', 'Galton DA']","['Acute Disease', 'Bronchial Neoplasms/drug therapy/radiotherapy', 'Busulfan/*adverse effects/therapeutic use', 'Cyclophosphamide/therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Leukemia/*chemically induced', 'Neoplasms, Multiple Primary', 'Pancytopenia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/589308/
730,busulfan,2070145,High dose busulfan and seizures.,"['De La Camara R', 'Tomas JF', 'Figuera A', 'Berberana M', 'Fernandez-Ranada JM']","['Adult', 'Bone Marrow Transplantation/adverse effects', 'Busulfan/*adverse effects/pharmacology', 'Dose-Response Relationship, Drug', 'Female', 'Graft Rejection/drug effects', 'Humans', 'Male', 'Seizures/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2070145/
731,busulfan,26419450,Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.,"['Choi B', 'Kim MG', 'Han N', 'Kim T', 'Ji E', 'Park S', 'Kim IW', 'Oh JM']","['Adolescent', 'Adult', 'Algorithms', 'Area Under Curve', 'Busulfan/administration & dosage/*pharmacokinetics/therapeutic use', 'Female', 'Gene Deletion', 'Genotype', 'Glutathione Transferase/*genetics', 'Graft vs Host Disease/immunology/prevention & control', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Immunosuppressive Agents/administration & dosage/*pharmacokinetics/therapeutic use', 'Male', 'Middle Aged', 'Models, Statistical', 'Polymorphism, Genetic/genetics', 'Population', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26419450/
732,caffeine,31818639,Impacts of Caffeine during Pregnancy.,"['Qian J', 'Chen Q', 'Ward SM', 'Duan E', 'Zhang Y']","['Animals', 'Caffeine/*pharmacology', 'Epigenesis, Genetic/*drug effects', 'Female', 'Humans', 'Maternal Nutritional Physiological Phenomena/physiology', 'Pregnancy/*drug effects/physiology', 'Prenatal Exposure Delayed Effects/chemically induced/*genetics']",https://pubmed.ncbi.nlm.nih.gov/31818639/
733,caffeine,26074744,Caffeine: cognitive and physical performance enhancer or psychoactive drug?,"['Cappelletti S', 'Piacentino D', 'Sani G', 'Aromatario M']","['Athletic Performance', 'Caffeine/adverse effects/pharmacokinetics/*pharmacology', 'Central Nervous System Stimulants/*pharmacology', 'Drug Utilization', 'Humans', 'Nootropic Agents/*pharmacology', 'Substance-Related Disorders/epidemiology/mortality']",https://pubmed.ncbi.nlm.nih.gov/26074744/
734,caffeine,33388079,International society of sports nutrition position stand: caffeine and exercise performance.,"['Guest NS', 'VanDusseldorp TA', 'Nelson MT', 'Grgic J', 'Schoenfeld BJ', 'Jenkins NDM', 'Arent SM', 'Antonio J', 'Stout JR', 'Trexler ET', 'Smith-Ryan AE', 'Goldstein ER', 'Kalman DS', 'Campbell BI']","['Anxiety/chemically induced/genetics', 'Athletic Performance/physiology', 'Caffeine/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Capsules', 'Chewing Gum', 'Cognition/drug effects', 'Cytochrome P-450 CYP1A2/genetics/metabolism', 'Doping in Sports', 'Drug Dosage Calculations', 'Energy Drinks', 'Exercise/*physiology', 'Hot Temperature', 'Humans', 'Movement/drug effects/physiology', 'Muscle Strength/drug effects/physiology', 'Muscle, Skeletal/drug effects/physiology', 'Performance-Enhancing Substances/pharmacology', 'Physical Endurance/drug effects/physiology', 'Physical Functional Performance', 'Receptor, Adenosine A2A/genetics/metabolism', 'Sleep/drug effects', '*Societies, Medical', '*Sports Nutritional Physiological Phenomena', '*Sports Nutritional Sciences']",https://pubmed.ncbi.nlm.nih.gov/33388079/
735,caffeine,30301595,Cardiovascular effects of caffeinated beverages.,"['Voskoboinik A', 'Koh Y', 'Kistler PM']","['Administration, Oral', 'Animals', 'Caffeine/*administration & dosage/adverse effects', 'Cardiovascular Diseases/diagnosis/*epidemiology/physiopathology/prevention & control', 'Cardiovascular System/*drug effects/physiopathology', 'Central Nervous System Stimulants/*administration & dosage/adverse effects', '*Coffee/adverse effects', '*Energy Drinks/adverse effects', 'Humans', 'Prognosis', 'Protective Factors', 'Recommended Dietary Allowances', 'Risk Assessment', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/30301595/
736,caffeine,28446037,"Caffeine, coffee, and appetite control: a review.","['Schubert MM', 'Irwin C', 'Seay RF', 'Clarke HE', 'Allegro D', 'Desbrow B']","['Appetite/*drug effects', 'Caffeine/*pharmacology', '*Coffee', 'Energy Intake/drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/28446037/
737,caffeine,30977054,Caffeine and Exercise: What Next?,"['Pickering C', 'Grgic J']","['Adaptation, Physiological', 'Athletes', 'Athletic Performance', 'Caffeine/administration & dosage/*pharmacology', 'Circadian Rhythm', '*Exercise', 'Genotype', 'Humans', 'Performance-Enhancing Substances/administration & dosage/*pharmacology', 'Sex Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/30977054/
738,caffeine,32589582,"Caffeine effects on systemic metabolism, oxidative-inflammatory pathways, and exercise performance.","['Barcelos RP', 'Lima FD', 'Carvalho NR', 'Bresciani G', 'Royes LF']","['Athletic Performance', 'Caffeine/administration & dosage/metabolism/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/pharmacology', 'Exercise/*physiology', 'Humans', 'Inflammation/*physiopathology', 'Metabolism/*drug effects', 'Oxidation-Reduction/drug effects', 'Oxidative Stress/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32589582/
739,caffeine,23075568,Caffeine's mechanisms of action and its cosmetic use.,"['Herman A', 'Herman AP']","['Animals', 'Antioxidants/pharmacology/therapeutic use', 'Blood Vessels/drug effects/physiology', 'Caffeine/*pharmacology/therapeutic use', 'Cosmetics/*pharmacology/therapeutic use', 'Hair/drug effects/growth & development', 'Humans', 'Lipodystrophy/drug therapy', 'Microcirculation/drug effects', 'Skin Absorption/drug effects']",https://pubmed.ncbi.nlm.nih.gov/23075568/
740,caffeine,36447122,Mental Performance and Sport: Caffeine and Co-consumed Bioactive Ingredients.,"['Kennedy DO', 'Wightman EL']","['Humans', 'Caffeine/pharmacology', 'Plant Extracts/pharmacology', '*Paullinia', '*Cacao', 'Attention']",https://pubmed.ncbi.nlm.nih.gov/36447122/
741,caffeine,28317317,The neuroprotective effects of caffeine in neurodegenerative diseases.,"['Kolahdouzan M', 'Hamadeh MJ']","['Animals', 'Caffeine/*therapeutic use', 'Humans', 'Neurodegenerative Diseases/*prevention & control', 'Neuroprotective Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28317317/
742,caffeine,33050315,Effect of Caffeine Consumption on the Risk for Neurological and Psychiatric Disorders: Sex Differences in Human.,"['Jee HJ', 'Lee SG', 'Bormate KJ', 'Jung YS']","['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Caffeine/*administration & dosage/*adverse effects/poisoning/therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Male', 'Mental Disorders/*etiology/*prevention & control', 'Middle Aged', 'Nervous System Diseases/*etiology/*prevention & control', '*Risk Assessment', 'Risk Factors', '*Sex Characteristics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33050315/
743,caffeine,29368182,Administration of Caffeine in Alternate Forms.,"['Wickham KA', 'Spriet LL']","['Athletes', 'Athletic Performance/*physiology', 'Bicycling', 'Caffeine/*administration & dosage/*pharmacology', 'Central Nervous System Stimulants/*administration & dosage', '*Chewing Gum', 'Female', 'Humans', 'Mouthwashes/administration & dosage/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/29368182/
744,caffeine,19774754,Caffeine ingestion and fluid balance: a review.,"['Maughan RJ', 'Griffin J']","['Beverages', 'Caffeine/administration & dosage/*pharmacology', 'Central Nervous System Agents/administration & dosage/*pharmacology', 'Coffee', 'Diuresis/*drug effects', 'Diuretics/administration & dosage/*pharmacology', 'Dose-Response Relationship, Drug', 'Drinking', 'Humans', 'Plant Extracts/administration & dosage/*pharmacology', 'Tea', 'Urination/*drug effects', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/19774754/
745,caffeine,30640237,Caffeine Intake Habits and the Perception of Its Effects on Health Among College Students.,"['Bucher J', 'Fitzpatrick D', 'Swanson AG', 'Abraham SP']","['Adult', 'Beverages/*statistics & numerical data', '*Caffeine/administration & dosage/adverse effects', 'Cross-Sectional Studies', '*Feeding Behavior', 'Female', '*Health Knowledge, Attitudes, Practice', 'Health Status', 'Humans', 'Indiana', 'Male', 'Review Literature as Topic', 'Students/*psychology/statistics & numerical data', 'Surveys and Questionnaires', 'Universities', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30640237/
746,caffeine,17724925,"[Caffeine: a nutrient, a drug or a drug of abuse].","['Pardo Lozano R', 'Alvarez Garcia Y', 'Barral Tafalla D', 'Farre Albaladejo M']","['Caffeine/adverse effects/*pharmacology', 'Cytochrome P-450 Enzyme System/metabolism', '*Food', 'Humans', 'Spain/epidemiology', 'Substance-Related Disorders/epidemiology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/17724925/
747,caffeine,34291426,Effects of Caffeine on Resistance Exercise: A Review of Recent Research.,['Grgic J'],"['Caffeine/pharmacology', 'Exercise', 'Female', 'Humans', 'Male', '*Performance-Enhancing Substances', 'Physical Endurance', '*Resistance Training']",https://pubmed.ncbi.nlm.nih.gov/34291426/
748,caffeine,34578966,Caffeine as a Factor Influencing the Functioning of the Human Body-Friend or Foe?,"['Rodak K', 'Kokot I', 'Kratz EM']","['Adolescent', 'Adult', 'Analgesics', 'Animals', 'Antioxidants', 'Caffeine/*adverse effects/pharmacokinetics/*pharmacology', 'Cardiovascular System/drug effects', 'Central Nervous System Stimulants', 'Child', 'Digestive System/drug effects', 'Humans', 'Immune System/drug effects', 'Mental Disorders/drug therapy', 'Neurodegenerative Diseases/drug therapy', 'Receptors, Purinergic P1', 'Respiratory System/drug effects', 'Urinary Tract/drug effects']",https://pubmed.ncbi.nlm.nih.gov/34578966/
749,caffeine,19077738,Effect of caffeine on sport-specific endurance performance: a systematic review.,"['Ganio MS', 'Klau JF', 'Casa DJ', 'Armstrong LE', 'Maresh CM']","['*Athletic Performance', 'Caffeine/*administration & dosage', 'Central Nervous System Stimulants/*administration & dosage', 'Female', 'Humans', 'Male', 'Muscle, Skeletal/drug effects', 'Physical Education and Training', 'Physical Endurance/*drug effects', 'Sensitivity and Specificity', 'Sports/*physiology']",https://pubmed.ncbi.nlm.nih.gov/19077738/
750,caffeine,23039391,Hypnic headache and caffeine.,"['Holle D', 'Obermann M']","['Animals', 'Caffeine/administration & dosage/adverse effects/*therapeutic use', 'Headache Disorders, Primary/diet therapy/etiology/*prevention & control', 'Humans', 'Hypothalamus/metabolism', 'Neurons/metabolism']",https://pubmed.ncbi.nlm.nih.gov/23039391/
751,caffeine,28845841,Caffeinated energy drink consumption among adolescents and potential health consequences associated with their use: a significant public health hazard.,"['De Sanctis V', 'Soliman N', 'Soliman AT', 'Elsedfy H', 'Di Maio S', 'El Kholy M', 'Fiscina B']","['Adolescent', 'Caffeine/*adverse effects', 'Energy Drinks/*adverse effects/analysis', 'Humans', 'Patient Education as Topic', 'Puberty', '*Public Health']",https://pubmed.ncbi.nlm.nih.gov/28845841/
752,candesartan,10914449,Angiotensin receptor antagonists.,"['Wong W', 'Howes L']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/therapeutic use', 'Benzoates/adverse effects/pharmacology/therapeutic use', 'Biphenyl Compounds/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/adverse effects/pharmacology/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10914449/
753,candesartan,38861046,Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.,"['Zhang Z', 'Yang H', 'Guo H']","['Humans', '*Angiotensin Receptor Antagonists/therapeutic use/adverse effects/administration & dosage', '*Antihypertensive Agents/therapeutic use/adverse effects', 'Blood Pressure/drug effects', '*Hypertension/drug therapy', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38861046/
754,candesartan,15592574,Candesartan.,"['Gleiter CH', 'Jagle C', 'Gresser U', 'Morike K']","['Angiotensin Receptor Antagonists', 'Animals', 'Benzimidazoles/chemistry/*pharmacology/*therapeutic use', 'Biphenyl Compounds', 'Germany', 'Humans', 'Randomized Controlled Trials as Topic', 'Receptors, Angiotensin/therapeutic use', 'Tetrazoles/chemistry/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15592574/
755,candesartan,28841231,Noncholestatic acute hepatocellular injury following candesartan administration.,"['Lammel-Lindemann JA', 'Flores-Villalba E', 'Martagon AJ', 'DeObeso-Gonzalez E', 'Puente-Gallegos F']","['Adult', 'Amlodipine/therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/*adverse effects', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*adverse effects', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Chemical and Drug Induced Liver Injury/blood/*diagnosis/etiology', 'Dose-Response Relationship, Drug', 'Humans', 'Hypertension/blood/*drug therapy', 'Liver Function Tests', 'Male', 'Tetrazoles/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28841231/
756,candesartan,16451099,Indapamide sustained release: a review of its use in the treatment of hypertension.,"['Robinson DM', 'Wellington K']","['Animals', 'Antihypertensive Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Diuretics/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Indapamide/*administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16451099/
757,candesartan,13678870,Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.,"['Granger CB', 'McMurray JJ', 'Yusuf S', 'Held P', 'Michelson EL', 'Olofsson B', 'Ostergren J', 'Pfeffer MA', 'Swedberg K']","['Aged', 'Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/*therapeutic use', 'Biphenyl Compounds', 'Cardiac Output, Low/drug therapy/epidemiology', 'Comorbidity', 'Cough/chemically induced', 'Female', 'Follow-Up Studies', 'Heart Failure/*drug therapy/epidemiology', 'Humans', 'Hypotension/chemically induced', 'Kidney Diseases/chemically induced', 'Male', 'Tetrazoles/*therapeutic use', 'Treatment Outcome', 'Ventricular Dysfunction, Left/*drug therapy/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/13678870/
758,candesartan,17020420,Candesartan for the management of heart failure: more than an alternative.,['McKelvie RS'],"['Angiotensin II Type 1 Receptor Blockers/metabolism/pharmacokinetics/*therapeutic use', 'Benzimidazoles/metabolism/pharmacokinetics/*therapeutic use', 'Biphenyl Compounds', 'Clinical Trials as Topic', 'Heart Failure/*drug therapy', 'Humans', 'Stroke Volume/drug effects', 'Tetrazoles/metabolism/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17020420/
759,candesartan,15969893,Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.,"['Bonner G', 'Fuchs W']","['*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Benzimidazoles/pharmacokinetics/pharmacology/*therapeutic use', 'Biphenyl Compounds/pharmacokinetics/pharmacology/*therapeutic use', 'Blood Pressure/*drug effects', 'Female', 'Germany', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Tetrazoles/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15969893/
760,candesartan,16230887,"Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.","['Bhatia V', 'Bhatia R', 'Mathew B']","['Adrenergic beta-Antagonists/therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Benzimidazoles/therapeutic use', 'Biphenyl Compounds', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Drug Therapy, Combination', 'Heart Failure/*drug therapy', 'Humans', 'Losartan/therapeutic use', 'Mineralocorticoid Receptor Antagonists/therapeutic use', 'Tetrazoles/therapeutic use', 'Valine/analogs & derivatives/therapeutic use', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/16230887/
761,candesartan,27250611,[What are the effects of fixed-dose combination of candesartan and amlodipine].,"['Vitovec J', 'Spinar J']","['Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Drug Combinations', 'Humans', 'Hypertension/drug therapy', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27250611/
762,candesartan,31732254,Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.,"['Ni S', 'Chen X', 'Yu Q', 'Xu Y', 'Hu Z', 'Zhang J', 'Zhang W', 'Li B', 'Yang X', 'Mao F', 'Huang J', 'Sun Y', 'Li J', 'Jia L']","['A549 Cells', 'Animals', 'Antineoplastic Agents/administration & dosage/chemistry/*pharmacology', 'Benzimidazoles/administration & dosage/chemistry/*pharmacology', 'Biphenyl Compounds/administration & dosage/chemistry/*pharmacology', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', '*Drug Discovery', 'Drug Screening Assays, Antitumor', 'Female', 'Humans', 'Injections, Intraperitoneal', 'Injections, Subcutaneous', 'Mice', 'Mice, Nude', 'Molecular Structure', 'Neoplasms, Experimental/drug therapy/pathology', 'Structure-Activity Relationship', 'Tetrazoles/administration & dosage/chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/31732254/
763,candesartan,30265168,"The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study.","['Sundstrom J', 'Lind L', 'Nowrouzi S', 'Lytsy P', 'Marttala K', 'Ekman I', 'Ohagen P', 'Ostlund O']","['Adult', 'Aged', 'Amlodipine/administration & dosage', 'Antihypertensive Agents/administration & dosage', 'Benzimidazoles/administration & dosage', 'Biomarkers/metabolism', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Blood Pressure Determination', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage', 'Hypertension/epidemiology/*therapy', 'Lisinopril/administration & dosage', 'Male', 'Middle Aged', '*Precision Medicine', 'Randomized Controlled Trials as Topic', 'Research Design', 'Risk Factors', 'Tetrazoles/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30265168/
764,candesartan,38418298,Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure.,"['Hanna SM', 'Rabea HM', 'Abdelrahim MEA', 'Mahmoud HB']","['Humans', '*Amlodipine/adverse effects', 'Valsartan/pharmacology/therapeutic use', 'Blood Pressure', '*Hypertension/drug therapy', 'Prospective Studies', 'Valine/pharmacology/therapeutic use', 'Antihypertensive Agents/adverse effects', 'Tetrazoles/adverse effects', 'Drug Therapy, Combination', '*Benzimidazoles', '*Biphenyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/38418298/
765,candesartan,10980901,Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.,"['Ennezat PV', 'Berlowitz M', 'Sonnenblick EH', 'Le Jemtel TH']","['Angiotensin-Converting Enzyme Inhibitors/*administration & dosage', 'Animals', 'Antihypertensive Agents/therapeutic use', 'Benzimidazoles/therapeutic use', 'Biphenyl Compounds', 'Drug Therapy, Combination', 'Enalapril/administration & dosage/therapeutic use', 'Heart Failure/*drug therapy/physiopathology', 'Humans', 'Randomized Controlled Trials as Topic', 'Tetrazoles/therapeutic use', 'Ventricular Dysfunction, Left/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/10980901/
766,candesartan,29701105,A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.,"['de Denus S', 'Dube MP', 'Fouodjio R', 'Huynh T', 'LeBlanc MH', 'Lepage S', 'Sheppard R', 'Giannetti N', 'Lavoie J', 'Mansour A', 'Provost S', 'Normand V', 'Mongrain I', 'Langlois M', ""O'Meara E"", 'Ducharme A', 'Racine N', 'Guertin MC', 'Turgeon J', 'Phillips MS', 'Rouleau JL', 'Tardif JC', 'White M']","['Aged', 'Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Biomarkers/blood', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Female', 'Heart Failure/blood/*drug therapy/genetics', 'Humans', 'Kidney Function Tests', 'Male', 'Natriuretic Peptide, Brain/blood', 'Peptide Fragments/blood', 'Pharmacogenetics', '*Polymorphism, Single Nucleotide', 'Prospective Studies', 'Receptor, Angiotensin, Type 1/*genetics', 'Renin-Angiotensin System/*drug effects/genetics', 'Tetrazoles/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29701105/
767,candesartan,17339065,Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.,"['Garcia Donaire JA', 'Ruilope LM']","['Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Diabetic Angiopathies/prevention & control', 'Diabetic Nephropathies/*drug therapy/epidemiology/*prevention & control', 'Glomerular Filtration Rate/drug effects', 'Humans', 'Hypertension/prevention & control', 'Kidney Failure, Chronic/prevention & control', 'Renal Circulation/drug effects/physiology', 'Tetrazoles/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17339065/
768,candesartan,21421652,A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.,"['Zhenfeng Zheng', 'Huilan Shi', 'Junya Jia', 'Dong Li', 'Shan Lin']","['Antihypertensive Agents/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Losartan/adverse effects/pharmacology/*therapeutic use', 'Publication Bias', 'Regression Analysis', 'Tetrazoles/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21421652/
769,candesartan,10073836,Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators.,"['Bell TP', 'DeQuattro V', 'Lasseter KC', 'Ruff D', 'Hardison JD', 'Cushing D', 'Kezer AE', 'Michelson EL']","['Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds/*administration & dosage', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Posture', 'Prodrugs/administration & dosage', '*Tetrazoles']",https://pubmed.ncbi.nlm.nih.gov/10073836/
770,candesartan,19101048,"Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery: comment on: Mehmet Ozaydin et al. ""Effect of renin-angiotensin aldosterone system blockers on postoperative atrial fibrillation"".","['Mariscalco G', 'Dominici C', 'Banach M', 'Sala A']","['Angiotensin II Type 1 Receptor Blockers/administration & dosage', 'Angiotensin-Converting Enzyme Inhibitors/*administration & dosage', 'Atrial Fibrillation/*drug therapy/etiology/metabolism', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Cardiac Surgical Procedures/*adverse effects', 'Humans', 'Mineralocorticoid Receptor Antagonists/administration & dosage', 'Postoperative Complications/*drug therapy/etiology/metabolism', 'Prospective Studies', 'Renin-Angiotensin System/*drug effects/physiology', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/19101048/
771,candesartan,27651039,Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus.,"['Karashima S', 'Yoneda T', 'Kometani M', 'Ohe M', 'Mori S', 'Sawamura T', 'Furukawa K', 'Yamagishi M', 'Takeda Y']","['Adult', 'Aged', 'Angiotensin Receptor Antagonists/administration & dosage', 'Antihypertensive Agents/administration & dosage', '*Benzimidazoles/administration & dosage/adverse effects', 'Biphenyl Compounds', 'Blood Pressure/*drug effects', '*Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy', 'Drug Monitoring/methods', 'Drug Therapy, Combination/methods', 'Eplerenone', 'Essential Hypertension', 'Female', 'Glycated Hemoglobin/analysis', 'Humans', '*Hydrochlorothiazide/administration & dosage/adverse effects', 'Hypertension/complications/diagnosis/drug therapy', 'Male', 'Middle Aged', 'Mineralocorticoid Receptor Antagonists/administration & dosage', 'Spironolactone/administration & dosage/adverse effects/*analogs & derivatives', '*Tetrazoles/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27651039/
772,carisoprodol,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
773,carisoprodol,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
774,carisoprodol,8322081,Carisoprodol (Soma): a new and cautious perspective on an old agent.,"['Littrell RA', 'Hayes LR', 'Stillner V']","['Carisoprodol/*adverse effects/pharmacokinetics', 'Drug and Narcotic Control', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Substance-Related Disorders/*etiology']",https://pubmed.ncbi.nlm.nih.gov/8322081/
775,carisoprodol,22939305,Pharmacogenomics and the future of toxicology testing.,"['Agrawal YP', 'Rennert H']","['Autopsy', 'Databases, Genetic', 'Drug Labeling', 'Humans', 'Pharmaceutical Preparations/analysis/metabolism', 'Pharmacogenetics/*methods', 'Toxicity Tests/*methods']",https://pubmed.ncbi.nlm.nih.gov/22939305/
776,carisoprodol,2671968,Is this really a muscle cramp?,['Eaton JM'],"['Carisoprodol/therapeutic use', 'Electromyography', 'Humans', '*Muscle Cramp/diagnosis/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/2671968/
777,carisoprodol,15542749,Recent trends of drug abuse and drug-associated deaths in Korea.,"['Chung H', 'Park M', 'Hahn E', 'Choi H', 'Choi H', 'Lim M']","['Drug Overdose', 'Humans', '*Illicit Drugs', 'Korea/epidemiology', 'Poison Control Centers/statistics & numerical data/trends', 'Substance-Related Disorders/*mortality']",https://pubmed.ncbi.nlm.nih.gov/15542749/
778,carisoprodol,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
779,carisoprodol,27550152,The Pharmacology and Toxicology of the 'Holy Trinity'.,"['Horsfall JT', 'Sprague JE']","['Analgesics, Opioid/administration & dosage/*adverse effects', 'Animals', 'Benzodiazepines/administration & dosage/*adverse effects', 'Carisoprodol/administration & dosage/*adverse effects', 'Contraindications', 'Dopamine/metabolism', 'Drug Dosage Calculations', 'Drug Synergism', 'Drug Therapy, Combination', 'Euphoria/*drug effects', 'GABA Modulators/administration & dosage/*adverse effects', 'Humans', 'Neuromuscular Agents/administration & dosage/*adverse effects', 'Nucleus Accumbens/*drug effects/metabolism/physiopathology', 'Opioid-Related Disorders/metabolism/physiopathology/psychology', 'Practice Guidelines as Topic', 'Respiration/drug effects', 'Respiratory Insufficiency/*chemically induced/metabolism/physiopathology', 'Risk Assessment', 'Signal Transduction/drug effects', 'gamma-Aminobutyric Acid/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27550152/
780,carisoprodol,25018153,Somadril and edgework in South Sulawesi.,"['Hardon AP', 'Ihsan A']","['Carisoprodol/*administration & dosage', 'Developing Countries', 'Female', 'Humans', 'Indonesia', 'Male', 'Muscle Relaxants, Central/*administration & dosage', 'Self Medication', '*Sex Workers', 'Sexual Behavior/*psychology', 'Substance-Related Disorders/*psychology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25018153/
781,carisoprodol,8635759,Acute overdose of zolpidem.,"['Winek CL', 'Wahba WW', 'Janssen JK', 'Rozin L', 'Rafizadeh V']","['Aged', 'Drug Overdose', 'Fatal Outcome', 'Female', 'Humans', 'Hypnotics and Sedatives/blood/*poisoning', 'Pyridines/blood/*poisoning', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8635759/
782,carisoprodol,22687764,Postmortem drug concentration intervals for the non-intoxicated state - A review.,['Linnet K'],"['Dose-Response Relationship, Drug', 'Drug Stability', 'Drug Tolerance', '*Forensic Toxicology', 'Humans', 'Pharmaceutical Preparations/*blood', 'Pharmacokinetics', 'Postmortem Changes', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/22687764/
783,carisoprodol,1985650,Carbidopa-levodopa overdose.,['Sporer KA'],"['Acetaminophen/poisoning', 'Carbidopa/*poisoning', 'Carisoprodol/poisoning', 'Female', 'Humans', 'Hydrocodone/poisoning', 'Ibuprofen/poisoning', 'Levodopa/*poisoning', 'Middle Aged', 'Poisoning/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/1985650/
784,carisoprodol,2327059,Skeletal muscle relaxant ingestion.,"['Lebby TI', 'Dugger K', 'Lipscomb JW', 'Leikin JB']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Overdose', 'Humans', 'Infant', 'Infant, Newborn', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', 'Muscles/*drug effects', '*Poison Control Centers', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2327059/
785,carisoprodol,4894737,Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief.,"['Eddy NB', 'Friebel H', 'Hahn KJ', 'Halbach H']","['Amides/therapeutic use', 'Analgesics/therapeutic use', 'Animals', 'Antitussive Agents/therapeutic use', 'Azepines/therapeutic use', 'Carisoprodol/therapeutic use', 'Cats', 'Chickens', 'Codeine/*therapeutic use', 'Cough/*drug therapy', 'Cyclazocine/therapeutic use', 'Dextropropoxyphene/therapeutic use', 'Diphenylacetic Acids/therapeutic use', 'Dogs', 'Ducks', 'Guinea Pigs', 'Humans', 'Indenes/therapeutic use', 'Indoles/therapeutic use', 'Isoquinolines/therapeutic use', 'Mice', 'Morphinans/therapeutic use', 'Nalorphine/therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Pain/*drug therapy', 'Pentazocine/therapeutic use', 'Phenethylamines/therapeutic use', 'Pyrrolidines/therapeutic use', 'Rats', 'Substance-Related Disorders', 'Thalidomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4894737/
786,carisoprodol,29457627,Combination pharmacotherapy for the treatment of fibromyalgia in adults.,"['Thorpe J', 'Shum B', 'Moore RA', 'Wiffen PJ', 'Gilron I']","['5-Hydroxytryptophan/therapeutic use', 'Acetaminophen/therapeutic use', 'Adult', 'Amitriptyline/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Benzodiazepines/therapeutic use', 'Carisoprodol/therapeutic use', 'Drug Therapy, Combination/methods', 'Duloxetine Hydrochloride/therapeutic use', 'Fibromyalgia/*drug therapy', 'Fluoxetine/therapeutic use', 'Humans', 'Magnesium/therapeutic use', 'Malates/therapeutic use', 'Melatonin/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Muscle Relaxants, Central/therapeutic use', 'Pregabalin/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29457627/
787,carisoprodol,17896902,Is the frequency of carisoprodol withdrawal syndrome increasing?,"['Reeves RR', 'Hammer JS', 'Pendarvis RO']","['Adult', 'Anxiety/etiology', 'Carisoprodol/administration & dosage/*adverse effects/metabolism', 'Female', 'Hallucinations/etiology', 'Humans', 'Meprobamate/metabolism', 'Muscle Relaxants, Central/administration & dosage/adverse effects/metabolism', 'Self Administration', 'Sleep Initiation and Maintenance Disorders/etiology', 'Substance Withdrawal Syndrome/diagnosis/*etiology/metabolism', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/17896902/
788,carisoprodol,1097611,Carisoprodol in the treatment of myofascial pain-dysfunction syndrome.,"['Gallardo F', 'Molgo J', 'Miyazaki C', 'Rossi E']","['Adolescent', 'Adult', 'Aged', 'Carisoprodol/*therapeutic use', 'Clinical Trials as Topic', '*Facial Muscles', 'Female', 'Humans', 'Male', '*Masticatory Muscles', 'Middle Aged', 'Muscular Diseases/*drug therapy', 'Pain/*drug therapy', 'Placebos/therapeutic use', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/1097611/
789,carisoprodol,9439144,Carisoprodol: a drug of continuing abuse.,"['Reeves RR', 'Pinkofsky HB', 'Carter OS']","['Adult', 'Carisoprodol/*adverse effects', 'Drug Prescriptions', 'Drug and Narcotic Control', 'Female', 'Humans', 'Male', 'Muscle Relaxants, Central/*adverse effects', 'Substance Withdrawal Syndrome/*etiology', 'Substance-Related Disorders/*etiology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/9439144/
790,carisoprodol,20828952,Pharmacogenetics and forensic toxicology.,"['Musshoff F', 'Stamer UM', 'Madea B']","['Analgesics, Opioid/pharmacokinetics', 'Anticonvulsants/pharmacokinetics', 'Antidepressive Agents/pharmacokinetics', 'Benzodiazepines/pharmacokinetics', 'Biomarkers/analysis', 'Carisoprodol/pharmacokinetics', 'Cytochrome P-450 Enzyme System/genetics', 'Ethnicity/genetics', '*Forensic Toxicology', 'Genetic Variation', 'Humans', 'Membrane Transport Proteins/genetics', 'Molecular Targeted Therapy', 'Muscle Relaxants, Central/pharmacokinetics', 'N-Methyl-3,4-methylenedioxyamphetamine/pharmacokinetics', '*Pharmacogenetics', 'Postmortem Changes']",https://pubmed.ncbi.nlm.nih.gov/20828952/
791,carmustine,25746091,Polymeric drug delivery for the treatment of glioblastoma.,"['Wait SD', 'Prabhu RS', 'Burri SH', 'Atkins TG', 'Asher AL']","['Antineoplastic Agents, Alkylating/*administration & dosage/adverse effects/*therapeutic use', 'Brain Neoplasms/*drug therapy', 'Carmustine/*administration & dosage/adverse effects/*therapeutic use', 'Drug Implants', 'Glioblastoma/*drug therapy', 'Humans', '*Infusion Pumps, Implantable', 'Polymers', 'Survival Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25746091/
792,carmustine,24578726,Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview.,"['Liu HL', 'Fan CH', 'Ting CY', 'Yeh CK']","['Blood-Brain Barrier/diagnostic imaging/drug effects', 'Brain Neoplasms/*drug therapy', 'Carmustine/administration & dosage', 'Contrast Media/pharmacology', 'Drug Delivery Systems/*methods', 'Glioma/therapy', 'Humans', 'Liposomes', '*Microbubbles/therapeutic use', 'Ultrasonography/*methods']",https://pubmed.ncbi.nlm.nih.gov/24578726/
793,carmustine,22440872,The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.,['Nagpal S'],"['Antineoplastic Agents, Alkylating/administration & dosage/*therapeutic use', 'Brain Neoplasms/*drug therapy', 'Carmustine/administration & dosage/*therapeutic use', 'Decanoic Acids/*therapeutic use', 'Delayed-Action Preparations/therapeutic use', 'Drug Carriers/therapeutic use', 'Glioma/*drug therapy', 'Humans', 'Polyesters/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22440872/
794,carmustine,24812626,The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience.,"['Lombardi G', 'Della Puppa A', 'Zustovich F', 'Pambuku A', 'Farina P', 'Fiduccia P', 'Roma A', 'Zagonel V']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Brain Neoplasms/*drug therapy', 'Carmustine/adverse effects/*therapeutic use', 'Disease-Free Survival', 'Female', 'Glioblastoma/*drug therapy', 'Humans', 'Kaplan-Meier Estimate', 'Karnofsky Performance Status', 'Male', 'Middle Aged', 'Nitrosourea Compounds/adverse effects/*therapeutic use', 'Organophosphorus Compounds/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24812626/
795,carmustine,1100221,Clinical comparison of the nitrosoureas.,"['Wasserman TH', 'Slavik M', 'Carter SK']","['Animals', 'Antineoplastic Agents/*therapeutic use', 'Brain Neoplasms/drug therapy', 'Breast Neoplasms/drug therapy', 'Carmustine/administration & dosage/adverse effects/therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Colonic Neoplasms/drug therapy', 'Drug Therapy, Combination', 'Hodgkin Disease/drug therapy', 'Humans', 'Lomustine/administration & dosage/adverse effects/therapeutic use', 'Lung Neoplasms/drug therapy', 'Lymphoma/drug therapy', 'Melanoma/drug therapy', 'Methylnitrosourea/administration & dosage/adverse effects/therapeutic use', 'Mice', 'Neoplasms, Experimental/drug therapy', 'Nitrosourea Compounds/*therapeutic use', 'Rectal Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1100221/
796,carmustine,2268962,Intra-arterial chemotherapy for brain tumors.,"['Hassenbusch SJ', 'Anderson JH', 'Whiting DM']","['Analysis of Variance', 'Animals', 'Brain Neoplasms/*drug therapy', 'Carmustine/*administration & dosage/therapeutic use', 'Ethanol/administration & dosage', 'Fluorocarbons/administration & dosage', 'Humans', 'Infusions, Intra-Arterial', 'Rabbits']",https://pubmed.ncbi.nlm.nih.gov/2268962/
797,carmustine,7207751,"1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.","['Selker RG', 'Jacobs SA', 'Moore PB', 'Wald M', 'Fisher ER', 'Cohen M', 'Bellot P']","['Adolescent', 'Adult', 'Aged', 'Biopsy', 'Brain Neoplasms/drug therapy', 'Carmustine/*adverse effects/therapeutic use', 'Female', 'Glioma/drug therapy', 'Humans', 'Lung/pathology', 'Male', 'Middle Aged', 'Pulmonary Diffusing Capacity', 'Pulmonary Fibrosis/*chemically induced/pathology']",https://pubmed.ncbi.nlm.nih.gov/7207751/
798,carmustine,37804814,Development and in vitro evaluation of carmustine delivery platform: A hypoxia-sensitive anti-drug resistant nanomicelle with BBB penetrating ability.,"['Li D', 'Ren T', 'Wang X', 'Xiao Z', 'Sun G', 'Zhang N', 'Zhao L', 'Zhong R']","['Humans', '*Carmustine/pharmacology/therapeutic use', 'Micelles', 'Blood-Brain Barrier', '*Glioma/drug therapy', 'Hypoxia/drug therapy', 'Tumor Microenvironment']",https://pubmed.ncbi.nlm.nih.gov/37804814/
799,carmustine,11898520,Drug delivery to tumors of the central nervous system.,"['Lesniak MS', 'Langer R', 'Brem H']","['Antineoplastic Agents/administration & dosage/pharmacokinetics/*therapeutic use', 'Biodegradation, Environmental', 'Blood-Brain Barrier', 'Brain Neoplasms/*drug therapy/mortality/therapy', 'Carmustine/administration & dosage/pharmacokinetics/therapeutic use', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Double-Blind Method', 'Drug Carriers', 'Drug Implants', 'Forecasting', 'Glioblastoma/drug therapy/mortality', 'Glioma/drug therapy/mortality/therapy', 'Humans', 'Injections, Intralesional', 'Injections, Spinal', 'Life Tables', 'Nitrosourea Compounds/administration & dosage/pharmacokinetics/therapeutic use', 'Polymers', 'Prodrugs/administration & dosage/pharmacokinetics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Survival Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11898520/
800,carmustine,11328624,Current treatment of Cutaneous T-Cell Lymphoma.,['Duvic M'],"['Administration, Oral', 'Administration, Topical', 'Anticarcinogenic Agents/*therapeutic use', 'Apoptosis/drug effects', 'Bexarotene', 'Biopsy', 'Carmustine/administration & dosage', 'Disease Progression', 'Drug Eruptions/etiology', 'Humans', 'Hypertriglyceridemia/chemically induced', 'Lymphoma, T-Cell, Cutaneous/*drug therapy/pathology', 'Mechlorethamine/administration & dosage/adverse effects', 'Neoplasm Staging', 'PUVA Therapy', 'Prognosis', 'Retinoids/therapeutic use', 'Sezary Syndrome/drug therapy/immunology', 'Tetrahydronaphthalenes/adverse effects/*therapeutic use', 'Vitamin D/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11328624/
801,carmustine,38526002,BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.,"['Stuver R', 'Mian A', 'Brown S', 'Devlin S', 'Caimi PF', 'Chinapen S', 'Dahi P', 'Dean R', 'Epstein-Peterson ZD', 'Hill B', 'Horwitz SM', 'Lahoud O', 'Lin R', 'Moskowitz AJ', 'Sauter C', 'Shah G', 'Winter A', 'Jagadeesh D', 'Scordo M']","['Humans', '*Hematopoietic Stem Cell Transplantation/methods', '*Lymphoma, T-Cell, Peripheral/therapy', '*Transplantation Conditioning/methods', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/administration & dosage/pharmacokinetics', 'Male', 'Middle Aged', 'Female', '*Transplantation, Autologous', 'Cytarabine/administration & dosage/pharmacokinetics/therapeutic use', 'Carmustine/administration & dosage/pharmacokinetics/therapeutic use', 'Adult', 'Melphalan/administration & dosage/therapeutic use/pharmacokinetics', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38526002/
802,carmustine,24740194,The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.,"['Olson JJ', 'Nayak L', 'Ormond DR', 'Wen PY', 'Kalkanis SN']","['Absorbable Implants', 'Adult', 'Antineoplastic Agents/administration & dosage/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Brain Neoplasms/*drug therapy/surgery', 'Carmustine/administration & dosage/therapeutic use', 'Chemotherapy, Adjuvant', 'Dacarbazine/administration & dosage/analogs & derivatives/therapeutic use', 'Disease Progression', 'Evidence-Based Medicine', 'Glioblastoma/*drug therapy/surgery', 'Humans', 'Temozolomide']",https://pubmed.ncbi.nlm.nih.gov/24740194/
803,carmustine,1951175,120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer.,"['Villar-Grimalt A', 'Candel MT', 'Delgado F', 'Garcia-Reinoso J', 'Sanchis C', 'Viciano V', 'Asencio F', 'Martinez-Abad M', 'Aguilo J', 'Sanchez JJ']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carcinoma/*drug therapy/mortality/secondary', 'Carmustine/administration & dosage', 'Colorectal Neoplasms/*drug therapy/mortality', 'Drug Administration Schedule', 'Female', 'Fluorouracil/administration & dosage', 'Humans', 'Infusions, Intravenous', 'Liver Neoplasms/secondary', 'Male', 'Middle Aged', 'Prognosis', 'Remission Induction', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/1951175/
804,carmustine,14707492,Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.,"['Guerin C', 'Olivi A', 'Weingart JD', 'Lawson HC', 'Brem H']","['Animals', 'Antineoplastic Agents, Alkylating/*administration & dosage/therapeutic use', 'Brain Neoplasms/*drug therapy/pathology', 'Carmustine/*administration & dosage/therapeutic use', 'Clinical Trials as Topic', '*Decanoic Acids', 'Drug Carriers', 'Glioma/*drug therapy/secondary', 'Humans', 'Instillation, Drug', 'Maximum Tolerated Dose', 'Neoplasm Recurrence, Local', '*Polyesters', 'Technology, Pharmaceutical']",https://pubmed.ncbi.nlm.nih.gov/14707492/
805,carmustine,10874145,The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.,['Engelhard HH'],"['Animals', 'Antineoplastic Agents, Alkylating/*administration & dosage/adverse effects', 'Biocompatible Materials', 'Brain Neoplasms/*drug therapy', 'Carmustine/*administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Drug Administration Routes', '*Drug Implants/adverse effects', 'Glioblastoma/drug therapy', 'Glioma/*drug therapy', 'Humans', 'Inflammation', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10874145/
806,carmustine,8841080,Contemporary chemotherapy issues for children with brainstem gliomas.,"['Allen JC', 'Siffert J']","['Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Brain Neoplasms/*drug therapy/pathology', 'Brain Stem/*pathology', 'Carboplatin/administration & dosage/adverse effects/*therapeutic use', 'Carmustine/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Etoposide/administration & dosage/adverse effects/*therapeutic use', 'Glioma/*drug therapy/pathology', 'Humans', 'Neoplasm Recurrence, Local', 'Thiotepa/administration & dosage/adverse effects/*therapeutic use', 'Vincristine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8841080/
807,carmustine,28083955,Cryptococcus laurentii diarrhea post hematopoietic stem cell transplant.,"['Bhat V', 'Vira H', 'Khattry N', 'Toshniwal M']","['Administration, Intravenous', 'Administration, Oral', 'Adult', 'Antibiotic Prophylaxis', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'C-Reactive Protein/analysis', 'Carmustine/adverse effects/therapeutic use', 'Cryptococcosis/blood/drug therapy/*microbiology', 'Cryptococcus/*isolation & purification', 'Cytarabine/adverse effects/therapeutic use', 'Diarrhea/blood/drug therapy/*microbiology', 'Etoposide/adverse effects/therapeutic use', 'Feces/microbiology', 'Fluconazole/therapeutic use', 'Hematopoietic Stem Cell Transplantation/*adverse effects', 'Hodgkin Disease/*surgery', 'Humans', 'Melphalan/adverse effects/therapeutic use', 'Microbial Sensitivity Tests', 'Transplantation Conditioning/adverse effects/methods', 'Transplantation, Autologous/adverse effects', 'Voriconazole/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28083955/
808,carmustine,10469900,The delivery of BCNU to brain tumors.,"['Wang CC', 'Li J', 'Teo CS', 'Lee T']","['Antineoplastic Agents, Alkylating/*administration & dosage', 'Brain Neoplasms/*drug therapy', 'Capillary Permeability', 'Carmustine/*administration & dosage/pharmacokinetics', '*Drug Delivery Systems', 'Humans', 'Models, Biological']",https://pubmed.ncbi.nlm.nih.gov/10469900/
809,carmustine,7272960,Nephrotoxicity of nitrosoureas.,"['Schacht RG', 'Feiner HD', 'Gallo GR', 'Lieberman A', 'Baldwin DS']","['Adolescent', 'Adult', 'Aged', 'Biopsy', 'Blood Urea Nitrogen', 'Brain Neoplasms/drug therapy', 'Carmustine/administration & dosage/adverse effects', 'Child', 'Creatinine/blood', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Kidney/pathology', 'Kidney Diseases/*chemically induced/metabolism/pathology', 'Lomustine/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Nitrosourea Compounds/*adverse effects', 'Retrospective Studies', 'Semustine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7272960/
810,chlorthalidone,37355779,Hypertension in chronic kidney disease-treatment standard 2023.,"['Georgianos PI', 'Agarwal R']","['Humans', 'Spironolactone/adverse effects', '*Hyperkalemia/chemically induced', 'Chlorthalidone/therapeutic use', '*Hypertension/drug therapy/etiology/diagnosis', 'Antihypertensive Agents/adverse effects', 'Mineralocorticoid Receptor Antagonists/therapeutic use', '*Renal Insufficiency, Chronic/drug therapy', 'Blood Pressure']",https://pubmed.ncbi.nlm.nih.gov/37355779/
811,chlorthalidone,34528418,[Hyponatremia and thiazides].,"['Bensabre S', 'Zisimopoulou S', 'Pechere-Bertschi A']","['Antihypertensive Agents/adverse effects', 'Chlorthalidone/adverse effects', 'Humans', '*Hyponatremia/chemically induced', '*Indapamide', 'Thiazides/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34528418/
812,chlorthalidone,34739197,Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.,"['Agarwal R', 'Sinha AD', 'Cramer AE', 'Balmes-Fenwick M', 'Dickinson JH', 'Ouyang F', 'Tu W']","['Aged', 'Albuminuria', 'Blood Pressure/drug effects', 'Chlorthalidone/administration & dosage/adverse effects/*therapeutic use', 'Creatinine/urine', 'Diuretics/administration & dosage/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Glomerular Filtration Rate/drug effects', 'Humans', 'Hypertension/complications/*drug therapy', 'Male', 'Middle Aged', 'Natriuretic Peptide, Brain/blood', 'Peptide Fragments/blood', 'Renal Insufficiency, Chronic/*complications', 'Severity of Illness Index', 'Sodium Chloride Symporter Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34739197/
813,chlorthalidone,36516076,Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.,"['Ishani A', 'Cushman WC', 'Leatherman SM', 'Lew RA', 'Woods P', 'Glassman PA', 'Taylor AA', 'Hau C', 'Klint A', 'Huang GD', 'Brophy MT', 'Fiore LD', 'Ferguson RE']","['Aged', 'Humans', 'Antihypertensive Agents/adverse effects/therapeutic use', 'Blood Pressure/drug effects', '*Chlorthalidone/adverse effects/therapeutic use', 'Diuretics/adverse effects/therapeutic use', '*Hydrochlorothiazide/adverse effects/therapeutic use', '*Hypertension/complications/drug therapy', 'Sodium Chloride Symporter Inhibitors/adverse effects/therapeutic use', 'Cardiovascular Diseases/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/36516076/
814,chlorthalidone,25733245,Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.,"['Roush GC', 'Ernst ME', 'Kostis JB', 'Tandon S', 'Sica DA']","['Blood Pressure/*drug effects', 'Chlorthalidone/*therapeutic use', 'Diuretics/therapeutic use', 'Humans', 'Hydrochlorothiazide/*therapeutic use', 'Hypertension/blood/*drug therapy', 'Hypokalemia/blood/chemically induced/prevention & control', 'Indapamide/*therapeutic use', 'Potassium/*blood', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25733245/
815,chlorthalidone,26270432,Diuretics for hypertension: Hydrochlorothiazide or chlorthalidone?,"['Cooney D', 'Milfred-LaForest S', 'Rahman M']","['Antihypertensive Agents/*therapeutic use', 'Chlorthalidone/*therapeutic use', 'Diuretics/*therapeutic use', 'Humans', 'Hydrochlorothiazide/*therapeutic use', 'Hypertension/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26270432/
816,chlorthalidone,38853071,Diuretics use in the management of hypertension.,['Morales-Olivas FJ'],"['Humans', '*Hypertension/drug therapy', '*Diuretics/adverse effects/administration & dosage/therapeutic use/pharmacology', '*Antihypertensive Agents/adverse effects/administration & dosage/pharmacology/therapeutic use', 'Sodium Chloride Symporter Inhibitors/adverse effects/therapeutic use/administration & dosage/pharmacology', 'Hydrochlorothiazide/adverse effects/administration & dosage/therapeutic use', 'Chlorthalidone/administration & dosage/therapeutic use/adverse effects', 'Female', 'Male', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38853071/
817,chlorthalidone,46960,Diuretic-induced oedema.,"['MacGregor GA', 'Tasker PR', 'de Wardener HE']","['Adult', 'Aldosterone/blood', 'Blood Volume', 'Body Weight', 'Chlorthalidone/adverse effects/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Edema/blood/*chemically induced/drug therapy/urine', 'Female', 'Furosemide/adverse effects/pharmacology/therapeutic use', 'Humans', 'Middle Aged', 'Potassium/administration & dosage/blood/urine', 'Renin/blood', 'Sodium/administration & dosage/blood/urine', 'Spironolactone/adverse effects/therapeutic use', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/46960/
818,chlorthalidone,32065600,Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.,"['Hripcsak G', 'Suchard MA', 'Shea S', 'Chen R', 'You SC', 'Pratt N', 'Madigan D', 'Krumholz HM', 'Ryan PB', 'Schuemie MJ']","['Antihypertensive Agents/adverse effects/*therapeutic use', 'Chlorthalidone/adverse effects/*therapeutic use', 'Female', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32065600/
819,chlorthalidone,25486449,Misconceptions and facts about treating hypertension.,"['Argulian E', 'Grossman E', 'Messerli FH']","['Antihypertensive Agents/pharmacology/*therapeutic use', 'Blood Pressure/drug effects', 'Chlorthalidone/therapeutic use', 'Humans', 'Hydrochlorothiazide/therapeutic use', 'Hypertension/*drug therapy/prevention & control', 'Indapamide/therapeutic use', 'Risk Factors', 'Sodium Chloride Symporter Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25486449/
820,chlorthalidone,30120478,Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.,"['Webster R', 'Salam A', 'de Silva HA', 'Selak V', 'Stepien S', 'Rajapakse S', 'Amarasekara S', 'Amarasena N', 'Billot L', 'de Silva AP', 'Fernando M', 'Guggilla R', 'Jan S', 'Jayawardena J', 'Maulik PK', 'Mendis S', 'Mendis S', 'Munasinghe J', 'Naik N', 'Prabhakaran D', 'Ranasinghe G', 'Thom S', 'Tisserra N', 'Senaratne V', 'Wijekoon S', 'Wijeyasingam S', 'Rodgers A', 'Patel A']","['Adult', 'Aged', 'Amlodipine/*administration & dosage/adverse effects', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage/adverse effects', 'Benzoates/*administration & dosage/adverse effects', 'Blood Pressure/drug effects', 'Chlorthalidone/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Medication Adherence', 'Middle Aged', 'Potassium/blood', 'Sri Lanka', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/30120478/
821,chlorthalidone,38716531,Chlorthalidone vs Hydrochlorothiazide for Hypertension-CV Events: Did the Design Influence the Outcome?,"['Pareek A', 'Messerli FH', 'Ram CVS']","['*Hydrochlorothiazide/adverse effects/therapeutic use', 'Humans', '*Chlorthalidone/therapeutic use/adverse effects', '*Hypertension/drug therapy', 'Aged', '*Antihypertensive Agents/therapeutic use/adverse effects', '*Diuretics/therapeutic use/adverse effects', 'Cardiovascular Diseases/prevention & control', 'Treatment Outcome', 'Male', 'Female']",https://pubmed.ncbi.nlm.nih.gov/38716531/
822,chlorthalidone,34941597,Electrolyte Disorders Common in Thiazide Diuretic Users.,['Rosenberg K'],"['*Chlorthalidone/adverse effects/therapeutic use', 'Cross-Sectional Studies', 'Humans', 'Hypokalemia/*complications/*drug therapy/epidemiology', 'Hyponatremia/*complications/*drug therapy/epidemiology', '*Sodium Chloride Symporter Inhibitors/adverse effects/therapeutic use', 'Water-Electrolyte Imbalance/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/34941597/
823,chlorthalidone,39051700,Preferred diuretic therapy for primary hypertension: Chlorthalidone or hydrochlorothiazide?,['Young TD'],"['Humans', '*Chlorthalidone/administration & dosage/therapeutic use', '*Hydrochlorothiazide/administration & dosage/therapeutic use', '*Hypertension/drug therapy', '*Diuretics/administration & dosage/therapeutic use', '*Antihypertensive Agents/administration & dosage/therapeutic use', 'Cardiovascular Diseases/prevention & control/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39051700/
824,chlorthalidone,37443261,Arterial Hypertension-clinical trials update 2023.,"['Gotzinger F', 'Kunz M', 'Lauder L', 'Bohm M', 'Mahfoud F']","['Humans', 'Antihypertensive Agents/therapeutic use/pharmacology', 'Blood Pressure', 'Chlorthalidone/pharmacology/therapeutic use', '*Hypertension/drug therapy', 'Kidney', 'Sympathectomy', 'Treatment Outcome', 'Clinical Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37443261/
825,chlorthalidone,37429505,Chlorthalidone versus hydrochlorothiazide for preventing cardiovascular disease in hypertension: Is the case closed?,"['Kollias A', 'Kyriakoulis KG', 'Stergiou GS']","['Humans', 'Aged', 'Chlorthalidone/therapeutic use/pharmacology', 'Hydrochlorothiazide/therapeutic use/pharmacology', '*Cardiovascular Diseases/prevention & control/drug therapy', 'Antihypertensive Agents/therapeutic use/pharmacology', '*Hypertension/complications/drug therapy', 'Diuretics/therapeutic use', 'Blood Pressure', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/37429505/
826,chlorthalidone,22745562,Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.,"['Shuster JE', 'Bleske BE', 'Dorsch MP']","['Angiotensin II Type 1 Receptor Blockers/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/*therapeutic use', 'Blood Pressure/*drug effects', 'Chlorthalidone/*therapeutic use', 'Diuretics/*therapeutic use', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Oxadiazoles/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22745562/
827,chlorthalidone,37855647,[Chlorthalidone or hydrochlorothiazide as the first choice in the treatment of people with hypertension].,['Steurer J'],"['Humans', '*Chlorthalidone/adverse effects', 'Hydrochlorothiazide/adverse effects', '*Hypertension/drug therapy', 'Antihypertensive Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37855647/
828,chlorthalidone,24704896,Considerations for dofetilide use in the elderly.,"['Crist LW', 'Dixon DL']","['Aged, 80 and over', 'Anti-Arrhythmia Agents/administration & dosage/*adverse effects/therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Atrial Fibrillation/complications/*drug therapy', 'Chlorthalidone/administration & dosage/adverse effects/therapeutic use', 'Drug Interactions', 'Female', 'Humans', 'Hypertension/complications/*drug therapy', 'Hypotension/*chemically induced/diagnosis', 'Phenethylamines/administration & dosage/*adverse effects/therapeutic use', 'Sulfonamides/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24704896/
829,chlorthalidone,35226524,"In advanced CKD with poorly controlled hypertension, chlorthalidone reduced BP at 12 wk.",['Crews DC'],"['Chlorthalidone/therapeutic use', 'Humans', '*Hypertension/complications/drug therapy', '*Renal Insufficiency, Chronic/complications']",https://pubmed.ncbi.nlm.nih.gov/35226524/
830,chlorzoxazone,24000301,The treatment and natural course of peripheral and central vertigo.,"['Strupp M', 'Dieterich M', 'Brandt T']","['Brain Diseases/*diagnosis/epidemiology/*therapy', 'Causality', 'Comorbidity', 'Disease Progression', 'Disease-Free Survival', '*Evidence-Based Medicine', 'Humans', 'Prevalence', 'Risk Factors', 'Treatment Outcome', 'Vertigo/*diagnosis/epidemiology/*therapy', 'Vestibular Diseases/*diagnosis/epidemiology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/24000301/
831,chlorzoxazone,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
832,chlorzoxazone,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
833,chlorzoxazone,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
834,chlorzoxazone,29618168,Higher chlorzoxazone clearance in obese children compared with nonobese peers.,"['Gade C', 'Dalhoff K', 'Petersen TS', 'Riis T', 'Schmeltz C', 'Chabanova E', 'Christensen HR', 'Mikus G', 'Burhenne J', 'Holm JC', 'Holst H']","['Administration, Oral', 'Adolescent', 'Area Under Curve', 'Body Mass Index', 'Child', 'Chlorzoxazone/administration & dosage/*pharmacokinetics', 'Cytochrome P-450 CYP2E1/*metabolism', 'Diabetes Mellitus', 'Dose-Response Relationship, Drug', 'Fatty Liver', 'Female', 'Humans', 'Hydroxylation', 'Male', 'Metabolic Clearance Rate/physiology', 'Obesity/blood/*metabolism/physiopathology/urine']",https://pubmed.ncbi.nlm.nih.gov/29618168/
835,chlorzoxazone,2327059,Skeletal muscle relaxant ingestion.,"['Lebby TI', 'Dugger K', 'Lipscomb JW', 'Leikin JB']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Overdose', 'Humans', 'Infant', 'Infant, Newborn', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', 'Muscles/*drug effects', '*Poison Control Centers', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2327059/
836,chlorzoxazone,27127017,The CYTONOX trial.,"['Gade C', 'Mikus G', 'Christensen HR', 'Dalhoff KP', 'Holm JC', 'Holst H']","['Adolescent', 'Caffeine/blood/*pharmacokinetics/urine', 'Child', 'Chlorzoxazone/blood/*pharmacokinetics/urine', 'Clinical Protocols', 'Cytochrome P-450 CYP1A2/*metabolism', 'Cytochrome P-450 CYP2E1/*metabolism', 'Cytochrome P-450 CYP3A/*metabolism', 'Denmark', 'Female', 'Humans', 'Male', 'Midazolam/blood/*pharmacokinetics/urine', 'Pediatric Obesity/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/27127017/
837,chlorzoxazone,1519785,Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance.,"['Yun CH', 'Wood M', 'Wood AJ', 'Guengerich FP']","['*Alfentanil/metabolism/pharmacokinetics', 'Benzoflavones/pharmacology', 'Cytochrome P-450 Enzyme System/*metabolism', 'Drug Interactions', 'Fentanyl/analogs & derivatives/metabolism', 'Humans', 'Microsomes, Liver/enzymology/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/1519785/
838,chlorzoxazone,30334271,CYP2E1 activity and children with obesity: possible confounding factors.,"['Kaur H', 'Sarma P', 'Prakash A', 'Medhi B']","['Child', '*Chlorzoxazone', '*Cytochrome P-450 CYP2E1', 'Ethanol', 'Humans', 'Obesity']",https://pubmed.ncbi.nlm.nih.gov/30334271/
839,chlorzoxazone,31745201,Automatic Dissolution Testing with High-Temporal Resolution for Both Immediate-Release and Fixed-Combination Drug Tablets.,"['Chi Z', 'Azhar I', 'Khan H', 'Yang L', 'Feng Y']","['Acetaminophen/chemistry/*metabolism', 'Analgesics, Non-Narcotic/chemistry/metabolism', 'Automation', '*Chemistry, Pharmaceutical', 'Chlorzoxazone/chemistry/*metabolism', 'Drug Combinations', '*Drug Liberation', 'Humans', 'Muscle Relaxants, Central/chemistry/metabolism', '*Quality Control', 'Solubility', 'Tablets/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31745201/
840,chlorzoxazone,11936218,Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes.,"['Kim JY', 'Lee S', 'Kim DH', 'Kim BR', 'Park R', 'Lee BM']","['Cell Culture Techniques', 'Cytochrome P-450 Enzyme System/*metabolism', 'Enzyme Inhibitors/*pharmacology', 'Flavonoids/*pharmacology', 'Humans', 'Lamiaceae/*chemistry', 'Microsomes, Liver/enzymology', 'Plant Extracts']",https://pubmed.ncbi.nlm.nih.gov/11936218/
841,chlorzoxazone,27160916,"Evidence for the Inhibition by Temozolomide, an Imidazotetrazine Family Alkylator, of Intermediate-Conductance Ca2+-Activated K+ Channels in Glioma Cells.","['Yeh PS', 'Wu SJ', 'Hung TY', 'Huang YM', 'Hsu CW', 'Sze CI', 'Hsieh YJ', 'Huang CW', 'Wu SN']","['Alkylating Agents/*toxicity', 'Benzimidazoles/pharmacology', 'Cell Line, Tumor', 'DNA Damage/*drug effects', 'Dacarbazine/*analogs & derivatives/toxicity', 'Glioma', 'Humans', 'Intermediate-Conductance Calcium-Activated Potassium Channels/antagonists & inhibitors/genetics/*metabolism', 'Ionomycin/pharmacology', 'Large-Conductance Calcium-Activated Potassium Channels/metabolism', 'Membrane Potentials/drug effects', 'Patch-Clamp Techniques', 'Potassium Channels, Inwardly Rectifying/metabolism', 'RNA Interference', 'RNA, Small Interfering/metabolism', 'Reverse Transcriptase Polymerase Chain Reaction', 'Temozolomide']",https://pubmed.ncbi.nlm.nih.gov/27160916/
842,chlorzoxazone,12033517,Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.,"['Umehara K', 'Shimokawa Y', 'Miyamoto G']","['Buprenorphine/*pharmacology', 'Catalysis', '*Cytochrome P-450 Enzyme Inhibitors', 'Enzyme Inhibitors/*pharmacology', 'Humans', 'In Vitro Techniques', 'Isoenzymes/antagonists & inhibitors', 'Kinetics', 'Microsomes, Liver/drug effects/enzymology/metabolism', 'Narcotic Antagonists/*pharmacology', 'Substrate Specificity']",https://pubmed.ncbi.nlm.nih.gov/12033517/
843,chlorzoxazone,16927538,Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.,"['Nakamura A', 'Tougou K', 'Kitazumi H', 'Yamada T', 'Honjou K', 'Nonaka K', 'Mukai H']","['Anti-Ulcer Agents/*pharmacology', 'Aryl Hydrocarbon Hydroxylases/metabolism', 'Cytochrome P-450 CYP1A1/metabolism', 'Cytochrome P-450 CYP2A6', 'Cytochrome P-450 CYP2B6', 'Cytochrome P-450 CYP2C19', 'Cytochrome P-450 CYP2C9', 'Cytochrome P-450 CYP2D6/metabolism', 'Cytochrome P-450 CYP2E1/metabolism', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/*metabolism', 'Humans', 'In Vitro Techniques', 'Isoenzymes/metabolism', 'Kinetics', 'Microsomes, Liver/drug effects/*enzymology', 'Mixed Function Oxygenases/metabolism', 'NADP/metabolism', 'Oxidoreductases, N-Demethylating/metabolism', 'Triazines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/16927538/
844,chlorzoxazone,26519380,Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.,"['Feil K', 'Bremova T', 'Muth C', 'Schniepp R', 'Teufel J', 'Strupp M']","['4-Aminopyridine/therapeutic use', 'Cerebellar Ataxia/complications/*drug therapy', 'Chlorzoxazone/therapeutic use', 'Drug Therapy/*methods/*trends', 'Humans', 'Leucine/analogs & derivatives/therapeutic use', 'Muscle Relaxants, Central/therapeutic use', 'Nystagmus, Pathologic/*drug therapy/etiology', 'Potassium Channel Blockers/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26519380/
845,chlorzoxazone,14993813,"Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes.","['Niwa T', 'Shiraga T', 'Hashimoto T', 'Kagayama A']","['Calcium Channel Blockers/*pharmacology', 'Cytochrome P-450 Enzyme System/*metabolism', 'Humans', 'In Vitro Techniques', 'Isoenzymes/metabolism', 'Microsomes, Liver/*drug effects/enzymology/metabolism', 'Nifedipine/*analogs & derivatives/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/14993813/
846,chlorzoxazone,16430028,Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.,"['Nakamura A', 'Tougou K', 'Kitazumi H', 'Yamada T', 'Honjou K', 'Zinno A', 'Nonaka K', 'Mukai H']","['Anti-Inflammatory Agents, Non-Steroidal/*pharmacology', 'Cytochrome P-450 Enzyme System/*metabolism', 'Etodolac/*pharmacology', 'Humans', 'In Vitro Techniques', 'Isoenzymes/metabolism', 'Microsomes, Liver/*enzymology', 'NADP/metabolism', 'Substrate Specificity']",https://pubmed.ncbi.nlm.nih.gov/16430028/
847,chlorzoxazone,31279830,Harnessing ionic mechanisms to achieve disease modification in neurodegenerative disorders.,"['Masi A', 'Narducci R', 'Mannaioni G']","['Animals', 'Cell Death', 'Humans', '*Neurodegenerative Diseases', 'Neurons/pathology', '*Retinal Diseases']",https://pubmed.ncbi.nlm.nih.gov/31279830/
848,chlorzoxazone,27083881,Update on the pharmacotherapy of cerebellar and central vestibular disorders.,"['Kalla R', 'Teufel J', 'Feil K', 'Muth C', 'Strupp M']","['4-Aminopyridine/therapeutic use', 'Cerebellar Diseases/complications/*drug therapy', 'Humans', 'Leucine/*analogs & derivatives/therapeutic use', 'Male', 'Nystagmus, Pathologic/drug therapy/etiology', 'Potassium Channel Blockers/*therapeutic use', 'Potassium Channels, Voltage-Gated/genetics', 'Vestibular Diseases/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27083881/
849,chlorzoxazone,25004912,Interaction of selected platinum(II) complexes containing roscovitine-based CDK inhibitors as ligands with human liver microsomal cytochrome P450.,"['Masek V', 'Starha P', 'Harvanova M', 'Michalova M', 'Milde D', 'Travnicek Z', 'Anzenbacherova E']","['Cytochrome P-450 CYP3A/*metabolism', 'Humans', 'Hydroxylation', 'Ligands', 'Microsomes, Liver/*metabolism', 'Oxidation-Reduction', 'Platinum Compounds/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/25004912/
850,cimetidine,6312110,Ranitidine.,['Strum WB'],"['Aged', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Cimetidine/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Duodenal Ulcer/drug therapy', 'Humans', 'Male', 'Mice', 'Ranitidine/adverse effects/metabolism/*therapeutic use', 'Rats', 'Stomach Ulcer/drug therapy', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6312110/
851,cimetidine,86721,Cimetidine and gastric cancer.,"['Elder JB', 'Ganguli PC', 'Gillespie IE']","['Adenocarcinoma/*chemically induced', 'Adult', 'Aged', 'Cimetidine/*adverse effects/analogs & derivatives/metabolism/therapeutic use', 'Female', 'Guanidines/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Nitroso Compounds/metabolism', 'Peptic Ulcer/drug therapy', 'Stomach Neoplasms/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/86721/
852,cimetidine,6375965,Cimetidine for stress-ulcer prophylaxis.,"['Greene WL', 'Bollinger RR']","['Antacids/adverse effects/therapeutic use', 'Cimetidine/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Gastric Juice/drug effects/metabolism', 'Gastric Mucosa/drug effects/metabolism', 'Humans', 'Peptic Ulcer/physiopathology/*prevention & control', 'Random Allocation', 'Stress, Physiological/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/6375965/
853,cimetidine,2874464,Actions of cimetidine and ranitidine at some cholinergic sites: implications in toxicology and anesthesia.,"['Gwee MC', 'Cheah LS']","['*Anesthesia', 'Animals', 'Antihypertensive Agents/adverse effects', 'Bradycardia/chemically induced', 'Cholinesterase Inhibitors/pharmacology', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Confusion/chemically induced', 'Cytochrome P-450 Enzyme System/pharmacology', 'Diarrhea/chemically induced', 'Drug Interactions', 'Erectile Dysfunction/chemically induced', 'Ganglionic Blockers/pharmacology', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Mixed Function Oxygenases/antagonists & inhibitors', 'Neuromuscular Blocking Agents/pharmacology', 'Peptic Ulcer/drug therapy', 'Ranitidine/*adverse effects/pharmacology/therapeutic use', 'Receptors, Cholinergic/*drug effects/physiology', 'Receptors, Histamine H2/drug effects', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2874464/
854,cimetidine,6146287,Medical management of gastric ulcer.,['LaBrooy SJ'],"['Aged', 'Animals', 'Antacids/*therapeutic use', 'Carbenoxolone/administration & dosage/*therapeutic use', 'Cimetidine/administration & dosage/therapeutic use', 'Clinical Trials as Topic', 'Dogs', 'Double-Blind Method', 'Gastric Acid/metabolism', 'Glycyrrhetinic Acid/*analogs & derivatives', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Ranitidine/therapeutic use', 'Recurrence', 'Stomach Ulcer/*drug therapy/etiology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6146287/
855,cimetidine,11243017,[About paracetamol again].,"['Hazai E', 'Monostory K', 'Bakos A', 'Zacher G', 'Vereczkey L']","['Acetaminophen/administration & dosage/*adverse effects/pharmacokinetics', 'Acetylcysteine/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/*adverse effects/pharmacokinetics', 'Antidotes/therapeutic use', 'Cimetidine/therapeutic use', 'Drug Overdose', 'Humans', 'Liver/*drug effects', 'Liver Failure, Acute/*chemically induced/drug therapy/metabolism/prevention & control/*therapy']",https://pubmed.ncbi.nlm.nih.gov/11243017/
856,cimetidine,6733633,Cimetidine-induced fever.,"['Landolfo K', 'Low DE', 'Rogers AG']","['Administration, Oral', 'Aged', 'Cimetidine/administration & dosage/*adverse effects', 'Duodenal Ulcer/drug therapy', 'Female', 'Fever/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/6733633/
857,cimetidine,620916,Safety of cimetidine.,"['Kruss DM', 'Littman A']","['Aspartate Aminotransferases/blood', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Creatinine/blood', 'Drug Interactions', 'Guanidines/*adverse effects', 'Humans', 'Liver/enzymology', 'Risk', 'Substance Withdrawal Syndrome']",https://pubmed.ncbi.nlm.nih.gov/620916/
858,cimetidine,7751419,Clinical aspects of cardiovascular effects of H2-receptor antagonists.,"['Hinrichsen H', 'Halabi A', 'Kirch W']","['Animals', 'Atrioventricular Node/drug effects', 'Blood Pressure/drug effects', 'Bradycardia/chemically induced', 'Cardiovascular System/*drug effects', 'Cimetidine/adverse effects/pharmacology', 'Electrocardiography/drug effects', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Histamine H2 Antagonists/chemistry/*pharmacology', 'Humans', 'Ranitidine/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7751419/
859,cimetidine,387498,"Clinical effects of trithiozine, a newer gastric anti-secretory agent.",['Pellegrini R'],"['Anti-Ulcer Agents/administration & dosage/adverse effects/*therapeutic use', 'Cimetidine/therapeutic use', 'Clinical Trials as Topic', 'Depression, Chemical', 'Double-Blind Method', 'Gastric Juice/*metabolism', 'Humans', 'Morpholines/administration & dosage/adverse effects/*therapeutic use', 'Peptic Ulcer/*drug therapy', 'Placebos', 'Propantheline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/387498/
860,cimetidine,6990675,Cimetidine in the prevention of acid aspiration during anesthesia.,"['Kirkegaard P', 'Sorensen O', 'Kirkegaard P']","['Adult', 'Anesthesia, General/*adverse effects', 'Anesthesia, Inhalation/adverse effects', 'Cimetidine/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Gastric Juice/analysis/drug effects', 'Guanidines/*therapeutic use', 'Humans', 'Hydrogen-Ion Concentration', 'Middle Aged', 'Placebos', 'Pneumonia, Aspiration/*prevention & control', 'Premedication', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6990675/
861,cimetidine,388168,Cimetidine and gastric ulcer healing: a double-blind controlled trial.,"['Landecker KD', 'Crawford J', 'Hunt JH', 'Gillespie P', 'Piper DW']","['Chronic Disease', 'Cimetidine/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Guanidines/*therapeutic use', 'Humans', 'Male', 'Outpatients', 'Random Allocation', 'Stomach Ulcer/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/388168/
862,cimetidine,4057034,"Cimetidine as pre-anesthetic agent for cesarean section: perinatal effects on the infant, the placental transfer of cimetidine and its elimination in the infants.","['Qvist N', 'Storm K', 'Holmskov A']","['*Cesarean Section', 'Cimetidine/adverse effects/*blood/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', '*Infant, Newborn', '*Maternal-Fetal Exchange', '*Preanesthetic Medication', 'Pregnancy', 'Prospective Studies', 'Umbilical Veins']",https://pubmed.ncbi.nlm.nih.gov/4057034/
863,cimetidine,2979221,Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation.,"['Jones DG', 'Langman MJ', 'Lawson DH', 'Vessey MP']","['Adult', 'Cimetidine/*adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', '*Product Surveillance, Postmarketing', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/2979221/
864,cimetidine,1289197,[Cimetidine hepatitis].,"['Zaidenstein R', 'Cohen N', 'Golik A']","['Acute Disease', 'Adult', 'Arthritis, Rheumatoid/complications', 'Chemical and Drug Induced Liver Injury/*etiology', 'Cimetidine/*adverse effects/therapeutic use', 'Duodenal Ulcer/complications/drug therapy', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/1289197/
865,cimetidine,2271376,The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.,"['Coleman MD', 'Scott AK', 'Breckenridge AM', 'Park BK']","['Adult', 'Cimetidine/administration & dosage/*pharmacology', 'Dapsone/administration & dosage/*metabolism/pharmacokinetics', 'Humans', 'Hydroxylation/drug effects', 'Male', 'Methemoglobinemia/blood']",https://pubmed.ncbi.nlm.nih.gov/2271376/
866,cimetidine,3570585,Treatment of female androgenetic alopecia with cimetidine.,['Aram H'],"['Adult', 'Alopecia/*drug therapy/etiology', 'Androgen Antagonists/therapeutic use', 'Androgens/physiology', 'Cimetidine/administration & dosage/pharmacology/*therapeutic use', 'Drug Evaluation', 'Female', 'Follow-Up Studies', 'Humans', 'Middle Aged', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3570585/
867,cimetidine,8844752,Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients.,"['Dohil M', 'Prendiville JS']","['Administration, Oral', 'Child', 'Child, Preschool', 'Cimetidine/administration & dosage/*therapeutic use', 'Facial Dermatoses/drug therapy/virology', 'Female', 'Histamine H2 Antagonists/administration & dosage/*therapeutic use', 'Humans', 'Immunocompetence', 'Infant', 'Male', 'Molluscum Contagiosum/*drug therapy', 'Remission Induction', 'Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/8844752/
868,cimetidine,2277761,Ascorbic acid prevents cimetidine-induced decrease of serum hydrocortisone concentrations.,"['Boidin MP', 'Stuurman A', 'Erdmann W']","['Abdomen/surgery', 'Aged', 'Ascorbic Acid/*pharmacology', 'Cimetidine/*adverse effects/therapeutic use', 'Humans', 'Hydrocortisone/*blood', 'Middle Aged', 'Prospective Studies', 'Vascular Surgical Procedures']",https://pubmed.ncbi.nlm.nih.gov/2277761/
869,cimetidine,3859910,The risk of gastric dysplasia in medical long-term treatment of peptic ulcer disease.,"['Di Mario F', 'Farinati F', 'Cardin F']","['Adult', 'Aged', 'Anti-Ulcer Agents/administration & dosage/*adverse effects', 'Benzodiazepinones/administration & dosage/adverse effects', 'Cimetidine/administration & dosage/adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Peptic Ulcer/*drug therapy', 'Pirenzepine', 'Ranitidine/administration & dosage/adverse effects', 'Risk', 'Stomach/*drug effects/pathology', 'Stomach Neoplasms/*chemically induced', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3859910/
870,cyclobenzaprine,27377815,EULAR revised recommendations for the management of fibromyalgia.,"['Macfarlane GJ', 'Kronisch C', 'Dean LE', 'Atzeni F', 'Hauser W', 'Fluss E', 'Choy E', 'Kosek E', 'Amris K', 'Branco J', 'Dincer F', 'Leino-Arjas P', 'Longley K', 'McCarthy GM', 'Makri S', 'Perrot S', 'Sarzi-Puttini P', 'Taylor A', 'Jones GT']","['*Activities of Daily Living', 'Acupuncture Therapy', 'Amitriptyline/analogs & derivatives/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Anticonvulsants/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Biofeedback, Psychology', 'Capsaicin/therapeutic use', 'Cognitive Behavioral Therapy', 'Europe', 'Evidence-Based Medicine', 'Exercise Therapy', 'Fatigue/physiopathology/*therapy', 'Fibromyalgia/physiopathology/*therapy', 'Human Growth Hormone/therapeutic use', 'Humans', 'Hydrotherapy', 'Hypnosis', 'Manipulation, Chiropractic', 'Massage', 'Mind-Body Therapies', 'Mindfulness', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Pain/physiopathology', '*Practice Guidelines as Topic', 'S-Adenosylmethionine/therapeutic use', 'Sensory System Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Sleep', 'Societies, Medical', 'Sodium Oxybate/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27377815/
871,cyclobenzaprine,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
872,cyclobenzaprine,18225966,Skeletal muscle relaxants.,"['See S', 'Ginzburg R']","['Drug Interactions', 'Humans', 'Muscle Relaxants, Central/adverse effects/classification/*therapeutic use', 'Musculoskeletal Diseases/drug therapy', 'Nervous System Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18225966/
873,cyclobenzaprine,26868680,"Maladaptive plasticity in tinnitus--triggers, mechanisms and treatment.","['Shore SE', 'Roberts LE', 'Langguth B']","['Animals', 'Auditory Cortex/pathology/physiopathology', 'Auditory Pathways/pathology/*physiopathology', 'Cochlear Nucleus/pathology/physiopathology', 'Humans', 'Neuronal Plasticity/*physiology', 'Noise/adverse effects', 'Tinnitus/*diagnosis/*physiopathology/therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26868680/
874,cyclobenzaprine,38355316,"""Fibromyalgia - are there any new approaches?"".","['Martinez JE', 'Guimaraes I']","['*Fibromyalgia/therapy/drug therapy', 'Humans', '*Cognitive Behavioral Therapy', 'Exercise Therapy', 'Pain Management/methods', 'Analgesics/therapeutic use', 'Patient Education as Topic', 'Combined Modality Therapy']",https://pubmed.ncbi.nlm.nih.gov/38355316/
875,cyclobenzaprine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
876,cyclobenzaprine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
877,cyclobenzaprine,39298168,Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.,"['Oldfield BJ', 'Gleeson B', 'Morford KL', 'Adams Z', 'Funaro MC', 'Becker WC', 'Merlin JS']","['Humans', '*Chronic Pain/drug therapy', 'Muscle Relaxants, Central/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39298168/
878,cyclobenzaprine,38621248,Rheumatology: What You May Have Missed in 2023.,"['Jalali K', 'Mandl LA']","['Humans', '*Glucocorticoids/therapeutic use/adverse effects/administration & dosage', 'Osteoporosis/drug therapy', 'Arthritis, Rheumatoid/drug therapy', 'Antirheumatic Agents/therapeutic use/adverse effects', 'Methotrexate/therapeutic use/adverse effects', 'Rheumatology/standards', 'Rheumatic Diseases/drug therapy/complications', 'Biosimilar Pharmaceuticals/therapeutic use/adverse effects', 'Polymyalgia Rheumatica/drug therapy', 'Fibromyalgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38621248/
879,cyclobenzaprine,27649348,Compounded Topical Analgesics for Chronic Pain.,"['Cline AE', 'Turrentine JE']","['Administration, Cutaneous', 'Amines/administration & dosage', 'Amitriptyline/administration & dosage/analogs & derivatives', 'Analgesics/*administration & dosage', 'Anesthetics, Local/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Baclofen/administration & dosage', 'Capsaicin/administration & dosage', 'Chronic Pain/*drug therapy', 'Clonidine/administration & dosage', 'Cyclohexanecarboxylic Acids/administration & dosage', 'Drug Combinations', 'Drug Compounding', 'Gabapentin', 'Humans', 'Ketamine/administration & dosage', 'Lidocaine/administration & dosage', 'Muscle Relaxants, Central/administration & dosage', 'gamma-Aminobutyric Acid/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27649348/
880,cyclobenzaprine,6620442,Cyclobenzaprine overdosage.,"['Linden CH', 'Mitchiner JC', 'Lindzon RD', 'Rumack BH']","['Adolescent', 'Adult', 'Amitriptyline/*analogs & derivatives/poisoning', 'Female', 'Humans', 'Male', 'Physostigmine/*therapeutic use', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/6620442/
881,cyclobenzaprine,19590258,Torticollis under cyclobenzaprine.,"['Reuss R', 'Reuter I', 'Jauss M', 'Fischer F', 'Muller SC', 'Stolz E']","['Amitriptyline/adverse effects/*analogs & derivatives/therapeutic use', 'Biperiden/therapeutic use', 'Humans', 'Male', 'Muscarinic Antagonists/therapeutic use', 'Muscle Relaxants, Central/*adverse effects/therapeutic use', 'Myoclonus/chemically induced/drug therapy', 'Torticollis/*chemically induced/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19590258/
882,cyclobenzaprine,3078905,Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience.,"['Katz WA', 'Dube J']","['Amitriptyline/*analogs & derivatives/therapeutic use', 'Humans', 'Muscle Relaxants, Central/*therapeutic use', 'Spasm/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3078905/
883,cyclobenzaprine,37165930,"Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial.","['Lederman S', 'Arnold LM', 'Vaughn B', 'Kelley M', 'Sullivan GM']","['Humans', 'Double-Blind Method', '*Fibromyalgia/diagnosis/drug therapy/complications', 'Pain/complications', 'Pain Measurement', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37165930/
884,cyclobenzaprine,2644679,Treatment of fibromyalgia syndrome.,['Goldenberg DL'],"['Amitriptyline/analogs & derivatives/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Fibromyalgia/*drug therapy/therapy', 'Humans', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/2644679/
885,cyclobenzaprine,1861061,Post-triathalon delirium.,"['Stephen JM', 'Ghezzi KT', 'Bailey K', 'Shesser R']","['Adult', '*Akathisia, Drug-Induced', 'Amitriptyline/*analogs & derivatives/poisoning', 'Delirium/*chemically induced/diagnosis/drug therapy', 'Humans', 'Male', 'Muscle Relaxants, Central/*poisoning', 'Physostigmine/therapeutic use', 'Psychomotor Agitation/drug therapy', 'Sports']",https://pubmed.ncbi.nlm.nih.gov/1861061/
886,cyclobenzaprine,27474822,PURLs: More isn't better with acute low back pain treatment.,"['Frazer K', 'Stevermer JJ']","['Acetaminophen/*therapeutic use', 'Amitriptyline/*analogs & derivatives/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Low Back Pain/*drug therapy', 'Male', 'Muscle Relaxants, Central/*therapeutic use', 'Naproxen/*therapeutic use', 'Oxycodone/*therapeutic use', 'Pain Measurement', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27474822/
887,cyclobenzaprine,31017819,Transfer of Cyclobenzaprine into Human Milk and Subsequent Infant Exposure.,"['Burra B', 'Datta P', 'Rewers-Felkins K', 'Baker T', 'Hale TW']","['Adult', 'Amitriptyline/adverse effects/*analogs & derivatives/pharmacokinetics', '*Breast Feeding', 'Diagnosis, Differential', 'Female', 'Humans', 'Infant, Newborn', 'Mass Spectrometry', 'Milk, Human/*chemistry/metabolism', 'Muscle Relaxants, Central/*adverse effects/pharmacokinetics', 'Pain/*drug therapy', 'Pregnancy', '*Prenatal Care']",https://pubmed.ncbi.nlm.nih.gov/31017819/
888,cyclobenzaprine,8187451,Fibromyalgia associated with female urethral syndrome.,['Paira SO'],"['Adult', 'Aged', 'Blood Sedimentation', 'Female', 'Fibromyalgia/*complications', 'Humans', 'Middle Aged', 'Retrospective Studies', 'Syndrome', 'Urethral Diseases/*complications/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/8187451/
889,dapsone,12165212,Dapsone.,"['Wolf R', 'Matz H', 'Orion E', 'Tuzun B', 'Tuzun Y']","['Animals', 'Dapsone/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Dermatologic Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12165212/
890,dapsone,28732451,Dapsone and azole interactions: A clinical perspective.,"['Corallo C', 'Coutsouvelis J', 'Avery S', 'Morgan S', 'Morrissey O']","['Anti-Infective Agents/adverse effects/*metabolism', 'Azoles/adverse effects/*metabolism', 'Dapsone/adverse effects/*metabolism', 'Drug Interactions/physiology', 'Hemolysis/drug effects/physiology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/28732451/
891,dapsone,22560144,Dapsone in the management of autoimmune bullous diseases.,"['Piette EW', 'Werth VP']","['Agranulocytosis/etiology', 'Animals', 'Autoimmune Diseases/*drug therapy/immunology', 'Dapsone/adverse effects/chemistry/*therapeutic use', 'Disease Management', 'Drug Hypersensitivity/etiology', 'Humans', 'Leprostatic Agents/*therapeutic use', 'Methemoglobinemia/etiology', 'Neutrophil Activation/drug effects', 'Neutrophils/drug effects/immunology', 'Skin Diseases, Vesiculobullous/*drug therapy/immunology']",https://pubmed.ncbi.nlm.nih.gov/22560144/
892,dapsone,29762952,Dapsone: An Update.,"['Karjigi S', 'Murthy SC', 'Kallappa H', 'Kusuma MR', 'Aruna B', 'Reddy YN']","['Agranulocytosis/etiology', 'Dapsone/adverse effects/*therapeutic use', 'Drug Hypersensitivity Syndrome/etiology', 'Humans', 'Leprostatic Agents/adverse effects/*therapeutic use', 'Leprosy/*drug therapy', 'Methemoglobinemia/etiology', 'Skin Diseases/etiology']",https://pubmed.ncbi.nlm.nih.gov/29762952/
893,dapsone,1894406,Superficial granulomatous pyoderma.,"['Lichter MD', 'Welykyj SE', 'Gradini R', 'Solomon LM']","['Adult', 'Chronic Disease', 'Dapsone/administration & dosage/therapeutic use', 'Diagnosis, Differential', 'Granuloma/drug therapy/*pathology', 'Humans', 'Male', 'Minocycline/administration & dosage/therapeutic use', 'Pyoderma/drug therapy/*pathology', 'Recurrence', 'Skin Ulcer/drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/1894406/
894,dapsone,27514363,Pemphigus foliaceus with circinated plaques and neutrophil pustules.,"['Mendez-Flores S', 'Avalos-Diaz E', 'Dominguez-Cherit J', 'Saeb-Lima M', 'Esquivel-Pedraza L']","['Dapsone/*administration & dosage/therapeutic use', 'Female', 'Humans', 'Neutrophils/*pathology', 'Pemphigus/*diagnosis/drug therapy/immunology', 'Prednisolone/*administration & dosage/therapeutic use', 'Recurrence', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27514363/
895,dapsone,21571168,"Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis.","['Bolotin D', 'Petronic-Rosic V']","['Anti-Infective Agents/administration & dosage/adverse effects/therapeutic use', 'Dapsone/administration & dosage/adverse effects/therapeutic use', 'Dermatitis Herpetiformis/*diagnosis/diet therapy/immunology/*therapy', 'Diet, Gluten-Free', 'Humans', 'Patient Care Team', 'Physical Examination', 'Prognosis', 'Serologic Tests', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21571168/
896,dapsone,11155588,Dapsone and sulfapyridine.,"['Paniker U', 'Levine N']","['Anti-Infective Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Dapsone/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Dermatologic Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Leprosy/drug therapy', 'Skin Diseases/*drug therapy', 'Sulfapyridine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11155588/
897,dapsone,24028818,Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.,"['Georgakopoulou EA', 'Scully C']","['Anti-Infective Agents/therapeutic use', 'Calcineurin Inhibitors/pharmacology/*therapeutic use', 'Colchicine/pharmacology/*therapeutic use', 'Cyclophosphamide/pharmacology/*therapeutic use', 'Cyclosporine/therapeutic use', 'Dapsone/pharmacology/*therapeutic use', 'Drug Interactions', 'Drug Monitoring', 'Facial Dermatoses/drug therapy', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Mouth Diseases/*drug therapy', 'Tacrolimus/therapeutic use', 'Thalidomide/pharmacology/*therapeutic use', 'Tubulin Modulators/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24028818/
898,dapsone,18811870,Dapsone-induced photosensitivity: a rare clinical presentation.,['Kar BR'],"['Adult', 'Dapsone/administration & dosage/*adverse effects', 'Humans', 'India', 'Leprostatic Agents/administration & dosage/*adverse effects', 'Leprosy, Lepromatous/*drug therapy/pathology', 'Male', 'Photosensitivity Disorders/*chemically induced/pathology']",https://pubmed.ncbi.nlm.nih.gov/18811870/
899,dapsone,38583518,Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.,"['Prosty C', 'Katergi K', 'Sorin M', 'Rjeily MB', 'Butler-Laporte G', 'McDonald EG', 'Lee TC']","['Humans', '*Pneumonia, Pneumocystis/prevention & control', '*Randomized Controlled Trials as Topic', '*Network Meta-Analysis', '*Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use/administration & dosage/adverse effects', '*Pneumocystis carinii/drug effects', '*HIV Infections/complications', 'AIDS-Related Opportunistic Infections/prevention & control/drug therapy', 'Dapsone/therapeutic use/adverse effects/administration & dosage', 'Pentamidine/therapeutic use/administration & dosage/adverse effects', 'Atovaquone/therapeutic use/adverse effects', 'Antifungal Agents/therapeutic use/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38583518/
900,dapsone,3013789,Dapsone-induced peripheral neuropathy.,"['Ahrens EM', 'Meckler RJ', 'Callen JP']","['Administration, Oral', 'Adult', 'Dapsone/administration & dosage/*adverse effects', 'Dermatitis Herpetiformis/drug therapy', 'Humans', 'Injections, Intramuscular', 'Male', 'Peripheral Nervous System Diseases/*chemically induced/drug therapy', 'Prednisone/administration & dosage', 'Sulfapyridine/administration & dosage', 'Time Factors', 'Vitamin B 12/administration & dosage', 'Vitamins/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3013789/
901,dapsone,31116809,Relapsing polychondritis in human immunodeficiency virus.,"['Quinn K', 'Lountzis N', 'Purcell SM']","['Adult', 'Dapsone/administration & dosage/therapeutic use', 'Diagnosis, Differential', 'Ear, External/pathology', '*HIV Infections', 'Humans', 'Male', 'Polychondritis, Relapsing/*diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31116809/
902,dapsone,8942159,Dapsone agranulocytosis in a leprosy patient.,"['Hiran S', 'Pande TK', 'Pani S', 'Vishwanathan KA']","['Adult', 'Agranulocytosis/*chemically induced/physiopathology', 'Dapsone/*adverse effects/therapeutic use', 'Female', 'Humans', 'Leprostatic Agents/*adverse effects/therapeutic use', 'Leprosy/diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8942159/
903,dapsone,15692440,[Disulone].,"['Begon E', 'Chosidow O', 'Wolkenstein P']","['*Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', '*Dapsone/pharmacology/therapeutic use', 'Humans', 'Skin Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15692440/
904,dapsone,9606476,Dapsone-induced methemoglobinemia.,"['Ward KE', 'McCarthy MW']","['Aged', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Antibiotic Prophylaxis', 'Dapsone/*adverse effects/therapeutic use', 'Female', 'Humans', 'Methemoglobinemia/*chemically induced', 'Pneumonia, Pneumocystis/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/9606476/
905,dapsone,39078587,Dapsone Use in Dermatology.,"['Lovell KK', 'Momin RI', 'Sangha HS', 'Feldman SR', 'Pichardo RO']","['*Dapsone/therapeutic use/pharmacology', 'Humans', '*Off-Label Use', 'Skin Diseases/drug therapy', 'Leprosy/drug therapy', 'Treatment Outcome', 'Leprostatic Agents/therapeutic use/adverse effects', 'Dermatitis Herpetiformis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39078587/
906,dapsone,21822117,Age old dapsone in the treatment of idiopathic thrombocytopenic purpura--a case report with review.,"['Kundu R', 'Sethi N', 'Ghose A', 'Chaudhary R']","['Anti-Inflammatory Agents/adverse effects/*therapeutic use', 'Dapsone/adverse effects/*therapeutic use', 'Female', 'Humans', 'Middle Aged', 'Purpura, Thrombocytopenic, Idiopathic/*drug therapy/physiopathology', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21822117/
907,dapsone,528697,Sulfones and sulfonamides in dermatology today.,['Lang PG Jr'],"['Agranulocytosis/chemically induced', 'Dapsone/metabolism/pharmacology/*therapeutic use', 'Drug Hypersensitivity/etiology', 'Hemolysis/drug effects', 'Humans', 'Kidney Diseases/chemically induced', 'Methemoglobinemia/chemically induced', 'Skin Diseases/*drug therapy', 'Sulfanilamides/*therapeutic use', 'Sulfapyridine/metabolism/pharmacology/*therapeutic use', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/528697/
908,dapsone,35249339,Efficacy and safety of dapsone gel for acne: a systematic review and meta-analysis.,"['Wang X', 'Wang Z', 'Sun L', 'Liu H', 'Zhang F']","['*Acne Vulgaris/chemically induced/drug therapy', 'Anti-Bacterial Agents/therapeutic use', 'Dapsone/adverse effects/therapeutic use', '*Eczema', 'Female', 'Humans', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/35249339/
909,diazepam,28101764,Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal.,['Weintraub SJ'],"['Alcohol Withdrawal Delirium/*drug therapy', 'Alcohol Withdrawal Seizures/*drug therapy', 'Benzodiazepines/administration & dosage/adverse effects/pharmacokinetics', 'Diazepam/*administration & dosage/adverse effects/pharmacokinetics', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects/pharmacokinetics', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/28101764/
910,diazepam,24552479,Classics in chemical neuroscience: diazepam (valium).,"['Calcaterra NE', 'Barrow JC']","['Anxiety Disorders/*drug therapy', 'Diazepam/*administration & dosage/*adverse effects', 'Dose-Response Relationship, Drug', 'Drug Design', 'Drug Overdose/*etiology/prevention & control', 'Humans', 'Respiration Disorders/*chemically induced/prevention & control', 'Seizures/*chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/24552479/
911,diazepam,1505149,"Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time.","['Friedman H', 'Greenblatt DJ', 'Peters GR', 'Metzler CM', 'Charlton MD', 'Harmatz JS', 'Antal EJ', 'Sanborn EC', 'Francom SF']","['Administration, Oral', 'Adult', 'Conscious Sedation', 'Diazepam/blood/*pharmacokinetics/pharmacology', 'Dose-Response Relationship, Drug', 'Electroencephalography/drug effects', 'Female', 'Humans', 'Male', 'Motor Activity/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1505149/
912,diazepam,11963349,Diazepam use during pregnancy: a review of the literature.,"['Iqbal MM', 'Sobhan T', 'Aftab SR', 'Mahmud SZ']","['Animals', 'Anti-Anxiety Agents/administration & dosage/*adverse effects', 'Anxiety/*drug therapy', 'Diazepam/administration & dosage/*adverse effects', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Infant, Newborn, Diseases/*chemically induced', 'Lactation/*drug effects', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Rats', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/11963349/
913,diazepam,2292778,Diazepam (Valium): its dependency liability.,['Murray JB'],"['Arousal/drug effects', '*Diazepam/adverse effects/pharmacokinetics', 'Drug Tolerance', 'Humans', 'Substance Withdrawal Syndrome/psychology', 'Substance-Related Disorders/*psychology']",https://pubmed.ncbi.nlm.nih.gov/2292778/
914,diazepam,7990791,Eclampsia.,"['Kaplan PW', 'Repke JT']","['Diagnosis, Differential', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics', 'Eclampsia/diagnosis/*etiology/therapy', 'Female', 'Humans', 'Infant, Newborn', 'Magnesium Sulfate/administration & dosage/adverse effects/pharmacokinetics', 'Neurologic Examination/drug effects', 'Phenytoin/administration & dosage/adverse effects/pharmacokinetics', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/7990791/
915,diazepam,6120393,Diazepam and the risk of breast cancer.,"['Kaufman DW', 'Shapiro S', 'Slone D', 'Rosenberg L', 'Helmrich SP', 'Miettinen OS', 'Stolley PD', 'Levy M', 'Schottenfeld D']","['Adult', 'Animals', 'Breast Neoplasms/*chemically induced', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Female', 'Humans', 'Menopause', 'Middle Aged', 'Rats', 'Risk', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6120393/
916,diazepam,27731571,Local Anesthetics Systemic Toxicity.,"['Jayanthi R', 'Nasser K', 'Monica K']","['Administration, Intravenous', 'Adult', 'Anesthetics, Local/administration & dosage/*adverse effects', 'Diazepam/administration & dosage/therapeutic use', 'Female', 'Humans', 'Lidocaine/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Seizures/*chemically induced/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27731571/
917,diazepam,19519511,The plastic phenomenon underlying the associative processes in the addictive properties of diazepam and other psychoactive drugs.,"['Ramirez OA', 'Perez MF']","['Animals', 'Behavior, Addictive/*chemically induced', 'Brain/drug effects/physiopathology', 'Diazepam/administration & dosage/*adverse effects/chemistry', 'Drug Tolerance', 'Humans', 'Psychotropic Drugs/administration & dosage/*adverse effects/chemistry', 'Substance-Related Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/19519511/
918,diazepam,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
919,diazepam,2185438,The pharmacokinetics of agents used to treat status epilepticus.,['Browne TR'],"['Anticonvulsants/*pharmacokinetics/therapeutic use', 'Diazepam/administration & dosage/blood/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Injections, Intramuscular', 'Lipid Metabolism', 'Phenobarbital/administration & dosage/pharmacokinetics', 'Phenytoin/administration & dosage/blood/pharmacokinetics', 'Solubility', 'Status Epilepticus/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185438/
920,diazepam,25538342,A case of etizolam dependence.,"['Gupta S', 'Garg B']","['Adult', 'Anti-Anxiety Agents/*adverse effects/therapeutic use', 'Anxiety Disorders/drug therapy', 'Diazepam/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Male', 'Substance-Related Disorders/*etiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25538342/
921,diazepam,1547766,Intrarectal diazepam in epileptic adults.,"['Remy C', 'Jourdil N', 'Villemain D', 'Favel P', 'Genton P']","['Administration, Rectal', 'Adult', 'Diazepam/*administration & dosage/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Electroencephalography', 'Epilepsies, Partial/drug therapy/physiopathology', 'Epilepsy/*drug therapy/physiopathology', 'Female', 'Humans', 'Male', 'Status Epilepticus/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/1547766/
922,diazepam,9448787,Use of inhalational and intravenous sedation in dentistry.,['Rodrigo MR'],"['Accidents', '*Anesthesia, Dental', '*Anesthesia, Inhalation', '*Anesthesia, Intravenous', 'Anesthesia, Local', 'Anesthetics, Inhalation/administration & dosage', 'Anesthetics, Intravenous/administration & dosage', 'Anti-Anxiety Agents/administration & dosage/adverse effects/antagonists & inhibitors', 'Antidotes/therapeutic use', 'Cause of Death', 'Computers', '*Conscious Sedation', 'Dental Care', 'Diazepam/administration & dosage/adverse effects/antagonists & inhibitors', 'Drug Overdose', 'Emergencies', 'Flumazenil/therapeutic use', 'GABA Modulators/therapeutic use', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Iatrogenic Disease', 'Infusion Pumps', 'Isoflurane/administration & dosage', 'Midazolam/administration & dosage', 'Nitrous Oxide/administration & dosage', 'Oxygen/administration & dosage', 'Practice Guidelines as Topic', 'Propofol/administration & dosage', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/9448787/
923,diazepam,25030,Pain and clinical thrombophlebitis following intravenous diazepam and lorazepam.,"['Graham CW', 'Pagano RR', 'Conner JT']","['Adolescent', 'Adult', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intravenous', 'Lorazepam/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Pain/*chemically induced', 'Thrombophlebitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25030/
924,diazepam,9097367,New drug therapy for acute seizure management.,"['Morton LD', 'Rizkallah E', 'Pellock JM']","['Acute Disease', 'Anticonvulsants/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Child', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Epilepsy/*drug therapy', 'Humans', 'Phenytoin/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Prodrugs/adverse effects/pharmacokinetics/therapeutic use', 'Seizures/*drug therapy', 'Valproic Acid/administration & dosage/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9097367/
925,diazepam,1454506,Influence of diazepam on prospective time estimation.,"['Unrug-Neervoort A', 'Kaiser J', 'Coenen A']","['Adult', 'Attention/drug effects', 'Diazepam/adverse effects/*pharmacology', 'Double-Blind Method', 'Humans', 'Placebos', 'Psychomotor Performance/*drug effects', 'Random Allocation', 'Time Perception/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1454506/
926,diazepam,329424,Selection among benzodiazepines for alcohol withdrawal.,"['Keeler MH', 'Miller WC']","['Administration, Oral', 'Benzodiazepines/administration & dosage/pharmacology/*therapeutic use', 'Central Nervous System/drug effects', 'Chlordiazepoxide/administration & dosage/pharmacology/therapeutic use', 'Clorazepate Dipotassium/administration & dosage/pharmacology/therapeutic use', 'Depression, Chemical', 'Diazepam/administration & dosage/pharmacology/therapeutic use', 'Drug Synergism', '*Ethanol', 'Half-Life', 'Humans', 'Oxazepam/administration & dosage/pharmacology/therapeutic use', 'Seizures/drug therapy', 'Substance Withdrawal Syndrome/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/329424/
927,diazepam,1068178,Human cardiorespiratory and analgesic effects of intravenous diazepam and local anesthesia.,"['Allen GD', 'Everett GB', 'Butler LA']","['*Analgesics', '*Anesthesia, Dental', '*Anesthesia, Local', 'Cardiac Output/drug effects', 'Diazepam/administration & dosage/*pharmacology', 'Female', 'Heart/*drug effects', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Lidocaine', 'Male', 'Mandibular Nerve', 'Nerve Block', 'Respiration/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1068178/
928,diazepam,34954745,Oxazepam Detected in Urine 79 Days After Withdrawal of Diazepam: A Case Report.,"['Serkland TT', 'Dale GH', 'Kaldestad IC', 'Berg JA', 'Methlie CB']","['Adult', 'Benzodiazepines/adverse effects', 'Diazepam/adverse effects/pharmacokinetics', 'Female', 'Humans', 'Oxazepam/adverse effects', '*Substance Withdrawal Syndrome/diagnosis/etiology', '*Substance-Related Disorders/complications']",https://pubmed.ncbi.nlm.nih.gov/34954745/
929,dicyclomine,31515515,Nausea and vomiting of pregnancy and hyperemesis gravidarum.,"['Fejzo MS', 'Trovik J', 'Grooten IJ', 'Sridharan K', 'Roseboom TJ', 'Vikanes A', 'Painter RC', 'Mullin PM']","['Antiemetics/therapeutic use', 'Dicyclomine/therapeutic use', 'Doxylamine/therapeutic use', 'Drug Combinations', 'Female', 'Growth Differentiation Factor 15/analysis', 'Humans', 'Hyperemesis Gravidarum/*diagnosis/epidemiology', 'Mass Screening/methods', 'Nausea/etiology', 'Pregnancy', 'Pyridoxine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31515515/
930,dicyclomine,29941700,Infantile Colic: An Update.,"['Sarasu JM', 'Narang M', 'Shah D']","['Behavior Therapy/methods', 'Colic/*diagnosis/etiology/therapy', 'Counseling/methods', 'Crying', 'Diet Therapy/methods', 'Humans', 'Infant', 'Infant, Newborn', 'Parasympatholytics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29941700/
931,dicyclomine,15160628,Infantile colic.,['Kanabar D'],"['Antifoaming Agents/therapeutic use', 'Anxiety/etiology', '*Colic/diagnosis/therapy', 'Controlled Clinical Trials as Topic', 'Crying', 'Dicyclomine/therapeutic use', 'Evidence-Based Medicine', 'Humans', '*Infant Welfare', 'Infant, Newborn', '*Lactose Intolerance/diagnosis/drug therapy', 'Parent-Child Relations', 'Simethicone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15160628/
932,dicyclomine,30306546,Dietary modifications for infantile colic.,"['Gordon M', 'Biagioli E', 'Sorrenti M', 'Lingua C', 'Moja L', 'Banks SS', 'Ceratto S', 'Savino F']","['Allergens', 'Colic/*diet therapy', 'Crying', 'Diet Therapy/methods', 'Female', 'Humans', 'Infant', '*Infant Formula', 'Lactase/administration & dosage', 'Male', 'Randomized Controlled Trials as Topic', 'Soybean Proteins/administration & dosage', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/30306546/
933,dicyclomine,26447441,Infantile Colic: Recognition and Treatment.,"['Johnson JD', 'Cocker K', 'Chang E']","['Colic/*diagnosis/*diet therapy/*drug therapy', 'Education, Medical, Continuing', 'Female', 'Gastrointestinal Agents/*therapeutic use', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Pediatrics/*standards', '*Practice Guidelines as Topic', 'Probiotics/*therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/26447441/
934,dicyclomine,27038970,The Link Between Infantile Colic and Migraine.,"['Qubty W', 'Gelfand AA']","['Colic/complications/diagnosis/*drug therapy', 'Dicyclomine/*therapeutic use', '*Diet Therapy', 'Humans', 'Migraine Disorders/complications/diagnosis/*drug therapy', 'Proton Pump Inhibitors/*therapeutic use', 'Simethicone/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27038970/
935,dicyclomine,3777291,Drugs and stillbirth.,"['Porter JB', 'Hunter-Mitchell J', 'Jick H', 'Walker AM']","['Abnormalities, Drug-Induced', 'Adult', 'Anti-Bacterial Agents/*adverse effects', 'Contraceptives, Oral/*adverse effects', 'Dicyclomine', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Fetal Death/*chemically induced', 'Health Surveys', 'Humans', 'Pregnancy', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Spermatocidal Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3777291/
936,dicyclomine,33993133,Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.,"['Brenner DM', 'Lacy BE']","['Abdominal Pain/*drug therapy', 'Chronic Pain/*drug therapy', 'Humans', 'North America', 'Parasympatholytics/*supply & distribution/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33993133/
937,dicyclomine,24548499,A new pharmacologic treatment for nausea and vomiting of pregnancy.,['Fantasia HC'],"['Abnormalities, Drug-Induced/prevention & control', 'Antiemetics/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Dicyclomine/administration & dosage/adverse effects/*therapeutic use', 'Doxylamine/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Drug Information Services', 'Female', 'Humans', 'Hyperemesis Gravidarum/*drug therapy/etiology', 'Morning Sickness/*drug therapy/etiology', 'Obstetric Nursing/standards', 'Pregnancy', 'Pyridoxine/administration & dosage/adverse effects/*therapeutic use', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/24548499/
938,dicyclomine,6384676,Effects of drugs and chemicals on the fetus and newborn (1).,"['Hill LM', 'Kleinberg F']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Antiemetics/adverse effects', 'Behavior/drug effects', 'Caffeine/adverse effects', 'Dicyclomine', 'Doxylamine/adverse effects', 'Drug Combinations/adverse effects', 'Embryo, Mammalian/drug effects', 'Female', 'Ferrous Compounds/adverse effects', 'Fetus/*drug effects', 'Humans', 'Infant, Newborn', 'Male', 'Maternal-Fetal Exchange', 'Nervous System/drug effects', 'Nonprescription Drugs/adverse effects', 'Oocytes/drug effects', 'Pregnancy', 'Prenatal Exposure Delayed Effects', 'Pyridoxine/adverse effects', 'Reproduction/drug effects', 'Spermatozoa/drug effects', 'Vitamins/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6384676/
939,dicyclomine,14994923,[Hyperemesis gravidarum--etiology and treatment].,"['Imperato F', 'Canova I', 'Basili R', 'Iuele T', 'Mossa B']","['Adrenal Cortex Hormones/administration & dosage/adverse effects/therapeutic use', 'Antiemetics/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dicyclomine', 'Doxylamine/administration & dosage/therapeutic use', 'Drug Combinations', 'Enteral Nutrition', 'Female', 'Histamine Antagonists/administration & dosage/therapeutic use', 'Humans', '*Hyperemesis Gravidarum/complications/drug therapy/etiology/psychology/therapy', 'Odds Ratio', 'Parenteral Nutrition', 'Placebos', 'Pregnancy', 'Pyridoxine/administration & dosage/therapeutic use', 'Risk Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/14994923/
940,dicyclomine,6734920,Comparison of dicyclomine with antacid and without antacid in dyspepsia.,"['Kagan G', 'Huddlestone L', 'Wolstencroft P']","['Antacids/adverse effects/*therapeutic use', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Dicyclomine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Evaluation', 'Drug Therapy, Combination', 'Dyspepsia/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/6734920/
941,dicyclomine,16822454,Clinical inquiries. What is the best treatment for infants with colic?,"['Crotteau CA', 'Wright ST', 'Eglash A']","['Breast Feeding', 'Colic/diet therapy/drug therapy/*therapy', 'Food Hypersensitivity/complications', 'Humans', 'Infant', '*Infant Formula']",https://pubmed.ncbi.nlm.nih.gov/16822454/
942,dicyclomine,22436257,Epidemiological evidence in forensic pharmacovigilance.,"['Persaud N', 'Healy D']","['Abnormalities, Drug-Induced/epidemiology', 'Antiemetics/adverse effects/toxicity', 'Breast Implantation/adverse effects/statistics & numerical data', '*Causality', 'Connective Tissue Diseases/epidemiology', 'Dicyclomine/adverse effects/toxicity', 'Doxylamine/adverse effects/toxicity', 'Drug Combinations', 'Female', 'Forensic Sciences/*legislation & jurisprudence/organization & administration', 'Humans', 'Pharmacoepidemiology/*legislation & jurisprudence/organization & administration', 'Pharmacology/legislation & jurisprudence/methods', '*Pharmacovigilance', 'Pregnancy', 'Pyridoxine/adverse effects/toxicity']",https://pubmed.ncbi.nlm.nih.gov/22436257/
943,dicyclomine,24798673,Should doxylamine-pyridoxine be used for nausea and vomiting of pregnancy?,"['Persaud N', 'Chin J', 'Walker M']","['Abnormalities, Drug-Induced', 'Antiemetics/*therapeutic use', 'Dicyclomine/*therapeutic use', 'Doxylamine/*therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Morning Sickness/*drug therapy', 'Neoplasms/chemically induced', 'Practice Guidelines as Topic', 'Pregnancy', 'Pyloric Stenosis/chemically induced', 'Pyridoxine/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/24798673/
944,dicyclomine,3927122,"The creation of therapeutic orphans--or, what have we learnt from the Debendox fiasco?","['Sheffield LJ', 'Batagol R']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Antiemetics/*adverse effects', 'Australia', 'Clinical Trials as Topic', 'Cyclohexanecarboxylic Acids/*adverse effects', 'Dicyclomine/*adverse effects', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Haplorhini', 'Humans', 'Infant, Newborn', 'Macaca fascicularis', 'Pregnancy', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Rabbits', 'Random Allocation', 'Rats', 'Risk', '*Teratogens', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/3927122/
945,dicyclomine,8486081,Preliminary note: dangerous use of anticholinergic drugs in Brazil.,['Carlini EA'],"['Adolescent', 'Adult', 'Brazil/epidemiology', 'Child', 'Cross-Sectional Studies', '*Developing Countries', 'Humans', 'Incidence', 'Parasympatholytics/*adverse effects', 'Substance-Related Disorders/epidemiology/*etiology']",https://pubmed.ncbi.nlm.nih.gov/8486081/
946,dicyclomine,32737240,Protection Versus Progress: The Challenge of Research on Cannabis Use During Pregnancy.,"['MacDuffie KE', 'Kleinhans NM', 'Stout K', 'Wilfond BS']","['Antiemetics/adverse effects', 'Dicyclomine/therapeutic use', 'Doxylamine/therapeutic use', 'Drug Approval', 'Drug Combinations', '*Ethics, Research', 'Female', 'Humans', 'Medical Marijuana/adverse effects/*therapeutic use', 'Morning Sickness/*therapy', 'Ondansetron/therapeutic use', 'Pediatrics/*ethics', 'Pregnancy', '*Pregnant People', 'Pyridoxine/therapeutic use', '*Research Subjects', 'Teratogens', 'Thalidomide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32737240/
947,dicyclomine,329860,Treatment of pregnancy sickness.,['Wheatley D'],"['Clinical Trials as Topic', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Dicyclomine/*therapeutic use', 'Double-Blind Method', 'Doxylamine/therapeutic use', 'Female', 'Humans', 'Nausea/*drug therapy', 'Placebos', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Trimester, First', 'Pyridoxine/*therapeutic use', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/329860/
948,dicyclomine,2772850,Bendectin and human congenital malformations.,"['Shiono PH', 'Klebanoff MA']","['Abnormalities, Drug-Induced/*etiology', 'Central Nervous System/abnormalities', 'Dicyclomine', 'Digestive System Abnormalities', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Head/abnormalities', 'Heart Defects, Congenital/chemically induced', 'Humans', 'Lung/abnormalities', 'Pregnancy', 'Pregnancy Trimester, First', 'Prospective Studies', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Urogenital Abnormalities', 'Vomiting']",https://pubmed.ncbi.nlm.nih.gov/2772850/
949,diflunisal,31997769,Interplay between inflammation and cancer.,"['Khandia R', 'Munjal A']","['Animals', 'Anti-Inflammatory Agents/pharmacology/therapeutic use', 'Antineoplastic Agents/pharmacology/therapeutic use', 'Humans', 'Inflammation/drug therapy/*immunology/metabolism/*pathology', 'Neoplasms/drug therapy/*immunology/metabolism/*pathology', 'Tumor Microenvironment/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31997769/
950,diflunisal,33852912,Reducing acetylated tau is neuroprotective in brain injury.,"['Shin MK', 'Vazquez-Rosa E', 'Koh Y', 'Dhar M', 'Chaubey K', 'Cintron-Perez CJ', 'Barker S', 'Miller E', 'Franke K', 'Noterman MF', 'Seth D', 'Allen RS', 'Motz CT', 'Rao SR', 'Skelton LA', 'Pardue MT', 'Fliesler SJ', 'Wang C', 'Tracy TE', 'Gan L', 'Liebl DJ', 'Savarraj JPJ', 'Torres GL', 'Ahnstedt H', 'McCullough LD', 'Kitagawa RS', 'Choi HA', 'Zhang P', 'Hou Y', 'Chiang CW', 'Li L', 'Ortiz F', 'Kilgore JA', 'Williams NS', 'Whitehair VC', 'Gefen T', 'Flanagan ME', 'Stamler JS', 'Jain MK', 'Kraus A', 'Cheng F', 'Reynolds JD', 'Pieper AA']","['Acetylation', 'Alzheimer Disease/*etiology/metabolism/*prevention & control', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Biomarkers/blood/metabolism', 'Brain Injuries, Traumatic/*complications/metabolism', 'Cell Line', 'Diflunisal/therapeutic use', 'Female', 'Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating)', 'Humans', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Neurons/metabolism', '*Neuroprotection', 'Salicylates/therapeutic use', 'Sirtuin 1/metabolism', 'p300-CBP Transcription Factors/antagonists & inhibitors/metabolism', 'tau Proteins/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/33852912/
951,diflunisal,31986086,"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.","['Rubin J', 'Maurer MS']","['Amyloid Neuropathies, Familial/*diagnosis/epidemiology/metabolism/therapy', 'Amyloidosis/diagnosis/metabolism/therapy', 'Arrhythmias, Cardiac/therapy', 'Benzoates/therapeutic use', 'Benzoxazoles/therapeutic use', 'Biopsy', 'Cardiac Pacing, Artificial', 'Cardiomyopathies/*diagnosis/epidemiology/metabolism/therapy', 'Diflunisal/therapeutic use', 'Disease Progression', 'Early Diagnosis', 'Early Medical Intervention', 'Echocardiography', 'Electrocardiography', 'Heart Failure/*diagnosis/epidemiology/metabolism/therapy', 'Humans', 'Immunoglobulin Light-chain Amyloidosis/*diagnosis/epidemiology/metabolism/therapy', 'Immunologic Factors/therapeutic use', 'Magnetic Resonance Imaging', 'Oligonucleotides/therapeutic use', 'Prealbumin/genetics', 'Prognosis', 'Proteasome Inhibitors/therapeutic use', 'Pyrazoles/therapeutic use', 'RNA, Small Interfering/therapeutic use', 'Radionuclide Imaging']",https://pubmed.ncbi.nlm.nih.gov/31986086/
952,diflunisal,35256455,Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.,"['Carroll A', 'Dyck PJ', 'de Carvalho M', 'Kennerson M', 'Reilly MM', 'Kiernan MC', 'Vucic S']","['*Amyloid Neuropathies, Familial/diagnosis/genetics/therapy', '*Heart Diseases/complications', 'Humans', '*Polyneuropathies/diagnosis', 'Prealbumin/genetics', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/35256455/
953,diflunisal,25604431,"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.",['Sekijima Y'],"['Amyloid Neuropathies, Familial/*diagnosis/drug therapy/genetics', 'Benzoxazoles/therapeutic use', 'Diflunisal/therapeutic use', 'Humans', 'Mutation', 'Prealbumin/*genetics']",https://pubmed.ncbi.nlm.nih.gov/25604431/
954,diflunisal,24482069,FAP neuropathy and emerging treatments.,"['Adams D', 'Theaudin M', 'Cauquil C', 'Algalarrondo V', 'Slama M']","['Amyloid Neuropathies, Familial/diagnosis/metabolism/*therapy', 'Animals', 'Benzoxazoles/*therapeutic use', 'Gene Silencing/physiology', 'Humans', '*Liver Transplantation', 'Mutation/*genetics', 'Prealbumin/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/24482069/
955,diflunisal,34633220,The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?,"['Zhong B', 'Huang X', 'Zheng Y', 'Guo X', 'Wu L']","['Amyloid/*antagonists & inhibitors/metabolism', 'Boron Compounds/chemistry/*pharmacology', 'Crown Ethers/chemistry/*pharmacology', '*Drug Development', 'Flavonoids/chemistry/*pharmacology', 'Humans', 'Prealbumin/*antagonists & inhibitors/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34633220/
956,diflunisal,26863524,Non-steroidal anti-inflammatory drugs for chronic low back pain.,"['Enthoven WT', 'Roelofs PD', 'Deyo RA', 'van Tulder MW', 'Koes BW']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Chronic Pain/*drug therapy', 'Diclofenac/therapeutic use', 'Disability Evaluation', 'Humans', 'Ibuprofen/therapeutic use', 'Indomethacin/therapeutic use', 'Low Back Pain/*drug therapy', 'Pain Measurement', 'Piroxicam/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/26863524/
957,diflunisal,23137151,Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).,"['Castellsague J', 'Riera-Guardia N', 'Calingaert B', 'Varas-Lorenzo C', 'Fourrier-Reglat A', 'Nicotra F', 'Sturkenboom M', 'Perez-Gutthann S']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Case-Control Studies', 'Dose-Response Relationship, Drug', 'Gastrointestinal Hemorrhage/*chemically induced', 'Humans', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/23137151/
958,diflunisal,25563511,"Recent advances bioactive 1,2,4-triazole-3-thiones.","['Kucukguzel SG', 'Cikla-Suzgun P']","['Animals', 'Drug Discovery/*methods', 'Humans', 'Thiones/*chemistry/*pharmacology', 'Triazoles/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/25563511/
959,diflunisal,26414123,Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews.,"['Moore RA', 'Derry S', 'Aldington D', 'Wiffen PJ']","['Acute Pain/*drug therapy', 'Administration, Oral', 'Adult', 'Analgesics/*administration & dosage/adverse effects', 'Humans', 'Pain, Postoperative/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26414123/
960,diflunisal,30688456,Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.,"['Yokoyama T', 'Mizuguchi M']","['Allosteric Site', 'Amyloidogenic Proteins/chemistry/*metabolism', 'Crown Ethers/*metabolism', 'Crystallography, X-Ray', 'Diflunisal/metabolism', 'Drug Discovery', 'Humans', 'Prealbumin/chemistry/*metabolism', 'Protein Binding', 'Protein Multimerization/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30688456/
961,diflunisal,6380278,Review of ibuprofen for osteoarthritis.,['Altman RD'],"['Acetaminophen/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Aspirin/therapeutic use', 'Clinical Trials as Topic', 'Diflunisal/therapeutic use', 'Drug Tolerance', 'Fenoprofen/therapeutic use', 'Humans', 'Ibuprofen/administration & dosage/*therapeutic use/toxicity', 'Indomethacin/therapeutic use', 'Meclofenamic Acid/therapeutic use', 'Naproxen/therapeutic use', 'Osteoarthritis/*drug therapy/psychology', 'Phenylbutazone/therapeutic use', 'Sulindac/therapeutic use', 'Tolmetin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6380278/
962,diflunisal,29962408,Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.,"['Yokoyama T', 'Mizuguchi M']","['Amyloid/*antagonists & inhibitors/metabolism', 'Amyloidosis/*drug therapy/genetics', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/therapeutic use', 'Benzoxazoles/pharmacology/therapeutic use', 'Biological Products/*pharmacology/therapeutic use', 'Diflunisal/pharmacology/therapeutic use', 'Humans', 'Mutation', 'Prealbumin/genetics/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/29962408/
963,diflunisal,2670397,Diclofenac sodium.,['Small RE'],"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal', 'Arthritis, Rheumatoid/drug therapy', 'Diclofenac/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Osteoarthritis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2670397/
964,diflunisal,26320814,Synthesis of Diflunisal Thiazolidinones as Anticancer Agents.,"['Senkardes S', 'Ozakpinar OB', 'Ozsavci D', 'Sener A', 'Cevik O', 'Kucukguzel SG']","['Animals', 'Antineoplastic Agents/*chemical synthesis/chemistry/*pharmacology', 'Cell Line, Tumor', 'Chemistry Techniques, Synthetic', 'Diflunisal/*chemistry/pharmacology', 'Drug Screening Assays, Antitumor', 'Humans', 'K562 Cells/drug effects', 'Mice', 'NIH 3T3 Cells']",https://pubmed.ncbi.nlm.nih.gov/26320814/
965,diflunisal,21718552,Sickle cell disease.,"['Meremikwu MM', 'Okomo U']","['Acute Disease', 'Analgesia, Patient-Controlled', '*Anemia, Sickle Cell/blood', 'Blood Transfusion', 'Humans', '*Hydroxyurea/therapeutic use', 'Pneumococcal Vaccines/immunology']",https://pubmed.ncbi.nlm.nih.gov/21718552/
966,diflunisal,25408161,Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.,"['Castano A', 'Drachman BM', 'Judge D', 'Maurer MS']","['Amyloid Neuropathies, Familial/*diagnosis/*therapy', 'Benzoxazoles/therapeutic use', 'Biomarkers', 'Cardiomyopathies/*therapy', 'Cyclooxygenase Inhibitors/therapeutic use', 'Defibrillators, Implantable', 'Diflunisal/therapeutic use', 'Doxycycline/therapeutic use', 'Heart Failure/*therapy', 'Humans', 'Oligonucleotides, Antisense/therapeutic use', 'Organ Transplantation', 'Pacemaker, Artificial', 'RNA, Small Interfering/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25408161/
967,diflunisal,28660543,Therapeutic Strategies Targeting Inherited Cardiomyopathies.,"['Varian K', 'Tang WHW']","['Anti-Arrhythmia Agents/therapeutic use', 'Arrhythmias, Cardiac/drug therapy/genetics', 'Brugada Syndrome/drug therapy', 'Cardiomyopathies/*genetics/*therapy', 'Diflunisal/therapeutic use', 'Genetic Therapy', 'Humans', 'Mexiletine/therapeutic use', 'Mutation', 'Myocardial Contraction']",https://pubmed.ncbi.nlm.nih.gov/28660543/
968,diflunisal,32882920,Applications and Limitations of Dendrimers in Biomedicine.,"['Chis AA', 'Dobrea C', 'Morgovan C', 'Arseniu AM', 'Rus LL', 'Butuca A', 'Juncan AM', 'Totan M', 'Vonica-Tincu AL', 'Cormos G', 'Muntean AC', 'Muresan ML', 'Gligor FG', 'Frum A']","['Animals', 'Anti-Inflammatory Agents/chemistry/pharmacology', '*Biomedical Technology', 'Cell Death', 'Dendrimers/chemical synthesis/*chemistry/toxicity', 'Diagnostic Imaging', 'Humans', 'Toxicity Tests']",https://pubmed.ncbi.nlm.nih.gov/32882920/
969,dipyridamole,10493274,Extended-release dipyridamole/aspirin.,"['Hervey PS', 'Goa KL']","['Animals', 'Aspirin/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Delayed-Action Preparations/pharmacokinetics/pharmacology/*therapeutic use', 'Dipyridamole/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Combinations', 'Humans', 'Platelet Aggregation Inhibitors/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10493274/
970,dipyridamole,20955431,Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia.,"['Melani A', 'Cipriani S', 'Corti F', 'Pedata F']","['Animals', 'Brain Ischemia/*drug therapy/psychology', 'Carotid Artery, Common', 'Dipyridamole/*administration & dosage', 'Disease Models, Animal', 'Humans', 'Infusions, Intravenous', 'Memory/drug effects', 'Neuroprotective Agents/administration & dosage', 'Rats', 'Stroke/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/20955431/
971,dipyridamole,1298987,Hypoxemia in thalassemia.,"['Fucharoen S', 'Winichagoon P', 'Siritanaratkul N', 'Sonakul D', 'Chantaraksri U', 'Bunyaratvej A', 'Piankijagum A', 'Wasi P']","['Aspirin/administration & dosage/pharmacology/therapeutic use', 'Blood Gas Analysis', 'Dipyridamole/administration & dosage/pharmacology/therapeutic use', 'Follow-Up Studies', 'Heart Failure/etiology', 'Humans', 'Hypoxia/blood/drug therapy/*etiology', '*Platelet Aggregation', 'Pulmonary Circulation', 'Pulmonary Heart Disease/etiology', 'Splenectomy', 'Thalassemia/*complications/surgery']",https://pubmed.ncbi.nlm.nih.gov/1298987/
972,dipyridamole,18367036,Use of antiplatelet agents to prevent stroke: what is the role for combinations of medications?,"['Schwartz NE', 'Albers GW']","['Aspirin/administration & dosage/adverse effects', 'Clinical Trials as Topic/statistics & numerical data', 'Clopidogrel', 'Dipyridamole/administration & dosage/adverse effects', 'Drug Interactions/physiology', 'Drug Therapy, Combination', 'Hemorrhage/chemically induced/physiopathology', 'Humans', 'Platelet Aggregation Inhibitors/*administration & dosage/*adverse effects', 'Risk Assessment', 'Stroke/*drug therapy/physiopathology/*prevention & control', 'Ticlopidine/administration & dosage/adverse effects/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/18367036/
973,dipyridamole,7025599,Antiplatelet therapy.,['Sloan RW'],"['Anticoagulants/therapeutic use', 'Arteriosclerosis/drug therapy/physiopathology', 'Aspirin/pharmacology/*therapeutic use', 'Blood Platelets/drug effects/physiology', 'Coronary Disease/drug therapy/physiopathology', 'Dipyridamole/pharmacology/*therapeutic use', 'Epoprostenol/adverse effects', 'Female', 'Heart Valve Prosthesis', 'Humans', 'Male', 'Platelet Aggregation/*drug effects', 'Sulfinpyrazone/pharmacology/*therapeutic use', 'Thrombophlebitis/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7025599/
974,dipyridamole,2656267,Dipyridamole-echocardiography test: historical background and physiologic basis.,['Picano E'],"['Coronary Disease/*diagnosis', '*Dipyridamole/adverse effects/physiology', 'Echocardiography/*methods', 'Exercise Test', 'Humans', 'Ischemia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2656267/
975,dipyridamole,19671560,Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy.,"['Adams C', 'Dhirendra A', 'Ames PR']","['Acute Disease', 'Adult', 'Brain Ischemia/*chemically induced/drug therapy', 'Dipyridamole/administration & dosage/*adverse effects', 'Female', 'Hemorrhage/*chemically induced/drug therapy', 'Humans', 'Iatrogenic Disease', 'Platelet Aggregation Inhibitors/administration & dosage/*adverse effects', 'Serotonin 5-HT1 Receptor Agonists/administration & dosage/*adverse effects', 'Stroke/*chemically induced/drug therapy', 'Sumatriptan/administration & dosage/*adverse effects', 'Thrombocytopenia/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19671560/
976,dipyridamole,10847250,Update on antiplatelet therapy for stroke prevention.,"['Sacco RL', 'Elkind MS']","['Aspirin/administration & dosage', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Dipyridamole/administration & dosage', 'Dose-Response Relationship, Drug', 'Humans', 'Ischemic Attack, Transient/complications', 'Platelet Aggregation Inhibitors/administration & dosage/*therapeutic use', 'Risk Factors', 'Stroke/etiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/10847250/
977,dipyridamole,18173959,Antiplatelet therapy for stroke prevention.,['Hankey GJ'],"['Anticoagulants/adverse effects/therapeutic use', 'Aspirin/adverse effects/*therapeutic use', 'Atherosclerosis/complications', 'Atrial Fibrillation/complications', 'Clinical Trials as Topic', 'Clopidogrel', 'Dipyridamole/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Platelet Aggregation Inhibitors/adverse effects/*therapeutic use', 'Stroke/etiology/*prevention & control', 'Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18173959/
978,dipyridamole,10453294,Dipyridamole stress echocardiography.,"['Picano E', 'Sicari R', 'Varga A']","['Adrenergic beta-Agonists', 'Cardiotonic Agents', 'Clinical Protocols', 'Coronary Disease/*diagnostic imaging/metabolism', '*Dipyridamole/administration & dosage/adverse effects', 'Dobutamine', 'Echocardiography/*methods', 'Electrocardiography', '*Exercise Test', 'Humans', 'Prognosis', 'Sensitivity and Specificity', '*Vasodilator Agents/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10453294/
979,dipyridamole,12765506,Antiplatelet drugs.,"['Hankey GJ', 'Eikelboom JW']","['Aspirin/pharmacology/therapeutic use', 'Clopidogrel', 'Dipyridamole/pharmacology/therapeutic use', 'Humans', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors', 'Primary Prevention', 'Pulmonary Embolism/prevention & control', 'Thrombosis/*drug therapy/physiopathology', 'Ticlopidine/analogs & derivatives/pharmacology/therapeutic use', 'Venous Thrombosis/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/12765506/
980,dipyridamole,17288680,ESPRIT study design and outcomes--a critical appraisal.,['Einhaupl K'],"['Aspirin/administration & dosage/adverse effects/*therapeutic use', 'Biomarkers', 'Brain Ischemia/epidemiology/prevention & control', 'Dipyridamole/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use', 'Hemorrhage/chemically induced/epidemiology', 'Humans', 'Myocardial Infarction/epidemiology/prevention & control', 'Patient Dropouts/statistics & numerical data', 'Prospective Studies', 'Research Design', 'Stroke/epidemiology/*prevention & control', 'Treatment Outcome', 'Vascular Diseases/mortality']",https://pubmed.ncbi.nlm.nih.gov/17288680/
981,dipyridamole,26021241,Association between coronary flow reserve and exercise capacity.,"['Eroglu S', 'Sade LE', 'Polat E', 'Bozbas H', 'Muderrisoglu H']","['Adult', 'Aged', 'Blood Flow Velocity/*physiology', 'Cardiovascular Physiological Phenomena/drug effects', 'Coronary Circulation/drug effects/physiology', 'Coronary Vessels/physiopathology', 'Diastole/drug effects/physiology', 'Dipyridamole/administration & dosage/adverse effects', 'Echocardiography, Doppler/methods', 'Echocardiography, Doppler, Pulsed', 'Exercise/*physiology', 'Exercise Test/methods', 'Female', 'Humans', 'Male', 'Microvessels/physiopathology', 'Middle Aged', 'Observer Variation']",https://pubmed.ncbi.nlm.nih.gov/26021241/
982,dipyridamole,3555016,Controlled trial of antiplatelet agents in mesangial IgA glomerulonephritis.,"['Chan MK', 'Kwan SY', 'Chan KW', 'Yeung CK']","['Adult', 'Aspirin/administration & dosage/*therapeutic use', 'Blood Platelets/*drug effects', 'Clinical Trials as Topic', 'Creatinine/blood', 'Delayed-Action Preparations', 'Dipyridamole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Glomerular Mesangium', 'Glomerulonephritis, IGA/*drug therapy', 'Humans', 'Immunoglobulin G/analysis', 'Male', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3555016/
983,dipyridamole,31804544,Dipyridamole-loaded 3D-printed bioceramic scaffolds stimulate pediatric bone regeneration in vivo without disruption of craniofacial growth through facial maturity.,"['Wang MM', 'Flores RL', 'Witek L', 'Torroni A', 'Ibrahim A', 'Wang Z', 'Liss HA', 'Cronstein BN', 'Lopez CD', 'Maliha SG', 'Coelho PG']","['Animals', 'Bioprinting/methods', 'Bone Regeneration/*drug effects', 'Calcium Phosphates/adverse effects/chemistry', 'Ceramics/adverse effects/chemistry', 'Child', 'Child Development/drug effects', 'Dipyridamole/*administration & dosage/adverse effects', 'Disease Models, Animal', 'Guided Tissue Regeneration/*methods', 'Humans', 'Maxillofacial Development/drug effects', 'Models, Animal', 'Printing, Three-Dimensional', 'Rabbits', 'Skull/drug effects/growth & development/*injuries', 'Tissue Engineering/methods', 'Tissue Scaffolds/adverse effects/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31804544/
984,dipyridamole,382146,Antiplatelet drugs in thromboembolism.,['Hirsh J'],"['Anticoagulants/administration & dosage', 'Aspirin/administration & dosage/*therapeutic use', 'Blood Platelets/*drug effects', 'Coronary Disease/prevention & control', 'Dipyridamole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Heart Valve Prosthesis', 'Humans', 'Sulfinpyrazone/administration & dosage/*therapeutic use', 'Thromboembolism/*prevention & control', 'Thrombophlebitis/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/382146/
985,dipyridamole,3717855,Dipyridamole-induced epistaxis.,"['Mittelman M', 'Ogarten U', 'Lewinski U', 'Djaldetti M']","['Aged', 'Dipyridamole/*adverse effects', 'Epistaxis/*chemically induced', 'Humans', 'Male', 'Platelet Aggregation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/3717855/
986,dipyridamole,845612,Transient ischaemic attacks and increased platelet aggregability associated with oral contraceptives. Treatment with dipyridamole and aspirin.,['Mazal S'],"['Adult', 'Aspirin/*therapeutic use', 'Contraceptives, Oral/*adverse effects', 'Dipyridamole/*therapeutic use', 'Female', 'Humans', 'Ischemic Attack, Transient/*chemically induced/drug therapy', 'Platelet Aggregation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/845612/
987,dipyridamole,21415156,Use of aspirin associates with longer primary patency of hemodialysis grafts.,"['Dixon BS', 'Beck GJ', 'Dember LM', 'Vazquez MA', 'Greenberg A', 'Delmez JA', 'Allon M', 'Himmelfarb J', 'Hu B', 'Greene T', 'Radeva MK', 'Davidson IJ', 'Ikizler TA', 'Braden GL', 'Lawson JH', 'Cotton JR Jr', 'Kusek JW', 'Feldman HI']","['Adult', 'Aged', '*Arteriovenous Shunt, Surgical/adverse effects', 'Aspirin/adverse effects/pharmacology/*therapeutic use', 'Aspirin, Dipyridamole Drug Combination', 'Chronic Disease', 'Dipyridamole/adverse effects/pharmacology/therapeutic use', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Kidney Diseases/*therapy', 'Male', 'Middle Aged', 'Platelet Aggregation Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Proportional Hazards Models', 'Renal Dialysis/*methods', 'Thrombosis/etiology/prevention & control', 'Treatment Outcome', '*Vascular Patency/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21415156/
988,dipyridamole,25697566,Dipyridamole: a drug with unrecognized antioxidant activity.,"['Ciacciarelli M', 'Zerbinati C', 'Violi F', 'Iuliano L']","['Animals', 'Antioxidants/chemistry/*pharmacology/therapeutic use', 'Cardiovascular Diseases/drug therapy/metabolism', 'Central Nervous System Diseases/drug therapy/metabolism', 'Dipyridamole/chemistry/*pharmacology/therapeutic use', 'Drug Discovery', 'Humans', 'Neoplasms/drug therapy/metabolism', 'Oxidative Stress/*drug effects', 'Vasodilator Agents/chemistry/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25697566/
989,droperidol,36925442,Droperidol Use in the Emergency Department: A Clinical Review.,"['Siegel RB', 'Motov SM', 'Marcolini EG']","['Humans', 'Analgesics/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Anti-Anxiety Agents/therapeutic use', 'Antiemetics/therapeutic use', '*Droperidol/therapeutic use', '*Emergency Service, Hospital', 'Hypnotics and Sedatives/therapeutic use', 'Ondansetron/therapeutic use', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36925442/
990,droperidol,27745766,"Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomized Clinical Trial.","['Taylor DM', 'Yap CYL', 'Knott JC', 'Taylor SE', 'Phillips GA', 'Karro J', 'Chan EW', 'Kong DCM', 'Castle DJ']","['Acute Disease', 'Adult', 'Benzodiazepines/*therapeutic use', 'Conscious Sedation/*methods', 'Double-Blind Method', 'Droperidol/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Female', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', 'Injections, Intravenous', 'Male', 'Midazolam/administration & dosage/*therapeutic use', 'Olanzapine', 'Psychomotor Agitation/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27745766/
991,droperidol,14528201,Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy.,"['Waring JP', 'Baron TH', 'Hirota WK', 'Goldstein JL', 'Jacobson BC', 'Leighton JA', 'Mallery JS', 'Faigel DO']","['Anesthesia, General', 'Anesthetics, Local', 'Anti-Anxiety Agents/therapeutic use', 'Benzodiazepines/therapeutic use', '*Conscious Sedation/standards', 'Droperidol/therapeutic use', '*Endoscopy, Gastrointestinal/standards', 'Humans', 'Hypnotics and Sedatives/administration & dosage', '*Monitoring, Physiologic/standards', 'Narcotic Antagonists/therapeutic use', 'Narcotics/therapeutic use', 'Pharynx/drug effects', 'Tranquilizing Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14528201/
992,droperidol,8856810,"Delirium. Advances in diagnosis, pathophysiology, and treatment.",['Trzepacz PT'],"['Adult', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Brain/physiopathology', 'Brain Mapping', 'Child', 'Delirium/*diagnosis/physiopathology/therapy', 'Droperidol/adverse effects/therapeutic use', 'Haloperidol/adverse effects/therapeutic use', 'Humans', '*Patient Care Team', 'Psychiatric Status Rating Scales', 'Receptors, Neurotransmitter/physiology', 'Risk Factors', 'Synaptic Transmission/physiology']",https://pubmed.ncbi.nlm.nih.gov/8856810/
993,droperidol,39137114,Coma After Droperidol Administration: A Case Report.,"['Vetter C', 'Biedermann C', 'Berger-Estilita J', 'Butikofer A']","['Humans', 'Female', 'Adult', '*Droperidol/adverse effects/administration & dosage', '*Coma/chemically induced', '*Uterine Myomectomy/adverse effects', 'Antiemetics/adverse effects/administration & dosage', 'Switzerland']",https://pubmed.ncbi.nlm.nih.gov/39137114/
994,droperidol,7396141,Droperidol and endotracheal intubation. Attenuation of pressor response to laryngoscopy and intubation.,"['Curran J', 'Crowley M', ""O'Sullivan G""]","['Adult', '*Anesthesia, Intravenous', 'Blood Pressure/*drug effects', '*Droperidol/pharmacology', 'Heart Rate/drug effects', 'Humans', '*Intubation, Intratracheal', '*Laryngoscopy', 'Pulse/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7396141/
995,droperidol,6623141,Droperidol in the treatment of vertigo.,['Baldwin RL'],"['Droperidol/administration & dosage/*therapeutic use', 'Humans', 'Labyrinth Diseases/complications', 'Vertigo/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/6623141/
996,droperidol,32839811,Reintegrating droperidol into emergency medicine practice.,"['Mattson A', 'Friend K', 'Brown CS', 'Cabrera D']","['Dose-Response Relationship, Drug', 'Droperidol/*administration & dosage/adverse effects', 'Drug Labeling', 'Drug Monitoring', 'Drug Utilization/*trends', 'Emergency Service, Hospital/trends', 'Emergency Treatment/*methods/trends', 'Humans', 'Long QT Syndrome/chemically induced/prevention & control', 'Migraine Disorders/drug therapy', 'Nausea/drug therapy', 'Pain/drug therapy', ""Practice Patterns, Physicians'/*trends"", 'Psychomotor Agitation/drug therapy', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/32839811/
997,droperidol,12565120,Droperidol: should the black box be light gray?,['Dershwitz M'],"['Adult', 'Aged', 'Antiemetics/*adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Droperidol/*adverse effects/therapeutic use', 'Drug Interactions', '*Drug Labeling', 'Female', 'Humans', 'Male', 'Middle Aged', 'Postoperative Nausea and Vomiting/prevention & control', 'Respiratory Mechanics/drug effects', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/12565120/
998,droperidol,1927235,Midazolam and amnesia in pediatric premedication.,"['Payne KA', 'Coetzee AR', 'Mattheyse FJ']","['Administration, Oral', 'Amnesia/*chemically induced', 'Child', 'Child, Preschool', 'Droperidol/administration & dosage', 'Humans', 'Injections, Intramuscular', 'Methadone/administration & dosage', 'Midazolam/administration & dosage/*pharmacology', '*Preanesthetic Medication', 'Trimeprazine/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1927235/
999,droperidol,6376480,Droperidol vs. haloperidol in the initial management of acutely agitated patients.,"['Resnick M', 'Burton BT']","['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Clinical Trials as Topic', 'Commitment of Persons with Psychiatric Disorders', 'Dangerous Behavior', 'Double-Blind Method', 'Droperidol/administration & dosage/*therapeutic use', 'Emergency Services, Psychiatric', 'Haloperidol/administration & dosage/*therapeutic use', 'Humans', 'Injections, Intramuscular', 'Middle Aged', 'Psychomotor Agitation/drug therapy/psychology', 'Psychotic Disorders/*drug therapy/psychology', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6376480/
1000,droperidol,7717493,Postoperative neuroleptic malignant syndrome.,"['Shaw A', 'Matthews EE']","['Child', 'Dantrolene/therapeutic use', 'Diuresis', 'Droperidol/*adverse effects', 'Female', 'Humans', 'Hyponatremia/complications', 'Metoclopramide/*adverse effects', 'Neuroleptic Malignant Syndrome/*etiology/therapy', 'Postoperative Complications/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7717493/
1001,droperidol,8599504,Angioedema associated with droperidol administration.,"['Palombaro JF', 'Klingelberger CE']","['Adult', 'Angioedema/*chemically induced', 'Antiemetics/*adverse effects', 'Droperidol/*adverse effects', 'Emergencies', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/8599504/
1002,droperidol,7473981,Neuroleptic malignant syndrome in a trauma patient.,"['Burke C', 'Fulda GJ', 'Castellano J']","['Adult', 'Antipsychotic Agents/*adverse effects', 'Dantrolene/therapeutic use', 'Droperidol/*adverse effects', 'Haloperidol/*adverse effects', 'Humans', 'Male', 'Multiple Trauma/*complications', 'Muscle Relaxants, Central/therapeutic use', 'Neuroleptic Malignant Syndrome/drug therapy/*etiology', 'Psychomotor Agitation/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/7473981/
1003,droperidol,28613368,[Rapid tranquillisation for agitated patients with psychostimulant intoxication].,"['Geerts P', 'Titeca K', 'Lemmens GMD', 'De Fruyt J']","['Aggression/drug effects', 'Antipsychotic Agents/*therapeutic use', 'Droperidol/therapeutic use', 'Humans', 'Psychomotor Agitation/*drug therapy', 'Psychotic Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28613368/
1004,droperidol,25271829,Dopamine antagonists for nausea and vomiting: special considerations.,['Welliver M'],"['Dopamine Antagonists/*therapeutic use', 'Droperidol/therapeutic use', 'Humans', 'Nausea/*drug therapy', 'Vomiting/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25271829/
1005,droperidol,2878630,Potentiation of epidural opioids with epidural droperidol. A one year retrospective study.,"['Bach V', 'Carl P', 'Ravlo O', 'Crawford ME', 'Werner M']","['Adult', 'Aged', 'Analgesics, Opioid/administration & dosage/*therapeutic use', 'Chronic Disease', 'Droperidol/administration & dosage/*therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'Drug Tolerance', 'Humans', 'Injections, Epidural', 'Middle Aged', 'Pain/*drug therapy', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2878630/
1006,droperidol,354615,Antiemetic effect of droperidol after ophthalmic surgery.,"['Iwamoto K', 'Schwartz H']","['Adolescent', 'Adult', 'Aged', 'Anesthesia, General/*adverse effects', '*Antiemetics', 'Clinical Trials as Topic', 'Double-Blind Method', 'Droperidol/*pharmacology', 'Eye Diseases/*surgery', 'Humans', 'Middle Aged', 'Vomiting/etiology']",https://pubmed.ncbi.nlm.nih.gov/354615/
1007,droperidol,33046432,Safety and effectiveness of olanzapine and droperidol for chemical restraint for non-consenting adults: a systematic review and meta-analysis.,"['Muir-Cochrane E', 'Grimmer K', 'Gerace A', 'Bastiampillai T', 'Oster C']","['Antipsychotic Agents/adverse effects/standards/therapeutic use', 'Droperidol/adverse effects/*standards/therapeutic use', 'Humans', 'Olanzapine/adverse effects/*standards/therapeutic use', 'Tranquilizing Agents/adverse effects/standards/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33046432/
1008,droperidol,25416184,Droperidol for the treatment of acute migraine headaches.,"['Thomas MC', 'Musselman ME', 'Shewmaker J']","['Acute Disease', 'Dopamine Antagonists/adverse effects/*therapeutic use', 'Droperidol/adverse effects/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy/physiopathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/25416184/
1009,duloxetine,36791450,Fibromyalgia: Diagnosis and Management.,"['Winslow BT', 'Vandal C', 'Dang L']","['Humans', 'Female', '*Fibromyalgia/diagnosis/therapy', '*Chronic Pain/drug therapy', 'Pregabalin/therapeutic use', 'Analgesics/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36791450/
1010,duloxetine,37670573,Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy.,"['Jang HN', 'Oh TJ']","['United States', 'Humans', '*Diabetic Neuropathies/complications/drug therapy', 'Capsaicin/therapeutic use', 'Quality of Life', 'Duloxetine Hydrochloride/therapeutic use', '*Neuralgia/drug therapy/etiology', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37670573/
1011,duloxetine,21366359,Duloxetine: clinical pharmacokinetics and drug interactions.,"['Knadler MP', 'Lobo E', 'Chappell J', 'Bergstrom R']","['Adrenergic Uptake Inhibitors/administration & dosage/adverse effects/*pharmacokinetics', 'Adult', 'Aged', 'Animals', 'Drug Interactions', 'Duloxetine Hydrochloride', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pharmacogenetics', 'Risk Assessment', 'Risk Factors', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/*pharmacokinetics', 'Thiophenes/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21366359/
1012,duloxetine,25952601,Burning mouth syndrome: a review and update.,"['Silvestre FJ', 'Silvestre-Rangil J', 'Lopez-Jornet P']","['Adult', 'Age Distribution', 'Aged', 'Algorithms', 'Amisulpride', 'Antidepressive Agents/therapeutic use', '*Burning Mouth Syndrome/diagnosis/epidemiology/physiopathology/psychology/therapy', 'Clonazepam/therapeutic use', 'Deficiency Diseases/complications', 'Dentures/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Male', 'Menopause', 'Middle Aged', 'Mood Disorders/epidemiology', 'Nerve Fibers, Unmyelinated/physiology', 'Orthodontic Appliances', 'Sex Distribution', 'Sulpiride/analogs & derivatives/therapeutic use', 'Tongue Habits']",https://pubmed.ncbi.nlm.nih.gov/25952601/
1013,duloxetine,37183813,Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions.,"['Fagan HA', 'Baldwin DS']","['Humans', '*Anti-Anxiety Agents/therapeutic use', 'Anxiety Disorders/drug therapy/psychology', 'Duloxetine Hydrochloride/therapeutic use', 'Pregabalin/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37183813/
1014,duloxetine,37085164,Combination therapy for painful diabetic neuropathy is safe and effective.,"['Saul H', 'Deeney B', 'Imison C', 'Tesfaye S']","['Humans', '*Diabetic Neuropathies/drug therapy', 'Pregabalin/therapeutic use', 'Analgesics/therapeutic use', 'Amitriptyline/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Treatment Outcome', 'Double-Blind Method', '*Diabetes Mellitus']",https://pubmed.ncbi.nlm.nih.gov/37085164/
1015,duloxetine,30016772,Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.,"['Fava GA', 'Benasi G', 'Lucente M', 'Offidani E', 'Cosci F', 'Guidi J']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Desvenlafaxine Succinate/adverse effects/therapeutic use', 'Duloxetine Hydrochloride/adverse effects/therapeutic use', 'Humans', 'Mood Disorders/drug therapy', '*Randomized Controlled Trials as Topic', 'Substance Withdrawal Syndrome/*diagnosis', 'Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30016772/
1016,duloxetine,38950403,Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.,"['Petimar J', 'Young JG', 'Yu H', 'Rifas-Shiman SL', 'Daley MF', 'Heerman WJ', 'Janicke DM', 'Jones WS', 'Lewis KH', 'Lin PD', 'Prentice C', 'Merriman JW', 'Toh S', 'Block JP']","['Humans', '*Antidepressive Agents/therapeutic use/adverse effects', 'Female', 'Male', '*Weight Gain/drug effects', 'Middle Aged', 'Adult', 'Bupropion/therapeutic use/adverse effects', 'Citalopram/therapeutic use/adverse effects', 'Duloxetine Hydrochloride/therapeutic use/adverse effects', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38950403/
1017,duloxetine,30838456,Serotonin and Norepinephrine Reuptake Inhibitors.,['Shelton RC'],"['Antidepressive Agents/chemistry/*pharmacology', 'Desvenlafaxine Succinate/*chemistry', 'Duloxetine Hydrochloride/chemistry/*pharmacology', 'Humans', '*Serotonin/pharmacology', '*Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30838456/
1018,duloxetine,37461044,Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis.,"['Migliorini F', 'Maffulli N', 'Eschweiler J', 'Baroncini A', 'Bell A', 'Colarossi G']","['Humans', 'Female', 'Adult', 'Middle Aged', 'Male', 'Duloxetine Hydrochloride/therapeutic use', '*Fibromyalgia/drug therapy/chemically induced', 'Thiophenes/adverse effects', 'Treatment Outcome', 'Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37461044/
1019,duloxetine,38574212,Diabetic Peripheral Neuropathy: Prevention and Treatment.,"['Bragg S', 'Marrison ST', 'Haley S']","['Humans', '*Diabetic Neuropathies/diagnosis/prevention & control', 'Duloxetine Hydrochloride/therapeutic use', 'Capsaicin/therapeutic use', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', 'Pain/drug therapy', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38574212/
1020,duloxetine,28293734,[Chemotherapy-induced peripheral neuropathy and neuropathic pain].,"['Schuler U', 'Heller S']","['Antineoplastic Agents/*adverse effects', 'Cryotherapy', 'Duloxetine Hydrochloride/therapeutic use', 'Humans', 'Neuralgia/*chemically induced/prevention & control/therapy', 'Peripheral Nervous System Diseases/*chemically induced/prevention & control/therapy', 'Physical Therapy Modalities', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28293734/
1021,duloxetine,35522835,Duloxetine-Associated Photodistributed Erythema Multiforme.,"['Gay P', 'Niezen S', 'Saenz-Davila B', 'Arellano-Mendoza I', 'Mercadillo P', 'Tirado-Sanchez A']","['Duloxetine Hydrochloride/adverse effects', '*Erythema Multiforme/chemically induced/diagnosis', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/35522835/
1022,duloxetine,34497420,Bioaccumulation of therapeutic drugs by human gut bacteria.,"['Klunemann M', 'Andrejev S', 'Blasche S', 'Mateus A', 'Phapale P', 'Devendran S', 'Vappiani J', 'Simon B', 'Scott TA', 'Kafkia E', 'Konstantinidis D', 'Zirngibl K', 'Mastrorilli E', 'Banzhaf M', 'Mackmull MT', 'Hovelmann F', 'Nesme L', 'Brochado AR', 'Maier L', 'Bock T', 'Periwal V', 'Kumar M', 'Kim Y', 'Tramontano M', 'Schultz C', 'Beck M', 'Hennig J', 'Zimmermann M', 'Sevin DC', 'Cabreiro F', 'Savitski MM', 'Bork P', 'Typas A', 'Patil KR']","['Animals', 'Antidepressive Agents/metabolism/pharmacokinetics', 'Bacteria/*metabolism', '*Bioaccumulation', 'Caenorhabditis elegans/metabolism', 'Cells/metabolism', 'Click Chemistry', 'Duloxetine Hydrochloride/adverse effects/*metabolism/pharmacokinetics', 'Gastrointestinal Microbiome/*physiology', 'Humans', 'Metabolomics', 'Models, Animal', 'Proteomics', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/34497420/
1023,duloxetine,35587348,Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.,"['Farag HM', 'Yunusa I', 'Goswami H', 'Sultan I', 'Doucette JA', 'Eguale T']","['Amitriptyline/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Fatigue/drug therapy', 'Female', '*Fibromyalgia/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Milnacipran/therapeutic use', 'Network Meta-Analysis', 'Pain/drug therapy', 'Pregabalin/therapeutic use', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/35587348/
1024,duloxetine,36890758,[Medical Treatment of Chronic Pain].,['Nodera H'],"['Humans', 'Analgesics/therapeutic use/adverse effects', '*Chronic Pain/drug therapy/chemically induced', 'Pregabalin/therapeutic use', 'Gabapentin/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', '*Diabetic Neuropathies/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36890758/
1025,duloxetine,29279555,Pharmacotherapy for Neuropathic Pain in Japan.,"['Masuda R', 'Ajimi J', 'Murata T']","['Aged', 'Algorithms', 'Amines/*administration & dosage/adverse effects', 'Analgesics, Opioid/*administration & dosage/adverse effects', 'Anticonvulsants/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Cyclohexanecarboxylic Acids/*administration & dosage/adverse effects', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/*administration & dosage/adverse effects', 'Female', 'Gabapentin', 'Humans', 'Japan', 'Neuralgia/classification/*drug therapy', 'Pain Management', 'Pregabalin/*administration & dosage/adverse effects', 'gamma-Aminobutyric Acid/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29279555/
1026,duloxetine,31290965,"Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).","['Fedgchin M', 'Trivedi M', 'Daly EJ', 'Melkote R', 'Lane R', 'Lim P', 'Vitagliano D', 'Blier P', 'Fava M', 'Liebowitz M', 'Ravindran A', 'Gaillard R', 'Ameele HVD', 'Preskorn S', 'Manji H', 'Hough D', 'Drevets WC', 'Singh JB']","['Administration, Intranasal', 'Administration, Oral', 'Adolescent', 'Adult', 'Antidepressive Agents/administration & dosage/*adverse effects/*therapeutic use', 'Citalopram/therapeutic use', 'Delayed-Action Preparations/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Ketamine/administration & dosage/*adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sertraline/therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31290965/
1027,duloxetine,30877484,Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial.,"['Bidari A', 'Moazen-Zadeh E', 'Ghavidel-Parsa B', 'Rahmani S', 'Hosseini S', 'Hassankhani A']","['Adult', 'Chronic Pain/*drug therapy', 'Depression/*drug therapy', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/*administration & dosage/therapeutic use', 'Female', 'Fibromyalgia/complications/*drug therapy', 'Humans', 'Medication Adherence', 'Middle Aged', 'Pregabalin/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30877484/
1028,duloxetine,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
1029,ethosuximide,8784210,Antiepileptic drug mechanisms of action.,"['Macdonald RL', 'Kelly KM']","['Acetates/pharmacology/therapeutic use', 'Action Potentials/drug effects', '*Amines', 'Animals', 'Anticonvulsants/*pharmacology/therapeutic use', 'Barbiturates/pharmacology/therapeutic use', 'Benzodiazepines/pharmacology/therapeutic use', 'Calcium Channels/drug effects', 'Carbamazepine/pharmacology/therapeutic use', 'Central Nervous System/drug effects', '*Cyclohexanecarboxylic Acids', 'Epilepsy/drug therapy', 'Gabapentin', 'Humans', 'Ion Channels/*drug effects', 'Lamotrigine', 'Phenytoin/pharmacology/therapeutic use', 'Rats', 'Receptors, GABA/drug effects', 'Receptors, N-Methyl-D-Aspartate/drug effects', 'Receptors, Neurotransmitter/*drug effects', 'Sodium Channels/drug effects', 'Triazines/pharmacology/therapeutic use', 'Trimethadione/pharmacology/therapeutic use', 'Valproic Acid/pharmacology/therapeutic use', 'Vigabatrin', 'gamma-Aminobutyric Acid/analogs & derivatives/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8784210/
1030,ethosuximide,29097018,Antiepileptic Drugs and Liver Disease.,"['Vidaurre J', 'Gedela S', 'Yarosz S']","['Anticonvulsants/*adverse effects', 'Epilepsy/drug therapy', 'Humans', 'Liver Diseases/*complications']",https://pubmed.ncbi.nlm.nih.gov/29097018/
1031,ethosuximide,12838266,Epilepsy.,"['Shneker BF', 'Fountain NB']","['Adult', '*Anticonvulsants/adverse effects/pharmacokinetics/therapeutic use', 'Child', '*Epilepsy/classification/drug therapy/physiopathology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/12838266/
1032,ethosuximide,30734897,A Practical Guide to Treatment of Childhood Absence Epilepsy.,"['Kessler SK', 'McGinnis E']","['Anticonvulsants/therapeutic use', 'Child', 'Child, Preschool', 'Drug-Related Side Effects and Adverse Reactions', 'Electroencephalography', 'Epilepsy, Absence/diagnosis/*drug therapy', 'Ethosuximide/therapeutic use', 'Female', 'Humans', 'Lamotrigine/therapeutic use', 'Male', 'Practice Guidelines as Topic', 'Seizures/drug therapy', 'Treatment Outcome', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30734897/
1033,ethosuximide,36194365,Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.,"['Strzelczyk A', 'Schubert-Bast S']","['*Autism Spectrum Disorder', 'Bromides', '*Cannabidiol', 'Clobazam', 'Cognition', 'Ethosuximide', 'Everolimus', 'Felbamate', 'Fenfluramine', 'Humans', 'Lacosamide', 'Lamotrigine', 'Levetiracetam', 'Pregabalin', '*Spasms, Infantile', 'Sulfides', 'Topiramate', 'Valproic Acid', 'Vigabatrin', 'Zinc Compounds', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/36194365/
1034,ethosuximide,3936329,Pyknoleptic petit mal.,"['Drury I', 'Dreifuss FE']","['Adolescent', 'Age Factors', 'Animals', '*Bibliographies as Topic', 'Child', 'Child, Preschool', 'Clonazepam/therapeutic use', 'Diagnosis, Differential', 'Electroencephalography', '*Epilepsy, Absence/classification/diagnosis/drug therapy/etiology/genetics/history/physiopathology', 'Ethosuximide/therapeutic use', 'Female', 'History, 18th Century', 'History, 19th Century', 'History, 20th Century', 'Humans', 'Prognosis', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3936329/
1035,ethosuximide,24365310,Use of antiepileptic drugs in hepatic and renal disease.,['Asconape JJ'],"['Anticonvulsants/*adverse effects', 'Chemical and Drug Induced Liver Injury/*etiology', 'Epilepsy/drug therapy', 'Humans', 'Kidney Diseases/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/24365310/
1036,ethosuximide,9203243,Established antiepileptic drugs.,"['Brodie MJ', 'Dichter MA']","['Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Drug Monitoring', 'Drug Therapy, Combination', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Pregnancy', 'Pregnancy Complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9203243/
1037,ethosuximide,9562728,[Antiepileptics].,['Overweg J'],"['Anticonvulsants/economics/*therapeutic use', 'Cost-Benefit Analysis', 'Drug Costs', 'Drug Therapy, Combination', 'Enzyme Induction/drug effects', 'Epilepsy/*drug therapy', 'Humans', 'Liver/enzymology']",https://pubmed.ncbi.nlm.nih.gov/9562728/
1038,ethosuximide,37378757,Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.,"['Chu H', 'Zhang X', 'Shi J', 'Zhou Z', 'Yang X']","['Humans', 'Child', '*Valproic Acid/adverse effects', 'Topiramate/therapeutic use', 'Network Meta-Analysis', 'Levetiracetam/therapeutic use', 'Ethosuximide/adverse effects', 'Anticonvulsants/adverse effects', '*Epilepsy, Generalized/drug therapy', 'Seizures/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37378757/
1039,ethosuximide,17560495,Antiepileptic drugs and visual function.,"['Verrotti A', 'Manco R', 'Matricardi S', 'Franzoni E', 'Chiarelli F']","['Anticonvulsants/*adverse effects', 'Child', 'Epilepsy/*drug therapy', 'Humans', 'Vision Disorders/*chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/17560495/
1040,ethosuximide,12418630,Anti-epileptic drugs.,"['Prabhakar S', 'Kharbanda PS']","['Anticonvulsants/adverse effects/*pharmacology/therapeutic use', 'Dose-Response Relationship, Drug', 'Epilepsy/drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/12418630/
1041,ethosuximide,25470190,The clinical pharmacology of traditional antiepileptic drugs.,"['Vajda FJ', 'Eadie MJ']","['Anticonvulsants/*chemistry/pharmacokinetics/*therapeutic use', 'Epilepsy/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/25470190/
1042,ethosuximide,6818015,Drug interactions with valproic acid.,"['Levy RH', 'Koch KM']","['Anticonvulsants/*metabolism', 'Carbamazepine/metabolism', 'Clonazepam/metabolism', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Ethosuximide/metabolism', 'Fatty Acids, Nonesterified/metabolism', 'Humans', 'Kinetics', 'Phenobarbital/metabolism', 'Phenytoin/metabolism', 'Primidone/metabolism', 'Salicylates/metabolism', 'Valproic Acid/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/6818015/
1043,ethosuximide,36193017,Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.,"['Tomson T', 'Battino D', 'Bromley R', 'Kochen S', 'Meador KJ', 'Pennell PB', 'Thomas SV']","['Breast Feeding', '*Cannabidiol', 'Carbamazepine/therapeutic use', 'Child', 'Clobazam/therapeutic use', 'Clonazepam/therapeutic use', '*Epilepsy/drug therapy', 'Ethosuximide/therapeutic use', 'Everolimus/therapeutic use', 'Felbamate/therapeutic use', 'Female', 'Fenfluramine/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', 'Infant', 'Lacosamide', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Oxcarbazepine', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Prospective Studies', 'Tiagabine', 'Topiramate', 'Valproic Acid/therapeutic use', 'Vigabatrin/therapeutic use', 'Zonisamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36193017/
1044,ethosuximide,8020533,The metabolism of ethosuximide.,"['Millership JS', 'Mifsud J', 'Collier PS']","['Animals', 'Ethosuximide/*metabolism/pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/8020533/
1045,ethosuximide,28472982,Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes.,"['Veroniki AA', 'Cogo E', 'Rios P', 'Straus SE', 'Finkelstein Y', 'Kealey R', 'Reynen E', 'Soobiah C', 'Thavorn K', 'Hutton B', 'Hemmelgarn BR', 'Yazdi F', ""D'Souza J"", 'MacDonald H', 'Tricco AC']","['*Abnormalities, Drug-Induced', 'Adult', 'Anticonvulsants/*adverse effects/therapeutic use', 'Bayes Theorem', 'Child', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Infant', 'Network Meta-Analysis', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28472982/
1046,ethosuximide,36617332,Features of the choice and the use of antiepileptic drugs as analgesics in elderly.,"['Ushkalova EA', 'Zyryanov SK', 'Butranova OI']","['Humans', 'Aged', '*Anticonvulsants/adverse effects/pharmacokinetics', '*Chronic Pain', 'Topiramate', 'Levetiracetam', 'Analgesics']",https://pubmed.ncbi.nlm.nih.gov/36617332/
1047,ethosuximide,3092003,Use of ethosuximide and valproate in the treatment of epilepsy.,['Wallace SJ'],"['Abnormalities, Drug-Induced/etiology', 'Brain Diseases/chemically induced', 'Drug Interactions', 'Epilepsies, Myoclonic/drug therapy', 'Epilepsies, Partial/drug therapy', 'Epilepsy/*drug therapy', 'Epilepsy, Absence/drug therapy', 'Ethosuximide/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Status Epilepticus/drug therapy', 'Succinimides/therapeutic use', 'Trimethadione/therapeutic use', 'Valproic Acid/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3092003/
1048,ethosuximide,27683026,[Childhood absence epilepsy: An update].,"['Garzon P', 'Lemelle L', 'Auvin S']","['Anticonvulsants/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/complications', 'Child', 'Cognition Disorders/complications', 'Diagnosis, Differential', 'Drug Resistance', 'Electroencephalography', 'Epilepsy, Absence/complications/*diagnosis/drug therapy', 'Humans', 'Prognosis']",https://pubmed.ncbi.nlm.nih.gov/27683026/
1049,famotidine,25750443,Urticaria pigmentosa-like disease in a dog.,"['Pariser MS', 'Gram DW']","['Animals', 'Anti-Allergic Agents/administration & dosage/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/therapeutic use', 'Cetirizine/administration & dosage/therapeutic use', 'Diphenhydramine/administration & dosage/therapeutic use', 'Dog Diseases/diagnosis/*pathology', 'Dogs', 'Famotidine/administration & dosage/therapeutic use', 'Male', 'Urticaria Pigmentosa/diagnosis/drug therapy/pathology/*veterinary']",https://pubmed.ncbi.nlm.nih.gov/25750443/
1050,famotidine,28153970,A Rare Case of Famotidine-Induced Delirium in a Peritoneal Dialysis Patient.,"['Chan GC', 'Lee KM', 'Kwan LP', 'Mok MM', 'Ma MK', 'Yap DY', 'Tang SC']","['Acute Disease', 'Delirium/*chemically induced/physiopathology', 'Dyspepsia/diagnosis/*drug therapy', 'Famotidine/*adverse effects/therapeutic use', 'Follow-Up Studies', 'Humans', 'Kidney Failure, Chronic/diagnosis/*therapy', 'Male', 'Middle Aged', 'Peritoneal Dialysis/*adverse effects/methods', 'Risk Assessment', 'Treatment Outcome', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/28153970/
1051,famotidine,32912894,"Angioedema, ACE inhibitor and COVID-19.","['Grewal E', 'Sutarjono B', 'Mohammed I']","['Angioedema/*chemically induced/*complications/drug therapy', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects', 'Anti-Allergic Agents/therapeutic use', 'Benzazepines/*adverse effects', '*Betacoronavirus', 'COVID-19', 'Coronavirus Infections/*complications', 'Diagnosis, Differential', 'Diphenhydramine/therapeutic use', 'Famotidine/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Pandemics', 'Pneumonia, Viral/*complications', 'SARS-CoV-2', 'Tranexamic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32912894/
1052,famotidine,24267478,The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.,"['Tuskey A', 'Peura D']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Anti-Ulcer Agents/therapeutic use', 'Drug Therapy, Combination', 'Famotidine/therapeutic use', 'Gastrointestinal Diseases/chemically induced/*drug therapy/prevention & control', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Intestinal Mucosa/*drug effects/pathology', 'Stomach Ulcer/chemically induced/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/24267478/
1053,famotidine,37722599,Oral famotidine reduces the plasma level of soluble P-selectin in children with sickle cell disease.,"['Allali S', 'Marquant F', 'Rignault-Bricard R', 'Taylor M', 'Brice J', 'de Montalembert M', 'Maciel TT', 'Elie C', 'Hermine O']","['Child', 'Humans', '*Famotidine/therapeutic use', 'P-Selectin/metabolism', 'Histamine', 'Prospective Studies', '*Anemia, Sickle Cell']",https://pubmed.ncbi.nlm.nih.gov/37722599/
1054,famotidine,24532249,WITHDRAWN: Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.,"['Huertas-Ceballos AA', 'Logan S', 'Bennett C', 'Macarthur C', 'Martin AE']","['Abdominal Pain/*drug therapy', 'Adolescent', 'Analgesics, Non-Narcotic/*therapeutic use', 'Child', 'Child, Preschool', 'Famotidine/therapeutic use', 'Humans', 'Irritable Bowel Syndrome/*drug therapy', 'Mentha piperita', 'Pizotyline/therapeutic use', 'Plant Oils/therapeutic use', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/24532249/
1055,famotidine,10410190,Famotidine in the management of schizophrenia.,['Martinez MC'],"['Clinical Trials as Topic', 'Famotidine/*therapeutic use', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10410190/
1056,famotidine,28867258,Risk factors for suboptimal drug concentration of posaconazole oral suspension in patients with hematologic malignancy.,"['Kim EJ', 'Yu KS', 'Na SH', 'Nam EY', 'Oh HS', 'Kim M', 'Yoon SH', 'Lee JO', 'Koh Y', 'Song KH', 'Choe PG', 'Cho JY', 'Song SH', 'Kim ES', 'Kim HB', 'Bang SM', 'Kim NJ', 'Oh MD', 'Kim I', 'Park WB']","['Administration, Oral', 'Adult', 'Aged', 'Antifungal Agents/*pharmacokinetics', 'Famotidine/therapeutic use', 'Female', 'Hematologic Neoplasms/*drug therapy', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Mycoses/prevention & control', '*Pre-Exposure Prophylaxis', 'Prospective Studies', 'Risk Factors', 'Triazoles/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28867258/
1057,famotidine,11967601,H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?,"['Wade EE', 'Rebuck JA', 'Healey MA', 'Rogers FB']","['Cimetidine/adverse effects', 'Critical Care', 'Famotidine/adverse effects', 'Histamine H2 Antagonists/*adverse effects/therapeutic use', 'Humans', 'Peptic Ulcer/*prevention & control', 'Ranitidine/adverse effects', 'Risk Factors', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11967601/
1058,famotidine,33135390,Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant.,"['Landry I', 'Aluri J', 'Hall N', 'Kumar D', 'Dayal S', 'Moline M', 'Reyderman L']","['Adult', 'Double-Blind Method', 'Drug Interactions/physiology', 'Famotidine/administration & dosage/*pharmacokinetics', 'Female', 'Gastric Acid/*metabolism', 'Histamine H2 Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Male', 'Orexin Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Pyridines/administration & dosage/*pharmacokinetics', 'Pyrimidines/administration & dosage/*pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33135390/
1059,famotidine,25318791,Iron-deficiency anemia caused by a proton pump inhibitor.,"['Hashimoto R', 'Matsuda T', 'Chonan A']","['Anemia, Iron-Deficiency/*chemically induced', 'Famotidine/therapeutic use', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*adverse effects/therapeutic use', 'Rabeprazole/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25318791/
1060,famotidine,7914403,Intestinal clearance of H2-antagonists.,"['Hui YF', 'Kolars J', 'Hu Z', 'Fleisher D']","[""4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/administration & dosage"", 'Animals', 'Cimetidine/analogs & derivatives/analysis/pharmacokinetics', 'Famotidine/pharmacokinetics', 'Histamine H2 Antagonists/*pharmacokinetics', 'Humans', 'Intestinal Mucosa/*metabolism', 'Jejunum/*metabolism', 'Methionine/administration & dosage', 'Perfusion', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/7914403/
1061,famotidine,24550598,Stevens-Johnson syndrome following use of metronidazole in a dental patient.,"['Mazumdar G', 'Shome K']","['*Dental Health Services', 'Dibenzoxepins/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Erythromycin/administration & dosage/therapeutic use', 'Famotidine/administration & dosage/therapeutic use', 'Humans', 'Lichen Planus, Oral/drug therapy', 'Male', 'Methylprednisolone/administration & dosage/therapeutic use', 'Metronidazole/administration & dosage/*adverse effects', 'Middle Aged', 'Olopatadine Hydrochloride', 'Stevens-Johnson Syndrome/drug therapy/*etiology', 'Triamcinolone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/24550598/
1062,famotidine,2979247,Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.,"['Orr WC', 'Robinson MG', 'Humphries TJ', 'Antonello J', 'Cagliola A']","['Adult', 'Aged', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Famotidine/administration & dosage/*therapeutic use', 'Gastric Acidity Determination', 'Gastroesophageal Reflux/*drug therapy/physiopathology', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2979247/
1063,famotidine,22419335,Histamine H2-receptor antagonists for urticaria.,"['Fedorowicz Z', 'van Zuuren EJ', 'Hu N']","['Cimetidine/adverse effects/therapeutic use', 'Diphenhydramine/adverse effects/therapeutic use', 'Drug Therapy, Combination/methods', 'Famotidine/adverse effects/therapeutic use', 'Histamine H1 Antagonists', 'Histamine H2 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Ranitidine/adverse effects/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22419335/
1064,famotidine,34609001,The association between famotidine and in-hospital mortality of patients with COVID-19.,"['Kuno T', 'So M', 'Takahashi M', 'Egorova NN']","['Famotidine/therapeutic use', 'Hospital Mortality', 'Humans', 'Retrospective Studies', 'SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/34609001/
1065,famotidine,11027567,Ghrelin stimulates gastric acid secretion and motility in rats.,"['Masuda Y', 'Tanaka T', 'Inomata N', 'Ohnuma N', 'Tanaka S', 'Itoh Z', 'Hosoda H', 'Kojima M', 'Kangawa K']","['Animals', 'Atropine/pharmacology', 'Dose-Response Relationship, Drug', 'Famotidine/pharmacology', 'Gastric Acid/*metabolism', 'Gastric Mucosa/metabolism', 'Ghrelin', 'Histamine/pharmacology', 'Histamine H2 Antagonists/pharmacology', 'Male', '*Peptide Hormones', 'Peptides/administration & dosage/antagonists & inhibitors/*pharmacology', 'Peristalsis/*drug effects', 'Rats', 'Rats, Sprague-Dawley', 'Stomach/*drug effects/innervation/physiology', 'Vagotomy']",https://pubmed.ncbi.nlm.nih.gov/11027567/
1066,famotidine,1625532,The clinical use of histamine-2 receptor antagonists.,"['Michocki RJ', 'Richardson JP']","['Cimetidine/administration & dosage/*therapeutic use', 'Drug Evaluation', 'Famotidine/administration & dosage/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Nizatidine/administration & dosage/*therapeutic use', 'Peptic Ulcer/*drug therapy', 'Ranitidine/administration & dosage/*therapeutic use', 'Recurrence', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1625532/
1067,famotidine,8305790,Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.,"['Ben-Joseph R', 'Segal R', 'Russell WL']","['Age Factors', 'Cimetidine/administration & dosage/*adverse effects', 'Drug Interactions', 'Famotidine/administration & dosage/*adverse effects', 'Female', 'Humans', 'Injections, Intravenous', 'Kidney Diseases/chemically induced', 'Male', 'Ranitidine/administration & dosage/*adverse effects', 'Regression Analysis', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/8305790/
1068,felodipine,1693718,Vascular selectivity of felodipine: clinical experience.,"['Thomas P', 'Sheridan DJ']","['Animals', 'Felodipine/pharmacology/*therapeutic use', 'Heart/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Muscle, Smooth, Vascular/*drug effects', 'Organ Specificity', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1693718/
1069,felodipine,9420451,How grapefruit juice potentiates drug bioavailability.,['Feldman EB'],"['Area Under Curve', '*Beverages', 'Biological Availability', 'Calcium Channel Blockers/blood/*pharmacokinetics', '*Citrus', 'Down-Regulation', 'Drug Synergism', 'Felodipine/blood/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9420451/
1070,felodipine,18666368,Effect of grapefruit juice in relation to human pharmacokinetic study.,"['Uno T', 'Yasui-Furukori N']","['*Beverages', 'Biological Availability', 'Calcium Channel Blockers/pharmacokinetics', '*Citrus paradisi', 'Cytochrome P-450 CYP3A/physiology', 'Felodipine/pharmacokinetics', '*Food-Drug Interactions', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/18666368/
1071,felodipine,9723817,Grapefruit juice-drug interactions.,"['Bailey DG', 'Malcolm J', 'Arnold O', 'Spence JD']","['Administration, Oral', '*Beverages', 'Biological Availability', 'Calcium Channel Blockers/pharmacokinetics', '*Citrus', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/metabolism', 'Felodipine/pharmacokinetics', '*Food-Drug Interactions', 'Humans', 'Intestine, Small/metabolism', 'Mixed Function Oxygenases/metabolism', '*Pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/9723817/
1072,felodipine,2280237,"Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes.","['Lundgren H', 'Bengtsson C', 'Lapidus L', 'Bengtsson L']","['Aged', 'Blood Glucose/*drug effects', 'Diabetes Mellitus/*chemically induced', 'Double-Blind Method', 'Felodipine/adverse effects/*therapeutic use', 'Female', 'Glucose Tolerance Test', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Metoprolol/adverse effects/*therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2280237/
1073,felodipine,8112371,A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.,"['Bainbridge AD', 'Herlihy O', 'Meredith PA', 'Elliott HL']","['Aged', 'Amlodipine/*pharmacokinetics/pharmacology', 'Blood Pressure/*drug effects', 'Delayed-Action Preparations', 'Felodipine/*pharmacokinetics/pharmacology', 'Female', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8112371/
1074,felodipine,9812220,Rational use of calcium-channel antagonists in Raynaud's phenomenon.,"['Sturgill MG', 'Seibold JR']","['Amlodipine/pharmacokinetics/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacokinetics/pharmacology/*therapeutic use', 'Diltiazem/pharmacokinetics/pharmacology/therapeutic use', 'Felodipine/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Isradipine/pharmacokinetics/pharmacology/therapeutic use', 'Nicardipine/pharmacokinetics/pharmacology/therapeutic use', 'Nifedipine/pharmacokinetics/pharmacology/therapeutic use', 'Raynaud Disease/*drug therapy/epidemiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/9812220/
1075,felodipine,7523062,Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.,['Cohn JN'],"['Clinical Trials as Topic', 'Drug Therapy, Combination', 'Enalapril/*therapeutic use', 'Exercise', 'Felodipine/*therapeutic use', 'Heart Failure/*drug therapy/mortality', 'Humans', 'Hydralazine/*therapeutic use', 'Isosorbide Dinitrate/*therapeutic use', 'Norepinephrine/blood', 'Oxygen Consumption', 'Prognosis', 'Stroke Volume/drug effects', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/7523062/
1076,felodipine,8720766,"Antihypertensive drugs and glucose metabolism: a comparison between a diuretic and felodipine, a new calcium antagonist, when added to a beta-blocker in non-diabetic hypertensive women.","['Bengtsson C', 'Lapidus L']","['Adrenergic beta-Antagonists/administration & dosage/therapeutic use', 'Aged', 'Calcium Channel Blockers/administration & dosage/*therapeutic use', 'Cross-Over Studies', 'Diuretics', 'Drug Therapy, Combination', 'Felodipine/administration & dosage/*therapeutic use', 'Female', 'Glucose/*metabolism', 'Glucose Tolerance Test', 'Humans', 'Hydrochlorothiazide/administration & dosage/*therapeutic use', 'Hypertension/*drug therapy', 'Insulin/blood', 'Middle Aged', 'Sodium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8720766/
1077,felodipine,1671113,Interaction of citrus juices with felodipine and nifedipine.,"['Bailey DG', 'Spence JD', 'Munoz C', 'Arnold JM']","['Biological Availability', 'Blood Pressure/drug effects', 'Citrus/*metabolism', 'Drug Interactions', 'Evaluation Studies as Topic', 'Felodipine/administration & dosage/blood/*pharmacokinetics', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1671113/
1078,felodipine,25973793,"Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris.","['Navadiya K', 'Tiwari S']","['Angina Pectoris/diagnosis/*drug therapy/physiopathology', 'Animals', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Calcium Channel Blockers/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Felodipine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Hypertension/diagnosis/*drug therapy/physiopathology', 'Treatment Outcome', 'Vasodilator Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25973793/
1079,felodipine,9675532,Felodipine-induced gingival hyperplasia.,"['Young PC', 'Turiansky GW', 'Sau P', 'Liebman MD', 'Benson PM']","['Aged', 'Calcium Channel Blockers/*adverse effects', 'Felodipine/*adverse effects', 'Female', 'Gingival Hyperplasia/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9675532/
1080,felodipine,1424224,"Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.",['DeQuattro V'],"['Aging/*physiology', 'Felodipine/adverse effects/pharmacokinetics/*therapeutic use', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/1424224/
1081,felodipine,3327674,Aspects on the benefit-risk balance of felodipine in hypertension.,"['Elmfeldt D', 'Westerling S']","['Antihypertensive Agents/adverse effects/*therapeutic use', 'Felodipine', 'Humans', 'Hypertension/complications/*drug therapy', 'Nitrendipine/adverse effects/*analogs & derivatives/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/3327674/
1082,felodipine,21515290,The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome.,"['Csiki Z', 'Garai I', 'Shemirani AH', 'Papp G', 'Zsori KS', 'Andras C', 'Zeher M']","['Adult', 'Drug Therapy, Combination/methods', 'Felodipine/pharmacology/*therapeutic use', 'Female', 'Fingers/*blood supply', 'Humans', 'Hyperemia/physiopathology', 'Hypertension/complications/physiopathology', 'Laser-Doppler Flowmetry', 'Metoprolol/pharmacology/*therapeutic use', 'Microcirculation/*drug effects/physiology', 'Middle Aged', 'Raynaud Disease/complications/*drug therapy/physiopathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21515290/
1083,felodipine,2404502,Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.,"['Blychert E', 'Wingstrand K', 'Edgar B', 'Lidman K']","['Adult', 'Biological Availability', 'Blood Pressure/drug effects', 'Delayed-Action Preparations', 'Double-Blind Method', 'Felodipine/administration & dosage/pharmacokinetics/*pharmacology', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Randomized Controlled Trials as Topic', 'Solubility', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/2404502/
1084,felodipine,3069435,"Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.","['Saltiel E', 'Ellrodt AG', 'Monk JP', 'Langley MS']","['Felodipine', 'Humans', 'Hypertension/*drug therapy', 'Metabolic Clearance Rate', 'Nitrendipine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3069435/
1085,felodipine,1693711,Long-term treatment of hypertension with felodipine.,['Flygt G'],"['Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Therapy, Combination', 'Felodipine/administration & dosage/adverse effects/*therapeutic use', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/1693711/
1086,felodipine,7574861,A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension.,"['Moncica I', 'Oh PI', 'ul Qamar I', 'Scolnik D', 'Arbus GS', 'Hebert D', 'Balfe JW', 'Koren G']","['Adolescent', 'Antihypertensive Agents/*therapeutic use', 'Child', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Felodipine/*therapeutic use', 'Humans', 'Hypertension, Renal/*drug therapy', 'Nifedipine/*therapeutic use', 'Patient Compliance']",https://pubmed.ncbi.nlm.nih.gov/7574861/
1087,felodipine,2676559,The clinical effect of felodipine and nifedipine in Raynaud's phenomenon.,"['Schmidt JF', 'Valentin N', 'Nielsen SL']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Felodipine/adverse effects/*therapeutic use', 'Female', 'Humans', 'Infant', 'Male', 'Nifedipine/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Raynaud Disease/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2676559/
1088,fenofibrate,38905569,Effect of Fenofibrate on Progression of Diabetic Retinopathy.,"['Preiss D', 'Logue J', 'Sammons E', 'Zayed M', 'Emberson J', 'Wade R', 'Wallendszus K', 'Stevens W', 'Cretney R', 'Harding S', 'Leese G', 'Currie G', 'Armitage J']","['Humans', '*Fenofibrate/therapeutic use/pharmacology', '*Diabetic Retinopathy/drug therapy', 'Male', 'Female', 'Middle Aged', '*Disease Progression', '*Hypolipidemic Agents/therapeutic use/administration & dosage', 'Aged', 'Adult', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38905569/
1089,fenofibrate,33137654,Fenofibrate treatment for severe hypertriglyceridemia in dogs.,"['Miceli DD', 'Vidal VP', 'Blatter MFC', 'Pignataro OP', 'Castillo VA']","['Animals', 'Diet, Fat-Restricted/*veterinary', 'Dog Diseases/blood/*drug therapy', 'Dogs', 'Fenofibrate/adverse effects/*therapeutic use', 'Gene Expression Regulation/drug effects', 'Glucose Transporter Type 4/genetics/metabolism', 'Hypertriglyceridemia/drug therapy/*veterinary', 'Hypolipidemic Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33137654/
1090,fenofibrate,25043542,[Efficacy studies].,"['Pedro-Botet J', 'Flores-Le Roux JA']","['Cardiovascular Diseases/etiology/*prevention & control', 'Cholesterol, HDL/blood', 'Drug Combinations', 'Dyslipidemias/complications/*drug therapy', 'Fenofibrate/administration & dosage/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/therapeutic use', 'Hypertriglyceridemia/complications/drug therapy', 'Hypolipidemic Agents/administration & dosage/therapeutic use', 'Lipids/blood', 'Pravastatin/administration & dosage/*therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/25043542/
1091,fenofibrate,38114295,5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge.,"['Giacomuzzi Moore B', 'Durigova A', 'Lamine F', 'Chtioui H', 'Salati E']","['Humans', 'Fenofibrate/therapeutic use', '*Fluorouracil/adverse effects', '*Hypertriglyceridemia/chemically induced/drug therapy', 'Pancreatitis/etiology']",https://pubmed.ncbi.nlm.nih.gov/38114295/
1092,fenofibrate,29110023,[Modern treatment of primary biliary cholangitis].,['Strassburg CP'],"['Bezafibrate/adverse effects/therapeutic use', 'Budesonide/adverse effects/therapeutic use', 'Chenodeoxycholic Acid/adverse effects/*analogs & derivatives/therapeutic use', 'Cohort Studies', 'Female', 'Fenofibrate/adverse effects/therapeutic use', 'Humans', 'Liver Cirrhosis, Biliary/diagnosis/*drug therapy', 'Liver Transplantation', 'Male', 'Multicenter Studies as Topic', 'PPAR alpha/agonists', 'Pregnancy', 'Prognosis', 'Quality of Life', 'Receptors, Cytoplasmic and Nuclear/drug effects', 'Risk Assessment', 'Treatment Outcome', 'Ursodeoxycholic Acid/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29110023/
1093,fenofibrate,16310551,Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.,"['Keech A', 'Simes RJ', 'Barter P', 'Best J', 'Scott R', 'Taskinen MR', 'Forder P', 'Pillai A', 'Davis T', 'Glasziou P', 'Drury P', 'Kesaniemi YA', 'Sullivan D', 'Hunt D', 'Colman P', ""d'Emden M"", 'Whiting M', 'Ehnholm C', 'Laakso M']","['Aged', 'Cardiovascular Diseases/etiology/*prevention & control', 'Cholesterol/*blood', 'Coronary Disease/mortality/prevention & control', 'Diabetes Mellitus, Type 2/blood/*complications', 'Double-Blind Method', 'Dyslipidemias/complications/*drug therapy', 'Female', 'Fenofibrate/adverse effects/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Triglycerides/*blood']",https://pubmed.ncbi.nlm.nih.gov/16310551/
1094,fenofibrate,25432393,Combination therapy with statins: who benefits?,"['Singh A', 'Davidson M']","['Cardiovascular Diseases/*drug therapy', 'Drug Therapy, Combination/adverse effects/*standards', 'Fenofibrate/adverse effects/*pharmacology', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*pharmacology', 'Hypolipidemic Agents/adverse effects/*pharmacology', 'Niacin/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25432393/
1095,fenofibrate,28243111,"Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.","['Tarantino N', 'Santoro F', 'De Gennaro L', 'Correale M', 'Guastafierro F', 'Gaglione A', 'Di Biase M', 'Brunetti ND']","['Animals', 'Biomarkers/blood', 'Drug Combinations', 'Dyslipidemias/blood/diagnosis/*drug therapy', 'Fenofibrate/*administration & dosage/adverse effects', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects', 'Lipoproteins, HDL/*blood', 'Simvastatin/*administration & dosage/adverse effects', 'Treatment Outcome', 'Triglycerides/*blood']",https://pubmed.ncbi.nlm.nih.gov/28243111/
1096,fenofibrate,32170673,The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.,"['Wojtowicz S', 'Strosznajder AK', 'Jezyna M', 'Strosznajder JB']","['Alzheimer Disease/drug therapy/*metabolism', 'Animals', 'Brain/drug effects/*metabolism', 'Drug Delivery Systems/*trends', 'Fenofibrate/administration & dosage/metabolism', 'Humans', 'Neurodegenerative Diseases/drug therapy/metabolism', 'PPAR alpha/agonists/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/32170673/
1097,fenofibrate,31974794,"Pemafibrate, a New Selective PPARalpha Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.","['Yamashita S', 'Masuda D', 'Matsuzawa Y']","['Animals', 'Atherosclerosis/*drug therapy/metabolism', 'Benzoxazoles/adverse effects/metabolism/*pharmacokinetics/*therapeutic use', 'Butyrates/adverse effects/metabolism/*pharmacokinetics/*therapeutic use', 'Cholesterol, HDL/blood', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/metabolism', 'Fenofibrate/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/adverse effects/therapeutic use', 'PPAR alpha/*metabolism', 'Treatment Outcome', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/31974794/
1098,fenofibrate,8318433,Phenofibrate-induced lichenoid photodermatitis.,"['Gardeazabal J', 'Gonzalez M', 'Izu R', 'Gil N', 'Aguirre A', 'Diaz-Perez JL']","['Dermatitis, Photoallergic/*etiology/pathology', 'Female', 'Fenofibrate/*adverse effects', 'Humans', 'Middle Aged', 'Skin/pathology']",https://pubmed.ncbi.nlm.nih.gov/8318433/
1099,fenofibrate,25227751,Protective factors in diabetic retinopathy: focus on blood-retinal barrier.,"['Zhang C', 'Wang H', 'Nie J', 'Wang F']","['Animals', 'Blood-Retinal Barrier/drug effects/pathology/*physiopathology', 'Diabetic Retinopathy/etiology/*physiopathology/*prevention & control', 'Erythropoietin/pharmacology', 'Fenofibrate/analogs & derivatives/pharmacology', 'Humans', 'Insulin-Like Growth Factor Binding Protein 3/physiology', 'Macular Edema/complications/pathology/physiopathology', 'Protective Factors', 'Pyrazines/pharmacology', 'Sitagliptin Phosphate', 'Triazoles/pharmacology', 'Vascular Endothelial Growth Factor A/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/25227751/
1100,fenofibrate,12481201,Update on fenofibrate.,['Guay DR'],"['Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', '*Fenofibrate/economics/pharmacology/therapeutic use', 'Humans', 'Hyperlipidemias/*drug therapy', '*Hypolipidemic Agents/economics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12481201/
1101,fenofibrate,38336772,Role of fenofibrate in multiple sclerosis.,"['Abulaban AA', 'Al-Kuraishy HM', 'Al-Gareeb AI', 'Elekhnawy E', 'Alanazi A', 'Alexiou A', 'Papadakis M', 'Batiha GE']","['Humans', '*Multiple Sclerosis/drug therapy/pathology', '*Fenofibrate/pharmacology/therapeutic use', 'Central Nervous System', 'Neurons/pathology', 'Inflammation/pathology']",https://pubmed.ncbi.nlm.nih.gov/38336772/
1102,fenofibrate,15269493,Fenofibrate-induced myopathy.,"['Ghosh B', 'Sengupta S', 'Bhattacharjee B', 'Majumder A', 'Sarkar SB']","['Fenofibrate/*adverse effects/therapeutic use', 'Humans', 'Hyperlipidemias/drug therapy', 'Hypolipidemic Agents/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Muscular Diseases/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/15269493/
1103,fenofibrate,15638786,Fenofibrate: metabolic and pleiotropic effects.,"['Tsimihodimos V', 'Miltiadous G', 'Daskalopoulou SS', 'Mikhailidis DP', 'Elisaf MS']","['Anti-Inflammatory Agents/metabolism/pharmacology', 'Antifibrinolytic Agents/metabolism/pharmacology', 'Antioxidants/metabolism/pharmacology/therapeutic use', 'Endothelium, Vascular/drug effects', 'Fenofibrate/*metabolism/pharmacology/*therapeutic use', 'Fibrinolytic Agents/pharmacology', 'Humans', 'PPAR alpha/drug effects/metabolism/therapeutic use', 'Prodrugs/metabolism/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15638786/
1104,fenofibrate,31928604,[Severe Thrombocitopenia Induced by Fenofibrate].,"['Clara A', 'Martins T', 'Martins A', 'Baptista A', 'Lazaro M']","['Aged', 'Fenofibrate/*adverse effects', 'Glucocorticoids/therapeutic use', 'Humans', 'Hypolipidemic Agents/*adverse effects', 'Male', 'Methylprednisolone/therapeutic use', 'Purpura, Thrombocytopenic/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31928604/
1105,fenofibrate,25989912,Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review.,"['Simo R', 'Ballarini S', 'Cunha-Vaz J', 'Ji L', 'Haller H', 'Zimmet P', 'Wong TY']","['Animals', 'Calcium Dobesilate/therapeutic use', 'Diabetic Retinopathy/*drug therapy', 'Fenofibrate/therapeutic use', 'Humans', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25989912/
1106,fenofibrate,21736529,Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.,"['Filippatos TD', 'Elisaf MS']","['Adult', 'Cardiovascular Diseases/epidemiology', 'Diabetes Complications/blood/drug therapy/metabolism', 'Drug Combinations', 'Drug Monitoring', 'Dyslipidemias/blood/*drug therapy/metabolism', 'Fenofibrate/*administration & dosage/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects/therapeutic use', 'Hypertriglyceridemia/blood/drug therapy/metabolism', 'Hypolipidemic Agents/*administration & dosage/adverse effects/therapeutic use', 'Lipoproteins/blood', 'Risk Factors', 'Simvastatin/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21736529/
1107,fenofibrate,26959124,Lipids and Diabetic Retinopathy.,"['Modjtahedi BS', 'Bose N', 'Papakostas TD', 'Morse L', 'Vavvas DG', 'Kishan AU']","['Diabetic Retinopathy/*physiopathology', 'Fenofibrate/analogs & derivatives/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hyperlipidemias/drug therapy/*physiopathology', 'Lipids/*physiology']",https://pubmed.ncbi.nlm.nih.gov/26959124/
1108,fluoxetine,24738878,Fluoxetine: a case history of its discovery and preclinical development.,"['Perez-Caballero L', 'Torres-Sanchez S', 'Bravo L', 'Mico JA', 'Berrocoso E']","['Animals', 'Antidepressive Agents, Second-Generation/chemistry/*pharmacokinetics/*pharmacology', 'Drug Discovery/*history', 'Drug Evaluation, Preclinical/history', 'Fluoxetine/chemistry/*pharmacokinetics/*pharmacology', 'History, 20th Century', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/24738878/
1109,fluoxetine,2878798,"Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.","['Benfield P', 'Heel RC', 'Lewis SP']","['Animals', 'Cardiovascular System/drug effects', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Endocrine Glands/drug effects', '*Fluoxetine/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Humans', 'Kinetics', 'Neurotransmitter Agents/metabolism', '*Propylamines/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Receptors, Neurotransmitter/metabolism', 'Serotonin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2878798/
1110,fluoxetine,7794331,The perils of Prozac.,['Manolis DC'],"['Depressive Disorder/*drug therapy/psychology', 'Family Practice', 'Fluoxetine/adverse effects/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/7794331/
1111,fluoxetine,9297715,Serotonin syndrome.,"['Ivanusa Z', 'Hecimovic H', 'Demarin V']","['Fluoxetine/adverse effects/therapeutic use', 'Humans', 'Monoamine Oxidase Inhibitors/administration & dosage/*adverse effects', 'Nervous System Diseases/*chemically induced/diagnosis/physiopathology', 'Receptors, Serotonin/*drug effects/physiology', 'Serotonin/*physiology', 'Serotonin Agents/administration & dosage/*adverse effects', 'Substance-Related Disorders/*diagnosis/physiopathology', 'Synaptic Transmission/*drug effects/physiology', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/9297715/
1112,fluoxetine,1813897,Pharmacokinetics of second generation antidepressants: fluoxetine.,['Goodnick PJ'],"['Antidepressive Agents/*pharmacokinetics', 'Fluoxetine/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1813897/
1113,fluoxetine,7960421,Psychotropic drugs in pregnancy and lactation.,['Goldberg HL'],"['Clozapine/therapeutic use', 'Embryonic and Fetal Development/drug effects', 'Female', 'Fluoxetine/therapeutic use', 'Humans', '*Lactation/drug effects', 'Lithium/therapeutic use', 'Mental Disorders/*drug therapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Prenatal Exposure Delayed Effects', 'Psychotropic Drugs/adverse effects/*therapeutic use', 'Puerperal Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7960421/
1114,fluoxetine,11772132,Once-weekly fluoxetine.,"['Wagstaff AJ', 'Goa KL']","['Administration, Oral', 'Antidepressive Agents, Second-Generation/*administration & dosage/pharmacokinetics/pharmacology', 'Delayed-Action Preparations', 'Depressive Disorder/*drug therapy', 'Drug Administration Schedule', 'Fluoxetine/*administration & dosage/pharmacokinetics/pharmacology', 'Half-Life', 'Humans', 'Patient Compliance', 'Randomized Controlled Trials as Topic', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11772132/
1115,fluoxetine,8730028,Fluoxetin-induced pulmonary granulomatosis.,"['de Kerviler E', 'Tredaniel J', 'Revlon G', 'Groussard O', 'Zalcman G', 'Ortoli JM', 'Espie M', 'Hirsch A', 'Frija J']","['Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use', 'Depressive Disorder/drug therapy', 'Diagnosis, Differential', 'Female', 'Fluoxetine/*adverse effects/therapeutic use', 'Granuloma, Giant Cell/*chemically induced/diagnosis/physiopathology', 'Humans', 'Lung Diseases/*chemically induced/diagnosis/physiopathology', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8730028/
1116,fluoxetine,7993290,Fluoxetine induced dyskinesia.,"['Mander A', 'McCausland M', 'Workman B', 'Flamer H', 'Christophidis N']","['Aged', 'Depressive Disorder/*drug therapy', '*Dyskinesia, Drug-Induced', 'Female', 'Fluoxetine/*adverse effects/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/7993290/
1117,fluoxetine,8984742,Prozac: panacea or puzzle?,['Stanford SC'],"['Animals', 'Brain Chemistry/drug effects', 'Catecholamines/metabolism', 'Fluoxetine/pharmacokinetics/*pharmacology', 'Humans', 'Selective Serotonin Reuptake Inhibitors/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8984742/
1118,fluoxetine,1543251,The pharmacotherapy of minor depression.,"['Stewart JW', 'Quitkin FM', 'Klein DF']","['Antidepressive Agents, Tricyclic/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Fluoxetine/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Imipramine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Monoamine Oxidase Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/1543251/
1119,fluoxetine,8863755,Depression: making the diagnosis and using SSRIs in the older patient.,['Reynolds CF 3rd'],"['1-Naphthylamine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Adult', 'Aged', 'Alzheimer Disease/diagnosis/psychology', 'Depressive Disorder/*diagnosis/*drug therapy/psychology', 'Diagnosis, Differential', 'Dose-Response Relationship, Drug', 'Fluoxetine/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Paroxetine/adverse effects/pharmacokinetics/*therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Sertraline']",https://pubmed.ncbi.nlm.nih.gov/8863755/
1120,fluoxetine,29691274,Negative myoclonus secondary to paroxetine intake.,"['Correia P', 'Ribeiro JA', 'Bento C', 'Sales F']","['Aged', 'Electroencephalography/methods', 'Fluoxetine/administration & dosage/therapeutic use', 'Humans', 'Male', 'Medical Errors/*adverse effects', 'Myoclonus/*chemically induced/diagnosis', 'Paroxetine/*adverse effects', 'Seizures/*chemically induced/diagnosis', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Somatosensory Cortex/physiopathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29691274/
1121,fluoxetine,1806635,Obsessive-compulsive disorder.,['George MS'],"['Clomipramine/adverse effects/therapeutic use', 'Fluoxetine/adverse effects/therapeutic use', 'Fluvoxamine/adverse effects/*therapeutic use', 'Humans', 'Obsessive-Compulsive Disorder/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1806635/
1122,fluoxetine,8162401,Seizures associated with fluoxetine therapy.,['Prasher VP'],"['Adult', 'Depressive Disorder/*drug therapy/psychology', 'Epilepsy, Tonic-Clonic/drug therapy', 'Female', 'Fluoxetine/*adverse effects/therapeutic use', 'Humans', 'Psychotic Disorders/*drug therapy/psychology', 'Seizures/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/8162401/
1123,fluoxetine,8930062,Ring chromosome 22 and mood disorders.,"['Sovner R', 'Stone A', 'Fox C']","['Adult', 'Anticonvulsants/administration & dosage/therapeutic use', 'Antidepressive Agents/administration & dosage/therapeutic use', 'Child', '*Chromosomes, Human, Pair 22', 'Drug Therapy, Combination', 'Female', 'Fluoxetine/administration & dosage/therapeutic use', 'Humans', 'Intellectual Disability/complications', 'Male', 'Middle Aged', 'Mood Disorders/complications/drug therapy/*genetics', '*Ring Chromosomes', 'Valproic Acid/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8930062/
1124,fluoxetine,1960381,A comparison of fluoxetine and amitriptyline in the treatment of major depression.,"['Keegan D', 'Bowen RC', 'Blackshaw S', 'Saleh S', 'Dayal N', 'Remillard F', 'Shrikhande S', 'Cebrian Perez S', 'Boulton A']","['Adolescent', 'Adult', 'Aged', 'Amitriptyline/adverse effects/*therapeutic use', 'Depressive Disorder/*drug therapy/psychology', 'Female', 'Fluoxetine/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales']",https://pubmed.ncbi.nlm.nih.gov/1960381/
1125,fluoxetine,2274996,A report of trazodone-associated laboratory abnormalities.,"['Perry PJ', 'Garvey MJ', 'Dunner DL', 'Rush AJ', 'Kyhl J']","['Double-Blind Method', 'Erythrocyte Count/drug effects', 'Female', 'Fluoxetine/*adverse effects/therapeutic use', 'Hematocrit/standards', 'Hemoglobins/*drug effects', 'Humans', 'Male', 'Reference Values', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2274996/
1126,fluoxetine,15890403,Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test.,"['Dulawa SC', 'Hen R']","['Analysis of Variance', 'Animals', 'Antidepressive Agents/*adverse effects/pharmacology', 'Behavior, Animal/physiology', 'Depression/*physiopathology', '*Disease Models, Animal', 'Dose-Response Relationship, Drug', 'Drinking/drug effects/*physiology', 'Drug Administration Schedule', 'Exploratory Behavior/*drug effects/physiology', 'Fluoxetine/administration & dosage/blood', 'Humans', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Predictive Value of Tests', 'Reaction Time/drug effects', 'Reproducibility of Results', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/15890403/
1127,fluoxetine,8063517,Fluoxetine and suicidal ideation--a review of the literature.,['Crundwell JK'],"['Depressive Disorder/*drug therapy/psychology', 'Fluoxetine/*adverse effects/therapeutic use', 'Humans', 'Suicide/*psychology/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/8063517/
1128,flurbiprofen,71974,Flurbiprofen at night.,"['Huskisson EC', 'Scott PJ', 'Boyle S', 'Patrick M']","['Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Flurbiprofen/administration & dosage/blood/*therapeutic use', 'Humans', 'Palliative Care', 'Placebos', 'Propionates/*therapeutic use', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/71974/
1129,flurbiprofen,27252062,[The Mechanisms and Pharmacological Strategy for Treatment of ER Stress-induced Metabolic Syndrome].,"['Hosoi T', 'Ozawa K']","['*Drug Discovery', 'Endoplasmic Reticulum Stress/drug effects/*physiology', 'Flurbiprofen/pharmacology/therapeutic use', 'Humans', 'Hypothalamus/metabolism', 'Leptin/metabolism/physiology', 'Metabolic Syndrome/*drug therapy/*etiology', 'Obesity/complications/drug therapy/physiopathology', 'Receptors, Leptin/metabolism/physiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/27252062/
1130,flurbiprofen,71968,A long-term assessment of flurbiprofen.,"['Sheldrake FE', 'Webber JM', 'Marsh BD']","['Arthritis/*drug therapy', 'Arthritis, Rheumatoid/drug therapy', 'Bone Diseases/*drug therapy', 'Female', 'Flurbiprofen/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Joint Diseases/*drug therapy', 'Male', 'Osteoarthritis/drug therapy', 'Palliative Care', 'Propionates/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/71968/
1131,flurbiprofen,2937024,A review of selected investigational nonsteroidal antiinflammatory drugs of the 1980s.,"['Marsh CC', 'Schuna AA', 'Sundstrom WR']","['Acetates/administration & dosage/adverse effects/metabolism/therapeutic use', 'Anti-Inflammatory Agents/metabolism/*pharmacology/therapeutic use', 'Diclofenac/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Drug Interactions', 'Etodolac', 'Flurbiprofen/administration & dosage/adverse effects/metabolism/therapeutic use', 'Humans', 'Kinetics', 'Phenylacetates/administration & dosage/adverse effects/metabolism/therapeutic use', '*Phenylbutyrates', 'Propionates/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Quinazolines/administration & dosage/adverse effects/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2937024/
1132,flurbiprofen,16565821,Anti-inflammatory agents in the management of alimentary mucositis.,"['Lalla RV', 'Schubert MM', 'Bensadoun RJ', 'Keefe D']","['Allopurinol/therapeutic use', 'Animals', 'Anti-Inflammatory Agents/*therapeutic use', 'Anti-Ulcer Agents/therapeutic use', 'Antineoplastic Agents/adverse effects', 'Benzydamine/therapeutic use', 'Clinical Trials as Topic', 'Drug Evaluation', 'Evidence-Based Medicine', 'Flurbiprofen/therapeutic use', 'Gastrointestinal Diseases/*drug therapy/etiology', 'Health Services Needs and Demand', 'Humans', 'Metalloproteins/therapeutic use', 'Misoprostol/therapeutic use', 'Mucositis/*drug therapy/etiology', '*Neoplasms/complications/therapy', 'Practice Guidelines as Topic', 'Radiation-Protective Agents/therapeutic use', 'Radiotherapy/adverse effects', 'Research Design', 'Severity of Illness Index', 'Stomatitis/*drug therapy/etiology', 'Triazines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16565821/
1133,flurbiprofen,71970,Efficacy and tolerance of flurbiprofen in the elderly using liquid and tablet formulations.,['Innes EH'],"['Aged', 'Aging', 'Dosage Forms', 'Female', 'Flurbiprofen/*administration & dosage/adverse effects/therapeutic use', 'Hip Joint', 'Humans', 'Male', 'Osteoarthritis/*drug therapy/psychology', 'Palliative Care', 'Patient Compliance', 'Propionates/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/71970/
1134,flurbiprofen,7027872,Flurbiprofen and intraocular pressure.,"['Gieser DK', 'Hodapp E', 'Goldberg I', 'Kass MA', 'Becker B']","['Adult', 'Aged', 'Clinical Trials as Topic', 'Dexamethasone/antagonists & inhibitors', 'Double-Blind Method', 'Female', 'Flurbiprofen/pharmacology/*toxicity', 'Humans', 'Intraocular Pressure/*drug effects', 'Male', 'Middle Aged', 'Propionates/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/7027872/
1135,flurbiprofen,12102196,Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application.,"['Pignatello R', 'Bucolo C', 'Spedalieri G', 'Maltese A', 'Puglisi G']","['*Acrylic Resins', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacokinetics/toxicity', '*Biocompatible Materials', 'Biological Availability', 'Eye/drug effects', 'Flurbiprofen/*administration & dosage/pharmacokinetics/toxicity', 'Humans', 'In Vitro Techniques', 'Materials Testing', 'Miosis/prevention & control', 'Nanotechnology', 'Ophthalmic Solutions', 'Rabbits']",https://pubmed.ncbi.nlm.nih.gov/12102196/
1136,flurbiprofen,1951476,Flurbiprofen-associated acute tubulointerstitial nephritis.,"['Kaufhold J', 'Wilkowski M', 'McCabe K']","['Adult', 'Biopsy', 'Flurbiprofen/*adverse effects/therapeutic use', 'Humans', 'Ibuprofen/therapeutic use', 'Kidney/pathology', 'Male', 'Nephritis, Interstitial/*chemically induced/pathology', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1951476/
1137,flurbiprofen,30772129,Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.,"['Liu H', 'Qiang X', 'Song Q', 'Li W', 'He Y', 'Ye C', 'Tan Z', 'Deng Y']","['Alzheimer Disease/*drug therapy/metabolism', 'Amyloid beta-Peptides/antagonists & inhibitors/metabolism', 'Animals', 'Antioxidants/chemistry/pharmacokinetics/pharmacology', 'Blood-Brain Barrier/metabolism', 'Cell Line', 'Cholinesterase Inhibitors/chemistry/pharmacokinetics/pharmacology', 'Drug Design', 'Drug Discovery', 'Electrophorus', 'Flurbiprofen/*analogs & derivatives/pharmacokinetics/*pharmacology', 'Humans', 'Mannich Bases/*chemistry/pharmacokinetics/*pharmacology', 'Molecular Docking Simulation', 'Peptide Fragments/antagonists & inhibitors/metabolism', 'Protein Aggregates/drug effects', 'Rats', 'Swine']",https://pubmed.ncbi.nlm.nih.gov/30772129/
1138,flurbiprofen,3593904,Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships.,"['Szpunar GJ', 'Albert KS', 'Bole GG', 'Dreyfus JN', 'Lockwood GF', 'Wagner JG']","['Adolescent', 'Adult', 'Biotransformation', 'Blood Proteins/metabolism', 'Dose-Response Relationship, Drug', 'Flurbiprofen/blood/*metabolism/urine', 'Humans', 'Kinetics', 'Male', 'Propionates/*metabolism', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/3593904/
1139,flurbiprofen,8240924,Rac-flurbiprofen is more ulcerogenic than its (S)-enantiomer.,"['Wechter WJ', 'Bigornia AE', 'Murray ED Jr', 'Levine BH', 'Young JW']","['Animals', 'Digestive System/drug effects/*pathology', 'Female', 'Flurbiprofen/chemistry/*toxicity', 'Gastrointestinal Diseases/*chemically induced/pathology', 'Jejunum/drug effects/pathology', 'Necrosis', 'Rats', 'Rats, Sprague-Dawley', 'Stereoisomerism', 'Ulcer/*chemically induced/pathology', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/8240924/
1140,flurbiprofen,28393633,CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.,"['Qiang L', 'Guan Y', 'Li X', 'Liu L', 'Mu Y', 'Sugano A', 'Takaoka Y', 'Sakaeda T', 'Imbimbo BP', 'Yamamura KI', 'Jin S', 'Li Z']","['Amyloidosis/genetics/*metabolism', 'Cyclopropanes/therapeutic use', 'Flurbiprofen/analogs & derivatives/therapeutic use', 'Genetic Diseases, Inborn/genetics/*metabolism', 'Humans', 'Prealbumin/genetics/*metabolism', 'Thyroxine/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/28393633/
1141,flurbiprofen,2757898,Differential effects of flurbiprofen and aspirin on acetazolamide disposition in humans.,"['Sweeney KR', 'Chapron DJ', 'Antal EJ', 'Kramer PA']","['Acetazolamide/blood/*pharmacokinetics', 'Adult', 'Aspirin/blood/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Flurbiprofen/blood/pharmacokinetics/*pharmacology', 'Humans', 'Male', 'Propionates/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2757898/
1142,flurbiprofen,27832658,Anaphylaxis to Over-the-Counter Flurbiprofen in a Child.,"['Giovannini M', 'Sarti L', 'Barni S', 'Pucci N', 'Novembre E', 'Mori F']","['Anaphylaxis/*chemically induced/*diagnosis', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Child', 'Female', 'Flurbiprofen/*adverse effects', 'Humans', 'Nonprescription Drugs/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27832658/
1143,flurbiprofen,15202730,Nitroflurbiprofen (NicOx).,['Scatena R'],"['Alzheimer Disease/drug therapy', 'Animals', 'Arthritis/drug therapy', 'Clinical Trials as Topic', 'Cyclooxygenase Inhibitors/pharmacokinetics/*therapeutic use', 'Flurbiprofen/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Humans', 'Nitric Oxide Donors/pharmacokinetics/*therapeutic use', 'Osteitis Deformans/drug therapy', 'Osteoporosis/drug therapy', 'Structure-Activity Relationship', 'Urinary Incontinence/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15202730/
1144,flurbiprofen,1930699,The analgesic efficacy of flurbiprofen compared to acetaminophen with codeine.,"['Cooper SA', 'Kupperman A']","['Acetaminophen/therapeutic use', 'Adult', 'Analysis of Variance', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Chi-Square Distribution', 'Codeine/*therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Flurbiprofen/administration & dosage/*therapeutic use', 'Humans', 'Male', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Tolmetin/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1930699/
1145,flurbiprofen,23703815,Flurbiprofen-induced generalized bullous fixed drug eruption.,"['Balta I', 'Simsek H', 'Simsek GG']","['Administration, Topical', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Blister/etiology', 'Combined Modality Therapy', 'Drug Eruptions/drug therapy/*physiopathology', 'Extremities', 'Flurbiprofen/*adverse effects', 'Histamine Antagonists/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Recurrence', 'Severity of Illness Index', 'Steroids/administration & dosage/therapeutic use', 'Torso', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23703815/
1146,flurbiprofen,2691542,Preoperative nonsteroidal anti-inflammatory medication for the prevention of postoperative dental pain.,"['Jackson DL', 'Moore PA', 'Hargreaves KM']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Flurbiprofen/therapeutic use', 'Humans', 'Ibuprofen/therapeutic use', 'Mouth/*surgery', 'Pain, Postoperative/physiopathology/*prevention & control', '*Premedication', 'Tooth Extraction/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2691542/
1147,flurbiprofen,3963013,Pharmacokinetics of flurbiprofen.,"['Kaiser DG', 'Brooks CD', 'Lomen PL']","['Aspirin/metabolism', 'Biological Availability', 'Chemical Phenomena', 'Chemistry', 'Drug Interactions', 'Flurbiprofen/administration & dosage/blood/*metabolism', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Propionates/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/3963013/
1148,furosemide,27238657,Furosemide.,"['Carone L', 'Oxberry SG', 'Twycross R', 'Charlesworth S', 'Mihalyo M', 'Wilcock A']","['Diuretics/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Interactions', 'Furosemide/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Hospice Care', 'Humans', 'Internet', 'Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/27238657/
1149,furosemide,34851962,Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis.,"['Lee TH', 'Kuo G', 'Chang CH', 'Huang YT', 'Yen CL', 'Lee CC', 'Fan PC', 'Chen JJ']","['Albumins/*administration & dosage/therapeutic use', 'Diuretics/*administration & dosage/therapeutic use', 'Drug Combinations', 'Furosemide/*administration & dosage/therapeutic use', 'Humans', 'Nephrotic Syndrome/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34851962/
1150,furosemide,2185908,Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).,"['Ponto LL', 'Schoenwald RD']","['Acute Kidney Injury/drug therapy', 'Furosemide/metabolism/*pharmacokinetics/pharmacology/therapeutic use', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/drug therapy', 'Liver Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185908/
1151,furosemide,46960,Diuretic-induced oedema.,"['MacGregor GA', 'Tasker PR', 'de Wardener HE']","['Adult', 'Aldosterone/blood', 'Blood Volume', 'Body Weight', 'Chlorthalidone/adverse effects/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Edema/blood/*chemically induced/drug therapy/urine', 'Female', 'Furosemide/adverse effects/pharmacology/therapeutic use', 'Humans', 'Middle Aged', 'Potassium/administration & dosage/blood/urine', 'Renin/blood', 'Sodium/administration & dosage/blood/urine', 'Spironolactone/adverse effects/therapeutic use', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/46960/
1152,furosemide,7752014,Furosemide-associated fever.,"['Clegg HW', 'Riopel DA']","['Child, Preschool', 'Female', 'Fever of Unknown Origin/*chemically induced/diagnosis', 'Follow-Up Studies', 'Furosemide/*adverse effects/therapeutic use', 'Heart Failure/*drug therapy', 'Humans', 'Recurrence', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7752014/
1153,furosemide,2191821,Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).,"['Ponto LL', 'Schoenwald RD']","['Animals', 'Furosemide/*pharmacokinetics/pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2191821/
1154,furosemide,25786394,Intravenous Furosemide for Acute Decompensated Congestive Heart Failure: What Is the Evidence?,"['Owen DR', 'MacAllister R', 'Sofat R']","['Administration, Intravenous', 'Administration, Oral', 'Diuretics/*administration & dosage/adverse effects/pharmacokinetics', 'Evidence-Based Medicine', 'Furosemide/*administration & dosage/adverse effects/pharmacokinetics', 'Heart Failure/diagnosis/*drug therapy/physiopathology', 'Humans', 'Patient Selection', 'Practice Guidelines as Topic', 'Risk Factors', 'Treatment Outcome', 'Water-Electrolyte Balance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25786394/
1155,furosemide,8425583,Inhaled loop diuretics as potential new anti-asthmatic drugs.,"['Bianco S', 'Pieroni MG', 'Refini RM', 'Robuschi M', 'Vaghi A', 'Sestini P']","['Administration, Inhalation', 'Animals', 'Asthma/*drug therapy', 'Bronchoconstriction/drug effects', 'Diuretics/*administration & dosage/pharmacology', 'Drug Evaluation', 'Drug Evaluation, Preclinical', 'Furosemide/administration & dosage', 'Humans', 'Loop of Henle/drug effects']",https://pubmed.ncbi.nlm.nih.gov/8425583/
1156,furosemide,22825380,[Loop diuretics: facts and fallacies].,"['Meschi M', 'Detrenis S', 'Bianchi L', 'Sacco M', 'Bertorelli M', 'Boffetti F', 'Caiazza A', 'Savazzi G']","['Drinking', 'Drug Administration Routes', 'Edema/*drug therapy/etiology', 'Furosemide/administration & dosage/pharmacology/therapeutic use', 'Heart Failure/complications/physiopathology', 'Humans', 'Hydrostatic Pressure', 'Liver Cirrhosis/complications/physiopathology', 'Loop of Henle/drug effects/physiopathology', 'Natriuresis/drug effects', 'Nephrotic Syndrome/complications/physiopathology', 'Sodium Potassium Chloride Symporter Inhibitors/administration & dosage/pharmacology/*therapeutic use', 'Water-Electrolyte Imbalance/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/22825380/
1157,furosemide,19333124,Advances in the pharmacological management of breathlessness.,"['Currow DC', 'Ward AM', 'Abernethy AP']","['Dyspnea/*drug therapy/therapy', 'Furosemide/administration & dosage/*therapeutic use', 'Humans', 'Morphine/*therapeutic use', 'Narcotics/*therapeutic use', 'Nebulizers and Vaporizers', 'Palliative Care', 'Sodium Potassium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19333124/
1158,furosemide,39579977,Hypertonic saline in acute decompensated heart failure (HSHF).,"['Agrawal S', 'Abhishek Batta S', 'Rao T', 'Selvam S']","['Humans', 'Saline Solution, Hypertonic/administration & dosage/therapeutic use', '*Heart Failure/drug therapy/physiopathology', 'Male', 'Female', 'Acute Disease', 'Middle Aged', '*Furosemide/therapeutic use/administration & dosage', 'Treatment Outcome', 'Aged', 'Diuretics/therapeutic use', 'Dose-Response Relationship, Drug']",https://pubmed.ncbi.nlm.nih.gov/39579977/
1159,furosemide,24239195,Forced diuresis with the RenalGuard system: impact on contrast induced acute kidney injury.,['Solomon R'],"['Acute Kidney Injury/*chemically induced/*prevention & control', 'Contrast Media/*adverse effects', 'Diuresis/drug effects/physiology', 'Diuretics/*administration & dosage/pharmacology', 'Furosemide/*administration & dosage/pharmacology', 'Humans', 'Pilot Projects', 'Randomized Controlled Trials as Topic', 'Time Factors', 'Urinary Catheterization/methods']",https://pubmed.ncbi.nlm.nih.gov/24239195/
1160,furosemide,8375728,"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.","['Cornelison TL', 'Reed E']","['Animals', 'Antineoplastic Agents/*adverse effects', 'Carboplatin/adverse effects', 'Cisplatin/*adverse effects', '*Fluid Therapy', 'Furosemide/adverse effects/therapeutic use', 'Humans', 'Kidney/*drug effects/pathology/physiopathology', 'Mannitol/therapeutic use', 'Organoplatinum Compounds/*adverse effects', 'Saline Solution, Hypertonic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8375728/
1161,furosemide,357764,Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension.,"['Araoye MA', 'Chang MY', 'Khatri IM', 'Freis ED']","['Blood Pressure/*drug effects', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Hydrochlorothiazide/administration & dosage/pharmacology/*therapeutic use', 'Hypertension/*drug therapy', 'Systole/drug effects']",https://pubmed.ncbi.nlm.nih.gov/357764/
1162,furosemide,940030,Diuretic effect of furosemide in acute glomerulonephritis.,"['Pruitt AW', 'Boles A']","['Acute Disease', 'Administration, Oral', 'Adolescent', 'Blood Urea Nitrogen', 'Child', 'Child, Preschool', 'Diuresis/*drug effects', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Furosemide/administration & dosage/blood/*therapeutic use', 'Glomerulonephritis/blood/*drug therapy', 'Half-Life', 'Humans', 'Injections, Intravenous']",https://pubmed.ncbi.nlm.nih.gov/940030/
1163,furosemide,5565464,Frusemide in heart failure of infancy.,['Richardson H'],"['Administration, Oral', 'Aortic Coarctation/drug therapy', 'Body Weight/drug effects', 'Chlorides/urine', 'Ductus Arteriosus, Patent/drug therapy', 'Female', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Heart Failure/*drug therapy/urine', 'Heart Septal Defects, Ventricular/drug therapy', 'Humans', 'Infant', 'Infant, Newborn', 'Infant, Newborn, Diseases/*drug therapy', 'Injections, Intramuscular', 'Male', 'Mitral Valve Stenosis/drug therapy', 'Osmolar Concentration', 'Potassium/urine', 'Pulmonary Edema/drug therapy', 'Respiration/drug effects', 'Sodium/urine', 'Urine']",https://pubmed.ncbi.nlm.nih.gov/5565464/
1164,furosemide,319263,An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide.,"['Fuller RK', 'Khambatta PB', 'Gobezie GC']","['Ascites/diet therapy/*drug therapy/etiology', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Diuretics/adverse effects', 'Furosemide/*therapeutic use', 'Humans', 'Liver Cirrhosis/*complications', 'Plasma Volume/drug effects', 'Sodium/administration & dosage', 'Spironolactone/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/319263/
1165,furosemide,9158273,Frusemide-induced bullous pemphigoid.,"['Panayiotou BN', 'Prasad MV', 'Zaman MN']","['Aged', 'Bumetanide/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Female', 'Furosemide/*adverse effects', 'Humans', 'Male', 'Pemphigoid, Bullous/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9158273/
1166,furosemide,1994940,Oral labetalol in hypertensive urgencies.,"['Zell-Kanter M', 'Leikin JB']","['Administration, Oral', 'Adult', 'Blood Pressure/drug effects', 'Clinical Protocols/*standards', '*Emergencies', 'Emergency Service, Hospital', 'Female', 'Furosemide/administration & dosage/therapeutic use', 'Hospitals, University', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Illinois', 'Injections, Intravenous', 'Labetalol/administration & dosage/pharmacology/*therapeutic use', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/1994940/
1167,furosemide,4550872,"Bumetanide: potent new ""loop"" diuretic.","['Asbury MJ', 'Gatenby PB', ""O'Sullivan S"", 'Bourke E']","['Administration, Oral', 'Adult', 'Aged', 'Butylamines/therapeutic use', 'Chlorides/urine', 'Clinical Trials as Topic', 'Diuretics/administration & dosage/adverse effects/*therapeutic use', 'Edema/drug therapy', 'Female', 'Furosemide/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Phenols/therapeutic use', 'Placebos', 'Potassium/urine', 'Sodium/urine', 'Sulfonamides/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/4550872/
1168,gemfibrozil,1888257,Gemfibrozil-induced myopathy.,"['Magarian GJ', 'Lucas LM', 'Colley C']","['Clofibrate/adverse effects', 'Drug Therapy, Combination', 'Gemfibrozil/*adverse effects/therapeutic use', 'Humans', 'Hypertriglyceridemia/drug therapy', 'Lovastatin/adverse effects', 'Male', 'Middle Aged', 'Muscular Diseases/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1888257/
1169,gemfibrozil,39273674,"Hypertriglyceridemia Therapy: Past, Present and Future Perspectives.","['Canfora I', 'Pierno S']","['Humans', '*Hypertriglyceridemia/drug therapy', '*Hypolipidemic Agents/therapeutic use', 'Fibric Acids/therapeutic use', 'PPAR alpha/metabolism', 'Animals', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Cardiovascular Diseases/drug therapy/prevention & control', 'Gemfibrozil/therapeutic use', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/39273674/
1170,gemfibrozil,20211755,The nasty surprise of a complex drug-drug interaction.,['Bode C'],"['Carbamates/*adverse effects/pharmacokinetics', 'Drug Approval', 'Drug Evaluation, Preclinical/*methods', 'Drug Industry/methods', '*Drug Interactions', 'Drug Therapy, Combination/*adverse effects', 'Gemfibrozil/*adverse effects/pharmacokinetics', 'Humans', 'Itraconazole/*adverse effects/pharmacokinetics', 'Models, Biological', 'Piperidines/*adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/20211755/
1171,gemfibrozil,31577610,SPPARM alpha: the Lazarus effect.,"['Fruchart JC', 'Santos RD']","['Animals', '*Atherosclerosis/drug therapy/metabolism/pathology', 'Benzoxazoles/adverse effects/*therapeutic use', 'Butyrates/adverse effects/*therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/metabolism/pathology', '*Dyslipidemias/drug therapy/metabolism/pathology', 'Fenofibrate/adverse effects/therapeutic use', 'Gemfibrozil/adverse effects/therapeutic use', 'Humans', 'PPAR alpha/*agonists/metabolism']",https://pubmed.ncbi.nlm.nih.gov/31577610/
1172,gemfibrozil,18042221,Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.,"['Bouhlel MA', 'Staels B', 'Chinetti-Gbaguidi G']","['*Atherosclerosis/drug therapy/metabolism/prevention & control', 'Cardiovascular Diseases/*drug therapy', 'Cholesterol/*metabolism', 'Clinical Trials as Topic', 'Fenofibrate/adverse effects/therapeutic use', 'Gemfibrozil/adverse effects/therapeutic use', 'Humans', 'Hypolipidemic Agents/*therapeutic use', 'Macrophages/*drug effects/metabolism', '*Peroxisome Proliferator-Activated Receptors/agonists/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/18042221/
1173,gemfibrozil,12762976,Combination lipid-lowering therapy in diabetes.,['Davidson MH'],"['Diabetes Mellitus/*blood', 'Drug Therapy, Combination', 'Fenofibrate/pharmacokinetics/therapeutic use', 'Gemfibrozil/pharmacokinetics/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/pharmacokinetics/*therapeutic use', 'Lipoproteins, HDL/blood', 'Lipoproteins, LDL/blood', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/12762976/
1174,gemfibrozil,1498281,Hyperlipidemia and transplantation: etiologic factors and therapy.,"['Pirsch JD', ""D'Alessandro AM"", 'Sollinger HW', 'Knechtle SJ', 'Reed A', 'Kalayoglu M', 'Belzer FO']","['Adrenal Cortex Hormones/adverse effects', 'Antihypertensive Agents/adverse effects', 'Coronary Disease/etiology/prevention & control', 'Diuretics/adverse effects', 'Gemfibrozil/therapeutic use', 'Humans', 'Hyperlipidemias/diet therapy/drug therapy/*etiology', 'Immunosuppressive Agents/adverse effects', 'Kidney Failure, Chronic/blood/*surgery', '*Kidney Transplantation', 'Lipid Metabolism', 'Lipoprotein Lipase/deficiency', 'Lovastatin/therapeutic use', 'Postoperative Complications/*etiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/1498281/
1175,gemfibrozil,32155958,The Peroxisome Proliferator-Activated Receptor alpha- Agonist Gemfibrozil Promotes Defense Against Mycobacterium abscessus Infections.,"['Kim YS', 'Kim JK', 'Hanh BTB', 'Kim SY', 'Kim HJ', 'Kim YJ', 'Jeon SM', 'Park CR', 'Oh GT', 'Park JW', 'Kim JM', 'Jang J', 'Jo EK']","['Animals', 'Gemfibrozil/pharmacology/*therapeutic use', 'Humans', 'Hypolipidemic Agents/pharmacology/*therapeutic use', 'Male', 'Mice', 'Mycobacterium Infections, Nontuberculous/*drug therapy', 'PPAR alpha/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32155958/
1176,gemfibrozil,12044585,Postprandial lipemia--effect of lipid-lowering drugs.,['Karpe F'],"['Clinical Trials as Topic', 'Coronary Disease/etiology', 'Drug Therapy, Combination', 'Gemfibrozil/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use', 'Hyperlipidemias/complications/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', '*Lipid Metabolism', 'Postprandial Period', 'Simvastatin/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12044585/
1177,gemfibrozil,15198967,Safety of statins: focus on clinical pharmacokinetics and drug interactions.,"['Bellosta S', 'Paoletti R', 'Corsini A']","['Binding, Competitive', 'Biological Availability', 'Calcium Channel Blockers/pharmacokinetics', 'Chemical and Drug Induced Liver Injury', 'Citrus', 'Cytochrome P-450 CYP2D6/genetics', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme Inhibitors', 'Cytochrome P-450 Enzyme System/physiology', 'Drug Interactions', 'Fenofibrate/pharmacokinetics', 'Gemfibrozil/pharmacokinetics', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacokinetics', 'Liver Function Tests', 'Polymorphism, Genetic', 'Polymyositis/chemically induced', 'Rhabdomyolysis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/15198967/
1178,gemfibrozil,28735742,Genotoxicity of gemfibrozil in the gilthead seabream (Sparus aurata).,"['Barreto A', 'Luis LG', 'Soares AMVM', 'Paiga P', 'Santos LHMLM', 'Delerue-Matos C', 'Hylland K', 'Loureiro S', 'Oliveira M']","['Animals', 'Comet Assay', '*DNA Breaks', 'Dose-Response Relationship, Drug', 'Erythrocytes/*drug effects/pathology', 'Gemfibrozil/*toxicity', 'Micronuclei, Chromosome-Defective/*chemically induced', 'Micronucleus Tests', 'Sea Bream/blood/*genetics', 'Water Pollutants, Chemical/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/28735742/
1179,gemfibrozil,2385552,Lovastatin-induced acute rhabdomyolysis.,"['Kogan AD', 'Orenstein S']","['Acute Disease', 'Age Factors', 'Aged', 'Drug Therapy, Combination', 'Female', 'Gemfibrozil/adverse effects', 'Humans', 'Kidney Failure, Chronic/complications/drug therapy', 'Lovastatin/*adverse effects/therapeutic use', 'Muscles/pathology', 'Rhabdomyolysis/*chemically induced/pathology']",https://pubmed.ncbi.nlm.nih.gov/2385552/
1180,gemfibrozil,2123013,Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.,"['Schulman KA', 'Kinosian B', 'Jacobson TA', 'Glick H', 'Willian MK', 'Koffer H', 'Eisenberg JM']","['Anticholesteremic Agents/*therapeutic use', 'Cholestyramine Resin/therapeutic use', 'Clinical Trials as Topic', 'Colestipol/therapeutic use', 'Cost-Benefit Analysis', 'Drug Therapy, Combination', 'Gemfibrozil/therapeutic use', 'Humans', 'Hypercholesterolemia/drug therapy/*economics', 'Lovastatin/therapeutic use', 'Niacin/therapeutic use', 'Probucol/therapeutic use', 'Sensitivity and Specificity']",https://pubmed.ncbi.nlm.nih.gov/2123013/
1181,gemfibrozil,21192242,Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.,"['Kar S', 'Chockalingam A']","['Acute Kidney Injury/diagnosis/*etiology/therapy', 'Aged, 80 and over', 'Coronary Artery Disease/*drug therapy', 'Drug Therapy, Combination', 'Gemfibrozil/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use', 'Hypolipidemic Agents/adverse effects/therapeutic use', 'Male', 'Myocardial Infarction/diagnosis/*etiology', 'Renal Dialysis/*adverse effects', 'Rhabdomyolysis/*chemically induced/complications/diagnosis', 'Simvastatin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21192242/
1182,gemfibrozil,10357573,Role of fibrates in the management of hypertriglyceridemia.,"['Rader DJ', 'Haffner SM']","['Anticholesteremic Agents/therapeutic use', 'Cardiovascular Diseases/etiology/prevention & control', 'Drug Therapy, Combination', 'Female', 'Gemfibrozil/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypertriglyceridemia/complications/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', 'Lovastatin/therapeutic use', 'Male', 'Randomized Controlled Trials as Topic', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/10357573/
1183,gemfibrozil,27548563,Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.,"['Tornio A', 'Neuvonen PJ', 'Niemi M', 'Backman JT']","['Cytochrome P-450 CYP2C8/drug effects', 'Cytochrome P-450 CYP2C8 Inhibitors/metabolism/*pharmacology', 'Drug Interactions', 'Gemfibrozil/analogs & derivatives/metabolism/*pharmacology', 'Glucuronates/metabolism/pharmacology', 'Humans', 'Hypolipidemic Agents/metabolism/pharmacology', 'Membrane Transport Proteins/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/27548563/
1184,gemfibrozil,11570656,Smoking diminishes the beneficial effect of statins: observations from the landmark trials.,"['Milionis HJ', 'Rizos E', 'Mikhailidis DP']","['Anticholesteremic Agents/*therapeutic use', 'Clinical Trials as Topic', 'Gemfibrozil/therapeutic use', 'Humans', 'Lovastatin/*therapeutic use', 'Myocardial Ischemia/*prevention & control', 'Pravastatin/*therapeutic use', 'Risk Factors', 'Simvastatin/*therapeutic use', 'Smoking/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11570656/
1185,gemfibrozil,2192877,Drug treatment of dyslipoproteinemia.,['Hunninghake DB'],"['Bile Acids and Salts/metabolism', 'Clofibrate/therapeutic use', 'Coronary Disease/prevention & control', 'Drug Therapy, Combination', 'Gemfibrozil/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'Hyperlipoproteinemias/*drug therapy', 'Hypolipoproteinemias/*drug therapy', 'Niacin/metabolism', 'Probucol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2192877/
1186,gemfibrozil,26932225,Gemfibrozil in Combination with Statins-Is It Really Contraindicated?,"['Wiggins BS', 'Saseen JJ', 'Morris PB']","['Cardiovascular Diseases/drug therapy', 'Drug Combinations', 'Gemfibrozil/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use', 'Hypolipidemic Agents/*therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/26932225/
1187,gemfibrozil,27642087,Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?,"['Templeton IE', 'Chen Y', 'Mao J', 'Lin J', 'Yu H', 'Peters S', 'Shebley M', 'Varma MV']","['Amiodarone/*pharmacokinetics', 'Animals', 'Area Under Curve', 'Drug Discovery', 'Drug Interactions', 'Gemfibrozil/*pharmacokinetics', 'Humans', 'Models, Biological', 'Sertraline/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27642087/
1188,gentamicin,1078798,Chronic polymicrobial bacteremia.,"['Grajwer LA', 'Mukhopadhyay D', 'Grossman BJ']","['Adolescent', 'Ampicillin/therapeutic use', 'Blood Bactericidal Activity', 'Carbenicillin/blood/therapeutic use', 'Chronic Disease', '*Enterobacteriaceae Infections/blood/drug therapy', 'Female', 'Gentamicins/adverse effects/pharmacology/therapeutic use', 'Humans', 'Kanamycin/blood/therapeutic use', 'Probenecid/therapeutic use', '*Sepsis/blood/drug therapy', 'Vestibule, Labyrinth/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1078798/
1189,gentamicin,27206240,"Use of Gentamicin as Empiric Coverage for Ventilator-Associated Pneumonia: The ""Con"" Perspective.","['Byrnes M', 'Dorman R']","['Anti-Bacterial Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Drug Therapy, Combination', 'Gentamicins/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Pneumonia, Ventilator-Associated/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27206240/
1190,gentamicin,807310,"Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus and Providencia species.","['Ducan IB', 'Penner JL']","['Drug Resistance, Microbial', 'Gentamicins/administration & dosage/pharmacology', 'Humans', 'Microbial Sensitivity Tests', 'Proteus/*drug effects', 'Proteus vulgaris/drug effects', 'Providencia/*drug effects', 'Pseudomonas aeruginosa/*drug effects', 'Tobramycin/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/807310/
1191,gentamicin,358884,Gentamicin in 1978.,"['Appel GB', 'Neu HC']","['Amikacin/pharmacology', 'Animals', 'Bacterial Infections/drug therapy', 'Drug Synergism', 'Ear Diseases/chemically induced', 'Gentamicins/adverse effects/metabolism/*pharmacology/therapeutic use', 'Humans', 'Kidney/metabolism', 'Kidney Diseases/chemically induced', 'Netilmicin/therapeutic use', 'Penicillin Resistance', 'Penicillins/pharmacology', 'Respiratory Tract Infections/drug therapy', 'Sisomicin/therapeutic use', 'Tobramycin/therapeutic use', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/358884/
1192,gentamicin,15150688,[Characterization of custom-made biomaterials containing antibiotics].,"['Pfefferle HJ', 'Nies B']","['Anti-Bacterial Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Bacterial Infections/*drug therapy/microbiology', 'Biological Availability', '*Bone Cements', 'Drug Carriers', 'Drug Compounding', 'Gentamicins/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Methylmethacrylates/adverse effects/pharmacokinetics/*therapeutic use', 'Microbial Sensitivity Tests', 'Osteomyelitis/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/15150688/
1193,gentamicin,938081,Gentamicin dosage in children.,"['Taylor M', 'Keane C']","['Bacterial Infections/drug therapy', 'Child', 'Child, Preschool', 'Gentamicins/*administration & dosage/blood/therapeutic use', 'Humans', 'Infant', 'Injections, Intramuscular']",https://pubmed.ncbi.nlm.nih.gov/938081/
1194,gentamicin,31279530,Electrospinning of silica nanoparticles-entrapped nanofibers for sustained gentamicin release.,"['Chen X', 'Xu C', 'He H']","['Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/pharmacology', 'Biocompatible Materials/chemistry', 'Delayed-Action Preparations/*chemistry', 'Drug Liberation', 'Escherichia coli/drug effects', 'Escherichia coli Infections/drug therapy/microbiology', 'Gentamicins/*administration & dosage/pharmacokinetics/pharmacology', 'Humans', 'Nanofibers/*chemistry/ultrastructure', 'Nanoparticles/chemistry', 'Porosity', 'Silicon Dioxide/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31279530/
1195,gentamicin,2281427,Inhaled micronised gentamicin powder: a new delivery system.,"['Goldman JM', 'Bayston SM', ""O'Connor S"", 'Meigh RE']","['Administration, Inhalation', 'Administration, Intranasal', 'Bronchoalveolar Lavage Fluid/chemistry', 'Bronchoscopy', 'Cough/chemically induced', 'Fiber Optic Technology', 'Gentamicins/*administration & dosage/adverse effects/analysis', 'Humans', 'Middle Aged', 'Powders']",https://pubmed.ncbi.nlm.nih.gov/2281427/
1196,gentamicin,1130930,Nephrotoxicity of combined cephalothin-gentamicin regimen.,"['Cabanillas F', 'Burgos RC', 'Rodriguez C', 'Baldizon C']","['Acute Kidney Injury/*chemically induced', 'Aged', 'Blood Urea Nitrogen', 'Bronchopneumonia/drug therapy', 'Cephalothin/administration & dosage/*adverse effects/therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Gentamicins/administration & dosage/*adverse effects/therapeutic use', 'Humans', 'Kidney Tubular Necrosis, Acute/*chemically induced', 'Kidney Tubules/pathology', 'Middle Aged', 'Proteus Infections/drug therapy', 'Pseudomonas Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1130930/
1197,gentamicin,32641561,Acute kidney failure after intra-articular use of gentamicin sponge.,"['Gommans EPAT', 'Aarnoudse ALHJ', 'van Wensen RJA', 'van Erp-van Boekel AAW', 'Grouls RJE', 'van der Linden CMJ']","['Acute Kidney Injury/*chemically induced', 'Aged', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Gentamicins/administration & dosage/*adverse effects', 'Hip Prosthesis/*adverse effects', 'Humans', 'Male', 'Prosthesis-Related Infections/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/32641561/
1198,gentamicin,15713316,The influence of cyclic loading on gentamicin release from acrylic bone cements.,"['Hendriks JG', 'Neut D', 'Hazenberg JG', 'Verkerke GJ', 'van Horn JR', 'van der Mei HC', 'Busscher HJ']","['Arthroplasty, Replacement, Hip/adverse effects/*methods', 'Bone Cements/*therapeutic use', 'Drug Delivery Systems/*methods', 'Gentamicins/*administration & dosage', 'Hip Prosthesis', 'Humans', 'Infection Control/methods', 'Materials Testing', '*Weight-Bearing']",https://pubmed.ncbi.nlm.nih.gov/15713316/
1199,gentamicin,9726669,Unilateral vestibulotoxicity due to systemic gentamicin therapy.,"['Waterston JA', 'Halmagyi GM']","['Aged', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Caloric Tests', 'Female', 'Gentamicins/administration & dosage/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Vertigo', 'Vestibular Diseases/*chemically induced/diagnosis/physiopathology', 'Vestibule, Labyrinth/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/9726669/
1200,gentamicin,21197583,Local antibiotic delivery with demineralized bone matrix.,"['Lewis CS', 'Supronowicz PR', 'Zhukauskas RM', 'Gill E', 'Cobb RR']","['Alkaline Phosphatase/metabolism', 'Animals', 'Anti-Bacterial Agents/*administration & dosage/*pharmacology', '*Bone Demineralization Technique', 'Bone Matrix/*metabolism', 'Cell Adhesion/drug effects', 'Cell Proliferation/drug effects', 'Drug Delivery Systems/*methods', 'Gentamicins/*administration & dosage/*pharmacology', 'Humans', 'Kinetics', 'Microbial Sensitivity Tests', 'Osseointegration/drug effects', 'Osteoblasts/cytology/drug effects/enzymology', 'Osteogenesis/drug effects', 'Rats', 'Staphylococcus aureus/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21197583/
1201,gentamicin,6337803,"Netilmicin (Netromycin, Schering-Plough).",['Guay DR'],"['Animals', 'Bacteria/drug effects', 'Chemical Phenomena', 'Chemistry', 'Costs and Cost Analysis', 'Gentamicins/*therapeutic use', 'Humans', 'Kinetics', 'Netilmicin/adverse effects/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6337803/
1202,gentamicin,1147809,Ocular penetration of topically applied gentamicin.,"['Ellerhost B', 'Golden B', 'Jarudi N']","['Animals', 'Conjunctiva/analysis', 'Cornea/analysis', 'Eye/*metabolism', 'Gentamicins/*administration & dosage/analysis/metabolism', 'Humans', 'Male', 'Ophthalmic Solutions', 'Rabbits']",https://pubmed.ncbi.nlm.nih.gov/1147809/
1203,gentamicin,9812246,The use of once-daily dosing of gentamicin in obstetrics and gynecology.,"['Wiesenfeld HC', 'Heine RP']","['Bacterial Infections/*drug therapy', 'Drug Administration Schedule', 'Drug Costs', 'Drug Resistance, Microbial', 'Female', 'Genital Diseases, Female/*drug therapy', 'Gentamicins/*administration & dosage/adverse effects/pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9812246/
1204,gentamicin,943947,Placental transfer of clindamycin and gentamicin in term pregnancy.,"['Weinstein AJ', 'Gibbs RS', 'Gallagher M']","['Bacterial Infections/prevention & control', 'Cesarean Section', 'Clindamycin/administration & dosage/*metabolism/therapeutic use', 'Female', 'Fetal Blood/metabolism', 'Gentamicins/administration & dosage/*metabolism/therapeutic use', 'Humans', 'Infant, Newborn', 'Kinetics', '*Maternal-Fetal Exchange', 'Placenta/*metabolism', '*Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/943947/
1205,gentamicin,994263,Increased dosage requirements of gentamicin in burn patients.,"['Zaske DE', 'Sawchuk RJ', 'Gerding DN', 'Strate RG']","['Adolescent', 'Adult', 'Burns/*complications', 'Child', 'Child, Preschool', 'Gentamicins/*administration & dosage/blood/therapeutic use', 'Half-Life', 'Humans', 'Infant', 'Middle Aged', 'Pseudomonas Infections/drug therapy', 'Wound Infection/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/994263/
1206,gentamicin,31102287,A review of population pharmacokinetic models of gentamicin in paediatric patients.,"['Crcek M', 'Zdovc J', 'Kerec Kos M']","['Anti-Bacterial Agents/*administration & dosage/*pharmacokinetics', 'Child', 'Databases, Factual', 'Gentamicins/*administration & dosage/*pharmacokinetics', 'Humans', 'Infusions, Intravenous/methods', 'Models, Biological']",https://pubmed.ncbi.nlm.nih.gov/31102287/
1207,gentamicin,7970794,Gentamicin vestibulotoxicity.,"['Halmagyi GM', 'Fattore CM', 'Curthoys IS', 'Wade S']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Gentamicins/administration & dosage/*adverse effects/blood', 'Humans', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Kidney Diseases/chemically induced/complications', 'Male', 'Middle Aged', 'Vestibular Diseases/*chemically induced/complications']",https://pubmed.ncbi.nlm.nih.gov/7970794/
1208,glimepiride,30265743,Novel therapeutic approaches to xeroderma pigmentosum.,"['Weon JL', 'Glass DA 2nd']","['Acetohexamide/pharmacology/therapeutic use', 'Administration, Cutaneous', 'Animals', 'Caloric Restriction', 'DNA Damage/*drug effects/radiation effects', 'DNA Repair/*drug effects', 'Dermatology/methods/trends', 'Disease Models, Animal', 'Humans', 'Niacinamide/pharmacology/therapeutic use', 'Protective Clothing', 'Randomized Controlled Trials as Topic', 'Sulfonylurea Compounds/pharmacology/*therapeutic use', 'Sunlight/adverse effects', 'Sunscreening Agents/*administration & dosage', 'Treatment Outcome', 'Ultraviolet Rays/adverse effects', 'Xeroderma Pigmentosum/genetics/*therapy']",https://pubmed.ncbi.nlm.nih.gov/30265743/
1209,glimepiride,36129997,Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.,"['Nathan DM', 'Lachin JM', 'Bebu I', 'Burch HB', 'Buse JB', 'Cherrington AL', 'Fortmann SP', 'Green JB', 'Kahn SE', 'Kirkman MS', 'Krause-Steinrauf H', 'Larkin ME', 'Phillips LS', 'Pop-Busui R', 'Steffes M', 'Tiktin M', 'Tripputi M', 'Wexler DJ', 'Younes N']","['Albuminuria/etiology/prevention & control', 'Blood Glucose/analysis', '*Cardiovascular Diseases/etiology/prevention & control', 'Comparative Effectiveness Research', '*Diabetes Complications/etiology/prevention & control', '*Diabetes Mellitus, Type 2/complications/drug therapy', 'Diabetic Neuropathies/diagnosis/etiology/prevention & control', 'Drug Therapy, Combination', 'Dyslipidemias/etiology/prevention & control', 'Glomerular Filtration Rate', '*Glycated Hemoglobin/analysis', 'Heart Failure/etiology/prevention & control', 'Humans', 'Hypertension/etiology/prevention & control', '*Hypoglycemic Agents/adverse effects/therapeutic use', 'Insulin Glargine/adverse effects/therapeutic use', 'Liraglutide/adverse effects/therapeutic use', '*Metformin/adverse effects/therapeutic use', 'Microvessels/drug effects', 'Sitagliptin Phosphate/adverse effects/therapeutic use', 'Sulfonylurea Compounds/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36129997/
1210,glimepiride,36300277,Evaluating gliclazide for the treatment of type 2 diabetes mellitus.,"['Tomlinson B', 'Li YH', 'Chan P']","['Humans', '*Gliclazide/adverse effects', '*Diabetes Mellitus, Type 2/drug therapy', 'Sulfonylurea Compounds/therapeutic use', 'Hypoglycemic Agents/adverse effects', 'Blood Glucose']",https://pubmed.ncbi.nlm.nih.gov/36300277/
1211,glimepiride,17076998,Are sulfonylureas passe?,"['Green JB', 'Feinglos MN']","['Diabetes Mellitus, Type 2/*drug therapy/physiopathology', 'Humans', 'Hypoglycemic Agents/adverse effects/therapeutic use', 'Sulfonylurea Compounds/adverse effects/*therapeutic use', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17076998/
1212,glimepiride,24948511,"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.","['Ridderstrale M', 'Andersen KR', 'Zeller C', 'Kim G', 'Woerle HJ', 'Broedl UC']","['Adult', 'Benzhydryl Compounds/*administration & dosage', 'Blood Glucose/drug effects/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Glucosides/*administration & dosage', 'Glycated Hemoglobin/drug effects/metabolism', 'Humans', 'Hypoglycemic Agents/*administration & dosage', 'Male', 'Metformin/*administration & dosage', 'Middle Aged', 'Sodium-Glucose Transporter 2', '*Sodium-Glucose Transporter 2 Inhibitors', 'Sulfonylurea Compounds/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24948511/
1213,glimepiride,15200348,The role of sulphonylureas in the management of type 2 diabetes mellitus.,['Rendell M'],"['Benzamides/therapeutic use', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Insulin/therapeutic use', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/15200348/
1214,glimepiride,37909653,Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database.,"['Li J', 'Wang Y', 'Yang X', 'Zhu H', 'Jiang Z']","['*Hypoglycemia/chemically induced/epidemiology', 'Humans', '*Databases, Factual', '*Adverse Drug Reaction Reporting Systems/statistics & numerical data', '*Pharmacovigilance', 'United States/epidemiology', '*United States Food and Drug Administration', '*Hypoglycemic Agents/adverse effects/administration & dosage', 'Male', 'Adult', 'Middle Aged', 'Female', 'Drug Labeling', 'Aged', 'Child', 'Young Adult', 'Adolescent', 'Child, Preschool']",https://pubmed.ncbi.nlm.nih.gov/37909653/
1215,glimepiride,32861392,Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?,"['John M', 'Kalra S', 'Nair T']","['Cardiovascular Diseases/etiology/*prevention & control', 'Diabetes Mellitus, Type 2/complications/*drug therapy', 'Humans', 'Hypoglycemic Agents/therapeutic use', 'Sulfonylurea Compounds/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32861392/
1216,glimepiride,33754231,Development of anti-acanthamoebic approaches.,"['Mungroo MR', 'Tong T', 'Khan NA', 'Anuar TS', 'Maciver SK', 'Siddiqui R']","['Acanthamoeba Keratitis/*drug therapy/*parasitology', 'Acanthamoeba castellanii/*drug effects', 'Acarbose/pharmacology', 'Antiprotozoal Agents/*pharmacology', 'Carbamates/pharmacology', 'Cell Line', 'Contact Lens Solutions/pharmacology', 'Contact Lenses/adverse effects/*parasitology', 'HaCaT Cells', 'Humans', 'Indenes/pharmacology', 'Inositol/pharmacology', 'Nanoparticles', 'Piperidines/pharmacology', 'Sulfonylurea Compounds/pharmacology', 'Triazines/pharmacology', 'Vildagliptin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33754231/
1217,glimepiride,22247979,A case of hypoglycemic hemiparesis and literature review.,"['Yoshino T', 'Meguro S', 'Soeda Y', 'Itoh A', 'Kawai T', 'Itoh H']","['Aged', 'Aged, 80 and over', 'Blood Glucose/analysis', 'Diabetes Mellitus/drug therapy', 'Humans', 'Hypoglycemia/*complications', 'Male', 'Metformin/administration & dosage/therapeutic use', 'Paresis/*diagnosis/etiology', 'Sulfonylurea Compounds/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22247979/
1218,glimepiride,36592466,"In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.","['Brown K', 'Donato AA']","['Humans', '*Diabetes Mellitus, Type 2/complications/drug therapy', 'Insulin Glargine/therapeutic use', 'Liraglutide/therapeutic use', 'Sitagliptin Phosphate/therapeutic use', 'Hypoglycemic Agents/therapeutic use', 'Drug Therapy, Combination', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36592466/
1219,glimepiride,38853720,"Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naive patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.","['Kim NH', 'Moon JS', 'Lee YH', 'Cho HC', 'Kwak SH', 'Lim S', 'Moon MK', 'Kim DL', 'Kim TH', 'Ko E', 'Lee J', 'Kim SG']","['Humans', '*Diabetes Mellitus, Type 2/drug therapy/blood', '*Metformin/therapeutic use/administration & dosage/adverse effects', '*Glucosides/administration & dosage/adverse effects/therapeutic use', 'Male', 'Female', '*Benzhydryl Compounds/therapeutic use/administration & dosage/adverse effects', 'Middle Aged', '*Drug Therapy, Combination', '*Dipeptides/adverse effects/administration & dosage/therapeutic use', '*Adamantane/analogs & derivatives/administration & dosage/adverse effects/therapeutic use', '*Hypoglycemic Agents/administration & dosage/therapeutic use/adverse effects', '*Glycated Hemoglobin/analysis/metabolism', 'Aged', 'Treatment Outcome', 'Hypoglycemia/chemically induced', 'Sulfonylurea Compounds/therapeutic use/administration & dosage/adverse effects', 'Blood Glucose/drug effects/metabolism', 'Adult', 'Weight Gain/drug effects', 'Sitagliptin Phosphate/therapeutic use/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38853720/
1220,glimepiride,17728849,Pioglitazone hydrochloride/glimepiride.,['Blake EW'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Drug Combinations', 'Humans', '*Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Pioglitazone', '*Sulfonylurea Compounds/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Thiazolidinediones/administration & dosage/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17728849/
1221,glimepiride,39546502,Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.,"['Seaquist ER', 'Phillips LS', 'Ghosh A', 'Baker C', 'Bergenstal RM', 'Crandall JP', 'Goland RS', 'Gramzinski MR', 'Hox SH', 'Hsia DS', 'Johnson ML', 'Lachin JM', 'Raskin P', 'Valencia WM', 'Waltje AH', 'Younes N']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Blood Glucose/drug effects/analysis', '*Diabetes Mellitus, Type 2/drug therapy/blood', 'Glycated Hemoglobin/analysis/metabolism', '*Hypoglycemia/chemically induced', '*Hypoglycemic Agents/therapeutic use/adverse effects', 'Insulin Glargine/therapeutic use/adverse effects/administration & dosage', 'Liraglutide/therapeutic use/adverse effects', 'Metformin/therapeutic use/adverse effects', 'Sitagliptin Phosphate/therapeutic use/adverse effects', 'Sulfonylurea Compounds/therapeutic use/adverse effects', 'Treatment Outcome', '*Glycemic Control']",https://pubmed.ncbi.nlm.nih.gov/39546502/
1222,glimepiride,21240619,Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.,"['Shimojima Y', 'Ishii W', 'Matsuda M', 'Tojo K', 'Watanabe R', 'Ikeda S']","['Diabetes Complications/*drug therapy', 'Drug Therapy, Combination', 'Glucocorticoids/administration & dosage/adverse effects', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects', 'Inositol/administration & dosage/adverse effects/*analogs & derivatives', 'Lupus Vasculitis, Central Nervous System/*drug therapy', 'Male', 'Middle Aged', 'Pneumatosis Cystoides Intestinalis/*chemically induced/diagnostic imaging', 'Prednisolone/administration & dosage/*adverse effects', 'Sulfonylurea Compounds/administration & dosage/*adverse effects', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/21240619/
1223,glimepiride,8864639,Clinical profile of the novel sulphonylurea glimepiride.,"['Rosskamp R', 'Wernicke-Panten K', 'Draeger E']","['Blood Glucose/metabolism', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Sulfonylurea Compounds/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8864639/
1224,glimepiride,10742816,[Metformin-induced lactic acidosis].,"['Reeker W', 'Schneider G', 'Felgenhauer N', 'Tempel G', 'Kochs E']","['Acidosis, Lactic/*chemically induced/diagnosis/therapy', 'Acute Disease', 'Coma/chemically induced/diagnosis/therapy', 'Combined Modality Therapy', 'Contraindications', 'Diabetes Mellitus, Type 2/complications/drug therapy', 'Diagnosis, Differential', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypoglycemic Agents/*adverse effects/therapeutic use', 'Metformin/*adverse effects/therapeutic use', 'Middle Aged', 'Sulfonylurea Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10742816/
1225,glimepiride,8911978,"Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.",['Riddle MC'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/therapeutic use', 'Insulin/administration & dosage/*therapeutic use', 'Sulfonylurea Compounds/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8911978/
1226,haloperidol,27023437,Possible biomarkers modulating haloperidol efficacy and/or tolerability.,"['Porcelli S', 'Crisafulli C', 'Calabro M', 'Serretti A', 'Rujescu D']","['Antipsychotic Agents/adverse effects/pharmacology/*therapeutic use', 'Biomarkers/analysis', 'Epigenesis, Genetic', 'Gene Expression Profiling', 'Genetic Markers', 'Genotype', 'Haloperidol/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Organ Specificity', 'Psychotic Disorders/*drug therapy/genetics']",https://pubmed.ncbi.nlm.nih.gov/27023437/
1227,haloperidol,7504573,Pharmacological profile of risperidone.,"['Ereshefsky L', 'Lacombe S']","['Antipsychotic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Brain/drug effects/metabolism', 'Dose-Response Relationship, Drug', 'Haloperidol/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Isoxazoles/administration & dosage/adverse effects/*pharmacokinetics', 'Metabolic Clearance Rate/physiology', 'Piperidines/administration & dosage/adverse effects/*pharmacokinetics', 'Receptors, Dopamine D2/drug effects/metabolism', 'Receptors, Serotonin/drug effects/metabolism', 'Risperidone', 'Schizophrenia/*blood/drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/7504573/
1228,haloperidol,2259358,Tardive eating dystonia.,"['Achiron A', 'Melamed E']","['Aged', 'Aggression/*drug effects', 'Blepharospasm/chemically induced', 'Deglutition Disorders/chemically induced', 'Dyskinesia, Drug-Induced/*etiology', 'Feeding and Eating Disorders/*chemically induced', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Male', 'Neurologic Examination', 'Substance Withdrawal Syndrome/*etiology']",https://pubmed.ncbi.nlm.nih.gov/2259358/
1229,haloperidol,11044761,Rational antipsychotic polypharmacy.,"['Kennedy NB', 'Procyshyn RM']","['Antipsychotic Agents/administration & dosage/pharmacokinetics/*therapeutic use', 'Clozapine/administration & dosage/pharmacokinetics/*therapeutic use', 'Cytochrome P-450 Enzyme System/drug effects', 'Drug Interactions', 'Haloperidol/administration & dosage/pharmacokinetics/*therapeutic use', 'Humans', 'Isoenzymes/drug effects', 'Polypharmacy', 'Psychotic Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11044761/
1230,haloperidol,26561842,[The neurotoxicity of pyridinium metabolites of haloperidol].,"['Gorska A', 'Marszall M', 'Sloderbach A']","['Antipsychotic Agents/*pharmacology', '*Biotransformation', 'Brain/*drug effects', 'Delirium/drug therapy', 'Haloperidol/*adverse effects/metabolism/pharmacology', 'Humans', 'Nausea/drug therapy', 'Neurodegenerative Diseases/*chemically induced', '*Neurotoxicity Syndromes', 'Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26561842/
1231,haloperidol,1933763,Haloperidol-induced bronchospasm.,"['Sethna R', 'Notkin R']","['Administration, Oral', 'Adult', 'Bronchial Spasm/*chemically induced', 'Female', 'Haloperidol/administration & dosage/*adverse effects', '*Hospitalization', 'Humans', 'Psychotic Disorders/*drug therapy/psychology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/1933763/
1232,haloperidol,12522522,Torsade de pointes associated with the administration of intravenous haloperidol.,"['Hassaballa HA', 'Balk RA']","['Administration, Oral', 'Antipsychotic Agents/administration & dosage/*adverse effects', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Injections, Intravenous', 'Torsades de Pointes/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12522522/
1233,haloperidol,30337420,BET 1: Haloperidol in cannabinoid hyperemesis syndrome.,"['Dida J', 'Walji N']","['Adult', 'Antiemetics/pharmacology/therapeutic use', 'Cannabinoids/*adverse effects/therapeutic use', 'Haloperidol/*pharmacology/therapeutic use', 'Humans', 'Male', 'Vomiting/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30337420/
1234,haloperidol,16822092,Risks versus benefits of different types of long-acting injectable antipsychotics.,['McEvoy JP'],"['Administration, Oral', 'Antipsychotic Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Fluphenazine/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Haloperidol/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Health Care Costs', 'Humans', 'Injections, Intramuscular', 'Microspheres', 'Quality of Life', 'Risk Assessment', 'Risperidone/administration & dosage/pharmacokinetics/therapeutic use', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Secondary Prevention', '*Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/16822092/
1235,haloperidol,15888517,Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review.,"['Christodoulou C', 'Kalaitzi C']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Diagnosis, Differential', 'Dystonia/*chemically induced/diagnosis', 'Female', 'Haloperidol/adverse effects/therapeutic use', 'Humans', 'Laryngeal Diseases/*chemically induced/diagnosis', 'Male', 'Psychotic Disorders/complications/drug therapy', 'Risk Factors', 'Schizophrenia/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15888517/
1236,haloperidol,2689040,Pharmacokinetics of haloperidol.,"['Froemming JS', 'Lam YW', 'Jann MW', 'Davis CM']","['Drug Interactions', 'Haloperidol/adverse effects/analogs & derivatives/metabolism/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2689040/
1237,haloperidol,11305682,Neuroleptic malignant syndrome in children and adolescents.,"['Ty EB', 'Rothner AD']","['Adolescent', 'Adult', 'Antipsychotic Agents/*adverse effects', 'Child', 'Depressive Disorder, Major/*drug therapy', 'Female', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Neuroleptic Malignant Syndrome/*diagnosis/etiology', 'Psychotic Disorders/*drug therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/11305682/
1238,haloperidol,1937339,[30 years experience with haloperidol].,"['Bandelow B', 'Muller P', 'Ruther E']","['Brain/drug effects', 'Dopamine Antagonists', 'Dyskinesia, Drug-Induced/blood/*etiology', 'Haloperidol/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Psychotic Disorders/blood/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1937339/
1239,haloperidol,8830064,Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.,"['Darby JK', 'Pasta DJ', 'Dabiri L', 'Clark L', 'Mosbacher D']","['Administration, Oral', 'Adult', 'Antipsychotic Agents/administration & dosage/*adverse effects/pharmacokinetics', 'Biological Availability', 'Chronic Disease', 'Dose-Response Relationship, Drug', 'Female', 'Haloperidol/administration & dosage/*adverse effects/pharmacokinetics', 'Humans', 'Long-Term Care', 'Male', 'Metabolic Clearance Rate/physiology', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Psychoses, Substance-Induced/blood/diagnosis/psychology', 'Schizophrenia/blood/*drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8830064/
1240,haloperidol,16915578,Pharmacokinetic parameters of bromperidol in Korean subjects.,"['Lee SY', 'Kim YG', 'Kim HG', 'Kim JW']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Basal Ganglia Diseases/chemically induced', 'Cytochrome P-450 CYP2D6/genetics/metabolism', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/genetics/metabolism', 'Dose-Response Relationship, Drug', 'Dystonia/chemically induced', 'Female', 'Genotype', 'Haloperidol/administration & dosage/adverse effects/*analogs & derivatives/blood/pharmacokinetics', 'Humans', 'Korea', 'Male', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/16915578/
1241,haloperidol,2544823,Haloperidol and cognitive shifting.,"['Berger HJ', 'van Hoof JJ', 'van Spaendonck KP', 'Horstink MW', 'van den Bercken JH', 'Jaspers R', 'Cools AR']","['Attention/drug effects', 'Basal Ganglia/drug effects', 'Cognition Disorders/*chemically induced', 'Female', 'Frontal Lobe/drug effects', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Neuropsychological Tests', 'Pattern Recognition, Visual/drug effects', 'Psychomotor Performance/drug effects', 'Receptors, Dopamine/drug effects', 'Synaptic Transmission/drug effects', 'Torticollis/*drug therapy', 'Verbal Behavior/drug effects', 'Verbal Learning/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2544823/
1242,haloperidol,8220668,Management of delirium associated with use of the intra-aortic balloon pump.,"['Sanders KM', 'Stern TA']","['Administration, Oral', 'Adult', 'Aged', 'Clinical Protocols', 'Coronary Disease/therapy', 'Delirium/diagnosis/*drug therapy/*etiology/nursing', 'Diagnosis, Differential', 'Female', 'Haloperidol/administration & dosage/*therapeutic use', 'Humans', 'Injections, Intravenous', 'Intensive Care Units', 'Intra-Aortic Balloon Pumping/*adverse effects', 'Male', 'Middle Aged', 'Referral and Consultation']",https://pubmed.ncbi.nlm.nih.gov/8220668/
1243,haloperidol,33068931,Haloperidol in palliative care: Indications and risks.,"['Zaporowska-Stachowiak I', 'Stachowiak-Szymczak K', 'Oduah MT', 'Sopata M']","['Antipsychotic Agents/adverse effects/*therapeutic use', 'Haloperidol/adverse effects/*therapeutic use', 'Humans', 'Palliative Care/*methods', 'Quality of Life', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/33068931/
1244,haloperidol,11232752,Weight change and atypical antipsychotic treatment in patients with schizophrenia.,"['Jones B', 'Basson BR', 'Walker DJ', 'Crawford AM', 'Kinon BJ']","['Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use', 'Behavior Therapy/methods', 'Benzodiazepines', 'Dose-Response Relationship, Drug', 'Follow-Up Studies', 'Haloperidol/administration & dosage/adverse effects/therapeutic use', 'Health Behavior', 'Humans', 'Obesity/chemically induced/prevention & control', 'Olanzapine', 'Pirenzepine/administration & dosage/*adverse effects/*analogs & derivatives/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Schizophrenia/*drug therapy', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/11232752/
1245,haloperidol,16127964,Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.,"['Zipursky RB', 'Christensen BK', 'Daskalakis Z', 'Epstein I', 'Roy P', 'Furimsky I', 'Sanger T', 'Kapur S']","['Acute Disease', 'Adolescent', 'Adult', 'Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Benzodiazepines/administration & dosage/adverse effects/pharmacokinetics', 'Corpus Striatum/diagnostic imaging/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Haloperidol/*administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Male', 'Olanzapine', '*Positron-Emission Tomography', 'Psychotic Disorders/diagnostic imaging/*drug therapy/psychology', 'Raclopride', 'Receptors, Dopamine D2/*drug effects', 'Schizophrenia/diagnostic imaging/*drug therapy', 'Schizophrenic Psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16127964/
1246,hydralazine,29808264,"Neonatal hypertension: cases, causes, and clinical approach.","['Starr MC', 'Flynn JT']","['Administration, Intravenous', 'Antihypertensive Agents/*administration & dosage/adverse effects', 'Birth Weight/physiology', 'Blood Pressure/drug effects/*physiology', 'Blood Pressure Determination/instrumentation/methods', 'Clinical Decision-Making', 'Gestational Age', 'Humans', 'Hydralazine/administration & dosage/adverse effects', 'Hypertension/*diagnosis/epidemiology/etiology/therapy', 'Incidence', 'Infant, Newborn', 'Infant, Newborn, Diseases/*diagnosis/epidemiology/etiology/therapy', 'Infant, Premature/*physiology', 'Intensive Care Units, Neonatal', 'Kidney/physiopathology/surgery', 'Labetalol/administration & dosage/adverse effects', 'Neuroblastoma/complications/surgery', 'Reference Values', 'Renal Artery Obstruction/complications/surgery', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29808264/
1247,hydralazine,8522630,Management of hypertensive urgencies and emergencies.,"['Abdelwahab W', 'Frishman W', 'Landau A']","['Administration, Oral', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Emergencies', 'Enalaprilat/therapeutic use', 'Female', 'Humans', 'Hydralazine/therapeutic use', 'Hypertension/classification/*drug therapy', 'Infusions, Parenteral', 'Labetalol/therapeutic use', 'Nicardipine/therapeutic use', 'Nitroglycerin/therapeutic use', 'Nitroprusside/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8522630/
1248,hydralazine,18827911,Perioperative hypertension management.,"['Varon J', 'Marik PE']","['Adrenergic beta-Antagonists/pharmacology', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Enalaprilat/pharmacology/therapeutic use', 'Fenoldopam/pharmacology/therapeutic use', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/pharmacology/therapeutic use', 'Hypertension/*drug therapy/epidemiology', 'Incidence', 'Labetalol/administration & dosage/pharmacology', 'Nicardipine/pharmacology/therapeutic use', 'Nitroglycerin/pharmacology', 'Nitroprusside/pharmacology', 'Perioperative Care', 'Postoperative Complications/*drug therapy', 'Propanolamines/pharmacology', 'Pyridines/pharmacology/therapeutic use', '*Surgical Procedures, Operative', 'Vascular Resistance/drug effects', 'Vasodilator Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18827911/
1249,hydralazine,26600442,Hypertensive Emergencies in Pregnancy.,"['Olson-Chen C', 'Seligman NS']","['Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Cesarean Section/standards', 'Chronic Disease', 'Congenital Abnormalities/*epidemiology/etiology', 'Emergencies', 'Esophageal Atresia/epidemiology/etiology', 'Female', 'Heart Defects, Congenital/epidemiology/etiology', 'Humans', 'Hydralazine/administration & dosage/adverse effects/therapeutic use', 'Hypertension/complications/drug therapy/epidemiology/physiopathology', 'Hypertension, Pregnancy-Induced/drug therapy/epidemiology/*physiopathology', 'Hypospadias/epidemiology/etiology', 'Labetalol/administration & dosage/adverse effects/therapeutic use', 'Labor, Induced/standards', 'Male', 'Nifedipine/administration & dosage/adverse effects/therapeutic use', 'Postnatal Care', 'Pre-Eclampsia/drug therapy/epidemiology/*physiopathology', 'Pregnancy', 'Pregnancy Outcome/*epidemiology', 'Prevalence', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/26600442/
1250,hydralazine,32927458,Genotype-Guided Hydralazine Therapy.,"['Collins KS', 'Raviele ALJ', 'Elchynski AL', 'Woodcock AM', 'Zhao Y', 'Cooper-DeHoff RM', 'Eadon MT']","['Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Arylamine N-Acetyltransferase/*genetics/metabolism', 'Dose-Response Relationship, Drug', 'Drug Resistance/genetics', 'Humans', 'Hydralazine/pharmacokinetics/*therapeutic use', 'Hypertension/*drug therapy/genetics', 'Nephrology/methods/standards', 'Pharmacogenomic Testing/standards', 'Pharmacogenomic Variants', 'Practice Guidelines as Topic', 'Precision Medicine/*methods/standards', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32927458/
1251,hydralazine,9543400,Parenteral hydralazine revisited.,"['Powers DR', 'Papadakos PJ', 'Wallin JD']","['Emergencies', 'Female', 'Humans', 'Hydralazine/pharmacology/*therapeutic use', 'Hypertension/*drug therapy', 'Infusions, Parenteral', 'Pre-Eclampsia/drug therapy', 'Pregnancy', 'Vasodilator Agents/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9543400/
1252,hydralazine,21896152,Direct-acting vasodilators.,"['Cohn JN', 'McInnes GT', 'Shepherd AM']","['Antihypertensive Agents/adverse effects/*therapeutic use', 'Hirsutism/chemically induced', 'Humans', 'Hydralazine/adverse effects/therapeutic use', 'Hypertension/*drug therapy', 'Minoxidil/adverse effects/therapeutic use', 'Tachycardia/chemically induced', 'Treatment Outcome', 'Vasodilator Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21896152/
1253,hydralazine,2196888,Severe preeclampsia: is vasodilation therapy with hydralazine dangerous for the preterm fetus?,"['Derham RJ', 'Robinson J']","['Female', 'Fetus/*drug effects', 'Humans', 'Hydralazine/*adverse effects', 'Hypotension/*chemically induced', 'Pre-Eclampsia/*drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/2196888/
1254,hydralazine,8710038,Hydralazine-induced constrictive pericarditis.,"['Franssen CF', 'el Gamal MI', 'Gans RO', 'Hoorntje SJ']","['Antibodies, Antineutrophil Cytoplasmic', 'Antihypertensive Agents/*adverse effects/therapeutic use', 'Autoantibodies/*analysis', 'Autoimmune Diseases/*chemically induced/physiopathology', 'Humans', 'Hydralazine/*adverse effects/therapeutic use', 'Hypertension/drug therapy', 'Male', 'Middle Aged', 'Pericarditis, Constrictive/*chemically induced/diagnosis', 'Peroxidase/immunology', 'Thoracotomy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8710038/
1255,hydralazine,18473924,Carbonyl-scavenging drugs & protection against carbonyl stress-associated cell injury.,"['Burcham PC', 'Kaminskas LM', 'Tan D', 'Pyke SM']","['Acrolein/*antagonists & inhibitors/toxicity', 'Alzheimer Disease/chemically induced/drug therapy', 'Animals', 'Atherosclerosis/chemically induced/drug therapy', 'Cell Death/drug effects', 'Free Radical Scavengers/chemistry/*pharmacology/therapeutic use', 'Humans', 'Hydralazine/analogs & derivatives/chemistry/*pharmacology', 'Liver Diseases, Alcoholic/drug therapy', 'Oxidative Stress/drug effects', 'Protective Agents/chemistry/*pharmacology/therapeutic use', 'Spinal Cord Injuries/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18473924/
1256,hydralazine,6349967,Vasodilator therapy in chronic congestive heart failure.,"['Schwartz AB', 'Chatterjee K']","['Captopril/therapeutic use', 'Chronic Disease', 'Drug Therapy, Combination', 'Heart Failure/*drug therapy/physiopathology', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/therapeutic use', 'Minoxidil/therapeutic use', 'Nitrates/therapeutic use', 'Piperazines/therapeutic use', 'Vasodilator Agents/classification/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6349967/
1257,hydralazine,36150895,A review on the clinical pharmacokinetics of hydralazine.,"['Shahzad Qamar A', 'Zamir A', 'Khalid S', 'Ashraf W', 'Imran I', 'Hussain I', 'Rehman AU', 'Saeed H', 'Majeed A', 'Alqahtani F', 'Rasool MF']","['Pregnancy', 'Female', 'Humans', 'Hydralazine/pharmacokinetics/therapeutic use', 'Vasodilator Agents', '*Hypertension/drug therapy', '*Heart Failure/drug therapy', '*Drug-Related Side Effects and Adverse Reactions', 'Pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/36150895/
1258,hydralazine,3511697,Vasodilator therapy.,['Sutton FJ'],"['Administration, Oral', 'Captopril/administration & dosage', 'Cardiac Output/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Heart Failure/*drug therapy', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/administration & dosage', 'Nitrates/administration & dosage', 'Physical Exertion/drug effects', 'Prazosin/administration & dosage', 'Random Allocation', 'Stroke Volume/drug effects', 'Time Factors', 'Vasodilator Agents/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3511697/
1259,hydralazine,6519160,Hydralazine-induced lupus: is there a toxic metabolic pathway?,"['Timbrell JA', 'Facchini V', 'Harland SJ', 'Mansilla-Tinoco R']","['Acetylation', 'Biotransformation', 'Creatinine/urine', 'Female', 'Humans', 'Hydralazine/*adverse effects/metabolism', 'Kinetics', 'Lupus Vulgaris/*chemically induced', 'Male', 'Phenotype', 'Sulfamethazine']",https://pubmed.ncbi.nlm.nih.gov/6519160/
1260,hydralazine,37989321,In vivo ameliorative effects of vitamin E against hydralazine-induced lupus.,"['Githaiga FM', 'Omwenga GI', 'Ngugi MP']","['Humans', 'Animals', 'Mice', '*Vitamin E/pharmacology/therapeutic use', '*Lupus Erythematosus, Systemic/chemically induced/drug therapy', 'Hydralazine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37989321/
1261,hydralazine,24673554,Biomimetic microfluidic device for in vitro antihypertensive drug evaluation.,"['Li L', 'Lv X', 'Ostrovidov S', 'Shi X', 'Zhang N', 'Liu J']","['Antihypertensive Agents/chemistry/*pharmacology', 'Biomimetic Materials/chemistry/*pharmacology', 'Biomimetics/*methods', 'Blood Vessels/drug effects', 'Cells, Cultured', 'Dimethylpolysiloxanes/chemistry', 'Drug Evaluation/methods', 'Endothelial Cells/drug effects', 'Human Umbilical Vein Endothelial Cells', 'Humans', 'Hydralazine/chemistry/pharmacology', 'In Vitro Techniques/methods', 'Lab-On-A-Chip Devices/*methods', 'Microfluidics/methods', 'Nylons/chemistry', 'Pressure', 'Shear Strength/drug effects', 'Stress, Mechanical']",https://pubmed.ncbi.nlm.nih.gov/24673554/
1262,hydralazine,3884988,Vasodilator drugs in the treatment of hypertension.,['Kincaid-Smith P'],"['Calcium Channel Blockers/therapeutic use', 'Captopril/administration & dosage/therapeutic use', 'Cardiac Output/drug effects', 'Diazoxide/adverse effects/therapeutic use', 'Diuretics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/administration & dosage/adverse effects/therapeutic use', 'Hypertension/*drug therapy', 'Infusions, Parenteral', 'Minoxidil/administration & dosage/adverse effects/therapeutic use', 'Prazosin/therapeutic use', 'Renal Circulation/drug effects', 'Vasodilator Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3884988/
1263,hydralazine,38542088,Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.,"['Kourek C', 'Briasoulis A', 'Papamichail A', 'Xanthopoulos A', 'Tsougos E', 'Farmakis D', 'Paraskevaidis I']","['Humans', '*Heart Failure', 'Stroke Volume', 'Hydralazine/pharmacology/therapeutic use', 'Isosorbide Dinitrate/pharmacology/therapeutic use', 'Angiotensin Receptor Antagonists/pharmacology', 'Multicenter Studies as Topic', 'Urea/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38542088/
1264,hydralazine,32044579,The flipside of hydralazine in pregnancy: A systematic review and meta-analysis.,"['Antza C', 'Dimou C', 'Doundoulakis I', 'Akrivos E', 'Stabouli S', 'Haidich AB', 'Goulis DG', 'Kotsis V']","['Antihypertensive Agents/*therapeutic use', 'Birth Weight', 'Female', 'Heart Rate', 'Humans', 'Hydralazine/*therapeutic use', 'Hypertension/*drug therapy', 'Hypertension, Pregnancy-Induced/*drug therapy', 'Infant, Newborn', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32044579/
1265,hydralazine,2666324,Bullous systemic lupus erythematosus.,"['Fleming MG', 'Bergfeld WF', 'Tomecki KJ', 'Tuthill RJ', 'Norris M', 'Benedetto EA', 'Weber LA']","['Adult', 'Aged', 'Dapsone/therapeutic use', 'Female', 'Fluorescent Antibody Technique', 'Humans', 'Hydralazine/*adverse effects', 'Lupus Erythematosus, Systemic/chemically induced/*complications/pathology', 'Skin Diseases, Vesiculobullous/chemically induced/*complications/immunology/pathology']",https://pubmed.ncbi.nlm.nih.gov/2666324/
1266,hydroxyzine,36843057,Efficacy and safety of hydroxyzine for sleep in adults: Systematic review.,"['Burgazli CR', 'Rana KB', 'Brown JN', 'Tillman F 3rd']","['Humans', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Hypnotics and Sedatives/pharmacology', 'Hydroxyzine/adverse effects', 'Prospective Studies', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/36843057/
1267,hydroxyzine,25397904,H1-antihistamines for chronic spontaneous urticaria.,"['Sharma M', 'Bennett C', 'Cohen SN', 'Carter B']","['Cetirizine/therapeutic use', 'Cyproheptadine/analogs & derivatives/therapeutic use', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Loratadine/analogs & derivatives/therapeutic use', 'Randomized Controlled Trials as Topic', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25397904/
1268,hydroxyzine,38980829,Managing Pruritus in Advanced Chronic Disease.,"['Kaya E', 'McDonald G', 'Gallagher R']","['Humans', '*Pruritus/drug therapy/etiology', 'Chronic Disease', 'Hydroxyzine/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38980829/
1269,hydroxyzine,6627988,Follicular dermographism.,"['Shelley WB', 'Shelley ED']","['Adolescent', 'Adult', 'Female', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Middle Aged', 'Physical Stimulation', 'Pruritus/etiology', 'Urticaria/drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/6627988/
1270,hydroxyzine,1979802,Recent advances in H1-receptor antagonist treatment.,['Simons FE'],"['Astemizole', 'Benzhydryl Compounds/*pharmacokinetics', 'Benzimidazoles/*pharmacokinetics', 'Cetirizine', 'Cyproheptadine/*analogs & derivatives/pharmacokinetics', 'Histamine H1 Antagonists/*pharmacokinetics', 'Humans', 'Hydroxyzine/*analogs & derivatives/pharmacokinetics', 'Loratadine', 'Receptors, Histamine H1/drug effects', 'Rhinitis, Allergic, Perennial/drug therapy', 'Terfenadine', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1979802/
1271,hydroxyzine,35976065,Topical cetirizine for treating androgenetic alopecia: A systematic review.,"['Chen X', 'Xiang H', 'Yang M']","['Humans', 'Administration, Topical', '*Alopecia/drug therapy', '*Cetirizine/administration & dosage/adverse effects', 'Hair', 'Minoxidil/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35976065/
1272,hydroxyzine,1686525,Cetirizine: more than an antihistamine?,"['Bernheim J', 'Arendt C', 'de Vos C']","['Allergens/immunology', 'Animals', 'Asthma/drug therapy/immunology/physiopathology', 'Cetirizine', 'Exercise', 'Histamine Antagonists/*pharmacology', 'Histamine H1 Antagonists/pharmacology', 'Humans', 'Hydroxyzine/*analogs & derivatives/pharmacology/therapeutic use', 'Hypersensitivity/physiopathology', 'Muscle Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1686525/
1273,hydroxyzine,36613097,"The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials.","['Skeie-Larsen M', 'Stave R', 'Gronli J', 'Bjorvatn B', 'Wilhelmsen-Langeland A', 'Zandi A', 'Pallesen S']","['Humans', '*Dreams', 'Randomized Controlled Trials as Topic', 'Prazosin/therapeutic use/pharmacology', 'Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Stress Disorders, Post-Traumatic', 'Hydroxyzine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36613097/
1274,hydroxyzine,11034010,Cetirizine-induce cholestasis.,"['Fong DG', 'Angulo P', 'Burgart LJ', 'Lindor KD']","['Adult', 'Cetirizine/*adverse effects/therapeutic use', 'Cholestasis, Intrahepatic/*chemically induced/diagnosis/pathology', 'Histamine H1 Antagonists/*adverse effects/therapeutic use', 'Humans', 'Liver/pathology', 'Male', 'Rhinitis, Allergic, Perennial/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11034010/
1275,hydroxyzine,9852800,Oral sedation.,['Dionne R'],"['Administration, Oral', 'Algorithms', 'Anesthesia, Dental/*methods', 'Anti-Anxiety Agents/*administration & dosage', 'Chloral Hydrate/adverse effects', 'Conscious Sedation/*methods', 'Dental Anxiety/*prevention & control', 'Diazepam/administration & dosage', 'Histamine H1 Antagonists/administration & dosage', 'Humans', 'Hydroxyzine/administration & dosage', 'Hypnotics and Sedatives/adverse effects', 'Midazolam/administration & dosage', 'Mutagens', 'Premedication', 'Triazolam/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/9852800/
1276,hydroxyzine,11414551,Pharmacotherapy of generalized anxiety disorder.,['Davidson JR'],"['Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents/administration & dosage/*therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Anxiety Disorders/*drug therapy/epidemiology/psychology', 'Benzodiazepines', 'Buspirone/therapeutic use', 'Comorbidity', 'Depressive Disorder/drug therapy/epidemiology', 'Heart Rate/drug effects', 'Humans', 'Hydroxyzine/therapeutic use', 'Serotonin Receptor Agonists/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11414551/
1277,hydroxyzine,1979793,H1-receptor antagonist treatment of seasonal allergic rhinitis.,['Kaiser HB'],"['Astemizole', 'Benzhydryl Compounds/pharmacokinetics/therapeutic use', 'Benzimidazoles/pharmacokinetics/therapeutic use', 'Cetirizine', 'Chlorpheniramine/pharmacokinetics/therapeutic use', 'Clemastine/pharmacokinetics/therapeutic use', 'Cyproheptadine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Histamine H1 Antagonists/pharmacokinetics/*therapeutic use', 'Humans', 'Hydroxyzine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Ketotifen/pharmacokinetics/therapeutic use', 'Loratadine', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Terfenadine']",https://pubmed.ncbi.nlm.nih.gov/1979793/
1278,hydroxyzine,11772135,Cetirizine/pseudoephedrine.,"['Wellington K', 'Jarvis B']","['Administration, Oral', 'Adrenergic Agents/adverse effects/pharmacokinetics/*pharmacology', 'Anxiety/chemically induced', 'Asthenia/chemically induced', 'Biological Availability', 'Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Chemistry, Pharmaceutical', 'Drug Administration Schedule', 'Ephedrine/adverse effects/pharmacokinetics/*pharmacology', 'Headache/chemically induced', 'Histamine H1 Antagonists/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Nasal Cavity', 'Pruritus/drug therapy', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy/pathology', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Tablets', 'Treatment Outcome', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11772135/
1279,hydroxyzine,10582736,Therapeutic index of H1-antihistamines: example of cetirizine.,['Rihoux JP'],"['Cetirizine/adverse effects/metabolism/*therapeutic use', 'Histamine H1 Antagonists/adverse effects/metabolism/*therapeutic use', 'Humans', 'Hypersensitivity, Immediate/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10582736/
1280,hydroxyzine,34818169,Urticaria and edema in a 2-year-old boy.,"['Cook JS', 'Angles A', 'Morley E']","['Amoxicillin/*adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Child, Preschool', 'Diagnosis, Differential', 'Drug Eruptions/*diagnosis/*drug therapy', 'Edema', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Otitis Media/*drug therapy', 'Triamcinolone/therapeutic use', 'Urticaria/*diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34818169/
1281,hydroxyzine,2871956,Repeat chemonucleolysis.,['Sutton JC Jr'],"['Adolescent', 'Adult', 'Anaphylaxis/etiology/*prevention & control', 'Chymopapain/adverse effects/*therapeutic use', 'Cimetidine/*therapeutic use', 'Female', 'Follow-Up Studies', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Hydroxyzine/*therapeutic use', 'Intervertebral Disc Displacement/*drug therapy', 'Lumbar Vertebrae', 'Male', 'Middle Aged', '*Premedication', 'Recurrence', 'Risk', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2871956/
1282,hydroxyzine,9146011,Hydroxyzine therapy for interstitial cystitis.,"['Theoharides TC', 'Sant GR']","['Cystitis, Interstitial/*drug therapy', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Hydroxyzine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9146011/
1283,hydroxyzine,22030083,Generalised anxiety disorder.,"['Gale CK', 'Millichamp J']","['Anxiety Disorders/drug therapy', 'Benzodiazepines/therapeutic use', '*Buspirone/therapeutic use', 'Humans', '*Hydroxyzine/therapeutic use', 'Psychiatric Status Rating Scales', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22030083/
1284,hydroxyzine,8833171,Aquagenic urticaria.,['Medeiros M Jr'],"['Adult', 'Cetirizine/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Urticaria/*diagnosis/drug therapy/*etiology', 'Water/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8833171/
1285,hydroxyzine,2188436,Potentiation of pain relief with hydroxyzine: a therapeutic myth?,['Glazier HS'],"['Drug Synergism', 'Humans', 'Hydroxyzine/adverse effects/*therapeutic use', 'Narcotics/adverse effects/*therapeutic use', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2188436/
1286,ipratropium,12643359,The 'crashing asthmatic.'.,['Higgins JC'],"['Adrenergic beta-Agonists/*therapeutic use', 'Albuterol/administration & dosage/*therapeutic use', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Furans/therapeutic use', 'Glucocorticoids/*therapeutic use', 'Humans', 'Intubation, Intratracheal', 'Ipratropium/administration & dosage/*therapeutic use', 'Methylprednisolone Hemisuccinate/*therapeutic use', '*Nebulizers and Vaporizers', 'Phenols/therapeutic use', 'Respiratory Function Tests', 'Status Asthmaticus/diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12643359/
1287,ipratropium,33621253,Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis.,"['Xu H', 'Tong L', 'Gao P', 'Hu Y', 'Wang H', 'Chen Z', 'Fang L']","['Administration, Inhalation', 'Adolescent', 'Albuterol/metabolism/*therapeutic use', 'Anti-Asthmatic Agents/therapeutic use', 'Asthma/*drug therapy/metabolism', 'Bronchodilator Agents/therapeutic use', 'Child', 'Child, Preschool', 'China', 'Disease Progression', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ipratropium/metabolism/*therapeutic use', 'Male']",https://pubmed.ncbi.nlm.nih.gov/33621253/
1288,ipratropium,19967500,Anticholinergic treatment in airways diseases.,"['Flynn RA', 'Glynn DA', 'Kennedy MP']","['Asthma/*drug therapy', 'Cholinergic Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Chronic Disease', 'Cost-Benefit Analysis', 'Humans', 'Ipratropium/administration & dosage/adverse effects/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Randomized Controlled Trials as Topic', 'Scopolamine Derivatives/administration & dosage/adverse effects/*therapeutic use', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/19967500/
1289,ipratropium,2962075,Ipratropium bromide and airways obstruction in childhood.,['Milner AD'],"['Age Factors', 'Airway Obstruction/*drug therapy', 'Asthma/*drug therapy', 'Atropine Derivatives/*therapeutic use', 'Bronchiolitis, Viral/drug therapy', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Humans', 'Ipratropium/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2962075/
1290,ipratropium,12169757,Anticholinergics in the treatment of chronic obstructive pulmonary disease.,"['Beeh KM', 'Welte T', 'Buhl R']","['Adrenergic beta-Agonists/pharmacology/therapeutic use', 'Cholinergic Antagonists/*pharmacology/*therapeutic use', 'Humans', 'Ipratropium/pharmacology/therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Scopolamine Derivatives/pharmacology/therapeutic use', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/12169757/
1291,ipratropium,33639629,Nebulized Ipratropium Bromide-induced Anisocoria: Why Is Anisocoria Observed?,"['Derinoz-Guleryuz O', 'Fidanci I', 'Men-Atmaca Y']","['Anisocoria/*diagnosis/*etiology/prevention & control', 'Child', 'Disease Management', 'Disease Susceptibility', 'Emergency Medical Services', 'Humans', 'Ipratropium/administration & dosage/*adverse effects', 'Nebulizers and Vaporizers', 'Symptom Assessment']",https://pubmed.ncbi.nlm.nih.gov/33639629/
1292,ipratropium,3155676,Ipratropium bromide.,"['Massey KL', 'Gotz VP']","['Animals', 'Asthma/drug therapy', 'Atropine Derivatives/*therapeutic use', 'Biotransformation', 'Bronchitis/drug therapy', 'Chemical Phenomena', 'Chemistry', 'Drug Therapy, Combination', 'Female', 'Humans', 'Intestinal Absorption', 'Ipratropium/administration & dosage/adverse effects/metabolism/pharmacology/*therapeutic use', 'Kinetics', 'Lung Diseases, Obstructive/*drug therapy', 'Pregnancy', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/3155676/
1293,ipratropium,19834421,Ipratropium bromide for acute asthma exacerbations in the emergency setting: a literature review of the evidence.,"['Dotson K', 'Dallman M', 'Bowman CM', 'Titus MO']","['Acute Disease', 'Asthma/*drug therapy', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Child', 'Emergency Treatment', 'Humans', 'Ipratropium/administration & dosage/*therapeutic use', 'Practice Guidelines as Topic', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/19834421/
1294,ipratropium,28249059,An overlooked Rx for nasal obstruction relief.,['Leventhal WD'],"['Humans', 'Ipratropium/*administration & dosage', 'Nasal Decongestants/administration & dosage', 'Nasal Obstruction/*drug therapy', 'Nasal Sprays']",https://pubmed.ncbi.nlm.nih.gov/28249059/
1295,ipratropium,10565879,Anticholinergic bronchodilators.,['Witek TJ Jr'],"['Adrenergic beta-Agonists/administration & dosage/therapeutic use', 'Albuterol/administration & dosage/therapeutic use', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Cholinergic Antagonists/administration & dosage/*therapeutic use', 'Drug Combinations', 'Humans', 'Ipratropium/administration & dosage/therapeutic use', 'Lung Diseases, Obstructive/drug therapy/physiopathology', 'Muscarinic Antagonists/therapeutic use', 'Nasal Mucosa/drug effects/metabolism', 'Respiratory Mechanics/drug effects', 'Rhinitis/drug therapy', 'Scopolamine Derivatives/administration & dosage/therapeutic use', 'Tiotropium Bromide', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10565879/
1296,ipratropium,8610719,Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease.,['Siefkin AD'],"['Adrenal Cortex Hormones/therapeutic use', 'Adrenergic beta-Agonists/therapeutic use', 'Asthma/drug therapy', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Critical Illness', 'Drug Combinations', 'Humans', 'Ipratropium/therapeutic use', 'Lung Diseases, Obstructive/*drug therapy/physiopathology', 'Muscarinic Antagonists/therapeutic use', 'Pulmonary Ventilation']",https://pubmed.ncbi.nlm.nih.gov/8610719/
1297,ipratropium,1460208,Intranasal anticholinergic therapy of rhinorrhea.,['Meltzer EO'],"['Administration, Intranasal', 'Humans', 'Ipratropium/administration & dosage/adverse effects', 'Nasal Mucosa/drug effects/*metabolism', 'Parasympatholytics/*administration & dosage', 'Rhinitis/*drug therapy', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Virus Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1460208/
1298,ipratropium,2523291,Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD.,"['LeDoux EJ', 'Morris JF', 'Temple WP', 'Duncan C']","['Administration, Inhalation', 'Aged', 'Atropine Derivatives/*administration & dosage', 'Double-Blind Method', 'Drug Combinations', 'Forced Expiratory Volume', 'Humans', 'Ipratropium/*administration & dosage/therapeutic use', 'Lung Diseases, Obstructive/drug therapy/*physiopathology', 'Male', 'Metaproterenol/*administration & dosage/therapeutic use', 'Middle Aged', 'Placebos', 'Random Allocation', 'Spirometry', 'Vital Capacity']",https://pubmed.ncbi.nlm.nih.gov/2523291/
1299,ipratropium,19916997,Inhaled tiotropium bromide and risk of stroke.,"['Grosso A', 'Douglas I', 'Hingorani AD', 'MacAllister R', 'Hubbard R', 'Smeeth L']","['Administration, Inhalation', 'Aged', 'Albuterol/administration & dosage/adverse effects/*analogs & derivatives', 'Androstadienes/administration & dosage/*adverse effects', 'Bronchodilator Agents/administration & dosage/*adverse effects', 'Cholinergic Antagonists/administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Female', 'Fluticasone', 'Humans', 'Ipratropium/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Risk Factors', 'Salmeterol Xinafoate', 'Scopolamine Derivatives/administration & dosage/*adverse effects', 'Stroke/*chemically induced', 'Tiotropium Bromide', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/19916997/
1300,ipratropium,2139094,Long-term safety and efficacy study of intranasal ipratropium bromide.,"['Milford CA', 'Mugliston TA', 'Lund VJ', 'Mackay IS']","['Administration, Intranasal', 'Adolescent', 'Adult', 'Aged', 'Atropine Derivatives/*administration & dosage', 'Clinical Trials as Topic', 'Epistaxis/chemically induced', 'Female', 'Headache/chemically induced', 'Humans', 'Ipratropium/*administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Nasal Mucosa/drug effects', 'Rhinitis/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2139094/
1301,ipratropium,154164,Intranasal ipratropium: inhibition of methacholine induced hypersecretion.,['Borum P'],"['Administration, Intranasal', 'Adult', 'Airway Resistance/drug effects', 'Atropine Derivatives/*pharmacology', 'Depression, Chemical', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Ipratropium/administration & dosage/*pharmacology', 'Male', 'Methacholine Compounds/administration & dosage/*pharmacology', 'Nasal Mucosa/drug effects/*metabolism', 'Placebos', 'Rhinitis/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/154164/
1302,ipratropium,6459357,Combination bronchodilator therapy in asthma.,"['Ruffin RE', 'McIntyre E', 'Crockett AJ', 'Zielonka K', 'Alpers JH']","['Adult', 'Aged', 'Asthma/*drug therapy', 'Atropine Derivatives/*therapeutic use', 'Bronchodilator Agents/*therapeutic use', 'Drug Therapy, Combination', 'Ethanolamines/*therapeutic use', 'Female', 'Fenoterol/adverse effects/*therapeutic use', 'Forced Expiratory Volume', 'Humans', 'Ipratropium/adverse effects/*therapeutic use', 'Male', 'Maximal Midexpiratory Flow Rate', 'Middle Aged', 'Parasympatholytics/therapeutic use', 'Sympathomimetics/therapeutic use', 'Vital Capacity']",https://pubmed.ncbi.nlm.nih.gov/6459357/
1303,ipratropium,2947463,Concomitant bronchodilator therapy and ipratropium bromide. A clinical review.,['Chervinsky P'],"['Asthma/drug therapy/physiopathology', 'Atropine Derivatives/*therapeutic use', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Drug Evaluation', 'Drug Therapy, Combination', 'Forced Expiratory Volume', 'Humans', 'Ipratropium/administration & dosage/*therapeutic use', 'Lung Diseases, Obstructive/drug therapy/physiopathology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2947463/
1304,ipratropium,27418820,Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.,"['Bhattacharya A', 'Bhargava S', 'Singh V', 'Talwar D', 'Whig J', 'Rebello J', 'Purandare S', 'Gogtay J']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects', 'Adult', '*Aerosol Propellants/adverse effects', 'Aged', 'Albuterol/*administration & dosage/adverse effects', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Combinations', 'Equipment Design', 'Female', 'Forced Expiratory Volume', 'Humans', '*Hydrocarbons, Fluorinated/adverse effects', 'India', 'Ipratropium/*administration & dosage/adverse effects', 'Lung/*drug effects/physiopathology', 'Male', '*Metered Dose Inhalers', 'Middle Aged', 'Muscarinic Antagonists/*administration & dosage/adverse effects', 'Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology', 'Severity of Illness Index', 'Therapeutic Equivalency', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27418820/
1305,ipratropium,2975286,Chronobiology and asthma. II. Body-time-dependent differences in the kinetics and effects of bronchodilator medications.,"['Smolensky MH', 'McGovern JP', 'Scott PH', 'Reinberg A']","['Adult', 'Airway Resistance/*drug effects', 'Asthma/blood/drug therapy/*physiopathology', 'Bronchodilator Agents/administration & dosage/pharmacokinetics/*pharmacology', '*Chronobiology Phenomena', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Epinephrine/administration & dosage/pharmacokinetics/pharmacology', 'Food', 'Humans', 'Ipratropium/administration & dosage/pharmacokinetics/pharmacology', 'Male', 'Metaproterenol/administration & dosage/pharmacokinetics/pharmacology', 'Peak Expiratory Flow Rate', 'Terbutaline/administration & dosage/pharmacokinetics/pharmacology', 'Theophylline/administration & dosage/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2975286/
1306,isoflurane,12751547,Halogenated inhalational anaesthetics.,"['Reichle FM', 'Conzen PF']","['Anesthetics, Inhalation/*adverse effects', 'Animals', 'Desflurane', 'Enflurane/adverse effects', 'Ethers/adverse effects', 'Halothane/adverse effects', 'Humans', 'Hydrocarbons, Fluorinated/adverse effects', 'Isoflurane/adverse effects/*analogs & derivatives', 'Kidney/drug effects', 'Liver/drug effects', 'Methyl Ethers/adverse effects', 'Organ Specificity', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/12751547/
1307,isoflurane,19271031,Inhaled anesthesia and cognitive performance.,"['Mandal PK', 'Schifilliti D', 'Mafrica F', 'Fodale V']","['Age Factors', 'Aged', 'Anesthetics, Inhalation/administration & dosage/*adverse effects', 'Cognition Disorders/epidemiology/*etiology', 'Desflurane', 'Humans', 'Isoflurane/administration & dosage/adverse effects/analogs & derivatives', 'Methyl Ethers/administration & dosage/adverse effects', 'Nitrous Oxide/administration & dosage/adverse effects', 'Postoperative Complications/epidemiology/*etiology', 'Risk Factors', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/19271031/
1308,isoflurane,9421064,Perioperative fever.,"['Lenhardt R', 'Negishi C', 'Sessler DI']","['Ambulatory Surgical Procedures', 'Anesthesia, General', 'Anesthetics, Inhalation/administration & dosage/pharmacology', 'Body Temperature Regulation', 'Desflurane', 'Drug Interactions', 'Fever/*etiology/physiopathology', 'Humans', 'Hypothermia/etiology/physiopathology', 'Infections/physiopathology', 'Interleukin-2/administration & dosage/pharmacology', 'Isoflurane/administration & dosage/analogs & derivatives/pharmacology', 'Postoperative Complications', 'Pyrogens/administration & dosage/pharmacology/physiology', 'Shivering/physiology', '*Surgical Procedures, Operative', 'Surgical Wound Infection/complications/physiopathology', 'Vasoconstriction/physiology']",https://pubmed.ncbi.nlm.nih.gov/9421064/
1309,isoflurane,28438069,Emerging graft protective strategies in clinical liver transplantation.,"['Nickkholgh A', 'Maluf D']","['Anesthetics, Inhalation/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Desflurane', 'Graft Rejection/*prevention & control', '*Graft Survival/drug effects', 'Humans', '*Ischemic Preconditioning', 'Isoflurane/analogs & derivatives/therapeutic use', 'Liver Transplantation/adverse effects/*methods', 'Methyl Ethers/therapeutic use', 'Methylprednisolone/therapeutic use', 'Organ Preservation/*methods', 'Reperfusion Injury/*prevention & control', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/28438069/
1310,isoflurane,7635558,New drugs in anesthesia.,['Eger EI 2nd'],"['Anesthesia, Inhalation', '*Anesthetics, Inhalation/chemistry/pharmacokinetics/pharmacology', 'Blood Circulation/drug effects', 'Desflurane', '*Ethers/chemistry/pharmacokinetics/pharmacology', 'Humans', 'Isoflurane/*analogs & derivatives/chemistry/pharmacokinetics/pharmacology', '*Methyl Ethers', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/7635558/
1311,isoflurane,7955772,Desflurane clinical pharmacokinetics and pharmacodynamics.,['Caldwell JE'],"['Aging/metabolism', 'Anesthetics/adverse effects/*pharmacokinetics/pharmacology', 'Animals', 'Cardiovascular System/drug effects', 'Central Nervous System/drug effects', 'Desflurane', 'Drug Interactions', 'Humans', 'In Vitro Techniques', 'Isoflurane/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Muscles/drug effects', 'Respiratory System/drug effects', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/7955772/
1312,isoflurane,30898682,Sex effects on behavioral markers of emergence from propofol and isoflurane anesthesia in rats.,"['Mansouri MT', 'Fidler JA', 'Meng QC', 'Eckenhoff RG', 'Garcia PS']","['*Anesthesia', 'Anesthetics, General/administration & dosage/pharmacokinetics/*pharmacology', 'Animals', 'Behavior, Animal/*drug effects', 'Female', 'Humans', 'Injections, Intraperitoneal', 'Isoflurane/administration & dosage/pharmacokinetics/*pharmacology', 'Male', 'Movement/*drug effects', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Rats', 'Rats, Sprague-Dawley', '*Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/30898682/
1313,isoflurane,25585653,[Isoflurane-induced malignant hyperthermia during intensive-care treatment].,"['Wendlandt B', 'Turinsky S', 'Schmitz M']","['Administration, Inhalation', 'Cardiopulmonary Resuscitation', 'Combined Modality Therapy', '*Conscious Sedation', 'Electric Countershock', 'Heart Massage', 'Humans', 'Hypothermia, Induced', '*Intensive Care Units', 'Isoflurane/administration & dosage/*adverse effects', 'Male', 'Malignant Hyperthermia/*etiology', 'Middle Aged', 'Myocardial Infarction/*drug therapy', '*Thrombolytic Therapy']",https://pubmed.ncbi.nlm.nih.gov/25585653/
1314,isoflurane,9849287,Gallstones and isoflurane hepatitis.,"['Meldrum DJ', 'Griffiths R', 'Kenna JG']","['Aged', 'Anesthetics, Inhalation/*adverse effects/immunology', 'Chemical and Drug Induced Liver Injury/etiology', 'Cholelithiasis/*complications', 'Drug Hypersensitivity/etiology', 'Female', 'Hepatitis/*etiology', 'Humans', 'Isoflurane/*adverse effects/immunology', '*Postoperative Complications']",https://pubmed.ncbi.nlm.nih.gov/9849287/
1315,isoflurane,30897103,Relevance of experimental paradigms of anesthesia induced neurotoxicity in the mouse.,"['Johnson SC', 'Pan A', 'Sun GX', 'Freed A', 'Stokes JC', 'Bornstein R', 'Witkowski M', 'Li L', 'Ford JM', 'Howard CRA', 'Sedensky MM', 'Morgan PG']","['Anesthetics, Inhalation/*adverse effects/pharmacology', 'Animals', 'Animals, Newborn', 'Behavior, Animal/*drug effects', 'Disease Models, Animal', 'Haplorhini', 'Humans', 'Isoflurane/*adverse effects/pharmacology', 'Mice', '*Neurotoxicity Syndromes/metabolism/pathology/physiopathology', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/30897103/
1316,isoflurane,28306680,Anaesthesia in patients with liver disease.,"['Starczewska MH', 'Mon W', 'Shirley P']","['Anesthesia/*adverse effects/methods', 'Desflurane', 'Elective Surgical Procedures/*adverse effects', 'End Stage Liver Disease/complications/epidemiology/metabolism/*surgery', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*adverse effects', 'Incidence', 'Isoflurane/administration & dosage/adverse effects/analogs & derivatives', 'Methyl Ethers/administration & dosage/adverse effects', 'Monitoring, Physiologic', 'Opiate Alkaloids/administration & dosage/adverse effects/metabolism', 'Perioperative Care/*methods', 'Postoperative Complications/epidemiology/etiology', 'Prognosis', 'Propofol/administration & dosage', 'Risk Assessment', 'Severity of Illness Index', 'Sevoflurane', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28306680/
1317,isoflurane,22735251,Postoperative global amnesia reversed with flumazenil.,"['Rinehart JB', 'Baker B', 'Raphael D']","['Amnesia/*drug therapy/*etiology', 'Analgesics/administration & dosage', 'Anesthesia, General/*adverse effects', 'Cholangiopancreatography, Endoscopic Retrograde', 'Desflurane', 'Diabetes Mellitus, Type 2', 'Fentanyl/administration & dosage', 'Flumazenil/*therapeutic use', 'GABA Modulators/*therapeutic use', 'Humans', 'Hydromorphone/administration & dosage', 'Isoflurane/administration & dosage/analogs & derivatives', 'Male', 'Midazolam/administration & dosage', 'Middle Aged', 'Pancreatitis/surgery', 'Postoperative Complications/*drug therapy', 'Propofol/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/22735251/
1318,isoflurane,12461828,Desflurane: a reappraisal.,"['Umbrain V', 'Shi L', 'Camu F']","['Anesthesia, Closed-Circuit/adverse effects', 'Anesthetics, Inhalation/*adverse effects/chemistry', 'Animals', 'Carbon Monoxide/chemistry', 'Carbon Monoxide Poisoning/etiology', 'Coronary Disease/physiopathology', 'Desflurane', 'Humans', 'Isoflurane/*adverse effects/*analogs & derivatives/chemistry', 'Malignant Hyperthermia/etiology', 'Respiratory System/drug effects', 'Sympathetic Nervous System/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/12461828/
1319,isoflurane,6391530,The pharmacology of isoflurane.,['Eger EI 2nd'],"['*Anesthesia, Inhalation', 'Animals', 'Biodegradation, Environmental', 'Brain/drug effects', 'Cats', 'Chemical Phenomena', 'Chemistry', 'Dogs', 'Dose-Response Relationship, Drug', 'Female', 'Heart/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Isoflurane/adverse effects/*pharmacology', 'Kidney/drug effects', 'Liver/drug effects', 'Methyl Ethers/*pharmacology', 'Muscles/drug effects', 'Neuromuscular Blocking Agents/pharmacology', 'Rats', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6391530/
1320,isoflurane,17599471,Effects of desflurane on middle ear pressure.,"['Ozturk O', 'Ilce Z', 'Demiraran Y', 'Iskender A', 'Guclu E', 'Yildizbas S']","['Acoustic Impedance Tests', 'Anesthetics, Inhalation/administration & dosage/*pharmacology', 'Child', 'Circumcision, Male', 'Desflurane', 'Ear, Middle/*drug effects', 'Humans', 'Isoflurane/administration & dosage/*analogs & derivatives/pharmacology', 'Male', 'Postoperative Care', '*Pressure', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/17599471/
1321,isoflurane,33080307,An Overview on the Mechanisms of Neuroprotection and Neurotoxicity of Isoflurane and Sevoflurane in Experimental Studies.,"['Neag MA', 'Mitre AO', 'Catinean A', 'Mitre CI']","['Animals', 'Humans', 'Isoflurane/*administration & dosage/adverse effects', 'Neuroprotection/*drug effects', 'Neuroprotective Agents/*administration & dosage', '*Neurotoxicity Syndromes', 'Sevoflurane/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33080307/
1322,isoflurane,22658370,Isoflurane hepatitis-induced liver failure: a case report.,"['Peiris LJ', 'Agrawal A', 'Morris JE', 'Basnyat PS']","['Aged', 'Anesthetics, Inhalation/administration & dosage/*adverse effects', 'Chemical and Drug Induced Liver Injury/*etiology/physiopathology', 'Fatal Outcome', 'Female', 'Humans', 'Isoflurane/administration & dosage/*adverse effects', 'Liver Failure, Acute/*chemically induced/physiopathology', 'Necrosis']",https://pubmed.ncbi.nlm.nih.gov/22658370/
1323,isoflurane,25733815,1-1-12 one-step wash-in scheme for desflurane low flow anesthesia: performance without nitrous oxide.,"['Sathitkarnmanee T', 'Tribuddharat S', 'Nonlhaopol D', 'Thananun M', 'Somdee W']","['Adolescent', 'Adult', 'Anesthesia, General/*methods', 'Blood Pressure/drug effects', 'Desflurane', 'Female', 'Heart Diseases/surgery', 'Heart Rate/drug effects', 'Humans', 'Isoflurane/administration & dosage/*analogs & derivatives/pharmacology', 'Lung Diseases/surgery', 'Male', 'Middle Aged', 'Nitrous Oxide/*administration & dosage', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25733815/
1324,isoflurane,29429516,Lipoic acid inhibited desflurane-induced hippocampal neuronal apoptosis through Caspase3 and NF-KappaB dependent pathway.,"['Zhao H', 'Bu M', 'Li B', 'Zhang Y']","['Anesthetics/*adverse effects', 'Animals', 'Animals, Newborn', 'Apoptosis/drug effects', 'Caspase 3/genetics', 'Desflurane', 'Hippocampus/drug effects', 'Humans', 'Isoflurane/adverse effects/*analogs & derivatives/therapeutic use', 'Mice', 'NF-kappa B/genetics', 'Neurons/*drug effects', 'Signal Transduction/drug effects', 'Thioctic Acid/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/29429516/
1325,isoflurane,15153210,Oral ketamine premedication can prevent emergence agitation in children after desflurane anaesthesia.,"['Kararmaz A', 'Kaya S', 'Turhanoglu S', 'Ozyilmaz MA']","['Adenoidectomy', 'Administration, Oral', 'Analgesics, Opioid/therapeutic use', '*Anesthesia Recovery Period', '*Anesthetics, Inhalation/adverse effects', 'Child', 'Child, Preschool', 'Desflurane', 'Double-Blind Method', 'Female', 'Humans', '*Isoflurane/adverse effects/*analogs & derivatives', 'Ketamine/*administration & dosage', 'Male', 'Pain, Postoperative/drug therapy', '*Preanesthetic Medication', 'Psychomotor Agitation/etiology/*prevention & control', 'Tonsillectomy', 'Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15153210/
1326,ketotifen,23949121,Ketotifen-induced nocturnal bruxism.,"['Italiano D', 'Bramanti P', 'Militi D', 'Mondello S', 'Calabro RS']","['Child, Preschool', 'Histamine H1 Antagonists/*adverse effects', 'Humans', 'Ketotifen/*adverse effects', 'Male', 'Sleep Bruxism/*chemically induced/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/23949121/
1327,ketotifen,2299110,Malignant idiopathic anaphylaxis.,"['Patterson R', 'Wong S', 'Dykewicz MS', 'Harris KE']","['Acute Disease', 'Adult', 'Anaphylaxis/classification/*diagnosis/drug therapy', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ketotifen/administration & dosage', 'Prednisone/administration & dosage', 'Recurrence', 'Terminology as Topic']",https://pubmed.ncbi.nlm.nih.gov/2299110/
1328,ketotifen,2116068,Prophylaxis in childhood asthma.,['Noche ML Jr'],"['Adolescent', 'Asthma/drug therapy/*prevention & control', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Ketotifen/therapeutic use', 'Male']",https://pubmed.ncbi.nlm.nih.gov/2116068/
1329,ketotifen,19652595,Multiple action agents and the eye: do they really stabilize mast cells?,"['Lambiase A', 'Micera A', 'Bonini S']","['Animals', 'Anti-Inflammatory Agents/pharmacology/therapeutic use', 'Arachidonic Acid/immunology', 'Conjunctivitis, Allergic/*drug therapy/immunology/*pathology', 'Cytokines/immunology', 'Dibenzazepines/pharmacology/therapeutic use', 'Dibenzoxepins/pharmacology/therapeutic use', 'Histamine/immunology', 'Histamine Antagonists/pharmacology/therapeutic use', 'Humans', 'Imidazoles/pharmacology/therapeutic use', 'Immunity, Innate/drug effects', 'Ketotifen/pharmacology/therapeutic use', 'Mast Cells/*drug effects/immunology/metabolism/pathology', 'Olopatadine Hydrochloride', 'Phthalazines/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19652595/
1330,ketotifen,23974685,Immunomodulators for conjunctivitis.,"['Pacharn P', 'Vichyanond P']","['Administration, Sublingual', 'Animals', 'Conjunctivitis, Allergic/*drug therapy', 'Cromolyn Sodium/therapeutic use', 'Desensitization, Immunologic/*methods', 'Histamine Antagonists/*therapeutic use', 'Humans', 'Immunomodulation', 'Ketotifen/therapeutic use', 'Mast Cells/*drug effects/immunology', '*Molecular Targeted Therapy']",https://pubmed.ncbi.nlm.nih.gov/23974685/
1331,ketotifen,1979793,H1-receptor antagonist treatment of seasonal allergic rhinitis.,['Kaiser HB'],"['Astemizole', 'Benzhydryl Compounds/pharmacokinetics/therapeutic use', 'Benzimidazoles/pharmacokinetics/therapeutic use', 'Cetirizine', 'Chlorpheniramine/pharmacokinetics/therapeutic use', 'Clemastine/pharmacokinetics/therapeutic use', 'Cyproheptadine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Histamine H1 Antagonists/pharmacokinetics/*therapeutic use', 'Humans', 'Hydroxyzine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Ketotifen/pharmacokinetics/therapeutic use', 'Loratadine', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Terfenadine']",https://pubmed.ncbi.nlm.nih.gov/1979793/
1332,ketotifen,26220424,Characterization and Validation of a Canine Pruritic Model.,"['Aberg GA', 'Arulnesan N', 'Bolger GT', 'Ciofalo VB', 'Pucaj K']","['Animals', 'Antimalarials/*adverse effects', 'Antipruritics/*administration & dosage/therapeutic use', 'Chloroquine/*adverse effects', 'Cross-Over Studies', 'Dog Diseases/*drug therapy/etiology', 'Dogs', 'Dose-Response Relationship, Drug', 'Female', 'Ketotifen/administration & dosage/*analogs & derivatives/therapeutic use', 'Male', 'Prednisolone/administration & dosage/metabolism', 'Pruritus/*drug therapy/etiology/veterinary', 'Pyrimidines/administration & dosage/therapeutic use', 'Sulfonamides/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26220424/
1333,ketotifen,1363195,Pharmacological treatment of allergies.,['De Vos C'],"['Animals', 'Cetirizine/pharmacology/*therapeutic use', 'Drug Evaluation', 'Drug Evaluation, Preclinical', 'Guinea Pigs', 'Histamine H1 Antagonists/pharmacology/*therapeutic use', 'Humans', 'Hypersensitivity/*drug therapy', 'Ketotifen/pharmacology/*therapeutic use', 'Papio', 'Phthalazines/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1363195/
1334,ketotifen,3544935,Ketotifen and methacholine-induced bronchospasm.,"['Tjwa MK', 'Smeets J', 'Maesen F']","['Adolescent', 'Adult', 'Bronchial Spasm/chemically induced/physiopathology/*prevention & control', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Forced Expiratory Volume', 'Humans', 'Ketotifen/*therapeutic use', 'Male', 'Methacholine Chloride', 'Methacholine Compounds/pharmacology', 'Peak Expiratory Flow Rate']",https://pubmed.ncbi.nlm.nih.gov/3544935/
1335,ketotifen,21293507,"IBS in 2010: advances in pathophysiology, diagnosis and treatment.","['Ford AC', 'Talley NJ']","['Central Nervous System/physiopathology', 'Colonoscopy', 'Gastrointestinal Agents/therapeutic use', 'Humans', 'Intestinal Diseases/microbiology', '*Irritable Bowel Syndrome/diagnosis/drug therapy/physiopathology', 'Ketotifen/therapeutic use', 'Peptides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21293507/
1336,ketotifen,16412767,Ketotifen improves sperm motility and sperm morphology in male patients with leukocytospermia and unexplained infertility.,"['Oliva A', 'Multigner L']","['Adult', 'Histamine H1 Antagonists/*administration & dosage', 'Humans', 'Infertility, Male/*drug therapy/pathology', 'Ketotifen/*administration & dosage', 'Leukocyte Count', 'Male', 'Middle Aged', 'Sperm Motility/*drug effects', 'Spermatozoa/cytology/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/16412767/
1337,ketotifen,17358042,Anti-inflammatory pharmacotherapy for wheezing in preschool children.,"['Kaditis AG', 'Winnie G', 'Syrogiannopoulos GA']","['Administration, Inhalation', 'Anti-Asthmatic Agents/administration & dosage', 'Anti-Inflammatory Agents/*administration & dosage', 'Asthma/*drug therapy/epidemiology', 'Cetirizine/administration & dosage', 'Child, Preschool', 'Cromolyn Sodium/administration & dosage', 'Glucocorticoids/*administration & dosage', 'Histamine H1 Antagonists/administration & dosage', 'Humans', 'Ketotifen/administration & dosage', 'Nedocromil/administration & dosage', 'Prognosis', 'Respiratory Sounds/*drug effects', 'Risk Factors', 'Xanthines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/17358042/
1338,ketotifen,25974154,Ketotifen suppression of NF1 neurofibroma growth over 30 years.,['Riccardi VM'],"['Administration, Oral', 'Adult', 'Female', '*Genes, Neurofibromatosis 1', 'Humans', 'Ketotifen/administration & dosage/pharmacology/*therapeutic use', 'Male', 'Mast Cells/drug effects', 'Mutation/genetics', 'Neurofibromatosis 1/*drug therapy/*genetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25974154/
1339,ketotifen,20068312,Childhood autism and eosinophilic colitis.,"['Chen B', 'Girgis S', 'El-Matary W']","['Autistic Disorder/*complications', 'Child', 'Colitis/*complications/diagnosis/drug therapy', 'Diagnosis, Differential', 'Eosinophilia/*complications/diagnosis/drug therapy', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Ketotifen/therapeutic use', 'Male']",https://pubmed.ncbi.nlm.nih.gov/20068312/
1340,ketotifen,24075128,Posttraumatic elbow joint contractures: defining pathologic capsular mechanisms and potential future treatment paradigms.,['Hildebrand KA'],"['Animals', 'Contracture/*drug therapy/etiology/pathology/*physiopathology', 'Disease Models, Animal', 'Elbow Joint/pathology', 'Humans', 'Joint Capsule/pathology/*physiopathology', 'Ketotifen/therapeutic use', 'Myofibroblasts', '*Elbow Injuries']",https://pubmed.ncbi.nlm.nih.gov/24075128/
1341,ketotifen,2003512,Benefit of ketotifen in patients with eosinophilic gastroenteritis.,"['Melamed I', 'Feanny SJ', 'Sherman PM', 'Roifman CM']","['Adolescent', 'Adult', 'Child', 'Eosinophilia/*drug therapy/immunology', 'Female', 'Gastroenteritis/*drug therapy/immunology', 'Humans', 'Immunoglobulin E/metabolism', 'Ketotifen/*therapeutic use', 'Male', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2003512/
1342,ketotifen,38528089,Ketotifen directly modifies the fibrotic response of human skin fibroblasts.,"['Leong E', 'Al-Bitar H', 'Marshall JS', 'Bezuhly M']","['Humans', 'Mice', 'Animals', '*Ketotifen/pharmacology/metabolism/therapeutic use', 'Fibrosis', 'Skin/metabolism', '*Scleroderma, Systemic/metabolism', 'Collagen/metabolism', 'Fibroblasts/metabolism', 'Bleomycin/pharmacology', 'Transforming Growth Factor beta1/metabolism', 'Cells, Cultured', 'Transforming Growth Factor beta/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38528089/
1343,ketotifen,1602294,Ketotifen--a therapeutic agent of eosinophilic fasciitis?,"['Ching DW', 'Leibowitz MR']","['Adult', 'Eosinophilia/*drug therapy', 'Fasciitis/complications/*drug therapy/pathology', 'Follow-Up Studies', 'Humans', 'Ketotifen/administration & dosage/*therapeutic use', 'Male', 'Scleroderma, Localized/complications', 'Time Factors', 'Vitiligo/complications']",https://pubmed.ncbi.nlm.nih.gov/1602294/
1344,ketotifen,38088363,Intranasal Morphology Transformation Nanomedicines for Long-Term Intervention of Allergic Rhinitis.,"['Teng Z', 'Yang J', 'Chen X', 'Liu Y']","['Humans', 'Administration, Intranasal', '*Nanomedicine', '*Rhinitis, Allergic/drug therapy', 'Nasal Mucosa', 'Nasal Cavity', 'Ketotifen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38088363/
1345,ketotifen,9586584,"A novel anti-allergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells.","['Kaminuma O', 'Ogawa K', 'Kikkawa H', 'Kikuchi M', 'Naito K', 'Ikezawa K']","['Adult', 'Anti-Allergic Agents/*pharmacology', 'Cell Division/drug effects', 'Cells, Cultured', 'Humans', 'Indicators and Reagents', 'Interleukin-5/*biosynthesis', 'Ketotifen/pharmacology', 'Male', 'Middle Aged', 'Monocytes/drug effects/*metabolism', 'Piperidines/*pharmacology', 'Pyridines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9586584/
1346,lamotrigine,33573557,"Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.","['Kaplan YC', 'Demir O']","['Anticonvulsants/adverse effects', 'Breast Feeding', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lamotrigine/adverse effects', 'Levetiracetam/adverse effects', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', '*Pregnancy Complications/drug therapy', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33573557/
1347,lamotrigine,38507750,"Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure.","['Hernandez-Diaz S', 'Straub L', 'Bateman BT', 'Zhu Y', 'Mogun H', 'Wisner KL', 'Gray KJ', 'Lester B', 'McDougle CJ', 'DiCesare E', 'Pennell PB', 'Huybrechts KF']","['Child', 'Female', 'Humans', 'Pregnancy', '*Anticonvulsants/adverse effects/therapeutic use', '*Autism Spectrum Disorder/chemically induced/epidemiology/etiology', 'Autistic Disorder/chemically induced/epidemiology/etiology', '*Lamotrigine/adverse effects/therapeutic use', '*Prenatal Exposure Delayed Effects/epidemiology/chemically induced/drug therapy', '*Topiramate/adverse effects/therapeutic use', '*Valproic Acid/adverse effects/therapeutic use', 'Epilepsy/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38507750/
1348,lamotrigine,30734897,A Practical Guide to Treatment of Childhood Absence Epilepsy.,"['Kessler SK', 'McGinnis E']","['Anticonvulsants/therapeutic use', 'Child', 'Child, Preschool', 'Drug-Related Side Effects and Adverse Reactions', 'Electroencephalography', 'Epilepsy, Absence/diagnosis/*drug therapy', 'Ethosuximide/therapeutic use', 'Female', 'Humans', 'Lamotrigine/therapeutic use', 'Male', 'Practice Guidelines as Topic', 'Seizures/drug therapy', 'Treatment Outcome', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30734897/
1349,lamotrigine,35523739,Individualizing doses of antiepileptic drugs.,"['Liparoti G', 'Burchiani B', 'Mencaroni E', 'Tripodi D', 'Di Cara G', 'Verrotti A']","['*Anticonvulsants/adverse effects', '*Carbamazepine/therapeutic use', 'Humans', 'Lamotrigine', 'Levetiracetam', 'Topiramate']",https://pubmed.ncbi.nlm.nih.gov/35523739/
1350,lamotrigine,39548057,Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes.,"['Madley-Dowd P', 'Ahlqvist VH', 'Forbes H', 'Rast JE', 'Martin FZ', 'Zhong C', 'Barry CS', 'Berglind D', 'Lundberg M', 'Lyall K', 'Newschaffer CJ', 'Tomson T', 'Davies NM', 'Magnusson C', 'Rai D', 'Lee BK']","['Humans', 'Pregnancy', 'Female', '*Anticonvulsants/adverse effects/therapeutic use', '*Prenatal Exposure Delayed Effects/chemically induced/epidemiology', 'Child', '*Intellectual Disability/epidemiology', '*Valproic Acid/adverse effects/therapeutic use', '*Carbamazepine/adverse effects/therapeutic use', 'Sweden/epidemiology', 'Pregnancy Complications/drug therapy', 'Lamotrigine/adverse effects/therapeutic use', 'Male', 'United Kingdom/epidemiology', 'Child, Preschool', 'Registries', 'Topiramate/adverse effects/therapeutic use', 'Autistic Disorder/drug therapy/chemically induced', 'Adult', 'Attention Deficit Disorder with Hyperactivity/drug therapy/epidemiology', 'Neurodevelopmental Disorders/chemically induced/epidemiology', 'Epilepsy/drug therapy', 'Cohort Studies', 'Adolescent', 'Infant']",https://pubmed.ncbi.nlm.nih.gov/39548057/
1351,lamotrigine,34523118,Lamotrigine in the maintenance treatment of bipolar disorder.,"['Hashimoto Y', 'Kotake K', 'Watanabe N', 'Fujiwara T', 'Sakamoto S']","['Adult', 'Anticonvulsants/therapeutic use', '*Bipolar Disorder/drug therapy', 'Humans', 'Lamotrigine/adverse effects', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34523118/
1352,lamotrigine,28862044,Acute lamotrigine overdose: a systematic review of published adult and pediatric cases.,"['Alyahya B', 'Friesen M', 'Nauche B', 'Laliberte M']","['Adult', 'Anticonvulsants/blood/*poisoning', 'Child', 'Drug Overdose/blood/*therapy', 'Humans', 'Lamotrigine/blood/*poisoning', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/28862044/
1353,lamotrigine,37047022,Understanding Lamotrigine's Role in the CNS and Possible Future Evolution.,"['Costa B', 'Vale N']","['Humans', 'Lamotrigine/therapeutic use', '*Depressive Disorder, Major/drug therapy', 'Anticonvulsants/pharmacology/therapeutic use', '*Epilepsy/drug therapy', 'Central Nervous System', 'Glutamic Acid', 'Ion Channels', 'Triazines/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37047022/
1354,lamotrigine,38497990,Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy.,"['Battino D', 'Tomson T', 'Bonizzoni E', 'Craig J', 'Perucca E', 'Sabers A', 'Thomas S', 'Alvestad S', 'Perucca P', 'Vajda F']","['Humans', 'Female', '*Anticonvulsants/adverse effects/therapeutic use', 'Adult', 'Pregnancy', 'Young Adult', 'Adolescent', '*Epilepsy/drug therapy/epidemiology', '*Abnormalities, Drug-Induced/epidemiology/etiology', 'Middle Aged', 'Longitudinal Studies', '*Pregnancy Complications/drug therapy/epidemiology', 'Prospective Studies', 'Valproic Acid/adverse effects/therapeutic use', 'Prenatal Exposure Delayed Effects/epidemiology/chemically induced', 'Phenytoin/adverse effects/therapeutic use', 'Lamotrigine/adverse effects/therapeutic use', 'Carbamazepine/adverse effects', 'Phenobarbital/adverse effects/therapeutic use', 'Cohort Studies', 'Oxcarbazepine/adverse effects/therapeutic use', 'Prevalence']",https://pubmed.ncbi.nlm.nih.gov/38497990/
1355,lamotrigine,38345991,Lamotrigine-Induced Hemophagocytic Lymphohistiocytosis with DRESS.,"['Wang H', 'Peng J', 'Zeng W', 'Pan X']","['Adult', 'Humans', 'Lamotrigine/adverse effects', '*Lymphohistiocytosis, Hemophagocytic/chemically induced/diagnosis/drug therapy', 'Anticonvulsants/adverse effects', '*Rheumatic Diseases', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/38345991/
1356,lamotrigine,30092918,Treatment of Peripartum Bipolar Disorder.,"['Clark CT', 'Wisner KL']","['Bipolar Disorder/*drug therapy/physiopathology', 'Electroconvulsive Therapy', 'Female', 'Humans', 'Lamotrigine/*therapeutic use', 'Peripartum Period/*drug effects', 'Phototherapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy/psychology', 'Pregnancy Outcome', 'Pregnant People', 'Recurrence', 'Triazines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30092918/
1357,lamotrigine,37782485,Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.,"['Cerulli Irelli E', 'Cocchi E', 'Morano A', 'Gesche J', 'Caraballo RH', 'Lattanzi S', 'Strigaro G', 'Catania C', 'Ferlazzo E', 'Pascarella A', 'Casciato S', 'Quarato P', 'Pizzanelli C', 'Pulitano P', 'Giuliano L', 'Viola V', 'Mostacci B', 'Fortunato F', 'Marini C', 'Di Gennaro G', 'Gambardella A', 'Labate A', 'Operto FF', 'Giallonardo AT', 'Baykan B', 'Beier CP', 'Di Bonaventura C']","['*Epilepsy/drug therapy', 'Retrospective Studies', 'Lamotrigine/therapeutic use', 'Cohort Studies', '*Anticonvulsants/adverse effects', 'Child', 'Humans', 'Immunoglobulin E/therapeutic use', 'Adult', 'Epilepsy, Generalized', 'Levetiracetam/therapeutic use', 'Female']",https://pubmed.ncbi.nlm.nih.gov/37782485/
1358,lamotrigine,11785058,[Epilepsy and pregnancy].,"['Dominguez M', 'Diaz Obregon MC', 'Bhathal H', 'Santiago R']","['Abnormalities, Drug-Induced', 'Adult', 'Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Epilepsy/*drug therapy/physiopathology', 'Female', 'Fetus/*drug effects/physiology', 'Humans', 'Lamotrigine', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Triazines/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11785058/
1359,lamotrigine,10417037,Lamotrigine-induced blepharospasm.,"['Verma A', 'Miller P', 'Carwile ST', 'Husain AM', 'Radtke RA']","['Anticonvulsants/*adverse effects/therapeutic use', 'Blepharospasm/*chemically induced', 'Humans', 'Lamotrigine', 'Male', 'Middle Aged', 'Seizures/drug therapy', 'Triazines/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10417037/
1360,lamotrigine,33838757,"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.","['Marson A', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton C', 'Hughes DA', 'Williamson P', 'Baker GA', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Anticonvulsants/*adverse effects', 'Child', '*Cost-Benefit Analysis', 'Epilepsies, Partial/*drug therapy', 'Female', 'Humans', 'Lamotrigine/*therapeutic use', 'Levetiracetam/*therapeutic use', 'Male', 'Middle Aged', '*Treatment Outcome', 'Young Adult', 'Zonisamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33838757/
1361,lamotrigine,35534674,Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics.,['Mushiroda T'],"['Humans', '*Anticonvulsants/adverse effects', 'Pharmacogenetics', 'Lamotrigine', 'Carbamazepine/adverse effects', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/35534674/
1362,lamotrigine,33774428,The effects of antiepileptic drugs on bone health: A systematic review.,"['Griepp DW', 'Kim DJ', 'Ganz M', 'Dolphin EJ', 'Sotudeh N', 'Burekhovich SA', 'Naziri Q']","['*Anticonvulsants/adverse effects', 'Bone Density', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Humans', 'Lamotrigine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33774428/
1363,lamotrigine,34710770,Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review.,"['Liguori C', 'Toledo M', 'Kothare S']","['Anticonvulsants/pharmacology/therapeutic use', '*Disorders of Excessive Somnolence/drug therapy', '*Epilepsy/complications/drug therapy', 'Humans', 'Lamotrigine/pharmacology/therapeutic use', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/34710770/
1364,lamotrigine,15744223,Lamotrigine in psychiatry: pharmacology and therapeutics.,['Jefferson JW'],"['Antidepressive Agents/adverse effects/*therapeutic use', 'Bipolar Disorder/diagnosis/*drug therapy/psychology', 'Controlled Clinical Trials as Topic', 'Drug Therapy, Combination', 'Humans', 'Lamotrigine', 'Treatment Outcome', 'Triazines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15744223/
1365,lamotrigine,23036173,"Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?","['Vajda FJ', 'Dodd S', 'Horgan D']","['Abnormalities, Drug-Induced/etiology', 'Anticonvulsants/*therapeutic use', 'Antipsychotic Agents/*therapeutic use', 'Epilepsy/complications/*drug therapy', 'Female', 'Humans', 'Lamotrigine', 'Mood Disorders/complications/*drug therapy', '*Pregnancy', 'Triazines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23036173/
1366,leflunomide,30173215,Rheumatoid Arthritis: A Brief Overview of the Treatment.,"['Bullock J', 'Rizvi SAA', 'Saleh AM', 'Ahmed SS', 'Do DP', 'Ansari RA', 'Ahmed J']","['Adrenal Cortex Hormones/adverse effects/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Antirheumatic Agents/adverse effects/therapeutic use', 'Arthritis, Rheumatoid/complications/*drug therapy/surgery', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Interleukin 1 Receptor Antagonist Protein/therapeutic use', 'Leflunomide/therapeutic use', 'Physical Therapy Modalities', 'Risk Factors', 'Tumor Necrosis Factor-alpha/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30173215/
1367,leflunomide,30114347,Takayasu arteritis: an update.,"['Keser G', 'Aksu K', 'Direskeneli H']","['Antibodies, Monoclonal, Humanized/therapeutic use', 'Biomarkers/metabolism', 'Endovascular Procedures/*methods', 'Guidelines as Topic', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Leflunomide/therapeutic use', 'Physical Examination', 'Prognosis', 'Radiology, Interventional', '*Takayasu Arteritis/diagnosis/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/30114347/
1368,leflunomide,21962758,Leflunomide in dermatology.,['Boyd AS'],"['Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide', 'Psoriasis/drug therapy', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21962758/
1369,leflunomide,39504368,Mitochondrial elongation impairs breast cancer metastasis.,"['Minarrieta L', 'Annis MG', 'Audet-Delage Y', 'Kuasne H', 'Pacis A', 'St-Louis C', 'Nowakowski A', 'Biondini M', 'Khacho M', 'Park M', 'Siegel PM', 'St-Pierre J']","['Humans', '*Breast Neoplasms/pathology/metabolism/genetics', 'Female', '*Mitochondria/metabolism/pathology', '*Mitochondrial Dynamics/drug effects', 'Animals', 'Cell Line, Tumor', '*Neoplasm Metastasis', 'Mice', 'Mitochondrial Proteins/metabolism/genetics', 'Leflunomide/pharmacology', 'Dynamins/metabolism/genetics']",https://pubmed.ncbi.nlm.nih.gov/39504368/
1370,leflunomide,12661795,Leflunomide.,"['Cohen SB', 'Iqbal I']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Female', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide', 'Male', 'Middle Aged', 'Product Surveillance, Postmarketing', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12661795/
1371,leflunomide,28867467,Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.,"['Alfaro-Lara R', 'Espinosa-Ortega HF', 'Arce-Salinas CA']","['Alanine Transaminase/blood', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Antirheumatic Agents/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Aspartate Aminotransferases/blood', 'C-Reactive Protein/analysis', 'Chemical and Drug Induced Liver Injury/etiology', 'Clinical Trials as Topic', 'Disability Evaluation', 'Drug Therapy, Combination', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Leflunomide/adverse effects/*therapeutic use', 'Methotrexate/adverse effects/*therapeutic use', 'Treatment Outcome', 'gamma-Glutamyltransferase/analysis']",https://pubmed.ncbi.nlm.nih.gov/28867467/
1372,leflunomide,29357281,Leflunomide: A promising drug with good antitumor potential.,"['Zhang C', 'Chu M']","['Angiogenesis Inhibitors/pharmacology/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Humans', 'Immunologic Factors/pharmacology/therapeutic use', 'Isoxazoles/pharmacology/*therapeutic use', 'Leflunomide', 'Neoplasms/*drug therapy/pathology', 'Neoplastic Stem Cells/drug effects/pathology']",https://pubmed.ncbi.nlm.nih.gov/29357281/
1373,leflunomide,27283340,Challenges and treatment options for rheumatoid arthritis during pregnancy.,"['Gerosa M', 'Schioppo T', 'Meroni PL']","['Antirheumatic Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/*epidemiology', 'Biological Products/therapeutic use', 'Female', 'Humans', 'Hydroxychloroquine/therapeutic use', 'Isoxazoles/therapeutic use', 'Leflunomide', 'Methotrexate/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy/*epidemiology', 'Sulfasalazine/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27283340/
1374,leflunomide,14971821,Leflunomide-induced acute hepatitis.,"['Sevilla-Mantilla C', 'Ortega L', 'Agundez JA', 'Fernandez-Gutierrez B', 'Ladero JM', 'Diaz-Rubio M']","['Adjuvants, Immunologic/*adverse effects/therapeutic use', 'Aged', 'Anion Exchange Resins/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Chemical and Drug Induced Liver Injury/drug therapy/*etiology/pathology', 'Cholestyramine Resin/therapeutic use', 'Female', 'Humans', 'Isoxazoles/*adverse effects/therapeutic use', 'Leflunomide', 'Liver/pathology']",https://pubmed.ncbi.nlm.nih.gov/14971821/
1375,leflunomide,31324351,[Treatment of giant cell arteritis].,"['Samson M', 'Greigert H', 'Ghesquiere T', 'Bonnotte B']","['Abatacept/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antibodies, Monoclonal, Humanized/*therapeutic use', 'Aspirin/therapeutic use', 'Azathioprine/therapeutic use', 'Drug Administration Schedule', 'Giant Cell Arteritis/complications/*drug therapy', 'Glucocorticoids/administration & dosage/*therapeutic use', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Leflunomide/therapeutic use', 'Methotrexate/*therapeutic use', 'Prednisone/*therapeutic use', 'Ustekinumab/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31324351/
1376,leflunomide,17094333,Leflunomide in clinical practice.,"['Pinto P', 'Dougados M']","['Antirheumatic Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Isoxazoles/*therapeutic use', 'Leflunomide']",https://pubmed.ncbi.nlm.nih.gov/17094333/
1377,leflunomide,39320955,Leflunomide nanocarriers: a new prospect of therapeutic applications.,['Zewail M'],"['*Leflunomide/chemistry/therapeutic use/pharmacology/pharmacokinetics', 'Humans', '*Hydroxybutyrates/chemistry', '*Antirheumatic Agents/administration & dosage/pharmacokinetics/chemistry/therapeutic use/pharmacology', '*Toluidines/chemistry/therapeutic use/pharmacokinetics', 'Animals', 'Nanoparticles/chemistry', 'Nitriles/chemistry', 'Drug Carriers/chemistry', 'Crotonates/chemistry/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Neoplasms/drug therapy', 'Multiple Sclerosis/drug therapy', 'Isoxazoles/chemistry/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39320955/
1378,leflunomide,12003373,Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.,"['Sanders S', 'Harisdangkul V']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Autoimmune Diseases/*drug therapy', 'Clinical Trials as Topic', 'Humans', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide']",https://pubmed.ncbi.nlm.nih.gov/12003373/
1379,leflunomide,12783594,Leflunomide for the treatment of rheumatoid arthritis.,"['Miceli-Richard C', 'Dougados M']","['Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Contraindications', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/adverse effects/*pharmacology', 'Isoxazoles/adverse effects/*pharmacology', 'Leflunomide', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/12783594/
1380,leflunomide,22961090,Leflunomide: friend or foe for systemic lupus erythematosus?,"['Wu GC', 'Xu XD', 'Huang Q', 'Wu H']","['Animals', 'Autoimmunity', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Isoxazoles/adverse effects/pharmacology/*therapeutic use', 'Leflunomide', 'Lupus Erythematosus, Systemic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22961090/
1381,leflunomide,15182800,Leflunomide-induced aseptic meningitis.,"['Cohen JD', 'Jorgensen C', 'Sany J']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Humans', 'Isoxazoles/*adverse effects/therapeutic use', 'Leflunomide', 'Male', 'Meningitis, Aseptic/*chemically induced', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/15182800/
1382,leflunomide,21801113,Leflunomide: dermatologic perspective.,"['Sehgal VN', 'Verma P']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Antirheumatic Agents/*therapeutic use', 'Dermatologic Agents/*therapeutic use', 'Dihydroorotate Dehydrogenase', 'Enzyme Inhibitors/therapeutic use', 'Humans', 'Isoxazoles/*therapeutic use', 'Leflunomide', 'Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21801113/
1383,leflunomide,29039518,Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma.,"['Ren A', 'Fu G', 'Qiu Y', 'Cui H']","['Animals', 'Apoptosis/drug effects', 'Carcinogenesis/*drug effects', 'Carcinoma, Squamous Cell/*etiology/*pathology', 'Cell Cycle/drug effects', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Disease Models, Animal', 'Humans', 'Isoxazoles/*pharmacology', 'Leflunomide', 'Mice', 'Mouth Neoplasms/*etiology/*pathology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/29039518/
1384,leflunomide,32356683,Noninfectious aortitis: A case report.,"['Jaikaran O', 'Nicoara M', 'Hingorani A']","['Abdominal Pain/etiology', 'Aged', 'Aortitis/diagnostic imaging/drug therapy/*etiology', 'Back Pain/etiology', 'Glucocorticoids/therapeutic use', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Leflunomide/therapeutic use', 'Male', 'Methylprednisolone/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32356683/
1385,leflunomide,15172042,Leflunomide.,"['Cannon GW', 'Kremer JM']","['Antirheumatic Agents/*pharmacology/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Clinical Trials as Topic', 'Drug Monitoring/methods', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/*pharmacology/therapeutic use', 'Isoxazoles/*pharmacology/therapeutic use', 'Joints/drug effects/pathology', 'Leflunomide', 'Liver/drug effects/pathology', 'Methotrexate/*therapeutic use', 'Models, Animal']",https://pubmed.ncbi.nlm.nih.gov/15172042/
1386,letrozole,27959613,Palbociclib and Letrozole in Advanced Breast Cancer.,"['Finn RS', 'Martin M', 'Rugo HS', 'Jones S', 'Im SA', 'Gelmon K', 'Harbeck N', 'Lipatov ON', 'Walshe JM', 'Moulder S', 'Gauthier E', 'Lu DR', 'Randolph S', 'Dieras V', 'Slamon DJ']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy', 'Cyclin-Dependent Kinases/antagonists & inhibitors', 'Disease-Free Survival', 'Double-Blind Method', 'Female', 'Humans', 'Letrozole', 'Middle Aged', 'Neutropenia/chemically induced', 'Nitriles/*administration & dosage/adverse effects', 'Piperazines/*administration & dosage/adverse effects', 'Postmenopause', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Pyridines/*administration & dosage/adverse effects', 'Receptors, Estrogen/analysis', 'Triazoles/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27959613/
1387,letrozole,38507751,Ribociclib plus Endocrine Therapy in Early Breast Cancer.,"['Slamon D', 'Lipatov O', 'Nowecki Z', 'McAndrew N', 'Kukielka-Budny B', 'Stroyakovskiy D', 'Yardley DA', 'Huang CS', 'Fasching PA', 'Crown J', 'Bardia A', 'Chia S', 'Im SA', 'Ruiz-Borrego M', 'Loi S', 'Xu B', 'Hurvitz S', 'Barrios C', 'Untch M', 'Moroose R', 'Visco F', 'Afenjar K', 'Fresco R', 'Severin I', 'Ji Y', 'Ghaznawi F', 'Li Z', 'Zarate JP', 'Chakravartty A', 'Taran T', 'Hortobagyi G']","['Female', 'Humans', 'Aminopyridines/administration & dosage/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', '*Breast Neoplasms/drug therapy/metabolism/mortality/pathology', '*Letrozole/administration & dosage/adverse effects/therapeutic use', 'Purines/administration & dosage/adverse effects/therapeutic use', 'Receptor, ErbB-2/metabolism', '*Aromatase Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Receptors, Estrogen', 'Receptors, Progesterone', 'Goserelin/administration & dosage/adverse effects/therapeutic use', 'Antineoplastic Agents, Hormonal', 'Male']",https://pubmed.ncbi.nlm.nih.gov/38507751/
1388,letrozole,37873987,[Not Available].,"['Dahlberg ES', 'Andersen D', 'Andersson PS', 'Birch K', 'Colmon L', 'Holt MD', 'Ingerslev K', 'Kirkegaard K', 'Lossl K', 'Poulsen LC', 'Wissing ML', 'Yde M', 'Bulow NS']","['Male', 'Female', 'Humans', 'Letrozole/therapeutic use', '*Anovulation/therapy', 'Fertility Agents, Female', 'Semen', 'Clomiphene/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37873987/
1389,letrozole,34220713,Letrozole for Female Infertility.,"['Yang AM', 'Cui N', 'Sun YF', 'Hao GM']","['Aromatase Inhibitors/*therapeutic use', 'Female', 'Humans', 'Infertility, Female/*drug therapy', 'Letrozole/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34220713/
1390,letrozole,36243120,"Letrozole: Pharmacology, toxicity and potential therapeutic effects.","['Mukherjee AG', 'Wanjari UR', 'Nagarajan D', 'K K V', 'V A', 'P JP', 'T TP', 'Chakraborty R', 'Renu K', 'Dey A', 'Vellingiri B', 'Gopalakrishnan AV']","['Female', 'Humans', 'Letrozole/pharmacology/therapeutic use', 'Nitriles/therapeutic use', 'Triazoles/pharmacology/therapeutic use', 'Aromatase Inhibitors/pharmacology/therapeutic use', '*Breast Neoplasms/drug therapy/metabolism', 'Estrogens/metabolism', '*Infertility, Female/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36243120/
1391,letrozole,27717303,"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.","['Hortobagyi GN', 'Stemmer SM', 'Burris HA', 'Yap YS', 'Sonke GS', 'Paluch-Shimon S', 'Campone M', 'Blackwell KL', 'Andre F', 'Winer EP', 'Janni W', 'Verma S', 'Conte P', 'Arteaga CL', 'Cameron DA', 'Petrakova K', 'Hart LL', 'Villanueva C', 'Chan A', 'Jakobsen E', 'Nusch A', 'Burdaeva O', 'Grischke EM', 'Alba E', 'Wist E', 'Marschner N', 'Favret AM', 'Yardley D', 'Bachelot T', 'Tseng LM', 'Blau S', 'Xuan F', 'Souami F', 'Miller M', 'Germa C', 'Hirawat S', ""O'Shaughnessy J""]","['Adult', 'Aged', 'Aged, 80 and over', 'Aminopyridines/*administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/pathology', 'Disease-Free Survival', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Kaplan-Meier Estimate', 'Letrozole', 'Middle Aged', 'Neoplasm Staging', 'Nitriles/*administration & dosage', 'Purines/*administration & dosage', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Receptors, Progesterone', 'Triazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27717303/
1392,letrozole,35263519,Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.,"['Hortobagyi GN', 'Stemmer SM', 'Burris HA', 'Yap YS', 'Sonke GS', 'Hart L', 'Campone M', 'Petrakova K', 'Winer EP', 'Janni W', 'Conte P', 'Cameron DA', 'Andre F', 'Arteaga CL', 'Zarate JP', 'Chakravartty A', 'Taran T', 'Le Gac F', 'Serra P', ""O'Shaughnessy J""]","['Aged', 'Aminopyridines/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality/pathology', 'Female', 'Humans', 'Intention to Treat Analysis', 'Letrozole/*administration & dosage/adverse effects', 'Middle Aged', 'Neoplasm Grading', 'Neutropenia/chemically induced', 'Purines/*administration & dosage/adverse effects', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/35263519/
1393,letrozole,38729566,"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.","['Goetz MP', 'Toi M', 'Huober J', 'Sohn J', 'Tredan O', 'Park IH', 'Campone M', 'Chen SC', 'Manso LM', 'Paluch-Shimon S', 'Freedman OC', ""O'Shaughnessy J"", 'Pivot X', 'Tolaney SM', 'Hurvitz SA', 'Llombart-Cussac A', 'Andre V', 'Saha A', 'van Hal G', 'Shahir A', 'Iwata H', 'Johnston SRD']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Middle Aged', '*Aminopyridines/administration & dosage/therapeutic use', 'Anastrozole/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Aromatase Inhibitors/therapeutic use/administration & dosage', '*Benzimidazoles/administration & dosage/therapeutic use', '*Breast Neoplasms/drug therapy/pathology/mortality', 'Double-Blind Method', '*Letrozole/administration & dosage/therapeutic use', 'Progression-Free Survival', 'Receptor, ErbB-2/metabolism/antagonists & inhibitors', 'Receptors, Estrogen/metabolism', 'Receptors, Progesterone/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38729566/
1394,letrozole,29804902,"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.","['Tripathy D', 'Im SA', 'Colleoni M', 'Franke F', 'Bardia A', 'Harbeck N', 'Hurvitz SA', 'Chow L', 'Sohn J', 'Lee KS', 'Campos-Gomez S', 'Villanueva Vazquez R', 'Jung KH', 'Babu KG', 'Wheatley-Price P', 'De Laurentiis M', 'Im YH', 'Kuemmel S', 'El-Saghir N', 'Liu MC', 'Carlson G', 'Hughes G', 'Diaz-Padilla I', 'Germa C', 'Hirawat S', 'Lu YS']","['Administration, Oral', 'Adult', 'Aminopyridines/*administration & dosage', 'Antineoplastic Agents, Hormonal/*administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Breast Neoplasms/*drug therapy/*genetics/mortality/pathology', 'Disease-Free Survival', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Internationality', 'Kaplan-Meier Estimate', 'Letrozole/administration & dosage', 'Middle Aged', 'Neoplasm Invasiveness/pathology', 'Neoplasm Staging', 'Premenopause/drug effects', 'Prognosis', 'Proportional Hazards Models', 'Purines/*administration & dosage', 'Survival Analysis', 'Tamoxifen/administration & dosage', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29804902/
1395,letrozole,30470497,Pharmacology of medications used for ovarian stimulation.,"['Quaas AM', 'Legro RS']","['Clomiphene/therapeutic use', 'Female', 'Fertility Agents, Female/classification/*therapeutic use', 'Gonadotropin-Releasing Hormone/therapeutic use', 'Gonadotropins/therapeutic use', 'Humans', 'Infertility, Female/complications/drug therapy', 'Letrozole/therapeutic use', 'Ovulation/drug effects/physiology', 'Ovulation Induction/adverse effects/*methods', 'Polycystic Ovary Syndrome/complications/drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/30470497/
1396,letrozole,34617955,"Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.","['Llombart-Cussac A', 'Perez-Garcia JM', 'Bellet M', 'Dalenc F', 'Gil-Gil M', 'Ruiz-Borrego M', 'Gavila J', 'Sampayo-Cordero M', 'Aguirre E', 'Schmid P', 'Marme F', 'Di Cosimo S', 'Gligorov J', 'Schneeweiss A', 'Albanell J', 'Zamora P', 'Wheatley D', 'Martinez-de Duenas E', 'Amillano K', 'Malfettone A', 'Cortes J']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Breast Neoplasms/pathology', 'Female', 'Fulvestrant', 'Humans', 'Letrozole/therapeutic use', 'Middle Aged', 'Piperazines', 'Pyridines', 'Receptor, ErbB-2']",https://pubmed.ncbi.nlm.nih.gov/34617955/
1397,letrozole,38295043,Ideal frozen embryo transfer regime.,"['Castillo J', 'Kol S']","['Humans', 'Female', '*Embryo Transfer/methods', 'Pregnancy', '*Cryopreservation/methods', 'Embryo Implantation/physiology', 'Progesterone/administration & dosage', 'Endometrium', 'Ovulation Induction/methods', 'Letrozole/therapeutic use', 'Fertilization in Vitro/methods', 'Pregnancy Rate']",https://pubmed.ncbi.nlm.nih.gov/38295043/
1398,letrozole,30632023,Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.,"['Rugo HS', 'Finn RS', 'Dieras V', 'Ettl J', 'Lipatov O', 'Joy AA', 'Harbeck N', 'Castrellon A', 'Iyer S', 'Lu DR', 'Mori A', 'Gauthier ER', 'Bartlett CH', 'Gelmon KA', 'Slamon DJ']","['Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Breast Neoplasms/*drug therapy/metabolism/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Letrozole/*administration & dosage/adverse effects', 'Piperazines/*administration & dosage/adverse effects', 'Postmenopause/psychology', 'Pyridines/*administration & dosage/adverse effects', 'Quality of Life/psychology', 'Receptor, ErbB-2/metabolism', 'Receptors, Estrogen/metabolism', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30632023/
1399,letrozole,32920843,Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial.,"['Bansal S', 'Goyal M', 'Sharma C', 'Shekhar S']","['Adult', 'Clomiphene/administration & dosage/*therapeutic use', 'Female', 'Fertility Agents, Female/administration & dosage/*therapeutic use', 'Humans', '*Infertility, Female', 'Letrozole/administration & dosage/*therapeutic use', '*Ovulation Induction', '*Polycystic Ovary Syndrome', 'Pregnancy', 'Pregnancy Rate', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32920843/
1400,letrozole,39073142,"The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.","['Fjermeros K', 'Ghannoum S', 'Geisler SB', 'Bhargava S', 'Tahiri A', 'Klajic J', 'Luders T', 'Fongard M', 'Nawaz MS', 'Bosnjak-Olsen T', 'Buvarp UE', 'Rosenskiold AKJ', 'Nguyen NT', 'Sletbak TT', 'Seyedzadeh M', 'Selsas K', 'Porojnicu AC', 'Skjerven HK', 'Hovda T', 'Sahlberg KK', 'Torland LA', 'Lyngra M', 'Hammarstrom CL', 'Honigsperger EB', 'Noone JC', 'Mathiassen S', 'Hurtado A', 'Goel S', 'Koff A', 'Tekpli X', 'Kristensen VN', 'Geisler J']","['Adult', 'Female', 'Humans', 'Middle Aged', '*Aminopyridines/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Breast Neoplasms/drug therapy/pathology', '*Letrozole/administration & dosage/therapeutic use', '*Neoadjuvant Therapy/methods', '*Purines/administration & dosage/therapeutic use', '*Receptor, ErbB-2/metabolism', '*Receptors, Estrogen/metabolism', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39073142/
1401,letrozole,35063278,"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.","['Slomovitz BM', 'Filiaci VL', 'Walker JL', 'Taub MC', 'Finkelstein KA', 'Moroney JW', 'Fleury AC', 'Muller CY', 'Holman LL', 'Copeland LJ', 'Miller DS', 'Coleman RL']","['*Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Drug Combinations', '*Endometrial Neoplasms/drug therapy/pathology', 'Estradiol', 'Estriol', 'Estrone', 'Everolimus/therapeutic use', 'Female', 'Humans', 'Letrozole/therapeutic use', '*Neoplasm Recurrence, Local/drug therapy/pathology', 'Phosphatidylinositol 3-Kinases']",https://pubmed.ncbi.nlm.nih.gov/35063278/
1402,letrozole,30683591,A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome.,"['Mejia RB', 'Summers KM', 'Kresowik JD', 'Van Voorhis BJ']","['Adolescent', 'Adult', 'Age Factors', 'Biomarkers/blood', 'Body Mass Index', 'Clomiphene/*administration & dosage/adverse effects', 'Female', 'Fertility/drug effects', 'Fertility Agents, Female/*administration & dosage/adverse effects', 'Humans', 'Infertility, Female/diagnosis/*drug therapy/physiopathology', 'Iowa', 'Letrozole/*administration & dosage/adverse effects', 'Live Birth', 'Ovulation/*drug effects', 'Ovulation Induction/adverse effects/*methods', 'Polycystic Ovary Syndrome/diagnosis/*drug therapy/physiopathology', 'Pregnancy', 'Pregnancy Rate', 'Progesterone/blood', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30683591/
1403,letrozole,37520487,Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial.,"['Al-Thuwaynee S', 'Swadi AAJ']","['Child', 'Female', 'Humans', 'Pregnancy', 'Clomiphene/therapeutic use', 'Fertility Agents, Female/therapeutic use', '*Infertility, Female/drug therapy/etiology', 'Letrozole/therapeutic use', 'Nitriles/therapeutic use', 'Ovulation Induction/methods', '*Polycystic Ovary Syndrome/drug therapy', 'Triazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37520487/
1404,letrozole,31125276,"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.","['Im SA', 'Mukai H', 'Park IH', 'Masuda N', 'Shimizu C', 'Kim SB', 'Im YH', 'Ohtani S', 'Huang Bartlett C', 'Lu DR', 'Iyer S', 'Mori Y', 'Mori A', 'Gauthier E', 'Finn RS', 'Toi M']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality/*pathology', 'Female', 'Humans', 'Letrozole/administration & dosage/pharmacokinetics', 'Middle Aged', 'Neoplasm Staging', 'Piperazines/administration & dosage/pharmacokinetics', 'Postmenopause', 'Prognosis', 'Pyridines/administration & dosage/pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31125276/
1405,letrozole,32221019,Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy.,"['Marchetti C', 'De Felice F', 'Ergasti R', 'Scambia G', 'Fagotti A']","['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Aromatase Inhibitors/administration & dosage', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Female', 'Humans', 'Letrozole/*administration & dosage', 'Ovarian Neoplasms/*drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32221019/
1406,loratadine,35396016,Loratadine.,"['AlMasoud N', 'Bakheit AH', 'Alshammari MFM', 'Abdel-Aziz HA', 'AlRabiah H']","['Humans', '*Hypersensitivity', '*Loratadine/chemistry/pharmacology/therapeutic use', 'Mass Spectrometry', 'Solubility', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/35396016/
1407,loratadine,25397904,H1-antihistamines for chronic spontaneous urticaria.,"['Sharma M', 'Bennett C', 'Cohen SN', 'Carter B']","['Cetirizine/therapeutic use', 'Cyproheptadine/analogs & derivatives/therapeutic use', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Loratadine/analogs & derivatives/therapeutic use', 'Randomized Controlled Trials as Topic', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25397904/
1408,loratadine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
1409,loratadine,12549956,Desloratadine: a nonsedating antihistamine.,"['Limon L', 'Kockler DR']","['Adult', 'Area Under Curve', 'Child', 'Female', 'Half-Life', '*Histamine H1 Antagonists, Non-Sedating/blood/pharmacokinetics/therapeutic use', 'Humans', '*Loratadine/analogs & derivatives/blood/pharmacokinetics/therapeutic use', 'Male', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12549956/
1410,loratadine,33893956,Antihistamines Modulate Functional Activity of Macrophages.,"['Plekhova NG', 'Eliseeva EV', 'Dubnyak IN']","['Animals', 'Cells, Cultured', 'Histamine Antagonists/*pharmacology', 'Humans', 'Hypersensitivity/metabolism', 'Loratadine/analogs & derivatives/pharmacology', 'Macrophages, Peritoneal/*drug effects/*metabolism', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/33893956/
1411,loratadine,38368709,Discovery of the novel and potent histamine H1 receptor antagonists for treatment of allergic diseases.,"['Chu Z', 'Cen L', 'Xu Q', 'Lin G', 'Mo J', 'Shao L', 'Zhao Y', 'Li J', 'Ye W', 'Fang T', 'Ren W', 'Zhu Q', 'He G', 'Xu Y']","['Humans', '*Histamine H1 Antagonists/pharmacology/therapeutic use', 'Receptors, Histamine H1/therapeutic use', 'Loratadine/pharmacology/therapeutic use/*analogs & derivatives', '*Hypersensitivity/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38368709/
1412,loratadine,9152563,Loratadine in the treatment of urticaria.,['Monroe EW'],"['Arrhythmias, Cardiac/chemically induced', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Loratadine/adverse effects/*therapeutic use', 'Urticaria/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/9152563/
1413,loratadine,11964751,Are antihistamines useful in managing asthma?,['Wilson AM'],"['Acetates/agonists/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Asthma/*drug therapy/prevention & control', 'Bronchospirometry/methods', 'Cetirizine/pharmacology', 'Cyclopropanes', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/metabolism/pharmacology/*therapeutic use', 'Humans', 'Loratadine/agonists/analogs & derivatives/*metabolism/pharmacology', 'Mannitol/administration & dosage/*metabolism', 'Quinolines/agonists/metabolism', 'Rhinitis/metabolism', 'Sulfides', 'Terfenadine/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11964751/
1414,loratadine,25752982,Loratadine analogues as MAGL inhibitors.,"['Patel JZ', 'Ahenkorah S', 'Vaara M', 'Staszewski M', 'Adams Y', 'Laitinen T', 'Navia-Paldanius D', 'Parkkari T', 'Savinainen JR', 'Walczynski K', 'Laitinen JT', 'Nevalainen TJ']","['Amidohydrolases/antagonists & inhibitors/metabolism', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/chemical synthesis/chemistry/*pharmacology', 'Humans', 'Loratadine/chemical synthesis/chemistry/*pharmacology', 'Models, Molecular', 'Molecular Structure', 'Monoacylglycerol Lipases/*antagonists & inhibitors/metabolism', 'Recombinant Proteins/metabolism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/25752982/
1415,loratadine,11583068,Triamcinolone: new and old indications.,['Doggrell SA'],"['Administration, Intranasal', 'Adult', 'Aerosols', 'Androstadienes/therapeutic use', 'Anti-Inflammatory Agents/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Astemizole/therapeutic use', 'Asthma/drug therapy', 'Child', 'Clinical Trials as Topic', 'Conjunctivitis, Allergic/drug therapy', 'Dose-Response Relationship, Drug', 'Fluticasone', 'Humans', 'Injections, Intramuscular', 'Loratadine/therapeutic use', 'Lung Diseases, Obstructive/drug therapy', 'Macular Degeneration/drug therapy', 'Molecular Structure', 'Nasal Mucosa/drug effects', 'Rhinitis, Allergic, Perennial/etiology', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Structure-Activity Relationship', 'Triamcinolone/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11583068/
1416,loratadine,11243502,Desloratadine in the treatment of chronic idiopathic urticaria.,"['Ring J', 'Hein R', 'Gauger A']","['Cholinergic Antagonists/pharmacology/*therapeutic use', 'Chronic Disease', 'Cytokines/drug effects', 'Histamine H1 Antagonists/pharmacology/*therapeutic use', 'Humans', 'Loratadine/analogs & derivatives/pharmacology/*therapeutic use', 'Severity of Illness Index', 'Time Factors', 'Treatment Outcome', 'Urticaria/*drug therapy/etiology/immunology']",https://pubmed.ncbi.nlm.nih.gov/11243502/
1417,loratadine,11398910,Desloratadine.,"['McClellan K', 'Jarvis B']","['Asthma/drug therapy', 'Clinical Trials as Topic', 'Drug Interactions', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Loratadine/analogs & derivatives/pharmacokinetics/pharmacology/*therapeutic use', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11398910/
1418,loratadine,10444237,Cardiovascular profile of loratadine.,"['Hey JA', 'Affrime M', 'Cobert B', 'Kreutner W', 'Cuss FM']","['Animals', 'Cardiovascular System/*drug effects', '*Cation Transport Proteins', '*DNA-Binding Proteins', 'Drug Interactions', 'ERG1 Potassium Channel', 'Electrocardiography/drug effects', 'Ether-A-Go-Go Potassium Channels', 'Histamine H1 Antagonists/*adverse effects', 'Humans', 'Loratadine/*adverse effects', 'Potassium Channels/drug effects', '*Potassium Channels, Voltage-Gated', '*Trans-Activators', 'Transcriptional Regulator ERG']",https://pubmed.ncbi.nlm.nih.gov/10444237/
1419,loratadine,28458435,Ciprofloxacin induced acute generallised exanthematous pustulosis.,"['Foti C', 'Romita P', 'Zanframundo G', 'Mastrolonardo M', 'Angelini G', 'Calogiuri G', 'Nettis E', 'Bonamonte D']","['Acute Generalized Exanthematous Pustulosis/*etiology/pathology', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Ciprofloxacin/administration & dosage/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Female', 'Fever/etiology', 'Humans', 'Intertrigo/drug therapy', 'Loratadine/administration & dosage/analogs & derivatives', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/28458435/
1420,loratadine,15245363,Antihistamines: do they work? Further well-controlled trials involving larger samples are needed.,"['Fumagalli F', 'Baiardini I', 'Pasquali M', 'Compalati E', 'Guerra L', 'Massacane P', 'Canonica GW']","['Anti-Allergic Agents/*therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Histamine H1 Antagonists/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hypersensitivity/*drug therapy', 'Loratadine/*analogs & derivatives/therapeutic use', 'Piperazines/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/15245363/
1421,loratadine,19473112,Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.,['Anolik R'],"['Clinical Trials as Topic', 'Drug Combinations', 'Histamine H1 Antagonists, Non-Sedating/pharmacology/*therapeutic use', 'Humans', 'Loratadine/*analogs & derivatives/pharmacology/therapeutic use', 'Nasal Decongestants/pharmacology/*therapeutic use', 'Nasal Obstruction/*drug therapy', 'Pseudoephedrine/pharmacology/*therapeutic use', 'Quality of Life', 'Rhinitis, Allergic, Perennial/*drug therapy', 'Rhinitis, Allergic, Seasonal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19473112/
1422,loratadine,38163866,Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer.,"['Liu X', 'Zhong R', 'Huang J', 'Chen Z', 'Xu H', 'Lin L', 'Cai Q', 'He M', 'Lao S', 'Deng H', 'Li C', 'Li J', 'Zheng Y', 'Liu X', 'Zeng R', 'He J', 'Liang W']","['Animals', 'Humans', '*Lung Neoplasms/drug therapy/genetics/pathology', 'Loratadine/pharmacology/therapeutic use', 'Retrospective Studies', 'Caspase 8', '*Antineoplastic Agents/pharmacology/therapeutic use', 'Apoptosis', 'Prognosis']",https://pubmed.ncbi.nlm.nih.gov/38163866/
1423,loratadine,17176780,Effect of desloratadine on the control of morning symptoms in patients with seasonal and perennial allergic rhinitis.,['Schenkel EJ'],"['Animals', 'Circadian Rhythm/*drug effects/physiology', 'Histamine H1 Antagonists, Non-Sedating/pharmacology/*therapeutic use', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Rhinitis, Allergic, Perennial/*drug therapy/*physiopathology', 'Rhinitis, Allergic, Seasonal/*drug therapy/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/17176780/
1424,loratadine,32043642,Desloratadine inhibits heterotopic ossification by suppression of BMP2-Smad1/5/8 signaling.,"['Kusano T', 'Nakatani M', 'Ishiguro N', 'Ohno K', 'Yamamoto N', 'Morita M', 'Yamada H', 'Uezumi A', 'Tsuchida K']","['Animals', 'Bone Morphogenetic Protein 2/*physiology', 'Cell Differentiation/drug effects', 'Loratadine/*analogs & derivatives/pharmacology/therapeutic use', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Ossification, Heterotopic/*prevention & control', 'Osteogenesis/drug effects', 'Receptor, Platelet-Derived Growth Factor alpha/analysis', 'Signal Transduction/drug effects', 'Smad Proteins/*physiology']",https://pubmed.ncbi.nlm.nih.gov/32043642/
1425,loratadine,29380864,The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.,"['Choonhakarn C', 'Chaowattanapanit S', 'Julanon N']","['Adult', 'Chronic Disease', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*administration & dosage/adverse effects', 'Humans', 'Loratadine/administration & dosage/adverse effects/*analogs & derivatives', 'Maintenance Chemotherapy/methods', 'Male', 'Middle Aged', 'Recurrence', 'Remission Induction/methods', 'Retreatment', 'Retrospective Studies', 'Treatment Outcome', 'Urticaria/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29380864/
1426,lorazepam,15762814,The effects of benzodiazepines on cognition.,['Stewart SA'],"['Activities of Daily Living/psychology', 'Anti-Anxiety Agents/adverse effects/pharmacology/therapeutic use', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/*adverse effects/*pharmacology/therapeutic use', 'Cognition/*drug effects', 'Cognition Disorders/*chemically induced/epidemiology/psychology', 'Female', 'Humans', 'Long-Term Care/statistics & numerical data', 'Lorazepam/adverse effects/pharmacology/therapeutic use', 'Middle Aged', 'Patient Education as Topic', 'Substance Withdrawal Syndrome/psychology']",https://pubmed.ncbi.nlm.nih.gov/15762814/
1427,lorazepam,11949276,Lorazepam.,['Noerr B'],"['Anti-Anxiety Agents/*administration & dosage/adverse effects', 'Anxiety/drug therapy/*prevention & control', 'Asphyxia Neonatorum/drug therapy/nursing', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant, Newborn', 'Intensive Care Units, Neonatal', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Neonatal Nursing/methods', 'Risk Assessment', 'Seizures/drug therapy/nursing', 'Sensitivity and Specificity']",https://pubmed.ncbi.nlm.nih.gov/11949276/
1428,lorazepam,21360232,Delirium and sedation in the ICU.,['Frontera JA'],"['Conscious Sedation/*adverse effects', 'Delirium/*chemically induced/diagnosis/mortality', 'Dexmedetomidine/administration & dosage/adverse effects', 'Diagnosis, Differential', 'Hospital Mortality', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', '*Intensive Care Units', 'Lorazepam/administration & dosage/adverse effects', 'Midazolam/administration & dosage/adverse effects', 'Neurologic Examination/drug effects', 'Prognosis', 'Risk Factors', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/21360232/
1429,lorazepam,32340820,Efficacy of ketamine for initial control of acute agitation in the emergency department: A randomized study.,"['Lin J', 'Figuerado Y', 'Montgomery A', 'Lee J', 'Cannis M', 'Norton VC', 'Calvo R', 'Sikand H']","['Adult', 'Aged', 'Aged, 80 and over', 'Anesthetics, Dissociative/administration & dosage/*therapeutic use', 'Anti-Anxiety Agents/administration & dosage/therapeutic use', 'Antipsychotic Agents/administration & dosage/therapeutic use', '*Emergency Service, Hospital', 'Female', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Ketamine/administration & dosage/*therapeutic use', 'Lorazepam/administration & dosage/therapeutic use', 'Male', 'Middle Aged', 'Pilot Projects', 'Prospective Studies', 'Psychomotor Agitation/*drug therapy', 'United States']",https://pubmed.ncbi.nlm.nih.gov/32340820/
1430,lorazepam,24741200,Lorazepam-induced diplopia.,"['Lucca JM', 'Ramesh M', 'Parthasarathi G', 'Ram D']","['Adult', 'Anti-Anxiety Agents/administration & dosage/*adverse effects/therapeutic use', 'Diplopia/*chemically induced/diagnosis', 'Humans', 'Lorazepam/administration & dosage/*adverse effects/therapeutic use', 'Male', 'Obsessive-Compulsive Disorder/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24741200/
1431,lorazepam,3605432,Lorazepam for psychogenic catatonia.,"['Salam SA', 'Pillai AK', 'Beresford TP']","['Adult', 'Aged', 'Catatonia/*drug therapy/psychology', 'Humans', 'Injections, Intramuscular', 'Lorazepam/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Psychophysiologic Disorders/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/3605432/
1432,lorazepam,39936259,"[Acute psychosis after ""puff bar"" use].","['Tehrani FM', 'Badawey J']","['Humans', 'Male', 'Adolescent', '*Psychoses, Substance-Induced/etiology/diagnosis', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Electrocardiography', 'Acute Disease', 'Cannabinoids/adverse effects', 'Long QT Syndrome/chemically induced', 'Lorazepam/therapeutic use/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39936259/
1433,lorazepam,30810723,Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.,"['Wu YC', 'Tseng PT', 'Tu YK', 'Hsu CY', 'Liang CS', 'Yeh TC', 'Chen TY', 'Chu CS', 'Matsuoka YJ', 'Stubbs B', 'Carvalho AF', 'Wada S', 'Lin PY', 'Chen YW', 'Su KP']","['Antipsychotic Agents/administration & dosage/*therapeutic use', 'Delirium/drug therapy/*prevention & control', 'Drug Therapy, Combination', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Indenes/administration & dosage/therapeutic use', 'Lorazepam/administration & dosage/therapeutic use', 'Network Meta-Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30810723/
1434,lorazepam,18073360,Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.,"['Pandharipande PP', 'Pun BT', 'Herr DL', 'Maze M', 'Girard TD', 'Miller RR', 'Shintani AK', 'Thompson JL', 'Jackson JC', 'Deppen SA', 'Stiles RA', 'Dittus RS', 'Bernard GR', 'Ely EW']","['Aged', 'Coma/*chemically induced/diagnosis', '*Conscious Sedation/economics', 'Delirium/*chemically induced/diagnosis', 'Dexmedetomidine/*administration & dosage/adverse effects/economics', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects/economics', 'Intensive Care Units/economics', 'Lorazepam/*administration & dosage/adverse effects/economics', 'Male', 'Middle Aged', 'Neuropsychological Tests', '*Respiration, Artificial/economics']",https://pubmed.ncbi.nlm.nih.gov/18073360/
1435,lorazepam,28975307,Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.,"['Hui D', 'Frisbee-Hume S', 'Wilson A', 'Dibaj SS', 'Nguyen T', 'De La Cruz M', 'Walker P', 'Zhukovsky DS', 'Delgado-Guay M', 'Vidal M', 'Epner D', 'Reddy A', 'Tanco K', 'Williams J', 'Hall S', 'Liu D', 'Hess K', 'Amin S', 'Breitbart W', 'Bruera E']","['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Anxiety Agents/*administration & dosage/adverse effects', 'Antipsychotic Agents/*administration & dosage/adverse effects', 'Delirium/*drug therapy/etiology', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Haloperidol/*administration & dosage/adverse effects', 'Hospitalization', 'Humans', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Neoplasms/*complications/psychology/therapy', '*Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/28975307/
1436,lorazepam,20138190,Atypical behavioural effects of lorazepam: clues to the design of novel therapies?,"['Giersch A', 'Boucart M', 'Elliott M', 'Vidailhet P']","['Attention/drug effects', 'Benzodiazepines/pharmacokinetics/*pharmacology/*therapeutic use', 'Cognition/*drug effects', 'Drug Discovery/*methods', 'Humans', 'Lorazepam/pharmacokinetics/*pharmacology/*therapeutic use', 'Memory/drug effects', 'Mental Disorders/*drug therapy', 'Receptors, GABA-A/drug effects', 'Visual Perception/drug effects']",https://pubmed.ncbi.nlm.nih.gov/20138190/
1437,lorazepam,2905805,"Lormetazepam, memory and information processing: a review.","['Bhatti JZ', 'Alford CA', 'Hindmarch I']","['Anti-Anxiety Agents/*pharmacology', '*Benzodiazepines', 'Humans', 'Lorazepam/*analogs & derivatives/pharmacology', 'Memory/*drug effects', 'Mental Processes/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/2905805/
1438,lorazepam,22721935,Homicide by methane gas.,"['De-Giorgio F', 'Grassi VM', 'Vetrugno G', 'Rossi R', 'Fucci N', ""d'Aloja E"", 'Pascali VL']","['Female', 'Forensic Pathology', '*Gases', '*Homicide', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', 'Lorazepam/administration & dosage/adverse effects', 'Lung/pathology', 'Male', 'Methane/*poisoning', 'Middle Aged', 'Myocardium/pathology', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/22721935/
1439,lorazepam,13599,Intramuscular premedication with lorazepam.,['Mundeleer P'],"['Adult', 'Age Factors', 'Aged', 'Amnesia/chemically induced', 'Anti-Anxiety Agents/*administration & dosage', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', '*Preanesthetic Medication']",https://pubmed.ncbi.nlm.nih.gov/13599/
1440,lorazepam,25030,Pain and clinical thrombophlebitis following intravenous diazepam and lorazepam.,"['Graham CW', 'Pagano RR', 'Conner JT']","['Adolescent', 'Adult', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intravenous', 'Lorazepam/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Pain/*chemically induced', 'Thrombophlebitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25030/
1441,lorazepam,30762,Clinical pharmacokinetics of lorazepam: a review.,"['Kyriakopoulos AA', 'Greenblatt DJ', 'Shader RI']","['Administration, Oral', 'Age Factors', 'Anti-Anxiety Agents/*metabolism', 'Chromatography, Gas', 'Dose-Response Relationship, Drug', 'Glucuronates/metabolism', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Kidney Failure, Chronic/metabolism', 'Kinetics', 'Lorazepam/administration & dosage/blood/*metabolism/urine', 'Metabolic Clearance Rate', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/30762/
1442,lorazepam,16179702,Status epilepticus: an evidence based guide.,['Walker M'],"['Anticonvulsants/adverse effects/*therapeutic use', 'Chronic Disease', 'Critical Care', 'Drug Administration Routes', 'Emergency Treatment', 'Evidence-Based Medicine', 'Humans', 'Lorazepam/administration & dosage/adverse effects', 'Midazolam/*administration & dosage/adverse effects', 'Phenobarbital/administration & dosage/adverse effects', 'Phenytoin/administration & dosage', 'Prognosis', 'Randomized Controlled Trials as Topic', 'Referral and Consultation', '*Status Epilepticus/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16179702/
1443,lorazepam,8032699,Cost-effectiveness analysis of antiemetic treatment.,"['Bleiberg H', 'Autier P', 'Michaux D']","['Antiemetics/adverse effects/*economics/*therapeutic use', 'Cost-Benefit Analysis', 'Costs and Cost Analysis', 'Dexamethasone/administration & dosage/adverse effects/economics/therapeutic use', 'Europe', 'European Union', 'Humans', 'Lorazepam/administration & dosage/adverse effects/economics/therapeutic use', 'Metoclopramide/administration & dosage/adverse effects/economics/therapeutic use', 'Ondansetron/administration & dosage/adverse effects/economics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Salvage Therapy', 'Serotonin Antagonists/adverse effects/economics/therapeutic use', 'Vomiting/economics/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8032699/
1444,lorazepam,1806620,Agitation in the demented elderly: a role for benzodiazepines?,"['Ancill RJ', 'Carlyle WW', 'Liang RA', 'Holliday SG']","['Aged', 'Alprazolam/adverse effects/*therapeutic use', 'Dementia/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Lorazepam/adverse effects/*therapeutic use', 'Male', 'Motor Activity/drug effects', 'Psychomotor Agitation/*drug therapy/psychology', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/1806620/
1445,lorazepam,11697755,"Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration.","['Wermeling DP', 'Miller JL', 'Archer SM', 'Manaligod JM', 'Rudy AC']","['Administration, Intranasal', 'Adult', 'Anti-Anxiety Agents/administration & dosage/blood/*pharmacokinetics', 'Area Under Curve', 'Biological Availability', 'Cross-Over Studies', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Lorazepam/administration & dosage/blood/*pharmacokinetics', 'Male', 'Metabolic Clearance Rate']",https://pubmed.ncbi.nlm.nih.gov/11697755/
1446,meclizine,33075160,Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.,"['Weibel S', 'Rucker G', 'Eberhart LH', 'Pace NL', 'Hartl HM', 'Jordan OL', 'Mayer D', 'Riemer M', 'Schaefer MS', 'Raj D', 'Backhaus I', 'Helf A', 'Schlesinger T', 'Kienbaum P', 'Kranke P']","['Adult', 'Anesthesia, General/*adverse effects', 'Antiemetics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', '*Network Meta-Analysis', 'Placebos/therapeutic use', 'Postoperative Nausea and Vomiting/*prevention & control', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33075160/
1447,meclizine,27170253,Meniere's disease.,"['Nakashima T', 'Pyykko I', 'Arroll MA', 'Casselbrant ML', 'Foster CA', 'Manzoor NF', 'Megerian CA', 'Naganawa S', 'Young YH']","['Antiemetics/pharmacology/therapeutic use', 'Audiometry/methods', 'Benzodiazepines/pharmacology/therapeutic use', 'Catheter Ablation/methods', 'Dimenhydrinate/pharmacology/therapeutic use', 'Ear, Inner/pathology/physiopathology', 'Endolymph/metabolism', 'Ganglia, Sensory/abnormalities/injuries', 'Hearing Loss/etiology', 'Humans', 'Magnetic Resonance Imaging/methods', 'Meclizine/pharmacology/therapeutic use', 'Meniere Disease/*complications/epidemiology/*physiopathology', 'Promethazine/pharmacology/therapeutic use', 'Quality of Life/psychology', 'Tinnitus/etiology', 'Vertigo/etiology']",https://pubmed.ncbi.nlm.nih.gov/27170253/
1448,meclizine,10367916,Mal de debarquement.,"['Hain TC', 'Hanna PA', 'Rheinberger MA']","['Adult', 'Aged', 'Chronic Disease', 'Disability Evaluation', 'Female', 'Humans', 'Male', 'Middle Aged', 'Motion Perception', 'Motion Sickness/*diagnosis/etiology/therapy', 'Risk Factors', 'Surveys and Questionnaires', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/10367916/
1449,meclizine,26684019,C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.,['Legeai-Mallet L'],"['Achondroplasia/*drug therapy/genetics', 'Animals', 'Humans', 'Natriuretic Peptide, C-Type/*analogs & derivatives/pharmacology', 'Receptor, Fibroblast Growth Factor, Type 3/*genetics']",https://pubmed.ncbi.nlm.nih.gov/26684019/
1450,meclizine,38569854,Promising horizons in achondroplasia along with the development of new drugs.,"['Ozono K', 'Kubota T', 'Michigami T']","['*Achondroplasia/drug therapy', 'Humans', '*Receptor, Fibroblast Growth Factor, Type 3/genetics', 'Drug Development', 'Natriuretic Peptide, C-Type/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38569854/
1451,meclizine,7874402,Approach to the dizzy patient.,['Baloh RW'],"['Anxiety Disorders/*complications/psychology', 'Brain Diseases/*complications/physiopathology', 'Diazepam/administration & dosage/therapeutic use', 'Dizziness/*etiology/physiopathology', 'Heart Diseases/*complications/physiopathology', 'Humans', 'Meclizine/administration & dosage/therapeutic use', 'Meniere Disease/*complications', 'Migraine Disorders/*complications', 'Prochlorperazine/administration & dosage/therapeutic use', 'Promethazine/administration & dosage/therapeutic use', 'Proprioception', 'Scopolamine/administration & dosage/therapeutic use', 'Substance-Related Disorders/*complications/physiopathology', 'Time Factors', 'Vertebrobasilar Insufficiency/*complications', 'Vertigo/drug therapy/*etiology', 'Vestibular Diseases/*complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7874402/
1452,meclizine,31887753,Vestibular Migraine: Treatment and Prognosis.,"['von Brevern M', 'Lempert T']","['Humans', 'Migraine Disorders/*diagnosis/*therapy', 'Prognosis', 'Vertigo/*diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/31887753/
1453,meclizine,9450266,Psychophysiological aspects of motion sickness.,['Murray JB'],"['Administration, Cutaneous', 'Dextroamphetamine/therapeutic use', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Meclizine/therapeutic use', 'Motion Sickness/diagnosis/drug therapy/*physiopathology', 'Promethazine/therapeutic use', 'Psychophysiology', 'Scopolamine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9450266/
1454,meclizine,12160366,Emergency contraception.,"['Grimes DA', 'Raymond EG']","['Age Factors', 'Contraceptives, Postcoital/adverse effects/*therapeutic use', 'Contraceptives, Postcoital, Hormonal/adverse effects/therapeutic use', 'Contraindications', 'Drug Combinations', 'Drug Interactions', 'Drug Prescriptions', 'Emergencies', 'Female', 'Fetus/drug effects', 'Humans', 'Intrauterine Devices', 'Jurisprudence', 'Mifepristone/therapeutic use', 'Nausea/prevention & control', 'Pregnancy', 'Pregnancy Tests', 'Pregnancy, Unwanted', 'Smoking/adverse effects', 'Time Factors', 'Vomiting/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/12160366/
1455,meclizine,35033871,Meclozine ameliorates skeletal muscle pathology and increases muscle forces in mdx mice.,"['Kawamura Y', 'Hida T', 'Ohkawara B', 'Matsushita M', 'Kobayashi T', 'Ishizuka S', 'Hiraiwa H', 'Tanaka S', 'Tsushima M', 'Nakashima H', 'Ito K', 'Imagama S', 'Ito M', 'Masuda A', 'Ishiguro N', 'Ohno K']","['Animals', 'Cell Differentiation/drug effects', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Extracellular Signal-Regulated MAP Kinases/metabolism', 'Humans', 'Male', 'Meclizine/*pharmacology/therapeutic use', 'Mice, Inbred C57BL', 'Mice, Inbred mdx', 'Motor Activity/drug effects', 'Muscle Development/drug effects', 'Muscle Strength/drug effects/*physiology', 'Muscle, Skeletal/*pathology/*physiopathology', 'Muscular Dystrophy, Duchenne/drug therapy/pathology/physiopathology', 'Phosphorylation/drug effects', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/35033871/
1456,meclizine,25450422,Use of ondansetron during pregnancy and congenital malformations in the infant.,"['Danielsson B', 'Wikner BN', 'Kallen B']","['Abnormalities, Drug-Induced/*etiology', 'Antiemetics/*adverse effects', 'Female', 'Heart Septal Defects/chemically induced', 'Humans', 'Infant, Newborn', 'Male', 'Ondansetron/*adverse effects', 'Pregnancy', 'Serotonin Antagonists/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25450422/
1457,meclizine,18523693,Vertigo - part 2 - management in general practice.,"['Kuo CH', 'Pang L', 'Chang R']","['Acute Disease', 'Antiemetics/administration & dosage', 'Automobile Driving', 'Brain Stem/physiology', 'Chronic Disease', '*Family Practice', 'Humans', 'Meclizine/administration & dosage/adverse effects', 'Methylprednisolone/administration & dosage', 'Patient Education as Topic', 'Physical Therapy Modalities', 'Posture', 'Vertigo/*etiology/rehabilitation/*therapy']",https://pubmed.ncbi.nlm.nih.gov/18523693/
1458,meclizine,20977989,Meclizine is neuroprotective in models of Huntington's disease.,"['Gohil VM', 'Offner N', 'Walker JA', 'Sheth SA', 'Fossale E', 'Gusella JF', 'MacDonald ME', 'Neri C', 'Mootha VK']","['Animals', 'Apoptosis/drug effects', 'Caenorhabditis elegans/drug effects', 'Cell Respiration/drug effects', 'Disease Models, Animal', 'Drosophila melanogaster/drug effects', 'Humans', 'Huntingtin Protein', 'Huntington Disease/*drug therapy/metabolism', 'Meclizine/*pharmacology/*therapeutic use', 'Mice', 'Nerve Tissue Proteins/genetics/metabolism', 'Neurons/drug effects/metabolism', 'Neuroprotective Agents/pharmacology/therapeutic use', 'Nuclear Proteins/genetics/metabolism', 'Peptides/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20977989/
1459,meclizine,773181,An evaluation of the teratogenicity of certain antinauseant drugs.,"['Milkovich L', 'van den Berg BJ']","['Abnormalities, Drug-Induced/epidemiology/mortality', 'Antiemetics/*adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Cyclizine/adverse effects', 'Dicyclomine/adverse effects', 'Doxylamine/adverse effects', 'Drug Combinations', 'Drug Evaluation', 'Female', 'Fetal Death/epidemiology', 'Humans', 'Hyperemesis Gravidarum/*drug therapy', 'Meclizine/adverse effects', 'Patient Compliance', 'Phenothiazines/adverse effects', 'Pregnancy', 'Prochlorperazine/adverse effects', 'Prospective Studies', 'Pyridoxine/adverse effects', '*Teratogens']",https://pubmed.ncbi.nlm.nih.gov/773181/
1460,meclizine,17484344,Airsickness prevention in helicopter passengers.,"['Estrada A', 'LeDuc PA', 'Curry IP', 'Phelps SE', 'Fuller DR']","['Acoustic Stimulation', 'Adolescent', 'Adult', '*Aircraft', 'Antiemetics/*therapeutic use', 'Health Surveys', 'Humans', 'Male', 'Meclizine/*therapeutic use', '*Military Medicine', '*Military Personnel', 'Motion Sickness/*prevention & control', 'Muscarinic Antagonists/therapeutic use', 'Promethazine/*therapeutic use', 'Scopolamine/*therapeutic use', 'Surveys and Questionnaires']",https://pubmed.ncbi.nlm.nih.gov/17484344/
1461,meclizine,31760071,The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.,"['Guan Y', 'Chen X', 'Wu M', 'Zhu W', 'Arslan A', 'Takeda S', 'Nguyen MH', 'Majeti R', 'Thomas D', 'Zheng M', 'Peltz G']","['Adult', 'Aged', 'Animals', 'Carcinoma, Hepatocellular/*drug therapy/*metabolism/pathology', 'Cell Survival/drug effects', 'Drug Therapy, Combination/methods', 'Female', 'Gene Knockout Techniques', 'Glycolysis/drug effects', 'Hep G2 Cells', 'Humans', 'Induced Pluripotent Stem Cells/drug effects/metabolism', 'Leukemia, Myeloid, Acute/*blood', 'Liver/embryology/growth & development/metabolism', 'Liver Neoplasms/*drug therapy/*metabolism/pathology', 'Male', 'Meclizine/*administration & dosage', 'Mice', 'Middle Aged', 'Organogenesis/drug effects/genetics', 'Organoids/drug effects/metabolism', 'Phosphatidylethanolamines/*antagonists & inhibitors/*biosynthesis', 'Pyridines/*administration & dosage', 'Quinolines/*administration & dosage', 'RNA Nucleotidyltransferases/deficiency/genetics', 'Retrospective Studies', 'Treatment Outcome', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/31760071/
1462,meclizine,26443596,Advances in treatment of achondroplasia and osteoarthritis.,"['Klag KA', 'Horton WA']","['Achondroplasia/*therapy', 'Animals', 'Genetic Therapy', 'Humans', 'Mice', 'Osteoarthritis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/26443596/
1463,meclizine,37796301,Virtual reality as a countermeasure for astronaut motion sickness during simulated post-flight water landings.,"['Lonner TL', 'Allred AR', 'Bonarrigo L', 'Gopinath A', 'Smith K', 'Kravets V', 'Groen EL', 'Oman C', 'DiZio P', 'Lawson BD', 'Clark TK']","['Humans', 'Astronauts', '*Space Flight', 'Space Motion Sickness/drug therapy', '*Motion Sickness', 'Nausea/etiology', '*Virtual Reality']",https://pubmed.ncbi.nlm.nih.gov/37796301/
1464,meclizine,1855348,No causal relationship between transdermal scopolamine and seizures: methodologic lessons for pharmacoepidemiology.,"['Strom BL', 'Carson JL', 'Schinnar R', 'Snyder ES', 'Shaw M', 'Waiter SL']","['Administration, Cutaneous', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Child', 'Child, Preschool', 'Cohort Studies', 'Female', 'Florida', 'Humans', 'Infant', 'Insurance Claim Reporting', 'Male', 'Medicaid', 'Medical Records', 'Michigan', 'Middle Aged', 'Retrospective Studies', 'Scopolamine/administration & dosage/*adverse effects', 'Seizures/*chemically induced/epidemiology', 'United States']",https://pubmed.ncbi.nlm.nih.gov/1855348/
1465,meclizine,6734040,"Transdermal scopolamine, oral meclizine, and placebo in motion sickness.","['Dahl E', 'Offer-Ohlsen D', 'Lillevold PE', 'Sandvik L']","['Administration, Oral', 'Adult', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Meclizine/adverse effects/*therapeutic use', 'Motion Sickness/*prevention & control', 'Scopolamine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6734040/
1466,megestrol,23543530,Megestrol acetate for treatment of anorexia-cachexia syndrome.,"['Ruiz Garcia V', 'Lopez-Briz E', 'Carbonell Sanchis R', 'Gonzalvez Perales JL', 'Bort-Marti S']","['Acquired Immunodeficiency Syndrome/complications', 'Anorexia/*drug therapy/etiology', 'Appetite Stimulants/adverse effects/*therapeutic use', 'Cachexia/*drug therapy/etiology', 'Humans', 'Megestrol Acetate/adverse effects/*therapeutic use', 'Neoplasms/complications', 'Randomized Controlled Trials as Topic', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/23543530/
1467,megestrol,30229678,Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.,"['Howard ML', 'Hossaini R', 'Tolar C', 'Gaviola ML']","['Adult', 'Appetite/*drug effects', 'Appetite Regulation/*drug effects', 'Appetite Stimulants/administration & dosage/*therapeutic use', 'Dronabinol/administration & dosage/therapeutic use', 'Eating/drug effects', 'Female', 'Humans', 'Inpatients', 'Male', 'Megestrol/administration & dosage/therapeutic use', 'Middle Aged', 'Mirtazapine/administration & dosage/therapeutic use', 'Retrospective Studies', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30229678/
1468,megestrol,26512437,An update on new orally administered contraceptives for women.,['Nelson AL'],"['Clinical Trials as Topic', 'Contraceptives, Oral/*administration & dosage/adverse effects', 'Estradiol/administration & dosage/adverse effects/analogs & derivatives', 'Estrogens/administration & dosage/adverse effects', 'Ethinyl Estradiol/administration & dosage/adverse effects', 'Female', 'Humans', 'Megestrol/administration & dosage/adverse effects', 'Nandrolone/administration & dosage/adverse effects/analogs & derivatives', 'Norpregnadienes/administration & dosage/adverse effects', 'Progestins/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26512437/
1469,megestrol,7773579,Management of cancer anorexia/cachexia.,['Loprinzi CL'],"['Anorexia/*drug therapy/etiology', 'Cachexia/*drug therapy/etiology', 'Controlled Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Megestrol/*analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Multicenter Studies as Topic', 'Neoplasms/complications', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/7773579/
1470,megestrol,24333799,"The ""newer"" progestogens and postmenopausal hormone therapy (HRT).",['Schindler AE'],"['Androstenes/*therapeutic use', 'Estradiol/administration & dosage/therapeutic use', 'Female', 'Humans', 'Megestrol/*therapeutic use', 'Nandrolone/*analogs & derivatives/therapeutic use', 'Norpregnadienes/*therapeutic use', 'Postmenopause', 'Progestins/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24333799/
1471,megestrol,11727176,Implant contraception.,"['Meckstroth KR', 'Darney PD']","['Cervix Mucus/drug effects', 'Clinical Trials as Topic', 'Contraceptive Agents, Female/*administration & dosage/economics/pharmacology', 'Counseling', '*Desogestrel', 'Drug Implants/*administration & dosage', 'Endometrium/drug effects', 'Female', 'Humans', 'Levonorgestrel/administration & dosage/pharmacology', 'Megestrol/administration & dosage/*analogs & derivatives/pharmacology', 'Norprogesterones/administration & dosage/pharmacology', 'Ovulation/drug effects', 'Patient Satisfaction', 'Pregnancy', 'Progesterone Congeners/*administration & dosage/economics/pharmacology', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Vinyl Compounds/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11727176/
1472,megestrol,19749678,[Nomegestrol acetate: clinical pharmacology].,['Lello S'],"['Biological Availability', 'Breast Diseases/drug therapy', 'Drug Therapy, Combination', 'Estradiol/administration & dosage/analogs & derivatives', 'Female', 'Hormone Replacement Therapy', 'Humans', 'Hypothalamo-Hypophyseal System/drug effects', 'Inactivation, Metabolic', 'Megestrol/adverse effects/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Menopause', 'Menstruation Disturbances/drug therapy', 'Molecular Structure', 'Norpregnadienes/adverse effects/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Ovulation Inhibition/drug effects', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/19749678/
1473,megestrol,17722275,Megestrol acetate in cachexia and anorexia.,"['Yeh SS', 'Schuster MW']","['Anorexia/*drug therapy', 'Cachexia/*drug therapy', 'Clinical Trials as Topic/*trends', 'Drug Carriers/chemistry', 'Humans', 'Megestrol Acetate/adverse effects/*chemistry/*therapeutic use', 'Nanoparticles/chemistry']",https://pubmed.ncbi.nlm.nih.gov/17722275/
1474,megestrol,7889638,Megestrol-induced Cushing's syndrome.,"['Steer KA', 'Kurtz AB', 'Honour JW']","['Adenocarcinoma/drug therapy', 'Adult', 'Cushing Syndrome/*chemically induced', 'Diabetes Mellitus, Type 1/complications', 'Female', 'Humans', 'Megestrol/*adverse effects', 'Uterine Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7889638/
1475,megestrol,27187588,Metabolic impact of combined hormonal contraceptives containing estradiol.,"['Grandi G', 'Napolitano A', 'Cagnacci A']","['Blood Pressure/drug effects', 'Contraceptives, Oral, Combined/*administration & dosage/adverse effects', 'Contraceptives, Oral, Hormonal/*administration & dosage/adverse effects', 'Estradiol/*administration & dosage/adverse effects', 'Ethinyl Estradiol/administration & dosage/adverse effects', 'Hemostasis/drug effects', 'Humans', 'Lipid Metabolism/drug effects', 'Megestrol/administration & dosage', 'Nandrolone/administration & dosage/analogs & derivatives', 'Norpregnadienes/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27187588/
1476,megestrol,17619035,Pharmacological treatment of geriatric cachexia: evidence and safety in perspective.,"['Yeh SS', 'Lovitt S', 'Schuster MW']","['Aged', 'Anabolic Agents/adverse effects/*therapeutic use', 'Appetite Stimulants/adverse effects/*therapeutic use', 'Cachexia/*drug therapy/etiology/physiopathology', 'Dronabinol/adverse effects/therapeutic use', '*Geriatrics', 'Humans', 'Megestrol Acetate/adverse effects/*therapeutic use', 'Parenteral Nutrition']",https://pubmed.ncbi.nlm.nih.gov/17619035/
1477,megestrol,14751131,Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.,"['Fiorica JV', 'Brunetto VL', 'Hanjani P', 'Lentz SS', 'Mannel R', 'Andersen W']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents, Hormonal/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Apoptosis/drug effects', 'Carcinoma, Endometrioid/drug therapy/pathology', 'Cell Differentiation/drug effects', 'Down-Regulation/drug effects', 'Drug Administration Schedule', 'Endometrial Neoplasms/*drug therapy/metabolism/pathology', 'Female', 'Humans', 'Megestrol Acetate/administration & dosage/adverse effects', 'Middle Aged', 'Receptors, Progesterone/metabolism', 'Tamoxifen/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/14751131/
1478,megestrol,22611833,"[Zoely, a combined oral contraceptive, monophasic pill containing estradiol and nomegestrol acetate].","['Pintiaux A', 'Gaspard U', 'Nisolle M']","['Animals', 'Contraception/adverse effects/methods', 'Contraceptives, Oral, Combined/adverse effects/chemistry/*therapeutic use', 'Drug Design', 'Estradiol/*administration & dosage/adverse effects', 'Humans', 'Megestrol/*administration & dosage/adverse effects', 'Norpregnadienes/*administration & dosage/adverse effects', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/22611833/
1479,megestrol,25076331,Quality of life in patients with pancreatic cancer.,"['Kiagia M', 'Syrigos KN', 'Saif MW']","['Cachexia/*drug therapy/etiology', 'Dronabinol/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Megestrol Acetate/adverse effects/therapeutic use', 'Pancreatectomy/adverse effects/methods', 'Pancreatic Neoplasms/*complications/surgery', '*Quality of Life', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/25076331/
1480,megestrol,7360074,Hounding the pill.,['Smibert J'],"['Animals', 'Australia', 'Breast Neoplasms/*chemically induced', 'Dogs', 'Drug and Narcotic Control', 'Female', 'Humans', 'Mammary Neoplasms, Experimental/chemically induced', 'Megestrol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7360074/
1481,megestrol,1721521,Management of anorexia-cachexia associated with cancer and HIV infection.,['Gorter R'],"['Anorexia/*drug therapy', 'Antineoplastic Agents/therapeutic use', 'Cachexia/*drug therapy', 'Dronabinol/therapeutic use', 'HIV Infections/*physiopathology', 'Humans', 'Hydrazines/therapeutic use', 'Megestrol/analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Metoclopramide/therapeutic use', 'Neoplasms/*physiopathology', 'Palliative Care/methods']",https://pubmed.ncbi.nlm.nih.gov/1721521/
1482,megestrol,27218795,Pharmacy Report: Megestrol Acetate-Induced Adrenal Insufficiency.,"['Nanjappa S', 'Thai C', 'Shah S', 'Snyder M']","['Adrenal Insufficiency/*etiology', 'Aged', 'Humans', 'Male', 'Megestrol Acetate/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/27218795/
1483,megestrol,11014096,[What's new in hormone replacement therapy for postmenopausal women? I. Advantages of hormone replacement therapy (HRT)].,"['Martin-Du Pan RC', 'Luzuy F']","['Aged', 'Alzheimer Disease/drug therapy', 'Cardiovascular Diseases/prevention & control', 'Cholesterol, HDL/blood', 'Depression/drug therapy', 'Dyspareunia/drug therapy', '*Estrogen Replacement Therapy', 'Female', 'Humans', 'Male', 'Megestrol/analogs & derivatives/therapeutic use', 'Middle Aged', 'Norpregnenes/therapeutic use', 'Osteoporosis/drug therapy', 'Postmenopause/*drug effects/physiology', 'Progesterone Congeners/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11014096/
1484,megestrol,39031821,Dose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis.,"['Talebi S', 'Zeraattalab-Motlagh S', 'Barkhordar M', 'Vaezi M', 'Ghoreishy SM', 'Ghavami A', 'Hosseini Y', 'Travica N', 'Mohammadi H']","['Humans', '*Cachexia/etiology/drug therapy', '*Megestrol Acetate/therapeutic use/pharmacology', '*Neoplasms/complications', '*Anorexia/etiology/drug therapy', '*Dietary Supplements', 'Quality of Life', 'Dose-Response Relationship, Drug', 'Body Weight']",https://pubmed.ncbi.nlm.nih.gov/39031821/
1485,megestrol,16144501,Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer.,"['Benedict A', 'Brown RE']","['Antineoplastic Agents, Hormonal/*economics/therapeutic use', 'Aromatase Inhibitors/economics', 'Breast Neoplasms/drug therapy/*economics/metabolism', 'Cost-Benefit Analysis', 'Decision Making', 'Female', 'Health Care Rationing', 'Health Expenditures', 'Humans', 'Megestrol/economics/therapeutic use', 'Models, Economic', 'Randomized Controlled Trials as Topic', 'Receptors, Estrogen/metabolism', 'Tamoxifen/economics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16144501/
1486,meperidine,9564390,Intrathecal pethidine: pharmacology and clinical applications.,['Ngan Kee WD'],"['Adjuvants, Anesthesia/administration & dosage/*pharmacology', 'Analgesics, Opioid/administration & dosage/*pharmacology', '*Anesthesia, Spinal', 'Humans', 'Injections, Spinal', 'Meperidine/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9564390/
1487,meperidine,6928910,Intramuscular sedation technique.,"['Jensen ST', 'Coke JM', 'Cohen L']","['Anesthesia, Dental/*methods', 'Anesthesia, General/*methods', 'Buttocks', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Injections, Intramuscular/methods', 'Meperidine/administration & dosage/pharmacology', 'Promethazine/administration & dosage', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6928910/
1488,meperidine,16114176,Nonpharmacological treatment options for epilepsy.,"['Sheth RD', 'Stafstrom CE', 'Hsu D']","['Allylamine/administration & dosage/analogs & derivatives', 'Biofeedback, Psychology/*methods', 'Diet Therapy/*methods', 'Drug Combinations', 'Electric Stimulation/*methods', 'Electroencephalography/methods', 'Epilepsy/classification/*therapy', 'Humans', 'Meperidine/administration & dosage/analogs & derivatives', 'Neurosurgery/*methods', 'Pyridoxine/therapeutic use', 'Vagus Nerve/physiopathology/radiation effects']",https://pubmed.ncbi.nlm.nih.gov/16114176/
1489,meperidine,8443849,Nasal ketamine for paediatric premedication.,"['Weksler N', 'Ovadia L', 'Muati G', 'Stav A']","['Administration, Intranasal', 'Anesthesia Recovery Period', 'Anesthesia, Inhalation', 'Child, Preschool', '*Conscious Sedation', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intramuscular', 'Ketamine/administration & dosage/*therapeutic use', 'Male', 'Meperidine/administration & dosage/therapeutic use', '*Preanesthetic Medication', 'Promethazine/administration & dosage/therapeutic use', 'Salivation/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8443849/
1490,meperidine,1585886,Lethal effects of normeperidine.,['Jiraki K'],"['Adult', 'Cholinesterase Inhibitors/pharmacokinetics/*poisoning', 'Half-Life', 'Humans', 'Kidney Failure, Chronic/*complications/etiology', 'Male', 'Meperidine/administration & dosage/*analogs & derivatives/*pharmacokinetics/poisoning', 'Substance-Related Disorders/*complications']",https://pubmed.ncbi.nlm.nih.gov/1585886/
1491,meperidine,12819163,Naloxone for narcotic exposed newborn infants: systematic review.,"['McGuire W', 'Fowlie PW']","['Analgesia, Obstetrical/*adverse effects', 'Analgesics, Opioid/*adverse effects/therapeutic use', 'Female', 'Humans', 'Infant, Newborn', 'Intensive Care, Neonatal', 'Meperidine/*adverse effects/therapeutic use', 'Naloxone/*therapeutic use', 'Narcotic Antagonists/*therapeutic use', 'Pregnancy', '*Prenatal Exposure Delayed Effects', 'Randomized Controlled Trials as Topic', 'Respiration, Artificial']",https://pubmed.ncbi.nlm.nih.gov/12819163/
1492,meperidine,11574125,Effect of epidural analgesia on the fetal heart rate.,['Capogna G'],"['Analgesics, Opioid/administration & dosage/therapeutic use', 'Anesthesia, Epidural/*adverse effects', 'Clinical Trials as Topic', 'Female', 'Heart Rate, Fetal/*drug effects', 'Humans', 'Hypotension/physiopathology', 'Meperidine/administration & dosage/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/physiopathology', 'Sufentanil/administration & dosage/therapeutic use', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11574125/
1493,meperidine,8239638,Postoperative narcotic analgesic administration.,['McDonald DD'],"['Adolescent', 'Adult', '*Appendectomy', 'Drug Utilization', 'Female', 'Humans', 'Length of Stay/statistics & numerical data', 'Male', 'Meperidine/administration & dosage/therapeutic use', 'Middle Aged', 'Narcotics/administration & dosage/*therapeutic use', 'Pain, Postoperative/*drug therapy/nursing', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/8239638/
1494,meperidine,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
1495,meperidine,9619217,Epidural pethidine: pharmacology and clinical experience.,['Ngan Kee WD'],"['Analgesia, Obstetrical', 'Analgesia, Patient-Controlled', 'Analgesics, Opioid/administration & dosage/*pharmacology', '*Anesthesia, Epidural', 'Female', 'Humans', 'Injections, Epidural', 'Meperidine/administration & dosage/*pharmacology', 'Pain, Postoperative/drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/9619217/
1496,meperidine,2354093,Analgesic efficacy of perioperative buccal morphine.,"['Manara AR', 'Bodenham AR', 'Park GR']","['Administration, Buccal', 'Adult', 'Delayed-Action Preparations', 'Female', 'Humans', 'Injections, Intramuscular', 'Meperidine/administration & dosage', 'Morphine/administration & dosage/adverse effects/*therapeutic use', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Patient Acceptance of Health Care', 'Random Allocation', 'Taste/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2354093/
1497,meperidine,3605428,Meperidine-induced delirium.,"['Eisendrath SJ', 'Goldman B', 'Douglas J', 'Dimatteo L', 'Van Dyke C']","['Adult', 'Aged', 'Delirium/*chemically induced', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Meperidine/*adverse effects/pharmacology', 'Middle Aged', 'Parasympatholytics/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3605428/
1498,meperidine,3355732,Patient-controlled analgesia with extradural morphine or pethidine.,"['Sjostrom S', 'Hartvig D', 'Tamsen A']","['Adult', 'Female', 'Humans', 'Injections, Epidural', 'Male', 'Meperidine/*administration & dosage/blood/therapeutic use', 'Middle Aged', 'Morphine/*administration & dosage/blood/therapeutic use', 'Pain, Postoperative/*drug therapy', 'Self Administration', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3355732/
1499,meperidine,2568289,Pharmacokinetics of meperidine in pregnancy.,"['Todd EL', 'Stafford DT', 'Bucovaz ET', 'Morrison JC']","['Female', 'Fetal Distress/chemically induced', 'Fetus/metabolism', 'Humans', 'Injections, Intravenous', 'Meperidine/administration & dosage/adverse effects/*pharmacokinetics', 'Pregnancy/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/2568289/
1500,meperidine,337983,Comparison of nefopam and pethidine in postoperative pain.,"['Tigerstedt I', 'Sipponen J', 'Tammisto T', 'Turunen M']","['Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Meperidine/administration & dosage/*therapeutic use', 'Nefopam/administration & dosage/*therapeutic use', 'Oxazocines/*therapeutic use', 'Pain, Postoperative/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/337983/
1501,meperidine,8007042,Meperidine neurotoxicity after organ transplantation.,"['Adair JC', 'Gilmore RL']","['Adult', 'Central Nervous System/*drug effects', 'Humans', '*Kidney Transplantation', 'Male', 'Meperidine/*adverse effects/blood', '*Pancreas Transplantation', 'Pancreatitis/drug therapy', 'Postoperative Complications/*chemically induced/drug therapy/physiopathology', 'Seizures/chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/8007042/
1502,meperidine,1609533,[Effectiveness and tolerance of tramadol with or without an antiemetic and pethidine in obstetric analgesia].,"['Kainz C', 'Joura E', 'Obwegeser R', 'Plockinger B', 'Gruber W']","['Adult', 'Analgesia, Obstetrical/*methods', 'Cardiotocography/drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant, Newborn', 'Injections, Intramuscular', 'Meperidine/*administration & dosage/adverse effects', 'Oxytocin/administration & dosage', 'Pain Measurement', 'Pregnancy', 'Prospective Studies', 'Tramadol/*administration & dosage/adverse effects', 'Triflupromazine/*administration & dosage/adverse effects', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1609533/
1503,meperidine,11782820,Meperidine: a critical review.,"['Latta KS', 'Ginsberg B', 'Barkin RL']","['*Adjuvants, Anesthesia/pharmacokinetics/pharmacology/therapeutic use', '*Analgesics, Opioid/pharmacokinetics/pharmacology/therapeutic use', 'Animals', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Humans', '*Meperidine/pharmacokinetics/pharmacology/therapeutic use', 'Muscle, Smooth/drug effects', 'Pain/drug therapy', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11782820/
1504,meperidine,2719235,Epidural pethidine or fentanyl during caesarean section: a double-blind comparison.,['Paech MJ'],"['Adult', '*Anesthesia, Obstetrical', '*Cesarean Section', 'Double-Blind Method', 'Female', 'Fentanyl/*administration & dosage/adverse effects', 'Humans', 'Injections, Epidural', 'Meperidine/*administration & dosage/adverse effects', 'Pain, Postoperative/*prevention & control', 'Pregnancy', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2719235/
1505,meperidine,4913784,Comparison of pentazocine and pethidine in labour.,"['Mowat J', 'Garrey MM']","['Adolescent', 'Adult', '*Anesthesia, Obstetrical', 'Clinical Trials as Topic', 'Female', 'Humans', 'Infant, Newborn', 'Injections, Intramuscular', '*Labor, Obstetric', 'Meperidine/*administration & dosage/adverse effects', 'Pentazocine/*administration & dosage/adverse effects', 'Physical Examination', 'Pre-Eclampsia', 'Pregnancy', 'Statistics as Topic', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/4913784/
1506,meprobamate,2859581,Generalized anxiety disorder.,"['Hoehn-Saric R', 'McLeod DR']","['Adrenergic beta-Antagonists/therapeutic use', 'Alprazolam', 'Animals', 'Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Anxiety Disorders/*diagnosis/physiopathology/therapy', 'Barbiturates/therapeutic use', 'Benzodiazepines/therapeutic use', 'Buspirone', 'Diagnosis, Differential', 'Electroencephalography', 'Humans', 'Meprobamate/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Obsessive-Compulsive Disorder/diagnosis/physiopathology/therapy', 'Panic', 'Phobic Disorders/diagnosis/physiopathology/therapy', 'Psychotherapy', 'Pyrimidines/therapeutic use', 'gamma-Aminobutyric Acid/physiology']",https://pubmed.ncbi.nlm.nih.gov/2859581/
1507,meprobamate,20873698,Serendipity and psychopharmacology.,['Howland RH'],"['Chlorpromazine/therapeutic use', 'Drug Discovery/*methods/trends', 'Drug Monitoring', 'Humans', '*Incidental Findings', 'Iproniazid/therapeutic use', 'Lamotrigine', 'Meprobamate/therapeutic use', ""Nurse's Role"", 'Psychiatric Nursing/*methods', 'Psychopharmacology', 'Psychotropic Drugs/*therapeutic use', 'Triazines/therapeutic use', 'Vagus Nerve Stimulation']",https://pubmed.ncbi.nlm.nih.gov/20873698/
1508,meprobamate,9776967,Carisoprodol-induced myoclonic encephalopathy.,"['Roth BA', 'Vinson DR', 'Kim S']","['Adult', 'Akathisia, Drug-Induced/blood', 'Carisoprodol/blood/*poisoning', 'Coma/chemically induced', 'Drug Overdose', 'Humans', 'Male', 'Muscle Relaxants, Central/blood/*poisoning', 'Myoclonus/*chemically induced', 'Tachycardia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9776967/
1509,meprobamate,17117615,The role of serendipity in drug discovery.,['Ban TA'],"['Animals', 'Anti-Anxiety Agents/history/pharmacology', 'Antimanic Agents/history/pharmacology/therapeutic use', 'Drug Industry', 'Hallucinogens/history/pharmacology', 'History, 19th Century', 'History, 20th Century', 'Humans', 'Lithium Chloride/history/pharmacology/therapeutic use', 'Lysergic Acid Diethylamide/history/pharmacology', 'Mental Disorders/drug therapy', 'Penicillins/history/pharmacology', 'Pharmacology/*history', 'Piperazines/history/pharmacology', 'Psychotropic Drugs/history/pharmacology', 'Purines', 'Sildenafil Citrate', 'Sulfones', 'Terminology as Topic', 'Vasodilator Agents/history/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17117615/
1510,meprobamate,22344494,The role of serendipity in the discovery of the clinical effects of psychotropic drugs: beyond of the myth.,"['Lopez-Munoz F', 'Baumeister AA', 'Hawkins MF', 'Alamo C']","['*Drug Discovery', 'Humans', 'Psychopharmacology/methods', 'Psychotropic Drugs/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/22344494/
1511,meprobamate,8322081,Carisoprodol (Soma): a new and cautious perspective on an old agent.,"['Littrell RA', 'Hayes LR', 'Stillner V']","['Carisoprodol/*adverse effects/pharmacokinetics', 'Drug and Narcotic Control', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Substance-Related Disorders/*etiology']",https://pubmed.ncbi.nlm.nih.gov/8322081/
1512,meprobamate,23128807,Carisoprodol: update on abuse potential and legal status.,"['Reeves RR', 'Burke RS', 'Kose S']","['*Carisoprodol/therapeutic use', '*Controlled Substances', 'Drug and Narcotic Control/*legislation & jurisprudence', 'Europe/epidemiology', 'Humans', '*Muscle Relaxants, Central/therapeutic use', 'Musculoskeletal Pain/drug therapy', 'Substance-Related Disorders/epidemiology/*prevention & control', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/23128807/
1513,meprobamate,2858083,"Anxiety, anxiolytics and brain stimulation reinforcement.",['Liebman JM'],"['Animals', 'Anti-Anxiety Agents/*pharmacology', 'Anticonvulsants/pharmacology', 'Anxiety/*physiopathology', 'Avoidance Learning/drug effects', 'Benzodiazepines', 'Brain/*physiology', 'Brain Chemistry/drug effects', 'Electric Stimulation', 'Humans', 'Hypnotics and Sedatives/pharmacology', 'Muscle Relaxants, Central/pharmacology', 'Receptors, GABA-A/drug effects', '*Reinforcement, Psychology', 'Self Stimulation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/2858083/
1514,meprobamate,22687764,Postmortem drug concentration intervals for the non-intoxicated state - A review.,['Linnet K'],"['Dose-Response Relationship, Drug', 'Drug Stability', 'Drug Tolerance', '*Forensic Toxicology', 'Humans', 'Pharmaceutical Preparations/*blood', 'Pharmacokinetics', 'Postmortem Changes', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/22687764/
1515,meprobamate,8635759,Acute overdose of zolpidem.,"['Winek CL', 'Wahba WW', 'Janssen JK', 'Rozin L', 'Rafizadeh V']","['Aged', 'Drug Overdose', 'Fatal Outcome', 'Female', 'Humans', 'Hypnotics and Sedatives/blood/*poisoning', 'Pyridines/blood/*poisoning', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8635759/
1516,meprobamate,27758843,Pharmacokinetic modeling of carisoprodol and meprobamate disposition in adults.,['Lewandowski TA'],"['Adult', 'Carisoprodol/*pharmacokinetics', 'Half-Life', 'Humans', 'Meprobamate/*pharmacokinetics', '*Models, Biological', 'Muscle Relaxants, Central/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27758843/
1517,meprobamate,34918,Uropharmacology: X. Central nervous system stimulants and depressants.,"['Bissada NK', 'Finkbeiner AE', 'Welch LT']","['Amphetamines/pharmacology', 'Anesthetics/pharmacology', 'Animals', 'Anti-Anxiety Agents/pharmacology', 'Antidepressive Agents, Tricyclic/pharmacology', 'Baclofen/pharmacology', 'Benzodiazepines', 'Central Nervous System Agents/*pharmacology', 'Chloral Hydrate/pharmacology', 'Humans', 'Imipramine/pharmacology', 'Levodopa/pharmacology', 'Meperidine/pharmacology', 'Meprobamate/pharmacology', 'Morphine/pharmacology', 'Nortriptyline/pharmacology', 'Paraldehyde/pharmacology', 'Phenothiazines/pharmacology', 'Phenytoin/pharmacology', 'Picrotoxin/pharmacology', 'Reserpine/pharmacology', 'Strychnine/pharmacology', 'Urinary Tract/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34918/
1518,meprobamate,3381792,Fatal meprobamate self-poisoning.,"['Kintz P', 'Tracqui A', 'Mangin P', 'Lugnier AA']","['Adult', 'Bile/analysis', 'Chromatography, Gas', 'Humans', 'Liver/analysis', 'Male', 'Meprobamate/analysis/*poisoning', 'Muscles/analysis', 'Myocardium/analysis', '*Suicide']",https://pubmed.ncbi.nlm.nih.gov/3381792/
1519,meprobamate,28009627,ECT-Related Anxiety: A Systematic Review.,"['Obbels J', 'Verwijk E', 'Bouckaert F', 'Sienaert P']","['Anxiety/epidemiology/*etiology/*psychology', 'Electroconvulsive Therapy/*psychology', 'Humans', 'Prevalence']",https://pubmed.ncbi.nlm.nih.gov/28009627/
1520,meprobamate,20592570,Carisoprodol withdrawal after internet purchase.,"['Eleid MF', 'Krahn LE', 'Agrwal N', 'Goodman BP']","['*Carisoprodol/adverse effects/metabolism/therapeutic use', 'Humans', '*Internet', 'Male', 'Meprobamate/metabolism/therapeutic use', 'Middle Aged', '*Muscle Relaxants, Central/adverse effects/metabolism/therapeutic use', '*Substance Withdrawal Syndrome/diagnosis/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/20592570/
1521,meprobamate,2869770,"Tranquilizers, analgetics and antidepressants in patients treated with hemodialysis.","['Forycki Z', 'Martens F', 'Thalhofer S', 'Ibe K']","['Acetaminophen/metabolism', 'Acute Kidney Injury/metabolism', 'Analgesics/administration & dosage/*metabolism/poisoning', 'Anti-Anxiety Agents/metabolism', 'Antidepressive Agents/administration & dosage/*metabolism/poisoning', 'Benzodiazepines', 'Drug Administration Schedule', 'Ethchlorvynol/metabolism', 'Half-Life', 'Humans', 'Kidney Failure, Chronic/metabolism', 'Kinetics', 'Meprobamate/metabolism', 'Narcotics/metabolism', 'Phenylbutazone/metabolism', 'Protein Binding/drug effects', '*Renal Dialysis', 'Tranquilizing Agents/administration & dosage/*metabolism/poisoning']",https://pubmed.ncbi.nlm.nih.gov/2869770/
1522,meprobamate,26929223,"Something old, something new: a successful case of meprobamate withdrawal.","['James AO', 'Nicholson TR', 'Hill R', 'Bearn J']","['Aged', 'Anxiety Disorders/drug therapy', 'Diazepam/*administration & dosage/therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Inpatients', 'Male', 'Meprobamate/*administration & dosage/adverse effects', 'Substance Withdrawal Syndrome/*drug therapy/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26929223/
1523,meprobamate,13878482,Stress-induced block of milk ejection.,"['CHAUDHURY RR', 'CHAUDHURY MR', 'LU FC']","['*Breast Feeding', '*Chlorpromazine', '*Epinephrine', 'Female', 'Guinea Pigs', 'Humans', 'Lactation/*physiology', '*Meprobamate', '*Milk Ejection', '*Reserpine', '*Stress, Physiological', 'Sympatholytics/*pharmacology', 'Tranquilizing Agents/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/13878482/
1524,meprobamate,20870445,"Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate.","['Pok PR', 'Mauras M', 'De Saint Leger MN', 'Kuhlmann E', 'Charpenel-Durat C', 'Navarette C', 'Duval ML', 'De Meo P']","['Aged', 'Anticonvulsants/*blood/poisoning', 'Autopsy', 'Benzodiazepines/*blood/poisoning', 'Clobazam', 'Clorazepate Dipotassium/*blood/poisoning', 'Drug Overdose', 'Fatal Outcome', 'Female', 'Humans', 'Meprobamate/*blood/poisoning']",https://pubmed.ncbi.nlm.nih.gov/20870445/
1525,meprobamate,33580520,The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ?,"['Loscher W', 'Sills GJ', 'White HS']","['Anticonvulsants/adverse effects/*therapeutic use', 'Carbamates/adverse effects/*therapeutic use', 'Chlorophenols/adverse effects/*therapeutic use', 'Epilepsy/*drug therapy', 'Humans', 'Tetrazoles/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33580520/
1526,methocarbamol,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
1527,methocarbamol,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
1528,methocarbamol,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
1529,methocarbamol,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
1530,methocarbamol,18049062,How to try this: detecting delirium.,['Waszynski CM'],"['Algorithms', 'Analgesics, Opioid/*adverse effects', '*Auditory Perceptual Disorders', '*Confusion', 'Delirium/chemically induced/*diagnosis/nursing', 'Humans', 'Hydromorphone/*adverse effects', 'Male', 'Methocarbamol/*adverse effects', 'Muscle Relaxants, Central/adverse effects', '*Psychomotor Agitation', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/18049062/
1531,methocarbamol,37481407,Impact of methocarbamol on opioid use after ventral incisional hernia repair.,"['Desai S', 'Carbonell C', 'Hoffman K', 'Hammond B', 'Crosier C', 'Blackhurst D', 'Carbonell AM', 'Love MW', 'Cobb WS', 'Warren JA']","['Humans', 'Analgesics, Opioid/therapeutic use', '*Methocarbamol/therapeutic use', '*Incisional Hernia/surgery', ""Practice Patterns, Physicians'"", '*Hernia, Ventral/surgery', '*Opioid-Related Disorders/prevention & control', 'Pain, Postoperative/drug therapy/surgery', 'Herniorrhaphy', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/37481407/
1532,methocarbamol,7097192,A fatal methocarbamol intoxication.,"['Kemal M', 'Imami R', 'Poklis A']","['Adult', 'Alcoholic Intoxication', 'Chromatography, Gas', 'Chromatography, High Pressure Liquid', 'Chromatography, Thin Layer', 'Ethanol/blood', 'Female', 'Humans', 'Methocarbamol/*poisoning', 'Spectrophotometry, Ultraviolet', 'Toxicology/methods']",https://pubmed.ncbi.nlm.nih.gov/7097192/
1533,methocarbamol,31306155,Multimodal analgesia for craniotomy.,"['Ban VS', 'Bhoja R', 'McDonagh DL']","['Analgesia/adverse effects/*methods', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects', 'Analgesics, Opioid/administration & dosage/adverse effects', 'Anesthesiologists/organization & administration', 'Anesthetics, Local/administration & dosage/adverse effects', 'Central Nervous System Diseases/diagnosis/etiology', 'Craniotomy/*adverse effects', 'Evidence-Based Medicine/methods', 'Humans', 'Nerve Block/methods', 'Neurosurgeons/organization & administration', 'Pain Management/adverse effects/*methods', 'Pain, Postoperative/*drug therapy/etiology', 'Patient Care Team/*organization & administration', 'Patient Safety', 'Perioperative Care/methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31306155/
1534,methocarbamol,2327059,Skeletal muscle relaxant ingestion.,"['Lebby TI', 'Dugger K', 'Lipscomb JW', 'Leikin JB']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Overdose', 'Humans', 'Infant', 'Infant, Newborn', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', 'Muscles/*drug effects', '*Poison Control Centers', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2327059/
1535,methocarbamol,461786,Urticaria of the colon.,"['Yousefzadeh DK', 'Teplick JG']","['Cecal Diseases/*complications', 'Colonic Diseases/chemically induced/complications/*diagnostic imaging', 'Drug Hypersensitivity/complications', 'Humans', 'Intestinal Obstruction/*complications/diagnostic imaging', 'Male', 'Methocarbamol/adverse effects', 'Middle Aged', 'Radiography', 'Thioridazine/adverse effects', 'Urticaria/chemically induced/complications/*diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/461786/
1536,methocarbamol,13618740,Use of methocarbamol in orthopedics.,['LEWIS WB'],"['*Cardiovascular Agents', '*Disease', 'Humans', '*Methocarbamol', 'Muscle Relaxants, Central/*therapeutic use', '*Muscles', '*Muscular Diseases', '*Nervous System Diseases', '*Orthopedics', '*Spasm']",https://pubmed.ncbi.nlm.nih.gov/13618740/
1537,methocarbamol,38320820,Atypical neuroleptic malignant syndrome in an incarcerated patient: a demographic who may be at increased risk.,"['Zabel M', 'Kandukuri R']","['Male', 'Humans', '*Neuroleptic Malignant Syndrome/diagnosis/etiology/drug therapy', '*Mutism', '*Antipsychotic Agents/adverse effects', 'Demography', '*Prisoners']",https://pubmed.ncbi.nlm.nih.gov/38320820/
1538,methocarbamol,20810461,Strychnine poisoning: gone but not forgotten.,"['Parker AJ', 'Lee JB', 'Redman J', 'Jolliffe L']","['Critical Care/methods', 'Critical Illness/therapy', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Female', 'Follow-Up Studies', 'Humans', 'Intubation, Intratracheal', 'Methocarbamol/*poisoning', 'Middle Aged', 'Pesticides/*poisoning', 'Risk Assessment', 'Strychnine/*poisoning', '*Suicide, Attempted', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20810461/
1539,methocarbamol,2083431,Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner.,['Stanko JR'],"['Humans', '*Muscle Relaxants, Central/administration & dosage/pharmacology/therapeutic use', 'Muscle Spasticity/drug therapy', 'Temporomandibular Joint Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2083431/
1540,methocarbamol,4451234,Tetanus: conservative management made easier by combination of muscle relaxants.,['Anah CO'],"['Adolescent', 'Child', 'Diazepam/*administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Injections, Intravenous', 'Male', 'Methocarbamol/*administration & dosage/therapeutic use', 'Muscle Rigidity/etiology', 'Tetanus/complications/*drug therapy/physiopathology', 'Tetanus Antitoxin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4451234/
1541,methocarbamol,37284760,Association Between Postoperative Methocarbamol and Postoperative Pain Opioid Dose Requirements: A Retrospective Cohort Study.,"['Komatsu R', 'Singleton MD', 'Wu J', 'Dinges EM', 'Bollag LA']","['Humans', '*Analgesics, Opioid/therapeutic use', 'Retrospective Studies', '*Methocarbamol/therapeutic use', 'Pain, Postoperative/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37284760/
1542,methocarbamol,7101197,Teratogens associated with congenital contractures in humans and in animals.,"['Hall JG', 'Reed SD']","['Animals', 'Arthrogryposis/chemically induced/*etiology', 'Bacterial Infections/*complications', 'Ethanol/toxicity', 'Female', 'Humans', 'Infant, Newborn', 'Male', 'Methocarbamol/toxicity', 'Muscular Dystrophies/complications', 'Myasthenia Gravis/complications', 'Plants, Toxic', 'Pregnancy', 'Pregnancy Complications', '*Teratogens', 'Tetracycline/adverse effects', 'Virus Diseases/*complications']",https://pubmed.ncbi.nlm.nih.gov/7101197/
1543,methocarbamol,6731242,Black widow spider bite.,['Kobernick M'],"['Antivenins/therapeutic use', '*Black Widow Spider', 'Calcium Gluconate/therapeutic use', 'Diazepam/therapeutic use', 'Humans', 'Hypertension/etiology', 'Methocarbamol/therapeutic use', 'Muscle Spasticity/etiology', 'Spider Bites/complications/*diagnosis/therapy', 'Spider Venoms', '*Spiders']",https://pubmed.ncbi.nlm.nih.gov/6731242/
1544,methocarbamol,9204163,Pain reduction in breast augmentation using methocarbamol.,['Schneider MS'],"['Adult', '*Breast Implants', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Methocarbamol/*administration & dosage/adverse effects', 'Muscle Relaxants, Central/*administration & dosage/adverse effects', 'Pain Measurement', 'Pain, Postoperative/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/9204163/
1545,methocarbamol,21681710,A case report of unusual vasculitic reaction after Methocarbamol injection.,"['Sahebari M', 'Jafarian AH', 'Abbasi B']","['Abdomen, Acute/chemically induced', 'Adult', 'Female', 'Humans', 'Methocarbamol/*adverse effects', 'Muscle Relaxants, Central/*adverse effects', 'Skin/pathology', 'Vasculitis, Leukocytoclastic, Cutaneous/*chemically induced/pathology']",https://pubmed.ncbi.nlm.nih.gov/21681710/
1546,miconazole,6988997,Ocular coccidioidomycosis.,"['Rodenbiker HT', 'Ganley JP']","['Adult', 'Aged', 'Amphotericin B/therapeutic use', 'Animals', 'Blepharitis/diagnosis', 'Child', 'Choroiditis/diagnosis', '*Coccidioidomycosis/complications/diagnosis/drug therapy', 'Conjunctivitis/diagnosis', 'Cornea', 'Dogs', 'Eye Diseases/*etiology', 'Female', 'Humans', 'Imidazoles/therapeutic use', 'Male', 'Miconazole/therapeutic use', 'Middle Aged', 'Ophthalmoplegia/etiology', 'Retinitis/diagnosis', 'Sclera', 'Uveitis/diagnosis', 'Uveitis, Anterior/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/6988997/
1547,miconazole,20347664,Otomycosis: Diagnosis and treatment.,"['Vennewald I', 'Klemm E']","['Administration, Topical', 'Amphotericin B/administration & dosage', 'Anti-Infective Agents/*administration & dosage', 'Antifungal Agents/*administration & dosage', 'Clotrimazole/administration & dosage', 'Drug Resistance, Fungal', 'Econazole/administration & dosage', 'Humans', 'Itraconazole/administration & dosage', 'Miconazole/administration & dosage/analogs & derivatives', 'Mycoses/*diagnosis/*drug therapy/microbiology', 'Ointments/administration & dosage', 'Otitis Externa/*diagnosis/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/20347664/
1548,miconazole,8473359,Drug-induced thrombocytosis.,"['Frye JL', 'Thompson DF']","['Anti-Bacterial Agents/adverse effects', 'Humans', 'Iron/adverse effects', 'Lactams', 'Miconazole/adverse effects', 'Thrombocytosis/*chemically induced/classification', 'Vinca Alkaloids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8473359/
1549,miconazole,392476,Dermatophyte infections.,['Clayton YM'],"['Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Clotrimazole/therapeutic use', 'Dermatomycoses/*drug therapy', 'Drug Resistance, Microbial', 'Griseofulvin/therapeutic use', 'Humans', 'Miconazole/therapeutic use', 'Phenyl Ethers/therapeutic use', 'Tolnaftate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/392476/
1550,miconazole,122639,Miconazole in coccidioidomycosis.,['Levine HB'],"['Animals', 'Coccidioidomycosis/*drug therapy', 'Humans', 'Mice', 'Miconazole/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/122639/
1551,miconazole,30818309,Therapeutic tools for oral candidiasis: Current and new antifungal drugs.,"['Quindos G', 'Gil-Alonso S', 'Marcos-Arias C', 'Sevillano E', 'Mateo E', 'Jauregizar N', 'Eraso E']","['Administration, Intravenous', 'Administration, Oral', 'Administration, Topical', 'Amphotericin B/therapeutic use', 'Anidulafungin/therapeutic use', 'Antifungal Agents/*administration & dosage/*pharmacology/*therapeutic use', 'Azoles/therapeutic use', 'Candidiasis, Oral/*drug therapy', 'Caspofungin/therapeutic use', 'Clotrimazole/therapeutic use', 'Databases, Factual', 'Drug Interactions', 'Echinocandins/therapeutic use', 'Fluconazole/therapeutic use', 'Humans', 'Miconazole/therapeutic use', 'Nitriles/therapeutic use', 'Nystatin/therapeutic use', 'Pyridines/therapeutic use', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30818309/
1552,miconazole,31287594,Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice.,"['Taudorf EH', 'Jemec GBE', 'Hay RJ', 'Saunte DML']","['Administration, Oral', 'Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Candidiasis, Cutaneous/*drug therapy', 'Clotrimazole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Evidence-Based Medicine', 'Fluconazole/administration & dosage/*therapeutic use', 'Humans', 'Ketoconazole/therapeutic use', 'Miconazole/administration & dosage/*therapeutic use', 'Nystatin/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31287594/
1553,miconazole,16597199,Miconazole: a historical perspective.,['Fothergill AW'],"['Animals', 'Antifungal Agents/chemistry/pharmacology/*therapeutic use', 'Humans', 'Miconazole/chemistry/pharmacology/*therapeutic use', 'Mycoses/drug therapy', 'Nonprescription Drugs/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16597199/
1554,miconazole,24209593,Candidiasis (oropharyngeal).,['Pankhurst CL'],"['Administration, Oral', 'Antifungal Agents/administration & dosage', '*Candidiasis, Oral', '*HIV Infections', 'Humans', 'Miconazole/therapeutic use', 'Oropharynx/microbiology']",https://pubmed.ncbi.nlm.nih.gov/24209593/
1555,miconazole,8252778,Tinea nigra palmaris.,"['Hughes JR', 'Moore MK', 'Pembroke AC']","['Administration, Topical', 'Adult', 'Female', 'Hand Dermatoses/drug therapy/*pathology', 'Humans', 'Miconazole/administration & dosage', 'Tinea/drug therapy/*pathology']",https://pubmed.ncbi.nlm.nih.gov/8252778/
1556,miconazole,29796560,Anti-staphylococcal biofilm activity of miconazoctylium bromide.,"['Tessier J', 'Golmohamadi M', 'Wilkinson KJ', 'Schmitzer AR']","['Anti-Bacterial Agents/chemical synthesis/*pharmacology/toxicity', 'Biofilms/*drug effects', 'Hemolysis/drug effects', 'Humans', 'Methicillin-Resistant Staphylococcus aureus/*drug effects', 'Miconazole/*analogs & derivatives/chemical synthesis/*pharmacology/toxicity', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/29796560/
1557,miconazole,22495075,Miconazole mucoadhesive tablets: a novel delivery system.,"['Vazquez JA', 'Sobel JD']","['Administration, Oral', 'Administration, Topical', 'Antifungal Agents/*administration & dosage/adverse effects', 'Candidiasis, Oral/*drug therapy', '*Drug Delivery Systems', 'Humans', 'Miconazole/*administration & dosage/adverse effects', 'Tablets/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22495075/
1558,miconazole,32690639,Combination of Miconazole and Domiphen Bromide Is Fungicidal against Biofilms of Resistant Candida spp.,"['Tits J', 'Cools F', 'De Cremer K', 'De Brucker K', 'Berman J', 'Verbruggen K', 'Gevaert B', 'Cos P', 'Cammue BPA', 'Thevissen K']","['Animals', 'Antifungal Agents/pharmacology/therapeutic use', 'Biofilms', '*Candida', 'Candida albicans', 'Female', 'Humans', '*Miconazole/pharmacology', 'Microbial Sensitivity Tests', 'Quaternary Ammonium Compounds', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/32690639/
1559,miconazole,8075276,Intraocular blastomycosis: case report and review.,"['Lopez R', 'Mason JO', 'Parker JS', 'Pappas PG']","['Amphotericin B/administration & dosage/therapeutic use', 'Betamethasone/adverse effects/therapeutic use', '*Blastomycosis/diagnosis/drug therapy', 'Dermatomycoses/complications/diagnosis/microbiology', 'Drug Therapy, Combination', 'Humans', 'Iritis/diagnosis/drug therapy/*microbiology', 'Lung Diseases, Fungal/chemically induced/complications/diagnosis', 'Male', 'Miconazole/administration & dosage/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8075276/
1560,miconazole,10515900,"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.","['Ghannoum MA', 'Rice LB']","['Amphotericin B/pharmacology', 'Animals', 'Antifungal Agents/*pharmacology', 'Bacteria/*drug effects', 'Cell Wall/drug effects', '*Drug Resistance, Microbial', 'Flucytosine/pharmacology', 'Humans', 'Miconazole/pharmacology', 'Naphthalenes/pharmacology', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/10515900/
1561,miconazole,2275233,Drugs for treatment of vulvovaginal candidiasis: comparative efficacy of agents and regimens.,"['Doering PL', 'Santiago TM']","['Antifungal Agents/administration & dosage/*therapeutic use', 'Candidiasis, Vulvovaginal/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Costs and Cost Analysis', 'Female', 'Humans', 'Imidazoles/administration & dosage/*therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2275233/
1562,miconazole,6281592,Current management of fungal enteritis.,"['Chretien JH', 'Garagusi VF']","['Amphotericin B/therapeutic use', 'Antifungal Agents/therapeutic use', 'Candidiasis/diagnosis/drug therapy', 'Diarrhea/etiology', 'Enteritis/drug therapy/*etiology', 'Histoplasmosis/diagnosis/drug therapy', 'Humans', 'Imidazoles/therapeutic use', 'Immunosuppression Therapy/adverse effects', 'Ketoconazole', 'Miconazole/therapeutic use', 'Mycoses/*diagnosis', 'Neoplasms/complications', 'Nystatin/therapeutic use', 'Paracoccidioidomycosis/diagnosis/drug therapy', 'Piperazines/therapeutic use', 'Sulfadiazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6281592/
1563,miconazole,33653857,Pharyngeal haematoma and partial airway obstruction caused by interaction between warfarin and topical miconazole gel.,['Reynolds H'],"['*Airway Obstruction/etiology', 'Anticoagulants/adverse effects', 'Drug Interactions', 'Hematoma/chemically induced', 'Humans', 'International Normalized Ratio', 'Male', 'Miconazole/adverse effects', '*Warfarin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33653857/
1564,miconazole,18505391,Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials.,"['Barasch A', 'Griffin AV']","['Antifungal Agents/*pharmacology/*therapeutic use', 'Fungi/*drug effects', 'Humans', 'Miconazole/*pharmacology/*therapeutic use', 'Microbial Viability', 'Mycoses/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18505391/
1565,miconazole,34360928,Isoconazole and Clemizole Hydrochloride Partially Reverse the Xeroderma Pigmentosum C Phenotype.,"['Kobaisi F', 'Sulpice E', 'Barette C', 'Fayyad N', 'Fauvarque MO', 'Badran B', 'Fayyad-Kazan M', 'Fayyad-Kazan H', 'Gidrol X', 'Rachidi W']","['Benzimidazoles/*pharmacology', 'Cell Line', 'Cell Survival/drug effects', 'Drug Repositioning', 'Humans', 'Miconazole/*analogs & derivatives/pharmacology', 'Skin Diseases/*drug therapy', 'Ultraviolet Rays/*adverse effects', 'Xeroderma Pigmentosum/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34360928/
1566,minoxidil,35920739,"Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.","['Gupta AK', 'Talukder M', 'Williams G']","['Male', 'Humans', '*Minoxidil/adverse effects', '*Finasteride/adverse effects', 'Dutasteride/adverse effects', 'Hair', 'Alopecia/drug therapy', '5-alpha Reductase Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35920739/
1567,minoxidil,32622136,Oral minoxidil treatment for hair loss: A review of efficacy and safety.,"['Randolph M', 'Tosti A']","['Administration, Oral', 'Alopecia/*drug therapy', 'Drug Administration Schedule', 'Humans', 'Medication Adherence', 'Minoxidil/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32622136/
1568,minoxidil,31496654,Minoxidil and its use in hair disorders: a review.,"['Suchonwanit P', 'Thammarucha S', 'Leerunyakul K']","['Animals', 'Antihypertensive Agents/administration & dosage/chemistry/*pharmacology', 'Hair/*drug effects/metabolism/pathology', 'Humans', 'Hypertrichosis/chemically induced', 'Minoxidil/administration & dosage/chemistry/*pharmacology', 'Molecular Structure', 'Sulfotransferases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/31496654/
1569,minoxidil,37871637,Medical Treatment for Androgenetic Alopecia.,['Panchaprateep R'],"['Male', 'Humans', 'Female', 'Alopecia/drug therapy', 'Finasteride/therapeutic use/adverse effects', 'Minoxidil/therapeutic use/adverse effects', '*Low-Level Light Therapy', '*Platelet-Rich Plasma', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37871637/
1570,minoxidil,37003900,Female-pattern hair loss: therapeutic update.,"['Muller Ramos P', 'Melo DF', 'Radwanski H', 'de Almeida RFC', 'Miot HA']","['Humans', 'Female', '*Finasteride/therapeutic use', '*Quality of Life', 'Alopecia/drug therapy/pathology', 'Minoxidil/therapeutic use/adverse effects', 'Hair/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37003900/
1571,minoxidil,32066284,A review of the treatment of male pattern hair loss.,"['York K', 'Meah N', 'Bhoyrul B', 'Sinclair R']","['Administration, Oral', 'Administration, Topical', 'Alopecia/*drug therapy/radiotherapy', 'Dry Needling', 'Finasteride/administration & dosage/*therapeutic use', 'Hair/drug effects/growth & development', 'Humans', 'Low-Level Light Therapy', 'Male', 'Minoxidil/administration & dosage/*therapeutic use', 'Prostaglandins/administration & dosage/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32066284/
1572,minoxidil,6108737,Minoxidil.,"['Linas SL', 'Nies AS']","['Adrenergic beta-Antagonists/therapeutic use', 'Angina Pectoris/chemically induced', 'Diuretics/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Hypertension/*drug therapy', 'Hypertrichosis/chemically induced', 'Kidney/drug effects', 'Minoxidil/adverse effects/*therapeutic use', 'Natriuresis/drug effects', 'Pyrimidines/*therapeutic use', 'Receptors, Adrenergic/drug effects', 'Sodium Chloride/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6108737/
1573,minoxidil,37558233,Systematic review of mesotherapy: a novel avenue for the treatment of hair loss.,"['Gupta AK', 'Polla Ravi S', 'Wang T', 'Talukder M', 'Starace M', 'Piraccini BM']","['Humans', '*Mesotherapy/adverse effects', 'Alopecia/drug therapy', 'Minoxidil/therapeutic use', 'Treatment Outcome', 'Injections, Intradermal']",https://pubmed.ncbi.nlm.nih.gov/37558233/
1574,minoxidil,19678603,Diagnosing and treating hair loss.,"['Mounsey AL', 'Reed SW']","['Administration, Topical', 'Alopecia/*diagnosis/*therapy', 'Alopecia Areata/diagnosis/therapy', 'Diagnosis, Differential', 'Female', 'Hair/drug effects', 'Humans', 'Male', 'Minoxidil/administration & dosage', 'Tinea Capitis/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/19678603/
1575,minoxidil,24566563,Androgenetic alopecia.,"['Piraccini BM', 'Alessandrini A']","['5-alpha Reductase Inhibitors/therapeutic use', '*Alopecia/diagnosis/drug therapy/epidemiology/etiology/physiopathology', 'Androgen Antagonists/therapeutic use', 'Biopsy', 'Comorbidity', 'Contraindications', 'Dermoscopy', 'Dietary Supplements', 'Female', 'Hair Follicle/pathology', 'Hirsutism/etiology', 'Humans', 'Hyperandrogenism/complications', 'Ketoconazole/therapeutic use', 'Male', 'Menopause', 'Minoxidil/adverse effects/therapeutic use', 'Prognosis', 'Receptors, Androgen/metabolism', 'Scalp/pathology', 'Sex Characteristics', 'Testosterone/analogs & derivatives/metabolism', 'Virilism/complications']",https://pubmed.ncbi.nlm.nih.gov/24566563/
1576,minoxidil,24848508,Androgenetic alopecia: an evidence-based treatment update.,"['Varothai S', 'Bergfeld WF']","['Administration, Oral', 'Administration, Topical', 'Alopecia/*drug therapy/epidemiology/pathology', 'Evidence-Based Medicine', 'Female', 'Finasteride/administration & dosage/adverse effects/*therapeutic use', 'Hair/transplantation', 'Humans', 'Male', 'Minoxidil/administration & dosage/adverse effects/*therapeutic use', 'Prevalence', 'Quality of Life', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/24848508/
1577,minoxidil,32516434,Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review.,"['Sharma AN', 'Michelle L', 'Juhasz M', 'Muller Ramos P', 'Atanaskova Mesinkovska N']","['Administration, Topical', 'Alopecia/drug therapy', '*Alopecia Areata', 'Female', 'Humans', '*Hypertrichosis', 'Male', 'Minoxidil/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32516434/
1578,minoxidil,22409453,"Minoxidil use in dermatology, side effects and recent patents.","['Rossi A', 'Cantisani C', 'Melis L', 'Iorio A', 'Scali E', 'Calvieri S']","['Administration, Topical', 'Alopecia/*drug therapy', 'Animals', 'Antihypertensive Agents/adverse effects/pharmacology/therapeutic use', 'Female', 'Hair/drug effects/metabolism', 'Humans', 'Male', 'Minoxidil/adverse effects/pharmacology/*therapeutic use', 'Patents as Topic', 'Potassium Channels/drug effects/metabolism', 'Vasodilator Agents/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22409453/
1579,minoxidil,37805090,Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence.,"['Santana FFV', 'Lozi AA', 'Goncalves RV', 'Da Silva J', 'Da Matta SLP']","['Adult', 'Male', 'Humans', 'Animals', 'Mice', '*Minoxidil/toxicity/therapeutic use', 'Finasteride/toxicity', 'Alopecia/chemically induced/drug therapy', 'Administration, Oral', '*Prostatic Hyperplasia/chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37805090/
1580,minoxidil,38598226,Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial.,"['Penha MA', 'Miot HA', 'Kasprzak M', 'Muller Ramos P']","['Humans', '*Minoxidil/administration & dosage/adverse effects', 'Male', '*Alopecia/drug therapy', 'Adult', 'Double-Blind Method', 'Administration, Oral', 'Middle Aged', 'Treatment Outcome', 'Young Adult', 'Administration, Topical', 'Adolescent', 'Hair/drug effects', 'Brazil', 'Scalp']",https://pubmed.ncbi.nlm.nih.gov/38598226/
1581,minoxidil,38466519,Treatment Options for Alopecia Areata in Children and Adolescents.,"['Westerkam LL', 'McShane DB', 'Nieman EL', 'Morrell DS']","['Humans', '*Alopecia Areata/drug therapy/therapy', 'Child', 'Adolescent', 'Minoxidil/therapeutic use/administration & dosage', 'Adrenal Cortex Hormones/therapeutic use/administration & dosage', 'Janus Kinase Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38466519/
1582,minoxidil,36169916,What's New in Therapy for Male Androgenetic Alopecia?,"['Saceda-Corralo D', 'Dominguez-Santas M', 'Vano-Galvan S', 'Grimalt R']","['Humans', 'Male', '*Alopecia/drug therapy', '*Dutasteride/therapeutic use', '*Finasteride/therapeutic use', '*Minoxidil/therapeutic use', 'Retrospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36169916/
1583,minoxidil,37645625,New Target for Minoxidil in the Treatment of Androgenetic Alopecia.,"['Shen Y', 'Zhu Y', 'Zhang L', 'Sun J', 'Xie B', 'Zhang H', 'Song X']","['Humans', '*Minoxidil/pharmacology/therapeutic use', 'Molecular Docking Simulation', '*Alopecia/drug therapy', 'Dietary Supplements', 'Estradiol']",https://pubmed.ncbi.nlm.nih.gov/37645625/
1584,minoxidil,30604379,Off-Label Use of Topical Minoxidil in Alopecia: A Review.,"['Stoehr JR', 'Choi JN', 'Colavincenzo M', 'Vanderweil S']","['Administration, Topical', 'Adult', 'Alopecia/*drug therapy/pathology', 'Animals', 'Humans', 'Minoxidil/*administration & dosage/adverse effects', '*Off-Label Use', 'Treatment Outcome', 'Vasodilator Agents/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30604379/
1585,minoxidil,32897622,Microneedling in androgenetic alopecia; comparing two different depths of microneedles.,"['Faghihi G', 'Nabavinejad S', 'Mokhtari F', 'Fatemi Naeini F', 'Iraji F']","['Adolescent', 'Adult', '*Alopecia/drug therapy', 'Hair', 'Humans', 'Middle Aged', '*Minoxidil/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32897622/
1586,mirtazapine,34823736,Understanding Stimulant Use and Use Disorders in a New Era.,"['Ciccarone D', 'Shoptaw S']","['Adrenergic alpha-2 Receptor Antagonists/therapeutic use', 'Adult', 'Anticonvulsants/therapeutic use', 'Behavior Therapy/methods', 'Bupropion/therapeutic use', 'Central Nervous System Stimulants/*adverse effects/pharmacology', 'Cocaine-Related Disorders/drug therapy/*epidemiology/mortality', 'Cognitive Dysfunction/chemically induced/epidemiology', 'Comorbidity', 'Dopamine Uptake Inhibitors/therapeutic use', 'Female', 'Humans', 'Illicit Drugs/adverse effects/pharmacology', 'Male', 'Mental Disorders/chemically induced/epidemiology', 'Methamphetamine/*adverse effects/pharmacology', 'Mirtazapine/therapeutic use', 'Neurobiology', 'Neurodegenerative Diseases/chemically induced/epidemiology', 'Opiate Overdose/*epidemiology/mortality', 'Substance Withdrawal Syndrome/*therapy', 'Topiramate/therapeutic use', 'Transgender Persons', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/34823736/
1587,mirtazapine,35234292,Pharmacotherapy for post traumatic stress disorder (PTSD).,"['Williams T', 'Phillips NJ', 'Stein DJ', 'Ipser JC']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Amitriptyline/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', '*Antipsychotic Agents/therapeutic use', 'Humans', 'Middle Aged', 'Mirtazapine/therapeutic use', 'Paroxetine/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Stress Disorders, Post-Traumatic/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/35234292/
1588,mirtazapine,31178367,"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.","['Furukawa TA', 'Cipriani A', 'Cowen PJ', 'Leucht S', 'Egger M', 'Salanti G']","['Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Mirtazapine/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31178367/
1589,mirtazapine,36253442,Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.,"['Kishi T', 'Ikuta T', 'Sakuma K', 'Okuya M', 'Hatano M', 'Matsuda Y', 'Iwata N']","['Female', 'Humans', 'Adult', '*Depressive Disorder, Major/drug therapy', 'Duloxetine Hydrochloride/therapeutic use', 'Sertraline/therapeutic use', 'Citalopram/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use', 'Fluoxetine/therapeutic use', 'Paroxetine/therapeutic use', 'Mirtazapine/therapeutic use', 'Amitriptyline/therapeutic use', 'Desvenlafaxine Succinate/therapeutic use', 'Fluvoxamine/therapeutic use', 'Reboxetine/therapeutic use', 'Network Meta-Analysis', 'Antidepressive Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36253442/
1590,mirtazapine,11607047,A review of the pharmacological and clinical profile of mirtazapine.,"['Anttila SA', 'Leinonen EV']","['Animals', 'Antidepressive Agents, Tricyclic/*therapeutic use', 'Drug Interactions', 'Humans', 'Mianserin/adverse effects/*analogs & derivatives/pharmacology/*therapeutic use', 'Mirtazapine']",https://pubmed.ncbi.nlm.nih.gov/11607047/
1591,mirtazapine,30081645,Clinical Management of Bleeding Risk With Antidepressants.,"['Bixby AL', 'VandenBerg A', 'Bostwick JR']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Antidepressive Agents/administration & dosage/*adverse effects', 'Bupropion/adverse effects', 'Gastrointestinal Hemorrhage/chemically induced/epidemiology', 'Hemorrhage/*chemically induced/epidemiology/*therapy', 'Humans', 'Mirtazapine/adverse effects', 'Risk Factors', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30081645/
1592,mirtazapine,34029378,New generation antidepressants for depression in children and adolescents: a network meta-analysis.,"['Hetrick SE', 'McKenzie JE', 'Bailey AP', 'Sharma V', 'Moller CI', 'Badcock PB', 'Cox GR', 'Merry SN', 'Meader N']","['Adolescent', 'Antidepressive Agents/adverse effects/*therapeutic use', 'Bias', 'Child', 'Citalopram/therapeutic use', 'Depressive Disorder, Major/*drug therapy/psychology', 'Desvenlafaxine Succinate/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Fluoxetine/therapeutic use', 'Humans', 'Male', 'Mirtazapine/therapeutic use', 'Network Meta-Analysis', 'Paroxetine/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use', 'Suicidal Ideation', 'Venlafaxine Hydrochloride/therapeutic use', 'Vilazodone Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34029378/
1593,mirtazapine,30229678,Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.,"['Howard ML', 'Hossaini R', 'Tolar C', 'Gaviola ML']","['Adult', 'Appetite/*drug effects', 'Appetite Regulation/*drug effects', 'Appetite Stimulants/administration & dosage/*therapeutic use', 'Dronabinol/administration & dosage/therapeutic use', 'Eating/drug effects', 'Female', 'Humans', 'Inpatients', 'Male', 'Megestrol/administration & dosage/therapeutic use', 'Middle Aged', 'Mirtazapine/administration & dosage/therapeutic use', 'Retrospective Studies', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30229678/
1594,mirtazapine,38451521,Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis.,"['Gerolymos C', 'Barazer R', 'Yon DK', 'Loundou A', 'Boyer L', 'Fond G']","['Humans', '*Antipsychotic Agents/adverse effects', 'Biperiden', 'Cyproheptadine', 'Gallopamil', 'Mianserin', 'Mirtazapine/therapeutic use', 'Network Meta-Analysis', 'Propranolol', 'Randomized Controlled Trials as Topic', 'Trazodone', 'Vitamin B 6', '*Akathisia, Drug-Induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38451521/
1595,mirtazapine,34051293,Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.,"['Hunter CN', 'Abdel-Aal HH', 'Elsherief WA', 'Farag DE', 'Riad NM', 'Alsirafy SA']","['Anorexia/drug therapy/etiology', '*Cachexia/drug therapy/etiology', 'Double-Blind Method', 'Hand Strength', 'Humans', 'Mirtazapine/therapeutic use', '*Neoplasms/complications']",https://pubmed.ncbi.nlm.nih.gov/34051293/
1596,mirtazapine,29862972,[Antipsychotic induced rhabdomyolysis].,"['Ratnam C', 'Saguin E', 'Keou S', 'Plantamura J', 'Mennessier C', 'Lahutte B', 'Delacour H']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Humans', 'Male', 'Mianserin/adverse effects/*analogs & derivatives/therapeutic use', 'Mirtazapine', 'Rhabdomyolysis/*chemically induced/diagnosis', 'Stress Disorders, Post-Traumatic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29862972/
1597,mirtazapine,37943296,Pharmacological update of mirtazapine: a narrative literature review.,"['Hassanein EHM', 'Althagafy HS', 'Baraka MA', 'Abd-Alhameed EK', 'Ibrahim IM']","['Humans', '*Mirtazapine/therapeutic use/pharmacology', 'Animals', 'Antidepressive Agents/therapeutic use/pharmacology', 'Antidepressive Agents, Tricyclic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37943296/
1598,mirtazapine,38403888,The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds.,"['Gheysens T', 'Van Den Eede F', 'De Picker L']","['Humans', '*Hyponatremia/chemically induced/epidemiology', '*Antidepressive Agents/adverse effects', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Mirtazapine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38403888/
1599,mirtazapine,38206631,Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.,"['Arrieta O', 'Cardenas-Fernandez D', 'Rodriguez-Mayoral O', 'Gutierrez-Torres S', 'Castanares D', 'Flores-Estrada D', 'Reyes E', 'Lopez D', 'Barragan P', 'Soberanis Pina P', 'Cardona AF', 'Turcott JG']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Anorexia/drug therapy/etiology', 'Appetite Stimulants/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/complications/drug therapy', 'Double-Blind Method', '*Lung Neoplasms/complications/drug therapy', 'Mirtazapine/therapeutic use', 'Quality of Life/psychology', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38206631/
1600,mirtazapine,36999619,Antidepressants for the treatment of depression in people with cancer.,"['Vita G', 'Compri B', 'Matcham F', 'Barbui C', 'Ostuzzi G']","['Adult', 'Humans', 'Antidepressive Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Depression/drug therapy/etiology', '*Depressive Disorder, Major/drug therapy', 'Mirtazapine/therapeutic use', '*Neoplasms/drug therapy', 'Selective Serotonin Reuptake Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/36999619/
1601,mirtazapine,37467797,Relationship between circulating mitochondrial DNA and microRNA in patients with major depression.,"['Ogata H', 'Higasa K', 'Kageyama Y', 'Tahara H', 'Shimamoto A', 'Takekita Y', 'Koshikawa Y', 'Nonen S', 'Kato T', 'Kinoshita T', 'Kato M']","['Humans', '*MicroRNAs/genetics/metabolism', 'DNA, Mitochondrial', '*Depressive Disorder, Major/drug therapy/genetics', 'Mirtazapine/therapeutic use', 'Depression', '*Cell-Free Nucleic Acids/genetics/metabolism', 'Mitochondria/metabolism', 'Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37467797/
1602,mirtazapine,12647431,[Mirtazapine--an antidepressant].,['Landowski J'],"['*Antidepressive Agents, Tricyclic/administration & dosage/pharmacology', 'Anxiety/etiology', 'Depressive Disorder/complications/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', '*Mianserin/administration & dosage/analogs & derivatives/pharmacology', 'Mirtazapine', 'Sleep Initiation and Maintenance Disorders/etiology', 'Syndrome', 'Thinness/etiology']",https://pubmed.ncbi.nlm.nih.gov/12647431/
1603,mirtazapine,34688369,"Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.","['Banerjee S', 'High J', 'Stirling S', 'Shepstone L', 'Swart AM', 'Telling T', 'Henderson C', 'Ballard C', 'Bentham P', 'Burns A', 'Farina N', 'Fox C', 'Francis P', 'Howard R', 'Knapp M', 'Leroi I', 'Livingston G', 'Nilforooshan R', 'Nurock S', ""O'Brien J"", 'Price A', 'Thomas AJ', 'Tabet N']","['Aged, 80 and over', '*Anti-Anxiety Agents/adverse effects/therapeutic use', 'Brief Psychiatric Rating Scale', 'Caregivers/psychology', 'Dementia/*complications', 'Double-Blind Method', 'Female', 'Humans', 'Male', '*Mirtazapine/adverse effects/therapeutic use', 'Psychomotor Agitation/*drug therapy', 'Quality of Life/psychology', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/34688369/
1604,mirtazapine,33432919,Residual daytime effects of esmirtazapine.,['Ivgy-May N'],"['Disease Progression', 'Double-Blind Method', 'Humans', 'Mirtazapine', '*Sleep Initiation and Maintenance Disorders']",https://pubmed.ncbi.nlm.nih.gov/33432919/
1605,mirtazapine,36470132,Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.,"['Yeh TC', 'Correll CU', 'Yang FC', 'Chen MH', 'Tseng PT', 'Hsu CW', 'Carvalho AF', 'Stubbs B', 'Thompson T', 'Chu CS', 'Yu CL', 'Il Shin J', 'Yang SN', 'Tu YK', 'Liang CS']","['Humans', '*Clozapine/therapeutic use', 'Network Meta-Analysis', 'Entropy', 'Memantine', 'Mirtazapine/pharmacology/therapeutic use', '*Antipsychotic Agents/therapeutic use', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36470132/
1606,modafinil,35366192,Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.,"['Schifano F', 'Catalani V', 'Sharif S', 'Napoletano F', 'Corkery JM', 'Arillotta D', 'Fergus S', 'Vento A', 'Guirguis A']","['Brain', '*Central Nervous System Stimulants/adverse effects', 'Cognition', 'Humans', '*Methylphenidate/pharmacology', 'Modafinil/pharmacology', '*Nootropic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35366192/
1607,modafinil,30468674,Modafinil and orexin system: interactions and medico-legal considerations.,"['Salerno M', 'Villano I', 'Nicolosi D', 'Longhitano L', 'Loreto C', 'Lovino A', 'Sessa F', 'Polito AN', 'Monda V', 'Chieffi S', 'Messina A', 'Monda M', 'Zammit C', 'Tafuri D', 'Messina G', 'Carotenuto M']","['Animals', 'Attention/drug effects/physiology', 'Central Nervous System/*drug effects/metabolism/physiology', 'Cognition/drug effects/physiology', 'Humans', 'Modafinil/metabolism/pharmacokinetics/*pharmacology', 'Neurons/drug effects/metabolism/physiology', 'Orexins/*metabolism', 'Wakefulness/*drug effects/physiology', 'Wakefulness-Promoting Agents/metabolism/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30468674/
1608,modafinil,9628108,Idiopathic hypersomnia.,"['Billiard M', 'Merle C', 'Carlander B', 'Ondze B', 'Alvarez D', 'Besset A']","['Adolescent', 'Adult', 'Benzhydryl Compounds/adverse effects/therapeutic use', 'Central Nervous System Stimulants/therapeutic use', 'Child', 'Diagnosis, Differential', 'Disorders of Excessive Somnolence/*diagnosis/drug therapy/genetics', 'Female', 'Humans', 'Male', 'Modafinil', 'Pedigree', 'Polysomnography']",https://pubmed.ncbi.nlm.nih.gov/9628108/
1609,modafinil,33085721,Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.,"['Elliott J', 'Johnston A', 'Husereau D', 'Kelly SE', 'Eagles C', 'Charach A', 'Hsieh SC', 'Bai Z', 'Hossain A', 'Skidmore B', 'Tsakonas E', 'Chojecki D', 'Mamdani M', 'Wells GA']","['Adult', 'Amphetamine/adverse effects/therapeutic use', 'Atomoxetine Hydrochloride/adverse effects/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/epidemiology/pathology', 'Bayes Theorem', 'Bupropion/adverse effects/therapeutic use', 'Central Nervous System Stimulants/*adverse effects', 'Dextroamphetamine/adverse effects/therapeutic use', 'Drug-Related Side Effects and Adverse Reactions/classification/*epidemiology/pathology', 'Female', 'Guanfacine/adverse effects/therapeutic use', 'Humans', 'Lisdexamfetamine Dimesylate/adverse effects/therapeutic use', 'Male', 'Methylphenidate/adverse effects/therapeutic use', 'Modafinil/adverse effects/therapeutic use', 'Network Meta-Analysis', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33085721/
1610,modafinil,31375202,Precision Medicine for Idiopathic Hypersomnia.,"['Arnulf I', 'Leu-Semenescu S', 'Dodet P']","['Central Nervous System Stimulants/therapeutic use', 'Clarithromycin/therapeutic use', 'Flumazenil/therapeutic use', 'GABA Modulators/*therapeutic use', 'Humans', 'Idiopathic Hypersomnia/*drug therapy/metabolism/physiopathology', 'Mazindol/therapeutic use', 'Modafinil/therapeutic use', 'Orexins/metabolism', 'Piperidines/therapeutic use', 'Polysomnography', 'Precision Medicine', 'Sleep', 'Sodium Oxybate/therapeutic use', 'Wakefulness', 'Wakefulness-Promoting Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31375202/
1611,modafinil,34173288,European guideline and expert statements on the management of narcolepsy in adults and children.,"['Bassetti CLA', 'Kallweit U', 'Vignatelli L', 'Plazzi G', 'Lecendreux M', 'Baldin E', 'Dolenc-Groselj L', 'Jennum P', 'Khatami R', 'Manconi M', 'Mayer G', 'Partinen M', 'Pollmacher T', 'Reading P', 'Santamaria J', 'Sonka K', 'Dauvilliers Y', 'Lammers GJ']","['Adult', '*Cataplexy', 'Child', 'Humans', 'Modafinil/therapeutic use', '*Narcolepsy/diagnosis/drug therapy', 'Sleep', '*Sodium Oxybate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34173288/
1612,modafinil,37194538,[Psychostimulants: An Overview].,"['Fukumoto S', 'Imanari E', 'Tomari S', 'Higashi T', 'Kosaka H']","['Humans', '*Central Nervous System Stimulants/therapeutic use', 'Lisdexamfetamine Dimesylate/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Methylphenidate/therapeutic use', 'Modafinil/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37194538/
1613,modafinil,37921201,Headache improves with armodafinil.,['Barone DA'],"['Humans', 'Modafinil/therapeutic use', '*Narcolepsy', 'Caffeine/therapeutic use', '*Cataplexy', 'Headache/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37921201/
1614,modafinil,33435717,A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.,"['Kakehi S', 'Tompkins DM']","['*Brain Injuries/drug therapy', 'Humans', 'Modafinil', 'Prospective Studies', 'Risk Assessment', '*Stroke']",https://pubmed.ncbi.nlm.nih.gov/33435717/
1615,modafinil,38508480,Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy With Modafinil or Vitamin Therapy With Thiamine.,"['Bager P', 'Hvas CL', 'Dahlerup JF']","['Humans', '*Modafinil/therapeutic use', '*Fatigue/drug therapy', '*Inflammatory Bowel Diseases/drug therapy/complications', '*Thiamine/therapeutic use', 'Treatment Outcome', 'Male', 'Female', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/38508480/
1616,modafinil,36759544,In utero exposure to ADHD medication and long-term offspring outcomes.,"['Bang Madsen K', 'Robakis TK', 'Liu X', 'Momen N', 'Larsson H', 'Dreier JW', 'Kildegaard H', 'Groth JB', 'Newcorn JH', 'Hove Thomsen P', 'Munk-Olsen T', 'Bergink V']","['Adult', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Pregnancy', 'Amphetamines/adverse effects/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', 'Clonidine/adverse effects/therapeutic use', 'Cohort Studies', 'Denmark/epidemiology', 'Gestational Age', '*Methylphenidate/adverse effects/therapeutic use', 'Modafinil/adverse effects/therapeutic use', '*Mothers/psychology', 'Neurodevelopmental Disorders/chemically induced', '*Prenatal Exposure Delayed Effects/chemically induced/epidemiology', 'Registries']",https://pubmed.ncbi.nlm.nih.gov/36759544/
1617,modafinil,33201262,"Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.","['Repantis D', 'Bovy L', 'Ohla K', 'Kuhn S', 'Dresler M']","['Adult', 'Attention/drug effects', 'Caffeine/*pharmacology', 'Central Nervous System Stimulants/*pharmacology', 'Cognition/*drug effects', 'Double-Blind Method', 'Fatigue/prevention & control', 'Humans', 'Male', 'Methylphenidate/*pharmacology', 'Modafinil/*pharmacology', 'Nootropic Agents/*pharmacology', 'Pilot Projects', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33201262/
1618,modafinil,33242419,"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.","['Nourbakhsh B', 'Revirajan N', 'Morris B', 'Cordano C', 'Creasman J', 'Manguinao M', 'Krysko K', 'Rutatangwa A', 'Auvray C', 'Aljarallah S', 'Jin C', 'Mowry E', 'McCulloch C', 'Waubant E']","['Adult', 'Amantadine/administration & dosage/adverse effects/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', '*Drug-Related Side Effects and Adverse Reactions', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Modafinil/administration & dosage/adverse effects/*pharmacology', 'Multiple Sclerosis/*complications', '*Outcome Assessment, Health Care', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33242419/
1619,modafinil,22310006,[Modafinil in the treatment of depression].,['Videbech P'],"['Antidepressive Agents/adverse effects/*therapeutic use', 'Benzhydryl Compounds/adverse effects/*therapeutic use', 'Bipolar Disorder/drug therapy', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Depressive Disorder, Major/drug therapy', 'Drug Interactions', 'Humans', 'Modafinil', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22310006/
1620,modafinil,24107292,"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.","['Dauvilliers Y', 'Bassetti C', 'Lammers GJ', 'Arnulf I', 'Mayer G', 'Rodenbeck A', 'Lehert P', 'Ding CL', 'Lecomte JM', 'Schwartz JC']","['Adult', 'Benzhydryl Compounds/administration & dosage/adverse effects/*pharmacology', 'Double-Blind Method', 'Female', 'Histamine Agonists/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Middle Aged', 'Modafinil', 'Narcolepsy/*drug therapy', 'Piperidines/administration & dosage/adverse effects/*pharmacology', 'Placebos', 'Severity of Illness Index', 'Treatment Outcome', 'Wakefulness-Promoting Agents/administration & dosage/adverse effects/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24107292/
1621,modafinil,30767208,Modafinil protects hippocampal neurons by suppressing excessive autophagy and apoptosis in mice with sleep deprivation.,"['Cao Y', 'Li Q', 'Liu L', 'Wu H', 'Huang F', 'Wang C', 'Lan Y', 'Zheng F', 'Xing F', 'Zhou Q', 'Li Q', 'Shi H', 'Zhang B', 'Wang Z', 'Wu X']","['Animals', 'Apoptosis/*drug effects', 'Autophagy/*drug effects', 'Central Nervous System Stimulants/*pharmacology', 'Hippocampus/*drug effects', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Modafinil/*pharmacology', 'Neurons/*drug effects', 'Protective Agents/*pharmacology', 'Sleep Deprivation/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30767208/
1622,modafinil,20488296,Medication effects on sleep.,"['Roux FJ', 'Kryger MH']","['Antiparkinson Agents/pharmacology', 'Antipsychotic Agents/pharmacology', 'Benzhydryl Compounds/pharmacology', 'Benzodiazepines/pharmacology', 'Histamine Antagonists/pharmacology', 'Humans', 'Lithium/pharmacology', 'Modafinil', 'Selective Serotonin Reuptake Inhibitors/pharmacology', 'Sleep/*drug effects', 'Theophylline/pharmacology', 'Wakefulness/physiology']",https://pubmed.ncbi.nlm.nih.gov/20488296/
1623,modafinil,37155992,Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.,"['Pitre T', 'Mah J', 'Roberts S', 'Desai K', 'Gu Y', 'Ryan C', 'Busse JW', 'Zeraatkar D']","['Humans', 'Autoreceptors', '*Disorders of Excessive Somnolence/drug therapy/etiology', 'Modafinil/adverse effects', 'Network Meta-Analysis', '*Sleep Apnea, Obstructive/complications/drug therapy', '*Wakefulness-Promoting Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37155992/
1624,modafinil,34173695,European guideline and expert statements on the management of narcolepsy in adults and children.,"['Bassetti CLA', 'Kallweit U', 'Vignatelli L', 'Plazzi G', 'Lecendreux M', 'Baldin E', 'Dolenc-Groselj L', 'Jennum P', 'Khatami R', 'Manconi M', 'Mayer G', 'Partinen M', 'Pollmacher T', 'Reading P', 'Santamaria J', 'Sonka K', 'Dauvilliers Y', 'Lammers GJ']","['Adult', '*Cataplexy', 'Child', 'Humans', 'Modafinil/therapeutic use', '*Narcolepsy/diagnosis/drug therapy', 'Sleep', '*Sodium Oxybate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34173695/
1625,modafinil,35670369,"Cognitive enhancement: Effects of methylphenidate, modafinil, and caffeine on latent memory and resting state functional connectivity in healthy adults.","['Becker M', 'Repantis D', 'Dresler M', 'Kuhn S']","['Adult', 'Brain/diagnostic imaging', 'Brain Mapping/methods', 'Caffeine/pharmacology', '*Central Nervous System Stimulants/pharmacology', 'Cognition', 'Double-Blind Method', 'Humans', 'Magnetic Resonance Imaging/methods', 'Male', '*Methylphenidate/pharmacology', 'Modafinil/pharmacology', 'Neural Pathways/diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/35670369/
1626,naratriptan,18223456,Triptans in pregnancy.,"['Soldin OP', 'Dahlin J', ""O'Mara DM""]","['Animals', 'Female', 'Humans', 'Migraine Disorders/*drug therapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', '*Prenatal Exposure Delayed Effects', 'Serotonin Receptor Agonists/*adverse effects', 'Tryptamines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18223456/
1627,naratriptan,25877672,Acute Migraine Treatment in Adults.,['Becker WJ'],"['Adult', 'Analgesics, Opioid/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Caffeine/administration & dosage', 'Dihydroergotamine/administration & dosage', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Migraine Disorders/*diagnosis/*drug therapy', 'Pain Management/*methods', 'Serotonin Receptor Agonists/administration & dosage', 'Treatment Outcome', 'Tryptamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25877672/
1628,naratriptan,27910087,Menstrual Migraine and Treatment Options: Review.,"['Maasumi K', 'Tepper SJ', 'Kriegler JS']","['Female', 'Humans', 'Menstruation/drug effects/physiology', 'Migraine Disorders/*drug therapy/physiopathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27910087/
1629,naratriptan,25600718,The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.,"['Marmura MJ', 'Silberstein SD', 'Schwedt TJ']","['Adult', 'Anti-Inflammatory Agents/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/*therapeutic use', 'Societies, Medical/standards/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/25600718/
1630,naratriptan,19126376,Clinical aspects of perimenstrual headaches.,['Taylor FR'],"['Female', 'Headache/diagnosis/*etiology/*therapy', 'Humans', 'Migraine without Aura/diagnosis/etiology/therapy', 'Premenstrual Syndrome/*complications/diagnosis/*therapy', 'Randomized Controlled Trials as Topic/methods']",https://pubmed.ncbi.nlm.nih.gov/19126376/
1631,naratriptan,12498013,Eletriptan Pfizer.,"['Strijbos PJ', 'Parsons AA', 'Fugelli A']","['Animals', 'Clinical Trials as Topic/methods/statistics & numerical data', 'Drug Industry/legislation & jurisprudence/*methods', 'Humans', 'Indoles/chemistry/*pharmacology/*therapeutic use', 'Pyrrolidines/chemistry/*pharmacology/*therapeutic use', 'Serotonin Receptor Agonists/pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12498013/
1632,naratriptan,17955173,Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.,['Tfelt-Hansen P'],"['Administration, Oral', 'Biological Availability', 'Humans', 'Infusions, Parenteral', 'Injections, Subcutaneous', 'Migraine Disorders/*drug therapy/physiopathology', 'Piperidines/*administration & dosage/blood/pharmacokinetics', 'Serotonin Receptor Agonists/*administration & dosage/blood/pharmacokinetics', 'Sumatriptan/*administration & dosage/blood/pharmacokinetics', 'Time Factors', 'Treatment Outcome', 'Tryptamines/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/17955173/
1633,naratriptan,39293828,Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.,"['Karlsson WK', 'Ostinelli EG', 'Zhuang ZA', 'Kokoti L', 'Christensen RH', 'Al-Khazali HM', 'Deligianni CI', 'Tomlinson A', 'Ashina H', 'Ruiz de la Torre E', 'Diener HC', 'Cipriani A', 'Ashina M']","['Adult', 'Humans', '*Migraine Disorders/diagnosis/drug therapy', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Tryptamines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39293828/
1634,naratriptan,12463278,Naratriptan.,['Massiou H'],"['Humans', 'Indoles/adverse effects/*therapeutic use', 'Migraine Disorders/*drug therapy', 'Piperidines/adverse effects/*therapeutic use', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12463278/
1635,naratriptan,11575714,Donitriptan (Pierre Fabre).,['Dukat M'],"['Animals', 'Clinical Trials, Phase I as Topic', 'Drug Evaluation, Preclinical', '*Drugs, Investigational', 'Humans', 'Migraine Disorders/drug therapy', 'Molecular Structure', 'Nitriles/chemistry/*pharmacology/therapeutic use/toxicity', 'Piperazines/chemistry/*pharmacology/therapeutic use/toxicity', 'Serotonin Receptor Agonists/chemistry/*pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/11575714/
1636,naratriptan,26252584,Acute Migraine Treatment.,['Becker WJ'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Dihydroergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Tryptamines/*therapeutic use', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26252584/
1637,naratriptan,15934888,Eletriptan review.,"['Farkkila M', 'Kallela M']","['Clinical Trials as Topic/statistics & numerical data', 'Dose-Response Relationship, Drug', 'Humans', 'Migraine Disorders/*drug therapy/metabolism', 'Pyrrolidines/metabolism/*therapeutic use', 'Serotonin Receptor Agonists/metabolism/*therapeutic use', 'Tryptamines/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15934888/
1638,naratriptan,12117355,Mechanisms of action of the 5-HT1B/1D receptor agonists.,"['Tepper SJ', 'Rapoport AM', 'Sheftell FD']","['Carbazoles/pharmacology', 'Humans', 'Indoles/pharmacology', 'Migraine Disorders/*drug therapy/*metabolism', 'Oxazolidinones/pharmacology', 'Piperidines/pharmacology', 'Pyrrolidines/pharmacology', 'Receptor, Serotonin, 5-HT1B', 'Receptor, Serotonin, 5-HT1D', 'Receptors, Serotonin/*drug effects', 'Serotonin Receptor Agonists/*pharmacology', 'Sumatriptan/pharmacology', 'Triazoles/pharmacology', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12117355/
1639,naratriptan,10463349,Antimigraine drugs.,"['Diener HC', 'Kaube H', 'Limmroth V']","['Analgesics/*therapeutic use', 'Antiemetics/*therapeutic use', 'Ergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/therapeutic use', 'Vasoconstrictor Agents/*therapeutic use', 'Vomiting/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/10463349/
1640,naratriptan,10643958,Newer intranasal migraine medications.,"['Logemann CD', 'Rankin LM']","['Administration, Intranasal', 'Administration, Oral', 'Analgesics, Non-Narcotic/*administration & dosage', 'Clinical Trials as Topic', 'Dihydroergotamine/*administration & dosage', 'Half-Life', 'Humans', 'Indoles/administration & dosage', 'Migraine Disorders/*drug therapy', 'Oxazoles/administration & dosage', '*Oxazolidinones', 'Piperidines/administration & dosage', 'Recurrence', 'Serotonin Receptor Agonists/*administration & dosage', 'Sumatriptan/*administration & dosage', 'Triazoles/administration & dosage', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/10643958/
1641,naratriptan,31389059,Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.,"['Tfelt-Hansen P', 'Messlinger K']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics', 'Arteries/drug effects/innervation', 'Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Migraine Disorders/*drug therapy/physiopathology', 'Nociception/drug effects/physiology', '*Randomized Controlled Trials as Topic', 'Serotonin 5-HT1 Receptor Agonists/administration & dosage/*pharmacokinetics', 'Thalamus/drug effects/physiopathology', 'Time Factors', 'Treatment Outcome', 'Trigeminal Ganglion/drug effects/physiopathology', 'Vasoconstriction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31389059/
1642,naratriptan,16389295,Preclinical neuropharmacology of naratriptan.,['Lambert GA'],"['Analgesia', 'Animals', 'Cardiovascular Diseases/chemically induced', 'Humans', 'Migraine Disorders/drug therapy', 'Piperidines/adverse effects/cerebrospinal fluid/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Serotonin Receptor Agonists/adverse effects/cerebrospinal fluid/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Tryptamines/adverse effects/cerebrospinal fluid/chemistry/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16389295/
1643,naratriptan,10692743,Naratriptan.,['Salonen R'],"['Adolescent', 'Adult', 'Aged', 'Delayed-Action Preparations', 'Female', 'Humans', 'Indoles/*administration & dosage', 'Male', 'Middle Aged', 'Migraine Disorders/*drug therapy', 'Piperidines/*administration & dosage', 'Recurrence', 'Serotonin Receptor Agonists/*administration & dosage', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/10692743/
1644,naratriptan,9916496,[Zolmitriptan].,"['Monseu G', 'Sternon J']","['Chemistry, Pharmaceutical', 'Humans', 'Indoles/therapeutic use', 'Migraine Disorders/*drug therapy', 'Oxazoles/economics/pharmacokinetics/pharmacology/*therapeutic use', '*Oxazolidinones', 'Piperidines/therapeutic use', 'Serotonin Receptor Agonists/economics/pharmacokinetics/pharmacology/*therapeutic use', 'Sumatriptan/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/9916496/
1645,naratriptan,12830928,Pharmacological approaches to migraine.,['Diener HCh'],"['Adrenergic beta-Antagonists/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12830928/
1646,nifedipine,8061479,Sublingual nifedipine: the continuing controversy.,['Oliver S'],"['Administration, Oral', 'Administration, Sublingual', 'Clinical Trials as Topic', 'Humans', 'Nifedipine/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8061479/
1647,nifedipine,1834848,Amlodipine: an effective once-daily antihypertensive agent.,['Tyler HM'],"['Amlodipine', '*Antihypertensive Agents/administration & dosage/therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/therapeutic use', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Longitudinal Studies', 'Nifedipine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1834848/
1648,nifedipine,38949541,Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.,"['Sanusi AA', 'Leach J', 'Boggess K', 'Dugoff L', 'Sibai B', 'Lawrence K', 'Hughes BL', 'Bell J', 'Aagaard K', 'Edwards RK', 'Gibson KS', 'Haas DM', 'Plante L', 'Metz TD', 'Casey B', 'Esplin S', 'Longo S', 'Hoffman MK', 'Saade GR', 'Hoppe KK', 'Foroutan J', 'Tuuli M', 'Owens MY', 'Simhan HN', 'Frey H', 'Rosen T', 'Palatnik A', 'Baker S', 'August P', 'Reddy UM', 'Su EJ', 'Krishna I', 'Nguyen NA', 'Norton ME', 'Skupski D', 'El-Sayed YY', 'Ogunyemi D', 'Galis ZS', 'Harper L', 'Ambalavanan N', 'Geller NL', 'Kuo HC', 'Sinkey RG', 'Librizzi R', 'Pereira L', 'Magann EF', 'Habli M', 'Williams S', 'Mari G', 'Pridjian G', 'McKenna DS', 'Parrish M', 'Chang E', 'Osmundson S', 'Quinones J', 'Szychowski JM', 'Tita ATN']","['Humans', 'Pregnancy', 'Female', '*Labetalol/administration & dosage/adverse effects/therapeutic use', '*Nifedipine/administration & dosage/adverse effects/therapeutic use', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Adult', '*Pregnancy Outcome', '*Hypertension/drug therapy', 'Infant, Newborn', 'Pregnancy Complications, Cardiovascular/drug therapy', 'Hypertension, Pregnancy-Induced/drug therapy', 'Administration, Oral', 'Infant, Small for Gestational Age', 'Pre-Eclampsia/drug therapy', 'Chronic Disease']",https://pubmed.ncbi.nlm.nih.gov/38949541/
1649,nifedipine,3912182,Felodipine in hypertension.,"['Mace PJ', 'Stallard TJ', 'Littler WA']","['Adult', 'Antihypertensive Agents/administration & dosage/blood/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Felodipine', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*analogs & derivatives/blood/therapeutic use', 'Norepinephrine/blood', 'Posture', 'Renin/blood', 'Time Factors', 'Vasodilator Agents/administration & dosage/blood/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3912182/
1650,nifedipine,3551600,"Sodium intake, high blood pressure, and calcium channel blockers.","['MacGregor GA', 'Cappuccio FP', 'Markandu ND']","['Animals', 'Blood Pressure/drug effects', 'Calcium/physiology', 'Calcium Channel Blockers/pharmacology/*therapeutic use', 'Humans', 'Hypertension/*chemically induced/drug therapy/physiopathology', 'Kidney/physiopathology', 'Nifedipine/pharmacology/therapeutic use', 'Sodium/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3551600/
1651,nifedipine,25728783,[Calcium channel blockers pharmacology and their use as tocolytics].,"['Bejan-Angoulvant T', 'Crochet J', 'Jonville-Bera AP']","['Adult', '*Calcium Channel Blockers/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Female', 'Humans', '*Nicardipine/administration & dosage/adverse effects/pharmacokinetics/pharmacology', '*Nifedipine/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Obstetric Labor, Premature/*drug therapy', 'Pregnancy', '*Tocolytic Agents/administration & dosage/adverse effects/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25728783/
1652,nifedipine,11434453,Barnidipine.,"['Malhotra HS', 'Plosker GL']","['Aged', 'Animals', 'Area Under Curve', 'Biological Availability', '*Calcium Channel Blockers/metabolism/pharmacokinetics/pharmacology/therapeutic use', 'Hemodynamics/drug effects', 'Humans', '*Hypertension/*drug therapy', 'Intestinal Absorption', 'Multicenter Studies as Topic', '*Nifedipine/*analogs & derivatives/metabolism/pharmacokinetics/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/11434453/
1653,nifedipine,2212122,Chilblains (perniosis).,['Goette DK'],"['Adult', 'Aged', 'Aged, 80 and over', 'Chilblains/etiology/*pathology/therapy', 'Child', 'Diagnosis, Differential', 'Female', 'Humans', 'Lymphocytes/pathology', 'Male', 'Nifedipine/administration & dosage/adverse effects/therapeutic use', 'San Francisco', 'Skin/pathology']",https://pubmed.ncbi.nlm.nih.gov/2212122/
1654,nifedipine,6764159,Calcium-channel blocking agents.,"['Leonard RG', 'Talbert RL']","['Adolescent', 'Benzazepines/*pharmacology', 'Calcium/physiology', 'Calcium Channel Blockers/*pharmacology', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Diltiazem/adverse effects/metabolism/*pharmacology/therapeutic use', 'Double-Blind Method', 'Heart/*drug effects', 'Heart Diseases/*drug therapy', 'Humans', 'Hypertension/drug therapy', 'Infant', 'Myocardial Contraction/drug effects', 'Nifedipine/adverse effects/metabolism/*pharmacology/therapeutic use', 'Pyridines/*pharmacology', 'Verapamil/adverse effects/metabolism/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6764159/
1655,nifedipine,1836870,"The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine.","['Elliott HL', 'Meredith PA']","['Amlodipine', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/adverse effects/metabolism/*pharmacokinetics/pharmacology', 'Humans', 'Hypertension/drug therapy', 'Nifedipine/adverse effects/*analogs & derivatives/metabolism/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1836870/
1656,nifedipine,3288468,"Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.","['Stanley NN', 'Thirkettle JL', 'Varma MP', 'Larkin H', 'Heath ID']","['Adult', 'Aged', 'Atenolol/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Creatinine/blood', 'Double-Blind Method', 'Drug Therapy, Combination', 'Drug Tolerance', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use', 'Potassium/blood', 'Random Allocation', 'Uric Acid/blood']",https://pubmed.ncbi.nlm.nih.gov/3288468/
1657,nifedipine,3234257,Subcutaneous administration of nifedipine.,"['Krichbaum DW', 'Malone PM']","['Aged', 'Emergencies', 'Female', 'Humans', 'Hypertension/drug therapy', 'Injections, Subcutaneous', 'Nifedipine/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3234257/
1658,nifedipine,6712894,Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine.,"['Walters BN', 'Redman CW']","['Adolescent', 'Adult', 'Blood Pressure/drug effects', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Nifedipine/adverse effects/*therapeutic use', 'Pilot Projects', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Puerperal Disorders/drug therapy', 'Pulse/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6712894/
1659,nifedipine,28233944,Therapeutic Differences in 24-h Ambulatory Blood Pressures in Patients Switched Between Bioequivalent Nifedipine Osmotic Systems With Differing Delivery Technologies.,"['Pollak PT', 'Herman RJ', 'Feldman RD']","['Aged', 'Blood Pressure/*drug effects', '*Blood Pressure Monitoring, Ambulatory', 'Demography', '*Drug Delivery Systems', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/*administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Osmosis', 'Systole/drug effects', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/28233944/
1660,nifedipine,3987547,"Antihypertensive and water and sodium balance effects of felodipine, a new vasodilating calcium antagonist, in hypertensive patients.","['Leonetti G', 'Fruscio M', 'Terzoli L', 'Rupoli L', 'Gradnik R', 'Sampieri L', 'Cuspidi C', 'Boselli L', 'Bolla G', 'Zanchetti A']","['Adult', 'Antihypertensive Agents/adverse effects/*pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/*pharmacology', 'Creatinine/blood', 'Felodipine', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/drug therapy/metabolism/*physiopathology', 'Male', 'Nifedipine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Sodium/*metabolism', 'Vasodilator Agents/*pharmacology', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/3987547/
1661,nifedipine,2731403,"Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged, and the elderly.","['van Harten J', 'Burggraaf J', 'Ligthart GJ', 'van Brummelen P', 'Breimer DD']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Aging/*metabolism/physiology', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/*analogs & derivatives/pharmacokinetics/pharmacology', 'Nisoldipine', 'Norepinephrine/blood', 'Vasodilator Agents/administration & dosage/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2731403/
1662,nifedipine,14959468,[Assessment of the efficacy and tolerance of delayed-action nifedipine as the monotherapy or in combination with metoprolol in patients with arterial hypertension].,"['Isaikina OIu', 'Gorbunov VM', 'Andreeva GF', 'Dmitrieva NA', 'Martsevich SIu']","['Blood Pressure/drug effects', 'Blood Pressure Monitoring, Ambulatory', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Drug Therapy, Combination', 'Electrocardiography', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Metoprolol/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14959468/
1663,nifedipine,3331321,Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS.,"['Frishman WH', 'Sherman D', 'Feinfeld DA']","['Administration, Cutaneous', 'Angina Pectoris/*drug therapy', 'Clinical Trials as Topic', 'Clonidine/*administration & dosage/pharmacokinetics/therapeutic use', 'Delayed-Action Preparations', 'Humans', 'Hypertension/*drug therapy', 'Nifedipine/*administration & dosage/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3331321/
1664,nifedipine,3689628,The trans-hepatic extraction of nifedipine.,"['Challenor VF', 'Waller DG', 'Renwick AG', 'Gruchy BS', 'George CF']","['Adult', 'Aged', 'Humans', 'Indocyanine Green', 'Injections, Intravenous', 'Liver/*metabolism', 'Male', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Nifedipine/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3689628/
1665,nifedipine,18203344,[Antihypertensive effects of nifedipine and changing for modified-release formula].,['Kuwajima I'],"['Antihypertensive Agents/*administration & dosage/*pharmacology', 'Delayed-Action Preparations', 'Humans', 'Nifedipine/*administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18203344/
1666,nimodipine,30073574,Bath-Related Headache.,"['Kumpinsky A', 'Nahas SJ']","['Animals', 'Antihypertensive Agents/*therapeutic use', 'Headache/complications/drug therapy', 'Headache Disorders, Primary/*drug therapy/physiopathology', 'Humans', 'Nimodipine/*therapeutic use', 'Vasoconstriction/drug effects', 'Vasospasm, Intracranial/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/30073574/
1667,nimodipine,31560289,Nimodipine Reappraised: An Old Drug With a Future.,"['Carlson AP', 'Hanggi D', 'Macdonald RL', 'Shuttleworth CW']","['Brain Injuries/*drug therapy', 'Brain Injuries, Traumatic/drug therapy', 'Brain Ischemia/drug therapy', 'Calcium Channel Blockers/*therapeutic use', 'Humans', 'Nimodipine/pharmacology/*therapeutic use', 'Stroke/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31560289/
1668,nimodipine,30450691,Nimodipine improves vocal fold and facial motion recovery after injury: A systematic review and meta-analysis.,"['Lin RJ', 'Klein-Fedyshin M', 'Rosen CA']","['Calcium Channel Blockers/*therapeutic use', 'Cranial Nerve Injuries/*drug therapy', 'Face/physiology', 'Humans', 'Nimodipine/*therapeutic use', 'Recovery of Function', 'Treatment Outcome', 'Vocal Cords/physiology']",https://pubmed.ncbi.nlm.nih.gov/30450691/
1669,nimodipine,22258943,Steroids for acute spinal cord injury.,['Bracken MB'],"['Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Drug Administration Schedule', 'Glucocorticoids/administration & dosage/*therapeutic use', 'Humans', 'Methylprednisolone/administration & dosage/*therapeutic use', 'Neuroprotective Agents/administration & dosage/*therapeutic use', 'Nimodipine/administration & dosage/therapeutic use', 'Randomized Controlled Trials as Topic', 'Spinal Cord Injuries/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22258943/
1670,nimodipine,7858806,Nimodipine.,"['Whitfield PC', 'Pickard JD']","['Brain Ischemia/etiology/*prevention & control', 'Humans', 'Nimodipine/*pharmacology/therapeutic use', 'Subarachnoid Hemorrhage/*complications']",https://pubmed.ncbi.nlm.nih.gov/7858806/
1671,nimodipine,8519003,Neuronal plasticity and function.,['Gispen WH'],"['Adult', 'Aging/physiology', 'Animals', 'Humans', 'Neuronal Plasticity/*physiology', 'Neurons/*physiology', 'Nimodipine/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8519003/
1672,nimodipine,12646222,Antioxidant activity of different dihydropyridines.,"['Cominacini L', 'Fratta Pasini A', 'Garbin U', 'Pastorino AM', 'Davoli A', 'Nava C', 'Campagnola M', 'Rossato P', 'Lo Cascio V']","['Amlodipine/chemistry/metabolism/pharmacology', 'Animals', 'Antioxidants/chemistry/metabolism/*pharmacology', 'Cattle', 'Cells, Cultured', 'Dihydropyridines/chemistry/metabolism/*pharmacology', 'Endothelium, Vascular/cytology/drug effects/*metabolism', 'Fluoresceins/metabolism', 'Humans', 'Lipoproteins, LDL/metabolism', 'Molecular Structure', 'Nifedipine/chemistry/metabolism/pharmacology', 'Nimodipine/chemistry/metabolism/pharmacology', 'Reactive Oxygen Species/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12646222/
1673,nimodipine,1950663,[Nimodipine in subarachnoid hemorrhage].,"['Ferro JM', 'Canhao P', 'Melo TP', 'Campos JG', 'Trindade A', 'Antunes JL']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Child', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nimodipine/*therapeutic use', 'Odds Ratio', 'Subarachnoid Hemorrhage/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1950663/
1674,nimodipine,20093501,Cerebral malaria: a vasculopathy.,"['Desruisseaux MS', 'Machado FS', 'Weiss LM', 'Tanowitz HB', 'Golightly LM']","['Animals', 'Artemether', 'Artemisinins/pharmacology/therapeutic use', 'Humans', 'Malaria, Cerebral/*complications/drug therapy/parasitology/physiopathology', 'Mice', 'Nimodipine/pharmacology/therapeutic use', 'Plasmodium berghei/drug effects/physiology', 'Vasospasm, Intracranial/*complications/drug therapy/parasitology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/20093501/
1675,nimodipine,25701766,Pharmacologic Management of Subarachnoid Hemorrhage.,"['Young AM', 'Karri SK', 'Helmy A', 'Budohoski KP', 'Kirollos RW', 'Bulters DO', 'Kirkpatrick PJ', 'Ogilvy CS', 'Trivedi RA']","['Adrenal Cortex Hormones/*therapeutic use', 'Animals', 'Anticoagulants/*therapeutic use', 'Apoptosis', 'Brain Ischemia/etiology/*prevention & control', 'Calcium Channel Blockers/*therapeutic use', 'Clinical Trials as Topic', 'Dexamethasone/administration & dosage', 'Dioxanes/administration & dosage/pharmacology', 'Disease Models, Animal', 'Drugs, Chinese Herbal/administration & dosage', 'Estrogens/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Free Radical Scavengers/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Magnesium Sulfate/therapeutic use', 'Neuroprotective Agents/*therapeutic use', 'Nimodipine/therapeutic use', 'Platelet Aggregation Inhibitors/*therapeutic use', 'Pregnatrienes/administration & dosage', 'Progesterone/administration & dosage/adverse effects', 'Pyridines/administration & dosage/pharmacology', 'Pyrimidines/administration & dosage/pharmacology', 'Receptor, Endothelin A/drug effects', 'Subarachnoid Hemorrhage/complications/*drug therapy', 'Sulfonamides/administration & dosage/pharmacology', 'Tetrazoles/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25701766/
1676,nimodipine,8518999,"Nimodipine: cognition, aging, and degeneration.","['de Jonge MC', 'Traber J']","['Aging/*psychology', 'Animals', 'Calcium/physiology', 'Cognition/*drug effects', 'Homeostasis/drug effects', 'Humans', 'Nerve Degeneration/*drug effects', 'Nimodipine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8518999/
1677,nimodipine,30758052,Calcium antagonists for acute ischemic stroke.,"['Zhang J', 'Liu J', 'Li D', 'Zhang C', 'Liu M']","['Acute Disease', 'Adult', 'Aged', 'Aged, 80 and over', 'Brain Ischemia/*drug therapy/mortality', 'Calcium/metabolism', 'Calcium Channel Blockers/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Flunarizine/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Isradipine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Nimodipine/administration & dosage/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Stroke/*drug therapy', 'Vasodilator Agents/administration & dosage/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30758052/
1678,nimodipine,22009036,Behavioural memory reconsolidation of food and fear memories.,"['Flavell CR', 'Barber DJ', 'Lee JL']","['Animals', 'Calcium Channel Blockers/pharmacology', 'Calcium Channels, L-Type/drug effects', '*Fear', '*Food', 'Male', '*Memory', 'Nimodipine/pharmacology', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/22009036/
1679,nimodipine,1613678,Nimodipine in acute alcohol withdrawal state.,"['Banger M', 'Benkert O', 'Roschke J', 'Herth T', 'Hebenstreit M', 'Philipp M', 'Aldenhoff JB']","['Acute Disease', 'Adolescent', 'Adult', 'Alcohol Withdrawal Delirium/diagnosis/*drug therapy', 'Chlormethiazole/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Male', 'Middle Aged', 'Neurologic Examination/drug effects', 'Nimodipine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1613678/
1680,nimodipine,30190294,Nimodipine for the treatment of otolaryngic indications.,"['Sin JH', 'Shafeeq H', 'Levy ZD']","['Calcium Channel Blockers/*therapeutic use', 'Humans', 'Meniere Disease/drug therapy', 'Neuroprotective Agents/*therapeutic use', 'Nimodipine/*therapeutic use', 'Otorhinolaryngologic Diseases/*drug therapy', 'Vasodilator Agents/therapeutic use', 'Vertigo/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30190294/
1681,nimodipine,39140392,When transfusion causes a splitting headache: A case report and rapid review of transfusion-associated reversible cerebral vasoconstriction syndrome.,"['Pelham-Webb B', 'Guo Y', 'Ramirez A', 'Waldron E', 'Emmanuele V', 'Vargas W', 'Kahn J', 'Stone EF']","['Female', 'Humans', 'Erythrocyte Transfusion/adverse effects', 'Headache/etiology', 'Nimodipine/therapeutic use', 'Syndrome', 'Transfusion Reaction', 'Vasoconstriction', '*Vasospasm, Intracranial/etiology', 'Adolescent']",https://pubmed.ncbi.nlm.nih.gov/39140392/
1682,nimodipine,37740138,Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage.,"['Caylor MM', 'Macdonald RL']","['Humans', '*Brain Ischemia/drug therapy/etiology/prevention & control', 'Calcium Channel Blockers/pharmacology/therapeutic use', 'Cerebral Infarction/complications', 'Nimodipine/pharmacology/therapeutic use', '*Subarachnoid Hemorrhage/complications/drug therapy', '*Vasospasm, Intracranial/drug therapy/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/37740138/
1683,nimodipine,22543491,Unresolved issues in the management of aneurysmal subarachnoid hemorrhage.,['Bautista C'],"['Anemia/complications', 'Blood Glucose/analysis', 'Fever/complications/drug therapy/nursing', 'Fibrinolysis/drug effects', 'Humans', 'Hyponatremia/complications/nursing', 'Incidence', 'Magnesium/administration & dosage', 'Nimodipine/therapeutic use', 'Seizures/complications/nursing/prevention & control', 'Subarachnoid Hemorrhage/complications/*drug therapy/epidemiology/nursing', 'United States/epidemiology', 'Vasospasm, Intracranial/drug therapy/nursing', 'Venous Thrombosis/nursing/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/22543491/
1684,nimodipine,7644052,The effect of nimodipine on essential tremor.,"['Biary N', 'Bahou Y', 'Sofi MA', 'Thomas W', 'al Deeb SM']","['Adult', 'Aged', 'Double-Blind Method', 'Electromyography', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nimodipine/adverse effects/*therapeutic use', 'Tremor/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7644052/
1685,nimodipine,32902829,Nimodipine Pharmacokinetic Variability in Various Patient Populations.,"['Mahmoud SH', 'Ji X', 'Isse FA']","['Animals', 'Biological Variation, Population', 'Drug Interactions', 'Epidemiologic Factors', 'Humans', 'Nimodipine/*pharmacokinetics/therapeutic use', 'Subarachnoid Hemorrhage/*drug therapy/*metabolism', 'Treatment Outcome', 'Vasodilator Agents/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32902829/
1686,nitrazepam,20726290,Best practice guide for the treatment of nightmare disorder in adults.,"['Aurora RN', 'Zak RS', 'Auerbach SH', 'Casey KR', 'Chowdhuri S', 'Karippot A', 'Maganti RK', 'Ramar K', 'Kristo DA', 'Bista SR', 'Lamm CI', 'Morgenthaler TI']","['Adult', 'Clonidine/therapeutic use', 'Cognitive Behavioral Therapy/methods', 'Dreams/drug effects/*psychology', 'Evidence-Based Medicine', 'Eye Movement Desensitization Reprocessing', 'Humans', 'Hypnosis', 'Norepinephrine/antagonists & inhibitors', 'Prazosin/therapeutic use', 'Psychotropic Drugs/therapeutic use', 'Randomized Controlled Trials as Topic', 'Relaxation Therapy', 'Stress Disorders, Post-Traumatic/diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/20726290/
1687,nitrazepam,4892037,Nitrazepam--a safe hypnotic.,"['Matthew H', 'Proudfoot AT', 'Aitken RC', 'Raeburn JA', 'Wright N']","['Adult', 'Aged', 'Barbiturates/therapeutic use', '*Benzazepines/poisoning/therapeutic use', 'Clinical Trials as Topic', 'Female', 'Humans', 'Hypnotics and Sedatives/*poisoning/*therapeutic use', 'Male', 'Middle Aged', 'Placebos', 'Sleep', 'Sleep Initiation and Maintenance Disorders/drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/4892037/
1688,nitrazepam,82859,One man's poison.,['Hunter A'],"['Capsules', 'Clinical Trials as Topic', 'Diphenhydramine/administration & dosage', 'Drug Combinations', 'Drug Evaluation', 'Flurazepam/administration & dosage', 'Humans', 'Methaqualone/administration & dosage', 'Nitrazepam/administration & dosage', 'Sleep/*drug effects', 'Temazepam/administration & dosage', '*Travel']",https://pubmed.ncbi.nlm.nih.gov/82859/
1689,nitrazepam,3117519,Febrile seizures.,['Rosman NP'],"['Child', 'Child, Preschool', 'Diagnosis, Differential', 'Diazepam/administration & dosage', 'Electroencephalography', 'Epilepsy/etiology', 'Female', 'Humans', 'Infant', 'Male', 'Nitrazepam/administration & dosage', 'Phenobarbital/therapeutic use', 'Risk Factors', '*Seizures, Febrile/complications/diagnosis/drug therapy/prevention & control', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3117519/
1690,nitrazepam,8692185,Genetic toxicology of four commonly used benzodiazepines: a review.,"['Giri AK', 'Banerjee S']","['Animals', 'Benzodiazepines/*toxicity', 'Chlordiazepoxide/toxicity', '*DNA Damage', 'Diazepam/toxicity', 'Humans', 'Mutagenicity Tests/*methods', 'Mutagens/*toxicity', 'Nitrazepam/toxicity', 'Oxazepam/toxicity']",https://pubmed.ncbi.nlm.nih.gov/8692185/
1691,nitrazepam,6124415,"Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.",['Kanto JH'],"['Anti-Anxiety Agents/adverse effects/*metabolism', 'Chlordiazepoxide/metabolism', 'Clorazepate Dipotassium/metabolism', 'Diazepam/metabolism', 'Female', 'Flunitrazepam/metabolism', 'Humans', 'Infant, Newborn', '*Labor, Obstetric', '*Lactation', 'Lorazepam/metabolism', 'Maternal-Fetal Exchange', 'Nitrazepam/metabolism', 'Oxazepam/metabolism', '*Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/6124415/
1692,nitrazepam,2985947,Myoclonus.,['Swaiman KF'],"['Adrenocorticotropic Hormone/therapeutic use', 'Child', 'Child, Preschool', 'Clonazepam/therapeutic use', 'Diagnosis, Differential', 'Electroencephalography', 'Epilepsies, Myoclonic/diagnosis/drug therapy', 'Humans', 'Infant', 'Infant, Newborn', 'Myoclonus/*classification', 'Nitrazepam/therapeutic use', 'Prednisone/therapeutic use', 'Spasms, Infantile/diagnosis/therapy', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2985947/
1693,nitrazepam,7725291,[Insomnia and hypnotics].,['Kayed K'],"['Humans', 'Hypnotics and Sedatives/*administration & dosage', 'Sleep Initiation and Maintenance Disorders/classification/diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7725291/
1694,nitrazepam,687502,Clobazam--a new hypnotic?,"['Kesson CM', 'Gray JM', 'Lawson DH']","['Adult', 'Age Factors', 'Aged', 'Benzodiazepinones/*pharmacology', 'Double-Blind Method', 'Female', 'Humans', '*Hypnotics and Sedatives', 'Male', 'Middle Aged', 'Nitrazepam/pharmacology', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/687502/
1695,nitrazepam,7572872,Two cases of lethal nitrazepam poisoning.,"['Brodsgaard I', 'Hansen AC', 'Vesterby A']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Nitrazepam/blood/*poisoning', '*Suicide, Assisted']",https://pubmed.ncbi.nlm.nih.gov/7572872/
1696,nitrazepam,6142468,Pharmacological studies on zopiclone.,"['Julou L', 'Bardone MC', 'Blanchard JC', 'Garret C', 'Stutzmann JM']","['Aggression/drug effects', 'Animals', 'Anti-Anxiety Agents/pharmacology', 'Anticonvulsants', 'Azabicyclo Compounds', 'Barbiturates/pharmacology', 'Benzodiazepines', 'Cats', 'Drug Tolerance', 'Electrophysiology', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Mice', 'Mice, Inbred Strains', 'Muscle Relaxants, Central', 'Piperazines/*pharmacology', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/6142468/
1697,nitrazepam,4717418,Benzodiazepines and tricyclic antidepressant plasma levels.,"['Silverman G', 'Braithwaite RA']","['Amitriptyline/*blood', 'Benzazepines/*pharmacology', 'Chlordiazepoxide/administration & dosage/pharmacology', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations', 'Drug Interactions', 'Female', 'Humans', 'Male', 'Nitrazepam/administration & dosage/pharmacology', 'Nortriptyline/*blood', 'Oxazepam/administration & dosage/pharmacology', 'Tranquilizing Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/4717418/
1698,nitrazepam,25926432,Gut Microbiota-Mediated Drug-Antibiotic Interactions.,['Kim DH'],"['Administration, Oral', 'Animals', 'Anti-Bacterial Agents/*administration & dosage/*metabolism', 'Drug Interactions/*physiology', 'Gastrointestinal Microbiome/*drug effects/*physiology', 'Gastrointestinal Tract/drug effects/metabolism/microbiology', 'Humans', 'Pharmaceutical Preparations/administration & dosage/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25926432/
1699,nitrazepam,6135296,Triazolam as a hypnotic for geriatric patients. A double-blind cross-over comparison of nitrazepam and triazolam regarding effects on sleep and psychomotor performance.,"['Dehlin O', 'Bjornson G']","['Aged', 'Anti-Anxiety Agents/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Motor Skills/*drug effects', 'Nitrazepam/adverse effects/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Stages/*drug effects', 'Triazolam/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6135296/
1700,nitrazepam,20418931,[Benzodiazepines in the treatment of epilepsy].,"['Nakken KO', 'Rytter EM', 'Brockmeier F']","['Administration, Buccal', 'Anticonvulsants/administration & dosage/*therapeutic use', 'Benzodiazepines/administration & dosage/*therapeutic use', 'Epilepsy/*drug therapy/prevention & control', 'Humans', 'Midazolam/administration & dosage', 'Status Epilepticus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20418931/
1701,nitrazepam,9022890,Benzodiazepine misuse by drug addicts.,"['Garretty DJ', 'Wolff K', 'Hay AW', 'Raistrick D']","['Alcoholism/drug therapy', 'Benzodiazepines/*therapeutic use/*urine', 'Chromatography, High Pressure Liquid/methods', 'Diazepam/therapeutic use/urine', 'Humans', 'Narcotics', 'Nitrazepam/therapeutic use/urine', 'Nordazepam/therapeutic use/urine', 'Substance-Related Disorders/drug therapy/*epidemiology', 'Temazepam/therapeutic use/urine']",https://pubmed.ncbi.nlm.nih.gov/9022890/
1702,nitrazepam,19450355,Insomnia in the elderly.,"['Montgomery P', 'Lilly J']","['Aged', 'Cognitive Behavioral Therapy', 'Flurazepam/pharmacology', 'Humans', 'Risk Factors', '*Sleep/drug effects', '*Sleep Initiation and Maintenance Disorders', 'Temazepam']",https://pubmed.ncbi.nlm.nih.gov/19450355/
1703,nitrazepam,1349894,An investigation of the association of benzodiazepines and other hypnotics with the incidence of falls in the elderly.,"['Trewin VF', 'Lawrence CJ', 'Veitch GB']","['*Accidental Falls', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Benzodiazepines', 'Female', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Incidence', 'Male', 'Risk Factors', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/1349894/
1704,nitrazepam,5071698,Factors leading to dependence on hypnotic drugs.,['Clift AD'],"['Amobarbital/*adverse effects', 'Benzazepines/*adverse effects', 'Diazepam/adverse effects', 'Family Practice', 'Female', 'Glutethimide/adverse effects', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Male', 'Nitrazepam/adverse effects', 'Personality Disorders/complications', 'Sleep Initiation and Maintenance Disorders/drug therapy/etiology', 'Substance-Related Disorders/complications/*etiology']",https://pubmed.ncbi.nlm.nih.gov/5071698/
1705,nitrazepam,6669627,Effects of hypnotics on memory.,"['Fossen A', 'Godlibsen OB', 'Loyning Y', 'Dreyfus JF']","['Adult', 'Azabicyclo Compounds', 'Female', 'Flunitrazepam/pharmacology', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Memory/*drug effects', 'Neuropsychological Tests', 'Piperazines/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6669627/
1706,nitroglycerin,3120566,Nitrate tolerance.,['Parker JO'],"['Dosage Forms', 'Drug Tolerance', 'Hemodynamics/drug effects', 'Humans', 'Isosorbide Dinitrate/administration & dosage/pharmacology/*therapeutic use', 'Nitroglycerin/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3120566/
1707,nitroglycerin,19267787,Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update.,"['Tfelt-Hansen PC', 'Tfelt-Hansen J']","['Headache Disorders, Primary/*chemically induced/*history', 'History, 19th Century', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Nitroglycerin/*adverse effects', 'Vasodilator Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19267787/
1708,nitroglycerin,4207612,Instability of nitroglycerin tablets.,['Mayer GA'],"['Angina Pectoris/drug therapy', '*Drug Stability', 'Headache/chemically induced', 'Humans', 'Middle Aged', 'Nitroglycerin/*administration & dosage/adverse effects/therapeutic use', 'Refrigeration', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/4207612/
1709,nitroglycerin,18658016,Recent advances in the pharmacotherapy of chronic anal fissure: an update.,"['Medhi B', 'Rao RS', 'Prakash A', 'Prakash O', 'Kaman L', 'Pandhi P']","['Administration, Topical', 'Adrenergic alpha-Antagonists/administration & dosage', 'Anal Canal', 'Botulinum Toxins/*administration & dosage', 'Calcium Channel Blockers/administration & dosage', 'Chronic Disease/*drug therapy', 'Clinical Trials as Topic', 'Diltiazem/administration & dosage', 'Fissure in Ano/*drug therapy', 'Headache/chemically induced', 'Humans', 'Indoramin/administration & dosage', 'Injections, Intralesional', 'Lidocaine/administration & dosage', 'Nifedipine/administration & dosage', 'Nitroglycerin/*administration & dosage/adverse effects', 'Ointments']",https://pubmed.ncbi.nlm.nih.gov/18658016/
1710,nitroglycerin,11723312,Progress in the understanding and treatment of chronic anal fissure.,"['McCallion K', 'Gardiner KR']","['Administration, Topical', 'Anal Canal/drug effects/surgery', 'Botulinum Toxins/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Chronic Disease', 'Dilatation/methods', 'Fissure in Ano/etiology/*therapy', 'Humans', 'Nitric Oxide Donors/therapeutic use', 'Nitroglycerin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/11723312/
1711,nitroglycerin,121456,Glyceryl trinitrate ointment in angina pectoris.,"['Salem HH', 'Singh SP']","['Adult', 'Angina Pectoris/*drug therapy', 'Clinical Trials as Topic', 'Exercise Test', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nitroglycerin/administration & dosage/*therapeutic use', 'Ointments', 'Placebos', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/121456/
1712,nitroglycerin,21212965,A literature review on the role of chemical sphincterotomy after Milligan-Morgan hemorrhoidectomy.,"['Siddiqui MR', 'Abraham-Igwe C', 'Shangumanandan A', 'Grassi V', 'Swift I', 'Abulafi AM']","['Anal Canal/drug effects/*surgery', 'Analgesia', 'Botulinum Toxins/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacology/therapeutic use', 'Digestive System Surgical Procedures/adverse effects/*methods', 'Health Planning Guidelines', 'Hemorrhoids/drug therapy/*surgery', 'Humans', 'Nitroglycerin/pharmacology/therapeutic use', 'Pain Measurement', 'Postoperative Complications/etiology', 'Randomized Controlled Trials as Topic', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21212965/
1713,nitroglycerin,3137070,Pharmacokinetics of organic nitrates in man: an overview.,['Bogaert MG'],"['Absorption', 'Administration, Cutaneous', 'Administration, Sublingual', 'Humans', 'Injections, Intravenous', 'Isosorbide Dinitrate/administration & dosage/analogs & derivatives/blood/*pharmacokinetics', 'Nitroglycerin/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3137070/
1714,nitroglycerin,8154634,Contact dermatitis from nitroglycerin.,"['de la Fuente Prieto R', 'Armentia Medina A', 'Diez Perez JM']","['Administration, Topical', 'Aged', 'Angina Pectoris/drug therapy', 'Dermatitis, Allergic Contact/*etiology', 'Humans', 'Male', 'Middle Aged', 'Nitroglycerin/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8154634/
1715,nitroglycerin,27213950,RNA Sequencing of Trigeminal Ganglia in Rattus Norvegicus after Glyceryl Trinitrate Infusion with Relevance to Migraine.,"['Hougaard Pedersen S', 'Maretty L', 'Ramachandran R', 'Sibbesen JA', 'Yakimov V', 'Elgaard-Christensen R', 'Hansen TF', 'Krogh A', 'Olesen J', 'Jansen-Olesen I']","['Animals', 'Disease Models, Animal', 'Gene Expression Profiling', 'Gene Expression Regulation/drug effects', 'Infusions, Intraventricular', 'Male', 'Migraine Disorders/*chemically induced/*genetics/metabolism', 'Nitroglycerin/administration & dosage/*adverse effects', 'Rats', 'Rats, Sprague-Dawley', 'Sequence Analysis, RNA', 'Trigeminal Ganglion/*drug effects/*metabolism', 'Vasodilator Agents/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27213950/
1716,nitroglycerin,3113911,Treatment of acute anginal attacks with nitrates.,['Nyberg G'],"['Administration, Oral', 'Angina Pectoris/*drug therapy', 'Humans', 'Nitrates/*therapeutic use', 'Nitroglycerin/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3113911/
1717,nitroglycerin,26027641,Use of nitrates in ischemic heart disease.,"['Giuseppe C', 'Paul J', 'Hans-Ulrich I']","['Angina Pectoris/drug therapy', 'Coronary Artery Disease/chemically induced/drug therapy', 'Delayed-Action Preparations', 'Drug Tolerance', 'Humans', 'Myocardial Ischemia/*drug therapy', 'Nitrates/administration & dosage/adverse effects/*therapeutic use', 'Nitroglycerin']",https://pubmed.ncbi.nlm.nih.gov/26027641/
1718,nitroglycerin,3129802,Nitroglycerine-induced volume loading.,"['Bunt TJ', 'Manczuk M', 'Varley KV']","['Aorta, Abdominal', 'Aortic Aneurysm/*surgery', 'Coronary Disease/complications', 'Drug Evaluation', 'Heart Ventricles/physiopathology', 'Hemodynamics/drug effects', 'Humans', 'Intraoperative Care', 'Intraoperative Complications/*prevention & control', 'Myocardial Infarction/*prevention & control', 'Nitroglycerin/*administration & dosage/pharmacology/therapeutic use', '*Premedication', 'Risk', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/3129802/
1719,nitroglycerin,10584234,[Pharmacological profiles of sildenafil (VIAGRA) in the treatment of erectile dysfunction: efficacy and drug interaction with nitrate].,['Omote M'],"['Animals', 'Blood Pressure/drug effects', 'Cyclic GMP/metabolism', 'Dogs', 'Drug Interactions', 'Erectile Dysfunction/*drug therapy', 'Humans', 'Male', 'Nitric Oxide/metabolism/physiology', 'Nitric Oxide Donors/pharmacology', 'Nitroglycerin/*pharmacology', 'Penile Erection/drug effects', 'Penis/metabolism', 'Phosphodiesterase Inhibitors/*pharmacology/therapeutic use', 'Piperazines/*pharmacology/therapeutic use', 'Purines', 'Rabbits', 'Sildenafil Citrate', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/10584234/
1720,nitroglycerin,10696937,Cut or paste? The use of glyceryl trinitrate paste in the treatment of acute and chronic anal fissure.,"['Ward DI', 'Miller BJ', 'Schache DJ', 'Cohen JR', 'Theile DE']","['Acute Disease', 'Chronic Disease', 'Combined Modality Therapy', 'Fissure in Ano/*drug therapy/surgery', 'Humans', 'Nitroglycerin/*administration & dosage', 'Ointments', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/10696937/
1721,nitroglycerin,1576038,Nitrates.,['Kuhn M'],"['Cardiovascular Diseases/*drug therapy', 'Coronary Disease/drug therapy/nursing', 'Drug Interactions', 'Hemodynamics/drug effects', 'Humans', 'Isosorbide Dinitrate/therapeutic use', 'Nitrates/adverse effects/pharmacology/*therapeutic use', 'Nitroglycerin/administration & dosage/therapeutic use', 'Patient Education as Topic']",https://pubmed.ncbi.nlm.nih.gov/1576038/
1722,nitroglycerin,10524660,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,"['Christiansen I', 'Thomsen LL', 'Daugaard D', 'Ulrich V', 'Olesen J']","['Adult', 'Analgesics/therapeutic use', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Migraine with Aura/*complications/metabolism', 'Migraine without Aura/*chemically induced/complications/drug therapy/metabolism', 'Nitric Oxide/*physiology', 'Nitroglycerin/*adverse effects', 'Pain Measurement', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/10524660/
1723,nitroglycerin,28598453,Effectiveness of 0.2% Glyceryl Trinitrate and 0.5% Nifedipine in the Treatment of Chronic Anal Fissure.,"['Shrestha SK', 'Thapa PB', 'Maharjan DK', 'Tamang TY']","['Drug Therapy, Combination', 'Female', 'Fissure in Ano/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/*therapeutic use', 'Nitroglycerin/*therapeutic use', 'Prospective Studies', 'Treatment Outcome', 'Vasodilator Agents/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28598453/
1724,nitroglycerin,17443133,Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin.,"['Benson C', 'Seger M', 'Voelker J']","['Administration, Oral', 'Adrenergic beta-Antagonists/therapeutic use', 'Aged', 'Angina Pectoris/drug therapy/physiopathology', 'Blood Pressure/*drug effects', 'Chronic Disease', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Interactions', 'Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypotension, Orthostatic/chemically induced', 'Indoles/administration & dosage/adverse effects/*pharmacology', 'Infusions, Intravenous', 'Male', 'Maleimides/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Nitroglycerin/administration & dosage/adverse effects/*pharmacology', 'Protein Kinase C/*antagonists & inhibitors', 'Protein Kinase C beta', 'Treatment Outcome', 'Vasodilator Agents/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17443133/
1725,nitroglycerin,32778123,Efficacy of Glyceryl trinitrate (GTN) to facilitate the rewarming process during cardiopulmonary bypass.,"['Mullane D', 'Lenihan M', 'Hanley C', 'Wall T', 'Bukowska I', 'Griffin M', 'Flood G']","['Aged', 'Body Temperature/drug effects', 'Cardiopulmonary Bypass/adverse effects/*methods', 'Humans', 'Hypothermia, Induced/methods', 'Infusions, Intravenous', 'Lactic Acid/blood', 'Middle Aged', 'Nitroglycerin/*administration & dosage', 'Prospective Studies', '*Rewarming', 'Time Factors', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/32778123/
1726,norfloxacin,31584459,Small Intestinal Bacterial Overgrowth: Clinical Features and Therapeutic Management.,"['Rao SSC', 'Bhagatwala J']","['Age Factors', 'Anti-Bacterial Agents/*therapeutic use', 'Bacteria/drug effects/isolation & purification', 'Blind Loop Syndrome/*diagnosis/epidemiology/etiology/therapy', 'Breath Tests', 'Clinical Trials as Topic', 'Colectomy/adverse effects', 'Female', 'Food, Formulated', 'Gastrointestinal Microbiome/*drug effects', 'Humans', 'Intestinal Mucosa/drug effects/*microbiology', 'Intestine, Small/drug effects/*microbiology', 'Male', 'Metronidazole/therapeutic use', 'Microbiological Techniques', 'Norfloxacin/therapeutic use', 'Prevalence', 'Probiotics/administration & dosage', 'Proton Pump Inhibitors/adverse effects', 'Rifaximin/therapeutic use', 'Risk Factors', 'Sex Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31584459/
1727,norfloxacin,8386356,Overview of the fluoroquinolone antibiotics.,['Just PM'],"['*Anti-Infective Agents/adverse effects/pharmacology', 'Bacterial Infections/drug therapy', 'Ciprofloxacin/pharmacology', 'Drug Interactions', 'Drug Resistance, Microbial', 'Enoxacin/pharmacology', '*Fluoroquinolones', 'Gram-Negative Aerobic Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Humans', 'Norfloxacin/pharmacology', 'Ofloxacin/pharmacology', 'Quinolones/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8386356/
1728,norfloxacin,7922402,Quinolone therapy in intensive care unit settings.,['Beam TR Jr'],"['Administration, Oral', 'Aged', 'Ciprofloxacin/pharmacokinetics/supply & distribution/*therapeutic use', 'Clinical Protocols', 'Clinical Trials as Topic', 'Cross Infection/*drug therapy/microbiology', 'Drug Interactions', 'Drug Resistance, Microbial', 'Gram-Negative Bacterial Infections/*drug therapy/microbiology', 'Humans', 'Infusions, Intravenous', '*Intensive Care Units', 'Male', 'Microbial Sensitivity Tests', 'Norfloxacin/pharmacokinetics/supply & distribution/*therapeutic use', 'Ofloxacin/pharmacokinetics/supply & distribution/*therapeutic use', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/7922402/
1729,norfloxacin,3312850,Symposium on antimicrobial agents. The quinolones.,"['Walker RC', 'Wright AJ']","['Adolescent', 'Adult', '*Anti-Bacterial Agents', 'Bacterial Infections/drug therapy', 'Ciprofloxacin/adverse effects/pharmacology', 'Drug Resistance, Microbial', 'Enoxacin', 'Female', 'Humans', 'Nalidixic Acid/adverse effects', 'Naphthyridines/adverse effects/pharmacology', 'Norfloxacin/adverse effects/pharmacology', 'Ofloxacin', '*Oxazines/adverse effects/pharmacology', '*Quinolines']",https://pubmed.ncbi.nlm.nih.gov/3312850/
1730,norfloxacin,2124212,Quinolone pharmacokinetics and metabolism.,"['Lode H', 'Hoffken G', 'Boeckk M', 'Deppermann N', 'Borner K', 'Koeppe P']","['Administration, Oral', 'Anti-Infective Agents/administration & dosage/*pharmacokinetics', 'Biological Availability', 'Biotransformation', 'Ciprofloxacin/administration & dosage/analogs & derivatives/pharmacokinetics', 'Enoxacin/administration & dosage/pharmacokinetics', 'Fleroxacin', 'Half-Life', 'Humans', 'Metabolic Clearance Rate', 'Norfloxacin/administration & dosage/pharmacokinetics', 'Ofloxacin/administration & dosage/pharmacokinetics', 'Pefloxacin/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2124212/
1731,norfloxacin,1919653,Otitis externa malignum.,['Sabbour MS'],"['Aged', 'Aged, 80 and over', 'Anti-Infective Agents/therapeutic use', 'Diabetes Complications', 'Female', 'Humans', 'Male', 'Norfloxacin/*therapeutic use', 'Otitis Externa/*drug therapy/microbiology', 'Pseudomonas Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1919653/
1732,norfloxacin,12052667,Clinical toxicological aspects of fluoroquinolones.,['Stahlmann R'],"['Anti-Infective Agents/*adverse effects/therapeutic use', 'Bacterial Infections/*drug therapy', 'Cardiovascular Diseases/chemically induced', 'Central Nervous System Diseases/chemically induced', 'Ciprofloxacin/adverse effects/therapeutic use', 'Connective Tissue Diseases/chemically induced', 'Diarrhea/chemically induced', 'Dizziness/chemically induced', 'Gastrointestinal Diseases/*chemically induced', 'Headache/chemically induced', 'Humans', 'Nausea/chemically induced', 'Norfloxacin/adverse effects/therapeutic use', 'Ofloxacin/adverse effects/therapeutic use', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12052667/
1733,norfloxacin,3283041,A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.,"['Edlund C', 'Nord CE']","['Ciprofloxacin/pharmacology', 'Enoxacin', 'Humans', 'Intestines/drug effects/*microbiology', 'Naphthyridines/pharmacology', 'Norfloxacin/analogs & derivatives/pharmacology', 'Ofloxacin', 'Oropharynx/drug effects/*microbiology', 'Oxazines/pharmacology', 'Pefloxacin', 'Quinolines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3283041/
1734,norfloxacin,2191864,Review of norfloxacin in lower urinary tract infections.,"['Miano L', 'Goldoni S', 'Tubaro A', 'Paradiso Galatioto G', 'Gandolfi P']","['Clinical Trials as Topic', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Norfloxacin/administration & dosage/adverse effects/*therapeutic use', 'Urinary Tract Infections/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/2191864/
1735,norfloxacin,3056259,"Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection.","['Sheehan GJ', 'Harding GK', 'Haase DA', 'Thomson MJ', 'Urias B', 'Kennedy JK', 'Hoban DJ', 'Ronald AR']","['Bacteriuria/drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Norfloxacin/administration & dosage/adverse effects/*therapeutic use', 'Prospective Studies', 'Random Allocation', 'Urinary Tract Infections/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3056259/
1736,norfloxacin,30969469,The Natural Product Elegaphenone Potentiates Antibiotic Effects against Pseudomonas aeruginosa.,"['Zhao W', 'Cross AR', 'Crowe-McAuliffe C', 'Weigert-Munoz A', 'Csatary EE', 'Solinski AE', 'Krysiak J', 'Goldberg JB', 'Wilson DN', 'Medina E', 'Wuest WM', 'Sieber SA']","['Anti-Bacterial Agents/chemical synthesis/chemistry/*pharmacology', 'Benzophenones/chemical synthesis/chemistry/*pharmacology', 'Biological Products/chemical synthesis/chemistry/*pharmacology', 'Cells, Cultured', 'Dose-Response Relationship, Drug', 'Humans', 'Macrophages/drug effects/microbiology', 'Microbial Sensitivity Tests', 'Molecular Structure', 'Norfloxacin/antagonists & inhibitors/chemistry/pharmacology', 'Pseudomonas aeruginosa/cytology/*drug effects', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/30969469/
1737,norfloxacin,3553053,Review of the 4-quinolones.,"['Eggleston M', 'Park SY']","['Anti-Bacterial Agents/metabolism/*pharmacology/therapeutic use', 'Bacteria/*drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/metabolism/pharmacology/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Enoxacin', 'Humans', 'Kinetics', 'Naphthyridines/metabolism/pharmacology/therapeutic use', 'Norfloxacin/metabolism/pharmacology/therapeutic use', 'Ofloxacin', 'Oxazines/metabolism/pharmacology/therapeutic use', 'Quinolines/metabolism/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3553053/
1738,norfloxacin,1805646,The fluoroquinolones.,"['Brody T', 'Pensak ML']","['Bacterial Infections/*drug therapy', 'Ciprofloxacin/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Norfloxacin/administration & dosage/pharmacology/*therapeutic use', 'Otitis Externa/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/1805646/
1739,norfloxacin,2760258,Effect of quinolone antimicrobials on theophylline pharmacokinetics.,"['Prince RA', 'Casabar E', 'Adair CG', 'Wexler DB', 'Lettieri J', 'Kasik JE']","['Adult', 'Ciprofloxacin/blood/*pharmacology', 'Half-Life', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Nalidixic Acid/blood/*pharmacology', 'Norfloxacin/blood/*pharmacology', 'Random Allocation', 'Theophylline/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2760258/
1740,norfloxacin,2225261,[Intraocular penetration of topical norfloxacin in humans. Preliminary study].,"['Bron A', 'Pechinot M', 'Chirpaz L', 'Razakarivony H', 'Kamcierkzak A', 'Adenis JP']","['Aged', 'Aged, 80 and over', 'Cataract Extraction', 'Clinical Trials as Topic', 'Female', 'Humans', 'Male', 'Middle Aged', 'Norfloxacin/administration & dosage/*pharmacokinetics', 'Ophthalmic Solutions']",https://pubmed.ncbi.nlm.nih.gov/2225261/
1741,norfloxacin,1488882,"Gentamicin, norfloxacin and lysozyme concentration in human tears: in vivo and in vitro study.","['Bron AM', 'Bonnin C', 'Garcher C', 'Lallemand A']","['Adolescent', 'Adult', 'Cornea/drug effects', 'Gentamicins/*pharmacology', 'Humans', 'In Vitro Techniques', 'Male', 'Muramidase/drug effects/*metabolism', 'Norfloxacin/*pharmacology', 'Ophthalmic Solutions', 'Tears/drug effects/*enzymology']",https://pubmed.ncbi.nlm.nih.gov/1488882/
1742,norfloxacin,9406312,Allergic nephropathy associated with norfloxacin and ciprofloxacin therapy. Report of two cases and review of the literature.,"['Hadimeri H', 'Almroth G', 'Cederbrant K', 'Enestrom S', 'Hultman P', 'Lindell A']","['Aged', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Biopsy', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Drug Hypersensitivity/diagnosis/epidemiology/*etiology', 'Female', 'Humans', 'Kidney/pathology', 'Nephritis, Interstitial/*chemically induced/diagnosis/epidemiology', 'Norfloxacin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9406312/
1743,norfloxacin,3286512,Pharmacokinetics of ciprofloxacin.,"['Bergan T', 'Dalhoff A', 'Rohwedder R']","['Anti-Infective Agents/pharmacokinetics', 'Biological Availability', 'Ciprofloxacin/*pharmacokinetics', 'Humans', 'Norfloxacin/pharmacokinetics', 'Ofloxacin', 'Oxazines/pharmacokinetics', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/3286512/
1744,norfloxacin,2404442,Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus.,"['Majima Y', 'Hirata K', 'Takeuchi K', 'Hattori M', 'Sakakura Y']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Carbocysteine/administration & dosage/pharmacology', 'Chronic Disease', 'Elasticity/drug effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Mucus/*drug effects/physiology', 'Nasal Mucosa/*metabolism', 'Norfloxacin/administration & dosage/pharmacology', 'Peptide Hydrolases/administration & dosage/pharmacology', 'Rheology', 'Sinusitis/physiopathology', 'Viscosity']",https://pubmed.ncbi.nlm.nih.gov/2404442/
1745,omeprazole,35787720,An update on drug-drug interactions associated with proton pump inhibitors.,"['Ben Ghezala I', 'Luu M', 'Bardou M']","['2-Pyridinylmethylsulfinylbenzimidazoles/pharmacology', 'Drug Interactions', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Esomeprazole/pharmacology', 'Humans', '*Omeprazole/pharmacokinetics', 'Prospective Studies', '*Proton Pump Inhibitors/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/35787720/
1746,omeprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
1747,omeprazole,38594198,Severe DRESS with myocarditis secondary to naproxen/esomeprazole.,"[""O'Mahony S"", 'Tobin AM', 'Donnelly TM']","['Humans', 'Male', '*Drug Hypersensitivity Syndrome/diagnosis', '*Eosinophilia/complications', 'Esomeprazole/adverse effects', '*Myocarditis/complications', 'Naproxen/adverse effects', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/38594198/
1748,omeprazole,26329348,Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.,"['Qi Q', 'Wang R', 'Liu L', 'Zhao F', 'Wang S']","['Esomeprazole/adverse effects/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Omeprazole/adverse effects/*therapeutic use', 'Proton Pump Inhibitors/*therapeutic use', 'Publication Bias']",https://pubmed.ncbi.nlm.nih.gov/26329348/
1749,omeprazole,22372726,Acetylsalicylic acid/esomeprazole fixed-dose combination.,"['Burness CB', 'Scott LJ']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Aspirin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Capsules', 'Cardiovascular Diseases/prevention & control', 'Drug Combinations', 'Esomeprazole/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Humans', 'Peptic Ulcer/prevention & control', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Prodrugs/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22372726/
1750,omeprazole,16520709,Intravenous proton pump inhibitors.,['Baker DE'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/*administration & dosage/pharmacokinetics', 'Benzimidazoles/*administration & dosage/pharmacokinetics', 'Biological Availability', 'Drug Interactions', 'Esomeprazole/*administration & dosage/*analogs & derivatives/pharmacokinetics', 'Humans', 'Hydrogen-Ion Concentration', 'Injections, Intravenous', 'Lansoprazole', 'Pantoprazole', '*Proton Pump Inhibitors', 'Stomach/chemistry', 'Sulfoxides/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16520709/
1751,omeprazole,20739778,Esomeprazole-induced photoallergic dermatitis.,"['Shukla A', 'Mahapatra A', 'Gogtay N', 'Khopkar U']","['Anti-Ulcer Agents/*adverse effects', 'Dermatitis, Photoallergic/*etiology', 'Esomeprazole/*adverse effects', 'Female', 'Heartburn/diagnosis/*drug therapy', 'Humans', 'Middle Aged', 'Ranitidine/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20739778/
1752,omeprazole,17472543,Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.,"['Morgner A', 'Miehlke S', 'Labenz J']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Anti-Ulcer Agents/adverse effects/*therapeutic use', 'Dyspepsia/drug therapy', 'Esomeprazole/adverse effects/*therapeutic use', 'Humans', '*Proton Pump Inhibitors', 'Stomach Ulcer/chemically induced/*drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/17472543/
1753,omeprazole,19210109,Esomeprazole: a proton pump inhibitor.,"['Vachhani R', 'Olds G', 'Velanovich V']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Drug Costs', 'Esomeprazole/adverse effects/economics/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Helicobacter Infections/drug therapy', 'Humans', 'Proton Pump Inhibitors/adverse effects/economics/*therapeutic use', 'Stomach Ulcer/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19210109/
1754,omeprazole,32935346,"Pharmacologic treatment of GERD: Where we are now, and where are we going?","['Scarpignato C', 'Hongo M', 'Wu JCY', 'Lottrup C', 'Lazarescu A', 'Stein E', 'Hunt RH']","['Cimetidine/therapeutic use', 'Esomeprazole/therapeutic use', 'Esophageal Mucosa/*pathology', 'Gastroesophageal Reflux/diagnosis/*drug therapy', 'Humans', 'Lansoprazole/therapeutic use', 'Omeprazole/therapeutic use', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/therapeutic use', 'Sulfonamides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32935346/
1755,omeprazole,10983736,Esomeprazole.,"['Spencer CM', 'Faulds D']","['Animals', 'Anti-Ulcer Agents/*therapeutic use', 'Clinical Trials as Topic', 'Duodenal Ulcer/drug therapy', 'Enzyme Inhibitors/*therapeutic use', 'Esomeprazole', 'Gastroesophageal Reflux/drug therapy', 'Helicobacter pylori/drug effects', 'Humans', 'Omeprazole/pharmacokinetics/pharmacology/*therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10983736/
1756,omeprazole,16335854,"What is potent acid inhibition, and how can it be achieved?","['Calvet X', 'Gomollon F']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/*administration & dosage', 'Benzimidazoles/administration & dosage', 'Clinical Trials as Topic', 'Esomeprazole', 'Gastric Acid/*metabolism', 'Humans', 'Lansoprazole', 'Omeprazole/administration & dosage/analogs & derivatives', 'Pantoprazole', 'Peptic Ulcer/*drug therapy', '*Proton Pump Inhibitors', 'Rabeprazole', 'Sulfoxides/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/16335854/
1757,omeprazole,39023173,Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.,"['Ivashkin V', 'Maev I', 'Poluektova E', 'Sinitsa A', 'Avalueva E', 'Mnatsakanyan M', 'Simanenkov V', 'Karpeeva J', 'Kopylova D', 'Kuprina I', 'Kucheryavyy Y', 'Lapina T', 'Solovyeva O', 'Soom M', 'Cheremushkina N', 'Maevskaya E', 'Maslennikov R']","['Humans', 'Double-Blind Method', '*Limosilactobacillus reuteri', '*Dyspepsia/microbiology/diagnosis/drug therapy/therapy', 'Male', 'Female', '*Helicobacter Infections/drug therapy/diagnosis/therapy/microbiology', 'Adult', '*Helicobacter pylori/isolation & purification', '*Probiotics/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', '*Amoxicillin/administration & dosage/adverse effects/therapeutic use', '*Clarithromycin/administration & dosage/therapeutic use/adverse effects', '*Drug Therapy, Combination', 'Treatment Outcome', '*Anti-Bacterial Agents/adverse effects/administration & dosage/therapeutic use', '*Quality of Life', 'Esomeprazole/administration & dosage/adverse effects/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/39023173/
1758,omeprazole,26661629,Esomeprazole induced galactorrhea: a novel side effect.,"['Pipaliya N', 'Solanke D', 'Rathi C', 'Patel R', 'Ingle M', 'Sawant P']","['Adult', 'Amenorrhea/*chemically induced', 'Esomeprazole/*adverse effects/therapeutic use', 'Female', 'Galactorrhea/*chemically induced', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Proton Pump Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26661629/
1759,omeprazole,36657136,Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.,"['Abdo-Francis JM', 'Cabrera-Alvarez G', 'Martinez-Torres H', 'Remes-Troche JM']","['Humans', '*Esomeprazole/adverse effects', 'Rabeprazole/therapeutic use', 'Prospective Studies', 'Treatment Outcome', '*Gastroesophageal Reflux/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36657136/
1760,omeprazole,29186640,[Esomeprazol-induced cutaneous lupus erythematosus].,"['Gliem N', 'Broekaert SMC', 'Seitz CS', 'Schon MP', 'Ellenrieder V']","['Aged', 'Biopsy', 'Esomeprazole/*adverse effects/therapeutic use', 'Female', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Lupus Erythematosus, Cutaneous/*chemically induced/pathology', 'Proton Pump Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29186640/
1761,omeprazole,39097924,"Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.","['Ding YM', 'Zhang QM', 'Li RL', 'Han ZX', 'Zhao Q', 'Xu LD', 'Wang KY', 'Nan XP', 'Duan M', 'Zeng SY', 'Kong QZ', 'Wang H', 'Wu XQ', 'Zhang N', 'Li YQ', 'Zuo XL', 'Li YY']","['Humans', '*Helicobacter Infections/drug therapy', '*Tetracycline/therapeutic use/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Female', '*Bismuth/therapeutic use/adverse effects', '*Anti-Bacterial Agents/therapeutic use/administration & dosage/adverse effects', 'Adult', '*Drug Therapy, Combination', '*Helicobacter pylori/drug effects', 'Treatment Outcome', 'China', 'Amoxicillin/therapeutic use/administration & dosage', 'Drug Administration Schedule', 'Esomeprazole/therapeutic use/administration & dosage', 'Aged', 'Young Adult', 'Breath Tests', 'Proton Pump Inhibitors/therapeutic use/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39097924/
1762,omeprazole,25019289,Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.,"['Goirand F', 'Le Ray I', 'Bardou M']","['Esomeprazole/adverse effects/*pharmacokinetics/therapeutic use', 'Esophagitis/drug therapy/pathology', 'Gastroesophageal Reflux/*drug therapy/epidemiology', 'Humans', 'Incidence', 'Proton Pump Inhibitors/adverse effects/*pharmacokinetics/therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/25019289/
1763,omeprazole,22122397,Hypomagnesaemia/hypokalemia associated with the use of esomeprazole.,"['Negri AL', 'Valle EE']","['Anti-Ulcer Agents/adverse effects/therapeutic use', 'Esomeprazole/*adverse effects/therapeutic use', 'Humans', 'Hypokalemia/*chemically induced', 'Magnesium/*blood/metabolism', 'Magnesium Deficiency/chemically induced', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/22122397/
1764,omeprazole,12120118,Esomeprazole magnesium (Nexium).,['Baker DE'],"['Anti-Ulcer Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Esomeprazole', 'Esophagitis/drug therapy', 'Gastroesophageal Reflux/drug therapy', 'Helicobacter Infections/drug therapy', 'Humans', 'Omeprazole/analogs & derivatives/pharmacokinetics/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12120118/
1765,oxaprozin,1603605,Oxaprozin: a new NSAID.,"['al-Faks MA', 'Pugh MC']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Double-Blind Method', 'Half-Life', 'Humans', 'Osteoarthritis/*drug therapy', 'Oxaprozin', 'Propionates/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/1603605/
1766,oxaprozin,38959933,A rare case of meloxicam-induced pseudoporphyria.,"['Benandi K', 'Sieving D', 'Wolf K']","['Humans', '*Meloxicam/adverse effects', 'Female', 'Middle Aged', '*Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Thiazoles/adverse effects', 'Porphyrias/chemically induced', 'Foot Dermatoses/chemically induced/pathology', 'Thiazines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38959933/
1767,oxaprozin,9831331,Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration.,['Kawai S'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Arthritis, Rheumatoid/drug therapy/enzymology', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Isoenzymes/metabolism', 'Membrane Proteins', 'Prostaglandin-Endoperoxide Synthases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/9831331/
1768,oxaprozin,9884815,Clinical pharmacokinetics of oxaprozin.,['Davies NM'],"['Age Factors', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Heart Failure/*metabolism', 'Humans', 'Kidney Diseases/metabolism', 'Liver Diseases/metabolism', 'Oxaprozin', 'Propionates/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9884815/
1769,oxaprozin,15934904,A review of the emerging profile of the anti-inflammatory drug oxaprozin.,"['Dallegri F', 'Bertolotto M', 'Ottonello L']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/chemistry/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/metabolism', 'Drug Industry/*trends', 'Humans', 'Oxaprozin', 'Propionates/chemistry/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15934904/
1770,oxaprozin,24075938,Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets.,"['Saxena A', 'Balaramnavar VM', 'Hohlfeld T', 'Saxena AK']","['Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology', 'Aspirin/*pharmacology', 'Blood Platelets/*drug effects/physiology', 'Catalytic Domain', 'Cyclooxygenase 1/chemistry/metabolism', 'Drug Interactions', 'Humans', 'Molecular Docking Simulation', 'Platelet Aggregation Inhibitors/*pharmacology', 'Platelet Function Tests']",https://pubmed.ncbi.nlm.nih.gov/24075938/
1771,oxaprozin,3220091,Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.,"['Scavone JM', 'Ochs HR', 'Greenblatt DJ', 'Matlis R']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics', 'Drug Interactions', 'Estrogens/*adverse effects', 'Female', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Oxaprozin', 'Propionates/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3220091/
1772,oxaprozin,6340971,Oxaprozin and sulindac in rheumatoid arthritis: a double-blind comparative trial.,"['Zuccollo R', 'Mackinnon MJ', 'Fraser KM', 'Hall SM', 'Palmer DG']","['Adult', 'Aged', 'Anti-Inflammatory Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Humans', 'Indenes/*therapeutic use', 'Male', 'Middle Aged', 'Oxaprozin', 'Propionates/adverse effects/*therapeutic use', 'Sulindac/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6340971/
1773,oxaprozin,1617910,Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug.,['Miller LG'],"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacokinetics/*therapeutic use', 'Drug Interactions', 'Humans', 'Oxaprozin', 'Propionates/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1617910/
1774,oxaprozin,3536423,"Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.","['Todd PA', 'Brogden RN']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/metabolism/pharmacology/*therapeutic use', 'Biological Availability', 'Drug Interactions', 'Humans', 'Joint Diseases/*drug therapy', 'Kinetics', 'Oxaprozin', 'Propionates/adverse effects/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3536423/
1775,oxaprozin,39081058,Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism.,"['Willems S', 'Busch R', 'Nawa F', 'Ballarotto M', 'Lillich FF', 'Kasch T', 'Lopez-Garcia U', 'Marschner JA', 'Ruger LA', 'Renelt B', 'Ohrndorf J', 'Arifi S', 'Zaienne D', 'Proschak E', 'Pabel J', 'Merk D']","['*Nuclear Receptor Subfamily 4, Group A, Member 2/agonists/metabolism/chemistry', 'Structure-Activity Relationship', 'Humans', 'Animals', 'Molecular Structure', 'Drug Inverse Agonism']",https://pubmed.ncbi.nlm.nih.gov/39081058/
1776,oxaprozin,8154406,A review of selected newer nonsteroidal anti-inflammatory drugs.,"['Cummings DM', 'Amadio P Jr']","['*Anti-Inflammatory Agents, Non-Steroidal/classification/economics/pharmacology/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', '*Butanones/economics/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Drug Costs', '*Etodolac/economics/pharmacology/therapeutic use', 'Gastrointestinal Diseases/chemically induced/epidemiology', 'Humans', 'Incidence', 'Ketorolac', 'Nabumetone', 'Osteoarthritis/drug therapy', 'Oxaprozin', '*Propionates/economics/pharmacology/therapeutic use', 'Tolmetin/*analogs & derivatives/economics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8154406/
1777,oxaprozin,3365912,Hepatic safety of two analgesics used over the counter: ibuprofen and aspirin.,"['Freeland GR', 'Northington RS', 'Hedrich DA', 'Walker BR']","['Alanine Transaminase/blood', 'Aspirin/*adverse effects', 'Humans', 'Ibuprofen/*adverse effects', 'Liver/*drug effects', 'Oxaprozin', 'Propionates/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3365912/
1778,oxaprozin,36356292,Two Binding Sites of SARS-CoV-2 Macrodomain 3 Probed by Oxaprozin and Meclomen.,"['Li J', 'Zhong F', 'Li M', 'Liu Y', 'Wang L', 'Liu M', 'Li F', 'Zhang J', 'Wu J', 'Shi Y', 'Zhang Z', 'Tu X', 'Ruan K', 'Gao J']","['Humans', 'Binding Sites', 'Meclofenamic Acid', 'Oxaprozin', '*SARS-CoV-2', 'Viral Nonstructural Proteins/metabolism', '*Coronavirus Papain-Like Proteases/chemistry', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/36356292/
1779,oxaprozin,15324530,Oxaprozin: kinetic and dynamic profile in the treatment of pain.,['Kean WF'],"['Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics/therapeutic use', 'Antirheumatic Agents/pharmacokinetics/therapeutic use', 'Diclofenac/*pharmacokinetics/therapeutic use', 'Humans', 'Oxaprozin', 'Periarthritis/complications/*drug therapy', 'Propionates/*pharmacokinetics/therapeutic use', 'Shoulder Joint', 'Shoulder Pain/drug therapy/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15324530/
1780,oxaprozin,38451034,Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA-Update with genetic correlations.,"['Bonkovsky HL', 'Ghabril M', 'Nicoletti P', 'Dellinger A', 'Fontana RJ', 'Barnhart H', 'Gu J', 'Daly AK', 'Aithal GP', 'Phillips EJ', 'Kleiner DE']","['Humans', '*Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Female', 'Middle Aged', 'Adult', 'Aged', 'Male', '*Chemical and Drug Induced Liver Injury/genetics/etiology', 'United States/epidemiology', 'Aged, 80 and over', 'Case-Control Studies', 'Young Adult', '*Diclofenac/adverse effects', 'Risk Factors', 'Celecoxib/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38451034/
1781,oxaprozin,26350105,Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects.,"['Lopes-de-Araujo J', 'Neves AR', 'Gouveia VM', 'Moura CC', 'Nunes C', 'Reis S']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/*pharmacokinetics', 'Caco-2 Cells', 'Cell Line', 'Drug Carriers/*chemistry', 'Folic Acid/chemistry', 'Humans', 'Mice', 'Nanoparticles/*chemistry', 'Oxaprozin', 'Permeability', 'Phosphatidylethanolamines/*chemistry', 'Polyethylene Glycols/*chemistry', 'Propionates/*administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26350105/
1782,oxaprozin,8862964,Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention.,"['Manoukian AV', 'Carson JL']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Case-Control Studies', '*Chemical and Drug Induced Liver Injury/etiology', 'Cohort Studies', 'Diclofenac/adverse effects', 'Humans', 'Incidence', 'Indomethacin/adverse effects', 'Liver/drug effects', 'Liver Diseases/prevention & control', 'Naproxen/adverse effects', 'Oxaprozin', 'Phenylbutazone/adverse effects', 'Propionates/adverse effects', 'Risk Factors', 'Sulindac/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8862964/
1783,oxaprozin,7841569,Oxaprozin-induced fulminant hepatitis.,"['Purdum PP 3rd', 'Shelden SL', 'Boyd JW', 'Shiffman ML']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Diabetes Mellitus, Type 1/complications', 'Female', 'Hepatic Encephalopathy/*chemically induced', 'Humans', 'Joint Diseases/complications/drug therapy', 'Middle Aged', 'Oxaprozin', 'Propionates/*adverse effects/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/7841569/
1784,phenytoin,15347487,Topical phenytoin for wound healing.,"['Bhatia A', 'Prakash S']","['Abscess/drug therapy', 'Administration, Topical', 'Burns/drug therapy', 'Collagenases/biosynthesis', 'Connective Tissue/drug effects', 'Diabetic Foot/drug therapy', 'Drug Evaluation', 'Enzyme Induction/drug effects', 'Fibroblasts/drug effects', 'Granulation Tissue/drug effects', 'Humans', 'Keratinocytes/drug effects', 'Phenytoin/administration & dosage/pharmacology/*therapeutic use', 'Powders', 'Skin Ulcer/drug therapy', 'Wound Healing/*drug effects', 'Wounds, Penetrating/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15347487/
1785,phenytoin,17075669,Phenytoin-induced parkinsonism.,"['Ertan S', 'Ulu MO', 'Hanimoglu H', 'Tanriverdi T', 'Kafadar AM', 'Acar ZU', 'Kiziltan G']","['Adult', 'Anticonvulsants/administration & dosage/*adverse effects', 'Cerebellar Ataxia/*chemically induced', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Parkinsonian Disorders/*chemically induced', 'Phenytoin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/17075669/
1786,phenytoin,10530693,Oxcarbazepine.,['Tecoma ES'],"['Adult', 'Animals', 'Anticonvulsants/pharmacokinetics/pharmacology/*therapeutic use', 'Biological Availability', 'Biotransformation', 'Carbamazepine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Controlled Clinical Trials as Topic', 'Disease Models, Animal', 'Drug Administration Schedule', 'Drug Interactions', 'Epilepsy/*drug therapy', 'Humans', 'Oxcarbazepine', 'Phenytoin/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10530693/
1787,phenytoin,3150279,Phenytoin-induced thrombocytopenia.,"['Brown JJ', 'Chun RW']","['Adolescent', 'Epilepsy, Tonic-Clonic/*drug therapy', 'Humans', 'Male', 'Phenytoin/*adverse effects/therapeutic use', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3150279/
1788,phenytoin,1925719,Phenytoin intoxication.,"['Murphy JM', 'Motiwala R', 'Devinsky O']","['Adult', 'Electrocardiography/drug effects', 'Female', 'Humans', 'Liver Function Tests', 'Male', 'Middle Aged', 'Nervous System Diseases/chemically induced', 'Phenytoin/administration & dosage/blood/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/1925719/
1789,phenytoin,9952260,Phenytoin penetration into brain after administration of phenytoin or fosphenytoin.,"['Walton NY', 'Uthman BM', 'El Yafi K', 'Kim JM', 'Treiman DM']","['Animals', 'Anticonvulsants/*administration & dosage/*pharmacokinetics', 'Blood-Brain Barrier/drug effects', 'Brain/*metabolism', 'Brain Chemistry/drug effects', 'Dose-Response Relationship, Drug', 'Femoral Vein', 'Humans', 'Infusions, Intravenous', 'Injections, Intravenous', 'Male', 'Phenytoin/*administration & dosage/*analogs & derivatives/analysis/*pharmacokinetics', 'Rats', 'Rats, Sprague-Dawley']",https://pubmed.ncbi.nlm.nih.gov/9952260/
1790,phenytoin,7207767,Phenytoin: pharmacokinetics and clinical therapeutics.,"['Olanow CW', 'Finn AL']","['Abnormalities, Drug-Induced/etiology', 'Biological Availability', 'Drug Interactions', 'Humans', 'Kidney Diseases/etiology', 'Liver Diseases/etiology', '*Phenytoin/adverse effects/blood/metabolism/pharmacology/therapeutic use', 'Seizures/drug therapy', 'Vitamin D Deficiency/etiology']",https://pubmed.ncbi.nlm.nih.gov/7207767/
1791,phenytoin,7990791,Eclampsia.,"['Kaplan PW', 'Repke JT']","['Diagnosis, Differential', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics', 'Eclampsia/diagnosis/*etiology/therapy', 'Female', 'Humans', 'Infant, Newborn', 'Magnesium Sulfate/administration & dosage/adverse effects/pharmacokinetics', 'Neurologic Examination/drug effects', 'Phenytoin/administration & dosage/adverse effects/pharmacokinetics', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/7990791/
1792,phenytoin,405624,Carbamazepine--a double-blind comparison with phenytoin.,"['Troupin A', 'Ojemann LM', 'Halpern L', 'Dodrill C', 'Wilkus R', 'Friel P', 'Feigl P']","['Adult', 'Ataxia/chemically induced', 'Carbamazepine/adverse effects/blood/*therapeutic use', 'Clinical Trials as Topic', 'Drug Evaluation', 'Epilepsies, Partial/*drug therapy', 'Hematocrit', 'Humans', 'Leukocyte Count', 'Phenytoin/adverse effects/blood/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/405624/
1793,phenytoin,563669,Anticonvulsant-induced osteomalacia.,"['Palmer KT', 'Smith AE', 'Taylor BB']","['Animals', 'Chick Embryo', 'Dose-Response Relationship, Drug', 'Female', 'Fractures, Bone/etiology', 'Humans', 'Osteomalacia/*chemically induced/complications', 'Phenytoin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/563669/
1794,phenytoin,27938813,Acral manifestations of systemic diseases: Drug-induced and infectious diseases.,"['Caccavale S', 'Ruocco E']","['Acrodermatitis/diagnosis/*microbiology', 'Administration, Intravenous', 'Antineoplastic Agents/*adverse effects', 'Drug Eruptions/*etiology/prevention & control', 'Erythema Multiforme/chemically induced/complications', 'Foot Dermatoses/*etiology', 'Hand Dermatoses/*etiology', 'Hand, Foot and Mouth Disease/*complications', 'Humans', 'Phenytoin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27938813/
1795,phenytoin,8520091,Phenytoin-folic acid interaction.,"['Lewis DP', 'Van Dyke DC', 'Willhite LA', 'Stumbo PJ', 'Berg MJ']","['Anticonvulsants/pharmacokinetics/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Epilepsy/drug therapy', 'Folic Acid/*pharmacology', 'Folic Acid Deficiency/drug therapy', 'Food, Fortified', '*Food-Drug Interactions', 'Humans', 'Phenytoin/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8520091/
1796,phenytoin,10687229,A clinical review of drug-induced gingival overgrowths.,"['Marshall RI', 'Bartold PM']","['Anticonvulsants/administration & dosage/adverse effects', 'Australia', 'Calcium Channel Blockers/adverse effects', 'Cyclosporine/administration & dosage/adverse effects', 'Drug Interactions', 'Gingival Overgrowth/*chemically induced/therapy', 'Humans', 'Immunosuppressive Agents/adverse effects', 'Oral Hygiene', 'Phenytoin/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10687229/
1797,phenytoin,3986867,Status epilepticus.,['Leppik IE'],"['Adult', 'Aged', 'Anticonvulsants/*therapeutic use', 'Diazepam/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenobarbital/therapeutic use', 'Phenytoin/administration & dosage/adverse effects/therapeutic use', 'Status Epilepticus/mortality/*therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3986867/
1798,phenytoin,1683079,Differences in phenytoin biotransformation and susceptibility to congenital malformations: a review.,"['Van Dyke DC', 'Berg MJ', 'Olson CH']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Biotransformation', 'Cytochrome P-450 Enzyme System/metabolism', 'Disease Susceptibility', 'Epoxide Hydrolases/metabolism', 'Female', 'Fetus/abnormalities/drug effects', 'Glutathione Transferase/metabolism', 'Humans', 'Hydantoins/metabolism', 'Phenytoin/adverse effects/*pharmacokinetics/pharmacology', 'Polymorphism, Restriction Fragment Length', 'Pregnancy', 'Tetrahydrofolate Dehydrogenase/metabolism']",https://pubmed.ncbi.nlm.nih.gov/1683079/
1799,phenytoin,4006880,Zonisamide in epilepsy: a pilot study.,"['Wilensky AJ', 'Friel PN', 'Ojemann LM', 'Dodrill CB', 'McCormick KB', 'Levy RH']","['Adolescent', 'Adult', 'Anticonvulsants/administration & dosage/adverse effects/blood/metabolism/*therapeutic use', 'Carbamazepine/blood/therapeutic use', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Isoxazoles/adverse effects/blood/metabolism/*therapeutic use', 'Male', 'Middle Aged', 'Oxazoles/*therapeutic use', 'Phenytoin/blood/therapeutic use', 'Time Factors', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/4006880/
1800,phenytoin,25044856,Angiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy.,"['Ying X', 'Wang Y', 'Liang J', 'Yue J', 'Xu C', 'Lu L', 'Xu Z', 'Gao J', 'Du Y', 'Chen Z']","['Amygdala/drug effects/physiopathology', 'Animals', 'Anticonvulsants/*administration & dosage/pharmacokinetics/therapeutic use', 'Blood-Brain Barrier/metabolism', 'Cell Line', 'Drug Delivery Systems', 'Electricity', 'Epilepsy/*drug therapy/physiopathology', 'Humans', 'Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry', 'Mice', 'Nanoparticles/*chemistry', 'Peptides/*chemistry', 'Phenytoin/*administration & dosage/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25044856/
1801,phenytoin,2185438,The pharmacokinetics of agents used to treat status epilepticus.,['Browne TR'],"['Anticonvulsants/*pharmacokinetics/therapeutic use', 'Diazepam/administration & dosage/blood/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Injections, Intramuscular', 'Lipid Metabolism', 'Phenobarbital/administration & dosage/pharmacokinetics', 'Phenytoin/administration & dosage/blood/pharmacokinetics', 'Solubility', 'Status Epilepticus/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185438/
1802,phenytoin,21675930,EMPACT syndrome.,"['Bilgili SG', 'Calka O', 'Karadag AS', 'Burakgazi AZ']","['Adult', 'Anticonvulsants/administration & dosage/*adverse effects/therapeutic use', 'Brain Neoplasms/complications/radiotherapy/secondary', 'Cranial Irradiation/*adverse effects', 'Erythema Multiforme/*chemically induced/diagnosis/drug therapy/etiology', 'Fatal Outcome', 'Female', 'Glucocorticoids/administration & dosage/therapeutic use', 'Humans', 'Phenytoin/administration & dosage/*adverse effects/therapeutic use', 'Prednisolone/administration & dosage/therapeutic use', 'Seizures/prevention & control', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/21675930/
1803,phenytoin,7294047,Phenytoin-induced hyperglycemia.,"['Carter BL', 'Small RE', 'Mandel MD', 'Starkman MT']","['Acidosis/etiology', 'Diabetes Complications', 'Female', 'Humans', 'Hyperglycemia/*chemically induced', 'Middle Aged', 'Phenytoin/*adverse effects/therapeutic use', 'Seizures/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7294047/
1804,pindolol,7443595,Pindolol-induced tremor.,"['Hod H', 'Har-Zahav J', 'Kaplinsky N', 'Frankl O']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pindolol/*adverse effects', 'Tremor/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7443595/
1805,pindolol,2859251,Hypertension and beta-blockers. Are they all the same?,"['Raftery EB', 'Carrageta MO']","['Adrenergic beta-Antagonists/*therapeutic use', 'Atenolol/therapeutic use', 'Blood Pressure/*drug effects', '*Circadian Rhythm', 'Humans', 'Hypertension/drug therapy/*physiopathology', 'Labetalol/therapeutic use', 'Metoprolol/therapeutic use', 'Pindolol/analogs & derivatives/therapeutic use', 'Receptors, Adrenergic, alpha/drug effects/physiology', 'Sotalol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2859251/
1806,pindolol,15309042,The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.,"['Celada P', 'Puig M', 'Amargos-Bosch M', 'Adell A', 'Artigas F']","['Autoreceptors/antagonists & inhibitors', 'Depressive Disorder, Major/drug therapy/*metabolism', 'Humans', 'Pindolol/pharmacology/therapeutic use', 'Receptor, Serotonin, 5-HT1A/drug effects/metabolism/*physiology', 'Receptors, Serotonin, 5-HT2/drug effects/metabolism/*physiology', 'Serotonin Antagonists/pharmacology/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15309042/
1807,pindolol,1706984,Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.,"['Harron DW', 'Goa KL', 'Langtry HD']","['*Adrenergic beta-Antagonists/pharmacokinetics/pharmacology/therapeutic use', 'Animals', 'Antihypertensive Agents/therapeutic use', 'Coronary Disease/drug therapy', 'Half-Life', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Kidney/drug effects', 'Pindolol/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/1706984/
1808,pindolol,9796861,Overcoming treatment resistance in depression.,['Nelson JC'],"['Antidepressive Agents/administration & dosage/*therapeutic use', 'Buspirone/therapeutic use', 'Depressive Disorder/*drug therapy', 'Drug Administration Schedule', 'Drug Resistance', 'Drug Therapy, Combination', 'Humans', 'Lithium/therapeutic use', 'Pindolol/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Treatment Outcome', 'Triiodothyronine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9796861/
1809,pindolol,9635544,The use of pindolol to potentiate antidepressant medication.,"['Blier P', 'Bergeron R']","['Animals', 'Antidepressive Agents/pharmacology/*therapeutic use', 'Autoreceptors/drug effects', 'Controlled Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Hippocampus/drug effects', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/pharmacology/therapeutic use', 'Pindolol/pharmacology/*therapeutic use', 'Rats', 'Receptors, Serotonin/drug effects', 'Serotonin Antagonists/pharmacology/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9635544/
1810,pindolol,12880941,Pindolol and the acceleration of the antidepressant response.,"['Plenge P', 'Mellerup ET']","['Depressive Disorder, Major/*drug therapy', 'Drug Administration Schedule', 'Humans', 'Pindolol/antagonists & inhibitors/*therapeutic use', 'Serotonin Antagonists/*therapeutic use', 'Selective Serotonin Reuptake Inhibitors/*pharmacology/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/12880941/
1811,pindolol,9067994,"[Pharmacological characteristics of the long-acting beta-blocker ""bopindolol""].","['Nagatomo T', 'Hosohata Y', 'Ohnuki T', 'Suzuki J']","['Adrenergic beta-Antagonists/*pharmacology', 'Animals', 'Antihypertensive Agents/pharmacology', 'Cell Membrane/drug effects', 'Heart/drug effects', 'Humans', 'In Vitro Techniques', 'Pindolol/*analogs & derivatives/pharmacology', 'Receptors, Adrenergic, alpha-1/drug effects', 'Receptors, Serotonin/drug effects', 'Renin/metabolism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/9067994/
1812,pindolol,9786309,Treatment of antidepressant nonresponders: augmentation or switch?,['Nelson JC'],"['Antidepressive Agents/administration & dosage/therapeutic use', 'Bupropion/administration & dosage/therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Humans', 'Lithium/administration & dosage/therapeutic use', 'Pindolol/administration & dosage/therapeutic use', 'Psychiatric Status Rating Scales/statistics & numerical data', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/*therapeutic use', 'Treatment Outcome', 'Triiodothyronine/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9786309/
1813,pindolol,6689277,Pharmacokinetics of mepindolol administered alone and in combination with hydrochlorothiazide--a bioequivalence study.,"['Krause W', 'Lennert C']","['Adult', 'Biological Availability', 'Drug Combinations/metabolism', 'Female', 'Half-Life', 'Humans', 'Hydrochlorothiazide/*metabolism/pharmacology', 'Kinetics', 'Male', 'Pindolol/*analogs & derivatives/metabolism/pharmacology', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/6689277/
1814,pindolol,6715080,Comparative clinical and hemodynamic investigations on two beta-receptor blocking agents (pindolol and mepindolol) in normal subjects.,['Wink K'],"['Adult', 'Blood Pressure/drug effects', 'Cardiac Output/drug effects', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Oxygen Consumption/drug effects', 'Physical Exertion', 'Pindolol/*analogs & derivatives/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6715080/
1815,pindolol,6367447,Studies on the effect of prazosin on blood pressure and serum lipids in Japanese hypertensive patients.,['Saruta T'],"['Blood Pressure/drug effects', 'Cholesterol/blood', 'Drug Evaluation', 'Humans', 'Hypertension/*drug therapy', 'Japan', 'Lipids/*blood', 'Pindolol/therapeutic use', 'Prazosin/*therapeutic use', 'Propranolol/therapeutic use', 'Quinazolines/*therapeutic use', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/6367447/
1816,pindolol,2156071,Beta-adrenergic receptor sensitivity in subjects practicing transcendental meditation.,"['Mills PJ', 'Schneider RH', 'Hill D', 'Walton KG', 'Wallace RK']","['Adult', 'Arousal/*physiology', 'Humans', 'Iodocyanopindolol', 'Lymphocytes/metabolism', 'Male', 'Personality Tests', 'Pindolol/analogs & derivatives/pharmacokinetics', 'Radioligand Assay', 'Receptors, Adrenergic, beta/*physiology', '*Relaxation Therapy', 'Type A Personality']",https://pubmed.ncbi.nlm.nih.gov/2156071/
1817,pindolol,8934951,An echocardiographic study of interactions between pindolol and epinephrine contained in a local anesthetic solution.,"['Sugimura M', 'Hirota Y', 'Shibutani T', 'Niwa H', 'Hori T', 'Kim Y', 'Matsuura H']","['Adrenergic beta-Antagonists/*pharmacology', 'Adult', 'Analysis of Variance', '*Anesthesia, Dental/adverse effects', 'Anesthetics, Local/pharmacology', 'Blood Pressure/drug effects', 'Cardiac Output/drug effects', '*Dental Care for Chronically Ill', 'Drug Interactions', 'Echocardiography/methods', 'Epinephrine/*pharmacology', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Pindolol/*pharmacology', 'Vasoconstrictor Agents/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8934951/
1818,pindolol,7104148,Effect of pindolol and propranolol on renal function of patients with hypertension.,"['Pasternack A', 'Porsti P', 'Poyhonen L']","['Adult', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Kidney Diseases/*chemically induced', 'Kidney Function Tests', 'Male', 'Middle Aged', 'Pindolol/*adverse effects/therapeutic use', 'Propranolol/*adverse effects/therapeutic use', 'Renal Circulation/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7104148/
1819,pindolol,1678154,Beta-adrenergic responsiveness of choroidal vasculature.,"['Grajewski AL', 'Ferrari-Dileo G', 'Feuer WJ', 'Anderson DR']","['Administration, Topical', 'Adrenergic beta-Antagonists/administration & dosage/metabolism', 'Adult', 'Animals', 'Autoradiography', 'Choroid/*blood supply/*metabolism', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Intraocular Pressure/drug effects', 'Male', 'Middle Aged', 'Pigment Epithelium of Eye/metabolism', 'Pindolol/analogs & derivatives/metabolism', 'Rabbits', 'Receptors, Adrenergic, beta/*metabolism', 'Retinal Vessels/*metabolism', 'Timolol/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1678154/
1820,pindolol,1678272,The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol.,"['MacDonald NJ', 'Grant AC', 'Rodger RS', 'Meredith PA', 'Elliott HL']","['Adrenergic beta-Antagonists/adverse effects/*metabolism/*pharmacokinetics', 'Adult', 'Female', 'Humans', 'Hypertension/complications/drug therapy', 'Kidney/drug effects', 'Kidney Failure, Chronic/complications/*metabolism', 'Male', 'Middle Aged', 'Pindolol/adverse effects/*analogs & derivatives/metabolism/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1678272/
1821,pindolol,6125094,Clinical pharmacology of pindolol.,['Aellig WH'],"['Adrenergic beta-Agonists', 'Cardiac Output/drug effects', 'Depression, Chemical', 'Dose-Response Relationship, Drug', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension/drug therapy', 'Physical Exertion', 'Pindolol/administration & dosage/*pharmacology/therapeutic use', 'Propranolol/pharmacology/therapeutic use', 'Regional Blood Flow/drug effects', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6125094/
1822,pindolol,6166800,Verapamil in the treatment of hypertension.,"['Anavekar SN', 'Christophidis N', 'Louis WJ', 'Doyle AE']","['Adult', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Pindolol/therapeutic use', 'Placebos', 'Random Allocation', 'Verapamil/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6166800/
1823,pindolol,1100097,Effect of pindolol on intraocular pressure.,"['Bonomi I', 'Steindler P']","['Adult', 'Aged', 'Aqueous Humor/drug effects', 'Clinical Trials as Topic', 'Female', 'Glaucoma/drug therapy', 'Humans', 'Intraocular Pressure/*drug effects', 'Male', 'Middle Aged', 'Pindolol/administration & dosage/pharmacology/*therapeutic use', 'Time Factors', 'Tonometry, Ocular']",https://pubmed.ncbi.nlm.nih.gov/1100097/
1824,probenecid,6218348,The penicillins.,"['Wright AJ', 'Wilkowske CJ']","['Amoxicillin/administration & dosage', 'Ampicillin/administration & dosage', 'Bacterial Infections/*drug therapy', 'Carbenicillin/administration & dosage', 'Drug Administration Schedule', 'Drug Evaluation', 'Drug Hypersensitivity', 'Drug Synergism', 'Humans', 'Penicillin G/administration & dosage', 'Penicillins/classification/pharmacology/*therapeutic use', 'Piperacillin', 'Probenecid/pharmacology', 'Ticarcillin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/6218348/
1825,probenecid,7848545,Risks and benefits of drugs used in the management and prevention of gout.,"['Conaghan PG', 'Day RO']","['Adrenocorticotropic Hormone/administration & dosage/adverse effects/therapeutic use', 'Allopurinol/administration & dosage/adverse effects/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Colchicine/administration & dosage/therapeutic use', 'Double-Blind Method', 'Glucocorticoids/administration & dosage/adverse effects/therapeutic use', 'Gout/*drug therapy/prevention & control', 'Gout Suppressants/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Probenecid/administration & dosage/adverse effects/therapeutic use', 'Sulfinpyrazone/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7848545/
1826,probenecid,27591828,Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.,"['Stamp L', 'Dalbeth N']","['Allopurinol/therapeutic use', '*Asymptomatic Diseases', 'Drug Eruptions/etiology', 'Drug Hypersensitivity/etiology', 'Febuxostat/therapeutic use', 'Gout Suppressants/therapeutic use', 'Humans', 'Hyperuricemia/*drug therapy', 'Probenecid/therapeutic use', 'Uricosuric Agents/*therapeutic use', 'Urolithiasis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/27591828/
1827,probenecid,1078798,Chronic polymicrobial bacteremia.,"['Grajwer LA', 'Mukhopadhyay D', 'Grossman BJ']","['Adolescent', 'Ampicillin/therapeutic use', 'Blood Bactericidal Activity', 'Carbenicillin/blood/therapeutic use', 'Chronic Disease', '*Enterobacteriaceae Infections/blood/drug therapy', 'Female', 'Gentamicins/adverse effects/pharmacology/therapeutic use', 'Humans', 'Kanamycin/blood/therapeutic use', 'Probenecid/therapeutic use', '*Sepsis/blood/drug therapy', 'Vestibule, Labyrinth/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1078798/
1828,probenecid,23844693,Probenecid: an emerging tool for neuroprotection.,"['Colin-Gonzalez AL', 'Santamaria A']","['Animals', 'Brain/*drug effects', 'Drug Interactions', 'Humans', 'Kynurenine/metabolism', 'Models, Neurological', 'Nervous System Diseases/*drug therapy', 'Neuroprotective Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Probenecid/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/23844693/
1829,probenecid,22321288,Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy.,"['Gutman J', 'Kachur SP', 'Slutsker L', 'Nzila A', 'Mutabingwa T']","['Antimalarials/*administration & dosage/adverse effects/pharmacokinetics', 'Chemoprevention/adverse effects/*methods', 'Drug Combinations', 'Drug Therapy, Combination/adverse effects/methods', 'Female', 'Humans', 'Malaria, Falciparum/drug therapy/*prevention & control', 'Pregnancy', 'Pregnancy Complications, Infectious/drug therapy/*prevention & control', 'Probenecid/*administration & dosage/adverse effects/pharmacokinetics', 'Pyrimethamine/*administration & dosage/adverse effects/pharmacokinetics', 'Sulfadoxine/*administration & dosage/adverse effects/pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22321288/
1830,probenecid,37157863,"Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial.","['Ando N', 'Mizushima D', 'Omata K', 'Nemoto T', 'Inamura N', 'Hiramoto S', 'Takano M', 'Aoki T', 'Watanabe K', 'Uemura H', 'Shiojiri D', 'Yanagawa Y', 'Tanuma J', 'Teruya K', 'Kikuchi Y', 'Gatanaga H', 'Oka S']","['Humans', 'Amoxicillin/adverse effects', 'Penicillin G Benzathine/therapeutic use', 'Anti-Bacterial Agents/adverse effects', '*HIV Infections/complications/drug therapy', 'HIV', 'Probenecid/adverse effects', '*Syphilis/drug therapy', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/37157863/
1831,probenecid,1242194,Cephalexin-related nephropathy.,"['Verma S', 'Kieff E']","['Administration, Oral', 'Adult', 'Cephalexin/administration & dosage/*adverse effects/therapeutic use', 'Drug Hypersensitivity', 'Endocarditis/drug therapy', 'Eosinophilia/*chemically induced/immunology', 'Hematuria/*chemically induced/immunology', 'Humans', 'Kidney Diseases/*chemically induced', 'Male', 'Probenecid/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1242194/
1832,probenecid,7471606,Probenecid-clofibrate interaction.,"['Veenendaal JR', 'Brooks PM', 'Meffin PJ']","['Adolescent', 'Adult', 'Clofibrate/*metabolism', 'Drug Interactions', 'Female', 'Glucuronates/metabolism', 'Humans', 'Indomethacin/metabolism', 'Metabolic Clearance Rate/drug effects', 'Probenecid/*pharmacology', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/7471606/
1833,probenecid,28990653,Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.,"['Alam N', 'Angeli MG', 'Greenblatt DJ']","['Adolescent', 'Adult', 'Aged', 'Antiviral Agents/pharmacokinetics/*pharmacology', 'Child', 'Child, Preschool', 'Cyclopropanes', 'Drug Interactions', 'Enzyme Inhibitors/pharmacology', 'Ethinyl Estradiol/metabolism', 'Glucuronosyltransferase/*antagonists & inhibitors', 'Humans', 'Lactams, Macrocyclic', 'Macrocyclic Compounds/pharmacokinetics/*pharmacology', 'Male', 'Microsomes, Liver/*drug effects/enzymology', 'Middle Aged', 'Probenecid/pharmacology', 'Proline/analogs & derivatives', 'Sulfonamides', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28990653/
1834,probenecid,18973812,Organic anion transporter 3 inhibitors as potential novel antihypertensives.,['Eraly SA'],"['Animals', 'Antihypertensive Agents/*pharmacology', 'Blood Pressure/drug effects', 'Eosine Yellowish-(YS)/pharmacology', 'Humans', 'Organic Anion Transporters, Sodium-Independent/*antagonists & inhibitors/physiology', 'Probenecid/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18973812/
1835,probenecid,30244431,International position paper on the appropriate use of uricosurics with the introduction of lesinurad.,"['Jansen TL', 'Perez-Ruiz F', 'Tausche AK', 'Richette P']","['Benzbromarone/administration & dosage/therapeutic use', 'Europe', 'Febuxostat/therapeutic use', 'Gout/*drug therapy', 'Humans', 'International Cooperation', 'Practice Guidelines as Topic', 'Probenecid/administration & dosage', 'Rheumatology/*standards', 'Thioglycolates/*therapeutic use', 'Triazoles/*therapeutic use', 'Uricosuric Agents/*therapeutic use', 'Xanthine Oxidase/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30244431/
1836,probenecid,8491057,Cephalosporin-probenecid drug interactions.,['Brown GR'],"['Cephalosporins/*pharmacokinetics', 'Drug Interactions', 'Humans', 'Probenecid/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8491057/
1837,probenecid,34508172,Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro.,"['Murray J', 'Hogan RJ', 'Martin DE', 'Blahunka K', 'Sancilio FD', 'Balyan R', 'Lovern M', 'Still R', 'Tripp RA']","['Animals', 'Antiviral Agents/*pharmacology', 'Chlorocebus aethiops', 'Epithelial Cells/*drug effects/virology', 'Humans', 'Lung/*drug effects/virology', 'Probenecid/*pharmacology', 'SARS-CoV-2/*physiology', 'Vero Cells', 'Virus Replication/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34508172/
1838,probenecid,25547991,Advances in pharmacotherapy for the treatment of gout.,"['Robinson PC', 'Dalbeth N']","['Adrenal Cortex Hormones/therapeutic use', 'Allopurinol/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Antibodies, Monoclonal/therapeutic use', 'Antibodies, Monoclonal, Humanized', 'Benzbromarone/therapeutic use', 'Clinical Trials, Phase III as Topic', 'Colchicine/therapeutic use', 'Febuxostat', 'Gout/*drug therapy', 'Gout Suppressants/administration & dosage', 'Humans', 'Polyethylene Glycols/therapeutic use', 'Probenecid/therapeutic use', 'Thiazoles/therapeutic use', 'Urate Oxidase/therapeutic use', 'Uric Acid/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25547991/
1839,probenecid,10709441,[Renal tolerance of cidofovir].,"['Bagnis C', 'Izzdine H', 'Deray G']","['Acidosis, Renal Tubular/blood/chemically induced', 'Acute Kidney Injury/chemically induced', 'Anti-HIV Agents/*adverse effects/pharmacokinetics', 'Cidofovir', 'Cytosine/adverse effects/*analogs & derivatives/pharmacokinetics', 'Glomerular Filtration Rate', 'Glycosuria/chemically induced', 'Humans', 'Inactivation, Metabolic', 'Kidney/*drug effects/metabolism', 'Kidney Diseases/blood/*chemically induced/prevention & control', '*Organophosphonates', 'Organophosphorus Compounds/*adverse effects/pharmacokinetics', 'Probenecid/therapeutic use', 'Proteinuria/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/10709441/
1840,probenecid,37596428,N-Acetylcysteine and Probenecid Adjuvant Therapy for Traumatic Brain Injury.,"['Clark RSB', 'Empey PE', 'Kochanek PM', 'Bell MJ']","['Child', 'Humans', '*Probenecid/therapeutic use/pharmacology', 'Acetylcysteine/therapeutic use/pharmacology', 'Pilot Projects', '*Brain Injuries, Traumatic/drug therapy', 'Brain', 'Blood-Brain Barrier']",https://pubmed.ncbi.nlm.nih.gov/37596428/
1841,probenecid,38005930,"Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19.","['Tripp RA', 'Martin DE']","['Humans', '*COVID-19', 'Probenecid/pharmacology', 'Antiviral Agents/pharmacology/therapeutic use', 'Drug Discovery', 'High-Throughput Screening Assays', 'Virus Replication']",https://pubmed.ncbi.nlm.nih.gov/38005930/
1842,probenecid,8157041,The effect of probenecid on paracetamol metabolism and pharmacokinetics.,['Kamali F'],"['Acetaminophen/*metabolism/*pharmacokinetics', 'Adult', 'Animals', '*Arabidopsis Proteins', 'Drug Interactions', 'Female', 'Glucosyltransferases/metabolism', 'Half-Life', 'Humans', 'In Vitro Techniques', 'Male', 'Microsomes, Liver/drug effects/enzymology/metabolism', 'Probenecid/*pharmacology', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/8157041/
1843,probenecid,4215559,Comparison of amoxicillin and ampicillin in single-dose oral treatment of males with gonococcal urethritis.,"['Mitchell RW', 'Robson HG']","['Administration, Oral', 'Amines/administration & dosage/adverse effects/therapeutic use', 'Ampicillin/*administration & dosage/adverse effects/therapeutic use', 'Diarrhea/chemically induced', 'Drug Evaluation', 'Follow-Up Studies', 'Gonorrhea/*drug therapy', 'Humans', 'Male', 'Microbial Sensitivity Tests', 'Nausea/chemically induced', 'Neisseria gonorrhoeae/isolation & purification', 'Penicillin G/pharmacology', 'Penicillins/*administration & dosage/adverse effects/analogs & derivatives/therapeutic use', 'Probenecid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4215559/
1844,promethazine,25233954,Pink urine.,"['Verhoeven E', 'Capron A', 'Hantson P']","['Alcoholism/pathology', 'Crystallization', 'Ethanol/blood', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Middle Aged', 'Pentanoic Acids/urine', 'Promethazine/blood/therapeutic use/urine', 'Tablets/administration & dosage/poisoning', 'Uric Acid/urine', 'Valerian/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/25233954/
1845,promethazine,27170253,Meniere's disease.,"['Nakashima T', 'Pyykko I', 'Arroll MA', 'Casselbrant ML', 'Foster CA', 'Manzoor NF', 'Megerian CA', 'Naganawa S', 'Young YH']","['Antiemetics/pharmacology/therapeutic use', 'Audiometry/methods', 'Benzodiazepines/pharmacology/therapeutic use', 'Catheter Ablation/methods', 'Dimenhydrinate/pharmacology/therapeutic use', 'Ear, Inner/pathology/physiopathology', 'Endolymph/metabolism', 'Ganglia, Sensory/abnormalities/injuries', 'Hearing Loss/etiology', 'Humans', 'Magnetic Resonance Imaging/methods', 'Meclizine/pharmacology/therapeutic use', 'Meniere Disease/*complications/epidemiology/*physiopathology', 'Promethazine/pharmacology/therapeutic use', 'Quality of Life/psychology', 'Tinnitus/etiology', 'Vertigo/etiology']",https://pubmed.ncbi.nlm.nih.gov/27170253/
1846,promethazine,6928910,Intramuscular sedation technique.,"['Jensen ST', 'Coke JM', 'Cohen L']","['Anesthesia, Dental/*methods', 'Anesthesia, General/*methods', 'Buttocks', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Injections, Intramuscular/methods', 'Meperidine/administration & dosage/pharmacology', 'Promethazine/administration & dosage', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6928910/
1847,promethazine,3615241,Promethazine-induced dystonic reaction.,"['DeGrandi T', 'Simon JE']","['Acute Disease', 'Adolescent', 'Dystonia/*chemically induced/drug therapy', 'Female', 'Gastroenteritis/complications', 'Humans', 'Promethazine/*adverse effects/therapeutic use', 'Suppositories', 'Vomiting/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/3615241/
1848,promethazine,7874402,Approach to the dizzy patient.,['Baloh RW'],"['Anxiety Disorders/*complications/psychology', 'Brain Diseases/*complications/physiopathology', 'Diazepam/administration & dosage/therapeutic use', 'Dizziness/*etiology/physiopathology', 'Heart Diseases/*complications/physiopathology', 'Humans', 'Meclizine/administration & dosage/therapeutic use', 'Meniere Disease/*complications', 'Migraine Disorders/*complications', 'Prochlorperazine/administration & dosage/therapeutic use', 'Promethazine/administration & dosage/therapeutic use', 'Proprioception', 'Scopolamine/administration & dosage/therapeutic use', 'Substance-Related Disorders/*complications/physiopathology', 'Time Factors', 'Vertebrobasilar Insufficiency/*complications', 'Vertigo/drug therapy/*etiology', 'Vestibular Diseases/*complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7874402/
1849,promethazine,27725018,Angio-oedema associated with colistin.,"['Abulfathi AA', 'Greyling T', 'Makiwane M', 'Esser M', 'Decloedt E']","['Acinetobacter baumannii/isolation & purification', '*Angioedema/chemically induced/diagnosis/physiopathology/therapy', 'Anti-Allergic Agents/administration & dosage', 'Anti-Bacterial Agents/administration & dosage/adverse effects', 'Colistin/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Female', 'Humans', 'Hydrocortisone/*administration & dosage', 'Middle Aged', 'Promethazine/*administration & dosage', 'Sepsis/diagnosis/*drug therapy/etiology', 'Treatment Outcome', 'Urinary Tract Infections/*complications/microbiology', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/27725018/
1850,promethazine,11764306,Standard treatment: the role of antihistamines.,['Merk HF'],"['Cyclizine/therapeutic use', 'Cytochrome P-450 Enzyme System/biosynthesis', 'Diphenhydramine/therapeutic use', 'Electrocardiography/adverse effects', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Promethazine/therapeutic use', 'Pyrilamine/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11764306/
1851,promethazine,8443849,Nasal ketamine for paediatric premedication.,"['Weksler N', 'Ovadia L', 'Muati G', 'Stav A']","['Administration, Intranasal', 'Anesthesia Recovery Period', 'Anesthesia, Inhalation', 'Child, Preschool', '*Conscious Sedation', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intramuscular', 'Ketamine/administration & dosage/*therapeutic use', 'Male', 'Meperidine/administration & dosage/therapeutic use', '*Preanesthetic Medication', 'Promethazine/administration & dosage/therapeutic use', 'Salivation/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8443849/
1852,promethazine,36183207,Use of tracking drugs for the search of intra-hospital adverse reactions: a pharmacovigilance study.,"['Correa Benedet Baesso K', 'Zapelini do Nascimento D', 'De Sa Soares A', 'Schuelter-Trevisol F']","['Adverse Drug Reaction Reporting Systems', 'Cross-Sectional Studies', 'Diphenhydramine/adverse effects', '*Drug-Related Side Effects and Adverse Reactions/epidemiology', 'Flumazenil', 'Hospitals', 'Humans', 'Loperamide', 'Naloxone', '*Pharmacovigilance', 'Promethazine']",https://pubmed.ncbi.nlm.nih.gov/36183207/
1853,promethazine,37122169,"Promethazine inhibits efflux, enhances antifungal susceptibility and disrupts biofilm structure and functioning in Trichosporon.","['Aguiar ALR', 'Silva BND', 'Fiallos NM', 'Pereira LMG', 'Silva ML', 'Souza PFSM', 'Portela FVM', 'Sidrim JJC', 'Rocha MFG', 'Castelo-Branco DSCM', 'Cordeiro RA']","['Microbial Sensitivity Tests', 'Basidiomycota', 'Promethazine/pharmacology/metabolism', '*Trichosporon', 'Plankton', '*Antifungal Agents/pharmacology/metabolism', 'Biofilms', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/37122169/
1854,promethazine,39699316,Injectable promethazine in clinics and hospitals: What's the alternative?,"['Overholser A', 'Sizemore M', 'Czech E']","['Humans', '*Promethazine/administration & dosage', 'Injections', 'Injections, Subcutaneous']",https://pubmed.ncbi.nlm.nih.gov/39699316/
1855,promethazine,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
1856,promethazine,24350243,Topical promethazine side effects: our experience and review of the literature.,"['Cantisani C', 'Ricci S', 'Grieco T', 'Paolino G', 'Faina V', 'Silvestri E', 'Calvieri S']","['Epidermis/*drug effects/*metabolism', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Inflammation/drug therapy', 'Promethazine/*adverse effects/*therapeutic use', 'Skin Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24350243/
1857,promethazine,11543005,Pharmacotherapeutics in space.,['Putcha L'],"['Acetaminophen/administration & dosage/pharmacokinetics', '*Aerospace Medicine', 'Analgesics, Non-Narcotic/administration & dosage/pharmacokinetics', 'Headache/drug therapy', 'Histamine H1 Antagonists/administration & dosage/pharmacokinetics', 'Humans', 'Muscarinic Antagonists/pharmacokinetics', '*Pharmacology, Clinical', 'Promethazine/administration & dosage/pharmacokinetics', 'Saliva/*metabolism', 'Scopolamine/administration & dosage/pharmacokinetics', '*Space Flight', 'Space Motion Sickness/drug therapy', '*Weightlessness']",https://pubmed.ncbi.nlm.nih.gov/11543005/
1858,promethazine,3675502,Mechanisms of antimotion sickness drugs.,"['Wood CD', 'Manno JE', 'Wood MJ', 'Manno BR', 'Redetzki HM']","['Adult', 'Dextroamphetamine/*therapeutic use', 'Dimenhydrinate/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Motion Sickness/*prevention & control', 'Placebos', 'Promethazine/*therapeutic use', 'Scopolamine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3675502/
1859,promethazine,33351859,Targeting bioenergetics is key to counteracting the drug-tolerant state of biofilm-grown bacteria.,"['Donnert M', 'Elsheikh S', 'Arce-Rodriguez A', 'Pawar V', 'Braubach P', 'Jonigk D', 'Haverich A', 'Weiss S', 'Musken M', 'Haussler S']","['Animals', 'Biofilms/*drug effects', 'Drug Tolerance/physiology', 'Energy Metabolism/*drug effects', 'Humans', 'Mice', 'Mice, Inbred BALB C', 'Promethazine/*pharmacology', 'Pseudomonas Infections', 'Pseudomonas aeruginosa/*drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/33351859/
1860,promethazine,8746124,Successful cancer therapy with promethazine: the rationale.,['Jones GR'],"['Antineoplastic Agents/adverse effects/*therapeutic use', 'Breast Neoplasms/drug therapy', 'Chlorpromazine/therapeutic use', 'Cyclophosphamide/therapeutic use', 'Female', 'Humans', 'Male', 'Neoplasms/*drug therapy/pathology', 'Pancreatic Neoplasms/drug therapy', 'Phenothiazines/therapeutic use', 'Promethazine/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8746124/
1861,promethazine,404894,Intraarterial analgesia in peripheral arteriography.,"['Guthaner DF', 'Silverman JF', 'Hayden WG', 'Wexler L']","['*Analgesia', '*Angiography', 'Diazepam', 'Humans', 'Injections, Intra-Arterial', 'Lidocaine/*administration & dosage', 'Meperidine', 'Premedication', 'Promethazine']",https://pubmed.ncbi.nlm.nih.gov/404894/
1862,promethazine,11538042,Comparison of efficacy of ginger with various antimotion sickness drugs.,"['Wood CD', 'Manno JE', 'Wood MJ', 'Manno BR', 'Mims ME']","['Administration, Oral', 'Adolescent', 'Adult', 'Antiemetics/administration & dosage/*therapeutic use', 'Dextroamphetamine/*therapeutic use', 'Dimenhydrinate/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Motion Sickness/drug therapy/*prevention & control', 'Plants, Medicinal/*metabolism', 'Promethazine/administration & dosage/therapeutic use', 'Rotation', 'Scopolamine/administration & dosage/therapeutic use', 'Spices']",https://pubmed.ncbi.nlm.nih.gov/11538042/
1863,promethazine,33858904,Promethazine-induced delirium with perceptual abnormalities: are we thinking broadly when assessing patients?,"['Abeysundera H', 'Craig B', 'Pullich Z']","['*Delirium/chemically induced/diagnosis', 'Humans', 'Nonprescription Drugs/adverse effects', 'Promethazine/adverse effects', '*Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/33858904/
1864,risperidone,33341539,Antipsychotics and hemodialysis: A systematic review.,"['Sutar R', 'Atlani MK', 'Chaudhary P']","['*Antipsychotic Agents/adverse effects', 'Benzodiazepines', 'Humans', 'Olanzapine', 'Renal Dialysis', 'Risperidone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33341539/
1865,risperidone,24794100,Role of atypical antipsychotics in the treatment of generalized anxiety disorder.,"['Hershenberg R', 'Gros DF', 'Brawman-Mintzer O']","['Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Anxiety Disorders/*drug therapy/psychology', 'Aripiprazole', 'Benzodiazepines/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dibenzothiazepines/administration & dosage/adverse effects/therapeutic use', 'Generalization, Psychological/*drug effects', 'Humans', 'Olanzapine', 'Piperazines/administration & dosage/adverse effects/therapeutic use', 'Quetiapine Fumarate', 'Quinolones/administration & dosage/adverse effects/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24794100/
1866,risperidone,12151468,Risperidone in children with autism and serious behavioral problems.,"['McCracken JT', 'McGough J', 'Shah B', 'Cronin P', 'Hong D', 'Aman MG', 'Arnold LE', 'Lindsay R', 'Nash P', 'Hollway J', 'McDougle CJ', 'Posey D', 'Swiezy N', 'Kohn A', 'Scahill L', 'Martin A', 'Koenig K', 'Volkmar F', 'Carroll D', 'Lancor A', 'Tierney E', 'Ghuman J', 'Gonzalez NM', 'Grados M', 'Vitiello B', 'Ritz L', 'Davies M', 'Robinson J', 'McMahon D']","['Adolescent', 'Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Autistic Disorder/*drug therapy/psychology', 'Child', 'Child Behavior/drug effects', 'Child, Preschool', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Risperidone/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12151468/
1867,risperidone,11869410,Drug-induced extrapyramidal reactions.,"['Teoh L', 'Allen H', 'Kowalenko N']","['Antipsychotic Agents/administration & dosage/*adverse effects', 'Attention Deficit Disorder with Hyperactivity/complications/*drug therapy', 'Basal Ganglia Diseases/*chemically induced', 'Child', 'Drug Therapy, Combination', 'Humans', 'Male', 'New South Wales', 'Risperidone/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11869410/
1868,risperidone,21294670,Aripiprazole for the treatment of irritability associated with autism.,"['Farmer CA', 'Aman MG']","['Antipsychotic Agents/adverse effects/pharmacokinetics/therapeutic use', 'Aripiprazole', 'Autistic Disorder/*drug therapy', 'Humans', 'Irritable Mood/*drug effects', 'Piperazines/adverse effects/pharmacokinetics/*therapeutic use', 'Quinolones/adverse effects/pharmacokinetics/*therapeutic use', 'Risperidone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21294670/
1869,risperidone,11584985,Long-term safety of risperidone.,['Davidson M'],"['Aged', 'Antipsychotic Agents/*adverse effects/pharmacokinetics/therapeutic use', 'Basal Ganglia Diseases/chemically induced/epidemiology', 'Cholinesterase Inhibitors/adverse effects/therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Dementia/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Dyskinesia, Drug-Induced/epidemiology/etiology', 'Humans', 'Incidence', 'Receptors, Dopamine/drug effects/metabolism', 'Receptors, Histamine/drug effects/metabolism', 'Receptors, Muscarinic/drug effects/metabolism', 'Risperidone/*adverse effects/pharmacokinetics/therapeutic use', 'Treatment Outcome', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/11584985/
1870,risperidone,8948000,Use of novel antipsychotic drugs.,['Raleigh F'],"['Antipsychotic Agents/*administration & dosage/adverse effects', 'Basal Ganglia Diseases/*chemically induced/drug therapy/prevention & control', 'Clozapine/*administration & dosage/adverse effects', 'Humans', 'Risperidone/*administration & dosage/adverse effects', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8948000/
1871,risperidone,8690833,Pharmacokinetics of clozapine and risperidone: a review of recent literature.,"['Byerly MJ', 'DeVane CL']","['Antipsychotic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Biological Availability', 'Clozapine/administration & dosage/adverse effects/*pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Metabolic Clearance Rate/physiology', 'Risperidone/administration & dosage/adverse effects/*pharmacokinetics', 'Schizophrenia/*blood/drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8690833/
1872,risperidone,22964442,Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder?,"['Schneebaum-Sender N', 'Goldberg-Stern H', 'Fattal-Valevski A', 'Kramer U']","['Age of Onset', 'Anticonvulsants/adverse effects/*therapeutic use', 'Attention/drug effects', 'Attention Deficit Disorder with Hyperactivity/drug therapy/etiology/genetics/*prevention & control', 'Central Nervous System Stimulants/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Evaluation', 'Drug Therapy, Combination', '*Electroencephalography/drug effects', 'Epilepsy/complications', 'Epilepsy, Rolandic/drug therapy/*physiopathology', 'Female', 'Humans', 'Infant', 'Male', 'Methylphenidate/administration & dosage/*therapeutic use', 'Retrospective Studies', 'Risperidone/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22964442/
1873,risperidone,18281731,Paliperidone for schizophrenia.,"['Dolder C', 'Nelson M', 'Deyo Z']","['Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Controlled Clinical Trials as Topic', 'Delayed-Action Preparations', 'Drug Interactions', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects/pharmacokinetics', 'Paliperidone Palmitate', 'Pyrimidines/*administration & dosage/adverse effects/pharmacokinetics', 'Risperidone/metabolism/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18281731/
1874,risperidone,16822092,Risks versus benefits of different types of long-acting injectable antipsychotics.,['McEvoy JP'],"['Administration, Oral', 'Antipsychotic Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Fluphenazine/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Haloperidol/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Health Care Costs', 'Humans', 'Injections, Intramuscular', 'Microspheres', 'Quality of Life', 'Risk Assessment', 'Risperidone/administration & dosage/pharmacokinetics/therapeutic use', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Secondary Prevention', '*Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/16822092/
1875,risperidone,15522979,Long-acting injectable risperidone.,"['Ehret MJ', 'Fuller MA']","['*Antipsychotic Agents/adverse effects/pharmacology/therapeutic use', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Humans', 'Injections, Intramuscular', 'Randomized Controlled Trials as Topic', '*Risperidone/adverse effects/pharmacology/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15522979/
1876,risperidone,29695153,Classics in Chemical Neuroscience: Risperidone.,"['Chopko TC', 'Lindsley CW']","['Animals', 'Humans', 'Mental Disorders/drug therapy', 'Risperidone/adverse effects/chemistry/pharmacology/*therapeutic use', 'Serotonin Antagonists/adverse effects/chemistry/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29695153/
1877,risperidone,9562211,Risperidone-induced tardive dyskinesia.,['Silberbauer C'],"['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Dyskinesia, Drug-Induced/*physiopathology', 'Humans', 'Male', 'Risperidone/*adverse effects/therapeutic use', 'Schizophrenia/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9562211/
1878,risperidone,10724129,"Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.",['Glazer WM'],"['Antipsychotic Agents/*adverse effects/pharmacology/therapeutic use', 'Basal Ganglia Diseases/*chemically induced', 'Benzodiazepines', 'Brain/drug effects', 'Clozapine/adverse effects/pharmacology/therapeutic use', 'Dibenzothiazepines/adverse effects/pharmacology/therapeutic use', 'Humans', 'Movement Disorders/*etiology', 'Olanzapine', 'Pirenzepine/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Quetiapine Fumarate', 'Receptors, Dopamine/drug effects', 'Receptors, Serotonin/drug effects', 'Risk Factors', 'Risperidone/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10724129/
1879,risperidone,19102665,"Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.",['Keith S'],"['Antipsychotic Agents/*administration & dosage/adverse effects/economics', 'Bipolar Disorder/drug therapy/economics', 'Clinical Trials as Topic', 'Cost-Benefit Analysis', 'Delayed-Action Preparations/economics/*therapeutic use', 'Humans', 'Medication Adherence', 'Risperidone/*administration & dosage/adverse effects/economics', 'Schizophrenia/*drug therapy/economics']",https://pubmed.ncbi.nlm.nih.gov/19102665/
1880,risperidone,9448664,The treatment of psychosis in late life.,"['Zayas EM', 'Grossberg GT']","['Age Factors', 'Aged', 'Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Clozapine/adverse effects/pharmacokinetics/therapeutic use', 'Decision Trees', 'Delirium/diagnosis/drug therapy', 'Diagnosis, Differential', 'Drug Administration Schedule', 'Female', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Nursing Homes/legislation & jurisprudence', 'Psychotic Disorders/diagnosis/*drug therapy/epidemiology', 'Risk Factors', 'Risperidone/adverse effects/pharmacokinetics/therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/9448664/
1881,risperidone,11232752,Weight change and atypical antipsychotic treatment in patients with schizophrenia.,"['Jones B', 'Basson BR', 'Walker DJ', 'Crawford AM', 'Kinon BJ']","['Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use', 'Behavior Therapy/methods', 'Benzodiazepines', 'Dose-Response Relationship, Drug', 'Follow-Up Studies', 'Haloperidol/administration & dosage/adverse effects/therapeutic use', 'Health Behavior', 'Humans', 'Obesity/chemically induced/prevention & control', 'Olanzapine', 'Pirenzepine/administration & dosage/*adverse effects/*analogs & derivatives/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Schizophrenia/*drug therapy', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/11232752/
1882,risperidone,33074724,CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review.,"['Maruf AA', 'Stein K', 'Arnold PD', 'Aitchison KJ', 'Muller DJ', 'Bousman C']","['Adolescent', 'Antipsychotic Agents/*therapeutic use', 'Child', 'Cytochrome P-450 CYP2D6/*genetics', '*Drug-Related Side Effects and Adverse Reactions', 'Humans', '*Pharmacogenetics', '*Risperidone/pharmacokinetics/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33074724/
1883,risperidone,8749887,Risperidone: efficacy and safety.,"['Umbricht D', 'Kane JM']","['Acute Disease', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Humans', 'Randomized Controlled Trials as Topic', 'Risperidone/adverse effects/*therapeutic use', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8749887/
1884,rosiglitazone,31776781,Thiazolidinediones: the Forgotten Diabetes Medications.,['Lebovitz HE'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin Resistance', 'Pioglitazone/adverse effects/therapeutic use', 'Rosiglitazone/adverse effects/therapeutic use', 'Thiazolidinediones/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31776781/
1885,rosiglitazone,35180475,ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury.,"['Wang Y', 'Zhang M', 'Bi R', 'Su Y', 'Quan F', 'Lin Y', 'Yue C', 'Cui X', 'Zhao Q', 'Liu S', 'Yang Y', 'Zhang D', 'Cao Q', 'Gao X']","['*Acute Kidney Injury/metabolism', 'Animals', 'Coenzyme A Ligases/genetics', 'Female', '*Ferroptosis/genetics', 'Humans', 'Male', 'Mice', 'Rosiglitazone/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/35180475/
1886,rosiglitazone,30645973,Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis.,"['Ishay-Ronen D', 'Diepenbruck M', 'Kalathur RKR', 'Sugiyama N', 'Tiede S', 'Ivanek R', 'Bantug G', 'Morini MF', 'Wang J', 'Hess C', 'Christofori G']","['3T3-L1 Cells', 'Adipocytes/*cytology', 'Adipogenesis', 'Animals', 'Breast Neoplasms/*drug therapy/metabolism', 'Cell Line, Tumor', 'Cell Movement', 'Cell Transdifferentiation/*drug effects', 'Epithelial-Mesenchymal Transition/drug effects', 'Female', 'Flavonoids/*administration & dosage/pharmacology', 'Humans', 'Mice', 'Neoplasm Metastasis/*drug therapy', 'Neoplasm Transplantation', 'Proto-Oncogene Proteins c-met/metabolism', 'Rosiglitazone/*administration & dosage/therapeutic use', 'Signal Transduction/drug effects', 'Transforming Growth Factor beta/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30645973/
1887,rosiglitazone,38594496,PPARgamma alleviates preeclampsia development by regulating lipid metabolism and ferroptosis.,"['Lai W', 'Yu L', 'Deng Y']","['Humans', 'Female', 'Pregnancy', 'Rats', 'Animals', 'Rosiglitazone/pharmacology/metabolism', 'PPAR gamma/metabolism', 'Lipid Metabolism', 'Placenta/metabolism', '*Pre-Eclampsia/drug therapy/prevention & control/metabolism', 'NF-E2-Related Factor 2/metabolism', '*Ferroptosis', 'Hypoxia/metabolism', 'Lipids']",https://pubmed.ncbi.nlm.nih.gov/38594496/
1888,rosiglitazone,24563375,Systematic reviews to ascertain the safety of diabetes medications.,"['Gionfriddo MR', 'Morey-Vargas OL', 'Brito JP', 'Leppin AL', 'Murad MH', 'Montori VM']","['Acidosis, Lactic/chemically induced', 'Blood Glucose/*drug effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Evidence-Based Medicine', 'Female', 'Fractures, Bone/chemically induced', 'Glycated Hemoglobin/*drug effects', 'Glycine/administration & dosage/adverse effects/analogs & derivatives', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Male', 'Meta-Analysis as Topic', 'Metformin/administration & dosage/adverse effects', 'Oxazoles/administration & dosage/adverse effects', 'Pancreatic Neoplasms/chemically induced', 'Risk Assessment', 'Rosiglitazone', 'Thiazolidinediones/administration & dosage/adverse effects', 'Urinary Bladder Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/24563375/
1889,rosiglitazone,33674341,"ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.","['Zhou T', 'Liu J', 'Xie Y', 'Yuan S', 'Guo Y', 'Bai W', 'Zhao K', 'Jiang W', 'Wang H', 'Wang H', 'Zhao T', 'Huang C', 'Gao S', 'Wang X', 'Yang S', 'Hao J']","['Animals', 'Cohort Studies', 'Disease Models, Animal', 'Humans', 'Hypoglycemic Agents/pharmacology', 'Mice', 'Mice, Inbred BALB C', 'Neoplastic Stem Cells/*drug effects/metabolism', 'Pancreatic Neoplasms/metabolism/*pathology', 'Pancreatic Stellate Cells/*drug effects/metabolism', 'Receptors, CXCR4/*metabolism', 'Rosiglitazone/*pharmacology', 'Transcription Factors/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/33674341/
1890,rosiglitazone,26690770,Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.,"['Stojanovic M', 'Prostran M', 'Radenkovic M']","['Animals', 'Endothelium, Vascular/drug effects', 'Humans', 'Pioglitazone', 'Randomized Controlled Trials as Topic', 'Rosiglitazone', 'Thiazolidinediones/*pharmacology/*therapeutic use', 'Vasodilation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/26690770/
1891,rosiglitazone,38605183,Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.,"['Rohm TV', 'Castellani Gomes Dos Reis F', 'Isaac R', 'Murphy C', 'Cunha E Rocha K', 'Bandyopadhyay G', 'Gao H', 'Libster AM', 'Zapata RC', 'Lee YS', 'Ying W', 'Miciano C', 'Wang A', 'Olefsky JM']","['Animals', '*Rosiglitazone/pharmacology', '*Extracellular Vesicles/metabolism/drug effects', 'Mice', '*Insulin Resistance', '*Macrophages/metabolism/drug effects', '*Adipose Tissue/metabolism/drug effects', 'Male', 'Humans', 'MicroRNAs/genetics/metabolism', 'Obesity/metabolism', 'Insulin/metabolism', 'Adipocytes/metabolism/drug effects', 'Mice, Inbred C57BL']",https://pubmed.ncbi.nlm.nih.gov/38605183/
1892,rosiglitazone,10400405,Rosiglitazone.,"['Balfour JA', 'Plosker GL']","['Animals', 'Blood Glucose/*drug effects', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Interactions', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Insulin/*metabolism', 'Islets of Langerhans/*drug effects', 'Polypharmacy', 'Rosiglitazone', 'Thiazoles/adverse effects/pharmacology/*therapeutic use', '*Thiazolidinediones']",https://pubmed.ncbi.nlm.nih.gov/10400405/
1893,rosiglitazone,20977573,Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?,"['Schernthaner G', 'Chilton RJ']","['Cardiovascular Diseases/*chemically induced', 'Diabetes Mellitus, Type 2/complications/*drug therapy', 'Diabetic Angiopathies/*chemically induced', 'Female', 'Humans', 'Male', '*Meta-Analysis as Topic', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Rosiglitazone', 'Thiazolidinediones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20977573/
1894,rosiglitazone,11410214,Lessons from the glitazones: a story of drug development.,['Gale EA'],"['Adverse Drug Reaction Reporting Systems', 'Chemical and Drug Induced Liver Injury/etiology', 'Chromans/administration & dosage/*adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Approval/*legislation & jurisprudence', 'Drug Therapy, Combination', 'Europe', 'Humans', 'Hypoglycemic Agents/administration & dosage/*adverse effects', 'Liver Failure/chemically induced', 'Pioglitazone', 'Rosiglitazone', 'Thiazoles/administration & dosage/*adverse effects', '*Thiazolidinediones', 'Troglitazone', 'United States']",https://pubmed.ncbi.nlm.nih.gov/11410214/
1895,rosiglitazone,32353383,LINCS dataset-based repositioning of rosiglitazone as a potential anti-human adenovirus drug.,"['Wang X', 'He S', 'Zhou Z', 'Bo X', 'Qi D', 'Fu X', 'Wang Z', 'Yang J', 'Wang S']","['A549 Cells', 'Adenovirus Infections, Human/drug therapy/virology', 'Adenoviruses, Human/*drug effects/physiology', 'Algorithms', 'Animals', 'Antiviral Agents/pharmacology/*therapeutic use', '*Databases, Pharmaceutical', '*Drug Repositioning', 'Epithelial Cells/drug effects/virology', 'Female', 'Humans', 'Immunocompromised Host', 'Mice', 'Mice, SCID', 'Rosiglitazone/pharmacology/*therapeutic use', 'Virus Replication/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/32353383/
1896,rosiglitazone,37864473,Decellularization-Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair.,"['Jin H', 'Kang Y', 'Gao H', 'Lin Z', 'Huang D', 'Zheng Z', 'Zhao J', 'Wang L', 'Jiang J']","['Humans', 'Rats', 'Animals', 'Heterografts', 'Rosiglitazone/pharmacology', '*Extracellular Matrix', '*Inflammation', 'Collagen', 'Tendons', 'Tissue Engineering', 'Tissue Scaffolds']",https://pubmed.ncbi.nlm.nih.gov/37864473/
1897,rosiglitazone,38131378,PPARgamma agonist treatment reduces fibroadipose tissue in secondary lymphedema by exhausting fibroadipogenic PDGFRalpha+ mesenchymal cells.,"['Chen Z', 'Ghavimi SAA', 'Wu M', 'McNamara J', 'Barreiro O', 'Maridas D', 'Kratchmarov R', 'Siegel A', 'Djeddi S', 'Gutierrez-Arcelus M', 'Brennan PJ', 'Padera TP', 'von Andrian U', 'Mehrara B', 'Greene AK', 'Kahn CR', 'Orgill DP', 'Sinha I', 'Rosen V', 'Agarwal S']","['Male', 'Female', 'Humans', 'Mice', 'Animals', '*Receptor, Platelet-Derived Growth Factor alpha', 'PPAR gamma', 'Rosiglitazone/pharmacology/therapeutic use', '*Lymphedema/drug therapy', 'Fibrosis']",https://pubmed.ncbi.nlm.nih.gov/38131378/
1898,rosiglitazone,15163284,Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.,"['Del Prato S', 'Volpe L']","['Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Humans', 'Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use', 'Metformin/administration & dosage/pharmacology/*therapeutic use', 'Rosiglitazone', 'Thiazoles/administration & dosage/pharmacology/*therapeutic use', 'Thiazolidinediones/administration & dosage/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15163284/
1899,rosiglitazone,30142096,Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications.,"['Bajaj HS', 'Al-Jabri B', 'Verma S']","['Biomarkers/blood', 'Blood Glucose/drug effects/metabolism', 'Blood Pressure/drug effects/*physiology', '*Cardiovascular Diseases/etiology/physiopathology/prevention & control', 'Diabetes Mellitus, Type 2/blood/complications/*drug therapy', 'Humans', 'Hypoglycemic Agents/therapeutic use', 'Lipids/blood', 'Prognosis', 'Rosiglitazone/*therapeutic use', '*Glucagon-Like Peptide-1 Receptor Agonists']",https://pubmed.ncbi.nlm.nih.gov/30142096/
1900,rosiglitazone,17975488,"Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus ""off-target"" effectors.",['Nemenoff RA'],"['Animals', 'Antineoplastic Agents/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/metabolism', 'PPAR gamma/*metabolism', 'Pioglitazone', 'Rosiglitazone', 'Signal Transduction/*drug effects', 'Thiazolidinediones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17975488/
1901,rosiglitazone,19162510,Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.,"['Inamoto T', 'Shah JB', 'Kamat AM']","['Adjuvants, Immunologic/administration & dosage/therapeutic use', 'Animals', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Apoptosis/drug effects', 'BCG Vaccine/administration & dosage/therapeutic use', 'Disease Progression', 'Humans', 'Neoplasm Invasiveness', 'PPAR gamma/*agonists/*metabolism', 'Rosiglitazone', 'Thiazolidinediones/pharmacology/*therapeutic use', 'Urinary Bladder Neoplasms/*drug therapy/*metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/19162510/
1902,rosiglitazone,17569897,Rosiglitazone and implications for pharmacovigilance.,['Kazi D'],"['Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/*adverse effects', 'Meta-Analysis as Topic', 'Product Surveillance, Postmarketing', 'Rosiglitazone', 'Thiazolidinediones/*adverse effects', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/17569897/
1903,rosiglitazone,21102545,Therapy: The second time as farce: rosiglitazone and the regulators.,['Gale EA'],"['Chromans/adverse effects/therapeutic use', 'Diabetes Mellitus/drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Rosiglitazone', 'Thiazolidinediones/adverse effects/*therapeutic use', 'Troglitazone']",https://pubmed.ncbi.nlm.nih.gov/21102545/
1904,scopolamine,3064540,Pharmacological treatment of vertigo.,"['Pyykko I', 'Magnusson M', 'Schalen L', 'Enbom H']","['Animals', 'Dimenhydrinate/therapeutic use', 'Humans', 'Meniere Disease/*drug therapy', 'Motion Sickness/drug therapy', 'Scopolamine/therapeutic use', 'Vertigo/drug therapy', 'Vestibule, Labyrinth/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/3064540/
1905,scopolamine,132123,Frey's syndrome.,"['Bednarek J', 'Reid W', 'Matsumoto T']","['Administration, Topical', 'Atropine/therapeutic use', 'Drug Eruptions/etiology', 'Drug Hypersensitivity/etiology', 'Female', 'Humans', 'Middle Aged', 'Scopolamine/adverse effects/therapeutic use', 'Sweating, Gustatory/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/132123/
1906,scopolamine,16175141,Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.,"['Renner UD', 'Oertel R', 'Kirch W']","['Humans', 'Muscarinic Antagonists/*pharmacokinetics', 'Scopolamine/administration & dosage/adverse effects/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/16175141/
1907,scopolamine,12398577,Sialorrhea - therapeutic drug options.,['Tscheng DZ'],"['Adolescent', 'Adult', 'Benztropine/adverse effects/*therapeutic use', 'Botulinum Toxins, Type A/adverse effects/*therapeutic use', 'Cerebral Palsy/complications', 'Child', 'Child, Preschool', 'Glycopyrrolate/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Scopolamine/adverse effects/*therapeutic use', 'Sialorrhea/*drug therapy/etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/12398577/
1908,scopolamine,32739296,Rapid acting antidepressants in the mTOR pathway: Current evidence.,"['K V A', 'Mohan AS', 'Chakravarty S']","['Animals', 'Antidepressive Agents/*administration & dosage/*metabolism', 'Depressive Disorder, Major/*drug therapy/*metabolism/psychology', 'Drug Administration Routes', 'Humans', 'Ketamine/administration & dosage/metabolism', 'Scopolamine/administration & dosage/metabolism', 'Signal Transduction/*drug effects/physiology', 'TOR Serine-Threonine Kinases/*metabolism', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/32739296/
1909,scopolamine,2296571,Scopolamine withdrawal syndrome.,"['Saxena K', 'Saxena S']","['Administration, Cutaneous', 'Female', 'Humans', 'Middle Aged', 'Motion Sickness/prevention & control', 'Paresthesia/*chemically induced', 'Scopolamine/administration & dosage/*adverse effects/pharmacology', '*Substance Withdrawal Syndrome', 'Sweating/*drug effects', 'Time Factors', 'Travel']",https://pubmed.ncbi.nlm.nih.gov/2296571/
1910,scopolamine,28643520,Main Plant Extracts' Active Properties Effective on Scopolamine-Induced Memory Loss.,"['Balmus IM', 'Ciobica A']","['Animals', 'Blood-Brain Barrier/metabolism', 'Brain/metabolism', 'Cognition/drug effects', 'Disease Models, Animal', 'Humans', 'Memory Disorders/*chemically induced', 'Plant Extracts/*administration & dosage', '*Scopolamine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28643520/
1911,scopolamine,382907,Atropine and hyoscine.,"['Shutt LE', 'Bowes JB']","['Arrhythmias, Cardiac/chemically induced', '*Atropine/adverse effects/metabolism/pharmacology/poisoning', 'Cardiac Output/drug effects', 'Central Nervous System/drug effects', 'Chemical Phenomena', 'Chemistry', 'Eye/drug effects', 'Female', 'Heart Rate/drug effects', 'Humans', 'Maternal-Fetal Exchange', 'Neostigmine/pharmacology', '*Preanesthetic Medication', 'Pregnancy', 'Respiration/drug effects', '*Scopolamine/adverse effects/metabolism/pharmacology', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/382907/
1912,scopolamine,990972,Anticholinergic premedication.,"['Leighton KM', 'Sanders HD']","['Atropine/*administration & dosage', 'Bronchi/drug effects/metabolism', 'Female', 'Humans', 'Male', 'Mouth Mucosa/drug effects/metabolism', '*Preanesthetic Medication', 'Scopolamine/*administration & dosage', 'Secretory Rate/drug effects', 'Trachea/drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/990972/
1913,scopolamine,19585799,The antidepressant effects of anticholinergic drugs.,['Howland RH'],"['Antidepressive Agents/adverse effects/*pharmacology/therapeutic use', 'Biperiden/adverse effects/pharmacology/therapeutic use', 'Cholinergic Antagonists/adverse effects/*pharmacology/therapeutic use', 'Depressive Disorder/*drug therapy', 'Humans', 'Muscarinic Antagonists/adverse effects/pharmacology/therapeutic use', 'Nicotinic Antagonists/adverse effects/pharmacology/therapeutic use', 'Scopolamine/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19585799/
1914,scopolamine,10783431,Antisecretory agents in gastrointestinal obstruction.,"['Muir JC', 'von Gunten CF']","['Abdominal Pain/etiology', 'Gastric Juice/drug effects', 'Gastrointestinal Agents/*therapeutic use', 'Glycopyrrolate/*therapeutic use', 'Humans', 'Intestinal Obstruction/*drug therapy/etiology/physiopathology', 'Intubation, Gastrointestinal/adverse effects', 'Muscarinic Antagonists/*therapeutic use', 'Octreotide/*therapeutic use', 'Palliative Care/*methods', 'Scopolamine/*therapeutic use', 'Terminal Care/*methods']",https://pubmed.ncbi.nlm.nih.gov/10783431/
1915,scopolamine,6355883,Measurement of cholinergic drug effects on memory in Alzheimer's disease.,"['Brinkman SD', 'Gershon S']","['Alzheimer Disease/*drug therapy', 'Arecoline/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Evaluation/methods', 'Humans', 'Memory/drug effects', 'Memory Disorders/diagnosis/*drug therapy', 'Parasympatholytics/*therapeutic use', 'Parasympathomimetics/*therapeutic use', 'Physostigmine/pharmacology/therapeutic use', 'Scopolamine/pharmacology/therapeutic use', 'Tacrine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6355883/
1916,scopolamine,16956462,Cutaneous reactions to transdermal therapeutic systems.,"['Musel AL', 'Warshaw EM']","['Administration, Cutaneous', 'Dermatitis, Allergic Contact/*etiology/pathology', 'Drug Delivery Systems/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Estradiol/administration & dosage', 'Fentanyl/administration & dosage', 'Humans', 'Nicotine/administration & dosage', 'Nitroglycerin/administration & dosage', 'Scopolamine/administration & dosage', 'Testosterone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/16956462/
1917,scopolamine,2492460,A review of contact dermatitis associated with transdermal therapeutic systems.,['Holdiness MR'],"['Administration, Cutaneous', 'Administration, Oral', 'Clonidine/administration & dosage/adverse effects', 'Dermatitis, Contact/*etiology/immunology', 'Estradiol/administration & dosage/adverse effects', 'Humans', 'Hypertension/drug therapy', 'Nitroglycerin/administration & dosage/adverse effects', 'Scopolamine/administration & dosage/adverse effects', 'Testosterone/administration & dosage/adverse effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2492460/
1918,scopolamine,15116278,Transdermal scopolamine use for post-rhytidectomy sialocele.,"['Lapid O', 'Kreiger Y', 'Sagi A']","['Administration, Cutaneous', 'Female', 'Fistula/etiology/prevention & control', 'Humans', 'Middle Aged', 'Muscarinic Antagonists/*administration & dosage', 'Parotid Diseases/etiology/prevention & control', 'Postoperative Complications/prevention & control', 'Rhytidoplasty/*adverse effects/rehabilitation', 'Salivation/*drug effects', 'Scopolamine/*administration & dosage', 'Sialorrhea/*drug therapy/etiology', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15116278/
1919,scopolamine,36054796,The effects of loperamide on excitatory and inhibitory neuromuscular function in the human colon.,"['Heitmann PT', 'Keightley L', 'Wiklendt L', 'Wattchow DA', 'Brookes SSJ', 'Spencer NJ', 'Costa M', 'Dinning PG']","['Animals', 'Colon', 'Electric Stimulation', 'Gastrointestinal Motility', 'Humans', '*Loperamide/pharmacology', 'Muscle Contraction/physiology', 'Naloxone/pharmacology', 'Nitroarginine/pharmacology', '*Scopolamine/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36054796/
1920,scopolamine,11198747,The use of Scopoderm in palliative care.,"['Spiller JA', 'Fallon M']","['Administration, Cutaneous', 'Bronchi/drug effects', 'Evidence-Based Medicine', 'Humans', 'Muscarinic Antagonists/pharmacology/*therapeutic use', 'Nausea/drug therapy', '*Palliative Care', 'Salivation/drug effects', 'Scopolamine/pharmacology/*therapeutic use', 'Terminal Care']",https://pubmed.ncbi.nlm.nih.gov/11198747/
1921,scopolamine,2339974,Acupressure and motion sickness.,"['Bruce DG', 'Golding JF', 'Hockenhull N', 'Pethybridge RJ']","['Acupuncture Therapy/*instrumentation', 'Humans', 'Motion Sickness/drug therapy/*therapy', 'Placebos', 'Scopolamine/therapeutic use', 'Time Factors', 'Transcutaneous Electric Nerve Stimulation']",https://pubmed.ncbi.nlm.nih.gov/2339974/
1922,scopolamine,7435925,Respiratory effects of Minaxolone.,"['Puchihewa VG', 'Whitwam JG', 'Morgan M', 'Lumley J']","['Anesthesia, Intravenous', 'Anesthetics/adverse effects/*pharmacology', 'Apnea/chemically induced', 'Atropine', 'Female', 'Humans', 'Lorazepam', 'Lung Volume Measurements', 'Papaverine', 'Preanesthetic Medication', 'Pregnanes/*pharmacology', 'Pregnanolone/analogs & derivatives/*pharmacology', 'Respiration/*drug effects', 'Scopolamine']",https://pubmed.ncbi.nlm.nih.gov/7435925/
1923,sulfadiazine,28700086,Antiseptics for burns.,"['Norman G', 'Christie J', 'Liu Z', 'Westby MJ', 'Jefferies JM', 'Hudson T', 'Edwards J', 'Mohapatra DP', 'Hassan IA', 'Dumville JC']","['Adult', 'Anti-Bacterial Agents/therapeutic use', 'Anti-Infective Agents, Local/adverse effects/*therapeutic use', 'Apitherapy/*methods', 'Bacterial Infections/etiology/*therapy', 'Bandages', 'Burns/*complications/*therapy', 'Chlorhexidine/therapeutic use', 'Disinfectants/therapeutic use', 'Honey', 'Humans', 'Merbromin/therapeutic use', 'Plant Preparations/therapeutic use', 'Povidone-Iodine/therapeutic use', 'Randomized Controlled Trials as Topic', 'Silver Sulfadiazine/therapeutic use', 'Sodium Hypochlorite/therapeutic use', 'Sulfadiazine/therapeutic use', '*Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/28700086/
1924,sulfadiazine,16766878,Silver in health care: antimicrobial effects and safety in use.,['Lansdown AB'],"['Administration, Cutaneous', 'Anti-Infective Agents/*administration & dosage/adverse effects', 'Humans', 'Silver/*administration & dosage/adverse effects/toxicity', 'Silver Nitrate/administration & dosage', 'Skin/*injuries', 'Skin Care', 'Sulfadiazine/administration & dosage', '*Textiles', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/16766878/
1925,sulfadiazine,35404714,Wound healing in second-degree burns in rats treated with silver sulfadiazine: a systematic review and meta-analysis.,"['Devi MV', 'Poornima V', 'Sivagnanam UT']","['Animals', '*Anti-Infective Agents, Local/pharmacology/therapeutic use', '*Burns/drug therapy', 'Humans', 'Ointments', 'Rats', 'Silver Sulfadiazine/pharmacology/therapeutic use', '*Soft Tissue Injuries', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/35404714/
1926,sulfadiazine,21718576,Burns (minor thermal).,"['Wasiak J', 'Cleland H']","['Bandages', 'Bandages, Hydrocolloid', '*Burns/drug therapy', 'Humans', 'Hydrogel, Polyethylene Glycol Dimethacrylate/pharmacology', 'Incidence', '*Silver Sulfadiazine/pharmacology', 'Sulfadiazine/pharmacology', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21718576/
1927,sulfadiazine,15114822,How safe is silver in wound care?,"['Lansdown AB', 'Williams A']","['Anti-Infective Agents, Local/pharmacokinetics/*therapeutic use', 'Bandages', 'Burns/drug therapy/nursing', 'Humans', 'Silver Nitrate/pharmacokinetics/*therapeutic use', 'Silver Sulfadiazine/pharmacokinetics/*therapeutic use', 'Skin/drug effects/metabolism', 'Skin Absorption', 'Tissue Distribution', 'Wound Healing/drug effects', 'Wounds and Injuries/*drug therapy/nursing']",https://pubmed.ncbi.nlm.nih.gov/15114822/
1928,sulfadiazine,15126971,A review of the use of silver in wound care: facts and fallacies.,['Lansdown AB'],"['Anti-Infective Agents, Local/adverse effects/pharmacology/*therapeutic use', 'Bandages', 'Humans', 'Silver/adverse effects/pharmacology/*therapeutic use', 'Silver Nitrate/pharmacology/therapeutic use', 'Silver Sulfadiazine/pharmacology/therapeutic use', 'Wound Healing/drug effects', 'Wounds and Injuries/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15126971/
1929,sulfadiazine,38861260,Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial.,"['Wei Y', 'Li Y', 'Li X', 'Zhao Y', 'Xu J', 'Wang H', 'Rong X', 'Xiong J', 'Chen X', 'Luo G', 'Lv G', 'Lin C', 'Han C', 'Yu H', 'Zhang Y', 'Tang S', 'Fan Y', 'Tu J', 'Xia C', 'Zu H', 'Liu W', 'Liu C', 'Liu J', 'Zhang B', 'Nong Q', 'Li T', 'Wang L', 'Song G', 'Su Y', 'Chen Z', 'Lai W', 'Fu Y', 'Yu J', 'Zhang P', 'Yang W', 'Yao G', 'Zhang H', 'Fan K', 'Dong H', 'Chen Y', 'Wu J']","['Humans', 'Male', 'Female', 'Middle Aged', 'Adult', '*Wound Infection/drug therapy', 'Anti-Infective Agents, Local/therapeutic use/administration & dosage', 'China', 'Silver Sulfadiazine/therapeutic use/administration & dosage', 'Treatment Outcome', 'Aged', 'Anti-Bacterial Agents/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38861260/
1930,sulfadiazine,6281592,Current management of fungal enteritis.,"['Chretien JH', 'Garagusi VF']","['Amphotericin B/therapeutic use', 'Antifungal Agents/therapeutic use', 'Candidiasis/diagnosis/drug therapy', 'Diarrhea/etiology', 'Enteritis/drug therapy/*etiology', 'Histoplasmosis/diagnosis/drug therapy', 'Humans', 'Imidazoles/therapeutic use', 'Immunosuppression Therapy/adverse effects', 'Ketoconazole', 'Miconazole/therapeutic use', 'Mycoses/*diagnosis', 'Neoplasms/complications', 'Nystatin/therapeutic use', 'Paracoccidioidomycosis/diagnosis/drug therapy', 'Piperazines/therapeutic use', 'Sulfadiazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6281592/
1931,sulfadiazine,12755974,Bromoderma.,"['Anzai S', 'Fujiwara S', 'Inuzuka M']","['Anti-Infective Agents, Local/therapeutic use', 'Anticonvulsants/administration & dosage/*adverse effects', 'Bromides/administration & dosage/*adverse effects', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Drug Eruptions/drug therapy/*etiology', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Potassium Compounds/administration & dosage/*adverse effects', 'Silver Sulfadiazine/therapeutic use', 'Skin Diseases, Vesiculobullous/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12755974/
1932,sulfadiazine,154920,Drugs causing fixed eruptions.,['Pasricha JS'],"['Antipyrine/adverse effects/*analogs & derivatives', 'Caffeine/*adverse effects', 'Cross Reactions', 'Drug Combinations', 'Drug Eruptions/*etiology', 'Humans', 'Penicillin G/adverse effects', 'Phenacetin/*adverse effects', 'Phenobarbital/adverse effects', 'Pyridones/*adverse effects', 'Sulfadiazine/adverse effects', 'Sulfanilamides/*adverse effects', 'Tetracycline/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/154920/
1933,sulfadiazine,30447857,"Types of antiseptics, presentations and rules of use.","['Del Rio-Carbajo L', 'Vidal-Cortes P']","['Alcohols/adverse effects/*pharmacology', 'Anti-Infective Agents, Local/adverse effects/classification/*pharmacology', 'Cations/adverse effects/pharmacology', 'Chlorhexidine/adverse effects/pharmacology', 'Drug Interactions', 'Ethanol/adverse effects/pharmacology', 'Humans', 'Hydrogen Peroxide/adverse effects/therapeutic use', 'Intensive Care Units', 'Iodine/adverse effects/pharmacology', 'Iodine Compounds/adverse effects/*pharmacology', 'Iodophors/adverse effects/pharmacology', 'Mercury Compounds/pharmacology', 'Propranolol/adverse effects/pharmacology', 'Sulfadiazine/adverse effects/pharmacology', 'Triclosan/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30447857/
1934,sulfadiazine,8726163,Toxicological aspects of topical silver pharmaceuticals.,['Hollinger MA'],"['Administration, Topical', 'Animals', 'Anti-Infective Agents, Local/administration & dosage/therapeutic use/*toxicity', 'Burns/drug therapy/metabolism', 'Drug Combinations', 'Electrodes/adverse effects', 'Humans', 'Immunity, Cellular/drug effects', 'Iontophoresis', 'Silver/administration & dosage/therapeutic use/*toxicity', 'Skin Absorption', 'Sulfadiazine/adverse effects', 'Wound Healing/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/8726163/
1935,sulfadiazine,38959345,Effects of topical insulin on second-degree burn wound healing: brief report.,"['da Silveira VF Jr', 'Gomes Silva JL', 'Lima MHM', 'Saad MJA']","['Humans', '*Burns/drug therapy/physiopathology', '*Wound Healing/drug effects', '*Insulin/therapeutic use/administration & dosage/pharmacology', 'Female', 'Male', '*Administration, Topical', 'Adult', 'Middle Aged', 'Silver Sulfadiazine/therapeutic use/pharmacology/administration & dosage', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/38959345/
1936,sulfadiazine,17130603,Best evidence topic report. Silver sulphadiazine cream in burns.,"['Hussain S', 'Ferguson C']","['Administration, Cutaneous', 'Adult', 'Anti-Infective Agents, Local/*therapeutic use', 'Burns/complications/*drug therapy', 'Emergencies', 'Evidence-Based Medicine', 'Female', 'Humans', 'Silver Sulfadiazine/*therapeutic use', 'Wound Infection/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/17130603/
1937,sulfadiazine,7662136,Serious silver sulphadiazine and mafenide acetate dermatitis.,"['McKenna SR', 'Latenser BA', 'Jones LM', 'Barrette RR', 'Sherman HF', 'Varcelotti JR']","['Adult', 'Burns/complications/*drug therapy', 'Drug Eruptions/diagnosis/*etiology', 'Humans', 'Mafenide/*adverse effects', 'Male', 'Silver Sulfadiazine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7662136/
1938,sulfadiazine,1836573,[Usefulness of folinic acid in cytopenia induced by antiparasitic drugs in AIDS patients].,"['Niyongabo T', 'Leport C', 'Vilde JL']","['Acquired Immunodeficiency Syndrome/*complications', 'Drug Therapy, Combination', 'Folic Acid/metabolism', 'Hematologic Diseases/chemically induced/complications/*prevention & control', 'Humans', 'Leucovorin/pharmacokinetics/*therapeutic use', 'Opportunistic Infections/complications/drug therapy/metabolism', 'Pneumonia, Pneumocystis/complications/*drug therapy/metabolism', 'Pyrimethamine/adverse effects/therapeutic use', 'Sulfadiazine/therapeutic use', 'Toxoplasmosis, Cerebral/complications/drug therapy/metabolism', 'Trimethoprim, Sulfamethoxazole Drug Combination/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1836573/
1939,sulfadiazine,30059387,Full-Thickness Chemical Burn From Trifluoroacetic Acid: A Case Report and Review of the Literature.,"['Rochlin DH', 'Rajasingh CM', 'Karanas YL', 'Davis DJ']","['Burns, Chemical/*therapy', 'Compression Bandages', 'Female', 'Humans', 'Occupational Exposure/*adverse effects', 'Silver Sulfadiazine/administration & dosage', 'Skin Transplantation', '*Trifluoroacetic Acid', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30059387/
1940,sulfadiazine,3979042,Patch testing with silver sulfadiazine cream.,"['Degreef H', 'Dooms-Goossens A']","['Cross Reactions', 'Dermatitis, Contact/*etiology', 'Fatty Alcohols/toxicity', 'Humans', 'Pharmaceutical Vehicles', 'Propylene Glycols/toxicity', 'Silver Sulfadiazine/*toxicity', 'Skin Tests', 'Sulfadiazine/*toxicity', 'Sulfonamides/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3979042/
1941,sulfadiazine,1409466,[Toxoplasmosis in AIDS].,"['Leport C', 'Remington JS']","['AIDS-Related Opportunistic Infections/diagnosis/etiology/therapy', 'Acquired Immunodeficiency Syndrome/*complications', 'Anti-Bacterial Agents/therapeutic use', 'Clindamycin/administration & dosage/therapeutic use', 'Humans', 'Lung Diseases, Parasitic/complications/diagnosis/therapy', 'Pyrimethamine/administration & dosage/therapeutic use', 'Recurrence', 'Sulfadiazine/administration & dosage/therapeutic use', 'Toxoplasmosis/diagnosis/*etiology/therapy', 'Toxoplasmosis, Cerebral/diagnosis/etiology/therapy', 'Toxoplasmosis, Ocular/diagnosis/etiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/1409466/
1942,sulfadiazine,32155122,Acute Radiation Therapy-related Dermatitis.,['Bolton L'],"['Adrenal Cortex Hormones/administration & dosage/therapeutic use', 'Dermatologic Agents/administration & dosage/*therapeutic use', 'Humans', 'Radiodermatitis/*drug therapy/prevention & control', 'Silver Sulfadiazine/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32155122/
1943,temozolomide,34419533,Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.,"['Tomar MS', 'Kumar A', 'Srivastava C', 'Shrivastava A']","['Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Drug Resistance, Neoplasm', 'Glioblastoma/*drug therapy', 'Glioma/*drug therapy', 'Humans', 'Temozolomide/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34419533/
1944,temozolomide,39079407,Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma.,"['Lan Y', 'Li X', 'Liu B', 'Lu J', 'Zuo B', 'Wang Y', 'Cao S', 'Fu X', 'Yue Q', 'Luo X', 'Zhong X', 'Dong Y', 'Wang Z', 'Yang T', 'Xie X', 'Zeng T', 'Zhang M', 'Wang Y', 'Shen Y', 'Zuo H', 'Zhao Y', 'Zhang C', 'Guo H']","['*Glioblastoma/drug therapy/pathology', '*Temozolomide/pharmacology/administration & dosage/therapeutic use', 'Humans', '*Brain Neoplasms/drug therapy/pathology/genetics', '*Antineoplastic Agents, Alkylating/pharmacology/therapeutic use', '*Nanoparticles/chemistry', 'Animals', '*Blood-Brain Barrier/metabolism/drug effects', 'Drug Resistance, Neoplasm/drug effects', 'Cell Line, Tumor', 'RNA-Binding Proteins/metabolism', 'DNA Repair Enzymes/metabolism/genetics', 'DNA Modification Methylases/metabolism', 'Nucleolin', 'Phosphoproteins/metabolism', 'Tumor Suppressor Proteins/metabolism/genetics', 'RNA, Small Interfering/administration & dosage', 'Nucleic Acids', 'Peptides']",https://pubmed.ncbi.nlm.nih.gov/39079407/
1945,temozolomide,36805210,Modeling glioblastoma complexity with organoids for personalized treatments.,"['Pawlowski KD', 'Duffy JT', 'Babak MV', 'Balyasnikova IV']","['Humans', '*Glioblastoma/drug therapy', '*Brain Neoplasms/drug therapy/pathology', 'Temozolomide/pharmacology/therapeutic use', 'Cell Culture Techniques', 'Organoids/pathology', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm', 'Tumor Microenvironment']",https://pubmed.ncbi.nlm.nih.gov/36805210/
1946,temozolomide,37697045,A designer peptide against the EAG2-Kvbeta2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma.,"['Dong W', 'Fekete A', 'Chen X', 'Liu H', 'Beilhartz GL', 'Chen X', 'Bahrampour S', 'Xiong Y', 'Yang Q', 'Zhao H', 'Kong T', 'Morioka MS', 'Jung G', 'Kim JE', 'Schramek D', 'Dirks PB', 'Song Y', 'Kim TH', 'He Y', 'Wanggou S', 'Li X', 'Melnyk RA', 'Wang LY', 'Huang X']","['Humans', 'Mice', 'Animals', '*Glioblastoma/drug therapy', 'Temozolomide/pharmacology/therapeutic use', 'Ether-A-Go-Go Potassium Channels/therapeutic use', 'Disease Models, Animal', 'Peptides/therapeutic use', 'Neurons/pathology']",https://pubmed.ncbi.nlm.nih.gov/37697045/
1947,temozolomide,39461382,Novel strategies to overcome chemoresistance in human glioblastoma.,"['Tang Q', 'Ren T', 'Bai P', 'Wang X', 'Zhao L', 'Zhong R', 'Sun G']","['*Glioblastoma/drug therapy/metabolism', 'Humans', '*Drug Resistance, Neoplasm/drug effects/physiology', '*Temozolomide/pharmacology/therapeutic use', '*Brain Neoplasms/drug therapy/metabolism/pathology', 'Antineoplastic Agents, Alkylating/therapeutic use/pharmacology', 'Tumor Microenvironment/drug effects/physiology', 'Animals']",https://pubmed.ncbi.nlm.nih.gov/39461382/
1948,temozolomide,35738390,Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.,"['Zou Y', 'Wang Y', 'Xu S', 'Liu Y', 'Yin J', 'Lovejoy DB', 'Zheng M', 'Liang XJ', 'Park JB', 'Efremov YM', 'Ulasov I', 'Shi B']","['Animals', 'Blood-Brain Barrier/metabolism', '*Brain Neoplasms/pathology', 'Cell Line, Tumor', 'Cisplatin/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', '*Glioblastoma/pathology', 'Mice', 'Temozolomide/pharmacology/therapeutic use', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/35738390/
1949,temozolomide,34274381,Antioxidant responses related to temozolomide resistance in glioblastoma.,"['Campos-Sandoval JA', 'Gomez-Garcia MC', 'Santos-Jimenez JL', 'Mates JM', 'Alonso FJ', 'Marquez J']","['Animals', 'Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Antioxidants/*metabolism', 'Brain Neoplasms/drug therapy/*metabolism', 'Drug Resistance, Neoplasm/*drug effects/physiology', 'Glioblastoma/drug therapy/*metabolism', 'Humans', 'Neoplastic Stem Cells/drug effects/metabolism', 'Reactive Oxygen Species/antagonists & inhibitors/metabolism', 'Temozolomide/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34274381/
1950,temozolomide,38353396,Kinome-Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma.,"['Vella V', 'Ditsiou A', 'Chalari A', 'Eravci M', 'Wooller SK', 'Gagliano T', 'Bani C', 'Kerschbamer E', 'Karakostas C', 'Xu B', 'Zhang Y', 'Pearl FMG', 'Lopez G', 'Peng L', 'Stebbing J', 'Klinakis A', 'Giamas G']","['Humans', 'Temozolomide/pharmacology/therapeutic use', '*Glioblastoma/drug therapy/metabolism', 'Proteomics', 'Antineoplastic Agents, Alkylating/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', '*Brain Neoplasms/drug therapy/metabolism', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/38353396/
1951,temozolomide,34678239,Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.,"['Tong S', 'Wang Y', 'Wu J', 'Long J', 'Zhong P', 'Wang B']","['Brain Neoplasms/*drug therapy/*genetics', 'DNA Repair/genetics', 'Glioma/*drug therapy/*genetics', 'Humans', 'Pharmacogenetics', 'Polymorphism, Genetic', 'Temozolomide/*pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34678239/
1952,temozolomide,38448295,Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.,"['Ye L', 'Gu L', 'Wang Y', 'Xing H', 'Li P', 'Guo X', 'Wang Y', 'Ma W']","['Humans', '*Glioblastoma/drug therapy/genetics', 'Temozolomide/pharmacology/therapeutic use', 'Histones', 'Multiomics', 'Protein Processing, Post-Translational', 'Sp1 Transcription Factor']",https://pubmed.ncbi.nlm.nih.gov/38448295/
1953,temozolomide,31984871,Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.,"['Rezaei V', 'Rabiee A', 'Khademi F']","['Antineoplastic Agents/administration & dosage/pharmacology/*therapeutic use', 'Blood-Brain Barrier/metabolism', 'Brain Neoplasms/*drug therapy/*pathology/therapy', 'Chemistry, Pharmaceutical/methods', 'Dendrimers/chemistry', 'Drug Carriers/chemistry', 'Environmental Exposure/adverse effects', 'Genetic Therapy/methods', 'Glioblastoma/*drug therapy/*pathology/therapy', 'Humans', 'Hyperthermia, Induced/methods', 'Liposomes/chemistry', 'Micelles', 'Nanotechnology', 'Neoplastic Stem Cells/pathology', 'Radiation, Ionizing', 'Risk Factors', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31984871/
1954,temozolomide,30470397,Chemotherapy Treatment and Trials in Low-Grade Gliomas.,"['Donovan LE', 'Lassman AB']","['Brain Neoplasms/*therapy', '*Chemoradiotherapy', '*Drug Therapy', 'Drug-Related Side Effects and Adverse Reactions', 'Glioma/*therapy', 'Humans', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30470397/
1955,temozolomide,36010607,Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.,"['Drakulic D', 'Schwirtlich M', 'Petrovic I', 'Mojsin M', 'Milivojevic M', 'Kovacevic-Grujicic N', 'Stevanovic M']","['*Brain Neoplasms/metabolism', '*Glioblastoma/metabolism', 'Humans', 'Signal Transduction', 'Temozolomide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36010607/
1956,temozolomide,35200546,Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.,"['Al-Toubah T', 'Morse B', 'Strosberg J']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Capecitabine/therapeutic use', 'Humans', '*Neuroendocrine Tumors/drug therapy/pathology', 'Retrospective Studies', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35200546/
1957,temozolomide,30171377,Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.,"['Taylor MA', 'Das BC', 'Ray SK']","['Antineoplastic Agents/pharmacology/*therapeutic use', 'Autophagosomes/metabolism', '*Autophagy/drug effects/radiation effects', 'Brain Neoplasms/pathology/*therapy', 'Cell Death/drug effects/radiation effects', '*Drug Resistance, Neoplasm/drug effects/radiation effects', 'Glioblastoma/pathology/*therapy', 'Humans', 'Radiation-Sensitizing Agents/pharmacology/therapeutic use', 'Temozolomide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30171377/
1958,temozolomide,32463097,Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.,"['Akazawa R', 'Umeda K', 'Saida S', 'Kato I', 'Hiramatsu H', 'Sakamoto A', 'Arakawa Y', 'Sumiyoshi S', 'Okamoto T', 'Moritake H', 'Adachi S', 'Takita J']","['Adolescent', 'Adult', 'Antineoplastic Agents, Alkylating/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bone Neoplasms/*drug therapy', 'Child', 'Etoposide/*therapeutic use', 'Female', 'Humans', 'Male', 'Neoplasm Recurrence, Local/*drug therapy', 'Osteosarcoma/*drug therapy', 'Prognosis', 'Retrospective Studies', 'Temozolomide/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32463097/
1959,temozolomide,34214730,Progress and prospect in tumor treating fields treatment of glioblastoma.,"['Liu S', 'Shi W', 'Zhao Q', 'Zheng Z', 'Liu Z', 'Meng L', 'Dong L', 'Jiang X']","['Animals', 'Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use', 'Brain Neoplasms/drug therapy/surgery/*therapy', 'Chemoradiotherapy/trends', 'Combined Modality Therapy', 'Glioblastoma/drug therapy/surgery/*therapy', 'Humans', 'Neoplasm Recurrence, Local', 'Neurosurgical Procedures', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34214730/
1960,temozolomide,32347934,"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.","['Hanna C', 'Kurian KM', 'Williams K', 'Watts C', 'Jackson A', 'Carruthers R', 'Strathdee K', 'Cruickshank G', 'Dunn L', 'Erridge S', 'Godfrey L', 'Jefferies S', 'McBain C', 'Sleigh R', 'McCormick A', 'Pittman M', 'Halford S', 'Chalmers AJ']","['Adult', 'Animals', 'Antineoplastic Agents, Alkylating/therapeutic use', '*Glioblastoma/drug therapy', 'Humans', 'Mice', 'Phthalazines/therapeutic use', 'Piperazines', 'Rats', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32347934/
1961,temozolomide,37261804,Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.,"['Mao L', 'Lian B', 'Li C', 'Bai X', 'Zhou L', 'Cui C', 'Chi Z', 'Sheng X', 'Wang X', 'Tang B', 'Yan X', 'Li S', 'Kong Y', 'Dai J', 'Wei X', 'Li J', 'Duan R', 'Xu H', 'Wu X', 'Yang Y', 'Cheng F', 'Zhang C', 'Xia F', 'Pang Z', 'Guo J', 'Si L']","['Male', 'Humans', 'Middle Aged', 'Temozolomide/therapeutic use', '*Vascular Endothelial Growth Factor A', '*Melanoma/pathology', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Melanoma, Cutaneous Malignant']",https://pubmed.ncbi.nlm.nih.gov/37261804/
1962,temozolomide,37866459,Mitochondrial response of glioma cells to temozolomide.,"['Lenz LS', 'Torgo D', 'Buss JH', 'Pereira LC', 'Bueno M', 'Filippi-Chiela EC', 'Lenz G']","['Humans', 'Temozolomide/pharmacology/therapeutic use', 'Dacarbazine/pharmacology/metabolism/therapeutic use', 'Apoptosis', 'Cell Line, Tumor', '*Glioma/drug therapy/metabolism', 'Mitochondria/metabolism', 'Antineoplastic Agents, Alkylating/pharmacology', '*Brain Neoplasms/drug therapy/metabolism', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/37866459/
1963,tizanidine,32563380,New directions in the treatment of opioid withdrawal.,"['Srivastava AB', 'Mariani JJ', 'Levin FR']","['Adrenergic alpha-2 Receptor Agonists/administration & dosage/adverse effects', 'Analgesics, Opioid/administration & dosage/adverse effects', 'Drug Administration Schedule', 'Humans', 'Narcotic Antagonists/administration & dosage/adverse effects', 'Opiate Substitution Treatment/*methods', 'Opioid-Related Disorders/*drug therapy', 'Substance Withdrawal Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32563380/
1964,tizanidine,38394496,"Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment.","['Haki M', 'Al-Biati HA', 'Al-Tameemi ZS', 'Ali IS', 'Al-Hussaniy HA']","['Humans', '*Multiple Sclerosis/epidemiology/etiology/therapy', 'Treatment Outcome', 'Chronic Disease', 'Muscle Spasticity/etiology']",https://pubmed.ncbi.nlm.nih.gov/38394496/
1965,tizanidine,22976059,"Spasticity: pathophysiology, evaluation and management.","['Kheder A', 'Nair KP']","['Humans', '*Motor Neuron Disease/diagnosis/physiopathology/therapy', '*Quadriplegia/diagnosis/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/22976059/
1966,tizanidine,18225966,Skeletal muscle relaxants.,"['See S', 'Ginzburg R']","['Drug Interactions', 'Humans', 'Muscle Relaxants, Central/adverse effects/classification/*therapeutic use', 'Musculoskeletal Diseases/drug therapy', 'Nervous System Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18225966/
1967,tizanidine,37059468,Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.,['Dalakas MC'],"['Child', 'Humans', 'Female', 'Aged', '*Stiff-Person Syndrome/therapy/drug therapy', 'Autoantibodies', 'Autoimmunity', 'Baclofen/therapeutic use', 'Spasm']",https://pubmed.ncbi.nlm.nih.gov/37059468/
1968,tizanidine,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
1969,tizanidine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
1970,tizanidine,29165784,Interventions for managing skeletal muscle spasticity following traumatic brain injury.,"['Synnot A', 'Chau M', 'Pitt V', ""O'Connor D"", 'Gruen RL', 'Wasiak J', 'Clavisi O', 'Pattuwage L', 'Phillips K']","['Baclofen/therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Brain Injuries, Traumatic/*complications', 'Casts, Surgical', 'Electric Stimulation Therapy', 'Head-Down Tilt', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Muscle Spasticity/etiology/*therapy', 'Neuromuscular Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29165784/
1971,tizanidine,25347760,Dystonia.,"['Snaith A', 'Wade D']","['Analgesics/therapeutic use', 'Anticonvulsants/therapeutic use', 'Dystonia/drug therapy/surgery/*therapy', 'Humans', 'Physical Therapy Modalities', 'Speech Therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25347760/
1972,tizanidine,39298168,Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.,"['Oldfield BJ', 'Gleeson B', 'Morford KL', 'Adams Z', 'Funaro MC', 'Becker WC', 'Merlin JS']","['Humans', '*Chronic Pain/drug therapy', 'Muscle Relaxants, Central/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39298168/
1973,tizanidine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
1974,tizanidine,38870050,An update on pharmacotherapy for trigeminal neuralgia.,"['Pergolizzi JV Jr', 'LeQuang JA', 'El-Tallawy SN', 'Wagner M', 'Ahmed RS', 'Varrassi G']","['*Trigeminal Neuralgia/drug therapy', 'Humans', '*Anticonvulsants/therapeutic use', '*Carbamazepine/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Migraine Disorders/drug therapy', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38870050/
1975,tizanidine,36948512,Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis.,"['Wewege MA', 'Bagg MK', 'Jones MD', 'Ferraro MC', 'Cashin AG', 'Rizzo RR', 'Leake HB', 'Hagstrom AD', 'Sharma S', 'McLachlan AJ', 'Maher CG', 'Day R', 'Wand BM', ""O'Connell NE"", 'Nikolakopolou A', 'Schabrun S', 'Gustin SM', 'McAuley JH']","['Humans', 'Adult', 'Female', 'Male', 'Acetaminophen/adverse effects', '*Low Back Pain/drug therapy', '*Tramadol/therapeutic use', 'Network Meta-Analysis', 'Analgesics/adverse effects', '*Acute Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36948512/
1976,tizanidine,19445753,Trigeminal neuralgia.,"['Zakrzewska JM', 'Linskey ME']","['Humans', 'Ophthalmic Solutions/therapeutic use', '*Pain/surgery', 'Pain Measurement', 'Phenytoin/therapeutic use', 'Radiosurgery', 'Trigeminal Ganglion', '*Trigeminal Neuralgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19445753/
1977,tizanidine,20927006,Managing spasticity with drugs.,"['Simon O', 'Yelnik AP']","['Administration, Oral', 'Baclofen/adverse effects/*therapeutic use', 'Botulinum Toxins, Type A/adverse effects/*therapeutic use', 'Clonidine/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Injections, Spinal', 'Muscle Relaxants, Central/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy', 'Neuromuscular Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20927006/
1978,tizanidine,35020700,Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report.,"['Ehrman-Dupre R', 'Kaigh C', 'Salzman M', 'Haroz R', 'Peterson LK', 'Schmidt R']","['Adrenergic Agonists/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Animals', '*Buprenorphine/therapeutic use', 'Clonidine', '*Dexmedetomidine/therapeutic use', 'Female', 'Gabapentin/therapeutic use', 'Humans', '*Opioid-Related Disorders/drug therapy', 'Phenobarbital/therapeutic use', '*Substance Withdrawal Syndrome/drug therapy', 'Xylazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35020700/
1979,tizanidine,16272661,Pharmacologic interventions for reducing spasticity in cerebral palsy.,"['Patel DR', 'Soyode O']","['Administration, Oral', 'Adrenergic alpha-Agonists/administration & dosage/*therapeutic use', 'Age Factors', 'Anti-Infective Agents, Local/administration & dosage/therapeutic use', 'Baclofen/administration & dosage/adverse effects/*therapeutic use', 'Botulinum Toxins/administration & dosage/*therapeutic use', 'Cerebral Palsy/*drug therapy/physiopathology', 'Child', 'Child, Preschool', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Dantrolene/administration & dosage/adverse effects/*therapeutic use', '*Diazepam/administration & dosage/adverse effects/therapeutic use', 'Ethanol/administration & dosage/therapeutic use', 'Humans', 'Infant', 'Injections, Intramuscular', 'Injections, Spinal', 'Muscle Relaxants, Central/administration & dosage/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy/physiopathology', 'Neuromuscular Agents/administration & dosage/therapeutic use', 'Phenol/administration & dosage/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/16272661/
1980,tizanidine,7970008,Pharmacokinetics and pharmacodynamics of tizanidine.,"['Roberts RC', 'Part NJ', 'Pokorny R', 'Muir C', 'Leslie GC', 'Emre M']","['Clonidine/administration & dosage/*analogs & derivatives/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Muscle Relaxants, Central/*administration & dosage/*pharmacokinetics', 'Muscle Spasticity/blood/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7970008/
1981,tizanidine,38421578,Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.,"['Shkodina AD', 'Bardhan M', 'Chopra H', 'Anyagwa OE', 'Pinchuk VA', 'Hryn KV', 'Kryvchun AM', 'Boiko DI', 'Suresh V', 'Verma A', 'Delva MY']","['Humans', '*Multiple Sclerosis/therapy/drug therapy', '*Trigeminal Neuralgia/complications/drug therapy', '*Acceptance and Commitment Therapy', '*Neuralgia/drug therapy/etiology', 'Antidepressive Agents/therapeutic use', 'Anticonvulsants/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38421578/
1982,tizanidine,39348794,Comparative effect of oral drugs in improving spasticity of different etiology: a network meta-analysis.,"['Otero-Luis I', 'Martinez-Rodrigo A', 'Cavero-Redondo I', 'Moreno-Herraiz N', 'Lopez-Lopez S', 'Saz-Lara A']","['Humans', '*Muscle Spasticity/drug therapy/etiology', '*Baclofen/administration & dosage/therapeutic use', '*Network Meta-Analysis as Topic', '*Diazepam/therapeutic use/administration & dosage', '*Muscle Relaxants, Central/therapeutic use/administration & dosage', 'Administration, Oral', 'Quality of Life', 'Propiophenones']",https://pubmed.ncbi.nlm.nih.gov/39348794/
1983,trazodone,34994734,Treatment of insomnia - effect of trazodone and hypnotics on sleep.,"['Wichniak A', 'Wierzbicka AE', 'Jarema M']","['Humans', 'Hypnotics and Sedatives/therapeutic use', 'Sleep', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Sleep Quality', '*Trazodone/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34994734/
1984,trazodone,27744763,A review of trazodone use in psychiatric and medical conditions.,['Khouzam HR'],"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Male', 'Mental Disorders/*drug therapy', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Trazodone/*pharmacology/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27744763/
1985,trazodone,29761479,Antidepressants for insomnia in adults.,"['Everitt H', 'Baldwin DS', 'Stuart B', 'Lipinska G', 'Mayers A', 'Malizia AL', 'Manson CC', 'Wilson S']","['Adult', 'Antidepressive Agents/adverse effects/*therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/therapeutic use', 'Fluoxetine/adverse effects/therapeutic use', 'Humans', 'Mianserin/adverse effects/therapeutic use', 'Paroxetine/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/adverse effects/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Trazodone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29761479/
1986,trazodone,9262526,Antidepressant withdrawal reactions.,['Wolfe RM'],"['Adult', 'Amitriptyline/adverse effects', 'Antidepressive Agents/administration & dosage/*adverse effects', 'Antidepressive Agents, Tricyclic/adverse effects', 'Clomipramine/adverse effects', 'Cyclohexanols/adverse effects', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/adverse effects', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Substance Withdrawal Syndrome/diagnosis/drug therapy', 'Trazodone/adverse effects', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/9262526/
1987,trazodone,11199305,[Trazodone-induced priapism].,"['Correas Gomez MA', 'Portillo Martin JA', 'Martin Garcia B', 'Hernandez Rodriguez R', 'Gutierrez Banos JL', 'del Valle Schaan JI', 'Roca Edreira A', 'Rado Velazquez MA', 'Hernandez Castrillo A']","['Adult', 'Antidepressive Agents, Second-Generation/*adverse effects', 'Humans', 'Male', 'Priapism/*chemically induced', 'Trazodone/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11199305/
1988,trazodone,33189083,Pharmacotherapies for sleep disturbances in dementia.,"['McCleery J', 'Sharpley AL']","['Alzheimer Disease/*complications', 'Azepines/adverse effects/therapeutic use', 'Caregiver Burden/drug therapy', 'Cognition/drug effects', 'Humans', 'Indenes/adverse effects/therapeutic use', 'Melatonin/adverse effects/therapeutic use', 'Pyridines/adverse effects/therapeutic use', 'Pyrimidines/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Sleep/drug effects/physiology', 'Sleep Wake Disorders/*drug therapy/etiology', 'Time Factors', 'Trazodone/adverse effects/therapeutic use', 'Triazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33189083/
1989,trazodone,3584080,Trazodone and priapism.,"['Warner MD', 'Peabody CA', 'Whiteford HA', 'Hollister LE']","['Adolescent', 'Adult', 'Age Factors', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Middle Aged', 'Priapism/*chemically induced', 'Time Factors', 'Trazodone/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3584080/
1990,trazodone,6624973,Trazodone and priapism.,"['Scher M', 'Krieger JN', 'Juergens S']","['Combined Modality Therapy', 'Depressive Disorder/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Middle Aged', 'Piperazines/*adverse effects', 'Priapism/*chemically induced/therapy', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6624973/
1991,trazodone,2310343,Trazodone-induced palinopsia.,"['Hughes MS', 'Lessell S']","['Adult', 'Afterimage/drug effects', 'Depression/drug therapy', 'Female', 'Hallucinations/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Trazodone/*adverse effects/therapeutic use', 'Vision Disorders/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2310343/
1992,trazodone,7021449,Trazodone in depression.,['Wheatley D'],"['Adult', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Imipramine/therapeutic use', 'Male', 'Middle Aged', 'Piperazines/*administration & dosage', 'Sleep Stages/drug effects', 'Trazodone/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7021449/
1993,trazodone,32888664,Trazodone-induced delirium: case report.,"['Pereira AT', 'Mota D', 'Ribeiro L', 'Rodrigues JD']","['Adult', 'Antidepressive Agents, Second-Generation/administration & dosage/*adverse effects', 'Delirium/*chemically induced', 'Female', 'Hospitalization', 'Humans', 'Trazodone/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32888664/
1994,trazodone,38842408,Coma Blister After Trazodone Misuse: A Case Report.,"['Yang S', 'Chen V', 'Bitar C']","['Humans', 'Blister/chemically induced/pathology', '*Coma/chemically induced', 'Drug Eruptions/pathology/etiology', 'Substance-Related Disorders/complications', '*Trazodone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38842408/
1995,trazodone,7044154,Trazodone in depressed outpatients.,"['Rickels K', 'Case WG']","['Adult', 'Ambulatory Care', 'Amitriptyline/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Piperazines/*therapeutic use', 'Trazodone/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7044154/
1996,trazodone,38224591,Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis : A Randomized Clinical Trial.,"['Mehrotra R', 'Cukor D', 'McCurry SM', 'Rue T', 'Roumelioti ME', 'Heagerty PJ', 'Unruh M']","['Humans', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Trazodone/adverse effects', 'Renal Dialysis/adverse effects', 'Treatment Outcome', 'Research Design']",https://pubmed.ncbi.nlm.nih.gov/38224591/
1997,trazodone,36634058,[Refractory ischemic priapism due to trazodone].,"['Vaesen F', 'Sempels M']","['Male', 'Humans', 'Adult', '*Priapism/chemically induced/drug therapy', 'Penis/surgery', '*Trazodone/adverse effects', 'Penile Erection']",https://pubmed.ncbi.nlm.nih.gov/36634058/
1998,trazodone,3790881,Trazodone-induced mania.,"['Knobler HY', 'Itzchaky S', 'Emanuel D', 'Mester R', 'Maizel S']","['Adult', 'Aged', 'Bipolar Disorder/*chemically induced/complications/drug therapy', 'Depressive Disorder/drug therapy', 'Female', 'Humans', 'Male', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3790881/
1999,trazodone,3236298,Antidepressant analgesia in rheumatoid arthritis.,"['Frank RG', 'Kashani JH', 'Parker JC', 'Beck NC', 'Brownlee-Duffeck M', 'Elliott TR', 'Haut AE', 'Atwood C', 'Smith E', 'Kay DR']","['Aged', 'Amitriptyline/therapeutic use', 'Antidepressive Agents/administration & dosage/*therapeutic use', 'Arthritis, Rheumatoid/complications/*drug therapy', 'Depression/drug therapy', 'Desipramine/therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pain/*drug therapy', 'Random Allocation', 'Trazodone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3236298/
2000,trazodone,38156419,Treatment of REM sleep behavior disorder with trazodone: report of 3 cases.,"['Barrow J', 'Vendrame M']","['Humans', '*Trazodone/therapeutic use', '*REM Sleep Behavior Disorder/drug therapy', 'Male', 'Female', 'Middle Aged', 'Polysomnography/drug effects', 'Adult', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38156419/
2001,trazodone,3624508,Antidepressant-related akathisia.,"['Zubenko GS', 'Cohen BM', 'Lipinski JF Jr']","['Adult', '*Akathisia, Drug-Induced', 'Antidepressive Agents/*adverse effects/therapeutic use', 'Bipolar Disorder/complications/drug therapy', 'Depressive Disorder/complications/drug therapy', 'Female', 'Humans', 'Imipramine/adverse effects', 'Male', 'Middle Aged', 'Trazodone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3624508/
2002,venlafaxine,36749328,Management of Menopausal Symptoms: A Review.,"['Crandall CJ', 'Mehta JM', 'Manson JE']","['Female', 'Humans', '*Estrogen Replacement Therapy/methods', 'Estrogens/therapeutic use', 'Estrogens, Conjugated (USP)/adverse effects', 'Hot Flashes/drug therapy/etiology', 'Medroxyprogesterone Acetate/therapeutic use', '*Menopause/drug effects', 'Neoplasms/drug therapy', 'Paroxetine/pharmacology', 'Venlafaxine Hydrochloride/pharmacology/therapeutic use', 'Venous Thromboembolism/drug therapy/etiology', 'Sweating', '*Female Urogenital Diseases/etiology', '*Autonomic Nervous System Diseases/etiology']",https://pubmed.ncbi.nlm.nih.gov/36749328/
2003,venlafaxine,31368838,Venlafaxine pharmacogenetics: a comprehensive review.,"['Suwala J', 'Machowska M', 'Wiela-Hojenska A']","['Antidepressive Agents/adverse effects/*therapeutic use', 'Cytochrome P-450 CYP2D6/*genetics', 'Depressive Disorder, Major/*drug therapy/genetics', 'Genotype', 'Humans', 'Pharmacogenetics', 'Polymorphism, Genetic', 'Venlafaxine Hydrochloride/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31368838/
2004,venlafaxine,31178367,"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.","['Furukawa TA', 'Cipriani A', 'Cowen PJ', 'Leucht S', 'Egger M', 'Salanti G']","['Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Mirtazapine/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31178367/
2005,venlafaxine,30016772,Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.,"['Fava GA', 'Benasi G', 'Lucente M', 'Offidani E', 'Cosci F', 'Guidi J']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Desvenlafaxine Succinate/adverse effects/therapeutic use', 'Duloxetine Hydrochloride/adverse effects/therapeutic use', 'Humans', 'Mood Disorders/drug therapy', '*Randomized Controlled Trials as Topic', 'Substance Withdrawal Syndrome/*diagnosis', 'Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30016772/
2006,venlafaxine,36920821,Posttraumatic Stress Disorder: Evaluation and Treatment.,"['Sartor Z', 'Kelley L', 'Laschober R']","['Humans', '*Stress Disorders, Post-Traumatic/diagnosis/therapy/psychology', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use', 'Fluoxetine/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36920821/
2007,venlafaxine,24964257,Clinical drug-drug interactions: focus on venlafaxine.,"['Magalhaes P', 'Alves G', 'LLerena A', 'Falcao A']","['Antidepressive Agents, Second-Generation/pharmacokinetics/pharmacology/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Humans', 'Serotonin and Noradrenaline Reuptake Inhibitors/pharmacokinetics/pharmacology/*therapeutic use', 'Venlafaxine Hydrochloride/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24964257/
2008,venlafaxine,27929271,Hormone Therapy and Other Treatments for Symptoms of Menopause.,"['Hill DA', 'Crider M', 'Hill SR']","['Acupuncture Therapy', 'Administration, Intravaginal', 'Amines/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Atrophy', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Dietary Supplements', 'Drug Therapy, Combination', 'Dyspareunia/*therapy', 'Estrogen Replacement Therapy/*methods', 'Estrogens/therapeutic use', 'Exercise Therapy', 'Female', 'Gabapentin', 'Hot Flashes/*therapy', 'Humans', 'Hypnosis', 'Indoles/therapeutic use', '*Menopause', 'Paroxetine/therapeutic use', 'Progestins/therapeutic use', 'Selective Estrogen Receptor Modulators/therapeutic use', 'Tamoxifen/analogs & derivatives/therapeutic use', 'Vagina', 'Vaginal Diseases/*therapy', 'Vasomotor System', 'Venlafaxine Hydrochloride/therapeutic use', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27929271/
2009,venlafaxine,28293734,[Chemotherapy-induced peripheral neuropathy and neuropathic pain].,"['Schuler U', 'Heller S']","['Antineoplastic Agents/*adverse effects', 'Cryotherapy', 'Duloxetine Hydrochloride/therapeutic use', 'Humans', 'Neuralgia/*chemically induced/prevention & control/therapy', 'Peripheral Nervous System Diseases/*chemically induced/prevention & control/therapy', 'Physical Therapy Modalities', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28293734/
2010,venlafaxine,12013367,Venlafaxine-associated vaginal bleeding.,"['Linnebur SA', 'Saseen JJ', 'Pace WD']","['Adult', 'Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use', 'Cyclohexanols/*adverse effects/therapeutic use', 'Depressive Disorder/complications/drug therapy', 'Female', 'Hemorrhage/*chemically induced', 'Humans', 'Menstruation/drug effects', 'Vaginal Diseases/*chemically induced', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/12013367/
2011,venlafaxine,31290965,"Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).","['Fedgchin M', 'Trivedi M', 'Daly EJ', 'Melkote R', 'Lane R', 'Lim P', 'Vitagliano D', 'Blier P', 'Fava M', 'Liebowitz M', 'Ravindran A', 'Gaillard R', 'Ameele HVD', 'Preskorn S', 'Manji H', 'Hough D', 'Drevets WC', 'Singh JB']","['Administration, Intranasal', 'Administration, Oral', 'Adolescent', 'Adult', 'Antidepressive Agents/administration & dosage/*adverse effects/*therapeutic use', 'Citalopram/therapeutic use', 'Delayed-Action Preparations/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Ketamine/administration & dosage/*adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sertraline/therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31290965/
2012,venlafaxine,35630043,Impact of Venlafaxine on Platelet Count and Activity-Case Report and Narrative Review.,"['Smolarczyk-Kosowska J', 'Kosowski M', 'Kunert L', 'Filipczyk K', 'Wojciechowski M', 'Piegza M', 'Gorczyca P', 'Okopien B', 'Pudlo R']","['*Cyclohexanols/pharmacology', 'Humans', 'Platelet Count', '*Serotonin', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Venlafaxine Hydrochloride/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35630043/
2013,venlafaxine,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
2014,venlafaxine,29509823,Clinical Inquiries: Does exercise relieve vasomotor menopausal symptoms?,"['Lyon C', 'Mullen R', 'Deffenbacher B', 'Reed A', 'Nashelsky J']","['Aged', 'Antidepressive Agents, Second-Generation/therapeutic use', 'Citalopram/therapeutic use', 'Estrogen Replacement Therapy', '*Exercise Therapy', 'Fatty Acids, Omega-3/therapeutic use', 'Female', 'Hot Flashes/*prevention & control', 'Humans', '*Menopause', 'Middle Aged', '*Sweating', 'Venlafaxine Hydrochloride/therapeutic use', 'Yoga']",https://pubmed.ncbi.nlm.nih.gov/29509823/
2015,venlafaxine,14700452,Improving antidepressant adherence.,['Nemeroff CB'],"['Antidepressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Bupropion/administration & dosage/adverse effects/*therapeutic use', 'Cyclohexanols/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Depressive Disorder/*drug therapy', '*Health Promotion', 'Humans', 'Paroxetine/administration & dosage/adverse effects/*therapeutic use', '*Patient Compliance', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/14700452/
2016,venlafaxine,31637686,Mania induced by tramadol-venlafaxine combination.,"['Hefzi N', 'Grekin J', 'Ahmed A']","['Analgesics, Opioid', '*Bipolar Disorder/chemically induced', '*Depressive Disorder, Major/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Tramadol/adverse effects/therapeutic use', '*Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31637686/
2017,venlafaxine,32345407,Evidence-based prescribing for post-traumatic stress disorder.,"['Bisson JI', 'Baker A', 'Dekker W', 'Hoskins MD']","['*Evidence-Based Medicine', 'Fluoxetine/therapeutic use', 'Humans', 'Paroxetine/therapeutic use', 'Sertraline/therapeutic use', 'Stress Disorders, Post-Traumatic/*drug therapy', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32345407/
2018,venlafaxine,37748003,Status Cataplecticus Induced by an Abrupt Duloxetine Withdrawal-A Case Report.,"['Cierny M', 'Feemster J', 'Hamid M', 'Battistini HA']","['Female', 'Humans', 'Aged', 'Duloxetine Hydrochloride/adverse effects', '*Cataplexy/drug therapy', '*Narcolepsy/drug therapy', 'Antidepressive Agents/adverse effects', 'Venlafaxine Hydrochloride/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37748003/
2019,venlafaxine,23045839,Warfarin: pharmacological profile and drug interactions with antidepressants.,"['Teles JS', 'Fukuda EY', 'Feder D']","['Administration, Oral', 'Anticoagulants/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Antidepressive Agents/*pharmacology', 'Biotransformation/drug effects', 'Cyclohexanols/pharmacology', 'Cytochrome P-450 Enzyme System/metabolism', 'Drug Interactions', 'Duloxetine Hydrochloride', 'Fluoxetine/pharmacology', 'Hemorrhage/chemically induced', 'Humans', 'Paroxetine/pharmacology', 'Thiophenes/pharmacology', 'Thrombophilia/drug therapy', 'Venlafaxine Hydrochloride', 'Vitamin K/antagonists & inhibitors', 'Warfarin/adverse effects/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23045839/
2020,venlafaxine,26355986,Multiple Subungual Pyogenic Granulomas Following Levothyroxine Treatment.,"['Keles MK', 'Yosma E', 'Aydogdu IO', 'Simsek T', 'Park TH']","['Antidepressive Agents, Second-Generation/therapeutic use', 'Female', 'Follow-Up Studies', 'Granuloma, Pyogenic/*chemically induced', 'Hormone Replacement Therapy/adverse effects', 'Humans', 'Hypothyroidism/drug therapy', 'Middle Aged', 'Nail Diseases/*chemically induced', 'Recurrence', 'Thyroxine/*adverse effects', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26355986/
2021,venlafaxine,30946169,Attrition in treatment-resistant depression: predictors and clinical impact.,"['Olgiati P', 'Serretti A', 'Souery D', 'Kasper S', 'Kraus C', 'Montgomery S', 'Zohar J', 'Mendlewicz J']","['Adult', 'Antidepressive Agents, Second-Generation/*therapeutic use', 'Citalopram/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy/*epidemiology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Patient Dropouts/*statistics & numerical data', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30946169/
2022,zafirlukast,9232368,Antileukotriene agents.,"['Tan RA', 'Spector SL']","['Anti-Asthmatic Agents/*therapeutic use', 'Asthma/*drug therapy', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Indoles', '*Leukotriene Antagonists', 'Leukotrienes/*physiology', 'Lipoxygenase Inhibitors/*therapeutic use', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9232368/
2023,zafirlukast,12879996,Leukotriene antagonists.,"['Davern TJ', 'Bass NM']","['Adult', 'Aged', 'Anti-Asthmatic Agents/*adverse effects/therapeutic use', 'Asthma/drug therapy', 'Chemical and Drug Induced Liver Injury/*etiology', 'Female', 'Humans', 'Indoles', 'Leukotriene Antagonists/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12879996/
2024,zafirlukast,10023966,Leukotriene-receptor antagonists.,['Lipworth BJ'],"['Acetates/administration & dosage/adverse effects/*therapeutic use', 'Adolescent', 'Adult', 'Anti-Asthmatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Asthma/*drug therapy', 'Child', 'Cyclopropanes', 'Drug Administration Schedule', 'Humans', 'Indoles', 'Leukotriene Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Phenylcarbamates', 'Quinolines/administration & dosage/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Perennial/drug therapy/physiopathology', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10023966/
2025,zafirlukast,20886028,The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field.,"['Nettis E', ""D'Erasmo M"", 'Di Leo E', 'Calogiuri G', 'Montinaro V', 'Ferrannini A', 'Vacca A']","['Acetates/therapeutic use', 'Animals', 'Cyclopropanes', 'Humans', 'Hypersensitivity/*drug therapy', 'Indoles', 'Leukotriene Antagonists/*therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Skin Diseases/*drug therapy', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20886028/
2026,zafirlukast,20880074,Silicone and autoimmunity.,"['Hajdu SD', 'Agmon-Levin N', 'Shoenfeld Y']","['Autoimmune Diseases/*chemically induced', 'Breast Implants/*adverse effects', 'Breast Neoplasms/*chemically induced', 'Female', 'Humans', 'Mastectomy/*methods', 'Plastic Surgery Procedures/*adverse effects', 'Risk Factors', 'Silicones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20880074/
2027,zafirlukast,17383148,[Antileukotrienes and Churg-Strauss syndrome].,"['Guilpain P', 'Pagnoux C', 'Lhote F', 'Mouthon L', 'Guillevin L']","['Acetates/adverse effects/therapeutic use', 'Adult', 'Anti-Asthmatic Agents/adverse effects/*therapeutic use', 'Antibodies, Antineutrophil Cytoplasmic', 'Asthma/complications/*drug therapy/etiology', 'Chromones/adverse effects/therapeutic use', 'Churg-Strauss Syndrome/chemically induced/complications/*diagnosis/epidemiology/etiology', 'Cohort Studies', 'Cyclopropanes', 'Humans', 'Incidence', 'Indoles', 'Leukotriene Antagonists/adverse effects/*therapeutic use', 'Leukotrienes/biosynthesis/metabolism', 'Phenylcarbamates', 'Quinolines/adverse effects/therapeutic use', 'Retrospective Studies', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17383148/
2028,zafirlukast,17225706,Leukotriene inhibitors in the treatment of allergy and asthma.,"['Scow DT', 'Luttermoser GK', 'Dickerson KS']","['Acetates/therapeutic use', 'Anti-Asthmatic Agents/therapeutic use', 'Asthma/*drug therapy', 'Asthma, Exercise-Induced/drug therapy', 'Cyclopropanes', 'Dermatitis, Atopic/drug therapy', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Hypersensitivity/*drug therapy', 'Indoles', 'Leukotriene Antagonists/*therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17225706/
2029,zafirlukast,8885816,Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.,['Smith LJ'],"['Animals', 'Anti-Asthmatic Agents/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Asthma/*drug therapy/*physiopathology', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Indoles', 'Inflammation', 'Inflammation Mediators/physiology', '*Leukotriene Antagonists', 'Leukotrienes/*physiology', 'Lipoxygenase Inhibitors/therapeutic use', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8885816/
2030,zafirlukast,29878767,Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.,"['Schierle S', 'Flauaus C', 'Heitel P', 'Willems S', 'Schmidt J', 'Kaiser A', 'Weizel L', 'Goebel T', 'Kahnt AS', 'Geisslinger G', 'Steinhilber D', 'Wurglics M', 'Rovati GE', 'Schmidtko A', 'Proschak E', 'Merk D']","['3T3 Cells', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology', 'Catalytic Domain', '*Drug Design', 'Epoxide Hydrolases/chemistry/metabolism', 'Hep G2 Cells', 'Humans', 'Indoles', 'Mice', 'Molecular Docking Simulation', 'PPAR gamma/chemistry/metabolism', 'Phenylcarbamates', '*Polypharmacology', 'Sulfonamides', 'Tosyl Compounds/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29878767/
2031,zafirlukast,10212622,Newer therapeutic agents for asthma.,"['Deykin A', 'Israel E']","['Adrenergic beta-Agonists/pharmacology/*therapeutic use', 'Albuterol/analogs & derivatives/therapeutic use', 'Androstadienes/therapeutic use', 'Anti-Asthmatic Agents/pharmacology/*therapeutic use', 'Asthma/*drug therapy/physiopathology', 'Bronchodilator Agents/pharmacology/*therapeutic use', 'Cyclosporine/therapeutic use', 'Fluticasone', 'Forced Expiratory Volume/drug effects', 'Humans', 'Immunoglobulins, Intravenous/therapeutic use', 'Immunosuppressive Agents/pharmacology/*therapeutic use', 'Indoles', 'Leukotriene Antagonists/pharmacology/*therapeutic use', 'Lidocaine/therapeutic use', 'Methotrexate/therapeutic use', 'Phenylcarbamates', 'Salmeterol Xinafoate', 'Sulfonamides', 'Tosyl Compounds/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10212622/
2032,zafirlukast,9742908,Anti-inflammatory drugs for controlling asthma.,"['Volcheck GW', ""O'Connell EJ""]","['Adult', 'Anti-Asthmatic Agents/*therapeutic use', 'Anti-Inflammatory Agents/*therapeutic use', 'Asthma/classification/*drug therapy/physiopathology', 'Child', 'Cromolyn Sodium/therapeutic use', 'Glucocorticoids/therapeutic use', 'Humans', 'Indoles', 'Inflammation/etiology', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9742908/
2033,zafirlukast,38852861,Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: Systematic review and meta-analysis of randomized clinical trials.,"['Rayner DG', 'Liu M', 'Chu AWL', 'Chu X', 'Guyatt GH', 'Oykhman P', 'Cao DJ', 'Moellman J', 'Ben-Shoshan M', 'Baker DR', 'Waserman S', 'Lang D', 'Sheikh J', 'Mathur SK', 'Beck LA', 'Khan DA', 'Oliver ET', 'Asiniwasis RN', 'Cole EF', 'Wheeler KE', 'Runyon L', 'Chan J', 'Trayes KP', 'Eftekhari S', 'Gardner DD', 'Winders T', 'Saini SS', 'Bernstein JA', 'Chu DK']","['Humans', 'Drug Therapy, Combination', 'Histamine Antagonists/therapeutic use', 'Histamine H1 Antagonists/therapeutic use', '*Leukotriene Antagonists/therapeutic use', 'Quality of Life', 'Randomized Controlled Trials as Topic', '*Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38852861/
2034,zafirlukast,17437683,Leukotriene synthesis inhibitors versus antagonists: the pros and cons.,"['Steinke JW', 'Culp JA']","['Acetates/therapeutic use', 'Animals', 'Anti-Asthmatic Agents/pharmacology/therapeutic use', 'Arachidonate 5-Lipoxygenase/physiology', 'Asthma/*drug therapy/physiopathology', 'Chromones/therapeutic use', 'Cyclopropanes', 'Humans', 'Hypersensitivity/*drug therapy/physiopathology', 'Indoles', 'Inflammation Mediators/antagonists & inhibitors/physiology', 'Leukotriene Antagonists/*pharmacology/therapeutic use', 'Leukotrienes/*biosynthesis/physiology', 'Lipoxygenase Inhibitors/pharmacology/therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Receptors, Leukotriene/*physiology', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17437683/
2035,zafirlukast,38663558,Leukotriene-modifying agents may increase the risk of depression: A cross-sectional study.,"['Yan J', 'Sun H', 'Xin X', 'Huang T', 'Shen J']","['Humans', 'Cross-Sectional Studies', 'Male', 'Female', 'Middle Aged', 'Adult', '*Depression/epidemiology/chemically induced', '*Nutrition Surveys', 'United States/epidemiology', 'Leukotriene Antagonists/pharmacology/adverse effects', 'Prevalence', 'Risk Factors', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38663558/
2036,zafirlukast,26980339,Antileukotrienes in adenotonsillar hypertrophy: a review of the literature.,"['Kar M', 'Altintoprak N', 'Muluk NB', 'Ulusoy S', 'Bafaqeeh SA', 'Cingi C']","['Adenoids/metabolism/*pathology', 'Humans', 'Hypertrophy/drug therapy', 'Inflammation/drug therapy', 'Leukotriene Antagonists/*therapeutic use', 'Palatine Tonsil/metabolism/*pathology', 'Receptors, Leukotriene/metabolism']",https://pubmed.ncbi.nlm.nih.gov/26980339/
2037,zafirlukast,27826703,Leukotriene Receptor Antagonists and Antiallergy Drugs.,"['Tamada T', 'Ichinose M']","['Adrenal Cortex Hormones/administration & dosage', 'Adrenergic beta-2 Receptor Agonists/therapeutic use', 'Animals', 'Anti-Allergic Agents/pharmacology/*therapeutic use', 'Asthma/*drug therapy', 'Cytokines/antagonists & inhibitors', 'Drug Therapy, Combination', 'Humans', 'Leukotriene Antagonists/pharmacology/*therapeutic use', 'Receptors, Leukotriene/physiology', 'Th2 Cells/immunology']",https://pubmed.ncbi.nlm.nih.gov/27826703/
2038,zafirlukast,31544544,Asthma pharmacotherapy: an update on leukotriene treatments.,"['Trinh HKT', 'Lee SH', 'Cao TBT', 'Park HS']","['Acetates/therapeutic use', 'Asthma/*drug therapy', 'Asthma, Aspirin-Induced/drug therapy', 'Chromones/therapeutic use', 'Cyclopropanes', 'Cysteine/*therapeutic use', 'Humans', 'Indoles', 'Leukotriene Antagonists/*therapeutic use', 'Leukotrienes/*therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31544544/
2039,zafirlukast,20525510,Systemic therapies in managing sinonasal inflammation.,"['DeMarcantonio MA', 'Han JK']","['Anti-Inflammatory Agents/therapeutic use', 'Combined Modality Therapy', 'Drug Therapy/*methods', 'Eosinophils', 'Histamine Antagonists/therapeutic use', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Immunologic Factors/therapeutic use', 'Indoles', 'Leukotriene Antagonists/therapeutic use', 'Otorhinolaryngologic Surgical Procedures/*methods', 'Phenylcarbamates', 'Rhinitis/*complications/*drug therapy/surgery', 'Sinusitis/*complications/*drug therapy/surgery', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20525510/
2040,zolpidem,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
2041,zolpidem,32044373,On the pathophysiology and treatment of akinetic mutism.,"['Arnts H', 'van Erp WS', 'Lavrijsen JCM', 'van Gaal S', 'Groenewegen HJ', 'van den Munckhof P']","['Adrenergic Uptake Inhibitors/*therapeutic use', '*Akinetic Mutism/drug therapy/pathology/physiopathology', 'Animals', 'Dopamine Agonists/*therapeutic use', 'Dopamine Uptake Inhibitors/*therapeutic use', '*Dopaminergic Neurons/drug effects/pathology/physiology', 'GABA-A Receptor Agonists/*therapeutic use', '*Gray Matter/drug effects/pathology/physiopathology', 'Humans', '*Motivation/drug effects/physiology', 'Zolpidem/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32044373/
2042,zolpidem,19584967,Novel zolpidem formulations.,['Owen RT'],"['Administration, Oral', 'Administration, Sublingual', 'Aerosols', 'Delayed-Action Preparations', 'Dosage Forms', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacokinetics/*pharmacology', 'Pyridines/administration & dosage/*pharmacokinetics/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19584967/
2043,zolpidem,31880796,Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.,"['Rosenberg R', 'Murphy P', 'Zammit G', 'Mayleben D', 'Kumar D', 'Dhadda S', 'Filippov G', 'LoPresti A', 'Moline M']","['Aged', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Middle Aged', 'Polysomnography', 'Pyridines/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31880796/
2044,zolpidem,38153735,Effect of Psychological and Medication Therapies for Insomnia on Daytime Functions: A Randomized Clinical Trial.,"['Morin CM', 'Chen SJ', 'Ivers H', 'Beaulieu-Bonneau S', 'Krystal AD', 'Guay B', 'Belanger L', 'Cartwright A', 'Simmons B', 'Lamy M', 'Busby M', 'Edinger JD']","['Adult', 'Female', 'Humans', 'Middle Aged', 'Behavior Therapy', 'Fatigue', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Trazodone', 'Zolpidem/therapeutic use', 'Male']",https://pubmed.ncbi.nlm.nih.gov/38153735/
2045,zolpidem,31953863,"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.","['Dauvilliers Y', 'Zammit G', 'Fietze I', 'Mayleben D', 'Seboek Kinter D', 'Pain S', 'Hedner J']","['Adult', 'Benzimidazoles/*administration & dosage/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Imidazoles', 'Middle Aged', 'Orexin Receptor Antagonists/adverse effects/therapeutic use', 'Pyrrolidines/*administration & dosage/adverse effects/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Treatment Outcome', 'Triazoles/*administration & dosage/adverse effects/therapeutic use', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31953863/
2046,zolpidem,38630476,Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.,"['Takeshima M', 'Yoshizawa K', 'Ogasawara M', 'Kudo M', 'Itoh Y', 'Ayabe N', 'Mishima K']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', 'Cohort Studies', 'Eszopiclone', 'Hypnotics and Sedatives/adverse effects', '*Indenes', 'Japan', 'Retrospective Studies', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Treatment Failure', '*Triazolam', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38630476/
2047,zolpidem,18221242,Zolpidem therapy for movement disorders.,['Abe K'],"['Animals', 'GABA Agonists/*therapeutic use', 'Humans', 'Movement Disorders/*drug therapy', 'Pyridines/*therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/18221242/
2048,zolpidem,37993186,Pharmacology in Treatment of Patients with Disorders of Consciousness.,['Marino MH'],"['Humans', '*Consciousness/physiology', 'Zolpidem/therapeutic use', 'Consciousness Disorders/drug therapy', '*Brain Injuries', 'Amantadine/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37993186/
2049,zolpidem,8853211,Polysomnographic effects of hypnotic drugs. A review.,"['Parrino L', 'Terzano MG']","['Adult', 'Anti-Anxiety Agents/pharmacology/*therapeutic use', 'Azabicyclo Compounds', 'Benzodiazepines', 'Humans', 'Hypnotics and Sedatives/pharmacology/*therapeutic use', 'Middle Aged', 'Piperazines/pharmacology/therapeutic use', 'Polysomnography/*drug effects', 'Pyridines/pharmacology/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8853211/
2050,zolpidem,27974380,Incorporation of Zolpidem into Hair and Its Distribution after a Single Administration.,"['Shima N', 'Sasaki K', 'Kamata T', 'Matsuta S', 'Wada M', 'Kakehashi H', 'Nakano S', 'Kamata H', 'Nishioka H', 'Sato T', 'Tsuchihashi H', 'Miki A', 'Katagi M']","['Adult', 'Biological Transport', 'Chromatography, Liquid', 'Drug Monitoring/*methods', 'Female', 'Hair/*chemistry', 'Healthy Volunteers', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacokinetics', 'Limit of Detection', 'Male', 'Pyridines/administration & dosage/*pharmacokinetics', 'Reproducibility of Results', 'Substance Abuse Detection/*methods', 'Tandem Mass Spectrometry', 'Time Factors', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/27974380/
2051,zolpidem,15651908,Zolpidem: a review of its use in the management of insomnia.,"['Swainston Harrison T', 'Keating GM']","['Age Factors', 'Clinical Trials as Topic/methods', 'Drug Administration Schedule', 'Drug Evaluation/methods', 'GABA Agonists/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*therapeutic use', 'Pyridines/adverse effects/pharmacokinetics/*therapeutic use', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Substance Withdrawal Syndrome/etiology', 'Treatment Outcome', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15651908/
2052,zolpidem,34818157,Successful accelerated taper for sleeping aid.,"['Franck L', 'Prescott D', 'Smith S']","['Drug Administration Schedule', 'Humans', 'Male', 'Middle Aged', 'Sleep Aids, Pharmaceutical/*administration & dosage', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Treatment Outcome', 'Zolpidem/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/34818157/
2053,zolpidem,22424586,Zolpidem for insomnia.,"['Greenblatt DJ', 'Roth T']","['Animals', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Pyridines/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/22424586/
2054,zolpidem,15352681,Zolpidem for postanoxic spasticity.,"['Shadan FF', 'Poceta JS', 'Kline LE']","['Adult', 'GABA Agonists/*therapeutic use', 'Heart Arrest/complications', 'Humans', 'Male', 'Muscle Spasticity/*drug therapy/etiology', 'Pyridines/*therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15352681/
2055,zolpidem,11062863,The effect of zolpidem and zopiclone on memory.,"['Isawa S', 'Suzuki M', 'Uchiumi M', 'Murasaki M']","['Adult', 'Azabicyclo Compounds', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Memory/*drug effects', 'Memory, Short-Term/drug effects', 'Mental Recall/drug effects', 'Piperazines/*pharmacology', 'Pyridines/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/11062863/
2056,zolpidem,16696581,Zolpidem extended-release.,"['Moen MD', 'Plosker GL']","['Adolescent', 'Adult', 'Delayed-Action Preparations/*administration & dosage/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Evaluation', 'Female', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/pharmacokinetics', 'Male', 'Middle Aged', 'Polysomnography', 'Practice Guidelines as Topic', 'Pyridines/*administration & dosage/pharmacokinetics', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy/metabolism', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/16696581/
2057,zolpidem,19644424,Catatonia recognition and treatment.,"['Cottencin O', 'Danel T', 'Goudemand M', 'Thomas P', 'Consoli SM']","['Catatonia/*diagnosis/*drug therapy', 'Female', 'Humans', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Pyridines/administration & dosage/therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19644424/
2058,zolpidem,28262178,Zolpidem's use for insomnia.,"['Monti JM', 'Spence DW', 'Buttoo K', 'Pandi-Perumal SR']","['Humans', 'Hypnotics and Sedatives/administration & dosage/pharmacokinetics/*pharmacology', 'Pyridines/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/28262178/
2059,zolpidem,30870203,A Pilot Crossover Trial of Sleep Medications for Sleep-disturbed Methadone Maintenance Patients.,"['Stein MD', 'Kurth ME', 'Anderson BJ', 'Blevins CE']","['Actigraphy', 'Adult', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'GABA-A Receptor Agonists/therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Methadone/*therapeutic use', 'Middle Aged', 'Mirtazapine/*therapeutic use', '*Opiate Substitution Treatment', 'Pilot Projects', 'Serotonin Antagonists/therapeutic use', 'Sleep/*drug effects', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Latency/drug effects', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30870203/
2060,zonisamide,10530691,Zonisamide.,['Leppik IE'],"['Adult', 'Animals', 'Anticonvulsants/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Disease Models, Animal', 'Drug Administration Schedule', 'Epilepsies, Myoclonic/drug therapy', 'Epilepsy/*drug therapy', 'Humans', 'Isoxazoles/pharmacokinetics/pharmacology/*therapeutic use', 'Treatment Outcome', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/10530691/
2061,zonisamide,36194365,Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.,"['Strzelczyk A', 'Schubert-Bast S']","['*Autism Spectrum Disorder', 'Bromides', '*Cannabidiol', 'Clobazam', 'Cognition', 'Ethosuximide', 'Everolimus', 'Felbamate', 'Fenfluramine', 'Humans', 'Lacosamide', 'Lamotrigine', 'Levetiracetam', 'Pregabalin', '*Spasms, Infantile', 'Sulfides', 'Topiramate', 'Valproic Acid', 'Vigabatrin', 'Zinc Compounds', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/36194365/
2062,zonisamide,30680679,Pharmacological Management of Dementia with Lewy Bodies.,"['Hershey LA', 'Coleman-Jackson R']","['Age Factors', 'Aged', 'Anticonvulsants/administration & dosage', 'Antiparkinson Agents/administration & dosage', 'Cholinesterase Inhibitors/administration & dosage', 'Clinical Trials, Phase II as Topic', 'Clonazepam/administration & dosage', 'Humans', 'Levodopa/administration & dosage', 'Lewy Body Disease/diagnosis/*drug therapy', 'Melatonin/administration & dosage', 'Randomized Controlled Trials as Topic', 'Zonisamide/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30680679/
2063,zonisamide,38460459,Teratogenicity of zonisamide and other little-used antiseizure medications.,"['Vajda FJE', ""O'Brien TJ"", 'Graham JE', 'Hitchcock AA', 'Perucca P', 'Lander CM', 'Eadie MJ']","['Humans', '*Zonisamide/adverse effects', '*Anticonvulsants/adverse effects', 'Female', 'Pregnancy', 'Australia', 'Isoxazoles/adverse effects', 'Abnormalities, Drug-Induced/etiology', 'Registries', 'Epilepsy/drug therapy', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38460459/
2064,zonisamide,33838757,"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.","['Marson A', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton C', 'Hughes DA', 'Williamson P', 'Baker GA', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Anticonvulsants/*adverse effects', 'Child', '*Cost-Benefit Analysis', 'Epilepsies, Partial/*drug therapy', 'Female', 'Humans', 'Lamotrigine/*therapeutic use', 'Levetiracetam/*therapeutic use', 'Male', 'Middle Aged', '*Treatment Outcome', 'Young Adult', 'Zonisamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33838757/
2065,zonisamide,26089654,Zonisamide in the management of epilepsy in the elderly.,"['Romigi A', 'Femia EA', 'Fattore C', 'Vitrani G', 'Di Gennaro G', 'Franco V']","['Aged', 'Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Drug Therapy, Combination', 'Epilepsy/*drug therapy', 'Humans', 'Isoxazoles/adverse effects/pharmacology/*therapeutic use', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/26089654/
2066,zonisamide,34204137,Glycine Receptors in Spinal Nociceptive Control-An Update.,"['Zeilhofer HU', 'Werynska K', 'Gingras J', 'Yevenes GE']","['Animals', 'Endocannabinoids/pharmacology', 'Humans', 'Nociception/drug effects/*physiology', 'Propofol/pharmacology', 'Protein Structure, Secondary', 'Receptors, Glycine/*agonists/chemistry/*metabolism', 'Spinal Cord Dorsal Horn/drug effects/*metabolism', 'Zonisamide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34204137/
2067,zonisamide,8019658,Developments in antiepileptic drug therapy.,"['Walker MC', 'Sander JW']","['Anticonvulsants/adverse effects/pharmacokinetics/*therapeutic use', 'Brain/drug effects/physiopathology', 'Dose-Response Relationship, Drug', 'Electroencephalography/drug effects', 'Epilepsy/blood/*drug therapy', 'Humans', 'Synaptic Transmission/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/8019658/
2068,zonisamide,34931602,Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.,"['Marson AG', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton CO', 'Hughes DA', 'Williamson PR', 'Baker G', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Child, Preschool', 'Female', 'Humans', 'Cost-Benefit Analysis', '*Epilepsies, Partial/drug therapy', '*Epilepsy/drug therapy', '*Lamotrigine/therapeutic use', '*Levetiracetam/therapeutic use', 'Quality of Life', '*Valproic Acid/therapeutic use', '*Zonisamide/therapeutic use', 'Child', 'Adolescent', 'Young Adult', 'Adult', 'Middle Aged', 'Aged', 'Aged, 80 and over', 'Male']",https://pubmed.ncbi.nlm.nih.gov/34931602/
2069,zonisamide,36193017,Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.,"['Tomson T', 'Battino D', 'Bromley R', 'Kochen S', 'Meador KJ', 'Pennell PB', 'Thomas SV']","['Breast Feeding', '*Cannabidiol', 'Carbamazepine/therapeutic use', 'Child', 'Clobazam/therapeutic use', 'Clonazepam/therapeutic use', '*Epilepsy/drug therapy', 'Ethosuximide/therapeutic use', 'Everolimus/therapeutic use', 'Felbamate/therapeutic use', 'Female', 'Fenfluramine/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', 'Infant', 'Lacosamide', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Oxcarbazepine', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Prospective Studies', 'Tiagabine', 'Topiramate', 'Valproic Acid/therapeutic use', 'Vigabatrin/therapeutic use', 'Zonisamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36193017/
2070,zonisamide,24522856,Zonisamide as a treatment for partial epileptic seizures: a systematic review.,"['Cox JH', 'Seri S', 'Cavanna AE']","['Anticonvulsants/*therapeutic use', 'Epilepsies, Partial/*drug therapy', 'Humans', 'Isoxazoles/*therapeutic use', 'Treatment Outcome', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/24522856/
2071,zonisamide,35157004,Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.,"['Pennell PB', 'Karanam A', 'Meador KJ', 'Gerard E', 'Kalayjian L', 'Penovich P', 'Matthews A', 'McElrath TM', 'Birnbaum AK']","['Adult', '*Anticonvulsants/adverse effects', 'Carbamazepine/therapeutic use', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lacosamide/therapeutic use', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Pregnancy', 'Prospective Studies', 'Topiramate/therapeutic use', 'Zonisamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35157004/
2072,zonisamide,19195742,[New antiepileptic drugs].,['Rouvel-Tallec A'],"['Amines/*therapeutic use', 'Anticonvulsants/adverse effects/*therapeutic use', 'Carbamazepine/analogs & derivatives/therapeutic use', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Epilepsies, Partial/drug therapy', 'Epilepsy/*drug therapy', 'Gabapentin', 'Humans', 'Isoxazoles/therapeutic use', 'Lamotrigine', 'Levetiracetam', 'Oxcarbazepine', 'Piracetam/analogs & derivatives/therapeutic use', 'Pregabalin', 'Triazines/*therapeutic use', 'Zonisamide', 'gamma-Aminobutyric Acid/analogs & derivatives/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19195742/
2073,zonisamide,25556809,Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.,"['Lerner PP', 'Miodownik C', 'Lerner V']","['Adrenergic Uptake Inhibitors/therapeutic use', 'Adrenergic beta-Antagonists/therapeutic use', 'Amantadine/therapeutic use', 'Anticonvulsants/therapeutic use', 'Antioxidants/therapeutic use', 'Antipsychotic Agents/*adverse effects', 'Clonazepam/therapeutic use', 'Dopamine Agents/therapeutic use', 'Drugs, Chinese Herbal/therapeutic use', 'Fatty Acids, Omega-3/therapeutic use', 'Ginkgo biloba', 'Humans', 'Isoleucine/therapeutic use', 'Isoxazoles/therapeutic use', 'Leucine/therapeutic use', 'Levetiracetam', 'Melatonin/therapeutic use', 'Movement Disorders/*drug therapy/etiology', 'Nootropic Agents/therapeutic use', 'Piracetam/analogs & derivatives/therapeutic use', 'Plant Extracts/therapeutic use', 'Propranolol/therapeutic use', 'Pyridoxine/therapeutic use', 'Resveratrol', 'Stilbenes/therapeutic use', 'Tetrabenazine/therapeutic use', 'Valine/therapeutic use', 'Vitamins/therapeutic use', 'Zonisamide', 'alpha-Tocopherol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25556809/
2074,zonisamide,27546759,Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.,"['Smetana KS', 'Cook AM', 'Bastin ML', 'Oyler DR']","['Acetamides/administration & dosage', 'Acute Kidney Injury/complications/*therapy', 'Amines/administration & dosage', 'Anticonvulsants/*administration & dosage/adverse effects', 'Carbamates/administration & dosage', 'Critical Illness', 'Cyclohexanecarboxylic Acids/administration & dosage', 'Dibenzazepines/administration & dosage', 'Dose-Response Relationship, Drug', 'Ethosuximide/administration & dosage', 'Felbamate', 'Fructose/administration & dosage/analogs & derivatives', 'Gabapentin', 'Humans', 'Isoxazoles/administration & dosage', 'Lacosamide', 'Lamotrigine', 'Levetiracetam', 'Phenobarbital/administration & dosage', 'Phenylcarbamates/administration & dosage', 'Phenylenediamines/administration & dosage', 'Phenytoin/administration & dosage', 'Piracetam/administration & dosage/analogs & derivatives', 'Propylene Glycols/administration & dosage', '*Renal Dialysis', 'Renal Replacement Therapy', 'Seizures/complications/*drug therapy', 'Topiramate', 'Triazines/administration & dosage', 'Valproic Acid/administration & dosage', 'Zonisamide', 'gamma-Aminobutyric Acid/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27546759/
2075,zonisamide,29733555,[The role of zonisamide in the treatment of women with epilepsy].,['Juhos V'],"['Anticonvulsants/*therapeutic use', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Isoxazoles/*therapeutic use', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/29733555/
2076,zonisamide,38165339,Comparative Risk of Major Congenital Malformations With Antiseizure Medication Combinations vs Valproate Monotherapy in Pregnancy.,"['Cohen JM', 'Alvestad S', 'Suarez EA', 'Schaffer A', 'Selmer RM', 'Havard A', 'Bateman BT', 'Cesta CE', 'Zoega H', 'Odsbu I', 'Huybrechts KF', 'Kjerpeseth LJ', 'Straub L', 'Leinonen MK', 'Bjork MH', 'Norgaard M', 'Gissler M', 'Ulrichsen SP', 'Hernandez-Diaz S', 'Tomson T', 'Furu K']","['Female', 'Humans', 'Pregnancy', 'Cohort Studies', '*Epilepsy, Generalized', 'Lamotrigine/therapeutic use', 'Levetiracetam', 'Topiramate', '*Valproic Acid/adverse effects', 'Zonisamide', 'Infant, Newborn', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/38165339/
2077,zonisamide,34092044,Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy.,"['Herzog R', 'Hellenbroich Y', 'Bruggemann N', 'Lohmann K', 'Grimmel M', 'Haack TB', 'von Spiczak S', 'Munchau A']","['Anticonvulsants/*therapeutic use', 'Female', 'Humans', 'Myoclonic Epilepsies, Progressive/diagnosis/*drug therapy/*genetics', 'Pedigree', 'Semaphorins/*genetics', 'Exome Sequencing/methods', 'Young Adult', 'Zonisamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34092044/
2078,zonisamide,17030393,Novel anticonvulsant drugs.,"['Stefan H', 'Feuerstein TJ']","['Amines/therapeutic use', 'Animals', 'Anticonvulsants/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Carbamazepine/analogs & derivatives/therapeutic use', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Epilepsy/*drug therapy', 'Fructose/analogs & derivatives/therapeutic use', 'Gabapentin', 'Humans', 'Isoxazoles/therapeutic use', 'Lamotrigine', 'Levetiracetam', 'Nipecotic Acids/therapeutic use', 'Piracetam/analogs & derivatives/therapeutic use', 'Pregabalin', 'Tiagabine', 'Topiramate', 'Treatment Outcome', 'Triazines/therapeutic use', 'Zonisamide', 'gamma-Aminobutyric Acid/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17030393/
2079,zonisamide,20196486,"[The discovery of an antiparkinsonian drug, zonisamide].",['Murata M'],"['Animals', 'Anticonvulsants/*therapeutic use', 'Dopamine/biosynthesis', 'Humans', 'Isoxazoles/*therapeutic use', 'Male', 'Middle Aged', 'Parkinson Disease/*drug therapy', 'Rats', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/20196486/
